{"62aca7f0b1d46795c95667709c97899eb01507ee": [["IntroductionThe importance of foodborne transmission of viruses is increasingly recognized [1] , and the World Health Organization has signaled an upward trend in their incidence [2] .", [["viruses", "PROBLEM", 56, 63]]], ["It is also understood that the burden of infection is grossly underestimated by routine surveillance [3, 4] .", [["infection", "DISEASE", 41, 50], ["infection", "PROBLEM", 41, 50], ["routine surveillance", "TEST", 80, 100], ["infection", "OBSERVATION", 41, 50], ["grossly", "OBSERVATION_MODIFIER", 54, 61]]], ["The aging population (with increasing numbers of people at risk for complications of enteric infections) and the globalization of infectious diseases due to rapid international travel and (food) trade add to the notion that the burden of illness is likely to increase in the years to come [5] .", [["enteric infections", "DISEASE", 85, 103], ["infectious diseases", "DISEASE", 130, 149], ["illness", "DISEASE", 238, 245], ["people", "ORGANISM", 49, 55], ["people", "SPECIES", 49, 55], ["enteric infections", "PROBLEM", 85, 103], ["infectious diseases", "PROBLEM", 130, 149], ["illness", "PROBLEM", 238, 245], ["population", "OBSERVATION_MODIFIER", 10, 20], ["enteric", "ANATOMY", 85, 92], ["infections", "OBSERVATION", 93, 103], ["infectious", "OBSERVATION", 130, 140]]], ["Vast outbreaks may occur due to contamination of food by a single foodhandler or at a single source, as has been documented on several occasions.IntroductionNumerous viruses can be found in the human intestinal tract ( Table 1 ).", [["intestinal tract", "ANATOMY", 200, 216], ["human", "ORGANISM", 194, 199], ["intestinal tract", "MULTI-TISSUE_STRUCTURE", 200, 216], ["human", "SPECIES", 194, 199], ["human", "SPECIES", 194, 199], ["Vast outbreaks", "PROBLEM", 0, 14], ["contamination of food", "PROBLEM", 32, 53], ["Numerous viruses", "PROBLEM", 157, 173], ["viruses", "OBSERVATION", 166, 173], ["intestinal tract", "ANATOMY", 200, 216]]], ["The food-and waterborne viruses can be divided into three disease categories : 1. viruses that cause gastroenteritis (e.g. astrovirus, rotavirus, the enteric adenoviruses, and the two genera of enteric caliciviruses, i.e. the small round structured viruses or 'Norwalk-like viruses' (NLV), and typical caliciviruses or 'Sapporo-like viruses' (SLV) ; 2. fecal^orally transmitted hepatitis viruses: hepatitis A virus (HAV), hepatitis E virus (HEV);Introduction3. viruses which cause other illness, e.g. enteroviruses.IntroductionIn addition, several viruses are listed that also replicate in the intestinal tract, but are not implicated in foodborne transmission, or whose role is unknown.IntroductionViruses, unlike bacteria, are strict intracellular parasites and cannot replicate in food or water.", [["intestinal tract", "ANATOMY", 594, 610], ["intracellular", "ANATOMY", 736, 749], ["gastroenteritis", "DISEASE", 101, 116], ["astrovirus, rotavirus", "DISEASE", 123, 144], ["enteric adenoviruses", "DISEASE", 150, 170], ["enteric caliciviruses", "DISEASE", 194, 215], ["hepatitis viruses", "DISEASE", 378, 395], ["hepatitis A virus (HAV), hepatitis E", "DISEASE", 397, 433], ["enteroviruses", "DISEASE", 501, 514], ["enteric adenoviruses", "ORGANISM", 150, 170], ["enteric caliciviruses", "ORGANISM", 194, 215], ["Norwalk-like viruses", "ORGANISM", 261, 281], ["Sapporo-like viruses", "ORGANISM", 320, 340], ["fecal^orally transmitted", "ORGANISM", 353, 377], ["hepatitis viruses", "ORGANISM", 378, 395], ["hepatitis A virus", "ORGANISM", 397, 414], ["HAV", "ORGANISM", 416, 419], ["hepatitis E virus", "ORGANISM", 422, 439], ["HEV", "ORGANISM", 441, 444], ["intestinal tract", "ORGAN", 594, 610], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 736, 749], ["hepatitis A virus", "SPECIES", 397, 414], ["hepatitis E virus", "SPECIES", 422, 439], ["NLV", "SPECIES", 284, 287], ["SLV", "SPECIES", 343, 346], ["hepatitis A virus", "SPECIES", 397, 414], ["HAV", "SPECIES", 416, 419], ["hepatitis E virus", "SPECIES", 422, 439], ["HEV", "SPECIES", 441, 444], ["waterborne viruses", "PROBLEM", 13, 31], ["viruses", "PROBLEM", 82, 89], ["gastroenteritis", "PROBLEM", 101, 116], ["astrovirus", "PROBLEM", 123, 133], ["rotavirus", "PROBLEM", 135, 144], ["the enteric adenoviruses", "PROBLEM", 146, 170], ["enteric caliciviruses", "PROBLEM", 194, 215], ["the small round structured viruses", "PROBLEM", 222, 256], ["'Norwalk-like viruses'", "PROBLEM", 260, 282], ["typical caliciviruses", "PROBLEM", 294, 315], ["fecal^orally transmitted hepatitis viruses", "PROBLEM", 353, 395], ["hepatitis A virus (HAV)", "PROBLEM", 397, 420], ["hepatitis E virus", "PROBLEM", 422, 439], ["viruses", "PROBLEM", 461, 468], ["other illness", "PROBLEM", 481, 494], ["enteroviruses", "PROBLEM", 501, 514], ["IntroductionIn", "TREATMENT", 515, 529], ["several viruses", "PROBLEM", 540, 555], ["IntroductionViruses", "TREATMENT", 687, 706], ["unlike bacteria", "PROBLEM", 708, 723], ["strict intracellular parasites", "PROBLEM", 729, 759], ["gastroenteritis", "OBSERVATION", 101, 116], ["enteric adenoviruses", "ANATOMY", 150, 170], ["enteric caliciviruses", "OBSERVATION", 194, 215], ["small", "OBSERVATION_MODIFIER", 226, 231], ["round", "OBSERVATION_MODIFIER", 232, 237], ["viruses", "OBSERVATION", 249, 256], ["caliciviruses", "OBSERVATION", 302, 315], ["hepatitis viruses", "OBSERVATION", 378, 395], ["hepatitis", "OBSERVATION", 397, 406], ["enteroviruses", "OBSERVATION", 501, 514], ["several", "OBSERVATION_MODIFIER", 540, 547], ["viruses", "OBSERVATION", 548, 555], ["intestinal tract", "ANATOMY", 594, 610], ["not implicated", "UNCERTAINTY", 620, 634], ["bacteria", "OBSERVATION", 715, 723], ["intracellular parasites", "OBSERVATION", 736, 759]]], ["Therefore, viral contamination of food will not increase during processing, and may actually decrease.", [["viral contamination of food", "PROBLEM", 11, 38], ["viral contamination", "OBSERVATION", 11, 30], ["decrease", "OBSERVATION_MODIFIER", 93, 101]]], ["This implies that viral infection via contaminated food depends on viral stability, amounts of virus shed by an infected individual, method of processing of food or water, dose needed to produce infection, and susceptibility of the host.", [["viral infection", "DISEASE", 18, 33], ["infection", "DISEASE", 195, 204], ["viral infection", "PROBLEM", 18, 33], ["viral stability", "PROBLEM", 67, 82], ["virus", "PROBLEM", 95, 100], ["infection", "PROBLEM", 195, 204], ["viral", "OBSERVATION_MODIFIER", 18, 23], ["infection", "OBSERVATION", 24, 33], ["viral stability", "OBSERVATION_MODIFIER", 67, 82], ["infected", "OBSERVATION", 112, 120], ["infection", "OBSERVATION", 195, 204]]], ["Most food-or waterborne viruses are non-enveloped and are relatively resistant to heat, disinfection and pH changes.", [["waterborne viruses", "PROBLEM", 13, 31], ["disinfection", "TREATMENT", 88, 100], ["pH changes", "PROBLEM", 105, 115]]], ["Problems in the detection of viral contamination of food or water are that\u011d enerally^the contaminated products will look, smell, and taste normal, and that (molecular) diagnostic methods for most of these viruses are not routinely available in food microbiology laboratories.", [["viral contamination of food", "PROBLEM", 29, 56], ["the contaminated products", "TREATMENT", 85, 110], ["smell", "PROBLEM", 122, 127], ["diagnostic methods", "TEST", 168, 186], ["these viruses", "PROBLEM", 199, 212], ["viral contamination", "OBSERVATION", 29, 48]]], ["In this paper, the major viral causes of foodborne infections will be reviewed.", [["foodborne infections", "DISEASE", 41, 61], ["foodborne infections", "PROBLEM", 41, 61], ["foodborne infections", "OBSERVATION", 41, 61]]], ["We have focussed on those viruses that are most commonly transmitted by food, namely NLV and HAV.Cost of illnessThe cost of illness due to viral foodborne infections is not known exactly, but it is likely to be high.", [["HAV", "DISEASE", 93, 96], ["illness", "DISEASE", 105, 112], ["illness", "DISEASE", 124, 131], ["viral foodborne infections", "DISEASE", 139, 165], ["food", "ORGANISM_SUBDIVISION", 72, 76], ["HAV", "ORGANISM", 93, 96], ["NLV", "SPECIES", 85, 88], ["HAV", "SPECIES", 93, 96], ["illness", "PROBLEM", 105, 112], ["illness", "PROBLEM", 124, 131], ["viral foodborne infections", "PROBLEM", 139, 165], ["illness", "OBSERVATION", 105, 112], ["viral", "OBSERVATION_MODIFIER", 139, 144], ["foodborne", "OBSERVATION", 145, 154], ["likely to be", "UNCERTAINTY", 198, 210], ["high", "OBSERVATION", 211, 215]]], ["In the USA, Mead et al. [6] recently estimated that foodborne diseases cause approximately 79 million illnesses, 325 000 hospitalizations, and 5000 deaths each year.", [["foodborne diseases", "DISEASE", 52, 70], ["deaths", "DISEASE", 148, 154]]], ["For just the few foodborne pathogens for which cost estimates have been made, medical charges and lost productivity already cost society US$ 5^6 billion annually in the USA [7] .", [["few", "OBSERVATION_MODIFIER", 13, 16], ["foodborne", "OBSERVATION_MODIFIER", 17, 26], ["pathogens", "OBSERVATION", 27, 36]]], ["The total costs of salmonellosis are estimated to be US$ 1.2^1.5 billion.", [["salmonellosis", "DISEASE", 19, 32], ["salmonellosis", "PROBLEM", 19, 32], ["total", "OBSERVATION_MODIFIER", 4, 9], ["salmonellosis", "OBSERVATION", 19, 32]]], ["Although viral infections until recently were not commonly diagnosed, it is becoming clear from epidemiological studies that caliciviruses alone may be as frequent causes of foodborne illness as Salmonella [6, 8] .", [["viral infections", "DISEASE", 9, 25], ["caliciviruses", "DISEASE", 125, 138], ["foodborne illness", "DISEASE", 174, 191], ["caliciviruses", "CANCER", 125, 138], ["Salmonella", "SPECIES", 195, 205], ["viral infections", "PROBLEM", 9, 25], ["epidemiological studies", "TEST", 96, 119], ["caliciviruses", "PROBLEM", 125, 138], ["foodborne illness", "PROBLEM", 174, 191], ["Salmonella", "PROBLEM", 195, 205], ["viral", "OBSERVATION_MODIFIER", 9, 14], ["infections", "OBSERVATION", 15, 25]]], ["Costs of illness can be high due to their frequent occurrence and high transmissibility [9, 10] .", [["illness", "DISEASE", 9, 16], ["illness", "PROBLEM", 9, 16], ["illness", "OBSERVATION", 9, 16]]], ["In addition, there are studies that suggest that viral enteric infections cause deaths in the elderly, deaths that are largely preventable [8,11^13] .Cost of illnessIn the USA, some 84 000 cases of hepatitis A are reported annually, of which an estimated 5% are foodborne or waterborne [6] .", [["viral enteric infections", "DISEASE", 49, 73], ["deaths", "DISEASE", 80, 86], ["deaths", "DISEASE", 103, 109], ["illness", "DISEASE", 158, 165], ["hepatitis A", "DISEASE", 198, 209], ["hepatitis A", "SPECIES", 198, 209], ["studies", "TEST", 23, 30], ["viral enteric infections", "PROBLEM", 49, 73], ["illness", "PROBLEM", 158, 165], ["hepatitis A", "PROBLEM", 198, 209], ["viral", "OBSERVATION_MODIFIER", 49, 54], ["enteric", "OBSERVATION_MODIFIER", 55, 62], ["infections", "OBSERVATION", 63, 73], ["illness", "OBSERVATION", 158, 165], ["hepatitis", "OBSERVATION", 198, 207]]], ["Common source foodborne hepatitis A outbreaks attract a great deal of public attention and concern, and require considerable public health control efforts.", [["foodborne hepatitis A", "DISEASE", 14, 35], ["hepatitis A", "SPECIES", 24, 35], ["foodborne hepatitis", "OBSERVATION", 14, 33]]], ["The estimated total cost of a single common source outbreak involving 43 persons, associated with an HAVinfected foodhandler, was approximately US$ 800 000 (Centers for Disease Control and Prevention (CDC), unpublished).", [["persons", "ORGANISM", 73, 80], ["persons", "SPECIES", 73, 80], ["Disease Control", "TREATMENT", 169, 184], ["total", "OBSERVATION_MODIFIER", 14, 19]]], ["Outbreaks associated with contaminated food-stu\u00a1s have resulted in nationwide recalls.IntroductionEpidemic and sporadic gastroenteritis is an important public health problem in both developed and developing countries [14, 15] .", [["IntroductionEpidemic", "DISEASE", 86, 106], ["gastroenteritis", "DISEASE", 120, 135], ["IntroductionEpidemic", "TREATMENT", 86, 106], ["sporadic gastroenteritis", "PROBLEM", 111, 135], ["sporadic", "OBSERVATION_MODIFIER", 111, 119], ["gastroenteritis", "OBSERVATION", 120, 135]]], ["In the last 27 years, several viruses have been identi\u00a2ed as etiological agents of viral gastroenteritis in humans [16] .", [["viral gastroenteritis", "DISEASE", 83, 104], ["humans", "ORGANISM", 108, 114], ["humans", "SPECIES", 108, 114], ["humans", "SPECIES", 108, 114], ["several viruses", "PROBLEM", 22, 37], ["viral gastroenteritis", "PROBLEM", 83, 104], ["viruses", "OBSERVATION", 30, 37], ["viral gastroenteritis", "OBSERVATION", 83, 104]]], ["In most studies of food-and waterborne viruses, samples have been screened for viruses by tissue culture isolation techniques or by electron microscopy (EM).", [["samples", "ANATOMY", 48, 55], ["tissue culture", "ANATOMY", 90, 104], ["samples", "CANCER", 48, 55], ["tissue", "TISSUE", 90, 96], ["waterborne viruses", "PROBLEM", 28, 46], ["viruses", "PROBLEM", 79, 86], ["electron microscopy", "TEST", 132, 151]]], ["Some enteric viruses, however, cannot be grown in tissue culture, and EM is rather insensitive with a detection limit of around 10 5^1 0 6 particles per ml of stool suspension.", [["tissue culture", "ANATOMY", 50, 64], ["tissue", "TISSUE", 50, 56], ["stool", "ORGANISM_SUBSTANCE", 159, 164], ["Some enteric viruses", "PROBLEM", 0, 20], ["tissue culture", "TEST", 50, 64], ["enteric", "OBSERVATION_MODIFIER", 5, 12], ["viruses", "OBSERVATION", 13, 20]]], ["Broadly reactive and user-friendly diagnostic tests, such as enzyme-linked immunosorbent assays (ELI-SA), have routinely been used for group A rotavirus and adenovirus in clinical specimens only.", [["specimens", "ANATOMY", 180, 189], ["A rotavirus", "ORGANISM", 141, 152], ["adenovirus", "ORGANISM", 157, 167], ["A rotavirus", "SPECIES", 141, 152], ["adenovirus", "SPECIES", 157, 167], ["diagnostic tests", "TEST", 35, 51], ["enzyme", "TEST", 61, 67], ["immunosorbent assays", "TEST", 75, 95], ["group A rotavirus", "PROBLEM", 135, 152], ["adenovirus", "PROBLEM", 157, 167], ["clinical specimens", "TEST", 171, 189], ["reactive", "OBSERVATION_MODIFIER", 8, 16]]], ["Recently, ELISAbased assays have been developed for detection of astroviruses and NLV [17^19], but the latter lack the broadness that is required for generic detection.", [["ELISAbased assays", "TEST", 10, 27], ["astroviruses", "PROBLEM", 65, 77], ["NLV", "TEST", 82, 85], ["generic detection", "TEST", 150, 167]]], ["No similar assays exist for testing food samples.", [["testing food samples", "TEST", 28, 48]]], ["As a result of these limitations, foodborne viral gastroenteritis is usually not diagnosed.IntroductionIn the absence of virus detection assays, a tentative diagnosis of viral gastroenteritis can be made based on epidemiological criteria described by Kaplan et al. [20] .", [["viral gastroenteritis", "DISEASE", 44, 65], ["viral gastroenteritis", "DISEASE", 170, 191], ["foodborne viral gastroenteritis", "PROBLEM", 34, 65], ["virus detection assays", "TEST", 121, 143], ["viral gastroenteritis", "PROBLEM", 170, 191], ["gastroenteritis", "OBSERVATION", 50, 65], ["viral", "OBSERVATION_MODIFIER", 170, 175], ["gastroenteritis", "OBSERVATION", 176, 191]]], ["Characteristic features are: acute onset after a 24^36-h incubation period, vomiting and/or diarrhea lasting a few days, a high attack rate (average 45%), and a high number of secondary cases [20, 21] .", [["vomiting", "DISEASE", 76, 84], ["diarrhea", "DISEASE", 92, 100], ["acute onset", "PROBLEM", 29, 40], ["vomiting", "PROBLEM", 76, 84], ["diarrhea", "PROBLEM", 92, 100], ["a high attack rate", "PROBLEM", 121, 139], ["acute", "OBSERVATION_MODIFIER", 29, 34], ["diarrhea", "OBSERVATION", 92, 100]]], ["Using this de\u00a2nition, an estimated 32^42% of foodborne enteric infections in the USA are caused by viruses.", [["foodborne enteric infections", "DISEASE", 45, 73], ["this de\u00a2nition", "TREATMENT", 6, 20], ["foodborne enteric infections in the USA", "PROBLEM", 45, 84], ["viruses", "PROBLEM", 99, 106], ["infections", "OBSERVATION", 63, 73], ["viruses", "OBSERVATION", 99, 106]]], ["Outbreaks of gastroenteritis may be caused by rotaviruses, astroviruses, adenoviruses, and the human enteric caliciviruses.", [["gastroenteritis", "DISEASE", 13, 28], ["enteric caliciviruses", "DISEASE", 101, 122], ["rotaviruses", "ORGANISM", 46, 57], ["astroviruses", "GENE_OR_GENE_PRODUCT", 59, 71], ["adenoviruses", "ORGANISM", 73, 85], ["human", "ORGANISM", 95, 100], ["enteric caliciviruses", "ORGANISM", 101, 122], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 95, 100], ["gastroenteritis", "PROBLEM", 13, 28], ["rotaviruses", "PROBLEM", 46, 57], ["astroviruses", "PROBLEM", 59, 71], ["adenoviruses", "PROBLEM", 73, 85], ["the human enteric caliciviruses", "PROBLEM", 91, 122], ["gastroenteritis", "OBSERVATION", 13, 28], ["may be caused", "UNCERTAINTY", 29, 42], ["rotaviruses", "OBSERVATION", 46, 57]]], ["The human caliciviruses are assigned to two genera, which are currently described as 'Norwalk-like viruses' (NLV), also known as small round structured viruses, and 'Sapporo-like viruses' (SLV), also known as typical caliciviruses [22^25] .", [["human", "ORGANISM", 4, 9], ["caliciviruses", "CANCER", 10, 23], ["Norwalk-like viruses", "ORGANISM", 86, 106], ["NLV", "CANCER", 109, 112], ["Sapporo-like viruses", "ORGANISM", 166, 186], ["SLV", "CANCER", 189, 192], ["human", "SPECIES", 4, 9], ["human caliciviruses", "SPECIES", 4, 23], ["NLV", "SPECIES", 109, 112], ["Sapporo-like viruses", "SPECIES", 166, 186], ["SLV", "SPECIES", 189, 192], ["The human caliciviruses", "PROBLEM", 0, 23], ["'Norwalk-like viruses'", "PROBLEM", 85, 107], ["small round structured viruses", "PROBLEM", 129, 159], ["'Sapporo-like viruses'", "PROBLEM", 165, 187], ["human", "ANATOMY", 4, 9], ["caliciviruses", "OBSERVATION", 10, 23], ["small", "OBSERVATION_MODIFIER", 129, 134], ["round", "OBSERVATION_MODIFIER", 135, 140], ["structured viruses", "OBSERVATION", 141, 159], ["typical", "OBSERVATION_MODIFIER", 209, 216], ["caliciviruses", "OBSERVATION", 217, 230]]], ["The NLV cause illness in people of all age groups, whereas the SLV predominantly cause illness in children [26] .IntroductionThe relative importance of the di\u00a1erent viruses as causes of food-and waterborne infections is not exactly known, but clearly NLV are the main cause of viral outbreaks [5, 20, 21, 27] , and their incidence reportedly has been in-IntroductionThe name Aichivirus has been given to (di\u00a1erent) viruses in the calicivirus family and in the picornavirus family.Introductioncreasing in recent years [1, 2, 28] .", [["illness", "DISEASE", 14, 21], ["SLV", "DISEASE", 63, 66], ["illness", "DISEASE", 87, 94], ["food-and waterborne infections", "DISEASE", 186, 216], ["Aichivirus", "CHEMICAL", 375, 385], ["people", "ORGANISM", 25, 31], ["children", "ORGANISM", 98, 106], ["NLV", "GENE_OR_GENE_PRODUCT", 251, 254], ["calicivirus", "ORGANISM", 430, 441], ["people", "SPECIES", 25, 31], ["children", "SPECIES", 98, 106], ["the di\u00a1erent viruses", "PROBLEM", 152, 172], ["waterborne infections", "PROBLEM", 195, 216], ["viral outbreaks", "PROBLEM", 277, 292], ["infections", "OBSERVATION", 206, 216], ["viral outbreaks", "OBSERVATION", 277, 292]]], ["This 'emergence' of NLV as the main foodborne virus most likely is not a true increase in incidence, but rather an increased awareness combined with improved diagnostic assays.", [["NLV", "DISEASE", 20, 23], ["NLV", "CANCER", 20, 23], ["NLV", "SPECIES", 20, 23], ["NLV", "TREATMENT", 20, 23], ["the main foodborne virus", "PROBLEM", 27, 51], ["an increased awareness", "PROBLEM", 112, 134], ["main", "OBSERVATION_MODIFIER", 31, 35], ["foodborne virus", "OBSERVATION", 36, 51], ["increase", "OBSERVATION_MODIFIER", 78, 86], ["increased", "OBSERVATION_MODIFIER", 115, 124]]], ["The remainder of this chapter will focus on NLV, unless otherwise indicated.BackgroundEpidemic non-bacterial gastroenteritis or 'winter vomiting disease' was described as early as 1929 but the numerous attempts to propagate the presumed viral etiologic agent in vitro have met with little success [29] .", [["gastroenteritis", "DISEASE", 109, 124], ["vomiting disease", "DISEASE", 136, 152], ["NLV", "CANCER", 44, 47], ["BackgroundEpidemic non-bacterial gastroenteritis", "PROBLEM", 76, 124], ["'winter vomiting disease'", "PROBLEM", 128, 153], ["non-bacterial", "OBSERVATION_MODIFIER", 95, 108], ["gastroenteritis", "OBSERVATION", 109, 124]]], ["A major breakthrough was the discovery of the Norwalk virus (NV) using immune EM (IEM) in fecal samples collected during an outbreak of gastroenteritis, which occurred in 1968 in an elementary school in Norwalk, OH, USA [30] .", [["fecal samples", "ANATOMY", 90, 103], ["gastroenteritis", "DISEASE", 136, 151], ["Norwalk virus", "ORGANISM", 46, 59], ["fecal samples", "ORGANISM_SUBSTANCE", 90, 103], ["Norwalk virus", "SPECIES", 46, 59], ["NV", "SPECIES", 61, 63], ["A major breakthrough", "PROBLEM", 0, 20], ["the Norwalk virus", "PROBLEM", 42, 59], ["fecal samples", "TEST", 90, 103], ["gastroenteritis", "PROBLEM", 136, 151], ["major", "OBSERVATION_MODIFIER", 2, 7], ["breakthrough", "OBSERVATION", 8, 20], ["fecal", "ANATOMY", 90, 95], ["gastroenteritis", "OBSERVATION", 136, 151]]], ["These viruses were non-enveloped and the particles had a 'fuzzy' amorphous appearance and measured 34^38 nm in diameter.", [["These viruses", "PROBLEM", 0, 13], ["a 'fuzzy' amorphous appearance", "PROBLEM", 55, 85], ["viruses", "OBSERVATION", 6, 13], ["amorphous", "OBSERVATION_MODIFIER", 65, 74], ["34^38 nm", "OBSERVATION_MODIFIER", 99, 107], ["diameter", "OBSERVATION_MODIFIER", 111, 119]]], ["Volunteer studies established NV as an enteric pathogen and, except for the unsuccessful cultivation of the virus, ful\u00a2lled Koch's postulates [31, 32] .", [["NV", "ORGANISM", 30, 32], ["NV", "SPECIES", 30, 32], ["Volunteer studies", "TEST", 0, 17], ["an enteric pathogen", "PROBLEM", 36, 55], ["the virus", "PROBLEM", 104, 113]]], ["Since then, additional studies have been carried out using fecal samples from other outbreaks of gastroenteritis, containing particles which were morphologically indistinguishable from NV [33, 34] .", [["fecal samples", "ANATOMY", 59, 72], ["gastroenteritis", "DISEASE", 97, 112], ["additional studies", "TEST", 12, 30], ["fecal samples", "TEST", 59, 72], ["gastroenteritis", "PROBLEM", 97, 112], ["gastroenteritis", "OBSERVATION", 97, 112]]], ["These viruses have often been named after the geographic setting in which the outbreak occurred, for example, Hawaii virus, Snow Mountain virus, Montgomery county virus, Toronto virus.", [["Hawaii virus", "ORGANISM", 110, 122], ["Snow Mountain virus", "ORGANISM", 124, 143], ["Montgomery county virus", "ORGANISM", 145, 168], ["Toronto virus", "ORGANISM", 170, 183], ["Hawaii virus", "SPECIES", 110, 122], ["Snow Mountain virus", "SPECIES", 124, 143], ["Toronto virus", "SPECIES", 170, 183], ["These viruses", "PROBLEM", 0, 13], ["Hawaii virus", "PROBLEM", 110, 122], ["Snow Mountain virus", "PROBLEM", 124, 143], ["Toronto virus", "TREATMENT", 170, 183], ["viruses", "OBSERVATION", 6, 13]]], ["This practice became a routine procedure and persists to the present day.BackgroundIn 1976, viruses with the typical calicivirus morphology were observed in the stools of infants su\u00a1ering from diarrhea [35, 36] .", [["diarrhea", "DISEASE", 193, 201], ["calicivirus", "ORGANISM", 117, 128], ["stools", "ORGANISM_SUBDIVISION", 161, 167], ["infants", "ORGANISM", 171, 178], ["infants", "SPECIES", 171, 178], ["a routine procedure", "TREATMENT", 21, 40], ["viruses", "PROBLEM", 92, 99], ["the typical calicivirus morphology", "PROBLEM", 105, 139], ["diarrhea", "PROBLEM", 193, 201], ["calicivirus", "OBSERVATION", 117, 128]]], ["Typical calicivirus particles measure 30^34 nm in diameter ; they can be identi\u00a2ed by their characteristic cup-shaped depressions.", [["depressions", "DISEASE", 118, 129], ["calicivirus", "ORGANISM", 8, 19], ["Typical calicivirus particles", "PROBLEM", 0, 29], ["shaped depressions", "PROBLEM", 111, 129], ["calicivirus", "OBSERVATION", 8, 19], ["particles", "OBSERVATION_MODIFIER", 20, 29], ["30^34 nm", "OBSERVATION_MODIFIER", 38, 46], ["diameter", "OBSERVATION_MODIFIER", 50, 58], ["characteristic", "OBSERVATION_MODIFIER", 92, 106], ["cup", "OBSERVATION_MODIFIER", 107, 110], ["shaped", "OBSERVATION_MODIFIER", 111, 117], ["depressions", "OBSERVATION", 118, 129]]], ["Astroviruses may have the \u00a2ve/six-pointed surface star on up to 20% of the particles, which makes it possible to distinguish them from typical caliciviruses [36] .", [["surface", "ANATOMY", 42, 49], ["caliciviruses", "DISEASE", 143, 156], ["Astroviruses", "PROBLEM", 0, 12], ["typical caliciviruses", "PROBLEM", 135, 156], ["caliciviruses", "OBSERVATION", 143, 156]]], ["However, because these viruses were detected as frequently in asymptomatic as in sick children, no clinical signi\u00a2cance could be attached to this \u00a2nding.", [["children", "ORGANISM", 86, 94], ["children", "SPECIES", 86, 94], ["these viruses", "PROBLEM", 17, 30], ["clinical signi\u00a2cance", "PROBLEM", 99, 119], ["viruses", "OBSERVATION", 23, 30]]], ["The \u00a2rst convincing association with disease came from a study of 'winter vomiting disease' which occurred in a school in London in January 1978 [37] , and since then, typical caliciviruses have been linked with cases of mild diarrhea in both infants and children and shown to induce illness in volunteers [38] .The virusesHuman caliciviruses are small, non-enveloped spherical viruses, measuring between 28 and 35 nm in size that contain a single-stranded RNA genome of 7.3^7.6 kb.", [["vomiting disease", "DISEASE", 74, 90], ["caliciviruses", "DISEASE", 176, 189], ["diarrhea", "DISEASE", 226, 234], ["illness", "DISEASE", 284, 291], ["caliciviruses", "CANCER", 176, 189], ["infants", "ORGANISM", 243, 250], ["children", "ORGANISM", 255, 263], ["virusesHuman caliciviruses", "ORGANISM", 316, 342], ["single-stranded RNA genome", "DNA", 441, 467], ["infants", "SPECIES", 243, 250], ["children", "SPECIES", 255, 263], ["virusesHuman caliciviruses", "SPECIES", 316, 342], ["disease", "PROBLEM", 37, 44], ["a study", "TEST", 55, 62], ["vomiting disease'", "PROBLEM", 74, 91], ["mild diarrhea", "PROBLEM", 221, 234], ["The virusesHuman caliciviruses", "TEST", 312, 342], ["small, non-enveloped spherical viruses", "PROBLEM", 347, 385], ["a single-stranded RNA genome", "PROBLEM", 439, 467], ["caliciviruses", "OBSERVATION", 176, 189], ["mild", "OBSERVATION_MODIFIER", 221, 225], ["diarrhea", "OBSERVATION", 226, 234], ["virusesHuman", "ANATOMY", 316, 328], ["caliciviruses", "OBSERVATION", 329, 342], ["small", "OBSERVATION_MODIFIER", 347, 352], ["non-enveloped", "OBSERVATION_MODIFIER", 354, 367], ["spherical viruses", "OBSERVATION", 368, 385], ["35 nm", "OBSERVATION_MODIFIER", 412, 417], ["size", "OBSERVATION_MODIFIER", 421, 425], ["single", "OBSERVATION_MODIFIER", 441, 447], ["stranded", "OBSERVATION_MODIFIER", 448, 456], ["RNA genome", "OBSERVATION", 457, 467]]], ["The genome is of positive polarity, and contains coding information for a set of non-structural proteins, located at the 5P-end of the genome, and one major structural pro-tein at the 3P-end [22] .", [["genome", "CELLULAR_COMPONENT", 135, 141], ["pro-tein", "GENE_OR_GENE_PRODUCT", 168, 176], ["non-structural proteins", "PROTEIN", 81, 104], ["5P-end", "PROTEIN", 121, 127], ["major structural pro-tein", "PROTEIN", 151, 176], ["3P", "PROTEIN", 184, 186], ["non-structural proteins", "PROBLEM", 81, 104], ["positive polarity", "OBSERVATION_MODIFIER", 17, 34]]], ["The distinguishing feature between the genome organization of NLV and SLV is the arrangement of the open reading frames (ORFs).", [["NLV", "CANCER", 62, 65], ["SLV", "CANCER", 70, 73], ["NLV", "DNA", 62, 65], ["SLV", "DNA", 70, 73], ["open reading frames", "DNA", 100, 119], ["ORFs", "DNA", 121, 125], ["genome organization", "OBSERVATION", 39, 58]]], ["In both genera, ORF1 encodes a large polyprotein (1789 amino acids for NV) with conserved regions of amino acid similarity with the picornavirus 2C helicase, 3C protease, and 3D polymerase [22, 24] .", [["amino acids", "CHEMICAL", 55, 66], ["amino acid", "CHEMICAL", 101, 111], ["amino acids", "CHEMICAL", 55, 66], ["amino acid", "CHEMICAL", 101, 111], ["ORF1", "GENE_OR_GENE_PRODUCT", 16, 20], ["amino acids", "AMINO_ACID", 55, 66], ["amino acid", "AMINO_ACID", 101, 111], ["picornavirus 2C", "GENE_OR_GENE_PRODUCT", 132, 147], ["3C protease", "GENE_OR_GENE_PRODUCT", 158, 169], ["ORF1", "DNA", 16, 20], ["NV", "PROTEIN", 71, 73], ["picornavirus 2C helicase, 3C protease", "PROTEIN", 132, 169], ["3D polymerase", "PROTEIN", 175, 188], ["a large polyprotein (1789 amino acids", "TREATMENT", 29, 66], ["NV", "PROBLEM", 71, 73], ["amino acid similarity", "PROBLEM", 101, 122], ["the picornavirus 2C helicase", "TREATMENT", 128, 156], ["3C protease", "TREATMENT", 158, 169], ["3D polymerase", "TEST", 175, 188], ["amino acid", "OBSERVATION", 101, 111]]], ["For NLV, the ORF2 region encodes the single major capsid protein (w56 kDa) [24] .", [["NLV", "CANCER", 4, 7], ["NLV", "DNA", 4, 7], ["ORF2 region", "DNA", 13, 24], ["capsid protein", "PROTEIN", 50, 64], ["w56 kDa", "PROTEIN", 66, 73], ["NLV", "PROBLEM", 4, 7]]], ["A third ORF encodes a minor structural protein with a predicted molecular mass of 22.5 kDa [39] .", [["ORF", "DNA", 8, 11], ["minor structural protein", "PROTEIN", 22, 46], ["A third ORF", "PROBLEM", 0, 11], ["a minor structural protein", "PROBLEM", 20, 46], ["a predicted molecular mass", "PROBLEM", 52, 78], ["mass", "OBSERVATION", 74, 78], ["22.5 kDa", "OBSERVATION_MODIFIER", 82, 90]]], ["In SLV, the region encoding the capsid protein (60 kDa for the prototype of this group, Manchester virus) is found in the same reading frame as ORF1, and is contiguous with the non-structural proteins.", [["SLV", "CANCER", 3, 6], ["Manchester virus", "ORGANISM", 88, 104], ["ORF1", "GENE_OR_GENE_PRODUCT", 144, 148], ["SLV", "PROTEIN", 3, 6], ["capsid protein", "PROTEIN", 32, 46], ["60 kDa", "PROTEIN", 48, 54], ["reading frame", "DNA", 127, 140], ["ORF1", "DNA", 144, 148], ["non-structural proteins", "PROTEIN", 177, 200], ["Manchester virus", "SPECIES", 88, 104], ["the capsid protein", "TEST", 28, 46], ["the non-structural proteins", "PROBLEM", 173, 200], ["region", "ANATOMY_MODIFIER", 12, 18], ["non-structural proteins", "OBSERVATION", 177, 200]]], ["Together, the non-structural genes and the major capsid gene form one long polyprotein, which occupies over 90% of the total genome [25] .", [["non-structural genes", "DNA", 14, 34], ["major capsid gene", "DNA", 43, 60], ["long polyprotein", "PROBLEM", 70, 86], ["non-structural genes", "OBSERVATION", 14, 34]]], ["Similar to NLV, SLV possess a small ORF at the 3P-end of the genome encoding a protein of 17.5 kDa.Clinical symptomsFollowing a 1^3-day incubation period, infected persons may develop (low-grade) fever and vomiting, diarrhea, and headache as prominent symptoms.", [["fever", "DISEASE", 196, 201], ["vomiting", "DISEASE", 206, 214], ["diarrhea", "DISEASE", 216, 224], ["headache", "DISEASE", 230, 238], ["NLV", "GENE_OR_GENE_PRODUCT", 11, 14], ["SLV", "GENE_OR_GENE_PRODUCT", 16, 19], ["persons", "ORGANISM", 164, 171], ["NLV", "DNA", 11, 14], ["SLV", "DNA", 16, 19], ["ORF", "DNA", 36, 39], ["3P-end", "DNA", 47, 53], ["17.5 kDa", "PROTEIN", 90, 98], ["persons", "SPECIES", 164, 171], ["NLV", "SPECIES", 11, 14], ["a small ORF", "PROBLEM", 28, 39], ["Clinical symptoms", "PROBLEM", 99, 116], ["low-grade)", "PROBLEM", 185, 195], ["fever", "PROBLEM", 196, 201], ["vomiting", "PROBLEM", 206, 214], ["diarrhea", "PROBLEM", 216, 224], ["headache", "PROBLEM", 230, 238], ["prominent symptoms", "PROBLEM", 242, 260], ["small", "OBSERVATION_MODIFIER", 30, 35], ["ORF", "OBSERVATION", 36, 39]]], ["The illness generally is considered mild and self-limiting, with symptoms lasting 2^3 days [20, 26] .", [["illness", "DISEASE", 4, 11], ["The illness", "PROBLEM", 0, 11], ["symptoms", "PROBLEM", 65, 73], ["illness", "OBSERVATION", 4, 11], ["mild", "OBSERVATION_MODIFIER", 36, 40]]], ["Data from a recently completed community-based cohort study in The Netherlands were surprising in that 20% of NLV-infected persons reported symptoms for more than 2 weeks, suggesting that NLV infections may be less innocuous (Rockx et al., in preparation) .", [["NLV-infected", "DISEASE", 110, 122], ["infections", "DISEASE", 192, 202], ["persons", "ORGANISM", 123, 130], ["persons", "SPECIES", 123, 130], ["NLV", "SPECIES", 188, 191], ["cohort study", "TEST", 47, 59], ["symptoms", "PROBLEM", 140, 148], ["NLV infections", "PROBLEM", 188, 202], ["infections", "OBSERVATION", 192, 202]]], ["In adults, projectile vomiting occurs frequently.", [["projectile vomiting", "DISEASE", 11, 30], ["projectile vomiting", "PROBLEM", 11, 30]]], ["Sometimes parenteral \u00a3uid therapy or even hospitalization is required, with up to 12% of cases hospitalized in a recent outbreak in military recruits [27, 33, 40, 41] .", [["\u00a3uid", "CHEMICAL", 21, 25], ["parenteral \u00a3uid therapy", "TREATMENT", 10, 33]]], ["Deaths associated with NLV outbreaks have been reported, but the etiologic association needs to be con\u00a2rmed [8, 12] .", [["NLV outbreaks", "PROBLEM", 23, 36]]], ["The average attack rate is high (typically 45% or more) [10] .", [["The average attack rate", "TEST", 0, 23], ["high", "OBSERVATION_MODIFIER", 27, 31]]], ["Virus is shed via stools and vomit, starting during the incubation period, and lasting up to 10 days, and possibly longer [20, 26, 42, 43] .", [["stools", "ANATOMY", 18, 24], ["Virus", "ORGANISM", 0, 5], ["stools", "ORGANISM_SUBSTANCE", 18, 24], ["Virus", "PROBLEM", 0, 5], ["vomit", "PROBLEM", 29, 34], ["stools", "OBSERVATION", 18, 24]]], ["NLV infections are highly contagious, resulting in a high rate of transmission to contacts.", [["infections", "DISEASE", 4, 14], ["NLV", "SPECIES", 0, 3], ["NLV infections", "PROBLEM", 0, 14], ["infections", "OBSERVATION", 4, 14], ["highly", "OBSERVATION_MODIFIER", 19, 25], ["contagious", "OBSERVATION_MODIFIER", 26, 36]]], ["Mixtures of symptoms may occur, since contaminated foods may contain multiple agents [44] .PathogenesisLittle is known about the mechanisms by which NLV cause diarrhea.", [["diarrhea", "DISEASE", 159, 167], ["NLV", "GENE_OR_GENE_PRODUCT", 149, 152], ["symptoms", "PROBLEM", 12, 20], ["diarrhea", "PROBLEM", 159, 167]]], ["In duodenal biopsies taken from infected volunteers, lesions were seen in the intestinal epithelium at 1 day post infection with the Norwalk virus or Hawaii virus as inoculum.", [["duodenal biopsies", "ANATOMY", 3, 20], ["lesions", "ANATOMY", 53, 60], ["intestinal epithelium", "ANATOMY", 78, 99], ["infection", "DISEASE", 114, 123], ["duodenal biopsies", "MULTI-TISSUE_STRUCTURE", 3, 20], ["volunteers", "ORGANISM", 41, 51], ["lesions", "PATHOLOGICAL_FORMATION", 53, 60], ["intestinal epithelium", "TISSUE", 78, 99], ["Norwalk virus", "ORGANISM", 133, 146], ["Hawaii virus", "ORGANISM", 150, 162], ["Norwalk virus", "SPECIES", 133, 146], ["Hawaii virus", "SPECIES", 150, 162], ["duodenal biopsies", "TEST", 3, 20], ["infected volunteers", "PROBLEM", 32, 51], ["lesions", "PROBLEM", 53, 60], ["infection", "PROBLEM", 114, 123], ["the Norwalk virus", "PROBLEM", 129, 146], ["Hawaii virus as inoculum", "PROBLEM", 150, 174], ["duodenal", "ANATOMY", 3, 11], ["biopsies", "OBSERVATION", 12, 20], ["infected", "OBSERVATION_MODIFIER", 32, 40], ["lesions", "OBSERVATION", 53, 60], ["intestinal epithelium", "ANATOMY", 78, 99], ["infection", "OBSERVATION", 114, 123], ["Norwalk virus", "OBSERVATION", 133, 146]]], ["The changes were villous broadening, abnormal epithelial cells, loss of and an in\u00a3ammatory response in the lamina propria with in\u00a2ltration of polymorphonuclear leukocytes and lymphocytes.", [["villous", "ANATOMY", 17, 24], ["epithelial cells", "ANATOMY", 46, 62], ["lamina propria", "ANATOMY", 107, 121], ["polymorphonuclear leukocytes", "ANATOMY", 142, 170], ["lymphocytes", "ANATOMY", 175, 186], ["villous", "TISSUE", 17, 24], ["epithelial cells", "CELL", 46, 62], ["lamina propria", "TISSUE", 107, 121], ["polymorphonuclear leukocytes", "CELL", 142, 170], ["lymphocytes", "CELL", 175, 186], ["abnormal epithelial cells", "CELL_TYPE", 37, 62], ["polymorphonuclear leukocytes", "CELL_TYPE", 142, 170], ["lymphocytes", "CELL_TYPE", 175, 186], ["villous broadening", "PROBLEM", 17, 35], ["abnormal epithelial cells", "PROBLEM", 37, 62], ["an in\u00a3ammatory response in the lamina propria", "PROBLEM", 76, 121], ["polymorphonuclear leukocytes", "PROBLEM", 142, 170], ["lymphocytes", "PROBLEM", 175, 186], ["villous", "OBSERVATION_MODIFIER", 17, 24], ["broadening", "OBSERVATION_MODIFIER", 25, 35], ["abnormal", "OBSERVATION_MODIFIER", 37, 45], ["epithelial cells", "OBSERVATION", 46, 62], ["loss", "OBSERVATION_MODIFIER", 64, 68], ["in\u00a3ammatory", "OBSERVATION_MODIFIER", 79, 90], ["response", "OBSERVATION_MODIFIER", 91, 99], ["lamina propria", "ANATOMY", 107, 121], ["polymorphonuclear leukocytes", "OBSERVATION", 142, 170], ["lymphocytes", "ANATOMY", 175, 186]]], ["At 5^6 days after ingestion villous shortening and crypt hypertrophy were observed.", [["villous", "ANATOMY", 28, 35], ["crypt", "ANATOMY", 51, 56], ["hypertrophy", "DISEASE", 57, 68], ["villous", "MULTI-TISSUE_STRUCTURE", 28, 35], ["villous shortening", "PROBLEM", 28, 46], ["crypt hypertrophy", "PROBLEM", 51, 68], ["villous shortening", "OBSERVATION", 28, 46], ["crypt hypertrophy", "OBSERVATION", 51, 68]]], ["D-Xylose absorption was signi\u00a2cantly reduced throughout this period [32, 45] .", [["D-Xylose", "CHEMICAL", 0, 8], ["D-Xylose", "CHEMICAL", 0, 8], ["D-Xylose", "SIMPLE_CHEMICAL", 0, 8], ["Xylose absorption", "TREATMENT", 2, 19]]], ["The observed in\u00a3ammatory response in the lamina propria was similar to the damage that has been observed following rotavirus infections, where pro-in\u00a3ammatory cytokines and chemokines are thought to trigger this process [46] .", [["lamina propria", "ANATOMY", 41, 55], ["rotavirus infections", "DISEASE", 115, 135], ["lamina propria", "TISSUE", 41, 55], ["rotavirus", "ORGANISM", 115, 124], ["pro-in\u00a3ammatory cytokines", "PROTEIN", 143, 168], ["chemokines", "PROTEIN", 173, 183], ["rotavirus", "SPECIES", 115, 124], ["the damage", "PROBLEM", 71, 81], ["rotavirus infections", "PROBLEM", 115, 135], ["pro-in\u00a3ammatory cytokines", "TREATMENT", 143, 168], ["chemokines", "TREATMENT", 173, 183], ["in\u00a3ammatory", "OBSERVATION_MODIFIER", 13, 24], ["response", "OBSERVATION_MODIFIER", 25, 33], ["lamina propria", "ANATOMY", 41, 55], ["damage", "OBSERVATION", 75, 81], ["rotavirus", "OBSERVATION_MODIFIER", 115, 124], ["infections", "OBSERVATION", 125, 135]]], ["There are no known systemic e\u00a1ects.Diagnosis in humansDespite numerous attempts by several groups of investigators, NLV have never been isolated in cell or tissue culture, and diagnosis has been made historically by visualization of virus particles by EM [30, 47] .", [["cell", "ANATOMY", 148, 152], ["tissue culture", "ANATOMY", 156, 170], ["humans", "ORGANISM", 48, 54], ["NLV", "CANCER", 116, 119], ["cell", "CELL", 148, 152], ["tissue", "TISSUE", 156, 162], ["humans", "SPECIES", 48, 54], ["humans", "SPECIES", 48, 54], ["known systemic e\u00a1ects", "PROBLEM", 13, 34], ["tissue culture", "TEST", 156, 170], ["no known", "UNCERTAINTY", 10, 18], ["systemic", "OBSERVATION_MODIFIER", 19, 27], ["e\u00a1ects", "OBSERVATION", 28, 34]]], ["However, EM is a relatively insensitive technique, requiring the presence of a minimum of around 10 5^1 0 6 particles per ml of stool sample, and^unlike some other enteric viruses^NLV are not shed to very high maximum titers.", [["stool sample", "ANATOMY", 128, 140], ["NLV", "SIMPLE_CHEMICAL", 180, 183], ["NLV", "SPECIES", 180, 183], ["stool sample", "TEST", 128, 140], ["some other enteric viruses", "PROBLEM", 153, 179], ["enteric", "ANATOMY", 164, 171], ["viruses", "OBSERVATION", 172, 179]]], ["This may not be a problem in outbreak investigations, when similar results may be obtained when stool samples have been collected promptly [48] .", [["stool samples", "ANATOMY", 96, 109], ["stool samples", "ORGANISM_SUBSTANCE", 96, 109], ["outbreak investigations", "TEST", 29, 52], ["stool samples", "TEST", 96, 109], ["may not be", "UNCERTAINTY", 5, 15]]], ["For community-based studies, however, this was an impediment until the complete genome of the NLV prototype, the Norwalk virus, was sequenced from cDNA clones derived from RNA that had been extracted from a bulk stool specimen [23, 24] .", [["specimen", "ANATOMY", 218, 226], ["NLV", "GENE_OR_GENE_PRODUCT", 94, 97], ["Norwalk virus", "ORGANISM", 113, 126], ["cDNA clones", "CELL", 147, 158], ["NLV prototype", "DNA", 94, 107], ["cDNA clones", "DNA", 147, 158], ["Norwalk virus", "SPECIES", 113, 126], ["community-based studies", "TEST", 4, 27], ["the Norwalk virus", "PROBLEM", 109, 126], ["cDNA clones", "PROBLEM", 147, 158], ["a bulk stool specimen", "TEST", 205, 226]]], ["From early work with IEM, and later sequence analysis of genomes of di\u00a1erent NLV strains, it became evident that the NLV are in fact an antigenically and genetically diverse group of viruses [49^53] .", [["NLV", "CANCER", 117, 120], ["di\u00a1erent NLV strains", "PROBLEM", 68, 88]]], ["At present, genome-based detection methods are available, in which fragments of the viral RNA are ampli\u00a2ed directly from stool samples by reverse-transcriptase polymerase chain reaction (RT-PCR) ( [54, 55] , reviewed in [47] ).", [["stool samples", "ANATOMY", 121, 134], ["stool samples", "ORGANISM_SUBSTANCE", 121, 134], ["viral RNA", "RNA", 84, 93], ["the viral RNA", "PROBLEM", 80, 93], ["stool samples", "TEST", 121, 134], ["viral RNA", "OBSERVATION", 84, 93]]], ["Initial studies using these methods to detect viral RNA in outbreak specimens con\u00a2rmed the unusual level of divergence, even when a highly conserved region of the viral genome was selected as a target for the RT-PCR [51,56^58] .", [["specimens", "ANATOMY", 68, 77], ["viral RNA", "RNA", 46, 55], ["viral genome", "DNA", 163, 175], ["Initial studies", "TEST", 0, 15], ["these methods", "TEST", 22, 35], ["viral RNA in outbreak specimens", "PROBLEM", 46, 77], ["the viral genome", "PROBLEM", 159, 175], ["the RT-PCR", "TEST", 205, 215], ["viral genome", "OBSERVATION", 163, 175]]], ["Since then, second generation assays have been developed, which have been optimized for detection of a broad range of NLV, by targeting conserved motifs in the non-structural protein genes [9, 57, 59, 60] .", [["NLV", "CANCER", 118, 121], ["non-structural protein genes", "DNA", 160, 188], ["second generation assays", "TEST", 12, 36], ["a broad range of NLV", "PROBLEM", 101, 121]]], ["Following detection of NLV by RT-PCR, the PCR products can be characterized further by sequencing (described in Section 2.9).Diagnosis in humansAlthough NLV cannot be grown in cell culture, e\u00a1orts have been made to develop antigen-based detection methods.", [["cell culture", "ANATOMY", 176, 188], ["NLV", "CANCER", 23, 26], ["humans", "ORGANISM", 138, 144], ["NLV", "CANCER", 153, 156], ["cell", "CELL", 176, 180], ["NLV", "DNA", 23, 26], ["PCR products", "DNA", 42, 54], ["humans", "SPECIES", 138, 144], ["NLV", "SPECIES", 23, 26], ["humans", "SPECIES", 138, 144], ["NLV", "TEST", 23, 26], ["RT-PCR", "TEST", 30, 36], ["the PCR products", "TEST", 38, 54], ["NLV", "PROBLEM", 153, 156], ["cell culture", "TEST", 176, 188], ["antigen", "TEST", 223, 230]]], ["For this purpose, recombinant NLV capsids have been developed for use as control antigens [18,19,60^65] .", [["NLV capsids", "ORGANISM", 30, 41], ["NLV", "SPECIES", 30, 33], ["recombinant NLV capsids", "TREATMENT", 18, 41]]], ["However, the current problem is that (hyper)immune responses are predominantly type-speci\u00a2c, and that assays based on these reagents are narrow in their applicability [19, 60, 65] .", [["hyper)immune responses", "PROBLEM", 38, 60], ["assays", "TEST", 102, 108], ["these reagents", "TEST", 118, 132], ["narrow", "OBSERVATION_MODIFIER", 137, 143]]], ["NLV are a diverse group of viruses, and can be divided into two, possibly three broad genogroups, based on antigenic and genetic criteria (see Section 2.9).", [["NLV", "GENE_OR_GENE_PRODUCT", 0, 3], ["NLV", "SPECIES", 0, 3], ["a diverse group of viruses", "PROBLEM", 8, 34], ["diverse", "OBSERVATION_MODIFIER", 10, 17], ["viruses", "OBSERVATION", 27, 34]]], ["Recently, a NV-speci\u00a2c monoclonal antibody was characterized with reactivity to strains from four out of \u00a2ve other variants within genogroup I NLV that were tested [66] .", [["NV-speci\u00a2c monoclonal antibody", "PROTEIN", 12, 42], ["genogroup I NLV", "PROTEIN", 131, 146], ["genogroup I NLV", "SPECIES", 131, 146], ["a NV-speci\u00a2c monoclonal antibody", "TEST", 10, 42], ["strains", "PROBLEM", 80, 87]]], ["Similarly, for genogroup II NLV, a common epitope has been identi\u00a2ed [67] .", [["genogroup II NLV", "PROTEIN", 15, 31], ["genogroup II NLV", "SPECIES", 15, 31]]], ["When tested in an ELISA, this monoclonal appeared to detect GGI viruses as well, suggesting that it detects a genus-speci\u00a2c epitope.", [["speci\u00a2c epitope", "PROTEIN", 116, 131], ["an ELISA", "TEST", 15, 23], ["GGI viruses", "PROBLEM", 60, 71], ["a genus-speci\u00a2c epitope", "PROBLEM", 108, 131]]], ["These monoclonal antibodies o\u00a1er the \u00a2rst hope for development of a more broadly reactive detection assay.", [["monoclonal antibodies", "PROTEIN", 6, 27], ["These monoclonal antibodies", "TEST", 0, 27], ["a more broadly reactive detection assay", "PROBLEM", 66, 105], ["reactive", "OBSERVATION", 81, 89]]], ["For a complete overview of NLV diagnostics see Atmar and Estes [47] .EpidemiologyFollowing the development of molecular detection methods, it has become clear that NLV infections are among the most important causes of gastroenteritis in adults and often occur as outbreaks which may be foodborne.", [["NLV infections", "DISEASE", 164, 178], ["gastroenteritis", "DISEASE", 218, 233], ["NLV", "ORGANISM", 164, 167], ["NLV", "SPECIES", 164, 167], ["molecular detection methods", "TEST", 110, 137], ["NLV infections", "PROBLEM", 164, 178], ["gastroenteritis", "PROBLEM", 218, 233], ["infections", "OBSERVATION", 168, 178], ["gastroenteritis", "OBSERVATION", 218, 233], ["may be", "UNCERTAINTY", 279, 285], ["foodborne", "OBSERVATION", 286, 295]]], ["However, an important message is also that the estimate of the proportion of foodborne NLV outbreaks varies greatly from one country to the other, due to di\u00a1erences in case de\u00a2nition, surveillance systems, and methods used.", [["NLV", "DISEASE", 87, 90], ["NLV", "SPECIES", 87, 90], ["surveillance systems", "TEST", 184, 204]]], ["In The Netherlands, approximately 80% of outbreaks of gastroenteritis that were reported in the past seven years to RIVM through health services NLV [9, 10, 68, 69] .", [["gastroenteritis", "DISEASE", 54, 69], ["gastroenteritis", "PROBLEM", 54, 69], ["gastroenteritis", "OBSERVATION", 54, 69]]], ["More than half of these outbreaks occurred in nursing homes [10, 68] .", [["outbreaks", "OBSERVATION", 24, 33]]], ["The proportion of foodborne outbreaks was 14% in 1994^2000, with 83% of these attributed to NLV.", [["NLV", "DISEASE", 92, 95], ["foodborne", "OBSERVATION_MODIFIER", 18, 27]]], ["In a survey of all outbreaks of infectious intestinal disease in England and Wales between 1992 and 1994, 27% outbreaks were caused by NLV (for comparison: 32% of the outbreaks were due to Salmonella spp.) [8] .", [["intestinal", "ANATOMY", 43, 53], ["infectious intestinal disease", "DISEASE", 32, 61], ["NLV", "CHEMICAL", 135, 138], ["intestinal", "ORGAN", 43, 53], ["Salmonella spp.", "ORGANISM", 189, 204], ["Salmonella spp.", "SPECIES", 189, 204], ["NLV", "SPECIES", 135, 138], ["Salmonella spp.", "SPECIES", 189, 204], ["infectious intestinal disease", "PROBLEM", 32, 61], ["the outbreaks", "PROBLEM", 163, 176], ["all", "OBSERVATION_MODIFIER", 15, 18], ["outbreaks", "OBSERVATION_MODIFIER", 19, 28], ["infectious", "OBSERVATION_MODIFIER", 32, 42], ["intestinal disease", "OBSERVATION", 43, 61]]], ["NLV were the cause of 6% of foodborne outbreaks.", [["NLV", "DISEASE", 0, 3], ["NLV", "GENE_OR_GENE_PRODUCT", 0, 3], ["NLV", "SPECIES", 0, 3], ["foodborne outbreaks", "PROBLEM", 28, 47]]], ["Since outbreak specimens were mostly examined by EM, the actual number of NLV outbreaks may be higher [8, 19] .", [["specimens", "ANATOMY", 15, 24], ["NLV", "DISEASE", 74, 77], ["specimens", "CANCER", 15, 24], ["NLV", "SPECIES", 74, 77], ["outbreak specimens", "TEST", 6, 24], ["NLV outbreaks", "PROBLEM", 74, 87]]], ["In the US, 86 of 90 (96%) outbreaks of non-bacterial acute gastroenteritis reported to CDC between January 1997 and June 1998 were caused by NLV infection.", [["gastroenteritis", "DISEASE", 59, 74], ["NLV infection", "DISEASE", 141, 154], ["NLV", "SPECIES", 141, 144], ["non-bacterial acute gastroenteritis", "PROBLEM", 39, 74], ["NLV infection", "PROBLEM", 141, 154], ["non-bacterial", "OBSERVATION_MODIFIER", 39, 52], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["gastroenteritis", "OBSERVATION", 59, 74], ["NLV", "OBSERVATION_MODIFIER", 141, 144], ["infection", "OBSERVATION", 145, 154]]], ["Several large outbreaks with a serious impact on troops on military aircraft carriers have been described [70] .", [["Several large outbreaks", "PROBLEM", 0, 23], ["large", "OBSERVATION_MODIFIER", 8, 13], ["outbreaks", "OBSERVATION", 14, 23]]], ["Nosocomial outbreaks are common [10, 71, 72] .", [["Nosocomial outbreaks", "PROBLEM", 0, 20]]], ["In Finland, hospital outbreaks (mostly on geriatric wards) are almost exclusively caused by NLV, but there is serious underreporting.", [["NLV", "SPECIES", 92, 95]]], ["Also in Finland, 56% of the epidemics reported as foodborne, from which stool samples (and foodstu\u00a1s, in some instances) were submitted for virological screening, were NLVpositive [73] .", [["stool samples", "ANATOMY", 72, 85], ["the epidemics", "PROBLEM", 24, 37], ["stool samples", "TEST", 72, 85], ["virological screening", "TEST", 140, 161]]], ["Of water epidemics 12/15 have been NLVpositive.", [["water epidemics", "PROBLEM", 3, 18]]], ["Since 1998 15 berry-related epidemics have occurred, which has resulted in a ban on the use of unheated berries in all catering and other large-scale kitchens [74] .", [["berries", "ANATOMY", 104, 111], ["berries", "ORGANISM_SUBDIVISION", 104, 111], ["unheated berries", "TREATMENT", 95, 111]]], ["Since then, some berry-associated outbreaks have occurred, in cases where the ban was ignored.", [["berry", "OBSERVATION_MODIFIER", 17, 22]]], ["Most of these outbreaks were linked to imported berries.", [["berries", "ANATOMY", 48, 55], ["berries", "ORGANISM_SUBDIVISION", 48, 55], ["outbreaks", "OBSERVATION", 14, 23]]], ["From molecular typing, based on a 125-bp fragment of a highly conserved region of the polymerase gene, it was shown that many di\u00a1erent lineages of NLV could be found, which illustrates that contamination of these foods was not linked to a single common source (Fig. 1 ).EpidemiologyIn addition to outbreaks, recent publications suggest that caliciviruses are among the most common causes of sporadic gastroenteritis [3, 4, 68, 75, 76] .", [["caliciviruses", "DISEASE", 341, 354], ["gastroenteritis", "DISEASE", 400, 415], ["NLV", "GENE_OR_GENE_PRODUCT", 147, 150], ["caliciviruses", "CANCER", 341, 354], ["125-bp fragment", "DNA", 34, 49], ["polymerase gene", "DNA", 86, 101], ["molecular typing", "TEST", 5, 21], ["a 125-bp fragment", "TREATMENT", 32, 49], ["many di\u00a1erent lineages of NLV", "PROBLEM", 121, 150], ["EpidemiologyIn", "TREATMENT", 270, 284], ["caliciviruses", "PROBLEM", 341, 354], ["sporadic gastroenteritis", "PROBLEM", 391, 415], ["caliciviruses", "OBSERVATION", 341, 354], ["sporadic", "OBSERVATION_MODIFIER", 391, 399], ["gastroenteritis", "OBSERVATION", 400, 415]]], ["In The Netherlands, a set of population-based case^control studies showed that overall^the incidence of gastroenteritis was quite high, at 280 cases/1000 persons per year for community cases of gastroenteritis, of which 8 cases/1000 persons per year seek treatment by a physician (1:35) [3, 77, 78] .", [["gastroenteritis", "DISEASE", 104, 119], ["gastroenteritis", "DISEASE", 194, 209], ["persons", "SPECIES", 233, 240], ["gastroenteritis", "PROBLEM", 104, 119], ["gastroenteritis", "PROBLEM", 194, 209], ["gastroenteritis", "OBSERVATION", 104, 119], ["gastroenteritis", "OBSERVATION", 194, 209]]], ["Five percent of the patients who visit their physician for gastroenteritis were infected with NLV (compared with 4% for Salmonella), as well as 17% of persons in a sentinel population who developed diarrhea during the course of a 1-year cohort study [3, 68, 79, 80] .", [["gastroenteritis", "DISEASE", 59, 74], ["NLV", "DISEASE", 94, 97], ["diarrhea", "DISEASE", 198, 206], ["patients", "ORGANISM", 20, 28], ["persons", "ORGANISM", 151, 158], ["patients", "SPECIES", 20, 28], ["persons", "SPECIES", 151, 158], ["NLV", "SPECIES", 94, 97], ["Salmonella", "SPECIES", 120, 130], ["gastroenteritis", "PROBLEM", 59, 74], ["NLV", "TREATMENT", 94, 97], ["Salmonella", "PROBLEM", 120, 130], ["diarrhea", "PROBLEM", 198, 206], ["diarrhea", "OBSERVATION", 198, 206]]], ["People from all age groups were affected, with a slightly higher incidence in very young chil-dren.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["Similar studies in the UK suggested a slightly lower incidence of community cases of gastroenteritis (190 cases/ 1000 persons per year) but with a higher rate of referral to the physician [4] .", [["gastroenteritis", "DISEASE", 85, 100], ["UK", "GENE_OR_GENE_PRODUCT", 23, 25], ["Similar studies", "TEST", 0, 15], ["gastroenteritis", "PROBLEM", 85, 100], ["slightly", "OBSERVATION_MODIFIER", 38, 46], ["lower incidence", "OBSERVATION_MODIFIER", 47, 62], ["gastroenteritis", "OBSERVATION", 85, 100]]], ["Again, NLV were surprisingly common causes of illness in people of all age groups.", [["illness", "DISEASE", 46, 53], ["people", "ORGANISM", 57, 63], ["people", "SPECIES", 57, 63], ["illness", "PROBLEM", 46, 53]]], ["The NLV are the second most common cause of gastroenteritis in young children [3, 75, 81, 82] .", [["gastroenteritis", "DISEASE", 44, 59], ["NLV", "CANCER", 4, 7], ["children", "ORGANISM", 69, 77], ["children", "SPECIES", 69, 77], ["gastroenteritis", "PROBLEM", 44, 59], ["gastroenteritis", "OBSERVATION", 44, 59]]], ["The course of illness appears to be somewhat milder than rotavirus gastroenteritis [75] .", [["illness", "DISEASE", 14, 21], ["rotavirus gastroenteritis", "DISEASE", 57, 82], ["illness", "PROBLEM", 14, 21], ["rotavirus gastroenteritis", "PROBLEM", 57, 82]]], ["This may explain the lower percentage of hospitalized children with NLV that has been reported [83, 84] .", [["NLV", "DISEASE", 68, 71], ["children", "ORGANISM", 54, 62], ["children", "SPECIES", 54, 62], ["lower", "OBSERVATION_MODIFIER", 21, 26], ["percentage", "OBSERVATION_MODIFIER", 27, 37]]], ["Asymptomatic infections are common [3, 82] .Risk groupsOutbreaks of NLV gastroenteritis (not only foodborne) are common in institutions such as nursing homes and hospitals.", [["infections", "DISEASE", 13, 23], ["gastroenteritis", "DISEASE", 72, 87], ["Asymptomatic infections", "PROBLEM", 0, 23], ["NLV gastroenteritis", "PROBLEM", 68, 87], ["infections", "OBSERVATION", 13, 23], ["NLV gastroenteritis", "OBSERVATION", 68, 87]]], ["The attack rates typically are high (40^50% on average, but up to 100%) in both residents and personnel of such institutions, which in turn leads to major under-sta\u2044ng problems during outbreaks [10, 85] .", [["The attack rates", "TEST", 0, 16], ["high", "OBSERVATION_MODIFIER", 31, 35]]], ["Sporadic cases of viral gastroenteritis also occur frequently in these settings.", [["viral gastroenteritis", "DISEASE", 18, 39], ["viral gastroenteritis", "PROBLEM", 18, 39], ["viral gastroenteritis", "OBSERVATION", 18, 39]]], ["The risk factors for these infections are currently under investigation in the UK and in The Netherlands.", [["infections", "DISEASE", 27, 37], ["The risk factors", "PROBLEM", 0, 16], ["these infections", "PROBLEM", 21, 37], ["infections", "OBSERVATION", 27, 37]]], ["According to Gerba et al. [86] the groups of individuals who would be at the greatest risk of serious illness and mortality from water-and foodborne enteric microorganisms include young children, the elderly, pregnant women, and the immunocompromised.", [["illness", "DISEASE", 102, 109], ["individuals", "ORGANISM", 45, 56], ["children", "ORGANISM", 186, 194], ["women", "ORGANISM", 218, 223], ["children", "SPECIES", 186, 194], ["women", "SPECIES", 218, 223], ["serious illness", "PROBLEM", 94, 109], ["the immunocompromised", "PROBLEM", 229, 250], ["serious", "OBSERVATION_MODIFIER", 94, 101], ["illness", "OBSERVATION", 102, 109], ["immunocompromised", "OBSERVATION", 233, 250]]], ["This segment of the population currently represents almost 20% of the population (in the USA) and is expected to increase signi\u00a2cantly in the years to come, due to increases in life-span and the number of immunocompromised individuals.", [["immunocompromised individuals", "PROBLEM", 205, 234], ["population", "OBSERVATION_MODIFIER", 20, 30], ["almost", "OBSERVATION_MODIFIER", 52, 58], ["20%", "OBSERVATION_MODIFIER", 59, 62], ["population", "OBSERVATION_MODIFIER", 70, 80], ["increase", "OBSERVATION_MODIFIER", 113, 121], ["increases", "OBSERVATION_MODIFIER", 164, 173], ["immunocompromised individuals", "OBSERVATION", 205, 234]]], ["Worldwide, diarrheal diseases account for millions of deaths annually, mostly in developing countries [15] .", [["diarrheal diseases", "DISEASE", 11, 29], ["deaths", "DISEASE", 54, 60], ["diarrheal diseases", "PROBLEM", 11, 29], ["diarrheal diseases", "OBSERVATION", 11, 29]]], ["In developed countries, mortality due to diarrhea is low, but does occur in young children [14, 87, 88] and in the elderly (where s 50% of all mortality occurs [11, 13, 86] ).", [["diarrhea", "DISEASE", 41, 49], ["children", "ORGANISM", 82, 90], ["children", "SPECIES", 82, 90], ["diarrhea", "PROBLEM", 41, 49]]], ["While speci\u00a2c mortality data on NLV are not available, given the high incidence of calicivirus infections in the elderly, it is likely that deaths resulting from calicivirus infection do occur [8, 12] .Molecular epidemiologyThe early studies demonstrating the great variability of NLV soon led to the notion that it was important to be able to distinguish between strains in order to better understand their epidemiology.", [["calicivirus infections", "DISEASE", 83, 105], ["deaths", "DISEASE", 140, 146], ["calicivirus infection", "DISEASE", 162, 183], ["calicivirus", "ORGANISM", 83, 94], ["calicivirus", "ORGANISM", 162, 173], ["calicivirus infections", "PROBLEM", 83, 105], ["calicivirus infection", "PROBLEM", 162, 183], ["The early studies", "TEST", 224, 241], ["strains", "PROBLEM", 364, 371], ["calicivirus", "OBSERVATION_MODIFIER", 83, 94], ["infections", "OBSERVATION", 95, 105], ["is likely", "UNCERTAINTY", 125, 134], ["calicivirus", "OBSERVATION", 162, 173], ["great", "OBSERVATION_MODIFIER", 260, 265], ["variability", "OBSERVATION_MODIFIER", 266, 277]]], ["Typically, variant viruses would be characterized by neutralization assays using hyperimmune sera or panels of monoclonal antibodies in a tissue culture infectivity assay.", [["sera", "ANATOMY", 93, 97], ["tissue culture", "ANATOMY", 138, 152], ["hyperimmune", "ORGANISM", 81, 92], ["sera", "ORGANISM_SUBSTANCE", 93, 97], ["tissue", "TISSUE", 138, 144], ["monoclonal antibodies", "PROTEIN", 111, 132], ["variant viruses", "PROBLEM", 11, 26], ["neutralization assays", "TEST", 53, 74], ["hyperimmune sera", "TEST", 81, 97], ["monoclonal antibodies", "PROBLEM", 111, 132], ["a tissue culture infectivity assay", "TEST", 136, 170], ["viruses", "OBSERVATION", 19, 26]]], ["However, because no one has succeeded in culturing these viruses in vitro, their antigenic relationships have been evaluated primarily by crosschallenge studies and IEM or solid phase IEM with viruses puri\u00a2ed from stool samples [20, 30, 33, 34, 52, 53] .", [["stool samples", "ANATOMY", 214, 227], ["crosschallenge studies", "TEST", 138, 160], ["IEM or solid phase IEM", "TEST", 165, 187], ["viruses", "PROBLEM", 193, 200], ["stool samples", "TEST", 214, 227], ["viruses", "OBSERVATION", 57, 64]]], ["Since this could not be done with every new variant that is identi\u00a2ed, genome characterization by sequence analysis has been used to provide an interim system of genotyping.", [["sequence analysis", "TEST", 98, 115]]], ["As the genotypes ideally would correlate with serotypes, the sequence of the major structural protein gene was used as the basis for phylogenetic analysis.", [["major structural protein gene", "DNA", 77, 106], ["serotypes", "PROBLEM", 46, 55], ["phylogenetic analysis", "TEST", 133, 154]]], ["Sequence analyses of viruses from di\u00a1erent outbreaks and di\u00a1erent geographical locations have con\u00a2rmed that NLV can be divided into two major genetic groups (termed genogroups) based on capsid sequence and polymerase sequence data [51,56^58] .", [["capsid sequence", "DNA", 186, 201], ["Sequence analyses", "TEST", 0, 17], ["viruses", "PROBLEM", 21, 28], ["capsid sequence", "TEST", 186, 201], ["polymerase sequence data", "TEST", 206, 230], ["viruses", "OBSERVATION", 21, 28]]], ["NV, Southampton virus, and Desert Shield virus are members of genogroup I. Snow Mountain virus, Hawaii virus, Toronto virus are members of genogroup II.", [["NV", "ORGANISM", 0, 2], ["Southampton virus", "ORGANISM", 4, 21], ["Desert Shield virus", "ORGANISM", 27, 46], ["genogroup I.", "ORGANISM", 62, 74], ["Snow Mountain virus", "ORGANISM", 75, 94], ["Hawaii virus", "ORGANISM", 96, 108], ["Toronto virus", "ORGANISM", 110, 123], ["genogroup II", "ORGANISM", 139, 151], ["Hawaii virus", "SPECIES", 96, 108], ["Toronto virus", "SPECIES", 110, 123], ["Southampton virus", "SPECIES", 4, 21], ["Desert Shield virus", "SPECIES", 27, 46], ["Snow Mountain virus", "SPECIES", 75, 94], ["Hawaii virus", "SPECIES", 96, 108], ["Toronto virus", "SPECIES", 110, 123], ["NV", "PROBLEM", 0, 2], ["Southampton virus", "PROBLEM", 4, 21], ["Desert Shield virus", "TREATMENT", 27, 46], ["Mountain virus", "PROBLEM", 80, 94], ["Toronto virus", "TREATMENT", 110, 123]]], ["In addition, a highly divergent virus (Alphatron) was assigned to a putative third genogroup.", [["a highly divergent virus", "PROBLEM", 13, 37]]], ["Within genogroups I and II stable lineages have been iden-ti\u00a2ed, based on phylogenetic analysis based on the complete capsid gene of at least two representatives per cluster [85, 91, 92] .", [["capsid gene", "DNA", 118, 129], ["phylogenetic analysis", "TEST", 74, 95], ["stable", "OBSERVATION_MODIFIER", 27, 33], ["lineages", "OBSERVATION", 34, 42]]], ["To date, 15 distinct genotypes have been recognized, but as more strains are characterized, this number is likely to increase [89, 90] .Molecular epidemiologyIt is well established that many di\u00a1erent genotypes of NLV cocirculate in the general population, causing sporadic cases and outbreaks [59,68,72,75,81,82,91^93] .", [["NLV", "GENE_OR_GENE_PRODUCT", 213, 216], ["NLV", "SPECIES", 213, 216], ["15 distinct genotypes", "PROBLEM", 9, 30]]], ["Typically, strain sequences are (almost) identical within outbreaks, and di\u00a1erent when specimens from di\u00a1erent outbreaks are analyzed.", [["specimens", "ANATOMY", 87, 96], ["strain sequences", "TEST", 11, 27]]], ["Thus, when identical sequences are found in di\u00a1erent patients or di\u00a1erent clusters of illness, a common source for the infection should be suspected [74,94^110] .", [["illness", "DISEASE", 86, 93], ["infection", "DISEASE", 119, 128], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["illness", "PROBLEM", 86, 93], ["the infection", "PROBLEM", 115, 128], ["infection", "OBSERVATION", 119, 128]]], ["Conversely, \u00a2nding di\u00a1erent sequences in people with a supposedly common source infection suggests independent contamination, unless there is an association with sewage-contaminated water: in epidemics due to sewage contamination, often more than one NLV genotype is encountered [73, 100, 110] .", [["infection", "DISEASE", 80, 89], ["people", "ORGANISM", 41, 47], ["\u00a2nding di\u00a1erent sequences", "DNA", 12, 37], ["people", "SPECIES", 41, 47], ["a supposedly common source infection", "PROBLEM", 53, 89], ["independent contamination", "PROBLEM", 99, 124], ["sewage contamination", "PROBLEM", 209, 229], ["infection", "OBSERVATION", 80, 89], ["contamination", "OBSERVATION", 111, 124]]], ["Occasionally, epidemics occur in which the majority of outbreaks are caused by a highly related group of viruses within a genotype, with only minimal di\u00a1erences in the conserved polymerase gene fragment that is used for genotyping [10,111^113] .", [["conserved polymerase gene fragment", "DNA", 168, 202], ["epidemics", "PROBLEM", 14, 23], ["a highly related group of viruses", "PROBLEM", 79, 112], ["minimal di\u00a1erences in the conserved polymerase gene fragment", "PROBLEM", 142, 202], ["viruses", "OBSERVATION", 105, 112], ["minimal", "OBSERVATION_MODIFIER", 142, 149], ["fragment", "OBSERVATION_MODIFIER", 194, 202]]], ["These epidemics may be widespread and even global [113] .", [["may be", "UNCERTAINTY", 16, 22], ["widespread", "OBSERVATION_MODIFIER", 23, 33]]], ["The mechanisms behind emergence of epidemic types or \u00a3uctuations in the prevalent genotypes of NLV are unknown.", [["NLV", "DISEASE", 95, 98], ["NLV", "CANCER", 95, 98]]], ["Hypotheses include large-scale foodborne transmission of a single strain, and the possibility of spillover from a non-human reservoir.ImmunityLittle is known about immunity to NLV infections.", [["infections", "DISEASE", 180, 190], ["NLV", "CANCER", 176, 179], ["NLV", "SPECIES", 176, 179], ["a single strain", "PROBLEM", 57, 72], ["spillover", "PROBLEM", 97, 106], ["a non-human reservoir", "TREATMENT", 112, 133], ["ImmunityLittle", "TREATMENT", 134, 148], ["NLV infections", "PROBLEM", 176, 190], ["large", "OBSERVATION_MODIFIER", 19, 24], ["-scale", "OBSERVATION_MODIFIER", 24, 30], ["spillover", "OBSERVATION", 97, 106], ["infections", "OBSERVATION", 180, 190]]], ["Antibody ELISA assays have been developed by using recombinant capsids as antigen, and preliminary studies suggest that^in outbreaks and in volunteer studiesp eople develop antibodies mostly restricted to the infecting genotype with some cross-reactivity.", [["studiesp eople", "ORGANISM", 150, 164], ["antibodies", "PROTEIN", 173, 183], ["Antibody ELISA assays", "TEST", 0, 21], ["preliminary studies", "TEST", 87, 106], ["outbreaks", "PROBLEM", 123, 132], ["volunteer studiesp eople", "TEST", 140, 164], ["antibodies", "PROBLEM", 173, 183], ["the infecting genotype", "PROBLEM", 205, 227]]], ["From experimental infections in volunteers it is known that infected persons may become protected from reinfection, but only for a short period, and again only when the challenge virus is closely related to the genotype of the strain that was used for the infection [60, 62] .", [["infections", "DISEASE", 18, 28], ["reinfection", "DISEASE", 103, 114], ["infection", "DISEASE", 256, 265], ["volunteers", "ORGANISM", 32, 42], ["persons", "ORGANISM", 69, 76], ["persons", "SPECIES", 69, 76], ["experimental infections", "PROBLEM", 5, 28], ["reinfection", "PROBLEM", 103, 114], ["the challenge virus", "PROBLEM", 165, 184], ["the strain", "PROBLEM", 223, 233], ["the infection", "PROBLEM", 252, 265], ["experimental", "OBSERVATION_MODIFIER", 5, 17], ["infections", "OBSERVATION", 18, 28], ["infected", "OBSERVATION", 60, 68], ["reinfection", "OBSERVATION", 103, 114]]], ["Seroprevalence studies with the recombinant antigens have shown that antibodies to NLV are very common in the population, even when the recombinant NV capsids are used in populations where viruses from the Norwalk cluster have not been identi\u00a2ed for a long time.", [["NLV", "GENE_OR_GENE_PRODUCT", 83, 86], ["NV capsids", "ORGANISM", 148, 158], ["recombinant antigens", "PROTEIN", 32, 52], ["antibodies", "PROTEIN", 69, 79], ["NLV", "SPECIES", 83, 86], ["NV", "SPECIES", 148, 150], ["Seroprevalence studies", "TEST", 0, 22], ["the recombinant antigens", "TEST", 28, 52], ["antibodies to NLV", "PROBLEM", 69, 86], ["the recombinant NV capsids", "TREATMENT", 132, 158], ["viruses", "PROBLEM", 189, 196]]], ["Volunteers with antibodies to the infecting genotype reportedly may have a higher risk of illness and a steeper dose^response curve [42, 114] .", [["illness", "DISEASE", 90, 97], ["Volunteers", "ORGANISM", 0, 10], ["antibodies", "PROTEIN", 16, 26], ["antibodies", "TREATMENT", 16, 26], ["illness", "PROBLEM", 90, 97], ["a steeper dose^response curve", "TREATMENT", 102, 131]]], ["Hinkula et al. [115] have shown that the seroprevalence may di\u00a1er markedly for di\u00a1erent antibody isotypes, suggesting that the lack of protection in part may be explained because a di\u00a1erent type of antibody was the better correlate of protection.", [["di\u00a1erent antibody isotypes", "PROTEIN", 79, 105], ["di\u00a1erent antibody isotypes", "PROBLEM", 79, 105], ["a di\u00a1erent type of antibody", "PROBLEM", 179, 206], ["antibody isotypes", "OBSERVATION", 88, 105]]], ["The lack of broadly reactive, long-lived immunity to natural infection suggests that development of a protective vaccine may be problematic.Modes of transmissionNLV are transmitted by direct person-to-person contact or indirectly via contaminated water [94, 96, 100, 102, 105, 106] , food [74,95,98,103,108^110] or contaminated environments [97, 101, 107, 116] .", [["infection", "DISEASE", 61, 70], ["person", "SPECIES", 191, 197], ["person", "SPECIES", 201, 207], ["broadly reactive", "PROBLEM", 12, 28], ["natural infection", "PROBLEM", 53, 70], ["a protective vaccine", "TREATMENT", 100, 120], ["broadly", "OBSERVATION_MODIFIER", 12, 19], ["reactive", "OBSERVATION_MODIFIER", 20, 28], ["infection", "OBSERVATION", 61, 70]]], ["Clearly, person-to-person transmission is by far the most common route of infection.", [["infection", "DISEASE", 74, 83], ["person", "SPECIES", 9, 15], ["infection", "PROBLEM", 74, 83], ["infection", "OBSERVATION", 74, 83]]], ["The infectious dose can be probably as low as 10^100 virus particles [114, 117] .", [["The infectious dose", "PROBLEM", 0, 19], ["infectious", "OBSERVATION", 4, 14]]], ["However, many foodborne NLV outbreaks have been described, often resulting from contamination by an infected foodhandler.", [["NLV", "SPECIES", 24, 27], ["many foodborne NLV outbreaks", "PROBLEM", 9, 37], ["an infected foodhandler", "PROBLEM", 97, 120], ["many", "OBSERVATION_MODIFIER", 9, 13], ["foodborne", "OBSERVATION_MODIFIER", 14, 23], ["NLV outbreaks", "OBSERVATION", 24, 37], ["infected", "OBSERVATION", 100, 108]]], ["In addition, several waterborne outbreaks of NLV have been described, both directly (e.g. consumption of tainted water) or indirectly (e.g. via washed fruits, by swimming or canoeing in recreational waters) [94, 96, 100, 102, 105, 106] .", [["fruits", "ANATOMY", 151, 157], ["NLV", "DISEASE", 45, 48], ["NLV", "CANCER", 45, 48], ["fruits", "ORGANISM_SUBDIVISION", 151, 157], ["NLV", "SPECIES", 45, 48], ["several", "OBSERVATION_MODIFIER", 13, 20], ["waterborne", "OBSERVATION_MODIFIER", 21, 31], ["outbreaks", "OBSERVATION", 32, 41]]], ["Of special interest is the \u00a2nding that a substantial proportion of bottled mineral waters contained caliciviral RNA [118] , although these \u00a2ndings need to be con\u00a2rmed by others.Modes of transmissionSince projectile vomiting is a common feature following NLV infection and viruses can be present in vomit [43, 119] , aerosolized vomit is recognized as an important vehicle for transmission, both by mechanical transmission from the vomit-contaminated environment and even by airborne transmission [97,116,117,119^122] .", [["projectile vomiting", "DISEASE", 204, 223], ["infection", "DISEASE", 258, 267], ["vomit", "ORGANISM_SUBDIVISION", 431, 436], ["caliciviral RNA", "RNA", 100, 115], ["NLV", "SPECIES", 254, 257], ["projectile vomiting", "PROBLEM", 204, 223], ["NLV infection", "PROBLEM", 254, 267], ["viruses", "PROBLEM", 272, 279], ["aerosolized vomit", "PROBLEM", 316, 333], ["infection", "OBSERVATION", 258, 267]]], ["The most compelling evidence for airborne transmission came from a study by Marks et al. [107] : they described an outbreak of gastroenteritis following a meal in a large hotel during which one of the guests vomited, and found an inverse relationship between attack rate per table and the distance from the person who got sick.Modes of transmissionIt is important to note that contamination may occur not only at the end of the food distribution chain, but at almost any step from farm to table.", [["gastroenteritis", "DISEASE", 127, 142], ["person", "SPECIES", 307, 313], ["airborne transmission", "PROBLEM", 33, 54], ["a study", "TEST", 65, 72], ["gastroenteritis", "PROBLEM", 127, 142], ["contamination", "PROBLEM", 377, 390], ["most compelling evidence for", "UNCERTAINTY", 4, 32], ["gastroenteritis", "OBSERVATION", 127, 142]]], ["Foodborne illness associated with consumption of oysters has been traced back to a crewmember of a harvesting boat [104] .", [["Foodborne illness", "DISEASE", 0, 17], ["Foodborne illness", "PROBLEM", 0, 17]]], ["From that same outbreak investigation, it was reported that 85% of oyster-harvesting boats in the area routinely disposed of sewage overboard.", [["oyster-harvesting boats", "TREATMENT", 67, 90], ["sewage overboard", "OBSERVATION", 125, 141]]], ["Little is known about the hygienic conditions in harvesting areas in other parts of the world, not only for shell\u00a2sh, but also for products such as fresh fruits.", [["fruits", "ANATOMY", 154, 160], ["fruits", "ORGANISM_SUBDIVISION", 154, 160]]], ["Infected foodhandlers may transmit infectious viruses during the incubation period and after recovery from illness [99, 109, 123] .", [["foodhandlers", "ANATOMY", 9, 21], ["infectious viruses", "DISEASE", 35, 53], ["illness", "DISEASE", 107, 114], ["Infected foodhandlers", "PROBLEM", 0, 21], ["transmit infectious viruses", "PROBLEM", 26, 53], ["illness", "PROBLEM", 107, 114], ["infectious", "OBSERVATION_MODIFIER", 35, 45]]], ["Another aspect of NLV epidemiology is that foodhandlers may unknowingly transmit viruses, e.g. when they have a sick child at home [98] .Modes of transmissionBesides person-to-person transmission via food vehicles, zoonotic transmission has been reported for some enteric viruses, although this appears to be of no signi\u00a2cance for foodborne infections [124] .", [["zoonotic transmission", "DISEASE", 215, 236], ["foodborne infections", "DISEASE", 331, 351], ["NLV", "CANCER", 18, 21], ["person", "SPECIES", 166, 172], ["person", "SPECIES", 176, 182], ["some enteric viruses", "PROBLEM", 259, 279], ["foodborne infections", "PROBLEM", 331, 351], ["viruses", "OBSERVATION", 272, 279]]], ["This may change, however, based on new data for NLV.", [["NLV", "PROBLEM", 48, 51]]], ["Until recently, the NLV were considered to be pathogens with humans as the sole host.", [["NLV", "GENE_OR_GENE_PRODUCT", 20, 23], ["humans", "ORGANISM", 61, 67], ["humans", "SPECIES", 61, 67], ["humans", "SPECIES", 61, 67]]], ["Recently, however, NLV were found in healthy pigs in Japan and in historic calf stool specimens from the UK and from Germany [125^128].", [["stool specimens", "ANATOMY", 80, 95], ["NLV", "GENE_OR_GENE_PRODUCT", 19, 22], ["pigs", "ORGANISM", 45, 49], ["NLV", "PROTEIN", 19, 22], ["pigs", "SPECIES", 45, 49], ["calf", "SPECIES", 75, 79], ["pigs", "SPECIES", 45, 49], ["historic calf stool specimens", "TEST", 66, 95], ["calf", "ANATOMY", 75, 79]]], ["The calf viruses, named Newbury agent and Jena virus, are pathogenic for young calves.", [["calf viruses", "ORGANISM", 4, 16], ["Newbury agent", "ORGANISM", 24, 37], ["Jena virus", "ORGANISM", 42, 52], ["calves", "ORGANISM", 79, 85], ["calf", "SPECIES", 4, 8], ["calves", "SPECIES", 79, 85], ["calf viruses", "SPECIES", 4, 16], ["Jena virus", "SPECIES", 42, 52], ["The calf viruses", "PROBLEM", 0, 16], ["Jena virus", "PROBLEM", 42, 52], ["calf", "ANATOMY", 4, 8], ["viruses", "OBSERVATION", 9, 16]]], ["The two bovine enteric caliciviruses and the pig enteric calicivirus are genetically distinct from human strains, but cluster within the NLV genus.", [["enteric caliciviruses", "DISEASE", 15, 36], ["enteric calicivirus", "DISEASE", 49, 68], ["bovine", "ORGANISM", 8, 14], ["enteric caliciviruses", "ORGANISM", 15, 36], ["pig enteric calicivirus", "ORGANISM", 45, 68], ["human", "ORGANISM", 99, 104], ["bovine", "SPECIES", 8, 14], ["pig enteric calicivirus", "SPECIES", 45, 68], ["human", "SPECIES", 99, 104], ["pig enteric calicivirus", "SPECIES", 45, 68], ["human", "SPECIES", 99, 104], ["The two bovine enteric caliciviruses", "PROBLEM", 0, 36], ["the pig enteric calicivirus", "TREATMENT", 41, 68], ["human strains", "PROBLEM", 99, 112], ["two", "OBSERVATION_MODIFIER", 4, 7], ["bovine enteric caliciviruses", "OBSERVATION", 8, 36], ["pig", "ANATOMY_MODIFIER", 45, 48], ["enteric calicivirus", "ANATOMY", 49, 68], ["human strains", "OBSERVATION", 99, 112], ["NLV genus", "OBSERVATION", 137, 146]]], ["In a pilot study in The Netherlands, pooled stool samples from calves, fattening pigs, and adult cows were tested for the presence of NLV [119] .", [["stool samples", "ANATOMY", 44, 57], ["calves", "ANATOMY", 63, 69], ["stool samples", "ORGANISM_SUBSTANCE", 44, 57], ["calves", "ORGANISM", 63, 69], ["pigs", "ORGANISM", 81, 85], ["cows", "ORGANISM", 97, 101], ["calves", "SPECIES", 63, 69], ["pigs", "SPECIES", 81, 85], ["cows", "SPECIES", 97, 101], ["pigs", "SPECIES", 81, 85], ["a pilot study", "TEST", 3, 16], ["pooled stool samples", "TEST", 37, 57], ["calves", "ANATOMY", 63, 69]]], ["Thirty-three (45%) of the calf herds tested positive for a NLV strains belonging to one cluster, with highest homology with the Newbury genotype.", [["calf", "ORGANISM", 26, 30], ["calf", "SPECIES", 26, 30], ["NLV", "SPECIES", 59, 62], ["the calf herds", "TEST", 22, 36], ["a NLV strains", "PROBLEM", 57, 70], ["calf", "ANATOMY", 26, 30]]], ["The Netherlands calf viruses were su\u2044ciently distinct to suggest that they may be a separate lineage (based on capsid sequencing).", [["Netherlands calf viruses", "ORGANISM", 4, 28], ["calf", "SPECIES", 16, 20], ["The Netherlands calf viruses", "PROBLEM", 0, 28], ["calf", "ANATOMY", 16, 20], ["viruses", "OBSERVATION", 21, 28]]], ["If con\u00a2rmed, that implies that in calves also several lineages or genotypes of NLV cocirculate, and that zoonotic transmission cannot be excluded by \u00a2nding distinct strains in animals and humans.", [["zoonotic transmission", "DISEASE", 105, 126], ["calves", "ORGANISM", 34, 40], ["NLV", "GENE_OR_GENE_PRODUCT", 79, 82], ["humans", "ORGANISM", 188, 194], ["calves", "SPECIES", 34, 40], ["humans", "SPECIES", 188, 194], ["NLV", "SPECIES", 79, 82], ["humans", "SPECIES", 188, 194], ["NLV cocirculate", "PROBLEM", 79, 94], ["cannot be excluded", "UNCERTAINTY", 127, 145]]], ["In addition, one pig herd was found positive for a virus, which was very similar to the pig calicivirus from Japan [119] .", [["pig", "ORGANISM", 17, 20], ["herd", "ORGANISM", 21, 25], ["pig calicivirus", "ORGANISM", 88, 103], ["pig", "SPECIES", 17, 20], ["pig calicivirus", "SPECIES", 88, 103], ["pig", "SPECIES", 17, 20], ["pig calicivirus", "SPECIES", 88, 103], ["a virus", "PROBLEM", 49, 56], ["the pig calicivirus", "PROBLEM", 84, 103], ["virus", "OBSERVATION", 51, 56]]], ["These \u00a2ndings raise important questions on the host range of the NLV.", [["NLV", "CANCER", 65, 68]]], ["At this stage the animal NLV appear to form genetically distinct stable lineages, but are su\u2044ciently related to the human NLV to suggest that under the right conditions interspecies transmission could occur.", [["NLV", "CANCER", 25, 28], ["human", "ORGANISM", 116, 121], ["NLV", "CANCER", 122, 125], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 116, 121], ["distinct", "OBSERVATION_MODIFIER", 56, 64], ["stable", "OBSERVATION_MODIFIER", 65, 71], ["lineages", "OBSERVATION", 72, 80], ["right", "ANATOMY_MODIFIER", 152, 157]]], ["Animal caliciviruses in another genus within the family Caliciviridae (the genus vesivirus) have a wide host range, and interspecies transmissions have repeatedly been documented [129] .IntroductionThe viruses which cause hepatitis can be divided into enterically transmitted viruses (HAV, HEV), and parenterally transmitted hepatitis viruses (hepatitis B, C, D, G).", [["hepatitis", "DISEASE", 222, 231], ["enterically transmitted viruses", "DISEASE", 252, 283], ["HAV, HEV)", "DISEASE", 285, 294], ["parenterally transmitted hepatitis viruses", "DISEASE", 300, 342], ["hepatitis B", "DISEASE", 344, 355], ["Caliciviridae", "GENE_OR_GENE_PRODUCT", 56, 69], ["vesivirus", "CANCER", 81, 90], ["HAV", "ORGANISM", 285, 288], ["HEV", "ORGANISM", 290, 293], ["parenterally transmitted", "ORGANISM", 300, 324], ["hepatitis viruses", "ORGANISM", 325, 342], ["HAV", "SPECIES", 285, 288], ["HEV", "SPECIES", 290, 293], ["hepatitis viruses", "SPECIES", 325, 342], ["Animal caliciviruses", "PROBLEM", 0, 20], ["The viruses", "PROBLEM", 198, 209], ["hepatitis", "PROBLEM", 222, 231], ["transmitted viruses (HAV", "PROBLEM", 264, 288], ["parenterally transmitted hepatitis viruses", "PROBLEM", 300, 342], ["hepatitis B", "TEST", 344, 355], ["caliciviruses", "OBSERVATION", 7, 20], ["viruses", "OBSERVATION", 202, 209], ["hepatitis", "OBSERVATION", 222, 231], ["viruses", "OBSERVATION", 276, 283], ["hepatitis viruses", "OBSERVATION", 325, 342]]], ["For food-or waterborne transmission, only the enterically transmitted viruses are relevant.", [["the enterically transmitted viruses", "PROBLEM", 42, 77], ["viruses", "OBSERVATION", 70, 77]]], ["HAV is a virus in the family Picornaviridae, to which the enteroviruses also belong (including poliovirus) [130] .", [["HAV", "DISEASE", 0, 3], ["HAV", "ORGANISM", 0, 3], ["enteroviruses", "ORGANISM", 58, 71], ["HAV", "SPECIES", 0, 3], ["a virus", "PROBLEM", 7, 14], ["Picornaviridae", "TREATMENT", 29, 43], ["the enteroviruses", "PROBLEM", 54, 71], ["virus", "OBSERVATION", 9, 14]]], ["HEV shows some resemblance with viruses from the family Caliciviridae (to which the NLV belong), but has not (yet) been included in a virus family because of unique characteristics [22] .IntroductionHepatitis E has only relatively recently been established as a cause of hepatitis, when large waterborne outbreaks occurred in India and Pakistan.", [["Hepatitis E", "DISEASE", 199, 210], ["hepatitis", "DISEASE", 271, 280], ["HEV", "ORGANISM", 0, 3], ["Hepatitis E", "ORGANISM", 199, 210], ["HEV", "SPECIES", 0, 3], ["Hepatitis E", "SPECIES", 199, 210], ["the family Caliciviridae", "TREATMENT", 45, 69], ["Hepatitis E", "PROBLEM", 199, 210], ["hepatitis", "PROBLEM", 271, 280], ["large waterborne outbreaks", "PROBLEM", 287, 313], ["viruses", "OBSERVATION", 32, 39], ["Hepatitis", "OBSERVATION", 199, 208], ["hepatitis", "OBSERVATION", 271, 280], ["large", "OBSERVATION_MODIFIER", 287, 292], ["waterborne", "OBSERVATION_MODIFIER", 293, 303], ["outbreaks", "OBSERVATION", 304, 313]]], ["The virus is endemic over a wide geographic area, primarily in countries with inadequate sanitation where HAV is endemic as well (southeast Asia, Indian subcontinent, Africa), but not as widespread as HAV.", [["HAV", "DISEASE", 106, 109], ["HAV", "DISEASE", 201, 204], ["HAV", "ORGANISM", 106, 109], ["HAV", "ORGANISM", 201, 204], ["HAV", "SPECIES", 106, 109], ["HAV", "SPECIES", 201, 204], ["The virus", "PROBLEM", 0, 9], ["inadequate sanitation", "TREATMENT", 78, 99], ["virus", "OBSERVATION", 4, 9], ["endemic", "OBSERVATION_MODIFIER", 13, 20], ["wide", "OBSERVATION_MODIFIER", 28, 32], ["geographic", "OBSERVATION_MODIFIER", 33, 43], ["area", "OBSERVATION_MODIFIER", 44, 48], ["endemic", "OBSERVATION_MODIFIER", 113, 120]]], ["In industrialized countries HEV infections are rare, and are usually travel-related [131^133].", [["HEV infections", "DISEASE", 28, 42], ["HEV", "ORGANISM", 28, 31], ["HEV", "SPECIES", 28, 31], ["HEV infections", "PROBLEM", 28, 42], ["infections", "OBSERVATION", 32, 42]]], ["HEV outbreaks can be distinguished based on the higher attack rate of clinically evident disease in persons 15^40 years of age compared with other groups, higher overall case fatality rates (0.5^3%), and the unusually high death toll in pregnant women (15^20%).", [["HEV outbreaks", "DISEASE", 0, 13], ["death", "DISEASE", 223, 228], ["HEV", "ORGANISM", 0, 3], ["women", "ORGANISM", 246, 251], ["persons", "SPECIES", 100, 107], ["women", "SPECIES", 246, 251], ["HEV", "SPECIES", 0, 3]]], ["In younger age groups, the majority of people with symptoms due to HEV infection may present without jaundice, unlike those infected with HAV [134^136].", [["HEV infection", "DISEASE", 67, 80], ["jaundice", "DISEASE", 101, 109], ["HAV", "DISEASE", 138, 141], ["people", "ORGANISM", 39, 45], ["HEV", "ORGANISM", 67, 70], ["people", "SPECIES", 39, 45], ["HEV", "SPECIES", 67, 70], ["HAV", "SPECIES", 138, 141], ["symptoms", "PROBLEM", 51, 59], ["HEV infection", "PROBLEM", 67, 80], ["jaundice", "PROBLEM", 101, 109], ["infection", "OBSERVATION", 71, 80]]], ["Since HEV can cause illness with high mortality in pregnant women, a study of foodborne virus transmission in our opinion should include HEV.", [["foodborne virus transmission", "DISEASE", 78, 106], ["HEV", "ORGANISM", 6, 9], ["women", "ORGANISM", 60, 65], ["HEV", "ORGANISM", 137, 140], ["women", "SPECIES", 60, 65], ["HEV", "SPECIES", 6, 9], ["HEV", "SPECIES", 137, 140], ["illness", "PROBLEM", 20, 27], ["a study", "TEST", 67, 74], ["foodborne virus transmission", "TREATMENT", 78, 106]]], ["The recent discovery that HEV is common in pigs and rats and that pig HEV have been found in humans is reason for a careful evaluation of HEV cases in countries where the virus is not endemic in the human population [137, 138] .", [["HEV", "ORGANISM", 26, 29], ["pigs", "ORGANISM", 43, 47], ["rats", "ORGANISM", 52, 56], ["pig HEV", "ORGANISM", 66, 73], ["humans", "ORGANISM", 93, 99], ["HEV", "ORGANISM", 138, 141], ["human", "ORGANISM", 199, 204], ["pigs", "SPECIES", 43, 47], ["rats", "SPECIES", 52, 56], ["pig", "SPECIES", 66, 69], ["humans", "SPECIES", 93, 99], ["human", "SPECIES", 199, 204], ["HEV", "SPECIES", 26, 29], ["pigs", "SPECIES", 43, 47], ["pig", "SPECIES", 66, 69], ["HEV", "SPECIES", 70, 73], ["humans", "SPECIES", 93, 99], ["HEV", "SPECIES", 138, 141], ["human", "SPECIES", 199, 204], ["pig HEV", "TREATMENT", 66, 73], ["a careful evaluation", "TEST", 114, 134], ["the virus", "PROBLEM", 167, 176]]], ["However, the primary source for HEV infection appears to be fecally contaminated water, and few human cases have been reported in regions where pig HEV is endemic, suggesting that interspecies transmissions of HEV are not common in countries with high standards of living.", [["HEV infection", "DISEASE", 32, 45], ["HEV", "DISEASE", 210, 213], ["HEV", "ORGANISM", 32, 35], ["human", "ORGANISM", 96, 101], ["pig HEV", "ORGANISM", 144, 151], ["HEV", "ORGANISM", 210, 213], ["human", "SPECIES", 96, 101], ["pig", "SPECIES", 144, 147], ["HEV", "SPECIES", 32, 35], ["human", "SPECIES", 96, 101], ["pig", "SPECIES", 144, 147], ["HEV", "SPECIES", 148, 151], ["HEV", "SPECIES", 210, 213], ["HEV infection", "PROBLEM", 32, 45], ["infection", "OBSERVATION", 36, 45]]], ["The subsequent discussion will focus on HAV [139^141].", [["HAV", "ORGANISM", 40, 43]]], ["Since excellent reviews are available for HAV in general, the focus of this section will be mostly on the possibility of foodborne transmission [135] .The virusHAV are small, non-enveloped spherical viruses, measuring between 27 and 32 nm in diameter.", [["HAV", "DISEASE", 42, 45], ["HAV", "ORGANISM", 42, 45], ["virusHAV", "GENE_OR_GENE_PRODUCT", 155, 163], ["HAV", "SPECIES", 42, 45], ["HAV", "PROBLEM", 42, 45], ["this section", "TREATMENT", 71, 83], ["small, non-enveloped spherical viruses", "PROBLEM", 168, 206], ["virusHAV", "ANATOMY", 155, 163], ["small", "OBSERVATION_MODIFIER", 168, 173], ["non-enveloped", "OBSERVATION_MODIFIER", 175, 188], ["spherical viruses", "OBSERVATION", 189, 206], ["32 nm", "OBSERVATION_MODIFIER", 233, 238], ["diameter", "OBSERVATION_MODIFIER", 242, 250]]], ["They contain a single (positive-) stranded RNA genome of approximately 7.5 kb in length that encodes a large polyprotein [142] .", [["single (positive-) stranded RNA genome", "DNA", 15, 53], ["a single (positive-) stranded RNA genome", "PROBLEM", 13, 53], ["a large polyprotein", "PROBLEM", 101, 120]]], ["The genome organization di\u00a1ers from that of the Caliciviridae, in that the genes encoding the non-structural proteins are located at the 3P-portion of the genome, and the genes encoding the structural proteins at the 5P-end [143] .", [["genome", "CELLULAR_COMPONENT", 155, 161], ["Caliciviridae", "DNA", 48, 61], ["non-structural proteins", "PROTEIN", 94, 117], ["3P-portion", "DNA", 137, 147], ["structural proteins", "PROTEIN", 190, 209], ["5P", "PROTEIN", 217, 219], ["the Caliciviridae", "TREATMENT", 44, 61], ["the non-structural proteins", "PROBLEM", 90, 117], ["non-structural proteins", "OBSERVATION", 94, 117], ["genome", "ANATOMY", 155, 161]]], ["The polyprotein is processed to four structural and seven non-structural proteins by proteinases encoded in and around the 3C region [144] .", [["non-structural proteins", "PROTEIN", 58, 81], ["proteinases", "PROTEIN", 85, 96], ["The polyprotein", "TREATMENT", 0, 15], ["proteinases", "TEST", 85, 96]]], ["Replication e\u2044ciency seems to be controlled by amino acid substitutions in the 2B and 2C regions [145] .Clinical symptomsInfection with HAV can produce asymptomatic or symptomatic infection after a median incubation period of 30 days (range 15^50 days).", [["amino acid", "CHEMICAL", 47, 57], ["HAV", "DISEASE", 136, 139], ["infection", "DISEASE", 180, 189], ["amino acid", "CHEMICAL", 47, 57], ["amino acid", "AMINO_ACID", 47, 57], ["HAV", "ORGANISM", 136, 139], ["HAV", "SPECIES", 136, 139], ["amino acid substitutions", "TREATMENT", 47, 71], ["Clinical symptomsInfection", "PROBLEM", 104, 130], ["HAV", "PROBLEM", 136, 139], ["asymptomatic or symptomatic infection", "PROBLEM", 152, 189], ["symptomatic", "OBSERVATION_MODIFIER", 168, 179], ["infection", "OBSERVATION", 180, 189]]], ["The illness caused by HAV infection is characterized by non-speci\u00a2c symptoms that can include fever, headache, fatigue, nausea and abdominal discomfort, followed by symptoms and signs of hepatitis 1^2 weeks later [134] .", [["abdominal", "ANATOMY", 131, 140], ["illness", "DISEASE", 4, 11], ["HAV infection", "DISEASE", 22, 35], ["fever", "DISEASE", 94, 99], ["headache", "DISEASE", 101, 109], ["fatigue", "DISEASE", 111, 118], ["nausea", "DISEASE", 120, 126], ["abdominal discomfort", "DISEASE", 131, 151], ["hepatitis", "DISEASE", 187, 196], ["HAV", "ORGANISM", 22, 25], ["abdominal", "ORGANISM_SUBDIVISION", 131, 140], ["HAV", "SPECIES", 22, 25], ["The illness", "PROBLEM", 0, 11], ["HAV infection", "PROBLEM", 22, 35], ["non-speci\u00a2c symptoms", "PROBLEM", 56, 76], ["fever", "PROBLEM", 94, 99], ["headache", "PROBLEM", 101, 109], ["fatigue", "PROBLEM", 111, 118], ["nausea", "PROBLEM", 120, 126], ["abdominal discomfort", "PROBLEM", 131, 151], ["symptoms", "PROBLEM", 165, 173], ["hepatitis", "PROBLEM", 187, 196], ["infection", "OBSERVATION", 26, 35], ["abdominal", "ANATOMY", 131, 140], ["discomfort", "OBSERVATION", 141, 151], ["hepatitis", "OBSERVATION", 187, 196]]], ["The likelihood of having symptoms with HAV infection is related to the age of the infected individual.", [["HAV infection", "DISEASE", 39, 52], ["HAV", "ORGANISM", 39, 42], ["HAV", "SPECIES", 39, 42], ["symptoms", "PROBLEM", 25, 33], ["HAV infection", "PROBLEM", 39, 52], ["the infected individual", "PROBLEM", 78, 101], ["infection", "OBSERVATION", 43, 52], ["infected", "OBSERVATION", 82, 90]]], ["Among children younger than 6 years of age, most infections are asymptomatic, and children with symptoms rarely develop jaundice.", [["infections", "DISEASE", 49, 59], ["jaundice", "DISEASE", 120, 128], ["children", "ORGANISM", 6, 14], ["children", "ORGANISM", 82, 90], ["children", "SPECIES", 6, 14], ["children", "SPECIES", 82, 90], ["symptoms", "PROBLEM", 96, 104], ["jaundice", "PROBLEM", 120, 128], ["jaundice", "OBSERVATION", 120, 128]]], ["Among older children and adults, infection is usually symptomatic, and jaundice occurs in the majority of patients [136, 146] .Clinical symptomsThe illness is generally self-limited, lasting up to several months, and infrequently causes fulminant disease.", [["infection", "DISEASE", 33, 42], ["jaundice", "DISEASE", 71, 79], ["illness", "DISEASE", 148, 155], ["children", "ORGANISM", 12, 20], ["patients", "ORGANISM", 106, 114], ["children", "SPECIES", 12, 20], ["patients", "SPECIES", 106, 114], ["infection", "PROBLEM", 33, 42], ["symptomatic", "PROBLEM", 54, 65], ["jaundice", "PROBLEM", 71, 79], ["Clinical symptoms", "PROBLEM", 127, 144], ["The illness", "PROBLEM", 144, 155], ["fulminant disease", "PROBLEM", 237, 254], ["infection", "OBSERVATION", 33, 42], ["jaundice", "OBSERVATION", 71, 79], ["illness", "OBSERVATION", 148, 155], ["fulminant", "OBSERVATION_MODIFIER", 237, 246], ["disease", "OBSERVATION", 247, 254]]], ["All patients with hepatitis A in a 4-year hospital-and physician-based surveillance regained normal liver function within 20 months of the acute illness [134] .", [["liver", "ANATOMY", 100, 105], ["hepatitis A", "DISEASE", 18, 29], ["acute illness", "DISEASE", 139, 152], ["patients", "ORGANISM", 4, 12], ["liver", "ORGAN", 100, 105], ["patients", "SPECIES", 4, 12], ["the acute illness", "PROBLEM", 135, 152], ["hepatitis", "OBSERVATION", 18, 27], ["liver", "ANATOMY", 100, 105], ["acute", "OBSERVATION_MODIFIER", 139, 144], ["illness", "OBSERVATION", 145, 152]]], ["However, the case fatality rate among persons s 50 years old with hepatitis A reported to the CDC in the USA is 1.8% [136] .", [["hepatitis A", "DISEASE", 66, 77], ["persons", "ORGANISM", 38, 45], ["persons", "SPECIES", 38, 45], ["hepatitis A", "PROBLEM", 66, 77], ["hepatitis", "OBSERVATION", 66, 75]]], ["Persons with chronic liver disease are at increased risk of fulminant hepatitis with hepatitis A [147^149].", [["liver", "ANATOMY", 21, 26], ["chronic liver disease", "DISEASE", 13, 34], ["fulminant hepatitis with hepatitis A", "DISEASE", 60, 96], ["Persons", "ORGANISM", 0, 7], ["liver", "ORGAN", 21, 26], ["Persons", "SPECIES", 0, 7], ["chronic liver disease", "PROBLEM", 13, 34], ["fulminant hepatitis", "PROBLEM", 60, 79], ["hepatitis A", "PROBLEM", 85, 96], ["chronic", "OBSERVATION_MODIFIER", 13, 20], ["liver", "ANATOMY", 21, 26], ["disease", "OBSERVATION", 27, 34], ["fulminant", "OBSERVATION_MODIFIER", 60, 69], ["hepatitis", "OBSERVATION", 70, 79], ["hepatitis", "OBSERVATION", 85, 94]]], ["HAV has not been shown to cause a persistent infection, and has not been associated with chronic liver disease.", [["liver", "ANATOMY", 97, 102], ["HAV", "DISEASE", 0, 3], ["infection", "DISEASE", 45, 54], ["chronic liver disease", "DISEASE", 89, 110], ["HAV", "ORGANISM", 0, 3], ["liver", "ORGAN", 97, 102], ["HAV", "SPECIES", 0, 3], ["a persistent infection", "PROBLEM", 32, 54], ["chronic liver disease", "PROBLEM", 89, 110], ["persistent", "OBSERVATION_MODIFIER", 34, 44], ["infection", "OBSERVATION", 45, 54], ["not been associated with", "UNCERTAINTY", 64, 88], ["chronic", "OBSERVATION_MODIFIER", 89, 96], ["liver", "ANATOMY", 97, 102], ["disease", "OBSERVATION", 103, 110]]], ["Prolonged or relapsing disease lasting up to 6 months occurs in 101 5% of patients [150^153].", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["Prolonged or relapsing disease", "PROBLEM", 0, 30], ["relapsing", "OBSERVATION_MODIFIER", 13, 22], ["disease", "OBSERVATION", 23, 30]]], ["Peak virus shedding of HAV in feces occurs during the 2 weeks before the onset of jaundice or liver enzyme elevation.", [["feces", "ANATOMY", 30, 35], ["liver", "ANATOMY", 94, 99], ["HAV", "DISEASE", 23, 26], ["jaundice", "DISEASE", 82, 90], ["HAV", "ORGANISM", 23, 26], ["feces", "ORGANISM_SUBSTANCE", 30, 35], ["liver", "ORGAN", 94, 99], ["HAV", "SPECIES", 23, 26], ["Peak virus shedding", "PROBLEM", 0, 19], ["HAV in feces", "PROBLEM", 23, 35], ["jaundice", "PROBLEM", 82, 90], ["liver enzyme elevation", "PROBLEM", 94, 116], ["virus", "OBSERVATION", 5, 10], ["HAV", "OBSERVATION", 23, 26], ["feces", "OBSERVATION", 30, 35], ["jaundice", "OBSERVATION", 82, 90], ["liver", "ANATOMY", 94, 99], ["enzyme elevation", "OBSERVATION", 100, 116]]], ["The concentration of virus in stool declines after jaundice appears, although prolonged shedding may occur, particularly among infants and children (reportedly up to 5 months post infection [134, 136] ).", [["stool", "ANATOMY", 30, 35], ["jaundice", "DISEASE", 51, 59], ["infection", "DISEASE", 180, 189], ["stool", "ORGANISM_SUBSTANCE", 30, 35], ["infants", "ORGANISM", 127, 134], ["children", "ORGANISM", 139, 147], ["infants", "SPECIES", 127, 134], ["children", "SPECIES", 139, 147], ["virus", "PROBLEM", 21, 26], ["jaundice", "PROBLEM", 51, 59], ["infection", "PROBLEM", 180, 189], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["virus", "OBSERVATION", 21, 26], ["jaundice", "OBSERVATION", 51, 59]]], ["Robertson et al. [154] found low levels of HAV RNA in stools from children for up to 10 weeks after the onset of symptoms.", [["HAV", "ORGANISM", 43, 46], ["stools", "ORGANISM_SUBDIVISION", 54, 60], ["children", "ORGANISM", 66, 74], ["HAV RNA", "RNA", 43, 50], ["children", "SPECIES", 66, 74], ["HAV", "SPECIES", 43, 46], ["low levels of HAV RNA in stools", "PROBLEM", 29, 60], ["symptoms", "PROBLEM", 113, 121], ["low levels", "OBSERVATION_MODIFIER", 29, 39]]], ["Reactivation of viral shedding can occur during relapsing illness.", [["viral shedding", "PROBLEM", 16, 30], ["relapsing illness", "PROBLEM", 48, 65], ["viral", "OBSERVATION", 16, 21]]], ["Viremia occurs soon after infection and persists through liver enzyme elevation.", [["liver", "ANATOMY", 57, 62], ["Viremia", "DISEASE", 0, 7], ["infection", "DISEASE", 26, 35], ["liver", "ORGAN", 57, 62], ["Viremia", "PROBLEM", 0, 7], ["infection", "PROBLEM", 26, 35], ["liver enzyme elevation", "PROBLEM", 57, 79], ["infection", "OBSERVATION", 26, 35], ["liver", "ANATOMY", 57, 62], ["enzyme", "OBSERVATION_MODIFIER", 63, 69], ["elevation", "OBSERVATION", 70, 79]]], ["In a recent study, HAV RNA in serum was detected an average of 17 days before the alanine aminotransferase peak, and viremia persisted for an average of 79 days after the liver enzyme peak.", [["serum", "ANATOMY", 30, 35], ["liver", "ANATOMY", 171, 176], ["alanine", "CHEMICAL", 82, 89], ["viremia", "DISEASE", 117, 124], ["alanine", "CHEMICAL", 82, 89], ["HAV", "ORGANISM", 19, 22], ["serum", "ORGANISM_SUBSTANCE", 30, 35], ["alanine", "AMINO_ACID", 82, 89], ["aminotransferase", "AMINO_ACID", 90, 106], ["liver", "ORGAN", 171, 176], ["HAV RNA", "RNA", 19, 26], ["alanine aminotransferase", "PROTEIN", 82, 106], ["HAV", "SPECIES", 19, 22], ["a recent study", "TEST", 3, 17], ["HAV RNA in serum", "TEST", 19, 35], ["the alanine aminotransferase peak", "TEST", 78, 111], ["viremia", "PROBLEM", 117, 124], ["the liver enzyme peak", "TEST", 167, 188], ["viremia", "OBSERVATION", 117, 124], ["liver", "ANATOMY", 171, 176]]], ["The average duration of viremia was 95 days (range, 36^391 days) [150] .PathogenesisThe exact pathogenesis of hepatitis A is not understood.", [["viremia", "DISEASE", 24, 31], ["hepatitis A", "DISEASE", 110, 121], ["hepatitis A", "CANCER", 110, 121], ["hepatitis A", "SPECIES", 110, 121], ["viremia", "PROBLEM", 24, 31], ["hepatitis A", "PROBLEM", 110, 121], ["average", "OBSERVATION_MODIFIER", 4, 11], ["viremia", "OBSERVATION", 24, 31], ["hepatitis", "OBSERVATION", 110, 119]]], ["Virus enters via the intestinal tract, and is transported to the liver following a viremic stage, in which virus can be detected in the blood stream.", [["intestinal tract", "ANATOMY", 21, 37], ["liver", "ANATOMY", 65, 70], ["blood stream", "ANATOMY", 136, 148], ["Virus", "ORGANISM", 0, 5], ["intestinal tract", "ORGAN", 21, 37], ["liver", "ORGAN", 65, 70], ["blood", "ORGANISM_SUBSTANCE", 136, 141], ["Virus", "PROBLEM", 0, 5], ["a viremic stage", "PROBLEM", 81, 96], ["virus", "PROBLEM", 107, 112], ["the blood stream", "TEST", 132, 148], ["intestinal tract", "ANATOMY", 21, 37], ["liver", "ANATOMY", 65, 70], ["viremic", "OBSERVATION", 83, 90]]], ["Hepatocytes are the site of replication, and virus is thought to be shed via the bile.", [["Hepatocytes", "ANATOMY", 0, 11], ["bile", "ANATOMY", 81, 85], ["Hepatocytes", "CELL", 0, 11], ["bile", "MULTI-TISSUE_STRUCTURE", 81, 85], ["Hepatocytes", "CELL_TYPE", 0, 11], ["Hepatocytes", "TREATMENT", 0, 11], ["replication", "PROBLEM", 28, 39], ["virus", "PROBLEM", 45, 50], ["replication", "OBSERVATION", 28, 39], ["bile", "ANATOMY", 81, 85]]], ["In experimental infections in non-human primates, HAV viral antigen and/or genomic material has been found in the spleen, kidney, tonsils and saliva, suggesting that other sites of replication may exist.", [["spleen", "ANATOMY", 114, 120], ["kidney", "ANATOMY", 122, 128], ["tonsils", "ANATOMY", 130, 137], ["saliva", "ANATOMY", 142, 148], ["infections", "DISEASE", 16, 26], ["non-human primates", "ORGANISM", 30, 48], ["HAV", "ORGANISM", 50, 53], ["spleen", "ORGAN", 114, 120], ["kidney", "ORGAN", 122, 128], ["tonsils", "ORGAN", 130, 137], ["saliva", "ORGANISM_SUBSTANCE", 142, 148], ["HAV viral antigen", "PROTEIN", 50, 67], ["HAV", "SPECIES", 50, 53], ["experimental infections in non-human primates", "PROBLEM", 3, 48], ["HAV viral antigen", "TEST", 50, 67], ["genomic material", "PROBLEM", 75, 91], ["infections", "OBSERVATION", 16, 26], ["spleen", "ANATOMY", 114, 120], ["kidney", "ANATOMY", 122, 128], ["tonsils", "ANATOMY", 130, 137], ["saliva", "ANATOMY", 142, 148], ["replication", "OBSERVATION", 181, 192]]], ["In vitro, cells are generally not destroyed by the virus, and the damage to liver epithelial cells in vivo often is limited [155] .Diagnosis in humansHepatitis A cannot be distinguished from other types of viral hepatitis on the basis of clinical features [136] .", [["cells", "ANATOMY", 10, 15], ["liver epithelial cells", "ANATOMY", 76, 98], ["Hepatitis A", "DISEASE", 150, 161], ["viral hepatitis", "DISEASE", 206, 221], ["cells", "CELL", 10, 15], ["liver epithelial cells", "CELL", 76, 98], ["humans", "ORGANISM", 144, 150], ["Hepatitis A", "ORGANISM", 150, 161], ["liver epithelial cells", "CELL_TYPE", 76, 98], ["humans", "SPECIES", 144, 150], ["humans", "SPECIES", 144, 150], ["the virus", "PROBLEM", 47, 56], ["the damage to liver epithelial cells", "PROBLEM", 62, 98], ["Hepatitis A", "PROBLEM", 150, 161], ["viral hepatitis", "PROBLEM", 206, 221], ["virus", "OBSERVATION", 51, 56], ["liver", "ANATOMY", 76, 81], ["epithelial cells", "OBSERVATION", 82, 98], ["Hepatitis", "OBSERVATION", 150, 159], ["viral hepatitis", "OBSERVATION", 206, 221]]], ["Diagnosis of acute hepatitis A is made by detection in serum of IgM antibody to the capsid proteins of HAV (IgM anti-HAV).", [["serum", "ANATOMY", 55, 60], ["acute hepatitis A", "DISEASE", 13, 30], ["serum", "ORGANISM_SUBSTANCE", 55, 60], ["IgM antibody", "GENE_OR_GENE_PRODUCT", 64, 76], ["HAV", "ORGANISM", 103, 106], ["IgM anti-HAV", "ORGANISM", 108, 120], ["IgM antibody", "PROTEIN", 64, 76], ["capsid proteins", "PROTEIN", 84, 99], ["IgM", "PROTEIN", 108, 111], ["HAV", "SPECIES", 103, 106], ["HAV", "SPECIES", 117, 120], ["acute hepatitis", "PROBLEM", 13, 28], ["IgM antibody", "TEST", 64, 76], ["HAV", "PROBLEM", 103, 106], ["acute", "OBSERVATION_MODIFIER", 13, 18], ["hepatitis", "OBSERVATION", 19, 28]]], ["In most persons with acute HAV infection, IgM anti-HAV becomes detectable 5^10 days before the onset of symptoms and can persist for up to 6 months [156] .", [["HAV infection", "DISEASE", 27, 40], ["persons", "ORGANISM", 8, 15], ["HAV", "ORGANISM", 27, 30], ["IgM", "PROTEIN", 42, 45], ["persons", "SPECIES", 8, 15], ["HAV", "SPECIES", 27, 30], ["HAV", "SPECIES", 51, 54], ["acute HAV infection", "PROBLEM", 21, 40], ["IgM anti-HAV", "PROBLEM", 42, 54], ["symptoms", "PROBLEM", 104, 112], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["HAV", "OBSERVATION_MODIFIER", 27, 30], ["infection", "OBSERVATION", 31, 40]]], ["Commercial diagnostic tests are available for the detection of IgM and total (IgM and IgG) anti-HAV in serum.", [["serum", "ANATOMY", 103, 108], ["IgM", "GENE_OR_GENE_PRODUCT", 63, 66], ["IgM", "GENE_OR_GENE_PRODUCT", 78, 81], ["IgG", "GENE_OR_GENE_PRODUCT", 86, 89], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["IgM", "PROTEIN", 63, 66], ["IgM", "PROTEIN", 78, 81], ["IgG", "PROTEIN", 86, 89], ["anti-HAV", "PROTEIN", 91, 99], ["Commercial diagnostic tests", "TEST", 0, 27], ["the detection", "TEST", 46, 59], ["IgM", "TEST", 63, 66], ["total (IgM", "TEST", 71, 81], ["IgG", "TEST", 86, 89], ["anti-HAV in serum", "TEST", 91, 108]]], ["Virus (up to 10 9 particles per ml) can be detected by molecular methods in stool and serum samples of infected individuals, but these methods are not generally used for diagnostic purposes [155] .", [["stool", "ANATOMY", 76, 81], ["serum samples", "ANATOMY", 86, 99], ["Virus", "ORGANISM", 0, 5], ["stool", "ORGANISM_SUBSTANCE", 76, 81], ["serum samples", "ORGANISM_SUBSTANCE", 86, 99], ["Virus", "PROBLEM", 0, 5], ["molecular methods in stool and serum samples", "TEST", 55, 99], ["infected individuals", "PROBLEM", 103, 123], ["diagnostic purposes", "TEST", 170, 189], ["infected", "OBSERVATION", 103, 111]]], ["Detection of sporadic cases or small clusters of foodborne hepatitis A is problematic because of di\u2044culties in recalling exposures during the long incubation period, the simultaneous occurrence of cases from person-to-person transmission, and the lack of routinely collected data about foodborne exposures.", [["foodborne hepatitis A", "DISEASE", 49, 70], ["person", "SPECIES", 208, 214], ["person", "SPECIES", 218, 224], ["sporadic cases", "PROBLEM", 13, 27], ["small clusters of foodborne hepatitis", "PROBLEM", 31, 68], ["sporadic", "OBSERVATION_MODIFIER", 13, 21], ["small", "OBSERVATION_MODIFIER", 31, 36], ["clusters", "OBSERVATION_MODIFIER", 37, 45], ["foodborne hepatitis", "OBSERVATION", 49, 68]]], ["For this, the use of molecular strain typing o\u00a1ers new possibilities (as described in Section 3.8).EpidemiologyWorldwide, di\u00a1ering patterns of HAV endemicity can be identi\u00a2ed, each characterized by distinct patterns of the prevalence of antibody to HAV (anti-HAV) and hepatitis A incidence, and associated with di\u00a1erent levels of prevailing environmental (sanitary and hygienic) and socioeconomic conditions.", [["HAV endemicity", "DISEASE", 143, 157], ["hepatitis A", "DISEASE", 268, 279], ["HAV", "ORGANISM", 143, 146], ["HAV", "ORGANISM", 249, 252], ["anti-HAV", "ORGANISM", 254, 262], ["hepatitis A", "ORGANISM", 268, 279], ["HAV", "SPECIES", 143, 146], ["HAV", "SPECIES", 249, 252], ["HAV", "SPECIES", 259, 262], ["hepatitis A", "SPECIES", 268, 279], ["molecular strain typing", "TEST", 21, 44], ["HAV endemicity", "PROBLEM", 143, 157], ["antibody to HAV", "PROBLEM", 237, 252], ["hepatitis A incidence", "PROBLEM", 268, 289], ["di\u00a1erent levels", "PROBLEM", 311, 326], ["socioeconomic conditions", "PROBLEM", 383, 407], ["HAV", "OBSERVATION_MODIFIER", 143, 146], ["endemicity", "OBSERVATION", 147, 157], ["hepatitis", "OBSERVATION", 268, 277]]], ["In much of the developing world, HAV infection is endemic, and the majority of persons are infected in early childhood ; virtually all adults are immune [136] .", [["HAV infection", "DISEASE", 33, 46], ["HAV", "ORGANISM", 33, 36], ["persons", "ORGANISM", 79, 86], ["adults", "ORGANISM", 135, 141], ["persons", "SPECIES", 79, 86], ["HAV", "SPECIES", 33, 36], ["HAV infection", "PROBLEM", 33, 46], ["endemic", "PROBLEM", 50, 57], ["infection", "OBSERVATION", 37, 46], ["endemic", "OBSERVATION_MODIFIER", 50, 57], ["infected", "OBSERVATION", 91, 99]]], ["In these areas, HAV transmission is primarily from person to person.", [["HAV", "DISEASE", 16, 19], ["HAV", "ORGANISM", 16, 19], ["person", "SPECIES", 51, 57], ["person", "SPECIES", 61, 67], ["HAV", "SPECIES", 16, 19]]], ["Outbreaks are rare because most infections occur among young children who generally remain asymptomatic.", [["infections", "DISEASE", 32, 42], ["children", "ORGANISM", 61, 69], ["children", "SPECIES", 61, 69], ["Outbreaks", "PROBLEM", 0, 9], ["asymptomatic", "PROBLEM", 91, 103], ["asymptomatic", "OBSERVATION", 91, 103]]], ["Paradoxically, as socioeconomic and environmental conditions improve and HAV decreases in endemicity (Fig. 2) , the overall incidence and average age of reported cases often increase because older individuals are susceptible and develop symptoms with infection [157] .", [["infection", "DISEASE", 251, 260], ["HAV", "SPECIES", 73, 76], ["socioeconomic and environmental conditions", "PROBLEM", 18, 60], ["symptoms", "PROBLEM", 237, 245], ["infection", "PROBLEM", 251, 260], ["decreases", "OBSERVATION_MODIFIER", 77, 86]]], ["An illustration of this can been seen from national surveillance data: for instance in England and Wales, the annual noti\u00a2cation rate of HAV infection has risen fourfold between 1987 and 1991 from 3.6 to 14.6 per 100 000 population [165] .", [["HAV infection", "DISEASE", 137, 150], ["HAV", "ORGANISM", 137, 140], ["HAV", "SPECIES", 137, 140], ["national surveillance data", "TEST", 43, 69], ["HAV infection", "PROBLEM", 137, 150], ["infection", "OBSERVATION", 141, 150]]], ["In Italy, data collected from a surveillance system for type-speci\u00a2c acute viral hepatitis (SEIEVA) showed that the incidence of HAV declined from 10/100 000 in 1985 to 2/100 000 during the period 1987^1990, while an increase was observed after 1991.", [["acute viral hepatitis", "DISEASE", 69, 90], ["HAV", "DISEASE", 129, 132], ["HAV", "ORGANISM", 129, 132], ["HAV", "SPECIES", 129, 132], ["a surveillance system", "TEST", 30, 51], ["type-speci\u00a2c acute viral hepatitis", "PROBLEM", 56, 90], ["HAV", "PROBLEM", 129, 132], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["viral hepatitis", "OBSERVATION", 75, 90]]], ["The highest attack rate was observed in the 15^24-year age group [158] .EpidemiologyThus, in the industrialized parts of the world where HAV endemicity is relatively low, hepatitis A occurs sporadically and in the context of community-wide epidemics that recur periodically [157] .", [["HAV endemicity", "DISEASE", 137, 151], ["hepatitis A", "DISEASE", 171, 182], ["HAV", "ORGANISM", 137, 140], ["HAV", "SPECIES", 137, 140], ["hepatitis A", "SPECIES", 171, 182], ["The highest attack rate", "TEST", 0, 23], ["HAV endemicity", "PROBLEM", 137, 151], ["hepatitis A", "PROBLEM", 171, 182], ["wide epidemics", "PROBLEM", 235, 249], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["low", "OBSERVATION_MODIFIER", 166, 169], ["hepatitis", "OBSERVATION", 171, 180]]], ["Transmission remains primarily from person to person, but large common source outbreaks also can occur.", [["person", "SPECIES", 36, 42], ["person", "SPECIES", 46, 52]]], ["Outbreaks of hepatitis A are common in crowded situations such as institutions, schools, prisons, and in military forces.", [["hepatitis A", "DISEASE", 13, 24], ["hepatitis A", "SPECIES", 13, 24], ["hepatitis A", "PROBLEM", 13, 24], ["hepatitis", "OBSERVATION", 13, 22]]], ["The increased number of susceptible individuals allows common source epidemics to evolve rapidly, and the likelihood of such epidemics is increasing [136] .", [["susceptible individuals", "PROBLEM", 24, 47], ["such epidemics", "PROBLEM", 120, 134], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["number", "OBSERVATION_MODIFIER", 14, 20], ["susceptible", "OBSERVATION_MODIFIER", 24, 35], ["rapidly", "OBSERVATION_MODIFIER", 89, 96], ["increasing", "OBSERVATION_MODIFIER", 138, 148]]], ["Foodborne outbreaks have been reported in most parts of the world except those with the highest and lowest HAV endemicity [159^171] .", [["HAV", "SPECIES", 107, 110]]], ["An outbreak in Shanghai in 1988 involving 250 000 cases occurred in association with consumption of contaminated clams [161] .", [["outbreak", "OBSERVATION_MODIFIER", 3, 11]]], ["In a recent outbreak in the USA, 213 persons developed hepatitis A after eating contaminated frozen strawberries that were distributed in school lunch programs [163] .", [["hepatitis A", "DISEASE", 55, 66], ["persons", "ORGANISM", 37, 44], ["persons", "SPECIES", 37, 44], ["hepatitis A", "PROBLEM", 55, 66], ["contaminated frozen strawberries", "PROBLEM", 80, 112], ["hepatitis", "OBSERVATION", 55, 64]]], ["In 1996 and 1997, a large HAV epidemic occurred in southern Italy, Puglia region, with 11 .000 no-ti\u00a2cations especially among young adults.", [["HAV", "DISEASE", 26, 29], ["HAV", "SPECIES", 26, 29], ["a large HAV epidemic", "PROBLEM", 18, 38], ["large", "OBSERVATION_MODIFIER", 20, 25], ["HAV", "OBSERVATION_MODIFIER", 26, 29], ["epidemic", "OBSERVATION", 30, 38]]], ["The main risk factor in this epidemic outbreak was consumption of mussels [166] .", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["A large HAV epidemic occurred in Finland among drug abusers (around 300 cases) due to contaminated amphetamine [172, 173] .", [["HAV", "DISEASE", 8, 11], ["amphetamine", "CHEMICAL", 99, 110], ["amphetamine", "CHEMICAL", 99, 110], ["amphetamine", "SIMPLE_CHEMICAL", 99, 110], ["HAV", "SPECIES", 8, 11], ["A large HAV epidemic", "PROBLEM", 0, 20], ["contaminated amphetamine", "PROBLEM", 86, 110], ["large", "OBSERVATION_MODIFIER", 2, 7], ["HAV", "OBSERVATION_MODIFIER", 8, 11], ["epidemic", "OBSERVATION", 12, 20]]], ["In outbreak situations, up to 20% of cases are due to secondary transmission.", [["secondary transmission", "PROBLEM", 54, 76]]], ["Waterborne outbreaks are unusual, but have been reported in association with drinking fecally contaminated water and swimming in contaminated swimming pools and lakes [136, 160] .Risk groupsIn the developed world, groups at increased risk of HAV can be identi\u00a2ed.", [["HAV", "DISEASE", 242, 245], ["HAV", "ORGANISM", 242, 245], ["HAV", "SPECIES", 242, 245], ["Waterborne outbreaks", "PROBLEM", 0, 20], ["HAV", "PROBLEM", 242, 245], ["outbreaks", "OBSERVATION", 11, 20]]], ["In case^control studies in England and Italy, factors associated with increased risk of HAV included international travel to areas of intermediate or high HAV endemicity, a household contact with hepatitis A, sharing a household with a child aged 3^10 years, consumption of bivalve mollusks, and consumption of untreated water [165] .", [["HAV", "DISEASE", 88, 91], ["HAV endemicity", "DISEASE", 155, 169], ["hepatitis A", "DISEASE", 196, 207], ["child", "SPECIES", 236, 241], ["HAV", "SPECIES", 88, 91], ["HAV", "SPECIES", 155, 158], ["HAV", "PROBLEM", 88, 91]]], ["In Italy, shell\u00a2sh consumption was the most frequently reported source of infection over the period considered [158] .", [["shell\u00a2sh", "CHEMICAL", 10, 18], ["infection", "DISEASE", 74, 83], ["infection", "PROBLEM", 74, 83], ["infection", "OBSERVATION", 74, 83]]], ["Other identi\u00a2ed potential sources of infection include association with child care centers (11^16%) and international travel (4^6%).", [["infection", "DISEASE", 37, 46], ["infection", "PROBLEM", 37, 46], ["infection", "OBSERVATION", 37, 46]]], ["Although several food-and waterborne outbreaks of HAV have been described [159, 160, 163, 167] , in the USA only 5% of reported cases occur in association with a recognized food-or waterborne outbreak [6] .", [["HAV", "DISEASE", 50, 53], ["HAV", "ORGANISM", 50, 53], ["HAV", "SPECIES", 50, 53], ["HAV", "PROBLEM", 50, 53]]], ["However, approximately 50% of reported cases do not have a recognized source of infection.", [["infection", "DISEASE", 80, 89], ["infection", "PROBLEM", 80, 89], ["infection", "OBSERVATION", 80, 89]]], ["In many countries in the developed world, cyclic outbreaks have occurred among users of injection drugs and men who have sex with men [173, 174] .", [["men", "ORGANISM", 108, 111], ["men", "ORGANISM", 130, 133], ["men", "SPECIES", 108, 111], ["men", "SPECIES", 130, 133], ["injection drugs", "TREATMENT", 88, 103]]], ["In The Netherlands, around 20% of HAV cases are related to international travel to high-risk areas; in areas of very low endemicity such as Scandinavia, in many years international travel accounts for the majority of reported cases.Risk groupsSince the case fatality rate of HAV infection increases with age, risks of more serious illness are higher for older age groups, provided they have not encountered HAV throughout their life [157] .", [["HAV", "DISEASE", 34, 37], ["HAV infection", "DISEASE", 275, 288], ["HAV", "DISEASE", 407, 410], ["HAV", "ORGANISM", 34, 37], ["HAV", "ORGANISM", 275, 278], ["HAV", "SPECIES", 34, 37], ["HAV", "SPECIES", 275, 278], ["HAV", "SPECIES", 407, 410], ["HAV cases", "PROBLEM", 34, 43], ["HAV infection", "PROBLEM", 275, 288], ["more serious illness", "PROBLEM", 318, 338], ["very", "OBSERVATION_MODIFIER", 112, 116], ["low", "OBSERVATION_MODIFIER", 117, 120], ["endemicity", "OBSERVATION", 121, 131], ["infection", "OBSERVATION", 279, 288]]], ["Persons with hepatitis C infection and possibly those with chronic hepatitis B are at increased risk of fulminant hepatitis following superinfection with HAV [147^149].Molecular epidemiologyMolecular detection and typing assays have been developed for HAV [163, 175, 177] .", [["hepatitis C infection", "DISEASE", 13, 34], ["chronic hepatitis B", "DISEASE", 59, 78], ["hepatitis", "DISEASE", 114, 123], ["superinfection", "DISEASE", 134, 148], ["HAV", "DISEASE", 154, 157], ["Persons", "ORGANISM", 0, 7], ["hepatitis C", "ORGANISM", 13, 24], ["HAV", "ORGANISM", 252, 255], ["Persons", "SPECIES", 0, 7], ["HAV", "SPECIES", 154, 157], ["HAV", "SPECIES", 252, 255], ["hepatitis C infection", "PROBLEM", 13, 34], ["chronic hepatitis B", "PROBLEM", 59, 78], ["fulminant hepatitis", "PROBLEM", 104, 123], ["superinfection", "PROBLEM", 134, 148], ["HAV", "PROBLEM", 154, 157], ["Molecular detection", "TEST", 190, 209], ["typing assays", "TEST", 214, 227], ["HAV", "PROBLEM", 252, 255], ["hepatitis", "OBSERVATION", 13, 22], ["infection", "OBSERVATION", 25, 34], ["chronic", "OBSERVATION_MODIFIER", 59, 66], ["hepatitis", "OBSERVATION", 67, 76], ["fulminant", "OBSERVATION_MODIFIER", 104, 113], ["hepatitis", "OBSERVATION", 114, 123], ["superinfection", "OBSERVATION", 134, 148]]], ["These assays can detect HAV in stool and serum specimens from patients with hepatitis [150, 177, 178] .", [["stool", "ANATOMY", 31, 36], ["serum specimens", "ANATOMY", 41, 56], ["hepatitis", "DISEASE", 76, 85], ["HAV", "ORGANISM", 24, 27], ["stool", "ORGANISM_SUBSTANCE", 31, 36], ["serum specimens", "ORGANISM_SUBSTANCE", 41, 56], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["HAV", "SPECIES", 24, 27], ["These assays", "TEST", 0, 12], ["HAV in stool and serum specimens", "TEST", 24, 56], ["hepatitis", "TEST", 76, 85]]], ["Seven genotypes of HAV have been recognized, four of which occur in humans.", [["HAV", "DISEASE", 19, 22], ["HAV", "ORGANISM", 19, 22], ["humans", "ORGANISM", 68, 74], ["humans", "SPECIES", 68, 74], ["HAV", "SPECIES", 19, 22], ["humans", "SPECIES", 68, 74], ["Seven genotypes of HAV", "PROBLEM", 0, 22], ["HAV", "OBSERVATION", 19, 22]]], ["The other three genotypes have been found in captive Old World monkeys [179] .", [["monkeys", "SPECIES", 63, 70], ["Old World monkeys", "SPECIES", 53, 70]]], ["Genetically distinct lineages are found in di\u00a1erent geographic regions and among patients in particular risk groups [154, 173, 174, 176, 180, 181] .", [["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["distinct", "OBSERVATION_MODIFIER", 12, 20], ["lineages", "OBSERVATION", 21, 29], ["di\u00a1erent", "OBSERVATION_MODIFIER", 43, 51], ["geographic", "OBSERVATION_MODIFIER", 52, 62]]], ["The genetic diversity of HAV has been used to verify the occurrence of outbreaks including foodborne [142, 153, 159, 163, 167, 169] and waterborne outbreaks [160] , and to link apparently sporadic cases to recognized foodborne and waterborne outbreaks [167, 182] .ImmunityOnly one serotype of HAV has been found so far, of which the antigenicity is determined by an immunodominant antigenic site [183] .", [["foodborne and waterborne outbreaks", "DISEASE", 217, 251], ["HAV", "DISEASE", 293, 296], ["HAV", "ORGANISM", 25, 28], ["HAV", "ORGANISM", 293, 296], ["HAV", "SPECIES", 25, 28], ["HAV", "SPECIES", 293, 296], ["HAV", "PROBLEM", 25, 28], ["HAV", "PROBLEM", 293, 296], ["an immunodominant antigenic site", "PROBLEM", 363, 395]]], ["A single HAV infection appears to induce lifelong immunity to the strains containing this epitope, but it remains to be seen if antigenic variants exist.", [["HAV infection", "DISEASE", 9, 22], ["HAV", "ORGANISM", 9, 12], ["HAV", "SPECIES", 9, 12], ["A single HAV infection", "PROBLEM", 0, 22], ["the strains", "PROBLEM", 62, 73], ["this epitope", "PROBLEM", 85, 97], ["antigenic variants", "PROBLEM", 128, 146], ["infection", "OBSERVATION", 13, 22]]], ["IgM appears rapidly, with the majority of cases positive at 3 days post onset of symptoms [156] .", [["IgM", "GENE_OR_GENE_PRODUCT", 0, 3], ["IgM", "PROTEIN", 0, 3], ["IgM", "TEST", 0, 3], ["cases positive", "PROBLEM", 42, 56], ["symptoms", "PROBLEM", 81, 89], ["rapidly", "OBSERVATION_MODIFIER", 12, 19]]], ["Levels of IgM readily decline, and after 6 months 75% of patients have no detectable IgM antibodies left.", [["IgM", "GENE_OR_GENE_PRODUCT", 10, 13], ["patients", "ORGANISM", 57, 65], ["IgM", "PROTEIN", 10, 13], ["IgM antibodies", "PROTEIN", 85, 99], ["patients", "SPECIES", 57, 65], ["Levels", "TEST", 0, 6], ["IgM", "TEST", 10, 13], ["detectable IgM antibodies left", "PROBLEM", 74, 104], ["IgM antibodies", "OBSERVATION", 85, 99]]], ["IgG anti-HAV begins to rise early in the course of infection and remains detectable for life, conferring protection against repeated HAV infection.", [["infection", "DISEASE", 51, 60], ["HAV infection", "DISEASE", 133, 146], ["IgG", "GENE_OR_GENE_PRODUCT", 0, 3], ["HAV", "ORGANISM", 133, 136], ["IgG anti-HAV", "PROTEIN", 0, 12], ["HAV", "SPECIES", 133, 136], ["IgG anti-HAV", "PROBLEM", 0, 12], ["infection", "PROBLEM", 51, 60], ["repeated HAV infection", "PROBLEM", 124, 146], ["infection", "OBSERVATION", 51, 60], ["infection", "OBSERVATION", 137, 146]]], ["Susceptibility to HAV infection can be determined using commercially available assays that detect IgM and total (IgG and IgM) antibody to HAV in serum.Modes of transmissionHAV is transmitted by the fecal^oral route, most often from person to person.", [["serum", "ANATOMY", 145, 150], ["oral", "ANATOMY", 204, 208], ["HAV infection", "DISEASE", 18, 31], ["transmissionHAV", "CHEMICAL", 160, 175], ["HAV", "ORGANISM", 18, 21], ["IgM", "GENE_OR_GENE_PRODUCT", 98, 101], ["IgG", "GENE_OR_GENE_PRODUCT", 113, 116], ["IgM", "GENE_OR_GENE_PRODUCT", 121, 124], ["HAV", "ORGANISM", 138, 141], ["serum", "ORGANISM_SUBSTANCE", 145, 150], ["fecal", "ORGANISM_SUBDIVISION", 198, 203], ["oral", "ORGANISM_SUBDIVISION", 204, 208], ["IgM", "PROTEIN", 98, 101], ["IgG", "PROTEIN", 113, 116], ["IgM", "PROTEIN", 121, 124], ["person", "SPECIES", 232, 238], ["person", "SPECIES", 242, 248], ["HAV", "SPECIES", 18, 21], ["HAV", "SPECIES", 138, 141], ["HAV infection", "PROBLEM", 18, 31], ["assays", "TEST", 79, 85], ["IgM", "TEST", 98, 101], ["total (IgG", "TEST", 106, 116], ["IgM) antibody", "TEST", 121, 134], ["HAV in serum", "TEST", 138, 150], ["infection", "OBSERVATION", 22, 31], ["fecal", "ANATOMY", 198, 203]]], ["This is exempli\u00a2ed by the high transmission rates among young children in developing countries, in areas where crowding is common and sanitation is poor, and in households and child care settings [136, 155] .", [["children", "ORGANISM", 62, 70], ["children", "SPECIES", 62, 70]]], ["One report suggests the possibility of HAV infection via contaminated drinking glasses in a bar [184] .", [["HAV infection", "DISEASE", 39, 52], ["HAV", "ORGANISM", 39, 42], ["HAV", "SPECIES", 39, 42], ["HAV infection", "PROBLEM", 39, 52], ["suggests the possibility of", "UNCERTAINTY", 11, 38], ["HAV", "OBSERVATION_MODIFIER", 39, 42], ["infection", "OBSERVATION", 43, 52]]], ["On rare occasions, HAV infection has been transmitted by transfusion of blood or blood products collected from donors during the viremic phase of infection, which appears to be much longer than was previously assumed [150, 159, 177, 180, 185, 186] .", [["blood", "ANATOMY", 72, 77], ["blood", "ANATOMY", 81, 86], ["HAV infection", "DISEASE", 19, 32], ["infection", "DISEASE", 146, 155], ["HAV", "ORGANISM", 19, 22], ["blood", "ORGANISM_SUBSTANCE", 72, 77], ["blood products", "ORGANISM_SUBSTANCE", 81, 95], ["donors", "ORGANISM", 111, 117], ["HAV", "SPECIES", 19, 22], ["HAV infection", "PROBLEM", 19, 32], ["transfusion of blood", "TREATMENT", 57, 77], ["blood products", "TREATMENT", 81, 95], ["infection", "PROBLEM", 146, 155], ["infection", "OBSERVATION", 23, 32], ["infection", "OBSERVATION", 146, 155]]], ["Although HAV has been detected in saliva of experimentally infected non-human primates, transmission by saliva has not been demonstrated.", [["HAV", "ORGANISM", 9, 12], ["saliva", "ORGANISM_SUBSTANCE", 34, 40], ["non-human", "ORGANISM", 68, 77], ["primates", "ORGANISM", 78, 86], ["saliva", "ORGANISM_SUBSTANCE", 104, 110], ["HAV", "SPECIES", 9, 12], ["HAV", "PROBLEM", 9, 12], ["experimentally", "OBSERVATION_MODIFIER", 44, 58], ["infected", "OBSERVATION", 59, 67], ["non-human primates", "OBSERVATION", 68, 86]]], ["A large outbreak among intravenous drug users in Finland was attributed to the possibility of fecal contamination of amphetamine associated with transportation of drugs in the gastrointestinal tract, which of course will be di\u2044cult to prove [172] .High risk foodstu\u00a1sBivalve molluscan shell\u00a2sh are notorious as a source of foodborne viral infections, because \u00a2lter-feeding shell\u00a2sh can concentrate HAV up to 100-fold from large volumes of water, allowing accumulation of virus from fecally contaminated water ( [95, 104, 110, 164, 166, 169, 187] ; for review see [188] ).", [["intravenous", "ANATOMY", 23, 34], ["fecal", "ANATOMY", 94, 99], ["gastrointestinal tract", "ANATOMY", 176, 198], ["amphetamine", "CHEMICAL", 117, 128], ["foodborne viral infections", "DISEASE", 323, 349], ["shell\u00a2sh", "CHEMICAL", 373, 381], ["amphetamine", "CHEMICAL", 117, 128], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 23, 34], ["fecal", "ORGANISM_SUBSTANCE", 94, 99], ["amphetamine", "SIMPLE_CHEMICAL", 117, 128], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 176, 198], ["shell\u00a2sh", "ORGANISM", 373, 381], ["HAV", "ORGANISM", 398, 401], ["HAV", "SPECIES", 398, 401], ["fecal contamination of amphetamine", "PROBLEM", 94, 128], ["drugs", "TREATMENT", 163, 168], ["foodborne viral infections", "PROBLEM", 323, 349], ["accumulation of virus", "PROBLEM", 455, 476], ["large", "OBSERVATION_MODIFIER", 2, 7], ["outbreak", "OBSERVATION_MODIFIER", 8, 16], ["fecal contamination", "OBSERVATION", 94, 113], ["gastrointestinal tract", "ANATOMY", 176, 198], ["Bivalve molluscan shell\u00a2sh", "OBSERVATION", 267, 293]]], ["Depuration, a practice that may reduce bacterial contamination, is far less e\u00a1ective in reducing viral contamination.", [["Depuration", "TREATMENT", 0, 10], ["bacterial contamination", "PROBLEM", 39, 62], ["reducing viral contamination", "PROBLEM", 88, 116], ["bacterial", "OBSERVATION_MODIFIER", 39, 48], ["contamination", "OBSERVATION", 49, 62], ["viral contamination", "OBSERVATION", 97, 116]]], ["Quality control of food and water on the basis of the detection of indicator organisms for fecal contamination has proven to be an unreliable predictor of viral contamination [187, 189] .", [["fecal", "ANATOMY", 91, 96], ["fecal contamination", "DISEASE", 91, 110], ["fecal", "ORGANISM_SUBSTANCE", 91, 96], ["indicator organisms", "PROBLEM", 67, 86], ["fecal contamination", "PROBLEM", 91, 110], ["viral contamination", "PROBLEM", 155, 174]]], ["For shell\u00a2sh, screening both of growing waters and of shell\u00a2sh could be done, but the relative sensitivities of these approaches need to be evaluated.High risk foodstu\u00a1sSeveral other foods, however, have also been implicated as vehicles of transmission (desserts, fruits, vegetables, salads, sandwiches): the bottomline message is that any food that has been handled manually and not (su\u2044ciently) heated subsequently is a possible source of infection [8] .", [["fruits", "ANATOMY", 264, 270], ["vegetables", "ANATOMY", 272, 282], ["infection", "DISEASE", 441, 450], ["fruits", "ORGANISM_SUBDIVISION", 264, 270], ["vegetables", "ORGANISM_SUBDIVISION", 272, 282], ["salads", "ORGANISM_SUBDIVISION", 284, 290], ["screening", "TEST", 14, 23], ["these approaches", "TREATMENT", 112, 128], ["High risk foodstu\u00a1s", "PROBLEM", 150, 169], ["infection", "PROBLEM", 441, 450], ["foods", "OBSERVATION", 183, 188], ["infection", "OBSERVATION", 441, 450]]], ["It is important to note, however, that contamination may occur not only at the end of the food chain, but at almost every step in the path from farm to table.High risk foodstu\u00a1sOutbreaks associated with food, particularly raw produce, contaminated before reaching the food service establishment have been recognized increasingly in recent years [74, 99, 159, 163, 168] .", [["High risk foodstu\u00a1s", "PROBLEM", 158, 177]]], ["This produce appears to have been contaminated during harvest, which could occur from handling by virus-infected individuals.", [["individuals", "ORGANISM", 113, 124], ["infected individuals", "PROBLEM", 104, 124], ["contaminated", "OBSERVATION", 34, 46], ["harvest", "OBSERVATION", 54, 61]]], ["However, a better understanding of the precise mechanisms whereby viral contamination of raw produce occurs is needed to better focus prevention e\u00a1orts in this area.", [["viral contamination", "PROBLEM", 66, 85]]], ["It is clear that some currently used industrial food processing methods will not su\u2044ciently inactivate viruses if present in the foods before processing [190] .High risk foodstu\u00a1sRecent studies with novel techniques show that infected foodhandlers may shed virus for longer periods of time [42, 178] and therefore may remain infectious even after full recovery [109] .", [["foodhandlers", "ORGANISM", 235, 247], ["industrial food processing methods", "TREATMENT", 37, 71], ["High risk foodstu\u00a1s", "PROBLEM", 160, 179], ["Recent studies", "TEST", 179, 193], ["novel techniques", "TEST", 199, 215], ["infected foodhandlers", "PROBLEM", 226, 247], ["infectious", "PROBLEM", 325, 335], ["clear", "OBSERVATION", 6, 11], ["infected", "OBSERVATION", 226, 234], ["may remain", "UNCERTAINTY", 314, 324], ["infectious", "OBSERVATION", 325, 335]]], ["Enteric viruses may persist for extended periods on materials that are commonly found in institutions and domestic environments (such as paper, cotton cloth, aluminum, china, glazed tiles, latex, and polystyrene [191] ).Virus detection in food and waterAlthough diagnostic methods have been developed for the detection of virus or viral RNA in food and water, they have not found their way to routine laboratories in most parts of the world [192^201] .", [["Enteric viruses", "DISEASE", 0, 15], ["paper, cotton cloth, aluminum, china, glazed tiles, latex, and polystyrene", "CHEMICAL", 137, 211], ["aluminum", "CHEMICAL", 158, 166], ["polystyrene", "CHEMICAL", 200, 211], ["Virus", "ORGANISM", 220, 225], ["viral RNA", "RNA", 331, 340], ["Enteric viruses", "PROBLEM", 0, 15], ["cotton cloth, aluminum, china, glazed tiles, latex", "TREATMENT", 144, 194], ["Virus detection", "TEST", 220, 235], ["diagnostic methods", "TEST", 262, 280], ["virus", "PROBLEM", 322, 327], ["viruses", "OBSERVATION", 8, 15]]], ["Most studies of virus detection in food have focussed on shell\u00a2sh, for which several groups have developed slightly di\u00a1erent protocols, and comparative studies are needed to determine which assays should be recommended (reviewed in [188] ).", [["virus detection", "TEST", 16, 31], ["slightly di\u00a1erent protocols", "TREATMENT", 107, 134], ["comparative studies", "TEST", 140, 159], ["virus", "OBSERVATION", 16, 21]]], ["Recently, some methods were reported for virus detection in other foods, but their application in the \u00a2eld remains anecdotal [202, 203] .", [["virus detection", "TEST", 41, 56]]], ["This information is needed before screening of such specimens can be done to monitor contamination.Virus detection in food and waterA special problem is that NLV cannot be grown in tissue culture, and HAV only with moderate success.", [["specimens", "ANATOMY", 52, 61], ["tissue culture", "ANATOMY", 181, 195], ["Virus", "ORGANISM", 99, 104], ["tissue culture", "CELL", 181, 195], ["HAV", "ORGANISM", 201, 204], ["NLV", "SPECIES", 158, 161], ["HAV", "SPECIES", 201, 204], ["screening of such specimens", "TEST", 34, 61], ["Virus detection in food", "PROBLEM", 99, 122], ["NLV", "PROBLEM", 158, 161], ["tissue culture", "TEST", 181, 195], ["moderate", "OBSERVATION_MODIFIER", 215, 223], ["success", "OBSERVATION", 224, 231]]], ["As a result, data on the correlation between the presence of viral genes (as tested by RT-PCR) and viable virus are lacking.", [["viral genes", "DNA", 61, 72], ["viral genes", "PROBLEM", 61, 72], ["RT-PCR", "TEST", 87, 93], ["viable virus", "PROBLEM", 99, 111], ["viral genes", "OBSERVATION", 61, 72], ["virus", "OBSERVATION", 106, 111]]], ["Arnal et al. [204] assayed the stability of HAV in arti\u00a2cial sterile seawater by RT-PCR and by cell culture.", [["cell", "ANATOMY", 95, 99], ["HAV", "ORGANISM", 44, 47], ["cell", "CELL", 95, 99], ["HAV", "SPECIES", 44, 47], ["HAV in arti\u00a2cial sterile seawater", "TREATMENT", 44, 77], ["PCR", "TEST", 84, 87], ["cell culture", "TEST", 95, 107]]], ["The HAV genome was detectable by RT-PCR for 232 days while virus particles were detectable in cell culture for only 35 days, suggesting that detection of the HAV genome by RT-PCR is not a reliable indicator of the presence of viable virus.", [["cell culture", "ANATOMY", 94, 106], ["HAV", "ORGANISM", 4, 7], ["cell culture", "CELL", 94, 106], ["HAV", "ORGANISM", 158, 161], ["HAV genome", "DNA", 4, 14], ["HAV genome", "DNA", 158, 168], ["HAV", "SPECIES", 4, 7], ["HAV", "SPECIES", 158, 161], ["The HAV genome", "PROBLEM", 0, 14], ["RT-PCR", "TEST", 33, 39], ["virus particles", "PROBLEM", 59, 74], ["cell culture", "TEST", 94, 106], ["the HAV genome", "PROBLEM", 154, 168], ["RT-PCR", "TEST", 172, 178], ["viable virus", "PROBLEM", 226, 238], ["viable virus", "OBSERVATION", 226, 238]]], ["Polish et al. [205] found that only stool specimens that were positive for HAV by ELI-SA were infectious for tamarins, suggesting that the viral load may be a determining factor of infectivity.Virus detection in food and waterFor outbreak diagnosis, the current approach is the screening of stool specimens from cases and controls, combined with an epidemiological investigation to assess food-speci\u00a2c attack rates.", [["stool specimens", "ANATOMY", 36, 51], ["stool specimens", "ANATOMY", 291, 306], ["HAV", "DISEASE", 75, 78], ["ELI-SA", "CHEMICAL", 82, 88], ["stool specimens", "ORGANISM_SUBSTANCE", 36, 51], ["HAV", "ORGANISM", 75, 78], ["ELI-SA", "ORGANISM", 82, 88], ["tamarins", "ORGANISM", 109, 117], ["Virus", "ORGANISM", 193, 198], ["stool specimens", "ORGANISM_SUBSTANCE", 291, 306], ["HAV", "SPECIES", 75, 78], ["stool specimens", "TEST", 36, 51], ["HAV", "PROBLEM", 75, 78], ["tamarins", "TREATMENT", 109, 117], ["the viral load", "PROBLEM", 135, 149], ["infectivity", "PROBLEM", 181, 192], ["Virus detection", "TEST", 193, 208], ["stool specimens", "TEST", 291, 306], ["an epidemiological investigation", "TEST", 346, 378], ["viral load", "OBSERVATION", 139, 149], ["infectivity", "OBSERVATION", 181, 192]]], ["Foods with a signi\u00a2cant odds ratio may then be examined by molecular methods, although no information is available about the sensitivity of these methods for outbreak diagnosis and^in the case of HAV^implicated foods usually have been consumed or discarded by the time the outbreak is recognized due to the long incubation period.", [["HAV", "ORGANISM", 196, 199], ["HAV", "SPECIES", 196, 199]]], ["Therefore, the combination of epidemiological outbreak investigations and molecular strain typing provides a powerful tool to establish transmission routes.Prevention and disinfectionIncreasing the awareness of all foodhandlers about transmission of enteric viruses is needed, with special emphasis on the risk of 'silent' transmission by asymptomatically infected persons and those continuing to shed virus following resolution of symptoms.", [["enteric viruses", "DISEASE", 250, 265], ["asymptomatically infected", "DISEASE", 339, 364], ["persons", "ORGANISM", 365, 372], ["persons", "SPECIES", 365, 372], ["epidemiological outbreak investigations", "TEST", 30, 69], ["molecular strain typing", "TEST", 74, 97], ["disinfection", "TREATMENT", 171, 183], ["enteric viruses", "PROBLEM", 250, 265], ["asymptomatically infected persons", "PROBLEM", 339, 372], ["symptoms", "PROBLEM", 432, 440], ["disinfection", "OBSERVATION", 171, 183], ["enteric", "ANATOMY", 250, 257], ["viruses", "OBSERVATION", 258, 265]]], ["While it may be unclear what proportion of foodborne infections can be attributed to workers in di\u00a1erent parts of the food chain, it is important that viruses become part of science-based hazard analysis and critical control point (HACCP) systems to identify risks and to help identify gaps in knowledge.", [["foodborne infections", "DISEASE", 43, 63], ["foodborne infections", "PROBLEM", 43, 63], ["hazard analysis", "TEST", 188, 203]]], ["Preventive measures di\u00a1er for the di\u00a1erent transmission routes.Prevention and disinfection(i) Shell\u00a2sh : for shell\u00a2sh, strict control of the quality of growing waters can prevent contamination of shell\u00a2sh.", [["shell\u00a2sh", "TREATMENT", 109, 117], ["contamination of shell\u00a2sh", "PROBLEM", 179, 204]]], ["This includes control of waste disposal by commercial and recreational boats.", [["waste disposal", "OBSERVATION", 25, 39], ["recreational boats", "OBSERVATION", 58, 76]]], ["Guidelines speci\u00a2cally aimed at reduction of viral contamination are needed, as it has become clear that the current indicators for water and shell-\u00a2sh quality are insu\u2044cient as predictors of viral contamination [189,199^201] .Prevention and disinfection(ii) Food items contaminated by infected foodhandlers: personal hygiene is most important in preventing foodborne viral infection, and includes frequent handwashing and wearing gloves.", [["foodborne viral infection", "DISEASE", 358, 383], ["Guidelines", "TREATMENT", 0, 10], ["viral contamination", "PROBLEM", 45, 64], ["water and shell-\u00a2sh quality", "TREATMENT", 132, 159], ["viral contamination", "PROBLEM", 192, 211], ["foodborne viral infection", "PROBLEM", 358, 383], ["wearing gloves", "TREATMENT", 423, 437], ["viral contamination", "OBSERVATION", 45, 64], ["infection", "OBSERVATION", 374, 383]]], ["The infectious dose of NLV appears to be extremely low [114] .", [["NLV", "CHEMICAL", 23, 26], ["infectious", "OBSERVATION", 4, 14]]], ["As a result, even with strict sanitary measures, infection may not always be prevented.", [["infection", "DISEASE", 49, 58], ["strict sanitary measures", "TREATMENT", 23, 47], ["infection", "PROBLEM", 49, 58], ["infection", "OBSERVATION", 49, 58]]], ["A common-sense guideline is to remove people with symptoms consistent with viral gastroenteritis from the production chain until at least 2 days after remission of the symptoms.", [["viral gastroenteritis", "DISEASE", 75, 96], ["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44], ["symptoms", "PROBLEM", 50, 58], ["viral gastroenteritis", "PROBLEM", 75, 96], ["the symptoms", "PROBLEM", 164, 176], ["consistent with", "UNCERTAINTY", 59, 74], ["viral gastroenteritis", "OBSERVATION", 75, 96]]], ["A practical problem with this guideline is that an unknown proportion of viral infections will be subclinical, viral shedding may last longer, and^even in the incubation period infected persons may shed su\u2044cient amounts of virus to cause food contamination [42, 123, 171, 177, 178] .", [["viral infections", "DISEASE", 73, 89], ["persons", "ORGANISM", 186, 193], ["persons", "SPECIES", 186, 193], ["A practical problem", "PROBLEM", 0, 19], ["this guideline", "TREATMENT", 25, 39], ["viral infections", "PROBLEM", 73, 89], ["viral shedding", "PROBLEM", 111, 125], ["virus", "PROBLEM", 223, 228], ["viral", "OBSERVATION_MODIFIER", 73, 78], ["infections", "OBSERVATION", 79, 89]]], ["The kinetics of viral shedding have only been studied in a few infected volunteers, and may not re\u00a3ect the real-life situation when people may have been infected with a low dose of infectious virus.", [["infectious virus", "DISEASE", 181, 197], ["volunteers", "ORGANISM", 72, 82], ["people", "ORGANISM", 132, 138], ["infectious virus", "ORGANISM", 181, 197], ["people", "SPECIES", 132, 138], ["viral shedding", "PROBLEM", 16, 30], ["infectious virus", "PROBLEM", 181, 197], ["viral", "OBSERVATION", 16, 21], ["infectious", "OBSERVATION", 181, 191]]], ["Given the highly infectious nature of NLV and HAV, and the documented risk of virus transmission to food during the incubation period, it is envisioned that guidelines should be developed that consider the occurrence of gastroenteritis in contacts (e.g. children) of people working in critical points in the food chain.", [["HAV", "DISEASE", 46, 49], ["gastroenteritis", "DISEASE", 220, 235], ["NLV", "CANCER", 38, 41], ["HAV", "ORGANISM", 46, 49], ["children", "ORGANISM", 254, 262], ["people", "ORGANISM", 267, 273], ["children", "SPECIES", 254, 262], ["people", "SPECIES", 267, 273], ["NLV", "SPECIES", 38, 41], ["HAV", "SPECIES", 46, 49], ["NLV", "PROBLEM", 38, 41], ["HAV", "PROBLEM", 46, 49], ["gastroenteritis", "PROBLEM", 220, 235], ["highly", "OBSERVATION_MODIFIER", 10, 16], ["infectious", "OBSERVATION", 17, 27], ["virus", "OBSERVATION", 78, 83], ["gastroenteritis", "OBSERVATION", 220, 235]]], ["This should be based on data on the kinetics of viral shedding following natural infection.", [["infection", "DISEASE", 81, 90], ["viral shedding", "PROBLEM", 48, 62], ["natural infection", "PROBLEM", 73, 90], ["infection", "OBSERVATION", 81, 90]]], ["It is important to note that contamination can be particularly widespread after vomiting, due to aerosol formation and subsequent transport of virus particles by air.Prevention and disinfectionThe globalization of the food market has hampered the implementation of control measures to assure safe food.", [["vomiting", "DISEASE", 80, 88], ["contamination", "PROBLEM", 29, 42], ["vomiting", "PROBLEM", 80, 88], ["aerosol formation", "PROBLEM", 97, 114], ["subsequent transport of virus particles", "TREATMENT", 119, 158], ["disinfection", "TREATMENT", 181, 193], ["control measures", "TREATMENT", 265, 281], ["disinfection", "OBSERVATION", 181, 193], ["globalization", "OBSERVATION_MODIFIER", 197, 210]]], ["It is not clear whether routine monitoring of food specimens for viral contamination will be feasible.", [["specimens", "ANATOMY", 51, 60], ["routine monitoring of food specimens", "TEST", 24, 60], ["viral contamination", "PROBLEM", 65, 84]]], ["However, for prevention of foodborne transmission, it is also essential that food items are not grown or washed in fecally contaminated water.Prevention and disinfectionHighly e\u00a1ective inactivated hepatitis A vaccines are available for use before exposure.", [["foodborne transmission", "DISEASE", 27, 49], ["hepatitis A", "DISEASE", 197, 208], ["hepatitis A", "SPECIES", 197, 208], ["foodborne transmission", "PROBLEM", 27, 49], ["Prevention", "TREATMENT", 142, 152], ["hepatitis A vaccines", "TREATMENT", 197, 217]]], ["To reduce the frequency with which foodhandlers with hepatitis A are identi\u00a2ed, vaccination of foodhandlers has been advocated and implemented in some cities in the USA [185] .", [["hepatitis A", "DISEASE", 53, 64], ["hepatitis A", "PROBLEM", 53, 64], ["vaccination of foodhandlers", "TREATMENT", 80, 107]]], ["Whether HAV vaccination is feasible for preventing foodborne transmission for speci\u00a2c countries or regions depends on many local factors (e.g. level of endemicity, hygienic conditions) and needs to be evaluated for these speci\u00a2c situations, based on HACCP analysis.", [["HAV", "ORGANISM", 8, 11], ["HAV", "SPECIES", 8, 11], ["HAV vaccination", "TREATMENT", 8, 23], ["speci\u00a2c countries", "TREATMENT", 78, 95], ["these speci\u00a2c situations", "PROBLEM", 215, 239], ["HACCP analysis", "TEST", 250, 264]]], ["Ig reportedly is more than 85% e\u00a1ective in preventing hepatitis A when given within 2 weeks of exposure [206] .", [["hepatitis A", "DISEASE", 54, 65], ["Ig", "GENE_OR_GENE_PRODUCT", 0, 2], ["Ig", "PROTEIN", 0, 2], ["hepatitis A", "SPECIES", 54, 65], ["Ig", "TEST", 0, 2], ["hepatitis A", "TREATMENT", 54, 65], ["hepatitis", "OBSERVATION", 54, 63]]], ["In the USA, when a foodhandler is identi\u00a2ed with hepatitis A, it is recommended that Ig be given to other foodhandlers at the establishment, and, under limited circumstances, to patrons.", [["hepatitis A", "DISEASE", 49, 60], ["Ig", "GENE_OR_GENE_PRODUCT", 85, 87], ["hepatitis A", "PROBLEM", 49, 60], ["Ig", "TREATMENT", 85, 87]]], ["Once cases are identi\u00a2ed that are associated with a food service establishment, it is generally too late to administer Ig to patrons, since the 2-week period during which Ig is e\u00a1ective will have passed.", [["Ig", "GENE_OR_GENE_PRODUCT", 119, 121], ["Ig", "GENE_OR_GENE_PRODUCT", 171, 173], ["Ig", "PROTEIN", 171, 173]]], ["This factor may explain some of the lack of success of Ig treatment as outbreak interventions [207] .Prevention and disinfectionHAV is resistant to low pH (up to pH 1) and to heating, surviving 1 h at 60 \u2021C [179] .", [["Ig", "GENE_OR_GENE_PRODUCT", 55, 57], ["Ig", "PROTEIN", 55, 57], ["Ig treatment", "TREATMENT", 55, 67], ["low pH", "PROBLEM", 148, 154], ["low pH", "OBSERVATION_MODIFIER", 148, 154]]], ["It appears to be extremely stable in the environment, with only a 100-fold decline in infectivity over 4 weeks at room temperature, and 31 0 months in water [155, 190] .", [["a 100-fold decline in infectivity", "PROBLEM", 64, 97], ["appears to be", "UNCERTAINTY", 3, 16], ["extremely", "OBSERVATION_MODIFIER", 17, 26], ["stable", "OBSERVATION", 27, 33], ["infectivity", "OBSERVATION_MODIFIER", 86, 97]]], ["HAV appears to be relatively resistant to free chlorine, especially when the virus is associated with organic matter.", [["chlorine", "CHEMICAL", 47, 55], ["chlorine", "CHEMICAL", 47, 55], ["HAV", "ORGANISM", 0, 3], ["chlorine", "SIMPLE_CHEMICAL", 47, 55], ["HAV", "SPECIES", 0, 3], ["free chlorine", "TREATMENT", 42, 55], ["the virus", "PROBLEM", 73, 82], ["organic matter", "PROBLEM", 102, 116], ["appears to be", "UNCERTAINTY", 4, 17], ["relatively", "OBSERVATION_MODIFIER", 18, 28], ["resistant", "OBSERVATION", 29, 38], ["free chlorine", "OBSERVATION", 42, 55], ["virus", "OBSERVATION", 77, 82], ["organic matter", "OBSERVATION", 102, 116]]], ["Heating foods (such as shell\u00a2sh) to temperatures s 85 \u2021C for 1 min and disinfecting surfaces with a 1:100 solution of sodium hypochlorite in tap water will inactivate HAV.", [["sodium hypochlorite", "CHEMICAL", 118, 137], ["HAV", "DISEASE", 167, 170], ["sodium hypochlorite", "CHEMICAL", 118, 137], ["sodium hypochlorite", "SIMPLE_CHEMICAL", 118, 137], ["HAV", "ORGANISM", 167, 170], ["HAV", "SPECIES", 167, 170], ["temperatures s", "TEST", 36, 50], ["sodium hypochlorite", "TREATMENT", 118, 137]]], ["Little is known about the stability of NLV outside the host, and infectivity can hardly be measured due to the absence of a cell culture system.", [["cell", "ANATOMY", 124, 128], ["NLV", "GENE_OR_GENE_PRODUCT", 39, 42], ["cell", "CELL", 124, 128], ["NLV", "SPECIES", 39, 42], ["a cell culture system", "TEST", 122, 143]]], ["From experiments with adult volunteers in the 1980s it has been suggested that NV is resistant to low pH (2.7), ether extraction, and heat treatment (30 min at 60 \u2021C) [26] .", [["ether", "CHEMICAL", 112, 117], ["volunteers", "ORGANISM", 28, 38], ["ether", "SIMPLE_CHEMICAL", 112, 117], ["NV", "PROBLEM", 79, 81], ["low pH", "PROBLEM", 98, 104], ["ether extraction", "TREATMENT", 112, 128], ["heat treatment", "TREATMENT", 134, 148]]], ["Steaming oysters may not prevent NLV gastroenteritis [208] .", [["gastroenteritis", "DISEASE", 37, 52], ["NLV", "SPECIES", 33, 36], ["Steaming oysters", "TREATMENT", 0, 16], ["NLV gastroenteritis", "PROBLEM", 33, 52], ["may not prevent", "UNCERTAINTY", 17, 32]]], ["The virus reportedly is quite resistant to chlorine as remains infectious after 30 min in the presence of 0.5^1 mg free chlorine per liter.", [["chlorine", "CHEMICAL", 43, 51], ["chlorine", "CHEMICAL", 120, 128], ["chlorine", "CHEMICAL", 43, 51], ["chlorine", "CHEMICAL", 120, 128], ["chlorine", "SIMPLE_CHEMICAL", 43, 51], ["chlorine", "SIMPLE_CHEMICAL", 120, 128], ["The virus", "PROBLEM", 0, 9], ["chlorine", "TREATMENT", 43, 51], ["infectious", "PROBLEM", 63, 73], ["virus", "OBSERVATION", 4, 9], ["infectious", "OBSERVATION", 63, 73]]], ["At higher concentrations, the virus is inactivated ( s 2 mg per liter free chlo-rine [26] ).", [["chlo-rine", "CHEMICAL", 75, 84], ["the virus", "PROBLEM", 26, 35]]], ["These \u00a2ndings have to be interpreted with caution, as data from recent dose^response studies makes it clear that very high doses of virus were used in earlier volunteer challenge experiments.", [["recent dose^response studies", "TEST", 64, 92], ["virus", "TREATMENT", 132, 137]]], ["Therefore, reduction of infectivity due to various treatments may not have been detected.", [["infectivity", "PROBLEM", 24, 35], ["various treatments", "TREATMENT", 43, 61], ["reduction", "OBSERVATION_MODIFIER", 11, 20], ["infectivity", "OBSERVATION", 24, 35]]], ["Based on semiquantitative detection by using PCR units, drinking water treatment processes using co-agulationsedimentation, \u00a2ltration, and disinfection with free chlorine, monochloramine, ozone, chlorine dioxide or UV irradiation all reduce the amount of NV more than four log steps [209] .Legislation, rules and regulationsStatutory sanitary control for shell\u00a2sh relies on microbiological criteria to de\u00a2ne the suitability of these products, as for instance in EU Council Directive 91/492/EC.", [["EC", "ANATOMY", 490, 492], ["chlorine", "CHEMICAL", 162, 170], ["monochloramine", "CHEMICAL", 172, 186], ["ozone", "CHEMICAL", 188, 193], ["chlorine dioxide", "CHEMICAL", 195, 211], ["UV", "CHEMICAL", 215, 217], ["chlorine", "CHEMICAL", 162, 170], ["monochloramine", "CHEMICAL", 172, 186], ["ozone", "CHEMICAL", 188, 193], ["chlorine dioxide", "CHEMICAL", 195, 211], ["chlorine", "SIMPLE_CHEMICAL", 162, 170], ["monochloramine", "SIMPLE_CHEMICAL", 172, 186], ["ozone", "SIMPLE_CHEMICAL", 188, 193], ["chlorine dioxide", "SIMPLE_CHEMICAL", 195, 211], ["EC", "CELL", 490, 492], ["91/492", "CELL_LINE", 483, 489], ["EC", "CELL_TYPE", 490, 492], ["semiquantitative detection", "TEST", 9, 35], ["PCR units", "TREATMENT", 45, 54], ["drinking water treatment processes", "TREATMENT", 56, 90], ["co-agulationsedimentation", "TREATMENT", 97, 122], ["\u00a2ltration", "TREATMENT", 124, 133], ["disinfection", "TREATMENT", 139, 151], ["free chlorine", "TREATMENT", 157, 170], ["monochloramine", "TREATMENT", 172, 186], ["ozone", "TREATMENT", 188, 193], ["chlorine dioxide", "TREATMENT", 195, 211], ["UV irradiation", "TREATMENT", 215, 229], ["microbiological criteria", "TEST", 374, 398]]], ["This European directive establishes that microbial quality of shell\u00a2sh should be monitored by measuring counts of total fecal coliform bacteria, Escherichia coli, and Salmonellae.", [["shell\u00a2sh", "SIMPLE_CHEMICAL", 62, 70], ["Escherichia coli", "ORGANISM", 145, 161], ["Escherichia coli", "SPECIES", 145, 161], ["Escherichia coli", "SPECIES", 145, 161], ["total fecal coliform bacteria", "PROBLEM", 114, 143], ["Escherichia coli", "PROBLEM", 145, 161], ["Salmonellae", "PROBLEM", 167, 178], ["fecal coliform", "ANATOMY", 120, 134], ["Escherichia coli", "OBSERVATION", 145, 161], ["Salmonellae", "OBSERVATION", 167, 178]]], ["The Directive establishes no speci\u00a2c microbiological criteria concerning the presence of enteric viruses, even though it has clearly been shown that there is no correlation between the presence of viruses and the presence of coliform bacteria and/or E. coli; in fact HAV, enteroviruses and NLV have been detected in mussels that otherwise meet bacteriological standards [187^189,199,200] .", [["enteric viruses", "DISEASE", 89, 104], ["enteroviruses", "DISEASE", 272, 285], ["E. coli", "ORGANISM", 250, 257], ["HAV", "ORGANISM", 267, 270], ["enteroviruses", "ORGANISM", 272, 285], ["NLV", "GENE_OR_GENE_PRODUCT", 290, 293], ["E. coli", "SPECIES", 250, 257], ["E. coli", "SPECIES", 250, 257], ["HAV", "SPECIES", 267, 270], ["NLV", "SPECIES", 290, 293], ["enteric viruses", "PROBLEM", 89, 104], ["viruses", "PROBLEM", 197, 204], ["coliform bacteria", "PROBLEM", 225, 242], ["E. coli", "PROBLEM", 250, 257], ["enteroviruses", "PROBLEM", 272, 285], ["NLV", "TREATMENT", 290, 293], ["enteric", "ANATOMY", 89, 96], ["viruses", "OBSERVATION", 97, 104], ["viruses", "OBSERVATION", 197, 204], ["coliform bacteria", "OBSERVATION", 225, 242], ["E. coli", "OBSERVATION", 250, 257], ["enteroviruses", "OBSERVATION", 272, 285]]], ["Similarly, it is not clear if and how depuration will reduce the levels of viral contaminants, especially for NLV, since quantitative methods for their detection are not yet available.RecommendationsTo provide baseline data for future intervention and prevention programs, studies are needed to estimate the burden of illness and cost of illness due to foodborne viral infections with special emphasis on determining the burden of illness in the elderly.", [["illness", "DISEASE", 318, 325], ["illness", "DISEASE", 338, 345], ["foodborne viral infections", "DISEASE", 353, 379], ["illness", "DISEASE", 431, 438], ["NLV", "SPECIES", 110, 113], ["viral contaminants", "PROBLEM", 75, 93], ["NLV", "PROBLEM", 110, 113], ["their detection", "TEST", 146, 161], ["future intervention", "TREATMENT", 228, 247], ["prevention programs", "TREATMENT", 252, 271], ["studies", "TEST", 273, 280], ["illness", "PROBLEM", 318, 325], ["illness", "PROBLEM", 338, 345], ["foodborne viral infections", "PROBLEM", 353, 379], ["illness", "PROBLEM", 431, 438], ["not", "UNCERTAINTY", 17, 20], ["clear", "OBSERVATION", 21, 26], ["viral contaminants", "OBSERVATION", 75, 93]]], ["To enable this, better surveillance for illness is needed, as well as tools for molecular tracing of viruses throughout the food chain and through populations.", [["illness", "DISEASE", 40, 47], ["illness", "PROBLEM", 40, 47], ["molecular tracing", "TEST", 80, 97], ["viruses", "PROBLEM", 101, 108], ["viruses", "OBSERVATION", 101, 108]]], ["Rapid methods for detection and typing of foodborne viruses should be developed and rapid exchange of typing information between laboratories and between countries should be encouraged.", [["foodborne viruses", "DISEASE", 42, 59], ["foodborne viruses", "PROBLEM", 42, 59]]], ["The feasibility of using these methods for food screening should be studied.", [["these methods", "TEST", 25, 38], ["food screening", "TEST", 43, 57]]], ["The mechanism of emergence of epidemic strains should be studied, including the possible link with animal calicivirus infections.RecommendationsPreventive measures directed at reduction of bacterial infections and general hygienic measures not always su\u2044ce to reduce viral infections and contamination.", [["calicivirus infections", "DISEASE", 106, 128], ["bacterial infections", "DISEASE", 189, 209], ["viral infections", "DISEASE", 267, 283], ["animal calicivirus", "ORGANISM", 99, 117], ["epidemic strains", "PROBLEM", 30, 46], ["animal calicivirus infections", "PROBLEM", 99, 128], ["Preventive measures", "TREATMENT", 144, 163], ["bacterial infections", "PROBLEM", 189, 209], ["general hygienic measures", "TREATMENT", 214, 239], ["viral infections", "PROBLEM", 267, 283], ["calicivirus", "OBSERVATION", 106, 117], ["bacterial", "OBSERVATION_MODIFIER", 189, 198], ["infections", "OBSERVATION", 199, 209], ["viral", "OBSERVATION_MODIFIER", 267, 272], ["infections", "OBSERVATION", 273, 283]]], ["Studies are needed to evaluate if public campaigns directed at prevention of viral foodborne infections are likely to be successful.", [["viral foodborne infections", "DISEASE", 77, 103], ["Studies", "TEST", 0, 7], ["public campaigns", "TREATMENT", 34, 50], ["viral foodborne infections", "PROBLEM", 77, 103], ["viral foodborne", "OBSERVATION", 77, 92]]], ["In order to achieve this, studies are needed that address the detection of viral contaminants, the e\u00a1ects of wastewater treatment on viral load, and the study of environmental factors that contribute to bioaccumulation and depuration of viruses.", [["viral contaminants", "PROBLEM", 75, 93], ["wastewater treatment", "TREATMENT", 109, 129], ["viral load", "TEST", 133, 143], ["the study", "TEST", 149, 158], ["environmental factors", "PROBLEM", 162, 183], ["viruses", "PROBLEM", 237, 244], ["viruses", "OBSERVATION", 237, 244]]], ["The use of sludge waste as fertilizer and of wastewater for irrigation should be evaluated for risks of viral contamination.", [["sludge waste", "TREATMENT", 11, 23], ["fertilizer", "TREATMENT", 27, 37], ["wastewater", "TREATMENT", 45, 55], ["irrigation", "TREATMENT", 60, 70], ["viral contamination", "PROBLEM", 104, 123], ["sludge waste", "OBSERVATION", 11, 23], ["viral contamination", "OBSERVATION", 104, 123]]], ["Hepatitis A vaccination should be considered as part of the HACCP approach to reduce the risk of foodborne hepatitis A.RecommendationsGiven the high incidence of foodborne viral infections, it is time for a conscious e\u00a1ort to raise the awareness about the risk of foodborne transmission of viruses.", [["Hepatitis A", "DISEASE", 0, 11], ["foodborne hepatitis A.Recommendations", "DISEASE", 97, 134], ["foodborne viral infections", "DISEASE", 162, 188], ["Hepatitis A", "ORGANISM", 0, 11], ["Hepatitis A", "SPECIES", 0, 11], ["Hepatitis A vaccination", "TREATMENT", 0, 23], ["the HACCP approach", "TREATMENT", 56, 74], ["foodborne hepatitis", "PROBLEM", 97, 116], ["foodborne viral infections", "PROBLEM", 162, 188], ["foodborne transmission of viruses", "PROBLEM", 264, 297], ["foodborne hepatitis", "OBSERVATION", 97, 116], ["foodborne", "OBSERVATION_MODIFIER", 162, 171], ["viral infections", "OBSERVATION", 172, 188], ["viruses", "OBSERVATION", 290, 297]]], ["Viruses should be included in all steps of the HACCP process.", [["Viruses", "PROBLEM", 0, 7], ["HACCP process", "OBSERVATION", 47, 60]]], ["While the role of virus-infected foodhandlers in transmission of NLV and HAV is well established, the risk of virus contamination is not limited to the \u00a2nal stages of the production process, and the potential role of infected harvesters or workers anywhere in the food chain should be considered.", [["HAV", "DISEASE", 73, 76], ["foodhandlers", "CELL", 33, 45], ["NLV", "CANCER", 65, 68], ["HAV", "ORGANISM", 73, 76], ["NLV", "SPECIES", 65, 68], ["HAV", "SPECIES", 73, 76], ["virus", "PROBLEM", 18, 23], ["infected foodhandlers", "PROBLEM", 24, 45], ["HAV", "PROBLEM", 73, 76], ["virus contamination", "PROBLEM", 110, 129], ["the production process", "PROBLEM", 167, 189], ["infected harvesters", "TREATMENT", 217, 236], ["virus", "OBSERVATION", 18, 23], ["infected", "OBSERVATION", 24, 32], ["virus", "OBSERVATION", 110, 115], ["production process", "OBSERVATION", 171, 189]]], ["The food industry and the scienti\u00a2c community should work together in a joint e\u00a1ort to develop an integrated plan of action to address foodborne viral infections.", [["foodborne viral infections", "DISEASE", 135, 161], ["foodborne viral infections", "PROBLEM", 135, 161], ["joint", "ANATOMY", 72, 77]]], ["This plan should identify both research priorities and strategies for implementation of the \u00a2ndings in HACCP systems.ConclusionsAlthough there are numerous fecal^orally transmitted viruses, the risk of foodborne transmission is highest for NLV and HAV.", [["foodborne transmission", "DISEASE", 202, 224], ["HAV", "DISEASE", 248, 251], ["fecal^orally", "ORGANISM", 156, 168], ["NLV", "SPECIES", 240, 243], ["HAV", "SPECIES", 248, 251], ["numerous fecal^orally transmitted viruses", "PROBLEM", 147, 188], ["NLV", "PROBLEM", 240, 243], ["HAV", "PROBLEM", 248, 251], ["numerous", "OBSERVATION_MODIFIER", 147, 155], ["fecal", "ANATOMY", 156, 161], ["^", "OBSERVATION", 161, 162], ["viruses", "OBSERVATION", 181, 188]]], ["The ease of foodborne transmission can in part be attributed to the extreme stability of the viruses outside their host, and to the highly infectious nature.", [["the extreme stability of the viruses", "PROBLEM", 64, 100], ["extreme", "OBSERVATION_MODIFIER", 68, 75], ["stability", "OBSERVATION", 76, 85], ["viruses", "OBSERVATION", 93, 100], ["highly", "OBSERVATION_MODIFIER", 132, 138], ["infectious", "OBSERVATION", 139, 149]]], ["NLV and HAV can be transmitted from person to person, or indirectly via food, water, or fomites contaminated with virus-containing feces or vomit.", [["NLV", "CHEMICAL", 0, 3], ["NLV", "GENE_OR_GENE_PRODUCT", 0, 3], ["HAV", "ORGANISM", 8, 11], ["feces", "ORGANISM_SUBSTANCE", 131, 136], ["vomit", "ORGANISM_SUBDIVISION", 140, 145], ["person", "SPECIES", 36, 42], ["person", "SPECIES", 46, 52], ["NLV", "SPECIES", 0, 3], ["HAV", "SPECIES", 8, 11], ["virus", "PROBLEM", 114, 119], ["vomit", "PROBLEM", 140, 145]]], ["People can be infected without showing symptoms.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["symptoms", "PROBLEM", 39, 47], ["infected", "OBSERVATION", 14, 22]]], ["The high frequency of secondary cases of NLV illness and^to a lesser extent^of hepatitis A following a foodborne outbreak results in am-pli\u00a2cation of the problem.", [["illness", "DISEASE", 45, 52], ["hepatitis A", "DISEASE", 79, 90], ["hepatitis A", "SPECIES", 79, 90], ["NLV illness", "PROBLEM", 41, 52], ["hepatitis A", "PROBLEM", 79, 90], ["high frequency", "OBSERVATION_MODIFIER", 4, 18], ["lesser extent", "OBSERVATION_MODIFIER", 62, 75], ["hepatitis", "OBSERVATION", 79, 88]]], ["The burden of illness is highest in the elderly, and is therefore likely to increase in the years to come due to the aging population.", [["illness", "DISEASE", 14, 21], ["illness", "PROBLEM", 14, 21], ["the aging population", "PROBLEM", 113, 133], ["burden", "OBSERVATION_MODIFIER", 4, 10], ["illness", "OBSERVATION", 14, 21], ["highest", "OBSERVATION_MODIFIER", 25, 32], ["therefore likely", "UNCERTAINTY", 56, 72], ["increase", "OBSERVATION_MODIFIER", 76, 84]]], ["For HAV, the burden of illness may increase following hygienic control measures, due to a decreasing population of naturally immune individuals and a concurrent increase in the population at risk.ConclusionsRecent advances in the research of NLV and HAV have led to the development of molecular methods which can be used for molecular tracing of virus strains.", [["HAV", "DISEASE", 4, 7], ["illness", "DISEASE", 23, 30], ["HAV", "DISEASE", 250, 253], ["HAV", "ORGANISM", 4, 7], ["NLV", "CANCER", 242, 245], ["HAV", "ORGANISM", 250, 253], ["HAV", "SPECIES", 4, 7], ["NLV", "SPECIES", 242, 245], ["HAV", "SPECIES", 250, 253], ["HAV", "PROBLEM", 4, 7], ["illness", "PROBLEM", 23, 30], ["hygienic control measures", "TREATMENT", 54, 79], ["a decreasing population of naturally immune individuals", "PROBLEM", 88, 143], ["HAV", "PROBLEM", 250, 253], ["molecular methods", "TREATMENT", 285, 302], ["virus strains", "PROBLEM", 346, 359], ["decreasing", "OBSERVATION_MODIFIER", 90, 100], ["increase", "OBSERVATION_MODIFIER", 161, 169]]], ["These methods can be and have been used for the detection of common source outbreaks.", [["common source outbreaks", "PROBLEM", 61, 84]]], ["While traditionally certain foods have been implicated in virus outbreaks, it is clear that almost any food item can be involved, provided it has been handled by an infected person.", [["person", "SPECIES", 174, 180], ["infected", "OBSERVATION", 165, 173]]], ["There are no established methods for detection of viruses in foods other than shell-\u00a2sh, and current microbiological quality control relies on bacterial counts, which are not correlated with the presence of viruses.", [["viruses in foods", "PROBLEM", 50, 66], ["bacterial counts", "TEST", 143, 159], ["viruses", "PROBLEM", 207, 214], ["no", "UNCERTAINTY", 10, 12], ["bacterial counts", "OBSERVATION_MODIFIER", 143, 159], ["viruses", "OBSERVATION", 207, 214]]], ["Little information is available on disinfection and preventive measures speci\u00a2cally for these viruses.", [["disinfection", "TREATMENT", 35, 47], ["preventive measures", "TREATMENT", 52, 71], ["these viruses", "PROBLEM", 88, 101]]], ["Studies addressing this issue are hampered by the lack of culture systems.", [["culture systems", "TEST", 58, 73]]], ["For HAV a vaccine is available, which confers full protection from illness.ConclusionsWhere does this leave us?", [["illness", "DISEASE", 67, 74], ["HAV", "ORGANISM", 4, 7], ["HAV", "SPECIES", 4, 7], ["HAV a vaccine", "TREATMENT", 4, 17], ["illness", "PROBLEM", 67, 74]]], ["Let's all face it: international foodborne viral outbreaks are an event waiting to happen, and may very well go unnoticed with the existing surveillance systems that focus almost exclusively on bacterial pathogens.", [["foodborne viral outbreaks", "DISEASE", 33, 58], ["surveillance systems", "TEST", 140, 160], ["bacterial pathogens", "PROBLEM", 194, 213]]], ["Well-standardized surveillance networks are needed that combine epidemiological and virological information for a combined laboratory-based rapid detection system for foodborne viral outbreaks.", [["foodborne viral outbreaks", "DISEASE", 167, 192], ["foodborne viral outbreaks", "PROBLEM", 167, 192]]], ["With better surveillance, documented outbreaks of foodborne infections could be reported faster, in time to take preventive measures to stop further spread.", [["foodborne infections", "DISEASE", 50, 70], ["foodborne infections", "PROBLEM", 50, 70], ["preventive measures", "TREATMENT", 113, 132], ["foodborne infections", "OBSERVATION", 50, 70]]]], "92e99304d6df52227598a5da5996127ee119f6fa": [["IntroductionRadix Isatidis is the dried root of Isatis indigotica Fort.", [["root", "ANATOMY", 40, 44], ["IntroductionRadix Isatidis", "TREATMENT", 0, 26], ["dried root", "OBSERVATION_MODIFIER", 34, 44]]], ["Cruciferae), which is known as Banlangen (BLG) or Bei-Banlangen.", [["Bei-Banlangen", "TREATMENT", 50, 63]]], ["Baphicacanthis cusiae Rhizoma et Radix is the dried rhizome and root of Baphicacanthus cusia (Nees) Bremek.", [["rhizome", "ANATOMY", 52, 59], ["root", "ANATOMY", 64, 68], ["Baphicacanthis cusiae Rhizoma et Radix", "CHEMICAL", 0, 38], ["Baphicacanthis cusiae", "ORGANISM", 0, 21], ["rhizome", "TISSUE", 52, 59], ["root", "ORGANISM_SUBDIVISION", 64, 68], ["Baphicacanthus cusia", "ORGANISM", 72, 92], ["Baphicacanthis cusiae", "SPECIES", 0, 21], ["Baphicacanthus cusia", "SPECIES", 72, 92], ["Baphicacanthis cusiae", "SPECIES", 0, 21], ["Baphicacanthus cusia", "SPECIES", 72, 92], ["Baphicacanthis cusiae Rhizoma", "TREATMENT", 0, 29], ["Rhizoma et", "OBSERVATION", 22, 32], ["Radix", "OBSERVATION_MODIFIER", 33, 38], ["dried rhizome", "OBSERVATION_MODIFIER", 46, 59], ["root", "OBSERVATION_MODIFIER", 64, 68]]], ["Acanthaceae), which is known as Nan-Banlangen (NBLG).", [["Acanthaceae", "SIMPLE_CHEMICAL", 0, 11], ["Acanthaceae", "TREATMENT", 0, 11]]], ["In several southern regions in China, NBLG has been improperly used as Radix Isatidis even though both have been officially listed in Chinese Pharmacopoeia (State Pharmacopoeia 2000) as two different crude herbs [1] [2] [3] [4] .IntroductionRadix Isatidis and its finished products have important functions in preventing and treating influenza, tonsillitis, and malignant infectious diseases [5] [6] [7] , especially severe acute respiratory syndrome (SARS) and H1N1-influenza [8] [9] [10] [11] because of its anti-viral, anti-bacterial, anti-inflammatory, anti-tumor, and immune regulatory functions.", [["NBLG", "CHEMICAL", 38, 42], ["Isatidis", "CHEMICAL", 247, 255], ["influenza", "DISEASE", 334, 343], ["tonsillitis", "DISEASE", 345, 356], ["malignant infectious diseases", "DISEASE", 362, 391], ["acute respiratory syndrome", "DISEASE", 424, 450], ["SARS", "DISEASE", 452, 456], ["H1N1-influenza [8] [9] [10", "CHEMICAL", 462, 488], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 212, 227], ["[8] [9] [10", "SIMPLE_CHEMICAL", 477, 488], ["anti-tumor", "CANCER", 557, 567], ["H1N1-influenza", "SPECIES", 462, 476], ["Chinese Pharmacopoeia (State Pharmacopoeia", "TREATMENT", 134, 176], ["crude herbs", "TEST", 200, 211], ["IntroductionRadix Isatidis", "TREATMENT", 229, 255], ["its finished products", "TREATMENT", 260, 281], ["influenza", "PROBLEM", 334, 343], ["tonsillitis", "PROBLEM", 345, 356], ["malignant infectious diseases", "PROBLEM", 362, 391], ["severe acute respiratory syndrome", "PROBLEM", 417, 450], ["SARS", "PROBLEM", 452, 456], ["H1N1", "PROBLEM", 462, 466], ["influenza", "PROBLEM", 467, 476], ["anti-bacterial", "TREATMENT", 522, 536], ["anti-inflammatory", "TREATMENT", 538, 555], ["anti-tumor", "TREATMENT", 557, 567], ["immune regulatory functions", "PROBLEM", 573, 600], ["several", "OBSERVATION_MODIFIER", 3, 10], ["southern", "OBSERVATION_MODIFIER", 11, 19], ["tonsillitis", "OBSERVATION", 345, 356], ["malignant", "OBSERVATION_MODIFIER", 362, 371], ["severe", "OBSERVATION_MODIFIER", 417, 423], ["acute", "OBSERVATION_MODIFIER", 424, 429], ["respiratory syndrome", "OBSERVATION", 430, 450]]], ["Moreover, numerous gratifying successes of the Radix Isatidis anti-viral effect have been reported [12] [13] [14] [15] .", [["Isatidis", "CHEMICAL", 53, 61], ["Radix Isatidis", "ORGANISM", 47, 61], ["[12] [13] [14] [15]", "SIMPLE_CHEMICAL", 99, 118], ["the Radix Isatidis anti-viral effect", "TREATMENT", 43, 79]]], ["Radix Isatidis has become an important component in various traditional Chinese medicine preparations (TCMPs), of which Banlangen Granules (BLGG) is widely used for toxic-heat removal and as an anti-viral drug in clinical practice.IntroductionThe chemical constituents in Radix Isatidis are as follows: nucleosides, glucosinolates, amino acids, polysaccharides, alkaloids, organic acid, trace elements, and so on [16] [17] [18] .", [["Radix Isatidis", "CHEMICAL", 0, 14], ["Banlangen Granules", "CHEMICAL", 120, 138], ["BLGG", "CHEMICAL", 140, 144], ["Radix Isatidis", "CHEMICAL", 272, 286], ["nucleosides", "CHEMICAL", 303, 314], ["glucosinolates", "CHEMICAL", 316, 330], ["amino acids, polysaccharides, alkaloids, organic acid", "CHEMICAL", 332, 385], ["nucleosides", "CHEMICAL", 303, 314], ["glucosinolates", "CHEMICAL", 316, 330], ["amino acids", "CHEMICAL", 332, 343], ["TCMPs", "SIMPLE_CHEMICAL", 103, 108], ["Banlangen Granules", "SIMPLE_CHEMICAL", 120, 138], ["BLGG", "SIMPLE_CHEMICAL", 140, 144], ["Radix Isatidis", "ORGANISM", 272, 286], ["nucleosides", "SIMPLE_CHEMICAL", 303, 314], ["glucosinolates", "SIMPLE_CHEMICAL", 316, 330], ["amino acids", "SIMPLE_CHEMICAL", 332, 343], ["polysaccharides", "SIMPLE_CHEMICAL", 345, 360], ["alkaloids", "SIMPLE_CHEMICAL", 362, 371], ["organic acid", "SIMPLE_CHEMICAL", 373, 385], ["[16] [17] [18]", "SIMPLE_CHEMICAL", 413, 427], ["Radix Isatidis", "SPECIES", 272, 286], ["Radix Isatidis", "PROBLEM", 0, 14], ["Chinese medicine preparations", "TREATMENT", 72, 101], ["toxic-heat removal", "TREATMENT", 165, 183], ["an anti-viral drug", "TREATMENT", 191, 209], ["nucleosides", "TREATMENT", 303, 314], ["amino acids", "TREATMENT", 332, 343], ["polysaccharides", "TREATMENT", 345, 360], ["alkaloids", "TREATMENT", 362, 371], ["organic acid", "TREATMENT", 373, 385], ["important", "OBSERVATION_MODIFIER", 29, 38], ["component", "OBSERVATION_MODIFIER", 39, 48], ["Radix Isatidis", "OBSERVATION", 272, 286]]], ["Compared with other Radix Isatidis extraction methods, the water extraction method has the most significant anti-viral, anti-bacterial, and anti-endotoxic effects, and the chemical constituents of glucosinolates (R,S-gotrin, progoitrin, epiproguotrin, and gluconapin) and nucleosides (hypoxanthine, adenosine, uridine, and guanosine) are the major bioactive components [19] [20] [21] .", [["glucosinolates", "CHEMICAL", 197, 211], ["R,S-gotrin", "CHEMICAL", 213, 223], ["progoitrin", "CHEMICAL", 225, 235], ["epiproguotrin", "CHEMICAL", 237, 250], ["gluconapin", "CHEMICAL", 256, 266], ["nucleosides", "CHEMICAL", 272, 283], ["hypoxanthine", "CHEMICAL", 285, 297], ["adenosine", "CHEMICAL", 299, 308], ["uridine", "CHEMICAL", 310, 317], ["guanosine", "CHEMICAL", 323, 332], ["glucosinolates", "CHEMICAL", 197, 211], ["S-gotrin", "CHEMICAL", 215, 223], ["progoitrin", "CHEMICAL", 225, 235], ["epiproguotrin", "CHEMICAL", 237, 250], ["gluconapin", "CHEMICAL", 256, 266], ["nucleosides", "CHEMICAL", 272, 283], ["hypoxanthine", "CHEMICAL", 285, 297], ["adenosine", "CHEMICAL", 299, 308], ["uridine", "CHEMICAL", 310, 317], ["guanosine", "CHEMICAL", 323, 332], ["glucosinolates", "SIMPLE_CHEMICAL", 197, 211], ["R,S-gotrin", "SIMPLE_CHEMICAL", 213, 223], ["progoitrin", "SIMPLE_CHEMICAL", 225, 235], ["epiproguotrin", "SIMPLE_CHEMICAL", 237, 250], ["gluconapin", "SIMPLE_CHEMICAL", 256, 266], ["nucleosides", "SIMPLE_CHEMICAL", 272, 283], ["hypoxanthine", "SIMPLE_CHEMICAL", 285, 297], ["adenosine", "SIMPLE_CHEMICAL", 299, 308], ["uridine", "SIMPLE_CHEMICAL", 310, 317], ["guanosine", "SIMPLE_CHEMICAL", 323, 332], ["[19] [20] [21]", "SIMPLE_CHEMICAL", 369, 383], ["other Radix Isatidis extraction methods", "TREATMENT", 14, 53], ["the water extraction method", "TREATMENT", 55, 82], ["anti-bacterial", "TREATMENT", 120, 134], ["anti-endotoxic effects", "TREATMENT", 140, 162], ["glucosinolates", "TREATMENT", 197, 211], ["gotrin", "TREATMENT", 217, 223], ["progoitrin", "TREATMENT", 225, 235], ["epiproguotrin", "TREATMENT", 237, 250], ["gluconapin", "TREATMENT", 256, 266], ["nucleosides", "TREATMENT", 272, 283], ["hypoxanthine", "TREATMENT", 285, 297], ["adenosine", "TREATMENT", 299, 308], ["uridine", "TREATMENT", 310, 317], ["guanosine", "TREATMENT", 323, 332], ["most significant", "OBSERVATION_MODIFIER", 91, 107], ["anti-viral", "OBSERVATION", 108, 118]]], ["Therefore, using the non-polar components of Indigotin, Indirubin, and the nonspecific amino acid constituent as quality control markers of Radix Isatidis is unsuitable [22] [23] [24] [25] [26] [27] .IntroductionGlucosinolates are one of the characteristic components of Cruciferae.", [["Indigotin", "CHEMICAL", 45, 54], ["Indirubin", "CHEMICAL", 56, 65], ["amino acid", "CHEMICAL", 87, 97], ["Isatidis", "CHEMICAL", 146, 154], ["Glucosinolates", "CHEMICAL", 212, 226], ["Cruciferae", "CHEMICAL", 271, 281], ["Indigotin", "CHEMICAL", 45, 54], ["Indirubin", "CHEMICAL", 56, 65], ["amino acid", "CHEMICAL", 87, 97], ["[22] [23] [24] [25] [26]", "CHEMICAL", 169, 193], ["Glucosinolates", "CHEMICAL", 212, 226], ["Indigotin", "SIMPLE_CHEMICAL", 45, 54], ["Indirubin", "SIMPLE_CHEMICAL", 56, 65], ["amino acid", "AMINO_ACID", 87, 97], ["[22] [23] [24] [25] [26] [27]", "SIMPLE_CHEMICAL", 169, 198], ["Glucosinolates", "SIMPLE_CHEMICAL", 212, 226], ["Cruciferae", "SIMPLE_CHEMICAL", 271, 281], ["Indigotin", "TREATMENT", 45, 54], ["Indirubin", "TREATMENT", 56, 65], ["the nonspecific amino acid constituent", "TREATMENT", 71, 109], ["Radix Isatidis", "TEST", 140, 154], ["IntroductionGlucosinolates", "TREATMENT", 200, 226], ["one of the characteristic", "OBSERVATION_MODIFIER", 231, 256], ["components", "OBSERVATION_MODIFIER", 257, 267], ["Cruciferae", "OBSERVATION", 271, 281]]], ["They degrade under endogenous myrosinase effects to work on multi-bioactivities including anti-virus and anti-bacteria [28, 29] .IntroductionR,S-goitrin reflects bioactivities that are relevant to the Radix Isatidis effects with high specificity.", [["S-goitrin", "CHEMICAL", 143, 152], ["myrosinase", "SIMPLE_CHEMICAL", 30, 40], ["anti-virus", "SIMPLE_CHEMICAL", 90, 100], ["S-goitrin", "SIMPLE_CHEMICAL", 143, 152], ["multi-bioactivities", "TREATMENT", 60, 79], ["anti-virus", "TREATMENT", 90, 100], ["anti-bacteria", "TREATMENT", 105, 118], ["IntroductionR", "TREATMENT", 129, 142], ["endogenous myrosinase", "OBSERVATION", 19, 40]]], ["In our previous studies, we established thin layer chromatography (TLC) identification and high-performance liquid chromatography (HPLC) assay methods for the quality control of Radix Isatidis using R,S-goitrin as the marker [30] , and these methods have been adopted by the ChP 2010 Edition [1] .", [["S-goitrin", "SIMPLE_CHEMICAL", 201, 210], ["Radix Isatidis", "SPECIES", 178, 192], ["thin layer chromatography", "TEST", 40, 65], ["TLC) identification", "TEST", 67, 86], ["high-performance liquid chromatography", "TREATMENT", 91, 129], ["HPLC", "TEST", 131, 135], ["Radix Isatidis", "TREATMENT", 178, 192], ["goitrin", "TREATMENT", 203, 210]]], ["Progoitrin, epiproguotrin, and R,S-gotrin all exist in Radix Isatidis.", [["Progoitrin", "CHEMICAL", 0, 10], ["epiproguotrin", "CHEMICAL", 12, 25], ["Progoitrin", "CHEMICAL", 0, 10], ["epiproguotrin, and R,S-gotrin", "CHEMICAL", 12, 41], ["Progoitrin", "SIMPLE_CHEMICAL", 0, 10], ["epiproguotrin", "SIMPLE_CHEMICAL", 12, 25], ["R", "GENE_OR_GENE_PRODUCT", 31, 32], ["S-gotrin", "SIMPLE_CHEMICAL", 33, 41], ["Radix Isatidis", "SPECIES", 55, 69], ["Progoitrin", "TREATMENT", 0, 10], ["epiproguotrin", "TREATMENT", 12, 25], ["gotrin", "TREATMENT", 35, 41], ["Radix Isatidis", "OBSERVATION", 55, 69]]], ["Under the effects of myrosinase, some parts or all of progoitrin and epiproguotrin transfer to R,S-goitrin via degradation [31] .IntroductionIn previous studies, based on the issues related to Radix Isatidis such as the improper use of NBLG, glucosinolate degradation, lack of specificity using amino acid as the BLGG quality control marker, establishing proper and scientific-based methods for quality control of Radix Isatidis and its finished products is necessary.", [["myrosinase", "CHEMICAL", 21, 31], ["progoitrin", "CHEMICAL", 54, 64], ["epiproguotrin", "CHEMICAL", 69, 82], ["R,S-goitrin", "CHEMICAL", 95, 106], ["Radix Isatidis", "CHEMICAL", 193, 207], ["NBLG", "CHEMICAL", 236, 240], ["glucosinolate", "CHEMICAL", 242, 255], ["amino acid", "CHEMICAL", 295, 305], ["Radix Isatidis", "CHEMICAL", 414, 428], ["myrosinase", "CHEMICAL", 21, 31], ["progoitrin", "CHEMICAL", 54, 64], ["epiproguotrin", "CHEMICAL", 69, 82], ["S-goitrin", "CHEMICAL", 97, 106], ["NBLG", "CHEMICAL", 236, 240], ["glucosinolate", "CHEMICAL", 242, 255], ["amino acid", "CHEMICAL", 295, 305], ["myrosinase", "SIMPLE_CHEMICAL", 21, 31], ["progoitrin", "SIMPLE_CHEMICAL", 54, 64], ["epiproguotrin", "SIMPLE_CHEMICAL", 69, 82], ["R", "GENE_OR_GENE_PRODUCT", 95, 96], ["S-goitrin", "SIMPLE_CHEMICAL", 97, 106], ["NBLG", "SIMPLE_CHEMICAL", 236, 240], ["glucosinolate", "SIMPLE_CHEMICAL", 242, 255], ["amino acid", "AMINO_ACID", 295, 305], ["BLGG", "SIMPLE_CHEMICAL", 313, 317], ["Radix Isatidis", "ORGANISM", 414, 428], ["Radix Isatidis", "SPECIES", 414, 428], ["myrosinase", "TREATMENT", 21, 31], ["progoitrin", "TREATMENT", 54, 64], ["epiproguotrin", "TREATMENT", 69, 82], ["previous studies", "TEST", 144, 160], ["Radix Isatidis", "TREATMENT", 193, 207], ["NBLG", "TREATMENT", 236, 240], ["glucosinolate degradation", "PROBLEM", 242, 267], ["amino acid", "TREATMENT", 295, 305], ["scientific-based methods", "TREATMENT", 366, 390], ["Radix Isatidis", "TREATMENT", 414, 428], ["Radix Isatidis", "OBSERVATION", 414, 428]]], ["Current studies about quantitative and chemical fingerprinting of Radix Isatidis depend on non-polar extracts or spots of chemical compositions [32] [33] [34] [35] .", [["extracts", "ANATOMY", 101, 109], ["Radix Isatidis", "CHEMICAL", 66, 80], ["Radix Isatidis", "ORGANISM", 66, 80], ["extracts", "ORGANISM_SUBSTANCE", 101, 109], ["[32] [33] [34] [35]", "SIMPLE_CHEMICAL", 144, 163], ["Radix Isatidis", "SPECIES", 66, 80], ["Current studies", "TEST", 0, 15], ["Radix Isatidis", "PROBLEM", 66, 80], ["chemical compositions", "TEST", 122, 143], ["Radix Isatidis", "OBSERVATION", 66, 80]]], ["Chemical fingerprint and quantitative analysis has become one of the most frequently applied approaches in the quality control of traditional Chinese medicine (TCM) and its finished products [36] [37] [38] [39] [40] [41] .", [["[36] [37] [38] [39] [40]", "CHEMICAL", 191, 215], ["[36] [37] [38] [39] [40]", "CHEMICAL", 191, 215], ["[36] [37] [38] [39] [40] [41]", "SIMPLE_CHEMICAL", 191, 220], ["Chemical fingerprint", "TEST", 0, 20], ["quantitative analysis", "TEST", 25, 46], ["traditional Chinese medicine", "TREATMENT", 130, 158]]], ["Studies about combining chromatographic fingerprint and multi-ingredient quantification by ultra-performance liquid chromatography with photodiode array detector (UPLC-PDA) for the quality control of Radix Isatidis and its preparations have not been reported.IntroductionThis study aims to reveal the correlation and consistency of quality control in crude herbs, prepared slices, and Radix Isatidis preparations.", [["slices", "ANATOMY", 373, 379], ["UPLC-PDA", "CHEMICAL", 163, 171], ["Radix Isatidis", "CHEMICAL", 200, 214], ["Radix Isatidis", "SPECIES", 200, 214], ["Radix Isatidis", "SPECIES", 385, 399], ["combining chromatographic fingerprint", "TEST", 14, 51], ["ultra-performance liquid chromatography", "TEST", 91, 130], ["photodiode array detector", "TEST", 136, 161], ["Radix Isatidis", "TREATMENT", 200, 214], ["This study", "TEST", 271, 281], ["crude herbs", "TREATMENT", 351, 362], ["Radix Isatidis preparations", "TREATMENT", 385, 412], ["Radix Isatidis", "OBSERVATION", 200, 214]]], ["A simple, accurate, and practical UPLC-PDA method was developed for the simultaneous determination of eight bioactive components in Radix Isatidis and its preparations.", [["Radix Isatidis", "CHEMICAL", 132, 146], ["Radix Isatidis", "SPECIES", 132, 146], ["Radix Isatidis", "TREATMENT", 132, 146], ["simple", "OBSERVATION_MODIFIER", 2, 8], ["bioactive components", "OBSERVATION", 108, 128], ["Radix Isatidis", "OBSERVATION", 132, 146]]], ["The chemical fingerprints of Radix Isatidis from various sources were established and investigated by similarity analysis (SA), hierarchical clustering analysis (HCA), and principal component analysis (PCA).", [["Radix Isatidis", "CHEMICAL", 29, 43], ["Radix Isatidis", "SPECIES", 29, 43], ["Radix Isatidis", "PROBLEM", 29, 43], ["similarity analysis", "TEST", 102, 121], ["Radix Isatidis", "OBSERVATION", 29, 43]]], ["The combination of chromatographic fingerprint analysis and the simultaneous determination of the eight bioactive components offer a more comprehensive strategy for the quality evaluation of Radix Isatidis and its finished products.Optimization of UPLC ConditionsDifferent UPLC parameters were examined and compared, including various columns, mobile phases, detection wavelengths, and gradient elution conditions to obtain as much chemical information as possible and to determine the best separation mechanism in chromatograms.", [["Radix Isatidis", "CHEMICAL", 191, 205], ["Radix Isatidis", "ORGANISM", 191, 205], ["Radix Isatidis", "SPECIES", 191, 205], ["chromatographic fingerprint analysis", "TEST", 19, 55], ["the quality evaluation", "TEST", 165, 187], ["Radix Isatidis", "PROBLEM", 191, 205], ["Different UPLC parameters", "TEST", 263, 288], ["detection wavelengths", "TEST", 359, 380], ["gradient elution conditions", "TREATMENT", 386, 413], ["Radix Isatidis", "OBSERVATION", 191, 205]]], ["Four kinds of reversed-phase columns, namely, Waters ACQUITY UPLC BEH C 18 (1.7 \u03bcm, 2.1 mm \u00d7 50 mm/100 mm) and Thermo Syncronis C 18 /Waters ACQUITY UPLC HSS T 3 (1.7 \u03bcm, 2.1 mm \u00d7 100 mm) were investigated and compared.", [["reversed-phase columns", "TREATMENT", 14, 36], ["Thermo Syncronis C", "TEST", 111, 129], ["reversed", "OBSERVATION_MODIFIER", 14, 22], ["-phase", "OBSERVATION_MODIFIER", 22, 28], ["columns", "OBSERVATION_MODIFIER", 29, 36]]], ["The Waters ACQUITY UPLC BEH C 18 (1.7 \u03bcm, 2.1 mm \u00d7 100 mm) column had good peak separation and sharp peaks.Optimization of UPLC ConditionsThe effect of mobile phase composition (methanol-water and acetonitrile-water with different modifiers including acetic acid, formic acid, phosphoric acid, and triethylamine) on chromatographic separation was investigated.", [["methanol-water and acetonitrile", "CHEMICAL", 178, 209], ["acetic acid", "CHEMICAL", 251, 262], ["formic acid", "CHEMICAL", 264, 275], ["phosphoric acid", "CHEMICAL", 277, 292], ["triethylamine", "CHEMICAL", 298, 311], ["methanol", "CHEMICAL", 178, 186], ["acetonitrile", "CHEMICAL", 197, 209], ["acetic acid", "CHEMICAL", 251, 262], ["formic acid", "CHEMICAL", 264, 275], ["phosphoric acid", "CHEMICAL", 277, 292], ["triethylamine", "CHEMICAL", 298, 311], ["methanol-water", "SIMPLE_CHEMICAL", 178, 192], ["acetonitrile", "SIMPLE_CHEMICAL", 197, 209], ["acetic acid", "SIMPLE_CHEMICAL", 251, 262], ["formic acid", "SIMPLE_CHEMICAL", 264, 275], ["phosphoric acid", "SIMPLE_CHEMICAL", 277, 292], ["triethylamine", "SIMPLE_CHEMICAL", 298, 311], ["The Waters ACQUITY", "TEST", 0, 18], ["BEH C", "TEST", 24, 29], ["sharp peaks", "PROBLEM", 95, 106], ["UPLC Conditions", "TREATMENT", 123, 138], ["mobile phase composition", "TREATMENT", 152, 176], ["methanol-water", "TREATMENT", 178, 192], ["acetonitrile", "TREATMENT", 197, 209], ["different modifiers", "TREATMENT", 221, 240], ["acetic acid", "TREATMENT", 251, 262], ["formic acid", "TREATMENT", 264, 275], ["phosphoric acid", "TREATMENT", 277, 292], ["triethylamine", "TREATMENT", 298, 311], ["chromatographic separation", "TREATMENT", 316, 342], ["peak separation", "OBSERVATION", 75, 90], ["sharp peaks", "OBSERVATION", 95, 106], ["UPLC Conditions", "OBSERVATION", 123, 138]]], ["Adding 0.1% triethylamine in the mobile phase and adjusting the pH to 4.0 with formic acid provided a better resolution and separation of the eight bioactivity components, and resulted in high precision sensitivity and selectivity.Optimization of UPLC ConditionsBased on the maximum absorption and full-scan experiment of the marker components in the UV spectra of the three-dimensional chromatograms obtained by PDA detection, the detection wavelengths at 210, 230, 254, 280 nm were selected to compare the peak number and peak resolution of all marker compounds.", [["triethylamine", "CHEMICAL", 12, 25], ["formic acid", "CHEMICAL", 79, 90], ["triethylamine", "CHEMICAL", 12, 25], ["formic acid", "CHEMICAL", 79, 90], ["triethylamine", "SIMPLE_CHEMICAL", 12, 25], ["formic acid", "SIMPLE_CHEMICAL", 79, 90], ["0.1% triethylamine", "TREATMENT", 7, 25], ["the pH", "TEST", 60, 66], ["formic acid", "TEST", 79, 90], ["the maximum absorption", "TEST", 271, 293], ["PDA detection", "TEST", 413, 426], ["the detection wavelengths", "TEST", 428, 453], ["peak", "OBSERVATION_MODIFIER", 524, 528], ["resolution", "OBSERVATION_MODIFIER", 529, 539], ["marker compounds", "OBSERVATION", 547, 563]]], ["Finally, the wavelength was set at 254 nm ( Figure 1 ).Optimization of Extraction MethodsSatisfactory extraction efficiency was obtained by comparing water-refluxing, ultrasonic, and soxhlet extraction methods.", [["Extraction MethodsSatisfactory extraction efficiency", "TREATMENT", 71, 123], ["ultrasonic", "TREATMENT", 167, 177], ["soxhlet extraction methods", "TREATMENT", 183, 209]]], ["Refluxing extraction was simpler and more effective for nucleosides and glucosinolates among the other methods.", [["nucleosides", "CHEMICAL", 56, 67], ["glucosinolates", "CHEMICAL", 72, 86], ["nucleosides", "CHEMICAL", 56, 67], ["glucosinolates", "CHEMICAL", 72, 86], ["nucleosides", "SIMPLE_CHEMICAL", 56, 67], ["glucosinolates", "SIMPLE_CHEMICAL", 72, 86], ["Refluxing extraction", "TREATMENT", 0, 20], ["nucleosides", "TREATMENT", 56, 67], ["glucosinolates", "TREATMENT", 72, 86]]], ["Therefore, this method was used in further experiments.", [["this method", "TREATMENT", 11, 22]]], ["In this study, different concentrations (0%, 20%, 50%, 75%, 90%, and 100%) of ethanol solutions, sample-solvent ratios (1:10, 1:20, 1:50, and 1:100, w/v), and extraction times (20, 30, 45 , and 60 min) were used for the BLG extraction procedure (Batch No. 20101121).", [["ethanol", "CHEMICAL", 78, 85], ["ethanol", "CHEMICAL", 78, 85], ["ethanol", "SIMPLE_CHEMICAL", 78, 85], ["this study", "TEST", 3, 13], ["ethanol solutions", "TREATMENT", 78, 95], ["sample-solvent ratios", "TEST", 97, 118], ["the BLG extraction procedure", "TREATMENT", 216, 244]]], ["As a result, the best extraction condition was established as follows: the samples were extracted by refluxing extraction using 20 mL of water as the extraction solvent, and the duration was 30 min.Method Validation of Quantitative AnalysisThe method was validated in terms of linearity, limit of detection (LOD), limit of quantification (LOQ), precision, reproducibility, stability, and recovery test.Calibration Curves, LOD, and LOQMethanol stock solutions containing eight analytes were diluted to appropriate concentrations for calibration curve construction.", [["samples", "ANATOMY", 75, 82], ["refluxing extraction", "TREATMENT", 101, 121], ["the extraction solvent", "TREATMENT", 146, 168], ["Method Validation", "TEST", 198, 215], ["Quantitative Analysis", "TEST", 219, 240], ["recovery test", "TEST", 388, 401], ["Calibration Curves", "TEST", 402, 420], ["LOD, and LOQMethanol stock solutions", "TREATMENT", 422, 458], ["eight analytes", "TREATMENT", 470, 484], ["calibration curve construction", "TREATMENT", 532, 562], ["refluxing", "OBSERVATION", 101, 110], ["stability", "OBSERVATION_MODIFIER", 373, 382]]], ["The analyte solutions at six different concentrations were injected in triplicate, and the calibration curves were established by plotting the peak area (Y) versus the concentration (x) of each component.", [["The analyte solutions", "TREATMENT", 0, 21], ["the calibration curves", "TEST", 87, 109], ["peak", "OBSERVATION_MODIFIER", 143, 147], ["area", "OBSERVATION_MODIFIER", 148, 152]]], ["LOD and LOQ, which were expressed by 3-and 10-fold of the signal-to-noise ratio (S/N), were also determined.", [["LOD and LOQ", "TEST", 0, 11]]], ["The detailed information regarding the calibration curves, linear ranges, LODs, and LOQs of the eight bioactive compounds are listed in Table 1 .", [["the calibration curves", "TEST", 35, 57], ["the eight bioactive compounds", "TREATMENT", 92, 121]]], ["Regression data, limits of detection (LODs), and limits of quantification (LOQs) for the eight bioactive constituents.CompoundRegression equation Y and x stand for the peak area and the injection quantity (\u03bcg) of each standard substance, respectively; b R = correlation coefficient, n = 6.Precision, Reproducibility, Stability, and RecoveryAs shown in Table 2 , the precision based on the peak area measurements of the eight bioactive components were higher than 0.48% (RSD, n = 6, S-01).", [["Regression data", "TEST", 0, 15], ["LODs", "TEST", 38, 42], ["CompoundRegression equation Y and x stand", "TREATMENT", 118, 159], ["the peak area", "TEST", 164, 177], ["the injection quantity", "TEST", 182, 204], ["the peak area measurements", "TEST", 385, 411], ["RSD", "TEST", 470, 473], ["Stability", "OBSERVATION_MODIFIER", 317, 326], ["peak", "OBSERVATION_MODIFIER", 389, 393], ["area", "OBSERVATION_MODIFIER", 394, 398], ["eight", "OBSERVATION_MODIFIER", 419, 424], ["bioactive", "OBSERVATION_MODIFIER", 425, 434], ["components", "OBSERVATION_MODIFIER", 435, 445], ["higher", "OBSERVATION_MODIFIER", 451, 457]]], ["The reproducibility (RSD, n = 6, S-01) of the proposed method based on six replicate injections was in the range of 0.10% to 1.24%.", [["The reproducibility", "TEST", 0, 19], ["RSD", "TEST", 21, 24], ["six replicate injections", "TREATMENT", 71, 95], ["reproducibility", "OBSERVATION_MODIFIER", 4, 19]]], ["The stability (RSD, n = 6, S-01) of the measurements over 3 days for the eight compounds was 0.22% to 1.44%.", [["RSD", "TEST", 15, 18], ["stability", "OBSERVATION_MODIFIER", 4, 13]]], ["The recovery test was performed by the standard addition method.", [["The recovery test", "TEST", 0, 17]]], ["Low, medium, and large high amounts of the standards were added to the known sample (S-01).", [["Low, medium", "PROBLEM", 0, 11], ["medium", "OBSERVATION_MODIFIER", 5, 11], ["large", "OBSERVATION_MODIFIER", 17, 22], ["high", "OBSERVATION_MODIFIER", 23, 27], ["amounts", "OBSERVATION_MODIFIER", 28, 35]]], ["Extraction and analysis were performed as described in Section 2.4.", [["Extraction and analysis", "TEST", 0, 23]]], ["The mean recovery was calculated according to the following formula: recovery (%) = (amount found\u2212original amount)/amount spiked \u00d7 100%, and RSD (%) = (SD/mean) \u00d7 100%.", [["RSD", "TEST", 141, 144]]], ["The mean recovery of the eight bioactive compounds was 99.5%-103.0%, and the RSD value was 0.73%-1.81%.Sample AnalysisThe newly established analytical method was subsequently applied to determine simultaneously the eight bioactive components in 21 commercial samples of Radix Isatidis and its finished products from different provinces or manufacturers in China.", [["samples", "ANATOMY", 259, 266], ["Radix Isatidis", "CHEMICAL", 270, 284], ["Radix Isatidis", "SPECIES", 270, 284], ["the eight bioactive compounds", "TEST", 21, 50], ["the RSD value", "TEST", 73, 86], ["Sample Analysis", "TEST", 103, 118], ["analytical method", "TREATMENT", 140, 157], ["Radix Isatidis", "TREATMENT", 270, 284], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["eight", "OBSERVATION_MODIFIER", 215, 220], ["bioactive", "OBSERVATION_MODIFIER", 221, 230], ["components", "OBSERVATION_MODIFIER", 231, 241], ["Radix Isatidis", "OBSERVATION", 270, 284]]], ["All samples were analyzed using the optimized extraction method in optimized UPLC conditions.", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11], ["the optimized extraction method", "TREATMENT", 32, 63]]], ["Each sample was analyzed in triplicate to determine the mean content (mg\u00b7g \u22121 ), and the results are tabulated in Table 3 .", [["sample", "ANATOMY", 5, 11], ["Each sample", "TEST", 0, 11]]], ["Table 4 ; b Values in mg g \u22121 of dry raw materials; and in mean \u00b1 SD, n = 3, the SD was < 4% of the mean, which is not shown for clarity; c (1) (2) (3) (4) (5) (6) (7) 9) mean the bioactive constituents number as listed in Figure 1 ; d N.D.: below LOD.Sample AnalysisGlucosinolates are the characteristic constituents in the Cruciferae plants [28, 29] .", [["SD", "DISEASE", 81, 83], ["AnalysisGlucosinolates", "CHEMICAL", 259, 281], ["AnalysisGlucosinolates", "CHEMICAL", 259, 281], ["2) (3) (4) (5) (6) (7)", "SIMPLE_CHEMICAL", 145, 167], ["AnalysisGlucosinolates", "SIMPLE_CHEMICAL", 259, 281], ["Cruciferae plants", "ORGANISM", 325, 342], ["Values", "TEST", 12, 18], ["the SD", "TEST", 77, 83], ["c (1) (2) (3) (4) (5) (6) (7) 9) mean the bioactive constituents", "PROBLEM", 138, 202], ["Sample AnalysisGlucosinolates", "TEST", 252, 281], ["not shown for", "UNCERTAINTY", 115, 128], ["constituents", "OBSERVATION_MODIFIER", 305, 317]]], ["The results from the quantitative analysis (Table 3) showed that the crude herbs generally contained the eight selected constituents and the glucosinolate content ranged from 6.48 mg g \u22121 to 73.63 mg g \u22121 .", [["glucosinolate", "CHEMICAL", 141, 154], ["glucosinolate", "CHEMICAL", 141, 154], ["glucosinolate", "SIMPLE_CHEMICAL", 141, 154], ["the quantitative analysis", "TEST", 17, 42], ["the crude herbs", "PROBLEM", 65, 80], ["the glucosinolate content", "TREATMENT", 137, 162]]], ["Table 3 and Figure 2 show that the average contents of epiprogoitrin, progoitrin, and R,S-goitrin in Radix Isatidis crude herbs are 5.86, 6.25, and 0.07 mg g \u22121 .", [["epiprogoitrin, progoitrin, and R,S-goitrin", "CHEMICAL", 55, 97], ["epiprogoitrin", "CHEMICAL", 55, 68], ["progoitrin, and R,S-goitrin", "CHEMICAL", 70, 97], ["epiprogoitrin", "SIMPLE_CHEMICAL", 55, 68], ["progoitrin", "SIMPLE_CHEMICAL", 70, 80], ["R", "SIMPLE_CHEMICAL", 86, 87], ["S-goitrin", "SIMPLE_CHEMICAL", 88, 97], ["Radix Isatidis", "ORGANISM", 101, 115], ["Radix Isatidis", "SPECIES", 101, 115], ["epiprogoitrin", "TREATMENT", 55, 68], ["progoitrin", "TREATMENT", 70, 80], ["S-goitrin in Radix Isatidis crude herbs", "TREATMENT", 88, 127], ["Radix", "ANATOMY", 101, 106]]], ["However, the average epiprogoitrin and progoitrin contents in prepared Radix Isatidis slices significantly decreased (2.53 and 2.68 mg g \u22121 , respectively), whereas the R,S-goitrin content clearly increased (0.64 mg g \u22121 ).", [["Isatidis slices", "ANATOMY", 77, 92], ["epiprogoitrin", "CHEMICAL", 21, 34], ["progoitrin", "CHEMICAL", 39, 49], ["S-goitrin", "CHEMICAL", 171, 180], ["epiprogoitrin", "CHEMICAL", 21, 34], ["progoitrin", "CHEMICAL", 39, 49], ["epiprogoitrin", "SIMPLE_CHEMICAL", 21, 34], ["progoitrin", "SIMPLE_CHEMICAL", 39, 49], ["Radix Isatidis slices", "ORGANISM", 71, 92], ["S-goitrin", "SIMPLE_CHEMICAL", 171, 180], ["the average epiprogoitrin and progoitrin contents", "TREATMENT", 9, 58], ["prepared Radix Isatidis slices", "TEST", 62, 92]]], ["The traditional processing methods improve the glucosinolate biotransformation and increase the degradation product (R,S-goitrin) content [31] .Sample AnalysisThe total content of eight compounds in different samples, especially those from different sources and harvesting times, were significantly different.", [["samples", "ANATOMY", 209, 216], ["glucosinolate", "CHEMICAL", 47, 60], ["R,S-goitrin", "CHEMICAL", 117, 128], ["glucosinolate", "CHEMICAL", 47, 60], ["glucosinolate", "SIMPLE_CHEMICAL", 47, 60], ["S-goitrin", "SIMPLE_CHEMICAL", 119, 128], ["The traditional processing methods", "TREATMENT", 0, 34], ["the glucosinolate biotransformation", "TREATMENT", 43, 78], ["the degradation product", "TREATMENT", 92, 115], ["Sample Analysis", "TEST", 144, 159], ["glucosinolate biotransformation", "OBSERVATION", 47, 78], ["total", "OBSERVATION_MODIFIER", 163, 168], ["content", "OBSERVATION_MODIFIER", 169, 176], ["eight compounds", "OBSERVATION_MODIFIER", 180, 195]]], ["Moreover, epiprogoitrin and progoitrin could not be distinctly detected (below LOD) in BLGG that was prepared and precipitated with ethanol by the water extracts of Radix Isatidis [1] .Sample AnalysisOverall, the internal qualities of 21 batches of Radix Isatidis samples from different sources with different geographical sources were varied, and the qualities needed evaluation by chemical fingerprinting.UPLC Fingerprint of Radix IsatidisAltogether, 15 batches of samples were analyzed, and all chromatograms were introduced into the Computer-Aided Similarity Evaluation System for Chromatographic Fingerprint of TCM (China Committee of Pharmacopeia, 2004).", [["extracts", "ANATOMY", 153, 161], ["samples", "ANATOMY", 467, 474], ["epiprogoitrin", "CHEMICAL", 10, 23], ["progoitrin", "CHEMICAL", 28, 38], ["ethanol", "CHEMICAL", 132, 139], ["Radix Isatidis", "CHEMICAL", 165, 179], ["epiprogoitrin", "CHEMICAL", 10, 23], ["progoitrin", "CHEMICAL", 28, 38], ["ethanol", "CHEMICAL", 132, 139], ["epiprogoitrin", "SIMPLE_CHEMICAL", 10, 23], ["progoitrin", "SIMPLE_CHEMICAL", 28, 38], ["BLGG", "SIMPLE_CHEMICAL", 87, 91], ["ethanol", "SIMPLE_CHEMICAL", 132, 139], ["samples", "CANCER", 467, 474], ["Radix Isatidis", "SPECIES", 165, 179], ["epiprogoitrin", "TREATMENT", 10, 23], ["progoitrin", "TREATMENT", 28, 38], ["ethanol", "TREATMENT", 132, 139], ["Sample AnalysisOverall", "TEST", 185, 207], ["Radix Isatidis samples", "TREATMENT", 249, 271], ["evaluation", "TEST", 369, 379], ["Radix IsatidisAltogether", "TREATMENT", 427, 451], ["samples", "TEST", 467, 474], ["all chromatograms", "TEST", 494, 511], ["Similarity Evaluation", "TEST", 552, 573], ["Radix", "ANATOMY", 427, 432]]], ["Peaks existing in all sample chromatograms were assigned as the \"common peak,\" and 10 common peaks were observed between 3 and 20 min in all 15 batches (Figure 1 ).", [["Peaks", "PROBLEM", 0, 5], ["all sample chromatograms", "TEST", 18, 42]]], ["Eight common peaks (peak 1, 2, 3, 4, 5, 6, 7, and 9) were identified as hypoxanthine, uridine, progoitrin, epiprogoitrin, adenosine, guanosine, R,S-goitrin, and gluconapin with reference substances (Figure 3 ).", [["hypoxanthine", "CHEMICAL", 72, 84], ["uridine", "CHEMICAL", 86, 93], ["progoitrin", "CHEMICAL", 95, 105], ["epiprogoitrin", "CHEMICAL", 107, 120], ["adenosine", "CHEMICAL", 122, 131], ["guanosine", "CHEMICAL", 133, 142], [", R,S-goitrin", "CHEMICAL", 142, 155], ["gluconapin", "CHEMICAL", 161, 171], ["hypoxanthine", "CHEMICAL", 72, 84], ["uridine", "CHEMICAL", 86, 93], ["progoitrin", "CHEMICAL", 95, 105], ["epiprogoitrin", "CHEMICAL", 107, 120], ["adenosine", "CHEMICAL", 122, 131], ["guanosine", "CHEMICAL", 133, 142], ["S-goitrin", "CHEMICAL", 146, 155], ["gluconapin", "CHEMICAL", 161, 171], ["hypoxanthine", "SIMPLE_CHEMICAL", 72, 84], ["uridine", "SIMPLE_CHEMICAL", 86, 93], ["progoitrin", "SIMPLE_CHEMICAL", 95, 105], ["epiprogoitrin", "SIMPLE_CHEMICAL", 107, 120], ["adenosine", "SIMPLE_CHEMICAL", 122, 131], ["guanosine", "SIMPLE_CHEMICAL", 133, 142], ["R,S-goitrin", "SIMPLE_CHEMICAL", 144, 155], ["gluconapin", "SIMPLE_CHEMICAL", 161, 171], ["Eight common peaks", "TEST", 0, 18], ["peak", "TEST", 20, 24], ["hypoxanthine", "TREATMENT", 72, 84], ["uridine", "TREATMENT", 86, 93], ["progoitrin", "TREATMENT", 95, 105], ["epiprogoitrin", "TREATMENT", 107, 120], ["adenosine", "TREATMENT", 122, 131], ["guanosine", "TREATMENT", 133, 142], ["goitrin", "TREATMENT", 148, 155], ["gluconapin", "TREATMENT", 161, 171]]], ["Peak 7 (R,S-goitrin, RT = 11 min), which was one of the most important active constituents of Radix Isatidis (China Pharmacopoeia Committee 2010), was chosen as the internal reference peak to calculate the relative retention time (RRT) and relative peak area (RPA) of the other peaks.", [["Radix Isatidis", "CHEMICAL", 94, 108], ["Peak", "TEST", 0, 4], ["RT", "TEST", 21, 23], ["relative peak area", "PROBLEM", 240, 258], ["active", "OBSERVATION_MODIFIER", 71, 77], ["constituents", "OBSERVATION_MODIFIER", 78, 90], ["Radix Isatidis", "OBSERVATION", 94, 108], ["peak", "OBSERVATION_MODIFIER", 249, 253], ["area", "OBSERVATION_MODIFIER", 254, 258]]], ["Figure 1 shows that the investigated nucleosides, glucosinolates, and other compounds in Radix Isatidis were separated and determined using the developed UPLC-PDA method.", [["nucleosides", "CHEMICAL", 37, 48], ["glucosinolates", "CHEMICAL", 50, 64], ["nucleosides", "CHEMICAL", 37, 48], ["glucosinolates", "CHEMICAL", 50, 64], ["nucleosides", "SIMPLE_CHEMICAL", 37, 48], ["glucosinolates", "SIMPLE_CHEMICAL", 50, 64], ["Radix Isatidis", "ORGANISM", 89, 103], ["Radix Isatidis", "SPECIES", 89, 103], ["the investigated nucleosides", "TREATMENT", 20, 48], ["glucosinolates", "TREATMENT", 50, 64], ["UPLC-PDA method", "TREATMENT", 154, 169]]], ["The differences of the water-soluble bioactive components from BLG and NBLG were recognized, and the components could be rapidly and efficiently differentiated by the chromatographic method ( Figure 1B,D) .", [["NBLG", "CHEMICAL", 71, 75], ["BLG", "SIMPLE_CHEMICAL", 63, 66], ["NBLG", "SIMPLE_CHEMICAL", 71, 75], ["BLG", "PROTEIN", 63, 66], ["the water-soluble bioactive components", "TREATMENT", 19, 57], ["the chromatographic method", "TEST", 163, 189], ["water-soluble", "OBSERVATION_MODIFIER", 23, 36], ["bioactive components", "OBSERVATION", 37, 57]]], ["Moreover, the bioactive constituents of glucosinolates and nucleosides were simultaneously shown by the same chromatographic method, and the high correlation between BLG and BLGG ( Figure 1B,C) provided a basis to investigate the relationship between Radix Isatidis and its preparations.Similarity Analysis (SA)The State Food and Drug Administration (SFDA) suggested that all herbal chromatograms should be evaluated in terms of similarity by calculating the correlation coefficient and/or angle cosine value of the original data [36] [37] [38] .", [["glucosinolates", "CHEMICAL", 40, 54], ["nucleosides", "CHEMICAL", 59, 70], ["glucosinolates", "CHEMICAL", 40, 54], ["nucleosides", "CHEMICAL", 59, 70], ["glucosinolates", "SIMPLE_CHEMICAL", 40, 54], ["nucleosides", "SIMPLE_CHEMICAL", 59, 70], ["BLG", "GENE_OR_GENE_PRODUCT", 166, 169], ["BLG", "PROTEIN", 166, 169], ["BLGG", "PROTEIN", 174, 178], ["Radix Isatidis", "SPECIES", 251, 265], ["glucosinolates", "TREATMENT", 40, 54], ["nucleosides", "TREATMENT", 59, 70], ["Radix Isatidis", "TREATMENT", 251, 265], ["Similarity Analysis", "TEST", 287, 306], ["Drug Administration (SFDA)", "TREATMENT", 330, 356], ["all herbal chromatograms", "TREATMENT", 372, 396]]], ["Therefore, SA was conducted based on the standard fingerprints, and the results are shown in Table 4 .", [["the standard fingerprints", "TEST", 37, 62]]], ["The same samples showed similarities (crude herbs: 0.752 to 0.820; prepared slices: 0.933 to 0.991).", [["samples", "ANATOMY", 9, 16], ["The same samples", "TEST", 0, 16], ["crude herbs", "TEST", 38, 49]]], ["The same samples had similar constituents with the slight difference resulting from the environmental conditions and the planting techniques.", [["samples", "ANATOMY", 9, 16], ["the slight difference", "PROBLEM", 47, 68], ["the planting techniques", "TREATMENT", 117, 140], ["slight", "OBSERVATION_MODIFIER", 51, 57], ["difference", "OBSERVATION_MODIFIER", 58, 68]]], ["However, the crude herbs and the prepared slices were significantly different because of the production process and the contents of main bioactive constituents.", [["slices", "ANATOMY", 42, 48], ["the crude herbs", "TREATMENT", 9, 24], ["the production process", "PROBLEM", 89, 111], ["main", "OBSERVATION_MODIFIER", 132, 136], ["bioactive constituents", "OBSERVATION", 137, 159]]], ["The biotransformation, the glucosinolate contents, and the degradation products have the most important influence on the similarities.", [["glucosinolate", "CHEMICAL", 27, 40], ["glucosinolate", "CHEMICAL", 27, 40], ["glucosinolate", "SIMPLE_CHEMICAL", 27, 40], ["the glucosinolate contents", "TEST", 23, 49], ["the degradation products", "TREATMENT", 55, 79], ["glucosinolate contents", "OBSERVATION", 27, 49]]], ["The HCA results clearly showed that the samples were appropriately divided into two main clusters related to the Radix Isatidis type (Figure 4 ).", [["samples", "ANATOMY", 40, 47], ["the samples", "TEST", 36, 47], ["Radix Isatidis", "OBSERVATION", 113, 127]]], ["Cluster-I was S01 to S08, which were the prepared slices of Radix Isatidis, whereas Cluster-II was S09 to S15, which were the crude herb samples.", [["slices", "ANATOMY", 50, 56], ["samples", "ANATOMY", 137, 144], ["Cluster-I", "GENE_OR_GENE_PRODUCT", 0, 9], ["Cluster-II", "GENE_OR_GENE_PRODUCT", 84, 94], ["S15", "GENE_OR_GENE_PRODUCT", 106, 109], ["Radix Isatidis", "SPECIES", 60, 74], ["Radix Isatidis", "PROBLEM", 60, 74], ["Radix Isatidis", "OBSERVATION", 60, 74]]], ["The HCA result was fully consistent with the actual situation of samples. .", [["samples", "ANATOMY", 65, 72]]], ["Ward's method was performed, and Squared Euclidean distance was selected as a measurement.Principal Component Analysis (PCA)PCA, which is an unsupervised multivariate data analysis approach, is appropriate when a function of many attributes is believed to be involved in different samples [40, 41] .", [["Ward's method", "TEST", 0, 13], ["a measurement", "TEST", 76, 89]]], ["PCA was employed to analyze the relationship of the 15 Radix Isatidis samples (seven crude herbs and eight prepared slices) from different sources, and the score plot derived from PCA is shown in Figure 5A .Principal Component Analysis (PCA)On the basis of eigenvalues > 1, the first two principal components, PC1 and PC2, are often used to provide a convenient visual aid for identifying inhomogeneity in the data sets.", [["slices", "ANATOMY", 116, 122], ["PC1", "DNA", 310, 313], ["PC2", "PROTEIN", 318, 321], ["PCA", "TREATMENT", 0, 3], ["the 15 Radix Isatidis samples", "TREATMENT", 48, 77], ["seven crude herbs", "TREATMENT", 79, 96], ["the score plot", "TEST", 152, 166], ["eigenvalues", "TEST", 257, 268], ["PC2", "TEST", 318, 321]]], ["The samples were clustered into two main groups.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11], ["main", "OBSERVATION_MODIFIER", 36, 40]]], ["The PCA loading plot ( Figure 5B ) indicated that peak 4 (progoitrin) and peak 7 (R,S-goitrin) showed the greatest influence on the scores.", [["progoitrin", "CHEMICAL", 58, 68], ["progoitrin", "SIMPLE_CHEMICAL", 58, 68], ["The PCA loading plot", "TEST", 0, 20], ["Figure 5B )", "TEST", 23, 34], ["peak", "TEST", 50, 54], ["progoitrin", "TEST", 58, 68], ["peak", "TEST", 74, 78], ["greatest", "OBSERVATION_MODIFIER", 106, 114]]], ["Peak 2 (uridine) and other compounds also affected the scores.", [["uridine", "CHEMICAL", 8, 15], ["uridine", "CHEMICAL", 8, 15], ["uridine", "SIMPLE_CHEMICAL", 8, 15], ["Peak", "TEST", 0, 4]]], ["Progoitrin content in the crude herbs was obviously higher than that in the prepared slices, whereas R,S-goitrin content had a reverse trend.", [["slices", "ANATOMY", 85, 91], ["Progoitrin", "CHEMICAL", 0, 10], ["R,S-goitrin", "CHEMICAL", 101, 112], ["Progoitrin", "CHEMICAL", 0, 10], ["Progoitrin", "SIMPLE_CHEMICAL", 0, 10], ["S-goitrin", "SIMPLE_CHEMICAL", 103, 112], ["Progoitrin content", "PROBLEM", 0, 18], ["the crude herbs", "TEST", 22, 37], ["higher", "OBSERVATION_MODIFIER", 52, 58]]], ["The difference between crude herbs and prepared Radix Isatidis slices could be generally tracked to the transformation of glucosinolates to their degradation products.Materials, Reagents, and ChemicalsEight BLG (prepared slices) batches, seven BLG (crude herbs) batches, six BLGG batches, and four NBLG batches were collected from different provinces or manufacturers in China, and were numbered from S-01 to S-25 (Table 4 ).", [["Isatidis slices", "ANATOMY", 54, 69], ["glucosinolates", "CHEMICAL", 122, 136], ["glucosinolates", "CHEMICAL", 122, 136], ["glucosinolates", "SIMPLE_CHEMICAL", 122, 136], ["BLG", "ORGANISM", 244, 247], ["Radix Isatidis", "SPECIES", 48, 62], ["crude herbs", "TREATMENT", 23, 34], ["prepared Radix Isatidis slices", "TREATMENT", 39, 69], ["their degradation products", "TREATMENT", 140, 166], ["Reagents", "TREATMENT", 178, 186], ["ChemicalsEight BLG (prepared slices) batches", "TREATMENT", 192, 236], ["seven BLG (crude herbs", "TREATMENT", 238, 260], ["batches", "TREATMENT", 262, 269], ["six BLGG batches", "TREATMENT", 271, 287], ["four NBLG batches", "TREATMENT", 293, 310], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["Radix Isatidis", "OBSERVATION", 48, 62]]], ["The BLG and NBLG samples were identified by Dr. Li-Hong Wu, and the voucher specimens were deposited in the Herbarium of Shanghai University of Traditional Chinese Medicine (Shanghai, China).R,S-goitrin was obtained from Shanghai Research and Development Center for Standardization ofTraditional Chinese Medicine (Shanghai, China).", [["NBLG samples", "ANATOMY", 12, 24], ["specimens", "ANATOMY", 76, 85], ["S-goitrin", "CHEMICAL", 193, 202], ["BLG", "GENE_OR_GENE_PRODUCT", 4, 7], ["NBLG samples", "CANCER", 12, 24], ["S-goitrin", "SIMPLE_CHEMICAL", 193, 202], ["BLG", "PROTEIN", 4, 7], ["The BLG and NBLG samples", "TEST", 0, 24], ["the voucher specimens", "TEST", 64, 85], ["Traditional Chinese Medicine", "TREATMENT", 144, 172], ["Standardization ofTraditional Chinese Medicine", "TREATMENT", 266, 312]]], ["Hypoxanthine, uridine, guanosine, and adenosine were purchased from the National Institute for Food and Drug control (Beijing, China).", [["Hypoxanthine", "CHEMICAL", 0, 12], ["uridine", "CHEMICAL", 14, 21], ["guanosine", "CHEMICAL", 23, 32], ["adenosine", "CHEMICAL", 38, 47], ["Hypoxanthine", "CHEMICAL", 0, 12], ["uridine", "CHEMICAL", 14, 21], ["guanosine", "CHEMICAL", 23, 32], ["adenosine", "CHEMICAL", 38, 47], ["Hypoxanthine", "SIMPLE_CHEMICAL", 0, 12], ["uridine", "SIMPLE_CHEMICAL", 14, 21], ["guanosine", "SIMPLE_CHEMICAL", 23, 32], ["adenosine", "SIMPLE_CHEMICAL", 38, 47], ["Hypoxanthine", "TREATMENT", 0, 12], ["uridine", "TREATMENT", 14, 21], ["guanosine", "TREATMENT", 23, 32], ["adenosine", "TREATMENT", 38, 47], ["Food and Drug control", "TREATMENT", 95, 116]]], ["Progoitrin, epiprogoitrin, and gluconapin were isolated from the root of Isatis indigotica Fort. and their structures were elucidated by mass spectrometry, 1 H nuclear magnetic resonance spectrometry, and 13 C nuclear magnetic resonance spectroscopy, and were confirmed by comparing the data with those of previous studies.", [["root", "ANATOMY", 65, 69], ["Progoitrin", "CHEMICAL", 0, 10], ["epiprogoitrin", "CHEMICAL", 12, 25], ["gluconapin", "CHEMICAL", 31, 41], ["Progoitrin", "CHEMICAL", 0, 10], ["epiprogoitrin", "CHEMICAL", 12, 25], ["gluconapin", "CHEMICAL", 31, 41], ["1 H", "CHEMICAL", 156, 159], ["Progoitrin", "SIMPLE_CHEMICAL", 0, 10], ["epiprogoitrin", "SIMPLE_CHEMICAL", 12, 25], ["gluconapin", "SIMPLE_CHEMICAL", 31, 41], ["root", "ORGAN", 65, 69], ["Isatis indigotica", "SPECIES", 73, 90], ["Progoitrin", "TREATMENT", 0, 10], ["epiprogoitrin", "TREATMENT", 12, 25], ["gluconapin", "TREATMENT", 31, 41], ["mass spectrometry", "TEST", 137, 154], ["nuclear magnetic resonance spectrometry", "TEST", 160, 199], ["nuclear magnetic resonance spectroscopy", "TEST", 210, 249], ["previous studies", "TEST", 306, 322]]], ["The compound purity was over 98% based on the HPLC area normalization method.", [["The compound purity", "TEST", 0, 19], ["the HPLC", "TEST", 42, 50], ["compound", "OBSERVATION_MODIFIER", 4, 12], ["purity", "OBSERVATION_MODIFIER", 13, 19]]], ["The standard structures are illustrated in Figure 6 .R,S-goitrin was obtained from Shanghai Research and Development Center for Standardization ofHPLC-grade acetonitrile, triethylamine, and formic acid (Tedia, Fairfield, OH, USA) were used for mobile phase preparation.", [["S-goitrin", "CHEMICAL", 55, 64], ["ofHPLC-grade acetonitrile, triethylamine", "CHEMICAL", 144, 184], ["formic acid", "CHEMICAL", 190, 201], ["acetonitrile", "CHEMICAL", 157, 169], ["triethylamine", "CHEMICAL", 171, 184], ["formic acid", "CHEMICAL", 190, 201], ["S-goitrin", "SIMPLE_CHEMICAL", 55, 64], ["ofHPLC-grade acetonitrile", "SIMPLE_CHEMICAL", 144, 169], ["triethylamine", "SIMPLE_CHEMICAL", 171, 184], ["formic acid", "SIMPLE_CHEMICAL", 190, 201], ["Tedia", "SIMPLE_CHEMICAL", 203, 208], ["Standardization ofHPLC", "TEST", 128, 150], ["grade acetonitrile", "TREATMENT", 151, 169], ["triethylamine", "TREATMENT", 171, 184], ["formic acid (Tedia", "TREATMENT", 190, 208], ["mobile phase preparation", "TREATMENT", 244, 268]]], ["Purified water was prepared with a Mili-Q water-purification system (Millipore, Bedford, MA, USA).", [["a Mili", "TREATMENT", 33, 39]]], ["Other solvents used for analyses were of analytical grade.Instrumentation and Chromatographic ConditionUPLC analysis was performed on a Waters ACQUITY UPLC H-Class system (Waters, Milford, MA, USA) equipped with a binary solvent delivery pump, an auto sampler, and a photodiode array detector (PDA) and was controlled by the Empower-II software.", [["Other solvents", "TREATMENT", 0, 14], ["Instrumentation", "TREATMENT", 58, 73], ["Chromatographic ConditionUPLC analysis", "TEST", 78, 116], ["a binary solvent delivery pump", "TREATMENT", 212, 242], ["an auto sampler", "TREATMENT", 244, 259], ["a photodiode array detector (PDA", "TREATMENT", 265, 297]]], ["UPLC fingerprinting analysis was carried out at 25 \u00b0C on a Waters ACQUITY UPLC BEH C 18 (1.7 \u03bcm, 2.1 mm \u00d7 100 mm).", [["UPLC fingerprinting analysis", "TEST", 0, 28]]], ["A binary gradient elution system composed of acetonitrile (phase A) and 0.1% triethylamine in water (phase B, the pH was adjusted to 4.0 with formic acid) was applied to the fingerprint analysis with the gradient elution as follows: 0 min to 5 min, 0% A; 5 min to 7 min, 0% to 3% A; 7 min to 10 min, 3% A; 10 min to 20 min, 3% to 10% A. The wavelength was set at 254 nm, the mobile flow rate at 0.3 mL min \u22121 , and the on-line UV spectra was recorded in the range of 190 nm to 500 nm.Preparation of Standard SolutionR,S-goitrin, progoitrin, epiprogoitrin, gluconapin, adenosine, uridine, guanosine, and hypoxanthine CRS were accurately weighed, and dissolved in methanol to produce a solution containing 1.0 mg mL \u22121 , which was used as the reference solution.Preparation of Sample SolutionThe crude herbs and the prepared BLG and NBLG slices were oven-dried at 50 \u00b0C until the weight remained constant.", [["NBLG slices", "ANATOMY", 831, 842], ["acetonitrile", "CHEMICAL", 45, 57], ["triethylamine", "CHEMICAL", 77, 90], ["formic acid", "CHEMICAL", 142, 153], ["S-goitrin", "CHEMICAL", 518, 527], ["progoitrin", "CHEMICAL", 529, 539], ["epiprogoitrin", "CHEMICAL", 541, 554], ["gluconapin", "CHEMICAL", 556, 566], ["adenosine", "CHEMICAL", 568, 577], ["uridine", "CHEMICAL", 579, 586], ["guanosine", "CHEMICAL", 588, 597], ["hypoxanthine", "CHEMICAL", 603, 615], ["acetonitrile", "CHEMICAL", 45, 57], ["triethylamine", "CHEMICAL", 77, 90], ["formic acid", "CHEMICAL", 142, 153], ["S-goitrin", "CHEMICAL", 518, 527], ["progoitrin", "CHEMICAL", 529, 539], ["epiprogoitrin", "CHEMICAL", 541, 554], ["gluconapin", "CHEMICAL", 556, 566], ["adenosine", "CHEMICAL", 568, 577], ["uridine", "CHEMICAL", 579, 586], ["guanosine", "CHEMICAL", 588, 597], ["hypoxanthine", "CHEMICAL", 603, 615], ["methanol", "CHEMICAL", 662, 670], ["acetonitrile", "SIMPLE_CHEMICAL", 45, 57], ["triethylamine", "SIMPLE_CHEMICAL", 77, 90], ["water", "SIMPLE_CHEMICAL", 94, 99], ["formic acid", "SIMPLE_CHEMICAL", 142, 153], ["S-goitrin", "SIMPLE_CHEMICAL", 518, 527], ["progoitrin", "SIMPLE_CHEMICAL", 529, 539], ["epiprogoitrin", "SIMPLE_CHEMICAL", 541, 554], ["gluconapin", "SIMPLE_CHEMICAL", 556, 566], ["adenosine", "SIMPLE_CHEMICAL", 568, 577], ["uridine", "SIMPLE_CHEMICAL", 579, 586], ["guanosine", "SIMPLE_CHEMICAL", 588, 597], ["hypoxanthine CRS", "SIMPLE_CHEMICAL", 603, 619], ["methanol", "SIMPLE_CHEMICAL", 662, 670], ["BLG", "GENE_OR_GENE_PRODUCT", 823, 826], ["NBLG slices", "MULTI-TISSUE_STRUCTURE", 831, 842], ["A binary gradient elution system", "TREATMENT", 0, 32], ["acetonitrile (phase A)", "TREATMENT", 45, 67], ["0.1% triethylamine in water (phase B", "TREATMENT", 72, 108], ["the pH", "TEST", 110, 116], ["formic acid)", "TREATMENT", 142, 154], ["the fingerprint analysis", "TEST", 170, 194], ["the gradient elution", "TEST", 200, 220], ["the mobile flow rate", "TEST", 371, 391], ["the on-line UV spectra", "TEST", 415, 437], ["Standard SolutionR", "TREATMENT", 499, 517], ["goitrin", "TREATMENT", 520, 527], ["progoitrin", "TREATMENT", 529, 539], ["epiprogoitrin", "TREATMENT", 541, 554], ["gluconapin", "TREATMENT", 556, 566], ["adenosine", "TREATMENT", 568, 577], ["uridine", "TREATMENT", 579, 586], ["guanosine", "TREATMENT", 588, 597], ["hypoxanthine CRS", "TREATMENT", 603, 619], ["methanol", "TREATMENT", 662, 670], ["a solution", "TREATMENT", 682, 692], ["Sample Solution", "TREATMENT", 775, 790], ["The crude herbs", "TREATMENT", 790, 805], ["the prepared BLG and NBLG slices", "TREATMENT", 810, 842], ["the weight", "TEST", 874, 884]]], ["Each sample (1.0 g powder) was extracted with 20 mL of water, which was subjected to reflux for 30 min.", [["sample", "ANATOMY", 5, 11], ["reflux", "DISEASE", 85, 91], ["reflux", "PROBLEM", 85, 91], ["reflux", "OBSERVATION", 85, 91]]], ["The final solution was filtered through a 0.22 \u03bcm membrane prior to use.", [["membrane", "ANATOMY", 50, 58], ["a 0.22 \u03bcm membrane", "TREATMENT", 40, 58]]], ["An aliquot of 2.0 \u03bcL of each sample solution was injected into the UPLC system for analysis.Method ValidationThe method was validated for linearity, LOD, LOQ, precision, reproducibility, stability, and accuracy following the International Conference on Harmonization (ICH) guideline and several reports on determination analysis [36, 38] .Data AnalysisData analysis was performed by the professional software of the Computer-Aided Similarity Evaluation System for Chromatographic Fingerprint of TCM (China Committee of Pharmacopeia, 2004A), which was recommended by the SFDA.", [["sample", "ANATOMY", 29, 35], ["ICH", "DISEASE", 268, 271], ["An aliquot of 2.0 \u03bcL of each sample solution", "TREATMENT", 0, 44], ["analysis", "TEST", 83, 91], ["determination analysis", "TEST", 306, 328], ["Data AnalysisData analysis", "TEST", 339, 365], ["stability", "OBSERVATION_MODIFIER", 187, 196]]], ["The software was employed for synchronization and quantitative comparison between different samples [37] .Data AnalysisIn addition, the RRT and RPA of each characteristic peak related to the reference peak (R,S-goitrin) were also statistically analyzed using the SPSS software packageConclusionsIn conclusion, the UPLC fingerprint and quantitative analysis of the water-soluble extract of Radix Isatidis were first established in this study to determine the eight bioactive constituents in Radix Isatidis and its finished products.ConclusionsMeanwhile, the results from the three chemometric techniques (SA, HCA, and PCA) showed good consistency with one another.", [["extract of Radix Isatidis", "CHEMICAL", 378, 403], ["Radix Isatidis", "CHEMICAL", 490, 504], ["Radix Isatidis", "ORGANISM", 389, 403], ["RPA", "PROTEIN", 144, 147], ["Radix Isatidis", "SPECIES", 389, 403], ["Radix Isatidis", "SPECIES", 490, 504], ["the RRT", "TEST", 132, 139], ["the UPLC fingerprint", "TEST", 310, 330], ["quantitative analysis", "TEST", 335, 356], ["the water-soluble extract", "TREATMENT", 360, 385], ["Radix Isatidis", "TREATMENT", 389, 403], ["this study", "TEST", 430, 440], ["Radix Isatidis", "TREATMENT", 490, 504], ["the three chemometric techniques", "TEST", 570, 602], ["SA", "TEST", 604, 606], ["HCA", "TEST", 608, 611], ["Radix Isatidis", "OBSERVATION", 389, 403], ["Radix Isatidis", "OBSERVATION", 490, 504]]], ["The samples from different locations of the same type (crude herbs or prepared slices) were still clustered into one group, and the eight bioactive components were mostly close, which indicates the similarity of internal quality of the samples in the same type.", [["samples", "ANATOMY", 4, 11], ["slices", "ANATOMY", 79, 85], ["samples", "ANATOMY", 236, 243], ["The samples", "TEST", 0, 11], ["different", "OBSERVATION_MODIFIER", 17, 26], ["eight", "OBSERVATION_MODIFIER", 132, 137], ["bioactive", "OBSERVATION_MODIFIER", 138, 147], ["components", "OBSERVATION_MODIFIER", 148, 158], ["internal", "OBSERVATION_MODIFIER", 212, 220]]], ["Furthermore, eight marker constituents were found to be specific variables, which could provide the most discrimination and quality control of Radix Isatidis and its finished products by quantitative analysis.", [["Radix Isatidis", "CHEMICAL", 143, 157], ["Radix Isatidis", "SPECIES", 143, 157], ["eight marker constituents", "TEST", 13, 38], ["Radix Isatidis", "PROBLEM", 143, 157], ["quantitative analysis", "TEST", 187, 208], ["Radix Isatidis", "OBSERVATION", 143, 157]]], ["The PCA loading plot identified the greatest impact factor of characteristic constituents to the classification.", [["The PCA loading plot", "TREATMENT", 0, 20], ["greatest", "OBSERVATION_MODIFIER", 36, 44]]], ["In addition, this chromatographic method was efficient and rapid in distinguishing Radix Isatidis from other species such as NBLG.ConclusionsBased on this study, the UPLC fingerprint and quantitative analysis methods provided reliable assurance on systematic and complete quality control on Radix Isatidis and its finished products, which would be helpful in improving reasonable developments in Radix Isatidis and its finished products.", [["Radix Isatidis", "CHEMICAL", 291, 305], ["Radix Isatidis", "CHEMICAL", 396, 410], ["Radix Isatidis", "SPECIES", 83, 97], ["Radix Isatidis", "SPECIES", 291, 305], ["Radix Isatidis", "SPECIES", 396, 410], ["this chromatographic method", "TEST", 13, 40], ["Radix Isatidis", "PROBLEM", 83, 97], ["this study", "TEST", 150, 160], ["the UPLC fingerprint", "TEST", 162, 182], ["quantitative analysis methods", "TEST", 187, 216], ["Radix Isatidis", "TREATMENT", 291, 305], ["Radix Isatidis", "TREATMENT", 396, 410], ["Radix Isatidis", "OBSERVATION", 83, 97], ["Radix Isatidis", "OBSERVATION", 396, 410]]]], "PMC5434339": [["Study Design ::: METHODSWe identified all HCT recipients and patients with HM with HCoV detected in clinical BAL samples from patients at the Fred Hutchinson Cancer Research Center, University of Washington, or Seattle Children\u2019s Hospital from May 2006 through February 2016.", [["HCT", "ANATOMY", 42, 45], ["BAL samples", "ANATOMY", 109, 120], ["Cancer", "DISEASE", 158, 164], ["HCT", "CANCER", 42, 45], ["patients", "ORGANISM", 61, 69], ["BAL samples", "CANCER", 109, 120], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 126, 134], ["Children", "SPECIES", 219, 227], ["HCoV", "SPECIES", 83, 87], ["all HCT recipients", "TREATMENT", 38, 56], ["HM", "PROBLEM", 75, 77], ["HCoV", "TREATMENT", 83, 87], ["clinical BAL samples", "TEST", 100, 120]]], ["We identified 3 additional HCT recipients with HCoV detected in BAL samples from a previously reported cohort [15].", [["HCT", "ANATOMY", 27, 30], ["BAL samples", "ANATOMY", 64, 75], ["HCT", "CANCER", 27, 30], ["HCoV", "CANCER", 47, 51], ["BAL samples", "CANCER", 64, 75], ["HCoV", "SPECIES", 47, 51], ["additional HCT recipients", "TREATMENT", 16, 41], ["HCoV", "TREATMENT", 47, 51], ["BAL samples", "TEST", 64, 75]]], ["Demographic and clinical data were collected from the above-mentioned institutions\u2019 databases and medical chart review.", [["clinical data", "TEST", 16, 29]]], ["We also compared HCT recipients with HCoV LRTD to previously reported cohorts of HCT recipients with LRTD caused by RSV, influenza virus, and PIV [16\u201318].", [["HCT", "ANATOMY", 17, 20], ["LRTD", "DISEASE", 101, 105], ["RSV, influenza virus", "DISEASE", 116, 136], ["HCT", "CANCER", 17, 20], ["HCT", "CANCER", 81, 84], ["RSV", "ORGANISM", 116, 119], ["influenza virus", "ORGANISM", 121, 136], ["influenza virus", "SPECIES", 121, 136], ["HCoV", "SPECIES", 37, 41], ["RSV", "SPECIES", 116, 119], ["influenza virus", "SPECIES", 121, 136], ["HCT recipients", "TREATMENT", 17, 31], ["HCoV", "TREATMENT", 37, 41], ["HCT recipients", "TREATMENT", 81, 95], ["LRTD", "TREATMENT", 101, 105], ["RSV", "PROBLEM", 116, 119], ["influenza virus", "PROBLEM", 121, 136], ["PIV", "TREATMENT", 142, 145], ["RSV", "ANATOMY", 116, 119], ["influenza virus", "OBSERVATION", 121, 136]]], ["The study was approved by the Institutional Review Board at the Fred Hutchinson Cancer Research Center.Laboratory Testing and Definitions ::: METHODSReverse-transcription polymerase chain reaction (RT-PCR) was performed for HCoV on BAL samples, serum specimens, lung biopsy, and autopsy samples according to a previously published protocol [19].", [["BAL samples", "ANATOMY", 232, 243], ["serum specimens", "ANATOMY", 245, 260], ["lung biopsy", "ANATOMY", 262, 273], ["samples", "ANATOMY", 287, 294], ["Cancer", "DISEASE", 80, 86], ["BAL samples", "ORGANISM_SUBSTANCE", 232, 243], ["serum specimens", "ORGANISM_SUBSTANCE", 245, 260], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 262, 273], ["HCoV", "SPECIES", 224, 228], ["The study", "TEST", 0, 9], ["Laboratory Testing", "TEST", 103, 121], ["METHODSReverse", "TEST", 142, 156], ["transcription polymerase chain reaction", "PROBLEM", 157, 196], ["RT-PCR", "TEST", 198, 204], ["BAL samples", "TEST", 232, 243], ["serum specimens", "TEST", 245, 260], ["lung biopsy", "TEST", 262, 273], ["autopsy samples", "TEST", 279, 294], ["Cancer", "OBSERVATION", 80, 86], ["lung", "ANATOMY", 262, 266]]], ["Viral load of HCoV was determined by quantitative RT-PCR using BAL samples.", [["BAL samples", "ANATOMY", 63, 74], ["Viral", "ORGANISM", 0, 5], ["HCoV", "GENE_OR_GENE_PRODUCT", 14, 18], ["HCoV", "PROTEIN", 14, 18], ["HCoV", "SPECIES", 14, 18], ["Viral load of HCoV", "TEST", 0, 18], ["quantitative RT-PCR", "TEST", 37, 56], ["BAL samples", "TEST", 63, 74]]], ["HCoV was identified from BAL specimens using the consensus HCoV assay, which is part of a multiplex PCR used to detect 12 respiratory viruses.", [["BAL specimens", "ANATOMY", 25, 38], ["respiratory viruses", "DISEASE", 122, 141], ["HCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["BAL specimens", "CANCER", 25, 38], ["HCoV", "DNA", 0, 4], ["HCoV", "SPECIES", 0, 4], ["BAL specimens", "TEST", 25, 38], ["the consensus HCoV assay", "TEST", 45, 69], ["a multiplex PCR", "TEST", 88, 103], ["12 respiratory viruses", "PROBLEM", 119, 141], ["respiratory viruses", "OBSERVATION", 122, 141]]], ["Strain-specific PCR was performed using saved BAL samples as described previously [19].", [["BAL samples", "ANATOMY", 46, 57], ["BAL samples", "CANCER", 46, 57], ["Strain-specific PCR", "TEST", 0, 19], ["BAL samples", "TEST", 46, 57]]], ["We performed RT-PCR to detect HCoV RNA in frozen serum samples that were drawn between 23 days before and 23 days after the BAL.", [["serum samples", "ANATOMY", 49, 62], ["BAL", "ANATOMY", 124, 127], ["HCoV", "GENE_OR_GENE_PRODUCT", 30, 34], ["serum samples", "ORGANISM_SUBSTANCE", 49, 62], ["HCoV RNA", "RNA", 30, 38], ["HCoV", "SPECIES", 30, 34], ["RT-PCR", "TEST", 13, 19], ["HCoV RNA", "PROBLEM", 30, 38], ["frozen serum samples", "TEST", 42, 62], ["the BAL", "TEST", 120, 127]]], ["When adequate lung tissue was available, curls were cut from fresh frozen tissue or formalin-fixed, paraffin-embedded (FFPE) tissue blocks for RT-PCR.", [["lung tissue", "ANATOMY", 14, 25], ["curls", "ANATOMY", 41, 46], ["tissue", "ANATOMY", 74, 80], ["FFPE", "ANATOMY", 119, 123], ["tissue", "ANATOMY", 125, 131], ["formalin", "CHEMICAL", 84, 92], ["lung tissue", "TISSUE", 14, 25], ["tissue", "TISSUE", 74, 80], ["FFPE", "TISSUE", 119, 123], ["tissue", "TISSUE", 125, 131], ["curls", "TEST", 41, 46], ["paraffin-embedded (FFPE) tissue blocks", "TREATMENT", 100, 138], ["RT-PCR", "TEST", 143, 149], ["lung", "ANATOMY", 14, 18], ["tissue", "OBSERVATION", 19, 25]]], ["FFPE samples and frozen samples were extracted using RNAeasy FFPE kit and RNAeasy mini kit, respectively (Qiagen, Hilden, Germany).", [["FFPE samples", "ANATOMY", 0, 12], ["samples", "ANATOMY", 24, 31], ["FFPE samples", "CANCER", 0, 12], ["FFPE samples", "TEST", 0, 12], ["frozen samples", "TEST", 17, 31]]], ["All samples underwent fragment size analysis for quality with RT-PCR targeting amplicons from housekeeping genes with sizes ranging from 100 to 600 base pairs (bp).Laboratory Testing and Definitions ::: METHODSHCoV LRTD was defined as HCoV detection in a BAL sample from a patient with signs of LRTD (eg cough, dyspnea) or new pulmonary infiltrates.", [["samples", "ANATOMY", 4, 11], ["BAL sample", "ANATOMY", 255, 265], ["pulmonary", "ANATOMY", 327, 336], ["LRTD", "DISEASE", 295, 299], ["cough", "DISEASE", 304, 309], ["dyspnea", "DISEASE", 311, 318], ["patient", "ORGANISM", 273, 280], ["pulmonary", "ORGAN", 327, 336], ["housekeeping genes", "DNA", 94, 112], ["patient", "SPECIES", 273, 280], ["HCoV", "SPECIES", 235, 239], ["All samples", "TEST", 0, 11], ["fragment size analysis", "TEST", 22, 44], ["RT-PCR targeting amplicons", "TREATMENT", 62, 88], ["sizes", "TEST", 118, 123], ["bp", "TEST", 160, 162], ["Laboratory Testing", "TEST", 164, 182], ["a BAL sample", "TEST", 253, 265], ["LRTD (eg cough", "PROBLEM", 295, 309], ["dyspnea", "PROBLEM", 311, 318], ["new pulmonary infiltrates", "PROBLEM", 323, 348], ["fragment size", "OBSERVATION_MODIFIER", 22, 35], ["sizes", "OBSERVATION_MODIFIER", 118, 123], ["new", "OBSERVATION_MODIFIER", 323, 326], ["pulmonary", "ANATOMY", 327, 336], ["infiltrates", "OBSERVATION", 337, 348]]], ["All BAL specimens underwent broad diagnostic tests including conventional cultures for bacteria, fungi, mycobacteria, and viruses, shell vial culture for cytomegalovirus, immunofluorescent antibody staining for Pneumocystis jirovecii and Legionella, fungal PCR, Aspergillus galactomannan enzyme-linked immunosorbent assay, and cytopathologic examination.", [["BAL specimens", "ANATOMY", 4, 17], ["Pneumocystis jirovecii", "DISEASE", 211, 233], ["BAL specimens", "CANCER", 4, 17], ["cytomegalovirus", "ORGANISM", 154, 169], ["Pneumocystis jirovecii", "ORGANISM", 211, 233], ["Pneumocystis jirovecii", "SPECIES", 211, 233], ["cytomegalovirus", "SPECIES", 154, 169], ["Pneumocystis jirovecii", "SPECIES", 211, 233], ["All BAL specimens", "TEST", 0, 17], ["broad diagnostic tests", "TEST", 28, 50], ["conventional cultures", "TEST", 61, 82], ["bacteria", "PROBLEM", 87, 95], ["fungi", "PROBLEM", 97, 102], ["mycobacteria", "PROBLEM", 104, 116], ["viruses", "PROBLEM", 122, 129], ["shell vial culture", "TEST", 131, 149], ["cytomegalovirus", "PROBLEM", 154, 169], ["immunofluorescent antibody staining", "TEST", 171, 206], ["Pneumocystis jirovecii", "PROBLEM", 211, 233], ["Legionella", "TEST", 238, 248], ["fungal PCR", "TEST", 250, 260], ["Aspergillus galactomannan enzyme", "TEST", 262, 294], ["immunosorbent assay", "TEST", 302, 321], ["cytopathologic examination", "TEST", 327, 353], ["mycobacteria", "OBSERVATION", 104, 116]]], ["HCoV was considered the sole respiratory pathogen if all above-mentioned microbiological test results on BAL specimens were negative.", [["BAL specimens", "ANATOMY", 105, 118], ["HCoV", "CHEMICAL", 0, 4], ["HCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["BAL specimens", "CANCER", 105, 118], ["HCoV", "SPECIES", 0, 4], ["the sole respiratory pathogen", "PROBLEM", 20, 49], ["microbiological test", "TEST", 73, 93], ["BAL specimens", "TEST", 105, 118]]], ["Pulmonary bacterial coinfection was defined as bacterial load of >103 colony-forming units per milliliter of BAL specimen with compatible radiological findings and clinical course.", [["Pulmonary", "ANATOMY", 0, 9], ["colony", "ANATOMY", 70, 76], ["BAL specimen", "ANATOMY", 109, 121], ["Pulmonary bacterial coinfection", "DISEASE", 0, 31], ["Pulmonary bacterial coinfection", "PROBLEM", 0, 31], ["bacterial load", "TEST", 47, 61], ["BAL specimen", "TEST", 109, 121], ["compatible radiological findings", "PROBLEM", 127, 159], ["bacterial", "OBSERVATION_MODIFIER", 10, 19], ["coinfection", "OBSERVATION", 20, 31]]], ["Any virus or fungus detected in BAL samples was considered a respiratory copathogen.", [["BAL samples", "ANATOMY", 32, 43], ["respiratory", "ANATOMY", 61, 72], ["BAL samples", "CANCER", 32, 43], ["Any virus", "PROBLEM", 0, 9], ["fungus", "PROBLEM", 13, 19], ["BAL samples", "TEST", 32, 43], ["a respiratory copathogen", "PROBLEM", 59, 83], ["virus", "OBSERVATION", 4, 9], ["fungus", "OBSERVATION", 13, 19], ["respiratory copathogen", "OBSERVATION", 61, 83]]], ["Highest steroid doses in the 2 weeks prior to HCoV LRTD and cell counts most immediately prior to HCoV LRTD were recorded.", [["cell", "ANATOMY", 60, 64], ["steroid", "CHEMICAL", 8, 15], ["steroid", "CHEMICAL", 8, 15], ["steroid", "SIMPLE_CHEMICAL", 8, 15], ["cell", "CELL", 60, 64], ["HCoV", "SPECIES", 46, 50], ["HCoV", "SPECIES", 98, 102], ["Highest steroid doses", "TREATMENT", 0, 21], ["HCoV LRTD", "TREATMENT", 46, 55], ["cell counts", "TEST", 60, 71], ["HCoV LRTD", "TREATMENT", 98, 107], ["cell counts", "OBSERVATION", 60, 71]]], ["Oxygen-free days and ventilator-free days are defined as days alive and free from oxygen support and mechanical ventilation, respectively [16].", [["Oxygen", "CHEMICAL", 0, 6], ["oxygen", "CHEMICAL", 82, 88], ["Oxygen", "CHEMICAL", 0, 6], ["oxygen", "CHEMICAL", 82, 88], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["oxygen", "SIMPLE_CHEMICAL", 82, 88], ["Oxygen", "TREATMENT", 0, 6], ["ventilator", "TREATMENT", 21, 31], ["oxygen support", "TREATMENT", 82, 96], ["mechanical ventilation", "TREATMENT", 101, 123]]], ["Respiratory death was defined as any death occurring as a consequence of respiratory failure.Laboratory Testing and Definitions ::: METHODSMorphologic re-review of available BAL samples, lung biopsies, and autopsy lung tissues was performed on hematoxylin and eosin\u2013stained sections by a board-certified pathologist with expertise in transplant pathology.Statistical Analysis ::: METHODSPatients\u2019 outcomes were compared using \u03c72 or Fisher exact test for categorical variables and Wilcoxon rank-sum test for continuous variables, as appropriate.", [["Respiratory", "ANATOMY", 0, 11], ["respiratory", "ANATOMY", 73, 84], ["BAL samples", "ANATOMY", 174, 185], ["lung biopsies", "ANATOMY", 187, 200], ["lung tissues", "ANATOMY", 214, 226], ["sections", "ANATOMY", 274, 282], ["Respiratory death", "DISEASE", 0, 17], ["death", "DISEASE", 37, 42], ["respiratory failure", "DISEASE", 73, 92], ["hematoxylin", "CHEMICAL", 244, 255], ["BAL samples", "CANCER", 174, 185], ["lung biopsies", "MULTI-TISSUE_STRUCTURE", 187, 200], ["lung tissues", "TISSUE", 214, 226], ["hematoxylin", "SIMPLE_CHEMICAL", 244, 255], ["Respiratory death", "PROBLEM", 0, 17], ["any death", "PROBLEM", 33, 42], ["respiratory failure", "PROBLEM", 73, 92], ["Laboratory Testing", "TEST", 93, 111], ["BAL samples", "TEST", 174, 185], ["lung biopsies", "TEST", 187, 200], ["autopsy lung tissues", "TEST", 206, 226], ["hematoxylin", "TREATMENT", 244, 255], ["Fisher exact test", "TEST", 432, 449], ["categorical variables", "TEST", 454, 475], ["Wilcoxon rank", "TEST", 480, 493], ["sum test", "TEST", 494, 502], ["respiratory failure", "OBSERVATION", 73, 92], ["lung", "ANATOMY", 187, 191], ["biopsies", "OBSERVATION", 192, 200], ["lung tissues", "ANATOMY", 214, 226], ["transplant", "ANATOMY", 334, 344], ["pathology", "OBSERVATION", 345, 354]]], ["Summary of the various patient cohorts according to analysis type is shown in Supplementary Figure 1.", [["patient", "ORGANISM", 23, 30], ["patient", "SPECIES", 23, 30]]], ["Only the first episode of HCoV LRTD per subject was used for outcome analyses.", [["LRTD", "DISEASE", 31, 35], ["HCoV", "SPECIES", 26, 30], ["HCoV LRTD", "TREATMENT", 26, 35], ["outcome analyses", "TEST", 61, 77]]], ["We also excluded 2 HCT recipients with a history of lung transplantation for outcome analyses except for evaluation of risk factors for mortality following HCoV LRTD.", [["lung", "ANATOMY", 52, 56], ["LRTD", "DISEASE", 161, 165], ["lung", "ORGAN", 52, 56], ["HCoV", "SPECIES", 156, 160], ["2 HCT recipients", "TREATMENT", 17, 33], ["lung transplantation", "TREATMENT", 52, 72], ["outcome analyses", "TEST", 77, 93], ["evaluation", "TEST", 105, 115], ["risk factors", "PROBLEM", 119, 131], ["mortality", "PROBLEM", 136, 145], ["HCoV LRTD", "TREATMENT", 156, 165], ["lung", "ANATOMY", 52, 56], ["transplantation", "OBSERVATION", 57, 72]]], ["Univariable Cox proportional hazards models were used to evaluate risk factors for overall mortality by day 90 after the diagnosis of HCoV LRTD.", [["LRTD", "DISEASE", 139, 143], ["HCoV", "SPECIES", 134, 138], ["Univariable Cox proportional hazards models", "TREATMENT", 0, 43], ["HCoV LRTD", "TREATMENT", 134, 143]]], ["Variables with a P value \u2264.2 in the univariable models were candidates for multivariable models.", [["a P value", "TEST", 15, 24], ["multivariable models", "TEST", 75, 95]]], ["A multivariable Cox regression model adjusted for respiratory viruses (HCoV, RSV, influenza, and PIV), cell source, neutrophil counts, lymphocyte counts, monocyte counts, presence of copathogens, steroid dosage, and oxygen use at diagnosis was performed.", [["cell", "ANATOMY", 103, 107], ["neutrophil", "ANATOMY", 116, 126], ["lymphocyte", "ANATOMY", 135, 145], ["monocyte", "ANATOMY", 154, 162], ["respiratory viruses", "DISEASE", 50, 69], ["influenza", "DISEASE", 82, 91], ["steroid", "CHEMICAL", 196, 203], ["oxygen", "CHEMICAL", 216, 222], ["steroid", "CHEMICAL", 196, 203], ["oxygen", "CHEMICAL", 216, 222], ["RSV", "ORGANISM", 77, 80], ["cell", "CELL", 103, 107], ["neutrophil", "CELL", 116, 126], ["lymphocyte", "CELL", 135, 145], ["monocyte", "CELL", 154, 162], ["steroid", "SIMPLE_CHEMICAL", 196, 203], ["oxygen", "SIMPLE_CHEMICAL", 216, 222], ["HCoV", "SPECIES", 71, 75], ["RSV", "SPECIES", 77, 80], ["A multivariable Cox regression model", "PROBLEM", 0, 36], ["respiratory viruses", "PROBLEM", 50, 69], ["HCoV", "TEST", 71, 75], ["RSV", "PROBLEM", 77, 80], ["influenza", "PROBLEM", 82, 91], ["PIV", "TEST", 97, 100], ["cell source", "TEST", 103, 114], ["neutrophil counts", "TEST", 116, 133], ["lymphocyte counts", "TEST", 135, 152], ["monocyte counts", "TEST", 154, 169], ["copathogens", "PROBLEM", 183, 194], ["steroid dosage", "TREATMENT", 196, 210], ["oxygen use", "TREATMENT", 216, 226], ["respiratory viruses", "OBSERVATION", 50, 69], ["neutrophil counts", "OBSERVATION", 116, 133]]], ["Patients with any respiratory viral copathogens were excluded for this analysis.", [["respiratory viral copathogens", "DISEASE", 18, 47], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["any respiratory viral copathogens", "PROBLEM", 14, 47], ["this analysis", "TEST", 66, 79], ["viral copathogens", "OBSERVATION", 30, 47]]], ["The probability of overall mortality in HCT recipients by day 90 following the diagnosis of LRTD was estimated using the Kaplan-Meier method.", [["HCT", "ANATOMY", 40, 43], ["LRTD", "DISEASE", 92, 96], ["HCT", "CANCER", 40, 43], ["HCT recipients", "TREATMENT", 40, 54], ["LRTD", "PROBLEM", 92, 96], ["overall", "OBSERVATION_MODIFIER", 19, 26], ["mortality", "OBSERVATION", 27, 36]]], ["The log-rank test was used to compare mortality curves among subgroups.", [["The log-rank test", "TEST", 0, 17]]], ["Two-sided P values <.05 were considered statistically significant.", [["Two-sided P values", "TEST", 0, 18], ["sided", "ANATOMY_MODIFIER", 4, 9]]], ["All statistical analyses were performed using SAS software version 9.4 for Windows (SAS Institute, Inc, Cary, North Carolina).Patient and Viral Characteristics ::: RESULTSWe identified a total of 35 patients (37 episodes) with HCoV detected by RT-PCR from BAL samples.", [["BAL samples", "ANATOMY", 256, 267], ["patients", "ORGANISM", 199, 207], ["HCoV", "CANCER", 227, 231], ["BAL samples", "CANCER", 256, 267], ["Patient", "SPECIES", 126, 133], ["patients", "SPECIES", 199, 207], ["HCoV", "SPECIES", 227, 231], ["All statistical analyses", "TEST", 0, 24], ["SAS software version", "TEST", 46, 66], ["HCoV", "PROBLEM", 227, 231], ["RT-PCR", "TEST", 244, 250], ["BAL samples", "TEST", 256, 267]]], ["Table 1 shows characteristics of HCT recipients and patients with HM.", [["HCT", "ANATOMY", 33, 36], ["HM", "DISEASE", 66, 68], ["HCT", "CANCER", 33, 36], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["HCT recipients", "TREATMENT", 33, 47], ["HCT recipients", "OBSERVATION", 33, 47]]], ["Two patients developed HCoV LRTD twice.", [["LRTD", "DISEASE", 28, 32], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["HCoV", "SPECIES", 23, 27]]], ["Two HCT recipients had a history of lung transplantation: 1 underwent lung transplantation for bronchiolitis obliterans related to previous HCT and the other received lung transplantation for cystic fibrosis before HCT.", [["lung", "ANATOMY", 36, 40], ["lung", "ANATOMY", 70, 74], ["lung", "ANATOMY", 167, 171], ["cystic", "ANATOMY", 192, 198], ["bronchiolitis obliterans", "DISEASE", 95, 119], ["HCT", "DISEASE", 140, 143], ["fibrosis", "DISEASE", 199, 207], ["HCT", "CANCER", 4, 7], ["lung", "ORGAN", 36, 40], ["lung", "ORGAN", 70, 74], ["lung", "ORGAN", 167, 171], ["Two HCT recipients", "TREATMENT", 0, 18], ["lung transplantation", "TREATMENT", 36, 56], ["lung transplantation", "TREATMENT", 70, 90], ["bronchiolitis obliterans", "PROBLEM", 95, 119], ["previous HCT", "TEST", 131, 143], ["lung transplantation", "TREATMENT", 167, 187], ["cystic fibrosis", "PROBLEM", 192, 207], ["HCT", "TEST", 215, 218], ["lung", "ANATOMY", 36, 40], ["transplantation", "OBSERVATION", 41, 56], ["lung", "ANATOMY", 70, 74], ["transplantation", "OBSERVATION", 75, 90], ["bronchiolitis obliterans", "OBSERVATION", 95, 119], ["lung", "ANATOMY", 167, 171], ["transplantation", "OBSERVATION", 172, 187], ["cystic", "OBSERVATION_MODIFIER", 192, 198], ["fibrosis", "OBSERVATION", 199, 207]]], ["Only 1 pediatric patient (8-year-old male) was identified in this cohort.", [["patient", "ORGANISM", 17, 24], ["patient", "SPECIES", 17, 24]]], ["The median time to HCoV LRTD after HCT in 28 recipients was 302 days (range, 8\u20137045 days): 20 (71%) and 12 (43%) patients developed HCoV LRTD >100 days and >365 days following transplant, respectively.", [["LRTD", "DISEASE", 24, 28], ["HCT", "DISEASE", 35, 38], ["LRTD", "DISEASE", 137, 141], ["HCT", "CANCER", 35, 38], ["recipients", "ORGANISM", 45, 55], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["HCoV", "SPECIES", 19, 23], ["HCoV", "SPECIES", 132, 136], ["HCT", "TEST", 35, 38], ["HCoV LRTD", "PROBLEM", 132, 141], ["transplant", "TREATMENT", 176, 186]]], ["All but 1 of the 20 patients with HCoV LRTD >100 days following transplant received either immunosuppressive therapy or chemotherapy to control their underlying disorders (eg, relapse of hematologic malignancy, graft-vs-host disease) prior to diagnosis of LRTD.", [["hematologic malignancy", "ANATOMY", 187, 209], ["graft", "ANATOMY", 211, 216], ["LRTD", "DISEASE", 39, 43], ["malignancy", "DISEASE", 199, 209], ["graft-vs-host disease", "DISEASE", 211, 232], ["LRTD", "DISEASE", 256, 260], ["patients", "ORGANISM", 20, 28], ["hematologic malignancy", "CANCER", 187, 209], ["graft", "TISSUE", 211, 216], ["patients", "SPECIES", 20, 28], ["HCoV", "SPECIES", 34, 38], ["HCoV LRTD", "TREATMENT", 34, 43], ["transplant", "TREATMENT", 64, 74], ["immunosuppressive therapy", "TREATMENT", 91, 116], ["chemotherapy", "TREATMENT", 120, 132], ["their underlying disorders", "PROBLEM", 144, 170], ["hematologic malignancy", "PROBLEM", 187, 209], ["host disease", "PROBLEM", 220, 232], ["LRTD", "PROBLEM", 256, 260], ["hematologic", "ANATOMY", 187, 198], ["malignancy", "OBSERVATION", 199, 209]]], ["Twenty-three recipients were transplanted after 1 May 2006 when respiratory viral PCR panel testing became routine.", [["recipients", "ORGANISM", 13, 23], ["respiratory viral PCR panel testing", "TEST", 64, 99]]], ["The median time to HCoV LRTD after HCT in these 23 patients was 340 days (range, 8\u20133618 days), which was similar to that of entire cohort.", [["LRTD", "DISEASE", 24, 28], ["HCT", "DISEASE", 35, 38], ["HCT", "CANCER", 35, 38], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["HCoV", "SPECIES", 19, 23], ["HCT", "TEST", 35, 38]]], ["At the time of BAL, acute respiratory symptoms and new pulmonary infiltrates were present in the majority of episodes (Table 2).", [["BAL", "ANATOMY", 15, 18], ["respiratory", "ANATOMY", 26, 37], ["pulmonary", "ANATOMY", 55, 64], ["pulmonary infiltrates", "PATHOLOGICAL_FORMATION", 55, 76], ["BAL", "TEST", 15, 18], ["acute respiratory symptoms", "PROBLEM", 20, 46], ["new pulmonary infiltrates", "PROBLEM", 51, 76], ["BAL", "ANATOMY", 15, 18], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["respiratory", "ANATOMY", 26, 37], ["new", "OBSERVATION_MODIFIER", 51, 54], ["pulmonary", "ANATOMY", 55, 64], ["infiltrates", "OBSERVATION", 65, 76]]], ["Among 23 available frozen BAL samples, 11 (48%) were identified as OC43, 5 (22%) as NL63, 4 (17%) as 229E, and 3 (13%) as HKU1.", [["BAL samples", "ANATOMY", 26, 37], ["BAL samples", "CANCER", 26, 37], ["OC43", "GENE_OR_GENE_PRODUCT", 67, 71], ["HKU1", "GENE_OR_GENE_PRODUCT", 122, 126], ["HKU1", "PROTEIN", 122, 126], ["frozen BAL samples", "TEST", 19, 37], ["OC43", "TEST", 67, 71], ["NL63", "TEST", 84, 88], ["HKU1", "TEST", 122, 126]]], ["The majority of episodes occurred in the winter and spring regardless of strain type (Figure 1A).Patient and Viral Characteristics ::: RESULTSOther respiratory pathogens were detected in BAL samples in 21 episodes (57%), including viruses (12 episodes), fungi (10 episodes), and bacteria (8 episodes) (Figure 1B).", [["BAL samples", "ANATOMY", 187, 198], ["BAL samples", "CANCER", 187, 198], ["Patient", "SPECIES", 97, 104], ["episodes", "PROBLEM", 16, 24], ["RESULTSOther respiratory pathogens", "PROBLEM", 135, 169], ["BAL samples", "TEST", 187, 198], ["viruses", "PROBLEM", 231, 238], ["fungi (10 episodes)", "PROBLEM", 254, 273], ["bacteria", "PROBLEM", 279, 287], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["episodes", "OBSERVATION", 16, 24], ["Viral Characteristics", "OBSERVATION", 109, 130]]], ["Two or more other respiratory copathogens were detected in approximately half of these episodes (10/21).", [["more other respiratory copathogens", "PROBLEM", 7, 41], ["respiratory copathogens", "OBSERVATION", 18, 41]]], ["Two patients had respiratory copathogen as well as concomitant bacteremia/fungemia; 1 patient was found to have Staphylococcus aureus in blood and BAL, and the other had both Clostridium non-perfringens and Candida glabrata in the blood only.Patient and Viral Characteristics ::: RESULTSRespiratory copathogens were found in 82% (9/11) of episodes with OC43 and only 42% (5/12) of episodes with other strains (P = .089).", [["respiratory", "ANATOMY", 17, 28], ["blood", "ANATOMY", 137, 142], ["BAL", "ANATOMY", 147, 150], ["blood", "ANATOMY", 231, 236], ["respiratory copathogen", "DISEASE", 17, 39], ["bacteremia", "DISEASE", 63, 73], ["fungemia", "DISEASE", 74, 82], ["Staphylococcus aureus", "DISEASE", 112, 133], ["Clostridium non-perfringens", "DISEASE", 175, 202], ["Candida glabrata", "DISEASE", 207, 223], ["patients", "ORGANISM", 4, 12], ["patient", "ORGANISM", 86, 93], ["Staphylococcus aureus", "ORGANISM", 112, 133], ["blood", "ORGANISM_SUBSTANCE", 137, 142], ["BAL", "ORGANISM_SUBSTANCE", 147, 150], ["Clostridium non-perfringens", "ORGANISM", 175, 202], ["Candida glabrata", "ORGANISM", 207, 223], ["blood", "ORGANISM_SUBSTANCE", 231, 236], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 86, 93], ["Staphylococcus aureus", "SPECIES", 112, 133], ["Clostridium non-perfringens", "SPECIES", 175, 202], ["Candida glabrata", "SPECIES", 207, 223], ["Patient", "SPECIES", 242, 249], ["Staphylococcus aureus", "SPECIES", 112, 133], ["Clostridium non-perfringens", "SPECIES", 175, 202], ["Candida glabrata", "SPECIES", 207, 223], ["respiratory copathogen", "PROBLEM", 17, 39], ["concomitant bacteremia", "PROBLEM", 51, 73], ["fungemia", "PROBLEM", 74, 82], ["Staphylococcus aureus in blood", "PROBLEM", 112, 142], ["BAL", "TEST", 147, 150], ["both Clostridium non-perfringens", "PROBLEM", 170, 202], ["Candida glabrata", "PROBLEM", 207, 223], ["RESULTSRespiratory copathogens", "TEST", 280, 310], ["OC43", "TEST", 353, 357], ["episodes", "PROBLEM", 381, 389], ["other strains", "PROBLEM", 395, 408], ["respiratory copathogen", "OBSERVATION", 17, 39], ["bacteremia", "OBSERVATION", 63, 73], ["fungemia", "OBSERVATION", 74, 82], ["Staphylococcus aureus", "OBSERVATION", 112, 133], ["Clostridium non-perfringens", "OBSERVATION", 175, 202], ["Candida glabrata", "OBSERVATION", 207, 223], ["Viral Characteristics", "OBSERVATION", 254, 275]]], ["The median viral loads of HCoV in BAL samples did not differ among strains (Figure 2).", [["BAL samples", "ANATOMY", 34, 45], ["HCoV", "GENE_OR_GENE_PRODUCT", 26, 30], ["HCoV", "SPECIES", 26, 30], ["The median viral loads of HCoV in BAL samples", "TEST", 0, 45]]], ["No HCoV RNA was detected in serum samples prior to and following HCoV LRTD available from 21 episodes.", [["serum samples", "ANATOMY", 28, 41], ["HCoV", "GENE_OR_GENE_PRODUCT", 3, 7], ["serum samples", "ORGANISM_SUBSTANCE", 28, 41], ["HCoV RNA", "RNA", 3, 11], ["HCoV", "SPECIES", 3, 7], ["HCoV", "SPECIES", 65, 69], ["HCoV RNA", "PROBLEM", 3, 11], ["serum samples", "TEST", 28, 41], ["RNA", "OBSERVATION", 8, 11]]], ["Five lung biopsy samples and 4 lung autopsy samples were tested for RT-PCR among 6 patients (3 FFPE samples and 6 fresh frozen samples), all obtained within 67 days after LRTD diagnosis.", [["lung biopsy samples", "ANATOMY", 5, 24], ["lung autopsy samples", "ANATOMY", 31, 51], ["FFPE samples", "ANATOMY", 95, 107], ["samples", "ANATOMY", 127, 134], ["lung biopsy samples", "CANCER", 5, 24], ["lung autopsy samples", "CANCER", 31, 51], ["patients", "ORGANISM", 83, 91], ["samples", "CANCER", 127, 134], ["patients", "SPECIES", 83, 91], ["Five lung biopsy samples", "TEST", 0, 24], ["4 lung autopsy samples", "TEST", 29, 51], ["RT-PCR", "TEST", 68, 74], ["FFPE samples", "TEST", 95, 107], ["fresh frozen samples", "TEST", 114, 134], ["lung", "ANATOMY", 5, 9], ["biopsy", "OBSERVATION", 10, 16], ["lung", "ANATOMY", 31, 35]]], ["Quality control fragment size analysis by RT-PCR of the RNA from these samples shows that all FFPE specimens could be reliably amplified to 100 bp while all frozen specimens were reliably amplified to 600 bp.", [["samples", "ANATOMY", 71, 78], ["FFPE specimens", "ANATOMY", 94, 108], ["specimens", "ANATOMY", 164, 173], ["samples", "CANCER", 71, 78], ["FFPE specimens", "CANCER", 94, 108], ["specimens", "CANCER", 164, 173], ["Quality control fragment size analysis", "TEST", 0, 38], ["RT-PCR", "TEST", 42, 48], ["the RNA", "TEST", 52, 59], ["these samples", "TEST", 65, 78], ["all FFPE specimens", "TEST", 90, 108], ["bp", "TEST", 144, 146], ["all frozen specimens", "TEST", 153, 173], ["bp", "TEST", 205, 207], ["fragment", "OBSERVATION_MODIFIER", 16, 24], ["size", "OBSERVATION_MODIFIER", 25, 29]]], ["Only 1 sample (lung tissue) was positive for HCoV by RT-PCR, which had been obtained on the same day as BAL.Outcomes ::: RESULTSPatients\u2019 outcomes were summarized after excluding patients with second episodes of HCoV LRTD or a history of lung transplantation (Tables 3 and 4).", [["sample", "ANATOMY", 7, 13], ["lung tissue", "ANATOMY", 15, 26], ["BAL", "ANATOMY", 104, 107], ["lung", "ANATOMY", 238, 242], ["LRTD", "DISEASE", 217, 221], ["lung tissue", "TISSUE", 15, 26], ["HCoV", "GENE_OR_GENE_PRODUCT", 45, 49], ["patients", "ORGANISM", 179, 187], ["lung", "ORGAN", 238, 242], ["patients", "SPECIES", 179, 187], ["HCoV", "SPECIES", 45, 49], ["HCoV", "SPECIES", 212, 216], ["1 sample (lung tissue", "TEST", 5, 26], ["HCoV", "PROBLEM", 45, 49], ["RT-PCR", "TEST", 53, 59], ["BAL", "TEST", 104, 107], ["HCoV LRTD", "TREATMENT", 212, 221], ["lung transplantation", "TREATMENT", 238, 258], ["lung", "ANATOMY", 15, 19], ["lung", "ANATOMY", 238, 242], ["transplantation", "OBSERVATION", 243, 258]]], ["Outcomes by day 28 and 90 after LRTD diagnosis were compared between HCT recipients and patients with HM.", [["HCT", "ANATOMY", 69, 72], ["HM", "DISEASE", 102, 104], ["HCT", "CANCER", 69, 72], ["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["HCT recipients", "TREATMENT", 69, 83], ["HM", "PROBLEM", 102, 104]]], ["HCT recipients were more likely to have fewer oxygen and ventilator-free days than patients with HM.", [["oxygen", "CHEMICAL", 46, 52], ["HM", "DISEASE", 97, 99], ["oxygen", "CHEMICAL", 46, 52], ["oxygen", "SIMPLE_CHEMICAL", 46, 52], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["HCT recipients", "PROBLEM", 0, 14], ["oxygen", "TREATMENT", 46, 52], ["fewer", "OBSERVATION_MODIFIER", 40, 45], ["oxygen", "OBSERVATION_MODIFIER", 46, 52]]], ["Outcomes by day 28 and 90 after HCoV diagnosis were also compared between patients with and without respiratory copathogens, with no statistical differences found.Pathology Results ::: RESULTSTwenty-eight patients had samples available for pathologic review, including 25 BAL samples, 5 lung biopsy samples, and 4 autopsy lung specimens; 6 of 7 patients without any other respiratory copathogens had either nonspecific findings of multinucleated giant cells or nuclear enlargement (Supplementary Figure 2A and 2B).", [["respiratory", "ANATOMY", 100, 111], ["samples", "ANATOMY", 218, 225], ["BAL samples", "ANATOMY", 272, 283], ["lung biopsy samples", "ANATOMY", 287, 306], ["lung specimens", "ANATOMY", 322, 336], ["respiratory", "ANATOMY", 372, 383], ["multinucleated giant cells", "ANATOMY", 431, 457], ["nuclear", "ANATOMY", 461, 468], ["respiratory copathogens", "DISEASE", 100, 123], ["respiratory copathogens", "DISEASE", 372, 395], ["patients", "ORGANISM", 74, 82], ["patients", "ORGANISM", 205, 213], ["BAL samples", "CANCER", 272, 283], ["lung biopsy samples", "CANCER", 287, 306], ["lung specimens", "CANCER", 322, 336], ["patients", "ORGANISM", 345, 353], ["multinucleated giant cells", "CELL", 431, 457], ["nuclear", "CELLULAR_COMPONENT", 461, 468], ["multinucleated giant cells", "CELL_TYPE", 431, 457], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 205, 213], ["patients", "SPECIES", 345, 353], ["HCoV", "SPECIES", 32, 36], ["HCoV diagnosis", "TEST", 32, 46], ["respiratory copathogens", "PROBLEM", 100, 123], ["pathologic review", "TEST", 240, 257], ["25 BAL samples", "TEST", 269, 283], ["5 lung biopsy samples", "TEST", 285, 306], ["4 autopsy lung specimens", "TEST", 312, 336], ["any other respiratory copathogens", "PROBLEM", 362, 395], ["multinucleated giant cells", "PROBLEM", 431, 457], ["nuclear enlargement", "PROBLEM", 461, 480], ["lung", "ANATOMY", 287, 291], ["lung", "ANATOMY", 322, 326], ["nonspecific", "OBSERVATION_MODIFIER", 407, 418], ["multinucleated", "OBSERVATION_MODIFIER", 431, 445], ["giant cells", "OBSERVATION", 446, 457], ["nuclear", "OBSERVATION_MODIFIER", 461, 468], ["enlargement", "OBSERVATION", 469, 480]]], ["Lung tissue from 1 patient was positive for HCoV by RT-PCR; the morphologic features noted in the lung biopsy were inflamed tissue with lymphocytes, neutrophils, and cytologic atypia (Supplementary Figure 3A and 3B).Comparison of Mortality With Other Respiratory Viruses and Risk Factors for Mortality ::: RESULTSThere was a total of 286 HCT recipients with a single respiratory virus identified in BAL samples for whom comparable clinical data were available (HCoV [n = 18], RSV [n = 113], influenza virus [n = 36], and PIV [n = 119]); demographics of these are shown in Supplementary Table 1.", [["Lung tissue", "ANATOMY", 0, 11], ["lung biopsy", "ANATOMY", 98, 109], ["tissue", "ANATOMY", 124, 130], ["lymphocytes", "ANATOMY", 136, 147], ["neutrophils", "ANATOMY", 149, 160], ["BAL samples", "ANATOMY", 399, 410], ["Respiratory Viruses", "DISEASE", 251, 270], ["influenza virus", "DISEASE", 491, 506], ["Lung tissue", "TISSUE", 0, 11], ["patient", "ORGANISM", 19, 26], ["HCoV", "GENE_OR_GENE_PRODUCT", 44, 48], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 98, 109], ["tissue", "TISSUE", 124, 130], ["lymphocytes", "CELL", 136, 147], ["neutrophils", "CELL", 149, 160], ["HCT", "CANCER", 338, 341], ["BAL samples", "CANCER", 399, 410], ["RSV", "ORGANISM", 476, 479], ["influenza virus", "ORGANISM", 491, 506], ["lymphocytes", "CELL_TYPE", 136, 147], ["neutrophils", "CELL_TYPE", 149, 160], ["patient", "SPECIES", 19, 26], ["influenza virus", "SPECIES", 491, 506], ["HCoV", "SPECIES", 44, 48], ["HCoV", "SPECIES", 461, 465], ["RSV", "SPECIES", 476, 479], ["Lung tissue", "TEST", 0, 11], ["HCoV", "PROBLEM", 44, 48], ["RT", "TEST", 52, 54], ["PCR", "TEST", 55, 58], ["the morphologic features", "TEST", 60, 84], ["the lung biopsy", "TEST", 94, 109], ["inflamed tissue", "PROBLEM", 115, 130], ["lymphocytes", "TEST", 136, 147], ["neutrophils", "TEST", 149, 160], ["cytologic atypia", "PROBLEM", 166, 182], ["Other Respiratory Viruses", "PROBLEM", 245, 270], ["286 HCT recipients", "TREATMENT", 334, 352], ["a single respiratory virus", "PROBLEM", 358, 384], ["BAL samples", "TEST", 399, 410], ["HCoV", "TEST", 461, 465], ["RSV [n", "TEST", 476, 482], ["influenza virus", "PROBLEM", 491, 506], ["PIV", "TEST", 521, 524], ["tissue", "ANATOMY", 5, 11], ["lung", "ANATOMY", 98, 102], ["biopsy", "OBSERVATION", 103, 109], ["inflamed", "OBSERVATION", 115, 123], ["lymphocytes", "ANATOMY", 136, 147], ["cytologic atypia", "OBSERVATION", 166, 182], ["Respiratory Viruses", "OBSERVATION", 251, 270], ["respiratory virus", "OBSERVATION", 367, 384]]], ["Overall mortality rates by day 90 following viral LRTD caused by HCoV, RSV, influenza virus, and PIV among HCT recipients without respiratory viral copathogens and without any copathogens were not different (P = .78 and P = .47, respectively) (Figure 3A and 3B).", [["LRTD", "DISEASE", 50, 54], ["RSV, influenza virus", "DISEASE", 71, 91], ["respiratory viral copathogens", "DISEASE", 130, 159], ["HCoV", "GENE_OR_GENE_PRODUCT", 65, 69], ["RSV", "ORGANISM", 71, 74], ["influenza virus", "ORGANISM", 76, 91], ["HCT recipients", "ORGANISM", 107, 121], ["influenza virus", "SPECIES", 76, 91], ["HCoV", "SPECIES", 65, 69], ["RSV", "SPECIES", 71, 74], ["PIV", "SPECIES", 97, 100], ["viral LRTD", "PROBLEM", 44, 54], ["HCoV", "PROBLEM", 65, 69], ["RSV", "PROBLEM", 71, 74], ["influenza virus", "PROBLEM", 76, 91], ["PIV among HCT recipients", "TREATMENT", 97, 121], ["respiratory viral copathogens", "PROBLEM", 130, 159], ["any copathogens", "PROBLEM", 172, 187], ["P", "TEST", 208, 209], ["P", "TEST", 220, 221], ["influenza virus", "OBSERVATION", 76, 91], ["viral copathogens", "OBSERVATION", 142, 159]]], ["Furthermore, no difference was seen when the cohort was stratified by those with and without oxygen requirement at the time of LRTD diagnosis (P = .", [["oxygen", "CHEMICAL", 93, 99], ["oxygen", "CHEMICAL", 93, 99], ["oxygen", "SIMPLE_CHEMICAL", 93, 99], ["oxygen requirement", "PROBLEM", 93, 111], ["no", "UNCERTAINTY", 13, 15], ["difference", "OBSERVATION_MODIFIER", 16, 26]]], ["Univariable Cox regression models were used to evaluate risk factors for overall mortality in HCT recipients with LRTD caused by HCoV, RSV, influenza virus, or PIV without respiratory viral copathogens (Table 5).", [["LRTD", "DISEASE", 114, 118], ["RSV, influenza virus", "DISEASE", 135, 155], ["respiratory viral copathogens", "DISEASE", 172, 201], ["HCT", "CANCER", 94, 97], ["HCoV", "ORGANISM", 129, 133], ["RSV", "ORGANISM", 135, 138], ["influenza virus", "ORGANISM", 140, 155], ["influenza virus", "SPECIES", 140, 155], ["HCoV", "SPECIES", 129, 133], ["RSV", "SPECIES", 135, 138], ["influenza virus", "SPECIES", 140, 155], ["PIV", "SPECIES", 160, 163], ["Univariable Cox regression models", "TEST", 0, 33], ["risk factors", "PROBLEM", 56, 68], ["overall mortality", "PROBLEM", 73, 90], ["HCT recipients", "TREATMENT", 94, 108], ["LRTD", "TREATMENT", 114, 118], ["HCoV", "PROBLEM", 129, 133], ["RSV", "PROBLEM", 135, 138], ["influenza virus", "PROBLEM", 140, 155], ["PIV", "TREATMENT", 160, 163], ["respiratory viral copathogens", "PROBLEM", 172, 201], ["influenza virus", "OBSERVATION", 140, 155]]], ["In multivariable models, cell source (bone marrow), respiratory bacterial or fungal copathogens, low neutrophil counts, low monocyte counts, steroid use, and oxygen requirement at diagnosis were associated with overall mortality (Table 6).", [["cell", "ANATOMY", 25, 29], ["bone marrow", "ANATOMY", 38, 49], ["neutrophil", "ANATOMY", 101, 111], ["monocyte", "ANATOMY", 124, 132], ["steroid", "CHEMICAL", 141, 148], ["oxygen", "CHEMICAL", 158, 164], ["steroid", "CHEMICAL", 141, 148], ["oxygen", "CHEMICAL", 158, 164], ["cell", "CELL", 25, 29], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 38, 49], ["neutrophil", "CELL", 101, 111], ["monocyte", "CELL", 124, 132], ["steroid", "SIMPLE_CHEMICAL", 141, 148], ["oxygen", "SIMPLE_CHEMICAL", 158, 164], ["cell source (bone marrow)", "PROBLEM", 25, 50], ["respiratory bacterial or fungal copathogens", "PROBLEM", 52, 95], ["low neutrophil counts", "PROBLEM", 97, 118], ["low monocyte counts", "PROBLEM", 120, 139], ["steroid use", "TREATMENT", 141, 152], ["oxygen requirement", "PROBLEM", 158, 176], ["bone marrow", "ANATOMY", 38, 49], ["respiratory", "ANATOMY", 52, 63], ["bacterial", "OBSERVATION_MODIFIER", 64, 73], ["fungal copathogens", "OBSERVATION", 77, 95], ["low neutrophil counts", "OBSERVATION", 97, 118], ["low monocyte", "OBSERVATION_MODIFIER", 120, 132], ["oxygen requirement", "OBSERVATION", 158, 176]]], ["Mortality due to HCoV LRTD was not significantly different from RSV LRTD (adjusted hazard ratio, 1.34 [95% confidence interval, .66\u20132.71], P = .41).", [["LRTD", "DISEASE", 68, 72], ["RSV", "ORGANISM", 64, 67], ["HCoV", "SPECIES", 17, 21], ["RSV", "SPECIES", 64, 67], ["HCoV LRTD", "PROBLEM", 17, 26], ["P", "TEST", 139, 140]]], ["Similarly, risk factors for overall mortality by day 90 in HCoV LRTD patients alone were evaluated using univariable and multivariable Cox regression models in HCT recipients; no risk factors significantly associated with mortality were found (Supplementary Tables 2 and 3).DISCUSSIONIn this study, we demonstrated that the presence of HCoV in BAL samples in immunocompromised hosts was significantly associated with high rates of respiratory support and mortality.", [["BAL samples", "ANATOMY", 344, 355], ["respiratory", "ANATOMY", 431, 442], ["patients", "ORGANISM", 69, 77], ["HCoV", "GENE_OR_GENE_PRODUCT", 336, 340], ["BAL samples", "ORGANISM_SUBSTANCE", 344, 355], ["HCoV", "PROTEIN", 336, 340], ["patients", "SPECIES", 69, 77], ["HCoV", "SPECIES", 59, 63], ["HCoV", "SPECIES", 336, 340], ["multivariable Cox regression models", "PROBLEM", 121, 156], ["HCT recipients", "TREATMENT", 160, 174], ["risk factors", "PROBLEM", 179, 191], ["this study", "TEST", 287, 297], ["HCoV in BAL samples", "PROBLEM", 336, 355], ["immunocompromised hosts", "PROBLEM", 359, 382], ["respiratory support", "TREATMENT", 431, 450], ["respiratory support", "OBSERVATION", 431, 450]]], ["HCT recipients appeared to be more affected than patients with HM.", [["HCT", "ANATOMY", 0, 3], ["HM", "DISEASE", 63, 65], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["HCT recipients", "PROBLEM", 0, 14], ["appeared to be", "UNCERTAINTY", 15, 29], ["more affected", "OBSERVATION_MODIFIER", 30, 43]]], ["Although respiratory copathogens were frequently detected, the clinical outcomes of these patients were similar to those without copathogens.", [["respiratory", "ANATOMY", 9, 20], ["respiratory copathogens", "DISEASE", 9, 32], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["respiratory copathogens", "PROBLEM", 9, 32], ["copathogens", "PROBLEM", 129, 140], ["respiratory copathogens", "OBSERVATION", 9, 32]]], ["The mortality rate of HCT recipients by day 90 after developing HCoV LRTD was similar to rates seen with established respiratory pathogens including RSV, influenza virus, and PIV (Figure 3 and Table 6) [16\u201318].", [["HCT", "ANATOMY", 22, 25], ["HCT", "DISEASE", 22, 25], ["LRTD", "DISEASE", 69, 73], ["respiratory pathogens including RSV, influenza virus", "DISEASE", 117, 169], ["HCT", "CANCER", 22, 25], ["RSV", "ORGANISM", 149, 152], ["influenza virus", "ORGANISM", 154, 169], ["influenza virus", "SPECIES", 154, 169], ["HCoV", "SPECIES", 64, 68], ["RSV", "SPECIES", 149, 152], ["HCT recipients", "TREATMENT", 22, 36], ["HCoV LRTD", "PROBLEM", 64, 73], ["established respiratory pathogens", "PROBLEM", 105, 138], ["RSV", "PROBLEM", 149, 152], ["influenza virus", "PROBLEM", 154, 169], ["PIV", "TREATMENT", 175, 178], ["respiratory pathogens", "OBSERVATION", 117, 138], ["influenza virus", "OBSERVATION", 154, 169]]], ["All 4 HCoV strains were identified in BAL samples regardless of the presence of copathogens, and at least 2 HCoV strains were present nearly half of the year.DISCUSSIONSARS and MERS are recognized as highly human-pathogenic coronaviruses, causing acute, severe, frequently fatal LRTD [20\u201322].", [["BAL samples", "ANATOMY", 38, 49], ["human-pathogenic coronaviruses", "DISEASE", 207, 237], ["LRTD", "DISEASE", 279, 283], ["HCoV", "GENE_OR_GENE_PRODUCT", 6, 10], ["BAL samples", "CANCER", 38, 49], ["human", "ORGANISM", 207, 212], ["coronaviruses", "ORGANISM", 224, 237], ["human", "SPECIES", 207, 212], ["HCoV", "SPECIES", 6, 10], ["HCoV", "SPECIES", 108, 112], ["human", "SPECIES", 207, 212], ["All 4 HCoV strains", "PROBLEM", 0, 18], ["BAL samples", "TEST", 38, 49], ["copathogens", "PROBLEM", 80, 91], ["2 HCoV strains", "PROBLEM", 106, 120], ["pathogenic coronaviruses", "PROBLEM", 213, 237], ["acute, severe, frequently fatal LRTD", "PROBLEM", 247, 283], ["acute", "OBSERVATION_MODIFIER", 247, 252], ["severe", "OBSERVATION_MODIFIER", 254, 260]]], ["Although 4 other strains of HCoV (229E, OC43, NL63, and HKU1) are also human pathogens, the clinical impact of HCoV LRTD remains unclear, especially in immunocompromised patients [4, 14, 23].", [["LRTD", "DISEASE", 116, 120], ["HCoV", "GENE_OR_GENE_PRODUCT", 28, 32], ["OC43", "GENE_OR_GENE_PRODUCT", 40, 44], ["NL63", "GENE_OR_GENE_PRODUCT", 46, 50], ["HKU1", "GENE_OR_GENE_PRODUCT", 56, 60], ["human", "ORGANISM", 71, 76], ["HCoV LRTD", "ORGANISM", 111, 120], ["patients", "ORGANISM", 170, 178], ["human", "SPECIES", 71, 76], ["patients", "SPECIES", 170, 178], ["HCoV", "SPECIES", 28, 32], ["human", "SPECIES", 71, 76], ["HCoV", "SPECIES", 111, 115], ["HCoV", "TEST", 28, 32], ["OC43", "TEST", 40, 44], ["NL63", "TEST", 46, 50], ["human pathogens", "PROBLEM", 71, 86], ["HCoV LRTD", "TREATMENT", 111, 120]]], ["A previous prospective study with weekly nasal surveillance sampling during the first 100 days after HCT demonstrated prolonged HCoV shedding in the upper respiratory tract (>3 weeks) in half of subjects including asymptomatic patients [8].", [["nasal", "ANATOMY", 41, 46], ["upper respiratory tract", "ANATOMY", 149, 172], ["HCoV", "CHEMICAL", 128, 132], ["HCoV", "GENE_OR_GENE_PRODUCT", 128, 132], ["upper respiratory", "ORGANISM_SUBDIVISION", 149, 166], ["tract", "ORGANISM_SUBDIVISION", 167, 172], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 227, 235], ["HCoV", "SPECIES", 128, 132], ["A previous prospective study", "TEST", 0, 28], ["weekly nasal surveillance sampling", "TEST", 34, 68], ["HCT", "TEST", 101, 104], ["prolonged HCoV shedding in the upper respiratory tract", "PROBLEM", 118, 172], ["upper", "ANATOMY_MODIFIER", 149, 154], ["respiratory tract", "ANATOMY", 155, 172]]], ["In addition, respiratory copathogens were identified in more than half the episodes in this study (57%).", [["respiratory", "ANATOMY", 13, 24], ["respiratory copathogens", "DISEASE", 13, 36], ["respiratory copathogens", "PROBLEM", 13, 36], ["this study", "TEST", 87, 97], ["respiratory copathogens", "OBSERVATION", 13, 36]]], ["Given the prolonged asymptomatic shedding and frequent detection of respiratory copathogens, attributing poor clinical outcomes to HCoV in the lower respiratory tract may be difficult.", [["respiratory", "ANATOMY", 68, 79], ["lower respiratory tract", "ANATOMY", 143, 166], ["respiratory copathogens", "DISEASE", 68, 91], ["HCoV", "CHEMICAL", 131, 135], ["HCoV", "CANCER", 131, 135], ["lower respiratory", "ORGANISM_SUBDIVISION", 143, 160], ["tract", "ORGANISM_SUBDIVISION", 161, 166], ["HCoV", "SPECIES", 131, 135], ["the prolonged asymptomatic shedding", "PROBLEM", 6, 41], ["respiratory copathogens", "PROBLEM", 68, 91], ["poor clinical outcomes to HCoV in the lower respiratory tract", "PROBLEM", 105, 166], ["respiratory copathogens", "OBSERVATION", 68, 91], ["lower", "ANATOMY_MODIFIER", 143, 148], ["respiratory tract", "ANATOMY", 149, 166]]], ["In the current study, follow-up BAL procedures were not performed to assess prolonged shedding in the lower respiratory tract; however, a prior study that included only 4 patients with cancer demonstrated that only 1 of 10 cases had HCoV detected in follow-up BAL specimens, arguing against asymptomatic prolonged shedding in the lower respiratory tract [14].", [["lower respiratory tract", "ANATOMY", 102, 125], ["cancer", "ANATOMY", 185, 191], ["BAL specimens", "ANATOMY", 260, 273], ["lower respiratory tract", "ANATOMY", 330, 353], ["cancer", "DISEASE", 185, 191], ["lower", "ORGANISM_SUBDIVISION", 102, 107], ["respiratory tract", "ORGANISM_SUBDIVISION", 108, 125], ["patients", "ORGANISM", 171, 179], ["cancer", "CANCER", 185, 191], ["HCoV", "CANCER", 233, 237], ["lower", "ORGANISM_SUBDIVISION", 330, 335], ["respiratory tract", "ORGANISM_SUBDIVISION", 336, 353], ["patients", "SPECIES", 171, 179], ["HCoV", "SPECIES", 233, 237], ["the current study", "TEST", 3, 20], ["follow-up BAL procedures", "TEST", 22, 46], ["prolonged shedding in the lower respiratory tract", "PROBLEM", 76, 125], ["a prior study", "TEST", 136, 149], ["cancer", "PROBLEM", 185, 191], ["HCoV", "TEST", 233, 237], ["BAL specimens", "TEST", 260, 273], ["asymptomatic prolonged shedding in the lower respiratory tract", "PROBLEM", 291, 353], ["lower", "ANATOMY_MODIFIER", 102, 107], ["respiratory tract", "ANATOMY", 108, 125], ["cancer", "OBSERVATION", 185, 191], ["prolonged", "OBSERVATION_MODIFIER", 304, 313], ["shedding", "OBSERVATION", 314, 322], ["lower", "ANATOMY_MODIFIER", 330, 335], ["respiratory tract", "ANATOMY", 336, 353]]], ["More data are needed to define shedding duration in the immunocompromised population.", [["the immunocompromised population", "PROBLEM", 52, 84]]], ["In our study, clinical outcomes including intensity of respiratory support, days alive without hospitalization, and mortality were not significantly different between patients with and without other copathogens, suggesting that HCoV in the lower respiratory tract can contribute to severity of LRTD regardless of copathogens.", [["respiratory", "ANATOMY", 55, 66], ["lower respiratory tract", "ANATOMY", 240, 263], ["HCoV", "CHEMICAL", 228, 232], ["LRTD", "DISEASE", 294, 298], ["patients", "ORGANISM", 167, 175], ["HCoV", "GENE_OR_GENE_PRODUCT", 228, 232], ["lower", "ORGANISM_SUBDIVISION", 240, 245], ["respiratory tract", "ORGANISM_SUBDIVISION", 246, 263], ["patients", "SPECIES", 167, 175], ["HCoV", "SPECIES", 228, 232], ["our study", "TEST", 3, 12], ["respiratory support", "TREATMENT", 55, 74], ["other copathogens", "PROBLEM", 193, 210], ["HCoV in the lower respiratory tract", "PROBLEM", 228, 263], ["copathogens", "PROBLEM", 313, 324], ["respiratory support", "OBSERVATION", 55, 74], ["lower", "ANATOMY_MODIFIER", 240, 245], ["respiratory tract", "ANATOMY", 246, 263]]], ["Lung tissue from 1 patient was positive for HCoV by RT-PCR.", [["Lung tissue", "ANATOMY", 0, 11], ["Lung tissue", "TISSUE", 0, 11], ["patient", "ORGANISM", 19, 26], ["HCoV", "GENE_OR_GENE_PRODUCT", 44, 48], ["patient", "SPECIES", 19, 26], ["HCoV", "SPECIES", 44, 48], ["Lung tissue", "TEST", 0, 11], ["HCoV", "PROBLEM", 44, 48], ["RT", "TEST", 52, 54], ["PCR", "TEST", 55, 58], ["tissue", "ANATOMY", 5, 11]]], ["This patient subsequently developed prolonged oxygen requirement, which also supports the potential pathogenicity of HCoV.DISCUSSIONTo further demonstrate the clinical significance of HCoV LRTD in HCT recipients, we compared mortality rates in HCT recipients with HCoV LRTD to other respiratory viruses using multivariable Cox regression analysis and found mortality rates in HCoV LRTD were comparable to those seen with RSV, influenza virus, and PIV.", [["HCT", "ANATOMY", 197, 200], ["HCT", "ANATOMY", 244, 247], ["oxygen", "CHEMICAL", 46, 52], ["LRTD", "DISEASE", 189, 193], ["LRTD", "DISEASE", 269, 273], ["influenza virus", "DISEASE", 426, 441], ["oxygen", "CHEMICAL", 46, 52], ["patient", "ORGANISM", 5, 12], ["oxygen", "SIMPLE_CHEMICAL", 46, 52], ["HCoV", "ORGANISM", 184, 188], ["HCT", "CANCER", 197, 200], ["HCT", "CANCER", 244, 247], ["HCoV", "ORGANISM", 264, 268], ["HCoV LRTD", "CANCER", 376, 385], ["RSV", "ORGANISM", 421, 424], ["influenza virus", "ORGANISM", 426, 441], ["patient", "SPECIES", 5, 12], ["influenza virus", "SPECIES", 426, 441], ["HCoV", "SPECIES", 184, 188], ["HCoV", "SPECIES", 264, 268], ["HCoV", "SPECIES", 376, 380], ["RSV", "SPECIES", 421, 424], ["influenza virus", "SPECIES", 426, 441], ["PIV", "SPECIES", 447, 450], ["prolonged oxygen requirement", "PROBLEM", 36, 64], ["HCT recipients", "TREATMENT", 197, 211], ["mortality rates", "TEST", 225, 240], ["HCT recipients", "TREATMENT", 244, 258], ["HCoV LRTD", "TREATMENT", 264, 273], ["other respiratory viruses", "PROBLEM", 277, 302], ["multivariable Cox regression analysis", "TEST", 309, 346], ["mortality rates in HCoV LRTD", "PROBLEM", 357, 385], ["RSV", "PROBLEM", 421, 424], ["influenza virus", "PROBLEM", 426, 441], ["PIV", "TREATMENT", 447, 450], ["prolonged", "OBSERVATION_MODIFIER", 36, 45], ["oxygen requirement", "OBSERVATION", 46, 64], ["respiratory viruses", "OBSERVATION", 283, 302], ["influenza virus", "OBSERVATION", 426, 441]]], ["Given the common perception of HCoV as a relatively benign pathogen based on limited data [5, 8], our data are somewhat surprising.", [["HCoV", "CANCER", 31, 35], ["HCoV", "SPECIES", 31, 35], ["HCoV", "PROBLEM", 31, 35], ["a relatively benign pathogen", "PROBLEM", 39, 67], ["our data", "TEST", 98, 106], ["benign", "OBSERVATION_MODIFIER", 52, 58], ["pathogen", "OBSERVATION", 59, 67]]], ["The adverse impact of oxygen requirement at the time of diagnosis on subsequent clinical outcome has been suggested [16, 24].", [["oxygen", "CHEMICAL", 22, 28], ["oxygen", "CHEMICAL", 22, 28], ["oxygen", "SIMPLE_CHEMICAL", 22, 28], ["oxygen requirement", "PROBLEM", 22, 40], ["adverse", "OBSERVATION_MODIFIER", 4, 11], ["oxygen requirement", "OBSERVATION", 22, 40]]], ["Once substantial acute lung injury occurs, clinical outcome can potentially be affected by inflammation rather than virus itself.", [["lung", "ANATOMY", 23, 27], ["lung injury", "DISEASE", 23, 34], ["inflammation", "DISEASE", 91, 103], ["lung", "ORGAN", 23, 27], ["substantial acute lung injury", "PROBLEM", 5, 34], ["inflammation", "PROBLEM", 91, 103], ["virus itself", "PROBLEM", 116, 128], ["substantial", "OBSERVATION_MODIFIER", 5, 16], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["lung", "ANATOMY", 23, 27], ["injury", "OBSERVATION", 28, 34], ["inflammation", "OBSERVATION", 91, 103]]], ["Therefore, mortality rates by day 90 following LRTD caused by HCoV, RSV, influenza virus, and PIV were also compared according to oxygen requirement at the time of LRTD diagnosis; no statistically significant difference was found.", [["influenza", "DISEASE", 73, 82], ["oxygen", "CHEMICAL", 130, 136], ["oxygen", "CHEMICAL", 130, 136], ["HCoV", "GENE_OR_GENE_PRODUCT", 62, 66], ["RSV", "ORGANISM", 68, 71], ["influenza virus", "ORGANISM", 73, 88], ["oxygen", "SIMPLE_CHEMICAL", 130, 136], ["influenza virus", "SPECIES", 73, 88], ["HCoV", "SPECIES", 62, 66], ["RSV", "SPECIES", 68, 71], ["PIV", "SPECIES", 94, 97], ["RSV", "PROBLEM", 68, 71], ["influenza virus", "PROBLEM", 73, 88], ["PIV", "TREATMENT", 94, 97], ["oxygen requirement", "PROBLEM", 130, 148], ["influenza virus", "OBSERVATION", 73, 88]]], ["These data combined suggest that HCoV LRTD is significantly associated with poor clinical outcome in this immunocompromised population.DISCUSSIONPrevious studies, mainly in immunocompetent hosts, have not demonstrated a distinct association between particular HCoV strains in upper respiratory tract samples and disease severity in LRTD [25\u201329].", [["upper respiratory tract samples", "ANATOMY", 276, 307], ["LRTD", "DISEASE", 332, 336], ["HCoV", "GENE_OR_GENE_PRODUCT", 33, 37], ["HCoV", "GENE_OR_GENE_PRODUCT", 260, 264], ["upper", "ORGANISM_SUBDIVISION", 276, 281], ["respiratory tract", "ORGANISM_SUBDIVISION", 282, 299], ["HCoV", "SPECIES", 33, 37], ["HCoV", "SPECIES", 260, 264], ["These data", "TEST", 0, 10], ["HCoV LRTD", "PROBLEM", 33, 42], ["this immunocompromised population", "PROBLEM", 101, 134], ["DISCUSSIONPrevious studies", "TEST", 135, 161], ["particular HCoV strains in upper respiratory tract samples", "PROBLEM", 249, 307], ["disease severity in LRTD", "PROBLEM", 312, 336], ["upper", "ANATOMY_MODIFIER", 276, 281], ["respiratory tract", "ANATOMY", 282, 299]]], ["Although there are case reports with each strain identified in lower respiratory tract as a sole pathogen in HCT recipients, systematic data are limited [9\u201312].", [["lower respiratory tract", "ANATOMY", 63, 86], ["HCT", "ANATOMY", 109, 112], ["lower", "ORGANISM_SUBDIVISION", 63, 68], ["respiratory tract", "ORGANISM_SUBDIVISION", 69, 86], ["HCT", "CANCER", 109, 112], ["each strain", "PROBLEM", 37, 48], ["lower respiratory tract", "PROBLEM", 63, 86], ["a sole pathogen", "PROBLEM", 90, 105], ["HCT recipients", "TREATMENT", 109, 123], ["systematic data", "TEST", 125, 140], ["lower", "ANATOMY_MODIFIER", 63, 68], ["respiratory tract", "ANATOMY", 69, 86]]], ["This is the first study to describe that all 4 HCoV strains can be detected in BAL samples with and without any other respiratory copathogens in a large immunocompromised population.", [["BAL samples", "ANATOMY", 79, 90], ["respiratory copathogens", "DISEASE", 118, 141], ["HCoV", "GENE_OR_GENE_PRODUCT", 47, 51], ["BAL samples", "CANCER", 79, 90], ["HCoV", "SPECIES", 47, 51], ["the first study", "TEST", 8, 23], ["all 4 HCoV strains", "PROBLEM", 41, 59], ["BAL samples", "TEST", 79, 90], ["any other respiratory copathogens", "PROBLEM", 108, 141], ["a large immunocompromised population", "PROBLEM", 145, 181], ["large", "OBSERVATION_MODIFIER", 147, 152], ["immunocompromised", "OBSERVATION", 153, 170]]], ["However, the few instances of each strain limited our ability to examine if specific HCoV strains are associated with increased disease severity in LRTD.", [["LRTD", "DISEASE", 148, 152], ["HCoV", "GENE_OR_GENE_PRODUCT", 85, 89], ["HCoV", "SPECIES", 85, 89], ["each strain", "PROBLEM", 30, 41], ["specific HCoV strains", "PROBLEM", 76, 97], ["increased disease severity in LRTD", "PROBLEM", 118, 152], ["few", "OBSERVATION_MODIFIER", 13, 16], ["increased", "OBSERVATION_MODIFIER", 118, 127], ["disease", "OBSERVATION", 128, 135]]], ["Further studies with larger sample sizes will help to characterize the role of particular HCoV strains.DISCUSSIONOur study showed relatively late presentation of HCoV LRTD following transplantation.", [["LRTD", "DISEASE", 167, 171], ["HCoV", "GENE_OR_GENE_PRODUCT", 90, 94], ["HCoV", "SPECIES", 90, 94], ["HCoV", "SPECIES", 162, 166], ["Further studies", "TEST", 0, 15], ["larger sample sizes", "TREATMENT", 21, 40], ["particular HCoV strains", "PROBLEM", 79, 102], ["DISCUSSIONOur study", "TEST", 103, 122], ["HCoV LRTD", "TREATMENT", 162, 171], ["transplantation", "TREATMENT", 182, 197], ["relatively", "OBSERVATION_MODIFIER", 130, 140], ["late", "OBSERVATION_MODIFIER", 141, 145]]], ["The median time to HCoV LRTD following HCT was 302 days, which was longer than median days to LRTD caused by RSV (52.5 days), PIV (78 days), and influenza (95 days) [16, 17, 30].", [["LRTD", "DISEASE", 24, 28], ["LRTD", "DISEASE", 94, 98], ["RSV", "DISEASE", 109, 112], ["influenza", "DISEASE", 145, 154], ["RSV", "ORGANISM", 109, 112], ["HCoV", "SPECIES", 19, 23], ["RSV", "SPECIES", 109, 112], ["HCT", "TEST", 39, 42], ["RSV", "PROBLEM", 109, 112], ["PIV", "TREATMENT", 126, 129], ["influenza", "PROBLEM", 145, 154]]], ["Because this may in part be due to the fact our cohort included some patients who were transplanted prior to the introduction of routine HCoV PCR testing, we separately analyzed patients who underwent transplantation after introduction of a respiratory viral PCR panel in 2006 and determined the median time of diagnosis remained similar (340 days).", [["patients", "ORGANISM", 69, 77], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 178, 186], ["HCoV", "SPECIES", 137, 141], ["routine HCoV PCR testing", "TEST", 129, 153], ["transplantation", "TREATMENT", 201, 216], ["a respiratory viral PCR panel", "TEST", 239, 268]]], ["The majority of patients who developed HCoV LRTD >100 days following transplant had received either chemotherapy or immunosuppressive therapy as predisposing factors.", [["LRTD", "DISEASE", 44, 48], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["HCoV", "SPECIES", 39, 43], ["HCoV LRTD", "PROBLEM", 39, 48], ["transplant", "TREATMENT", 69, 79], ["chemotherapy", "TREATMENT", 100, 112], ["immunosuppressive therapy", "TREATMENT", 116, 141]]], ["This does not explain why there is a relatively lower incidence of HCoV LRTD early after transplant.", [["LRTD", "DISEASE", 72, 76], ["HCoV", "SPECIES", 67, 71], ["HCoV LRTD", "TREATMENT", 67, 76], ["transplant", "TREATMENT", 89, 99]]], ["Differences in infection control practices early after transplant and factors that affect progression to LRTD early vs late after transplant may play a role.", [["infection", "DISEASE", 15, 24], ["LRTD", "DISEASE", 105, 109], ["infection control practices", "TREATMENT", 15, 42], ["transplant", "TREATMENT", 55, 65], ["transplant", "TREATMENT", 130, 140], ["infection", "OBSERVATION", 15, 24]]], ["Further studies are needed to determine why HCoV often causes LRTD late after transplant.DISCUSSIONThis study evaluated the largest cohort of HCoV LRTD confirmed with BAL in patients with HCT and HM by HCoV strain-specific and quantitative PCR in BAL samples.", [["BAL", "ANATOMY", 167, 170], ["BAL samples", "ANATOMY", 247, 258], ["LRTD", "DISEASE", 62, 66], ["LRTD", "DISEASE", 147, 151], ["HCoV", "GENE_OR_GENE_PRODUCT", 44, 48], ["HCoV LRTD", "CANCER", 142, 151], ["BAL", "ORGANISM_SUBSTANCE", 167, 170], ["patients", "ORGANISM", 174, 182], ["HCT", "CANCER", 188, 191], ["BAL samples", "CANCER", 247, 258], ["patients", "SPECIES", 174, 182], ["HCoV", "SPECIES", 44, 48], ["HCoV", "SPECIES", 142, 146], ["HCoV", "SPECIES", 202, 206], ["Further studies", "TEST", 0, 15], ["transplant", "TREATMENT", 78, 88], ["BAL", "TEST", 167, 170], ["HCT", "TEST", 188, 191], ["HCoV strain", "PROBLEM", 202, 213], ["quantitative PCR", "TEST", 227, 243], ["BAL samples", "TEST", 247, 258]]], ["In addition, RT-PCR was performed on serum specimens, lung biopsy samples, and autopsy samples.", [["serum specimens", "ANATOMY", 37, 52], ["lung biopsy samples", "ANATOMY", 54, 73], ["samples", "ANATOMY", 87, 94], ["serum specimens", "ORGANISM_SUBSTANCE", 37, 52], ["lung biopsy samples", "MULTI-TISSUE_STRUCTURE", 54, 73], ["RT-PCR", "TEST", 13, 19], ["serum specimens", "TEST", 37, 52], ["lung biopsy samples", "TEST", 54, 73], ["autopsy samples", "TEST", 79, 94], ["lung", "ANATOMY", 54, 58]]], ["The main limitation of this study was the relatively small sample size, which prevented us from detecting small differences and performing multivariable analyses to evaluate risk factors for mortality in patients with HCoV LRTD.", [["LRTD", "DISEASE", 223, 227], ["patients", "ORGANISM", 204, 212], ["patients", "SPECIES", 204, 212], ["HCoV", "SPECIES", 218, 222], ["this study", "TEST", 23, 33], ["multivariable analyses", "TEST", 139, 161], ["risk factors", "PROBLEM", 174, 186], ["HCoV LRTD", "TREATMENT", 218, 227], ["main", "OBSERVATION_MODIFIER", 4, 8], ["limitation", "OBSERVATION_MODIFIER", 9, 19], ["small", "OBSERVATION_MODIFIER", 53, 58], ["sample", "OBSERVATION_MODIFIER", 59, 65], ["size", "OBSERVATION_MODIFIER", 66, 70], ["small", "OBSERVATION_MODIFIER", 106, 111]]], ["Another limitation is the fact that BAL samples were available in only two-thirds of the patients for strain identification, which limited our ability to compare clinical and virological differences among each HCoV strain.", [["BAL samples", "ANATOMY", 36, 47], ["BAL samples", "CANCER", 36, 47], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["HCoV", "SPECIES", 210, 214], ["BAL samples", "TEST", 36, 47], ["strain identification", "TEST", 102, 123], ["each HCoV strain", "PROBLEM", 205, 221]]], ["Among a total of 9 lung biopsy and autopsy samples, only 1 lung biopsy sample, which was taken on the same day as the BAL, was positive for HCoV by RT-PCR.", [["lung biopsy", "ANATOMY", 19, 30], ["samples", "ANATOMY", 43, 50], ["lung biopsy sample", "ANATOMY", 59, 77], ["BAL", "ANATOMY", 118, 121], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 19, 30], ["autopsy samples", "CANCER", 35, 50], ["lung biopsy", "CANCER", 59, 70], ["HCoV", "GENE_OR_GENE_PRODUCT", 140, 144], ["HCoV", "SPECIES", 140, 144], ["9 lung biopsy", "TEST", 17, 30], ["autopsy samples", "TEST", 35, 50], ["1 lung biopsy sample", "TEST", 57, 77], ["the BAL", "TEST", 114, 121], ["HCoV", "PROBLEM", 140, 144], ["RT", "TEST", 148, 150], ["PCR", "TEST", 151, 154], ["lung", "ANATOMY", 19, 23], ["biopsy", "OBSERVATION", 24, 30], ["lung", "ANATOMY", 59, 63], ["biopsy", "OBSERVATION", 64, 70]]], ["The lower rate of detection may be due to the fact that the negative samples were obtained from 19 days to 67 days after the diagnosis of LRTD, suggesting that the timing of collecting samples may have been too late to identify HCoV in lung specimens.", [["samples", "ANATOMY", 69, 76], ["samples", "ANATOMY", 185, 192], ["lung specimens", "ANATOMY", 236, 250], ["LRTD", "DISEASE", 138, 142], ["HCoV", "GENE_OR_GENE_PRODUCT", 228, 232], ["lung specimens", "CANCER", 236, 250], ["HCoV", "SPECIES", 228, 232], ["collecting samples", "TEST", 174, 192], ["HCoV in lung specimens", "PROBLEM", 228, 250], ["lung", "ANATOMY", 236, 240], ["specimens", "OBSERVATION", 241, 250]]], ["Furthermore, not all samples were optimally preserved for RT-PCR, and thus the sensitivity for HCoV may have been suboptimal.DISCUSSIONWe demonstrated high rates of respiratory support including oxygen use and mechanical ventilation requirement as well as a high mortality in immunocompromised patients with HCoV identified in the lower respiratory tract.", [["samples", "ANATOMY", 21, 28], ["respiratory", "ANATOMY", 165, 176], ["lower respiratory tract", "ANATOMY", 331, 354], ["oxygen", "CHEMICAL", 195, 201], ["oxygen", "CHEMICAL", 195, 201], ["HCoV", "GENE_OR_GENE_PRODUCT", 95, 99], ["oxygen", "SIMPLE_CHEMICAL", 195, 201], ["patients", "ORGANISM", 294, 302], ["HCoV", "CANCER", 308, 312], ["lower", "ORGANISM_SUBDIVISION", 331, 336], ["respiratory tract", "ORGANISM_SUBDIVISION", 337, 354], ["patients", "SPECIES", 294, 302], ["HCoV", "SPECIES", 95, 99], ["HCoV", "SPECIES", 308, 312], ["RT-PCR", "TEST", 58, 64], ["the sensitivity", "TEST", 75, 90], ["HCoV", "TEST", 95, 99], ["respiratory support", "TREATMENT", 165, 184], ["oxygen use", "TREATMENT", 195, 205], ["mechanical ventilation requirement", "TREATMENT", 210, 244], ["HCoV", "TREATMENT", 308, 312], ["high", "OBSERVATION_MODIFIER", 151, 155], ["respiratory support", "OBSERVATION", 165, 184], ["mechanical ventilation", "OBSERVATION", 210, 232], ["lower", "ANATOMY_MODIFIER", 331, 336], ["respiratory tract", "ANATOMY", 337, 354]]], ["Mortality rates associated with HCoV LRTD in transplant recipients were similar to those seen with other respiratory viral pathogens including RSV, influenza virus, and PIV.", [["LRTD", "DISEASE", 37, 41], ["respiratory viral pathogens including RSV, influenza virus", "DISEASE", 105, 163], ["recipients", "ORGANISM", 56, 66], ["RSV", "ORGANISM", 143, 146], ["influenza virus", "ORGANISM", 148, 163], ["RSV", "SPECIES", 143, 146], ["influenza virus", "SPECIES", 148, 163], ["HCoV", "SPECIES", 32, 36], ["RSV", "SPECIES", 143, 146], ["influenza virus", "SPECIES", 148, 163], ["PIV", "SPECIES", 169, 172], ["Mortality rates", "PROBLEM", 0, 15], ["HCoV LRTD", "TREATMENT", 32, 41], ["transplant recipients", "TREATMENT", 45, 66], ["other respiratory viral pathogens", "PROBLEM", 99, 132], ["RSV", "PROBLEM", 143, 146], ["influenza virus", "PROBLEM", 148, 163], ["PIV", "TREATMENT", 169, 172], ["respiratory", "ANATOMY", 105, 116], ["viral pathogens", "OBSERVATION", 117, 132], ["influenza virus", "OBSERVATION", 148, 163]]], ["Thus, we conclude that HCoV appears to be a significant respiratory pathogen in the populations studied.", [["HCoV", "CHEMICAL", 23, 27], ["HCoV", "GENE_OR_GENE_PRODUCT", 23, 27], ["HCoV", "SPECIES", 23, 27], ["a significant respiratory pathogen", "PROBLEM", 42, 76], ["appears to be", "UNCERTAINTY", 28, 41], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["respiratory pathogen", "OBSERVATION", 56, 76]]], ["This is an important observation because HCoVs are highly prevalent in immunocompromised hosts.", [["HCoVs", "GENE_OR_GENE_PRODUCT", 41, 46]]], ["The appreciation of HCoV as an important lower respiratory tract pathogen could impact clinical management including risk stratification in future studies and provide a rationale to develop antiviral therapies.", [["lower respiratory tract", "ANATOMY", 41, 64], ["HCoV", "GENE_OR_GENE_PRODUCT", 20, 24], ["lower", "ORGANISM_SUBDIVISION", 41, 46], ["respiratory tract", "ORGANISM_SUBDIVISION", 47, 64], ["HCoV", "SPECIES", 20, 24], ["HCoV", "TREATMENT", 20, 24], ["an important lower respiratory tract pathogen", "PROBLEM", 28, 73], ["clinical management", "TREATMENT", 87, 106], ["future studies", "TEST", 140, 154], ["antiviral therapies", "TREATMENT", 190, 209], ["respiratory tract", "ANATOMY", 47, 64]]], ["Further studies are needed to clarify if particular HCoV strains and viral load are correlated with clinical outcome and to identify risk factors for progression to LRTD.", [["LRTD", "DISEASE", 165, 169], ["HCoV strains", "ORGANISM", 52, 64], ["HCoV", "SPECIES", 52, 56], ["Further studies", "TEST", 0, 15], ["particular HCoV strains", "PROBLEM", 41, 64], ["viral load", "PROBLEM", 69, 79], ["risk factors", "PROBLEM", 133, 145], ["progression to LRTD", "PROBLEM", 150, 169]]]], "9b034efc9d262e8687f1ad7adb78fa7374d3e5ad": [["IntroductionInfluenza A viruses are enveloped RNA viruses of the family Orthomyxoviridae, and a major cause of morbidity and mortality in both humans and livestock, worldwide [1, 2, 3] .", [["Influenza A viruses", "DISEASE", 12, 31], ["Influenza A viruses", "ORGANISM", 12, 31], ["humans", "ORGANISM", 143, 149], ["Influenza A viruses", "SPECIES", 12, 31], ["humans", "SPECIES", 143, 149], ["Influenza A viruses", "SPECIES", 12, 31], ["humans", "SPECIES", 143, 149], ["IntroductionInfluenza A viruses", "PROBLEM", 0, 31], ["morbidity", "PROBLEM", 111, 120], ["morbidity", "OBSERVATION", 111, 120]]], ["Spread may be via direct contact, over short distances on large 'cough' droplets (diameter .10 mm), over longer distances in aerosols of small droplet nuclei (diameter ,10 mm) and on fomites [4, 5] .", [["droplet nuclei", "ANATOMY", 143, 157], ["cough", "DISEASE", 65, 70], ["small", "OBSERVATION_MODIFIER", 137, 142], ["droplet nuclei", "OBSERVATION", 143, 157], ["diameter", "OBSERVATION_MODIFIER", 159, 167], ["10 mm", "OBSERVATION_MODIFIER", 169, 174]]], ["Meteorological variables such as air temperature, relative humidity, rainfall and wind have been suggested as important drivers of the spread and seasonality of influenza in both human [5, 6, 7, 8] and animal populations [9] .", [["influenza", "DISEASE", 161, 170], ["human", "ORGANISM", 179, 184], ["human", "SPECIES", 179, 184], ["human", "SPECIES", 179, 184], ["Meteorological variables", "TEST", 0, 24], ["air temperature", "PROBLEM", 33, 48], ["influenza", "PROBLEM", 161, 170]]], ["Recently, Lowen et al. described, under laboratory conditions, how relative humidity and ambient temperature combine to influence the transmission of both seasonal (A/H3N2) and pandemic (A/H1N1) human influenza A [6, 8, 10] .", [["pandemic", "DISEASE", 177, 185], ["influenza", "DISEASE", 201, 210], ["A/H3N2", "ORGANISM", 165, 171], ["A/H1N1", "ORGANISM", 187, 193], ["human", "ORGANISM", 195, 200], ["human", "SPECIES", 195, 200], ["influenza", "SPECIES", 201, 210], ["A/H3N2", "SPECIES", 165, 171], ["A/H1N1", "SPECIES", 187, 193], ["human influenza A", "SPECIES", 195, 212], ["ambient temperature", "TREATMENT", 89, 108], ["both seasonal (A/H3N2)", "PROBLEM", 150, 172], ["pandemic", "PROBLEM", 177, 185], ["human influenza A", "PROBLEM", 195, 212]]], ["The effects of several other environmental variables (soil pH, sunlight and surface permeability) on the survivability of influenza A viruses were established in earlier laboratory-based experimentation [11, 12] .", [["surface", "ANATOMY", 76, 83], ["influenza A viruses", "ORGANISM", 122, 141], ["influenza A viruses", "SPECIES", 122, 141], ["soil pH", "TEST", 54, 61], ["surface permeability", "TEST", 76, 96], ["influenza A viruses", "PROBLEM", 122, 141]]], ["Analyses of the contribution of wind to the spread of epidemics of influenza, and indeed other infectious diseases, are more limited.", [["influenza", "DISEASE", 67, 76], ["infectious diseases", "DISEASE", 95, 114], ["epidemics", "PROBLEM", 54, 63], ["influenza", "PROBLEM", 67, 76], ["indeed other infectious diseases", "PROBLEM", 82, 114], ["influenza", "OBSERVATION", 67, 76], ["infectious", "OBSERVATION", 95, 105]]], ["Most studies present either circumstantial evidence that the mean direction of epidemic spread coincides with prevailing wind conditions at the time of an outbreak [13, 14] , analyses of data aggregated to a low temporal or spatial resolution [15, 16] , or associate spread from a small number of sources with atmospheric dispersal modelling outputs [17] .", [["Most studies", "TEST", 0, 12], ["epidemic spread", "PROBLEM", 79, 94], ["small", "OBSERVATION_MODIFIER", 281, 286]]], ["Such research must also overcome the added complexity of movement of individuals within the population at risk.IntroductionIn their animal model of human influenza A transmission, Lowen et.al. have shown that dry cool conditions (low relative humidity and cold ambient temperatures) increase the spread of influenza [6] .", [["influenza A transmission", "DISEASE", 154, 178], ["influenza", "DISEASE", 306, 315], ["human", "ORGANISM", 148, 153], ["human", "SPECIES", 148, 153], ["human influenza A", "SPECIES", 148, 165], ["dry cool conditions", "PROBLEM", 209, 228], ["low relative humidity", "PROBLEM", 230, 251], ["cold ambient temperatures", "PROBLEM", 256, 281], ["influenza", "PROBLEM", 306, 315], ["dry", "OBSERVATION_MODIFIER", 209, 212], ["cool", "OBSERVATION", 213, 217]]], ["They suggest that this mechanism is mediated by a complex interaction that affects the survivability of both aerosol droplet nuclei and virus particles.", [["nuclei", "ANATOMY", 125, 131], ["nuclei", "CELLULAR_COMPONENT", 125, 131], ["both aerosol droplet nuclei", "TREATMENT", 104, 131], ["virus particles", "PROBLEM", 136, 151]]], ["A detailed analysis, at high spatial and temporal resolution, comparing actual influenza outbreak data with concurrent meteorological data is required to validate and provide context to their model outside of controlled laboratory environments, thus furthering our understanding of how meteorological factors truly influence influenza spread.", [["influenza", "DISEASE", 325, 334], ["A detailed analysis", "TEST", 0, 19], ["actual influenza outbreak data", "PROBLEM", 72, 102], ["influenza spread", "PROBLEM", 325, 341], ["temporal", "OBSERVATION_MODIFIER", 41, 49], ["resolution", "OBSERVATION_MODIFIER", 50, 60]]], ["Outbreaks of disease in animal populations present a unique opportunity to study such effects, 'in the field'.", [["disease", "PROBLEM", 13, 20], ["disease", "OBSERVATION", 13, 20]]], ["Firstly, human populations move about on a daily basis (albeit with some regularity).", [["human", "ORGANISM", 9, 14], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14]]], ["Implementing a complete human movement standstill ('a 24 hour curfew') to control and contain an outbreak is considered an extraordinary and perhaps unfeasible social distancing measure, reserved for the most severe of human influenza pandemics [21] .", [["influenza pandemics", "DISEASE", 225, 244], ["human", "ORGANISM", 24, 29], ["human", "ORGANISM", 219, 224], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 219, 224], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 219, 224], ["a complete human movement standstill", "TREATMENT", 13, 49], ["human influenza pandemics", "PROBLEM", 219, 244]]], ["Conversely, the movements of farm animal populations (such as horses, cattle and sheep) are mostly confined to within single premises, and in the event of an emergency animal disease outbreak, a complete movement ban is often the first control measure to be implemented [22] .", [["horses", "ORGANISM_SUBDIVISION", 62, 68], ["sheep", "ORGANISM_SUBDIVISION", 81, 86], ["cattle", "SPECIES", 70, 76], ["sheep", "SPECIES", 81, 86], ["cattle", "SPECIES", 70, 76], ["sheep", "SPECIES", 81, 86], ["an emergency animal disease outbreak", "PROBLEM", 155, 191]]], ["Furthermore, ethical concerns (namely privacy) may constrain the research of human outbreak data, limiting the amount of detailed information that can be collated on the movement of individual people.", [["human", "ORGANISM", 77, 82], ["people", "ORGANISM", 193, 199], ["human", "SPECIES", 77, 82], ["people", "SPECIES", 193, 199], ["human", "SPECIES", 77, 82]]], ["Given that certain human and animal sub-types of influenza A share generally similar modes and patterns of transmission [5] , research that utilises detailed animal outbreak datasets has the potential to inform our understanding of the complex mechanisms that influence human influenza A spread and seasonality.", [["influenza", "DISEASE", 49, 58], ["human", "ORGANISM", 19, 24], ["influenza A", "ORGANISM", 49, 60], ["human", "ORGANISM", 270, 275], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 270, 275], ["human", "SPECIES", 19, 24], ["human influenza A", "SPECIES", 270, 287], ["influenza", "PROBLEM", 49, 58], ["human influenza A spread", "PROBLEM", 270, 294]]], ["The 2007 outbreak of equine influenza in Australia presented an excellent opportunity to study the effects of meteorology on the spread of an influenza A virus as it infected a mostly immunologically naive population, spatially confined (in paddocks).IntroductionEquine influenza virus (A/H3N8) is a highly contagious cause of low mortality, high morbidity respiratory disease capable of infecting all members of the horse family (Equidae).", [["respiratory", "ANATOMY", 357, 368], ["influenza", "DISEASE", 28, 37], ["influenza A virus", "DISEASE", 142, 159], ["Equine influenza virus", "DISEASE", 263, 285], ["respiratory disease", "DISEASE", 357, 376], ["equine", "ORGANISM", 21, 27], ["influenza A virus", "ORGANISM", 142, 159], ["Equine influenza virus", "ORGANISM", 263, 285], ["A/H3N8", "ORGANISM", 287, 293], ["horse", "ORGANISM", 417, 422], ["equine", "SPECIES", 21, 27], ["influenza A virus", "SPECIES", 142, 159], ["Equine influenza virus", "SPECIES", 263, 285], ["horse", "SPECIES", 417, 422], ["influenza A virus", "SPECIES", 142, 159], ["Equine influenza virus", "SPECIES", 263, 285], ["A/H3N8", "SPECIES", 287, 293], ["equine influenza", "PROBLEM", 21, 37], ["an influenza A virus", "PROBLEM", 139, 159], ["IntroductionEquine influenza virus", "PROBLEM", 251, 285], ["low mortality", "PROBLEM", 327, 340], ["high morbidity respiratory disease", "PROBLEM", 342, 376], ["influenza virus", "OBSERVATION", 270, 285], ["low mortality", "OBSERVATION_MODIFIER", 327, 340]]], ["It is considered endemic to equine populations across most of the world [2] .", [["endemic", "OBSERVATION_MODIFIER", 17, 24]]], ["The disease is similar in many clinical and epidemiological respects to seasonal human influenza A, and major outbreaks have occurred when novel strains of equine influenza have gained entry into highly susceptible equine populations [2] .", [["influenza A", "DISEASE", 87, 98], ["influenza", "DISEASE", 163, 172], ["human", "ORGANISM", 81, 86], ["equine influenza", "ORGANISM", 156, 172], ["equine", "ORGANISM", 215, 221], ["human", "SPECIES", 81, 86], ["equine influenza", "SPECIES", 156, 172], ["human influenza A", "SPECIES", 81, 98], ["equine", "SPECIES", 156, 162], ["The disease", "PROBLEM", 0, 11], ["seasonal human influenza A", "PROBLEM", 72, 98], ["equine influenza", "PROBLEM", 156, 172], ["disease", "OBSERVATION", 4, 11], ["similar", "OBSERVATION_MODIFIER", 15, 22]]], ["The typical incubation period of equine influenza is 1-3 days [23, 24, 25] , however delayed onset of clinical signs of up to 5 days has been observed after low dose aerosol exposure [26] .", [["influenza", "DISEASE", 40, 49], ["equine", "ORGANISM", 33, 39], ["equine", "SPECIES", 33, 39], ["equine influenza", "PROBLEM", 33, 49], ["clinical signs", "PROBLEM", 102, 116], ["low dose aerosol exposure", "TREATMENT", 157, 182]]], ["In 2007, following a breach in the quarantine of infected imported horses [27] , Australia experienced its first ever outbreak of equine influenza.", [["influenza", "DISEASE", 137, 146], ["equine", "ORGANISM", 130, 136], ["equine", "SPECIES", 130, 136], ["equine influenza", "PROBLEM", 130, 146], ["equine influenza", "OBSERVATION", 130, 146]]], ["Less than 900 horses are imported annually into Australia from countries that vaccinate for equine influenza [27] , therefore almost the entire horse population was susceptible at the start of this outbreak.", [["influenza", "DISEASE", 99, 108], ["horses", "ORGANISM", 14, 20], ["equine influenza", "ORGANISM", 92, 108], ["horse", "ORGANISM", 144, 149], ["equine influenza", "SPECIES", 92, 108], ["horse", "SPECIES", 144, 149], ["horses", "SPECIES", 14, 20], ["horse", "SPECIES", 144, 149], ["equine influenza", "PROBLEM", 92, 108]]], ["Over the course of 4 months, nearly 70 000 horses were infected, on over 9 000 premises in two Australian States-New South Wales (NSW) and Queensland (QLD) [27] .", [["horses", "ORGANISM", 43, 49], ["horses", "SPECIES", 43, 49]]], ["Timely and complete implementation of a horse movement ban has been widely credited as the most effective of the control measures that facilitated the rapid eradication of this disease from the Australian horse population [27] .", [["horse", "ORGANISM", 40, 45], ["horse", "ORGANISM", 205, 210], ["horse", "SPECIES", 40, 45], ["horse", "SPECIES", 205, 210], ["horse", "SPECIES", 40, 45], ["a horse movement ban", "TREATMENT", 38, 58], ["the control measures", "TREATMENT", 109, 129], ["this disease", "PROBLEM", 172, 184]]], ["Although vaccination was used to eradicate the disease, its implementation only commenced 6 weeks into the outbreak, well after the peak of reported daily infections [28] .", [["infections", "DISEASE", 155, 165], ["vaccination", "TREATMENT", 9, 20], ["the disease", "PROBLEM", 43, 54], ["disease", "OBSERVATION", 47, 54]]], ["Vaccination was initially restricted to disease containment zones and the protection of high value horses [28] .IntroductionContact-tracing early in the 2007 outbreak revealed that the disease initially spread through a network of equestrian events, linked by the movement of infected horses prior to detection of the outbreak, producing clusters of infected premises in widespread locations [27, 29] .", [["Vaccination", "TREATMENT", 0, 11], ["disease containment zones", "TREATMENT", 40, 65], ["the disease", "PROBLEM", 181, 192], ["infected horses", "PROBLEM", 276, 291], ["the outbreak", "PROBLEM", 314, 326], ["disease", "OBSERVATION", 185, 192], ["infected", "OBSERVATION", 276, 284], ["clusters", "OBSERVATION_MODIFIER", 338, 346], ["infected", "OBSERVATION_MODIFIER", 350, 358], ["widespread", "OBSERVATION_MODIFIER", 371, 381]]], ["Epidemiological investigations noted rare instances of presumed windborne spread over short ranges (#1.5 km, and rarely up to 5 km) based on failure to identify other potential means of transmission (i.e. close contact or on fomites) [30] .", [["Epidemiological investigations", "TEST", 0, 30], ["windborne spread", "PROBLEM", 64, 80], ["failure", "OBSERVATION", 141, 148]]], ["Previous epidemiological analyses of this outbreak have investigated the spatial and network components of early spread [29, 30, 31, 32] , and premises-level risk factors for disease spread such as compliance with advised biosecurity measures [33] .", [["this outbreak", "PROBLEM", 37, 50], ["disease spread", "PROBLEM", 175, 189], ["early", "OBSERVATION_MODIFIER", 107, 112], ["spread", "OBSERVATION_MODIFIER", 113, 119]]], ["Two further analyses have specifically investigated environmental factors that might have influenced the spread of this outbreak [13, 34] .", [["Two further analyses", "TEST", 0, 20]]], ["In one cluster of 437 infected premises, a relationship was observed between prevailing wind conditions and the global direction of spread [13] .IntroductionIn this paper we present a comprehensive analysis of the influence of meteorological variables on time to infection based on an influenza A virus outbreak dataset.", [["infection", "DISEASE", 263, 272], ["influenza A virus", "ORGANISM", 285, 302], ["influenza A virus", "SPECIES", 285, 302], ["influenza A virus", "SPECIES", 285, 302], ["a comprehensive analysis", "TEST", 182, 206], ["infection", "PROBLEM", 263, 272], ["an influenza A virus outbreak dataset", "PROBLEM", 282, 319], ["infected", "OBSERVATION", 22, 30]]], ["This spatio-temporal analysis aims to identify and quantify the association between four meteorological variables (air temperature, relative humidity, rainfall, wind velocity) and time to infection in the largest cluster of the 2007 equine influenza (A/H3N8) outbreak in Australia.", [["infection", "DISEASE", 188, 197], ["influenza", "DISEASE", 240, 249], ["A/H3N8", "ORGANISM", 251, 257], ["A/H3N8", "SPECIES", 251, 257], ["This spatio-temporal analysis", "TEST", 0, 29], ["air temperature", "PROBLEM", 115, 130], ["relative humidity", "PROBLEM", 132, 149], ["infection", "PROBLEM", 188, 197], ["influenza", "PROBLEM", 240, 249], ["infection", "OBSERVATION", 188, 197], ["largest", "OBSERVATION_MODIFIER", 205, 212]]], ["We are unaware of any previously published analysis that combines such a large and spatio-temporally detailed influenza outbreak dataset with concurrent daily meteorological data, to allow meaningful estimation of the contribution of such factors in the spread of an influenza A outbreak.The equine influenza datasetThe state government of New South Wales provided contacttracing and laboratory testing data on all horses investigated during the 2007 outbreak.", [["equine", "ORGANISM", 292, 298], ["any previously published analysis", "PROBLEM", 18, 51], ["a large and spatio", "PROBLEM", 71, 89], ["such factors", "PROBLEM", 234, 246], ["an influenza A outbreak", "PROBLEM", 264, 287], ["The equine influenza dataset", "PROBLEM", 288, 316], ["laboratory testing data", "TEST", 384, 407], ["large", "OBSERVATION_MODIFIER", 73, 78], ["influenza", "OBSERVATION", 267, 276]]], ["This dataset was collected at the level of individual horses and aggregated to the premises level for analysis.", [["horses", "ORGANISM", 54, 60], ["This dataset", "TEST", 0, 12], ["analysis", "TEST", 102, 110]]], ["Premises attribute records included address, geocoded coordinates (based on premises centroid), number of horses, date of onset of clinical signs in the first horse affected ('onset date'), vaccination status and date of vaccination.", [["horse", "ORGANISM_SUBDIVISION", 159, 164], ["horse", "SPECIES", 159, 164], ["clinical signs", "PROBLEM", 131, 145], ["vaccination", "TREATMENT", 221, 232]]], ["Premises were defined as infected (IP) if they held horses that had been observed with the classical clinical signs of equine influenza (cough, elevated temperature, nasal discharge and lethargy).", [["nasal", "ANATOMY", 166, 171], ["influenza", "DISEASE", 126, 135], ["cough", "DISEASE", 137, 142], ["lethargy", "DISEASE", 186, 194], ["horses", "ORGANISM", 52, 58], ["equine", "ORGANISM", 119, 125], ["nasal", "ORGANISM_SUBDIVISION", 166, 171], ["equine", "SPECIES", 119, 125], ["equine influenza", "PROBLEM", 119, 135], ["cough", "PROBLEM", 137, 142], ["elevated temperature", "PROBLEM", 144, 164], ["nasal discharge", "PROBLEM", 166, 181], ["lethargy", "PROBLEM", 186, 194], ["infected", "OBSERVATION_MODIFIER", 25, 33], ["nasal", "ANATOMY", 166, 171]]], ["This status was confirmed by laboratory testing based on real-time reverse transcription polymerase chain reaction assay [36] , however, around the peak of the outbreak not all horses were tested due to resource constraints [30] .", [["laboratory testing", "TEST", 29, 47]]], ["Contact-tracing records included the date of the movement, the addresses and unique identifiers for the origin and destination premises between which horses were moved prior to the horse movement ban.Study extent: cluster delineationThere was a single 'index' for the 2007 outbreak of equine influenza in Australia: an equestrian event located 160 km north of Sydney, at which transmission was known to have occurred.", [["influenza", "DISEASE", 292, 301], ["horses", "ORGANISM", 150, 156], ["horse", "ORGANISM", 181, 186], ["equine", "ORGANISM", 285, 291], ["equine", "SPECIES", 285, 291], ["equine influenza", "PROBLEM", 285, 301]]], ["This analysis focused on local spread within the single largest cluster of the outbreak, centred 60 km northwest of Sydney's city centre ( Figure 1 ).", [["This analysis", "TEST", 0, 13], ["local spread", "PROBLEM", 25, 37], ["largest", "OBSERVATION_MODIFIER", 56, 63]]], ["To maintain a computationally tractable dataset, premises were selected for inclusion in the study (from the equine influenza dataset) if their centroid was within 15 km of nine contact-traced 'source' premises.", [["the study", "TEST", 89, 98], ["the equine influenza dataset", "TREATMENT", 105, 133]]], ["All nine contact-traced premises were identified (based on an earlier likelihood-based analysis [32] ) to have been infected in the first week of the outbreak following the movement of infected horses from the 'index'.", [["horses", "ORGANISM", 194, 200], ["infected horses", "PROBLEM", 185, 200], ["infected", "OBSERVATION", 116, 124], ["infected", "OBSERVATION", 185, 193]]], ["The 15 km buffer used to delineate the cluster was selected based on a previous analysis in which we identified that 98% of premises infected in the first month of the outbreak were within this distance of a contact-traced 'source' premises [29] .", [["The 15 km buffer", "TREATMENT", 0, 16], ["a previous analysis", "TEST", 69, 88]]], ["The 'Northwest Sydney' cluster studied was approximately 65 km in diameter, bounded to the North and West by national parks (where horses are prohibited) and to the South and East by metropolitan Sydney.Exploratory spatial and temporal analysesThe dataset was imported into the R statistical package version 2.13.0 [37] , and an epidemic curve constructed as the count of infected premises reported per day.", [["horses", "ORGANISM_SUBDIVISION", 131, 137], ["Exploratory spatial and temporal analyses", "TEST", 203, 244], ["an epidemic curve", "TEST", 326, 343], ["infected", "OBSERVATION", 372, 380]]], ["Extraction mapping was used to investigate the spatial pattern of risk of infection over time.", [["infection", "DISEASE", 74, 83], ["Extraction mapping", "TEST", 0, 18], ["infection", "PROBLEM", 74, 83], ["infection", "OBSERVATION", 74, 83]]], ["To identify areas of elevated risk, relative risk surfaces with upper 95% tolerance contours were estimated as the Gaussian-smoothed kernel density surface of infected horse premises divided by the surface of the population of horse premises at risk in 4-week time periods.", [["surface", "ANATOMY", 198, 205], ["horse", "ORGANISM", 168, 173], ["horse", "ORGANISM", 227, 232], ["horse", "SPECIES", 168, 173], ["horse", "SPECIES", 227, 232], ["horse", "SPECIES", 168, 173], ["elevated risk", "PROBLEM", 21, 34], ["relative risk surfaces", "PROBLEM", 36, 58], ["upper 95% tolerance contours", "PROBLEM", 64, 92], ["infected horse premises", "PROBLEM", 159, 182], ["elevated risk", "OBSERVATION", 21, 34], ["risk", "OBSERVATION_MODIFIER", 45, 49], ["surfaces", "OBSERVATION_MODIFIER", 50, 58], ["upper", "ANATOMY_MODIFIER", 64, 69], ["density", "OBSERVATION_MODIFIER", 140, 147], ["surface", "OBSERVATION_MODIFIER", 148, 155], ["infected", "OBSERVATION_MODIFIER", 159, 167], ["horse premises", "OBSERVATION", 168, 182], ["surface", "OBSERVATION_MODIFIER", 198, 205], ["population", "OBSERVATION_MODIFIER", 213, 223], ["horse premises", "OBSERVATION", 227, 241]]], ["A spatially adaptive variable smoothing parameter was used to prepare the relative risk surfaces [38] , with edge effect correction, implemented in R with the 'sparr' library [39] .", [["A spatially adaptive variable smoothing parameter", "TREATMENT", 0, 49]]], ["The amount of smoothing (bandwidth) applied varied across the study extent in inverse proportion to the population at risk in each time period.", [["smoothing (bandwidth)", "TREATMENT", 14, 35], ["the study", "TEST", 58, 67], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["smoothing", "OBSERVATION_MODIFIER", 14, 23], ["population", "OBSERVATION", 104, 114]]], ["To test for directional spread, the mean geographic centre of the outbreak was estimated by week as the mean of the coordinates of the infected premises with dates of onset in each week of the outbreak [40] .Survival analysisWe applied semi-parametric Cox regression modelling to estimate the association between potential risk factors and the times to infection of individual premises.", [["infection", "DISEASE", 353, 362], ["directional spread", "PROBLEM", 12, 30], ["Survival analysisWe", "TREATMENT", 208, 227], ["Cox regression modelling", "PROBLEM", 252, 276], ["potential risk factors", "PROBLEM", 313, 335], ["infected", "OBSERVATION", 135, 143]]], ["A geodatabase was compiled in Microsoft Access 2007 (Microsoft Corporation, Redmond, WA, USA) to maintain all premises and meteorological data, with spatial covariates added using ArcMap 9.3 (ESRI, Redlands, CA, USA).", [["meteorological data", "TEST", 123, 142], ["ArcMap", "TEST", 180, 186]]], ["The dataset was structured into a daily 'counting process' formulation to enable investigation of the effects of time-varying predictors [41] , in this case time-lagged premiseslevel meteorological variables.", [["a daily 'counting process' formulation", "TREATMENT", 32, 70]]], ["See Supporting Information S1 for a sample of the survival dataset used in this analysis.", [["the survival dataset", "TEST", 46, 66], ["this analysis", "TEST", 75, 88]]], ["Time-varying covariates and the counting process formulation were arranged using the R statistical package.Survival analysisIn the counting process generalisation of the Cox proportional hazards model, the hazard function depends on time in ways other than only through the baseline hazard function [42] .", [["the counting process formulation", "TREATMENT", 28, 60], ["the R statistical package", "TREATMENT", 81, 106], ["Survival analysisIn", "TREATMENT", 107, 126]]], ["This enables covariate values for individual subjects to either be time-invariant or to change with time, and to be incorporated into a generalised Cox regression model [41] of the form:Survival analysiswhere h i (t) is the hazard that an individual, i, from the population yet to experience an event, will experience the event at time t; h 0 (t) is the baseline hazard at time t; b1 and b2 are the regression coefficients for the time-invariant, x i1 , and time-dependent covariates, x i2(t) , respectively.", [["covariate values", "TEST", 13, 29]]], ["The partial likelihood specification for the counting process Cox regression model is described in detail by Anderson and Gill (1982) , and is estimated including a term for each unique event time, summing over those observations that are still at risk at each actual event time.", [["the counting process", "TEST", 41, 61], ["partial", "OBSERVATION_MODIFIER", 4, 11], ["likelihood specification", "OBSERVATION", 12, 36]]], ["As there is no overlap in intervals of risk in the set of observations for each subject, the likelihood never involves more than one observation for a subject [44] .", [["no", "UNCERTAINTY", 12, 14], ["overlap", "OBSERVATION_MODIFIER", 15, 22]]], ["Network and spatial spread in the early outbreak period (the first 14 days of this outbreak) is described in detail elsewhere [32] .", [["spatial", "OBSERVATION_MODIFIER", 12, 19], ["spread", "OBSERVATION_MODIFIER", 20, 26]]], ["To focus this analysis on the meteorological factors associated with local spread, we excluded any premises that may have been infected in the first 10 days of the outbreak, before the complete implementation of horse movement bans (i.e. any premises with an onset date in the first 14 days of the outbreak), setting the origin of the survival analysis at 30 August 2007.", [["horse", "ORGANISM", 212, 217], ["horse", "SPECIES", 212, 217], ["horse", "SPECIES", 212, 217], ["this analysis", "TEST", 9, 22], ["local spread", "PROBLEM", 69, 81], ["infected", "OBSERVATION_MODIFIER", 127, 135]]], ["This period ends one typical incubation period (3 days) after movement bans were implemented, with an additional 1 day error margin for delay in observation and reporting [33] .", [["typical", "OBSERVATION_MODIFIER", 21, 28], ["incubation", "OBSERVATION_MODIFIER", 29, 39]]], ["All premises that remained uninfected on the 131 st day of the outbreak (25 December 2007, the reported date of onset of the last known infected premises) were right censored on this date.Survival analysisExplanatory variables.", [["Survival analysisExplanatory variables", "TEST", 188, 226], ["uninfected", "OBSERVATION", 27, 37], ["right", "ANATOMY_MODIFIER", 160, 165]]], ["Explanatory covariates tested for associations with the time to infection of premises in the Northwest Sydney cluster are listed in Table 1 .", [["infection", "DISEASE", 64, 73]]], ["These boundaries were used to generate a continuous variable representing the length of fence that each horse premises shared with any contiguous horse premises in the equine influenza dataset.", [["horse", "ORGANISM", 104, 109], ["horse", "ORGANISM", 146, 151], ["equine", "ORGANISM", 168, 174]]], ["Premises elevation was extracted from a digital elevation model of Australia [45] , which is a grid of ground level elevation covering the whole of Australia with a grid spacing of approximately 250 metres, as the mean of all grid cells needed to cover a premises.", [["grid cells", "ANATOMY", 226, 236], ["cells", "CELL", 231, 236], ["grid cells", "CELL_TYPE", 226, 236], ["Premises elevation", "PROBLEM", 0, 18], ["ground level elevation", "PROBLEM", 103, 125], ["a grid spacing", "TREATMENT", 163, 177], ["all grid cells", "TREATMENT", 222, 236], ["elevation", "OBSERVATION_MODIFIER", 9, 18], ["elevation", "OBSERVATION_MODIFIER", 48, 57]]], ["Distance to the nearest main road was calculated from the premises boundary using vector data of road Classes 1-3 (freeways, highways, primary and arterial roads) [46] .", [["arterial", "ANATOMY", 147, 155], ["road Classes", "TEST", 97, 109], ["arterial", "ANATOMY", 147, 155]]], ["Human population density, within approximately 1 km of the premises centroid, was estimated based on high resolution gridded population data from 2005 [47] , adjusted by 3% for population growth between 2005 and 2007 [48] .Estimation of meteorological time-varying predictors.Hourly wind velocity data (wind direction and speed) and daily data for five other meteorological variables (rainfall, minimum and maximum daily air temperature, and relative humidity measured at 9 am and 3 pm) were obtained from 132 weather stations.", [["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human population density", "PROBLEM", 0, 24], ["Hourly wind velocity data", "TEST", 276, 301], ["daily data", "TEST", 333, 343], ["maximum daily air temperature", "TEST", 407, 436], ["relative humidity", "TEST", 442, 459], ["population", "OBSERVATION_MODIFIER", 6, 16], ["density", "OBSERVATION", 17, 24]]], ["All of these weather stations were operated by the Australian Bureau of Meteorology during the study period, and were located either within the cluster or within 20 km of the cluster boundary.", [["the study", "TEST", 91, 100]]], ["Ordinary kriging [49] was used to interpolate daily values at each individual premises location for the meteorological time-varying predictors: maximum wind speed (km hour 21 ), rainfall (mm), maximum and minimum surface air temperature (uC), and relative humidity (%, measured at 9 am and 3 pm).", [["surface", "ANATOMY", 213, 220], ["uC", "TEST", 238, 240]]], ["Each time-varying meteorological covariate was then time-lagged by 1-5 days to encompass the full range of incubation periods observed in experimental infection studies [26] .Estimation of meteorological time-varying predictors.Kriging is a geostatistical smoothing technique that involves modelling the underlying spatial dependency (autocorrelation) in spatially continuous data based on a covariance function ( Figure 2a ) [49] .", [["infection", "DISEASE", 151, 160], ["experimental infection studies", "PROBLEM", 138, 168], ["a geostatistical smoothing technique", "TREATMENT", 239, 275], ["modelling the underlying spatial dependency", "PROBLEM", 290, 333], ["a covariance function", "TEST", 390, 411], ["infection", "OBSERVATION", 151, 160], ["spatial dependency", "OBSERVATION", 315, 333]]], ["For each observation point (hour or day), for each meteorological variable, a binned isotropic empirical variogram was plotted that represented covariance (as semivariance) up until half of the maximum pairwise distance between any two weather stations contributing data at that time point, with bin widths (h) of approximately 10% of the average distance between weather stations [50] .", [["a binned isotropic empirical variogram", "TREATMENT", 76, 114]]], ["A stationary exponential variogram model was then fit to the empirical variogram, using iterative least squares regression, and parameter estimates used to interpolate values at each premises location [49] .Estimation of meteorological time-varying predictors.Generation of wind speed covariates.", [["A stationary exponential variogram model", "TEST", 0, 40], ["the empirical variogram", "TEST", 57, 80], ["iterative least squares regression", "TREATMENT", 88, 122], ["parameter estimates", "TEST", 128, 147], ["wind speed", "OBSERVATION", 274, 284]]], ["Hourly wind velocity data were available from sixteen of the weather stations, automatically measured on masts at 10(metres above the earth's surface.", [["surface", "ANATOMY", 142, 149], ["Hourly wind velocity data", "TEST", 0, 25], ["masts", "TEST", 105, 110]]], ["These wind data were supplied in a polar coordinate structure, comprising the average direction of origin of the wind (in degrees from true north) and the maximum wind speed (in kilometres hour(1), measured over the 10(minutes leading up to the observation time.", [["These wind data", "TEST", 0, 15], ["polar", "ANATOMY_MODIFIER", 35, 40], ["average", "OBSERVATION_MODIFIER", 78, 85], ["direction", "OBSERVATION_MODIFIER", 86, 95], ["origin", "ANATOMY_MODIFIER", 99, 105], ["wind", "OBSERVATION_MODIFIER", 113, 117], ["maximum", "OBSERVATION_MODIFIER", 155, 162]]], ["To avoid the issue of northerly bearings being split at true north (i.e. true bearings of 1( and 359( seeming distant when they are only 2( apart), prior to variography and kriging, the wind velocity data was converted into a Cartesian coordinate system-defined by two components (Figure 2b ,c): ''u'' representing the East-to-West component of the wind velocity, and ''v'' representing the North-to-South component [51] .", [["northerly bearings", "PROBLEM", 22, 40], ["the wind velocity data", "TEST", 182, 204], ["wind velocity", "OBSERVATION", 349, 362]]], ["A negative value for the ''u'' component therefore represents a wind from one of the westerly bearings (i.e. NW, W or SW).Estimation of meteorological time-varying predictors.Kriging was then conducted on the two wind velocity vector components [51] .", [["negative", "OBSERVATION", 2, 10]]], ["Hourly wind velocity vectors were interpolated for each premises and back-transformed into the original polar coordinates (direction of wind origin and maximum wind speed).Estimation of meteorological time-varying predictors.Two approaches were taken to aggregate the hourly wind velocity vectors for each premises into daily maximum wind speed covariates.", [["Hourly wind velocity vectors", "TREATMENT", 0, 28], ["polar", "OBSERVATION_MODIFIER", 104, 109]]], ["First, to test the hypothesis that increased wind speed from any direction was associated with increased hazard of infection we generated 'undirected' maximum daily wind speed covariates ('WIND_SPD undir ') without making any directional assumptions, taking the maximum of all hourly wind speed estimates for each premises on each day.Estimation of meteorological time-varying predictors.Next, to explore the directionality of wind exposure risk we generated 'directed' maximum daily wind speed covariates ('WIND_SPD dir ') based only on wind coming from within the direction of the nearest k infected premises (for k = 1,2,3) by selecting wind from within 45u arcs centred on the bearing of the nearest k infected premises to each premises on each day.", [["infection", "DISEASE", 115, 124], ["increased hazard of infection", "PROBLEM", 95, 124], ["'WIND_SPD dir ')", "TREATMENT", 507, 523], ["k", "TEST", 616, 617], ["infection", "OBSERVATION", 115, 124]]], ["For each premises, on each day of observation, we identified the nearest three infected premises from amongst those infected premises that had a date of onset (of clinical signs in the first horse infected on the premises) within the previous 14 days.", [["horse", "ORGANISM", 191, 196], ["horse", "SPECIES", 191, 196], ["clinical signs", "PROBLEM", 163, 177]]], ["Though it is known that individual unvaccinated horses remain infectious for up to 7 days [2, 52] , the duration of infectivity may vary on multi-horse premises because of differences in contact rates between individual horses, and individual variability in susceptibility, latency and virus shedding.", [["horses", "ORGANISM", 48, 54], ["horses", "SPECIES", 48, 54], ["individual unvaccinated horses", "PROBLEM", 24, 54], ["infectious", "PROBLEM", 62, 72], ["infectivity", "PROBLEM", 116, 127], ["individual variability in susceptibility", "PROBLEM", 232, 272], ["latency and virus shedding", "PROBLEM", 274, 300]]], ["To infer which premises were holding infectious horses at each time point we assumed that the period of infectivity was 14 days for all premises based on case reports from horse premises of a range of sizes [53, 54, 55] , intra-herd simulation modelling [28] and that almost the entire population was immunologically naive to equine influenza at the start of the outbreak.Estimation of meteorological time-varying predictors.Finally, these time-varying predictors were lagged by 1-5 days to serve as proxies for wind within the range of incubation periods that have been observed for equine influenza, producing 20 timelagged explanatory covariates: 'WIND_SPD undir t 21 , t 22 , \u2026, t 25 ' and 'WIND_SPD dir(k) t 21 , t 22 , \u2026, t 25 ', for k = 1,2,3.Univariable analysisInstantaneous hazard curves were constructed for each timeinvariant covariate with the 'epiR' library in R [56] , categorising continuous variables into quartiles.", [["influenza", "DISEASE", 333, 342], ["influenza", "DISEASE", 591, 600], ["horse", "ORGANISM", 172, 177], ["equine", "ORGANISM", 326, 332], ["epiR' library", "DNA", 858, 871], ["horse", "SPECIES", 172, 177], ["equine", "SPECIES", 584, 590], ["equine", "SPECIES", 326, 332], ["equine influenza", "SPECIES", 584, 600], ["infectivity", "PROBLEM", 104, 115], ["equine influenza", "PROBLEM", 326, 342], ["equine influenza", "PROBLEM", 584, 600], ["t", "TEST", 673, 674], ["t", "TEST", 683, 684], ["SPD dir", "TEST", 700, 707], ["t", "TEST", 711, 712], ["t", "TEST", 718, 719], ["\u2026", "TEST", 725, 726], ["t", "TEST", 728, 729], ["k", "TEST", 740, 741], ["Univariable analysisInstantaneous hazard curves", "TREATMENT", 750, 797]]], ["The instantaneous hazard rate, h(t), is the rate at time t, that a randomly-selected individual from the population yet to experience an event, experiences the event at time t [43] , and is mathematically defined as:Univariable analysiswhere T is the time that an event is experienced.", [["The instantaneous hazard rate", "TEST", 0, 29]]], ["In this study, the unit of interest was the horse premises, and events were defined as the infection of horses with equine influenza virus on a previously uninfected premises.", [["infection", "DISEASE", 91, 100], ["equine influenza virus", "DISEASE", 116, 138], ["horse", "ORGANISM", 44, 49], ["horses", "ORGANISM", 104, 110], ["equine influenza virus", "ORGANISM", 116, 138], ["horse", "SPECIES", 44, 49], ["equine influenza virus", "SPECIES", 116, 138], ["equine influenza virus", "SPECIES", 116, 138], ["this study", "TEST", 3, 13], ["the infection of horses", "PROBLEM", 87, 110], ["equine influenza virus", "PROBLEM", 116, 138], ["infection", "OBSERVATION", 91, 100]]], ["Time-changing covariate. b Maximum daily wind speed was either based on wind from all directions ('undirected') or wind only from within 45u arcs centred on the direction of the k nearest infected premises for k = 1,2,3 (see Figure 2 for details) assuming that premises were infectious for 14 days and one of the nearest k infective premises was the source of infection.", [["infection", "DISEASE", 360, 369], ["infectious", "PROBLEM", 275, 285], ["infection", "PROBLEM", 360, 369], ["infectious", "OBSERVATION", 275, 285], ["infection", "OBSERVATION", 360, 369]]], ["Univariable Cox models were then constructed and the statistical strength of the association between each variable (categorical or continuous) and the outcome assessed using likelihood ratio tests [35] .", [["Univariable Cox models", "TEST", 0, 22], ["likelihood ratio tests", "TEST", 174, 196]]], ["The linearity of the relationship between log hazard of infection and each continuous variable was assessed graphically using restricted cubic splines [57] with knots spaced at quintiles in the data.", [["infection", "DISEASE", 56, 65], ["infection", "PROBLEM", 56, 65], ["restricted cubic splines", "TREATMENT", 126, 150], ["linearity", "OBSERVATION_MODIFIER", 4, 13], ["infection", "OBSERVATION", 56, 65]]], ["To differentiate linear and nonlinear component terms, partial likelihood ratio tests were conducted comparing a model containing all spline terms to a nested model containing only a single linear term [57] .", [["partial likelihood ratio tests", "TEST", 55, 85], ["a model containing all spline terms", "TREATMENT", 111, 146], ["a nested model", "TREATMENT", 150, 164], ["linear", "OBSERVATION_MODIFIER", 17, 23], ["nonlinear", "OBSERVATION_MODIFIER", 28, 37], ["component", "OBSERVATION_MODIFIER", 38, 47], ["partial", "OBSERVATION_MODIFIER", 55, 62]]], ["If a highly non-linear relationship was detected, the spline of the continuous variable was retained for multivariable analysis.", [["multivariable analysis", "TEST", 105, 127]]], ["All continuous covariates were tested for collinearity in pairs by calculating Spearman's rank correlation coefficient (r).", [["All continuous covariates", "TREATMENT", 0, 25], ["collinearity in pairs", "PROBLEM", 42, 63]]], ["Intrinsic temporal autocorrelation was expected amongst certain groups of time-lagged time-varying meteorological predictors, such as:Univariable analysis.", [["Univariable analysis", "TEST", 134, 154]]], ["From amongst any pair of highly correlated (r.|0.70|) time-invariant covariates, and from amongst intrinsically temporally autocorrelated groups of time-varying predictors, only the variable with the strongest statistical association with the outcome was retained for further analysis [58] .Multivariable analysisAll remaining variables (unconditionally statistically associated with the log hazard of infection at P-value,0.25) were entered into a generalised 'counting process' Cox regression model [41] .", [["infection", "DISEASE", 402, 411], ["further analysis", "TEST", 268, 284], ["Multivariable analysis", "TEST", 291, 313], ["infection", "PROBLEM", 402, 411], ["Cox regression model", "TEST", 480, 500], ["infection", "OBSERVATION", 402, 411]]], ["The time-varying predictor representing vaccination status was forced into all multivariable models as it was considered a priori to confound disease spread.", [["vaccination status", "PROBLEM", 40, 58], ["confound disease spread", "PROBLEM", 133, 156]]], ["The linearity of the relationship between the outcome and each continuous variable still included in the model was assessed again, using restricted cubic splines [57] .", [["restricted cubic splines", "TREATMENT", 137, 161], ["linearity", "OBSERVATION_MODIFIER", 4, 13]]], ["Finally, tests were conducted for all two-way interactions of terms in the preliminary main effects model.Multivariable analysisGoodness of fit of the final model was assessed using 'Martingale' residuals.", [["tests", "TEST", 9, 14], ["'Martingale' residuals", "TREATMENT", 182, 204]]], ["The influence of every individual observation was tested by omitting it and observing for change in the regression coefficients [59] .", [["every individual observation", "TEST", 17, 45]]], ["To test for spatial dependency (autocorrelation) we examined the spatial structure of the residuals of the final model by mapping normalised martingale residuals ('deviance residuals') and plotting an empirical semivariogram [60] .Exploratory spatial and temporal analysisThe Northwest Sydney cluster of the 2007 equine influenza outbreak in Australia contained 3624 horse premises, of which 1922 were reported to be infected during the 131 day outbreak (cumulative incidence = 53.0%, 95% CI: 51.4, 54.7%).Exploratory spatial and temporal analysisSurfaces of spatial relative risk by four week period are included as Figure 3 .", [["influenza", "DISEASE", 320, 329], ["horse", "ORGANISM", 367, 372], ["horse", "SPECIES", 367, 372], ["spatial dependency", "PROBLEM", 12, 30], ["plotting an empirical semivariogram", "TEST", 189, 224], ["Exploratory spatial and temporal analysis", "TEST", 231, 272], ["CI", "TEST", 489, 491], ["Exploratory spatial", "TEST", 506, 525], ["infected", "OBSERVATION", 417, 425], ["temporal", "OBSERVATION_MODIFIER", 530, 538]]], ["In the first 4 weeks of the outbreak there were two areas of elevated spatial risk localised around the nine source premises for this cluster.", [["elevated spatial risk", "PROBLEM", 61, 82], ["areas", "OBSERVATION_MODIFIER", 52, 57], ["elevated", "OBSERVATION_MODIFIER", 61, 69], ["spatial risk", "OBSERVATION", 70, 82]]], ["Over the next 4 weeks, the two areas of elevated risk coalesced and expanded.", [["elevated risk", "PROBLEM", 40, 53], ["elevated", "OBSERVATION_MODIFIER", 40, 48], ["risk", "OBSERVATION_MODIFIER", 49, 53], ["coalesced", "OBSERVATION_MODIFIER", 54, 63], ["expanded", "OBSERVATION_MODIFIER", 68, 76]]], ["Between weeks 9 to 12, the areas of spatial risk dissipated into several smaller pockets of infection.", [["infection", "DISEASE", 92, 101], ["infection", "PROBLEM", 92, 101], ["spatial risk", "OBSERVATION", 36, 48], ["several", "OBSERVATION_MODIFIER", 65, 72], ["smaller", "OBSERVATION_MODIFIER", 73, 80], ["pockets", "OBSERVATION_MODIFIER", 81, 88], ["infection", "OBSERVATION", 92, 101]]], ["Over the remainder of the outbreak, the spatial risk faded out in isolated pockets of infection.Exploratory spatial and temporal analysisThe mean centre of the outbreak did not move predominantly in any single direction over the study period, moving Northwest at 3.0 km week 21 in the first 4 weeks, then Southwest at 3.9 km week 21 for 4 weeks, before moving back to the East at 4.1 km week 21 whilst the epidemic faded out.Survival analysisThe complete survival dataset included 3153 premises containing 1727 events (infections) during the study period.", [["infection", "DISEASE", 86, 95], ["infections", "DISEASE", 519, 529], ["infection", "PROBLEM", 86, 95], ["Exploratory spatial and temporal analysis", "TEST", 96, 137], ["Survival analysis", "TEST", 425, 442], ["infections", "PROBLEM", 519, 529], ["the study", "TEST", 538, 547], ["pockets", "OBSERVATION_MODIFIER", 75, 82], ["infection", "OBSERVATION", 86, 95], ["mean", "OBSERVATION_MODIFIER", 141, 145], ["outbreak", "OBSERVATION", 160, 168]]], ["Data on 57 infected horse premises were excluded because their onset dates occurred in the first 14 days of the outbreak (a period when they could possibly have been infected by the movement of infected horses rather than by local spatial spread).", [["horse", "ORGANISM", 20, 25], ["horse", "SPECIES", 20, 25], ["infected horses", "PROBLEM", 194, 209]]], ["Sixty-seven infected premises were missing a date of onset, and 347 premises (71 infected and 276 uninfected premises) were missing data on their number of horses.", [["horses", "ORGANISM_SUBDIVISION", 156, 162], ["missing data", "PROBLEM", 124, 136]]], ["The median survival time, the point at which half of the premises in this cluster were infected, was day 55 of this outbreak (95% CI : 52, 61).", [["infected", "OBSERVATION", 87, 95]]], ["The instantaneous hazard, the proportion of infections per day in the population surviving uninfected until that day, peaked on day 28 ( Figure 4) ; 92 premises were reported to be infected on this day.Univariable analysisMeteorological covariates and hazard of infection.", [["infections", "DISEASE", 44, 54], ["infection", "DISEASE", 262, 271], ["infections", "PROBLEM", 44, 54], ["Univariable analysis", "TEST", 202, 222], ["infection", "PROBLEM", 262, 271], ["instantaneous", "OBSERVATION_MODIFIER", 4, 17], ["infections", "OBSERVATION", 44, 54], ["infected", "OBSERVATION", 181, 189], ["infection", "OBSERVATION", 262, 271]]], ["Most horse premises were relatively close to a weather station, with the mean distance to the nearest weather station reporting wind data being 11.7 km (SD = 5.4 km, maximum = 27.4 km).", [["horse", "ORGANISM", 5, 10], ["horse", "SPECIES", 5, 10], ["wind data", "TEST", 128, 137], ["SD", "TEST", 153, 155], ["maximum", "TEST", 166, 173]]], ["For all meteorological data, there was a paucity of weather stations in the Northwest corner of the study extent (because this region is bordered by a national park).Univariable analysisDaily rainfall data were available from 127 weather stations in the study extent.Univariable analysisOver the study period, the median estimated daily rainfall per premises was 0.1 mm day 21 (IQR: 0 to 2.8 mm day 21 , maximum = 106.5 mm day 21 ).", [["all meteorological data", "TEST", 4, 27], ["Univariable analysisDaily rainfall data", "TEST", 166, 205], ["IQR", "TEST", 378, 381], ["paucity", "OBSERVATION_MODIFIER", 41, 48]]], ["No statistically significant associations were detected between time-lagged rainfall covariates and hazard of infection (Table 2) .", [["infection", "DISEASE", 110, 119], ["infection", "PROBLEM", 110, 119], ["statistically", "OBSERVATION_MODIFIER", 3, 16], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["infection", "OBSERVATION", 110, 119]]], ["Moderate temporal correlation (r<0.60) was observed between rainfall data 1 day apart, and between rainfall and relative humidity measurements conducted within 1 day of each other.", [["Moderate temporal correlation", "PROBLEM", 0, 29], ["relative humidity measurements", "TEST", 112, 142], ["temporal", "OBSERVATION_MODIFIER", 9, 17]]], ["A detailed correlation matrix of all continuous covariates is provided in Supporting Information S1.Univariable analysisRelative humidity data measured twice daily (at 9 am and 3 pm) were available from eighteen weather stations (Figure 5a ).", [["all continuous covariates", "TREATMENT", 33, 58], ["Univariable analysisRelative humidity data", "TEST", 100, 142]]], ["The mean of the estimated 9 am and 3 pm relative humidity measurements for the horse premises under observation were 70.8% (SD = 17.5%) and 52.9% (SD = 20.3%), respectively.", [["horse", "ORGANISM", 79, 84], ["horse", "SPECIES", 79, 84], ["relative humidity measurements", "TEST", 40, 70], ["SD", "TEST", 124, 126], ["SD", "TEST", 147, 149], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["Conditions were drier when measured at the same station at 3 pm compared to 9 am, on any given day, with paired relative humidity measurements 16.0% on average lower in the afternoon (95% CI: 15.3, 16.8%).", [["paired relative humidity measurements", "TEST", 105, 142], ["CI", "TEST", 188, 190]]], ["Moderate to high temporal autocorrelation (r<0.70) was observed between 9 am and 3 pm relative humidity data on the same day and at the same time 1 day apart.Univariable analysisA negative cubic relationship was observed between relative humidity and hazard of infection (Figure 5b) .", [["infection", "DISEASE", 261, 270], ["Moderate to high temporal autocorrelation", "PROBLEM", 0, 41], ["Univariable analysisA", "TEST", 158, 179], ["infection", "PROBLEM", 261, 270], ["high", "OBSERVATION_MODIFIER", 12, 16], ["temporal", "OBSERVATION_MODIFIER", 17, 25], ["infection", "OBSERVATION", 261, 270]]], ["Risk of equine influenza infection was highest in dry conditions (,20% relative humidity), decayed rapidly until increasing at intermediate relative humidity (40-60%) .", [["influenza infection", "DISEASE", 15, 34], ["equine", "ORGANISM", 8, 14], ["equine", "SPECIES", 8, 14], ["equine influenza infection", "PROBLEM", 8, 34], ["equine", "OBSERVATION_MODIFIER", 8, 14], ["influenza", "OBSERVATION", 15, 24]]], ["The strongest statistical association was with the 3 pm measurement time-lagged by 5 days, thus, 'RH_3PM t 25 ' was selected as a proxy for relative humidity, irrespective of diurnal variation or time-lag.Univariable analysisDaily surface air temperature data were available from 21 weather stations (Figure 5c ).", [["surface", "ANATOMY", 231, 238], ["Univariable analysisDaily surface air temperature data", "TEST", 205, 259]]], ["The mean of the estimated daily maximum and minimum temperatures at the 3153 horse premises was 24.0uC (95% CI: 22.4, 25.7), and 12.6uC (95% CI: 9.1, 16.1uC), respectively.", [["horse", "SPECIES", 77, 82], ["minimum temperatures", "TEST", 44, 64], ["uC", "TEST", 100, 102], ["CI", "TEST", 108, 110], ["uC", "TEST", 133, 135], ["CI", "TEST", 141, 143], ["uC", "TEST", 154, 156], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["There was an increasing trend in temperature across the study period as the season changed from spring to summer, and a low level of correlation (r<0.40) between maximum and minimum temperature measured on the same day.", [["the study", "TEST", 52, 61], ["minimum temperature", "TEST", 174, 193], ["increasing", "OBSERVATION_MODIFIER", 13, 23], ["trend", "OBSERVATION_MODIFIER", 24, 29], ["temperature", "OBSERVATION_MODIFIER", 33, 44]]], ["Minimum daily temperature data 1-4 days apart were moderately to highly correlated (0.61#r#0.75), less correlation was observed between maximum daily temperatures 1 day apart (r<0.53), and a low cross-correlation (0.30,r,0.50) was observed between minimum daily temperature, rainfall and 9 am relative humidity data for 1-5 days.Univariable analysisA highly nonlinear relationship was observed between infection and maximum daily air temperature (Figure 5d) , with risk of infection greatest toward both extremes of the range of observed maximum temperatures (,16uC and .28uC).", [["infection", "DISEASE", 402, 411], ["infection", "DISEASE", 473, 482], ["Minimum daily temperature data", "TEST", 0, 30], ["a low cross-correlation", "TEST", 189, 212], ["Univariable analysisA", "TEST", 329, 350], ["infection", "PROBLEM", 402, 411], ["maximum daily air temperature", "PROBLEM", 416, 445], ["infection", "PROBLEM", 473, 482], ["maximum temperatures", "TEST", 538, 558], ["infection", "OBSERVATION", 402, 411], ["infection", "OBSERVATION", 473, 482]]], ["Hazard of infection increased linearly as minimum daily temperatures decreased, and the statistical strength of this association was also greatest when a time-lag of 3 days was applied.", [["infection", "DISEASE", 10, 19], ["infection", "PROBLEM", 10, 19], ["infection", "OBSERVATION", 10, 19], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["linearly", "OBSERVATION_MODIFIER", 30, 38], ["decreased", "OBSERVATION_MODIFIER", 69, 78]]], ["Combining daily maximum and minimum measurements into a midpoint daily temperature resulted in weaker associations (data not shown).Univariable analysisHourly wind velocity data were available from sixteen weather stations (Figure 2b ).", [["a midpoint daily temperature", "TEST", 54, 82], ["Univariable analysisHourly wind velocity data", "TEST", 132, 177]]], ["Wind conditions varied considerably in time with little temporal autocorrelation observed (see correlation matrix in Supporting Information S1).", [["Wind conditions", "PROBLEM", 0, 15], ["little temporal autocorrelation", "PROBLEM", 49, 80]]], ["There was no clearly discernible predominant wind pattern over the study period.", [["no clearly", "UNCERTAINTY", 10, 20], ["discernible", "OBSERVATION_MODIFIER", 21, 32], ["predominant", "OBSERVATION_MODIFIER", 33, 44], ["wind pattern", "OBSERVATION", 45, 57]]], ["The univariate relationship between hazard of infection and wind speed, making no directional assumptions ('undirected'), is presented in Figure 6 , by time-lag.", [["infection", "DISEASE", 46, 55], ["infection", "PROBLEM", 46, 55], ["infection", "OBSERVATION", 46, 55]]], ["Increased hazard of infection was observed on days when the maximum daily wind speed was .30 km hour 21 .", [["infection", "DISEASE", 20, 29], ["Increased hazard of infection", "PROBLEM", 0, 29], ["infection", "OBSERVATION", 20, 29]]], ["The univariate relationships between hazard of infection and maximum daily wind speed from the direction of the k nearest neighbours are presented in Table 3 , and plots of the restricted cubic splines of these relationships are shown in Figure 7 (only for a time-lag of 3 days).", [["infection", "DISEASE", 47, 56], ["infection", "PROBLEM", 47, 56], ["the restricted cubic splines", "TREATMENT", 173, 201], ["infection", "OBSERVATION", 47, 56], ["restricted", "OBSERVATION_MODIFIER", 177, 187], ["cubic splines", "OBSERVATION", 188, 201]]], ["The strongest statistical association between any wind speed covariate and hazard of infection was identified based on 'directed' wind speed from the direction of the three nearest neighbours, time-lagged by 3 days.Univariable analysisThe following five candidate meteorological variables were consequently selected for multivariable analysis: linear terms for rainfall and minimum daily air temperature, both time-lagged by 3 days, a restricted cubic spline for relative humidity measured at 3 pm time-lagged by 5 days, and splines of maximum daily air temperature and maximum daily wind speed from the direction of the three nearest infected premises, both time-lagged by 3 days.", [["infection", "DISEASE", 85, 94], ["infection", "PROBLEM", 85, 94], ["Univariable analysis", "TEST", 215, 235], ["multivariable analysis", "TEST", 320, 342], ["a restricted cubic spline", "TREATMENT", 433, 458], ["relative humidity", "TREATMENT", 463, 480], ["infection", "OBSERVATION", 85, 94]]], ["Medium sized (4.8-15.2 acres) and medium density premises (1-5 acres per horse) were at increased risk of infection, as were horse premises that shared a fence with another horse premises.", [["infection", "DISEASE", 106, 115], ["horse", "ORGANISM", 73, 78], ["horse", "ORGANISM", 173, 178], ["horse", "SPECIES", 73, 78], ["horse", "SPECIES", 125, 130], ["horse", "SPECIES", 173, 178], ["horse", "SPECIES", 125, 130], ["Medium sized (4.8-15.2 acres) and medium density premises", "PROBLEM", 0, 57], ["infection", "PROBLEM", 106, 115], ["sized", "OBSERVATION_MODIFIER", 7, 12], ["4.8-15.2 acres", "OBSERVATION_MODIFIER", 14, 28], ["medium density", "OBSERVATION_MODIFIER", 34, 48], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["risk of", "OBSERVATION_MODIFIER", 98, 105], ["infection", "OBSERVATION", 106, 115]]], ["Hazard also increased with the number of horses held on a premises; this trend was well represented by categorisation based on quartiles.Univariable analysisA trend existed across the study area in terms of premises elevation and surrounding human population density.", [["human", "ORGANISM", 242, 247], ["human", "SPECIES", 242, 247], ["human", "SPECIES", 242, 247], ["Univariable analysisA", "TEST", 137, 158], ["the study area", "TEST", 180, 194], ["surrounding human population density", "PROBLEM", 230, 266], ["increased", "OBSERVATION_MODIFIER", 12, 21], ["elevation", "OBSERVATION", 216, 225], ["human", "OBSERVATION_MODIFIER", 242, 247], ["population", "OBSERVATION_MODIFIER", 248, 258], ["density", "OBSERVATION", 259, 266]]], ["Hazard of infection was higher on horses premises located at lower elevations (,45 m) and .2.2 km from main roads (Table 4 ).", [["infection", "DISEASE", 10, 19], ["infection", "PROBLEM", 10, 19], ["infection", "OBSERVATION", 10, 19], ["higher", "OBSERVATION_MODIFIER", 24, 30], ["lower", "ANATOMY_MODIFIER", 61, 66]]], ["Risk was also higher on horse premises located in peri-urban areas (human population densities between 1-500 people km 22 ) compared to premises located either away from residential areas (human population density within 1 km = 0) or within urban areas (.500 people km 22 ) (Figure 8b) .Univariable analysisPremises area and premises horse density were the only highly correlated pairing (r = 20.74), amongst the premises attribute variables.", [["horse", "ORGANISM_SUBDIVISION", 24, 29], ["human", "ORGANISM", 68, 73], ["human", "ORGANISM", 189, 194], ["horse", "ORGANISM_SUBDIVISION", 334, 339], ["horse", "SPECIES", 24, 29], ["human", "SPECIES", 68, 73], ["people", "SPECIES", 109, 115], ["human", "SPECIES", 189, 194], ["people", "SPECIES", 259, 265], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 189, 194], ["human population densities", "PROBLEM", 68, 94], ["Univariable analysisPremises area", "PROBLEM", 287, 320], ["higher", "OBSERVATION_MODIFIER", 14, 20], ["horse density", "OBSERVATION", 334, 347]]], ["Of these two covariates, premises area was the more strongly associated with the outcome.", [["two", "OBSERVATION_MODIFIER", 9, 12], ["covariates", "OBSERVATION", 13, 23]]], ["The following premises attribute variables were therefore included in multivariable analysis: splines of premises area and local human population density, number of horses, length of shared fence with other horse premises, premises elevation and distance to the nearest main road.", [["human", "ORGANISM", 129, 134], ["human", "SPECIES", 129, 134], ["horse", "SPECIES", 207, 212], ["human", "SPECIES", 129, 134], ["multivariable analysis", "TEST", 70, 92], ["local", "OBSERVATION_MODIFIER", 123, 128], ["human", "OBSERVATION_MODIFIER", 129, 134], ["population", "OBSERVATION_MODIFIER", 135, 145], ["density", "OBSERVATION", 146, 153]]], ["Vaccination status was retained as it was considered an a priori confounder.Multivariable analysisThe final model is presented in Table 5 .", [["Multivariable analysis", "TEST", 76, 98]]], ["The shape of the restricted cubic splines representing the nonlinear relationships between hazard of infection and relative humidity, maximum daily air temperature, maximum daily wind speed (from the direction of the nearest three infected premises), premises area and human population density, were all largely unchanged from their crude forms (as presented in Figures 5, 6, 7, 8) .", [["infection", "DISEASE", 101, 110], ["human", "ORGANISM", 269, 274], ["human", "SPECIES", 269, 274], ["human", "SPECIES", 269, 274], ["the restricted cubic splines", "TREATMENT", 13, 41], ["infection", "PROBLEM", 101, 110], ["relative humidity", "PROBLEM", 115, 132], ["shape", "OBSERVATION_MODIFIER", 4, 9], ["restricted", "OBSERVATION_MODIFIER", 17, 27], ["cubic splines", "OBSERVATION", 28, 41], ["infection", "OBSERVATION", 101, 110], ["humidity", "OBSERVATION_MODIFIER", 124, 132], ["human", "OBSERVATION_MODIFIER", 269, 274], ["population", "OBSERVATION_MODIFIER", 275, 285], ["density", "OBSERVATION", 286, 293], ["largely", "OBSERVATION_MODIFIER", 304, 311], ["unchanged", "OBSERVATION_MODIFIER", 312, 321]]], ["The increased hazard amongst premises with higher numbers of horses persisted, as did the reduction in hazard amongst premises at higher elevations, with a 42% reduction in risk for every order of magnitude increase in elevation.", [["The increased hazard", "PROBLEM", 0, 20], ["higher elevations", "PROBLEM", 130, 147], ["a 42% reduction", "TREATMENT", 154, 169], ["magnitude increase in elevation", "PROBLEM", 197, 228], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["higher", "OBSERVATION_MODIFIER", 43, 49], ["numbers", "OBSERVATION_MODIFIER", 50, 57], ["reduction", "OBSERVATION_MODIFIER", 90, 99], ["elevation", "OBSERVATION", 219, 228]]], ["Premises that were adjacent to another horse premises were at increased hazard of equine influenza infection.Multivariable analysisModel goodness-of-fit and residual analysis.", [["influenza infection", "DISEASE", 89, 108], ["horse", "ORGANISM", 39, 44], ["equine", "ORGANISM", 82, 88], ["horse", "SPECIES", 39, 44], ["equine influenza infection", "PROBLEM", 82, 108], ["Multivariable analysisModel goodness", "TEST", 109, 145], ["residual analysis", "TEST", 157, 174], ["increased", "OBSERVATION_MODIFIER", 62, 71], ["equine influenza infection", "OBSERVATION", 82, 108]]], ["The final model accounted for a quarter of the variability in the data (Schemper and Stare pseudo-R 2 = 25.8%).", [["the data", "TEST", 62, 70], ["Schemper", "TEST", 72, 80], ["Stare pseudo", "TEST", 85, 97]]], ["No issues were identified based on inspection of martingale and deviance residuals, both overall, and when plotted against each variable included in the final model.", [["issues", "PROBLEM", 3, 9], ["inspection of martingale", "TEST", 35, 59], ["deviance residuals", "PROBLEM", 64, 82]]], ["Residual spatial structure was not evident in the empirical semivariogram of the deviance residuals, suggesting that spatial correlation was not unduly influencing our effect estimates (or their associated standard errors).", [["Residual spatial structure", "PROBLEM", 0, 26], ["the empirical semivariogram", "TEST", 46, 73], ["spatial structure", "OBSERVATION", 9, 26], ["not evident", "UNCERTAINTY", 31, 42]]], ["Influence statistics identified only one important outlying premises, infected 36 days after the vaccination of the 2 horses on the property.", [["the vaccination", "TREATMENT", 93, 108]]], ["These horses did not receive a second vaccination, whilst up to three doses may be required to attain protective immunity.DiscussionTo our knowledge, this empirical analysis provides the first estimates of the contribution of humidity, air temperature and wind to the spread of an actual outbreak of influenza ('in the field').", [["influenza", "DISEASE", 300, 309], ["horses", "ORGANISM", 6, 12], ["a second vaccination", "TREATMENT", 29, 49], ["this empirical analysis", "TEST", 150, 173], ["air temperature", "PROBLEM", 236, 251], ["influenza", "PROBLEM", 300, 309]]], ["We have demonstrated that it is possible to detect an association between wind velocity and disease spread, and directly estimate the strength of such an association.", [["wind velocity and disease spread", "PROBLEM", 74, 106], ["wind velocity", "OBSERVATION", 74, 87], ["disease", "OBSERVATION", 92, 99]]], ["This advances our understanding of the windborne spread of influenza from purely circumstantial association to a hypothesis statistically-tested with empirical data.Relative humidity and influenza spreadOur analysis shows that influenza spread in this cluster was highly dependent on relative humidity.", [["influenza", "DISEASE", 59, 68], ["influenza", "DISEASE", 227, 236], ["influenza", "PROBLEM", 59, 68], ["empirical data", "TEST", 150, 164], ["Relative humidity", "PROBLEM", 165, 182], ["influenza spread", "PROBLEM", 187, 203], ["Our analysis", "TEST", 203, 215], ["influenza spread", "PROBLEM", 227, 243], ["influenza spread", "OBSERVATION", 187, 203], ["influenza", "OBSERVATION", 227, 236], ["dependent", "OBSERVATION_MODIFIER", 271, 280]]], ["Recent reviews [4, 5, 61] present contradictory results from laboratory trials of influenza A virus survival at intermediate humidities [62, 63] , and disagreement concerning the importance of aerosol transmission.", [["influenza A virus", "ORGANISM", 82, 99], ["influenza A virus", "SPECIES", 82, 99], ["influenza", "PROBLEM", 82, 91], ["aerosol transmission", "TREATMENT", 193, 213]]], ["The negative cubic relationship that we observed between hazard of infection and relative humidity provides field validation for some of these laboratory trials.", [["infection", "DISEASE", 67, 76], ["infection", "PROBLEM", 67, 76], ["field validation", "TEST", 108, 124], ["negative cubic", "OBSERVATION_MODIFIER", 4, 18], ["infection", "OBSERVATION", 67, 76]]], ["The curve in Figure 5b across the whole range of relative humidities observed under natural conditions, exactly complements the results presented by Hemmes et. al. [62] of inactivation of aerosolised influenza A virus under controlled conditions.", [["aerosolised", "ORGANISM", 188, 199], ["influenza A virus", "ORGANISM", 200, 217], ["influenza A virus", "SPECIES", 200, 217], ["influenza A virus", "SPECIES", 200, 217], ["aerosolised influenza A virus", "PROBLEM", 188, 217], ["influenza", "OBSERVATION", 200, 209]]], ["Our findings also support the theory presented by Lowen et al. [6] that the relationship between influenza transmission and relative humidity is mediated by both virion and aerosol droplet nuclei stability.", [["nuclei", "ANATOMY", 189, 195], ["influenza", "DISEASE", 97, 106], ["influenza transmission", "TREATMENT", 97, 119], ["relative humidity", "TREATMENT", 124, 141], ["aerosol droplet nuclei stability", "TREATMENT", 173, 205], ["aerosol droplet", "OBSERVATION", 173, 188], ["nuclei stability", "OBSERVATION", 189, 205]]], ["In cool dry conditions, droplets are desiccated and remain small, which may stabilise influenza aerosols and facilitate longer range transmission, whereas at high relative humidity, the droplets absorb water and settle [61] .", [["influenza", "DISEASE", 86, 95], ["droplets", "TREATMENT", 24, 32], ["influenza aerosols", "TREATMENT", 86, 104], ["the droplets absorb water", "TREATMENT", 182, 207], ["small", "OBSERVATION_MODIFIER", 59, 64]]], ["The small rise in hazard of infection at intermediate relative humidities (40-60%) is perhaps due to a summation of two effects: as relative humidity increases within this range so too does viral survival [63] , whilst droplet nuclei settle more readily.", [["droplet nuclei", "ANATOMY", 219, 233], ["infection", "DISEASE", 28, 37], ["The small rise", "PROBLEM", 0, 14], ["infection", "PROBLEM", 28, 37], ["relative humidity increases", "PROBLEM", 132, 159], ["small", "OBSERVATION_MODIFIER", 4, 9], ["rise", "OBSERVATION_MODIFIER", 10, 14], ["infection", "OBSERVATION", 28, 37]]], ["This rise was most pronounced in the spline of relative humidity time-lagged by 3 days, yet the 5 day time-lagged variable was the predictor in the group with the strongest statistical association with hazard of infection.", [["infection", "DISEASE", 212, 221], ["infection", "PROBLEM", 212, 221], ["most pronounced", "OBSERVATION_MODIFIER", 14, 29], ["humidity", "OBSERVATION_MODIFIER", 56, 64], ["infection", "OBSERVATION", 212, 221]]], ["Amongst all other groupings of autocorrelated meteorological variables, a time-lag of 3 days was the predictor with the strongest statistical association with hazard of infection, corresponding closely with the typical 1-3 day incubation period of equine influenza.Relative humidity and influenza spreadRecent research has suggested that in certain situations absolute humidity may better represent the relationship between air humidity and influenza A virus survival [64] and aerosol transmission [65] .", [["infection", "DISEASE", 169, 178], ["influenza", "DISEASE", 255, 264], ["influenza A virus", "ORGANISM", 441, 458], ["influenza A virus", "SPECIES", 441, 458], ["infection", "PROBLEM", 169, 178], ["equine influenza", "PROBLEM", 248, 264], ["influenza spreadRecent research", "TREATMENT", 287, 318], ["air humidity", "TREATMENT", 424, 436], ["influenza A virus survival", "TREATMENT", 441, 467], ["infection", "OBSERVATION", 169, 178], ["influenza", "OBSERVATION", 255, 264]]], ["However, the dependency is perhaps more complex [8] , because the amount of water vapour that air can hold increases with temperature.", [["water", "SIMPLE_CHEMICAL", 76, 81], ["more complex", "OBSERVATION_MODIFIER", 35, 47], ["amount", "OBSERVATION_MODIFIER", 66, 72], ["water vapour", "OBSERVATION", 76, 88]]], ["Absolute and relative humidity are related metrics for the amount of water vapour in moist air.", [["water", "SIMPLE_CHEMICAL", 69, 74], ["humidity", "OBSERVATION_MODIFIER", 22, 30], ["moist air", "OBSERVATION", 85, 94]]], ["Absolute humidity is the mass of water vapour per cubic meter of total moist air, whereas, relative humidity is absolute humidity expressed as a percentage of the amount of water vapour needed for saturation at a specific temperature.", [["water", "SIMPLE_CHEMICAL", 173, 178], ["Absolute humidity", "TREATMENT", 0, 17], ["the mass", "PROBLEM", 21, 29], ["water vapour", "TREATMENT", 173, 185], ["mass", "OBSERVATION", 25, 29], ["total", "OBSERVATION_MODIFIER", 65, 70], ["moist air", "OBSERVATION", 71, 80], ["absolute humidity", "OBSERVATION", 112, 129]]], ["We used relative humidity rather than absolute humidity because: the relative humidity data were more complete over the study period, corresponding 9 am and 3 pm air temperature data were not available for all data points so back-transformation of relative humidity measurements into absolute humidity would have resulted in less complete data, and we wanted to ensure we could directly compare our results with the original research describing the dependency between relative humidity, air temperature and influenza virus transmission and survival [6, 62] .Air temperature and influenza spreadThe shape of the highly nonlinear relationship that we observed between hazard of equine influenza infection and maximum daily air temperature suggests two mechanisms of influenza transmission.", [["influenza infection", "DISEASE", 683, 702], ["influenza transmission", "DISEASE", 764, 786], ["equine", "ORGANISM", 676, 682], ["influenza virus", "SPECIES", 507, 522], ["relative humidity", "TREATMENT", 8, 25], ["absolute humidity", "TREATMENT", 38, 55], ["3 pm air temperature data", "TEST", 157, 182], ["air temperature", "PROBLEM", 487, 502], ["influenza virus transmission", "TREATMENT", 507, 535], ["Air temperature", "PROBLEM", 558, 573], ["influenza spread", "PROBLEM", 578, 594], ["equine influenza infection", "PROBLEM", 676, 702], ["maximum daily air temperature", "PROBLEM", 707, 736], ["influenza transmission", "PROBLEM", 764, 786], ["influenza spread", "OBSERVATION", 578, 594], ["shape", "OBSERVATION_MODIFIER", 598, 603], ["highly nonlinear", "OBSERVATION_MODIFIER", 611, 627], ["equine influenza infection", "OBSERVATION", 676, 702], ["influenza", "OBSERVATION", 764, 773]]], ["Hazard was lowest on days when the maximum air temperature was between 20-25uC, and greatly increased on days with lower and higher maximum temperatures.", [["the maximum air temperature", "TEST", 31, 58], ["increased", "OBSERVATION_MODIFIER", 92, 101]]], ["Aerosol transmission of influenza A viruses has been shown to be enhanced in cooler conditions [6] , and on days when maximum daily Estimates are based only on hourly wind data from within 45u arcs centred on the direction of the k nearest infected premises, for k = 1,2,3.", [["influenza A viruses", "DISEASE", 24, 43], ["influenza A viruses", "ORGANISM", 24, 43], ["influenza A viruses", "SPECIES", 24, 43], ["influenza A viruses", "SPECIES", 24, 43], ["influenza A viruses", "PROBLEM", 24, 43], ["hourly wind data", "TEST", 160, 176], ["k", "TEST", 263, 264]]], ["Arcs may overlap if nearest k infected premises are in the same direction (see Figure 2c for details).", [["Arcs", "GENE_OR_GENE_PRODUCT", 0, 4]]], ["Dashed lines represent 95% confidence intervals. doi:10.1371/journal.pone.0035284.g007 Table 3 .", [["doi:10.1371/journal.pone.0035284.g007", "CHEMICAL", 49, 86], ["Dashed lines", "CELL", 0, 12], ["Dashed lines", "TREATMENT", 0, 12]]], ["Univariable analysis of the association between directed wind speed covariates (time-changing and timelagged) and time to infection of premises in the largest cluster (n = 3153), northwest of Sydney, during the 2007 equine influenza outbreak in Australia.Air temperature and influenza spreadMeteorological Factor Time-lag Term LRT df P-value b temperature was ,20uC the air temperature would be expected to remain in the optimal range for aerosol transmission equine influenza for longer.", [["infection", "DISEASE", 122, 131], ["influenza", "DISEASE", 223, 232], ["influenza", "DISEASE", 467, 476], ["equine", "ORGANISM", 460, 466], ["Univariable analysis", "TEST", 0, 20], ["Air temperature", "TEST", 255, 270], ["influenza spread", "PROBLEM", 275, 291], ["value b temperature", "TEST", 336, 355], ["the air temperature", "PROBLEM", 366, 385], ["aerosol transmission equine influenza", "TREATMENT", 439, 476], ["largest", "OBSERVATION_MODIFIER", 151, 158]]], ["The marked increase in hazard of infection when maximum temperature was .25uC is also consistent with recent research.", [["infection", "DISEASE", 33, 42], ["infection", "PROBLEM", 33, 42], ["maximum temperature", "TEST", 48, 67], ["marked", "OBSERVATION_MODIFIER", 4, 10], ["increase", "OBSERVATION_MODIFIER", 11, 19], ["infection", "OBSERVATION", 33, 42], ["consistent with", "UNCERTAINTY", 86, 101]]], ["Whilst high temperatures block aerosol transmission of influenza A viruses, the success of animal-to-animal contact transmission increases at high temperatures [10] perhaps explaining the spread of influenza in warm tropical environments.Wind velocity and influenza spreadThere is some consensus in the literature that airborne transmission of influenza is at least possible; however, there is strong disagreement about its importance [5] .", [["influenza A viruses", "DISEASE", 55, 74], ["influenza", "DISEASE", 198, 207], ["influenza", "DISEASE", 344, 353], ["influenza A viruses", "ORGANISM", 55, 74], ["influenza A viruses", "SPECIES", 55, 74], ["high temperatures block", "PROBLEM", 7, 30], ["influenza A viruses", "PROBLEM", 55, 74], ["high temperatures", "PROBLEM", 142, 159], ["influenza", "PROBLEM", 198, 207], ["Wind velocity", "TEST", 238, 251], ["influenza spread", "PROBLEM", 256, 272], ["influenza", "PROBLEM", 344, 353], ["influenza", "OBSERVATION", 198, 207], ["velocity", "OBSERVATION_MODIFIER", 243, 251], ["influenza spread", "OBSERVATION", 256, 272], ["influenza", "OBSERVATION", 344, 353]]], ["In the cluster investigated, we observed an association between hazard of infection and increasing wind speed from the direction of nearby potential sources of equine influenza infection.", [["infection", "DISEASE", 74, 83], ["influenza infection", "DISEASE", 167, 186], ["equine influenza", "ORGANISM", 160, 176], ["infection", "PROBLEM", 74, 83], ["increasing wind speed", "PROBLEM", 88, 109], ["equine influenza infection", "PROBLEM", 160, 186], ["infection", "OBSERVATION", 74, 83], ["equine influenza infection", "OBSERVATION", 160, 186]]], ["A similar association was found when wind speed covariates were generated without making any directional assumptions, in effect testing the general hypothesis that hazard of infection was increased on days with increased wind speed (from any direction).", [["infection", "DISEASE", 174, 183], ["infection", "PROBLEM", 174, 183], ["increased wind speed", "PROBLEM", 211, 231], ["infection", "OBSERVATION", 174, 183]]], ["Irrespective of our approach, wind speeds .30 km hour 21 , lagged by 3 days, were consistently associated with increased hazard of infection.Wind velocity and influenza spreadIn developing proxy covariates for the directed formulation of the daily wind speed covariates ('WIND_SPD dir(k) ') certain assumptions were required.", [["infection", "DISEASE", 131, 140], ["increased hazard of infection", "PROBLEM", 111, 140], ["Wind velocity", "TEST", 141, 154], ["influenza spread", "PROBLEM", 159, 175], ["the directed formulation", "TREATMENT", 210, 234], ["'WIND_SPD dir(k) '", "TREATMENT", 271, 289], ["increased", "OBSERVATION_MODIFIER", 111, 120], ["infection", "OBSERVATION", 131, 140], ["velocity", "OBSERVATION_MODIFIER", 146, 154], ["influenza spread", "OBSERVATION", 159, 175]]], ["The nearest k infected premises were assumed to be the only windborne source of equine influenza virus for a susceptible premises, and we assumed the duration of infectivity at the premises level was 14 days for all premises.", [["influenza virus", "DISEASE", 87, 102], ["equine influenza virus", "ORGANISM", 80, 102], ["equine influenza virus", "SPECIES", 80, 102], ["equine influenza virus", "SPECIES", 80, 102], ["The nearest k infected premises", "PROBLEM", 0, 31], ["equine influenza virus", "PROBLEM", 80, 102], ["infectivity", "PROBLEM", 162, 173]]], ["The statistical strength of association between hazard of infection and wind speed increased as more nearest neighbours were cumulatively incorporated into the method of wind covariate generation, suggesting that the nearest neighbour was not always the only source of windborne infection.", [["infection", "DISEASE", 58, 67], ["infection", "DISEASE", 279, 288], ["infection", "PROBLEM", 58, 67], ["windborne infection", "PROBLEM", 269, 288], ["infection", "OBSERVATION", 58, 67], ["infection", "OBSERVATION", 279, 288]]], ["We can state that incorporating three nearest infected neighbours is better than only one or two, that our findings are relatively robust to the assumptions that we made whilst generating directed wind speed covariates, and that the detected association between hazard of infection and wind speed appears related to the direction of proximate infected premises.Wind velocity and influenza spreadThe associations that we have detected between increasing wind speed and hazard of infection need to be interpreted in the context of our study design.", [["infection", "DISEASE", 272, 281], ["infection", "DISEASE", 478, 487], ["infection", "PROBLEM", 272, 281], ["Wind velocity", "TEST", 361, 374], ["influenza spread", "PROBLEM", 379, 395], ["infection", "PROBLEM", 478, 487], ["our study", "TEST", 529, 538], ["infection", "OBSERVATION", 272, 281], ["infected", "OBSERVATION", 343, 351], ["velocity", "OBSERVATION_MODIFIER", 366, 374], ["influenza spread", "OBSERVATION", 379, 395], ["infection", "OBSERVATION", 478, 487]]], ["There is potential for ecological fallacy in aggregated data analyses such as this, in which the unit of interest is not an individual animal but a group.", [["potential for", "UNCERTAINTY", 9, 22], ["ecological", "OBSERVATION_MODIFIER", 23, 33], ["fallacy", "OBSERVATION", 34, 41]]], ["Furthermore, it is not possible in such observational epidemiological analyses to definitively identify windborne spread from any other transmission route (direct contact, cough droplet and spread on fomites).", [["cough", "DISEASE", 172, 177], ["windborne spread", "PROBLEM", 104, 120], ["cough droplet", "PROBLEM", 172, 185], ["not possible", "UNCERTAINTY", 19, 31]]], ["Nonetheless, the detected association, presumably representing windborne spread of equine influenza, is biologically plausible, and its increasing strength with increasing wind speed from the direction of nearby infected premises is difficult to explain by spread through other means alone.Wind velocity and influenza spreadAt wind speeds of .30 km hour 21 an aerosol of influenza droplet nuclei would only need to be stable for minutes to be able to infect horses on nearby premises.", [["droplet nuclei", "ANATOMY", 381, 395], ["equine influenza", "DISEASE", 83, 99], ["equine influenza", "ORGANISM", 83, 99], ["equine influenza", "SPECIES", 83, 99], ["equine influenza", "PROBLEM", 83, 99], ["its increasing strength", "PROBLEM", 132, 155], ["Wind velocity", "TEST", 290, 303], ["influenza spread", "PROBLEM", 308, 324], ["an aerosol of influenza droplet nuclei", "TREATMENT", 357, 395], ["presumably representing", "UNCERTAINTY", 39, 62], ["windborne", "OBSERVATION_MODIFIER", 63, 72], ["spread", "OBSERVATION_MODIFIER", 73, 79], ["equine influenza", "OBSERVATION", 83, 99], ["increasing", "OBSERVATION_MODIFIER", 136, 146], ["strength", "OBSERVATION_MODIFIER", 147, 155], ["infected", "OBSERVATION", 212, 220], ["velocity", "OBSERVATION_MODIFIER", 295, 303], ["influenza spread", "OBSERVATION", 308, 324]]], ["Equine influenza viruses have been shown to survive for periods of hours to days in soil and water, even in direct sunlight [12] , and infected horses shed large amounts of virus (.10 3 EID 50 /ml, 50% egg infective dose per ml of swab extract) throughout the roughly 7 days that they are infectious [66] .", [["extract", "ANATOMY", 236, 243], ["influenza viruses", "DISEASE", 7, 24], ["Equine influenza viruses", "ORGANISM", 0, 24], ["horses", "ORGANISM", 144, 150], ["Equine influenza viruses", "SPECIES", 0, 24], ["Equine influenza viruses", "SPECIES", 0, 24], ["Equine influenza viruses", "PROBLEM", 0, 24], ["swab extract", "TREATMENT", 231, 243], ["infectious", "OBSERVATION", 289, 299]]], ["Infection is more reliably achieved by inhalation of aerosolised virus that intranasal inoculation [26] , with a minimum infective dose of 10 2 EID 50 /ml.", [["Infection", "PROBLEM", 0, 9], ["aerosolised virus", "PROBLEM", 53, 70], ["a minimum infective dose", "TREATMENT", 111, 135]]], ["We therefore consider it plausible that infected horses on one premises could cough or otherwise produce a sufficient quantity of aerosolised equine influenza virus, which after travelling wind-assisted could constitute an infectious dose for a horse on a nearby premises (whether inhaled immediately or after surviving a short period on soil or in drinking water).", [["cough", "DISEASE", 78, 83], ["influenza", "DISEASE", 149, 158], ["horses", "ORGANISM", 49, 55], ["equine influenza virus", "ORGANISM", 142, 164], ["horse", "ORGANISM", 245, 250], ["equine influenza virus", "SPECIES", 142, 164], ["horse", "SPECIES", 245, 250], ["equine influenza virus", "SPECIES", 142, 164], ["horse", "SPECIES", 245, 250], ["cough", "PROBLEM", 78, 83], ["aerosolised equine influenza virus", "PROBLEM", 130, 164], ["infected", "OBSERVATION", 40, 48], ["influenza virus", "OBSERVATION", 149, 164], ["infectious", "OBSERVATION", 223, 233]]], ["A recent time-series analysis investigated correlation between the frequency of paediatric influenza A hospital admissions and several meteorological variables including wind velocity [15] .", [["influenza", "DISEASE", 91, 100], ["series analysis", "TEST", 14, 29], ["wind velocity", "TEST", 170, 183]]], ["A statistically significant univariable association was observed between increasing wind velocity and increased influenza A hospital admissions, in data collected from one hospital and one weather station [15] .", [["increasing wind velocity", "PROBLEM", 73, 97], ["increased", "OBSERVATION_MODIFIER", 102, 111], ["influenza", "OBSERVATION", 112, 121]]], ["However, in multivariable analyses no association was observed between wind velocity and influenza A hospitalisations, perhaps due to the level of spatial and temporal data aggregation (across the hospital catchment and into 14-day time intervals).", [["influenza A", "SPECIES", 89, 100], ["multivariable analyses", "TEST", 12, 34], ["wind velocity", "TEST", 71, 84], ["influenza", "PROBLEM", 89, 98], ["spatial and temporal data aggregation", "PROBLEM", 147, 184]]], ["Aggregated analyses of the association of meteorological factors with the spread of the severe acute respiratory syndrome (SARS) in Beijing [16] , and hand, foot and mouth disease (HFMD) of humans in Hong Kong [67] , have found statistically significant associations with increasing wind velocity, albeit at much lower wind velocities.", [["hand", "ANATOMY", 151, 155], ["foot", "ANATOMY", 157, 161], ["mouth", "ANATOMY", 166, 171], ["acute respiratory syndrome", "DISEASE", 95, 121], ["SARS", "DISEASE", 123, 127], ["hand, foot and mouth disease", "DISEASE", 151, 179], ["HFMD", "DISEASE", 181, 185], ["hand", "ORGANISM_SUBDIVISION", 151, 155], ["foot", "ORGANISM_SUBDIVISION", 157, 161], ["mouth", "ORGANISM_SUBDIVISION", 166, 171], ["humans", "ORGANISM", 190, 196], ["meteorological factors", "PROTEIN", 42, 64], ["humans", "SPECIES", 190, 196], ["humans", "SPECIES", 190, 196], ["meteorological factors", "PROBLEM", 42, 64], ["the severe acute respiratory syndrome", "PROBLEM", 84, 121], ["hand, foot and mouth disease", "PROBLEM", 151, 179], ["increasing wind velocity", "PROBLEM", 272, 296], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["respiratory syndrome", "OBSERVATION", 101, 121], ["hand", "ANATOMY", 151, 155], ["foot", "ANATOMY", 157, 161], ["mouth", "ANATOMY", 166, 171], ["disease", "OBSERVATION", 172, 179], ["increasing", "OBSERVATION_MODIFIER", 272, 282], ["wind velocity", "OBSERVATION", 283, 296], ["velocities", "OBSERVATION_MODIFIER", 324, 334]]], ["Atmospheric dispersal modelling of the picornavirus that causes foot and mouth disease (FMD) in cloven-hoofed ungulates has consistently found that the virus is likely to be dispersed even in calm conditions [17, 68, 69] .", [["foot", "ANATOMY", 64, 68], ["mouth", "ANATOMY", 73, 78], ["picornavirus", "DISEASE", 39, 51], ["foot and mouth disease", "DISEASE", 64, 86], ["FMD", "DISEASE", 88, 91], ["picornavirus", "ORGANISM", 39, 51], ["foot", "ORGANISM_SUBDIVISION", 64, 68], ["mouth", "ORGAN", 73, 78], ["FMD", "SPECIES", 88, 91], ["the picornavirus", "PROBLEM", 35, 51], ["foot and mouth disease", "PROBLEM", 64, 86], ["the virus", "PROBLEM", 148, 157], ["picornavirus", "OBSERVATION", 39, 51], ["foot", "ANATOMY", 64, 68], ["mouth", "ANATOMY", 73, 78], ["disease", "OBSERVATION", 79, 86], ["virus", "OBSERVATION", 152, 157]]], ["The dependency of influenza A virus survival on relative humidity [6, 62] is completely different to that of poliovirus [62] , HFMD [70] and FMD virus [68] (all much smaller RNA viruses of the family Picornaviridae).", [["HFMD", "DISEASE", 127, 131], ["influenza A virus", "ORGANISM", 18, 35], ["poliovirus [62", "ORGANISM", 109, 123], ["FMD virus", "ORGANISM", 141, 150], ["FMD virus", "SPECIES", 141, 150], ["influenza A virus", "SPECIES", 18, 35], ["FMD virus", "SPECIES", 141, 150], ["influenza", "PROBLEM", 18, 27], ["poliovirus", "TEST", 109, 119], ["HFMD", "PROBLEM", 127, 131], ["FMD virus", "PROBLEM", 141, 150], ["influenza", "OBSERVATION", 18, 27]]], ["Therefore, it is perhaps not unexpected that the survival of aerosols of influenza A viruses and picornaviruses could depend on different wind conditions.Wind velocity and influenza spreadWhen interpolating meteorological covariates and estimating nearest neighbour distances we used centroids to reduce the complexity of the analytical methods.", [["influenza A viruses", "ORGANISM", 73, 92], ["picornaviruses", "ORGANISM", 97, 111], ["influenza A viruses", "SPECIES", 73, 92], ["influenza A viruses", "PROBLEM", 73, 92], ["picornaviruses", "PROBLEM", 97, 111], ["Wind velocity", "TEST", 154, 167], ["influenza spread", "PROBLEM", 172, 188], ["centroids", "TREATMENT", 284, 293], ["perhaps not", "UNCERTAINTY", 17, 28], ["velocity", "OBSERVATION_MODIFIER", 159, 167], ["influenza spread", "OBSERVATION", 172, 188]]], ["For .99% of the premises in our dataset we estimate that the maximum distance between the centroid and premises boundary was ,500 m.", [["centroid", "ANATOMY_MODIFIER", 90, 98]]], ["When the largest 1% of premises (in area) were excluded from the final model, the only regression coefficients to change by .20% were the two highest order spline components for relative humidity and maximum daily temperature, and these changes were not discernible in post-adjustment plots.", [["relative humidity", "TREATMENT", 178, 195], ["maximum daily temperature", "TEST", 200, 225], ["largest", "OBSERVATION_MODIFIER", 9, 16]]], ["We therefore consider our findings to be insensitive to measurement bias introduced by representing premises by their centroids.Wind velocity and influenza spreadEnvironmental variables capable of influencing airborne disease spread (such as local horse density, tree density or terrain undulation) vary considerably in the different regions and clusters of premises infected during the 2007 equine influenza outbreak in Australia.", [["influenza", "DISEASE", 399, 408], ["horse", "ORGANISM_SUBDIVISION", 248, 253], ["horse", "SPECIES", 248, 253], ["Wind velocity", "TEST", 128, 141], ["influenza spread", "PROBLEM", 146, 162], ["influencing airborne disease spread", "PROBLEM", 197, 232], ["local horse density", "PROBLEM", 242, 261], ["tree density", "PROBLEM", 263, 275], ["terrain undulation)", "PROBLEM", 279, 298], ["velocity", "OBSERVATION_MODIFIER", 133, 141], ["influenza spread", "OBSERVATION", 146, 162], ["airborne disease", "OBSERVATION", 209, 225], ["tree", "OBSERVATION_MODIFIER", 263, 267], ["density", "OBSERVATION", 268, 275], ["terrain undulation", "OBSERVATION_MODIFIER", 279, 297], ["clusters", "OBSERVATION_MODIFIER", 346, 354], ["infected", "OBSERVATION_MODIFIER", 367, 375]]], ["A potential limitation of this analysis was that we focussed on only one cluster (the largest and most dense cluster in terms of population at risk) from a very large outbreak.", [["this analysis", "TEST", 26, 39], ["a very large outbreak", "PROBLEM", 154, 175], ["largest", "OBSERVATION_MODIFIER", 86, 93], ["most dense", "OBSERVATION_MODIFIER", 98, 108], ["cluster", "OBSERVATION_MODIFIER", 109, 116], ["very", "OBSERVATION_MODIFIER", 156, 160], ["large", "OBSERVATION_MODIFIER", 161, 166], ["outbreak", "OBSERVATION", 167, 175]]], ["There were two considered reasons for our detailed focus: counting process survival analysis involves analysing a very large dataset (204,909 observations on 3153 premises); and owing to a wide variance in local environmental characteristics and potential for differences in disease transmission dynamics, mixing clusters in the same analysis might dilute any meaningful results.", [["survival analysis", "TEST", 75, 92], ["a wide variance", "PROBLEM", 187, 202], ["differences in disease transmission dynamics", "PROBLEM", 260, 304]]], ["Before generalising our findings to the whole outbreak, or indeed other outbreaks, followup research to assess the importance of the risk factors investigated in broadly dissimilar environments, is therefore required.Wind velocity and influenza spreadA classical geostatistical approach [49] (kriging based on a least squares fit of an empirical variogram) was applied to interpolate premises-level meteorological covariates from weather station data.", [["followup research", "TEST", 83, 100], ["the risk factors", "PROBLEM", 129, 145], ["Wind velocity", "TEST", 217, 230], ["influenza", "PROBLEM", 235, 244], ["an empirical variogram)", "TREATMENT", 333, 356], ["velocity", "OBSERVATION_MODIFIER", 222, 230], ["influenza", "OBSERVATION", 235, 244]]], ["A more sophisticated model-based geostatistical approach [71] (maximum-likelihood based model fitting that does not rely on an empirical variogram) may be more appropriate.", [["an empirical variogram", "TEST", 124, 146]]], ["However, we considered that the numerous fine adjustments required to undertake a model-based approach to be impractical for fitting the 5616 separate models (117 days624 hours62 wind component vectors) that were required to produce hourly wind vector estimates at each of the 3153 individual premises locations across the entire study period.", [["a model-based approach", "TREATMENT", 80, 102]]], ["It was also not possible to assess the assumptions of stationarity or isotropy for each of the thousands of semivariogram models required to generate all of the daily meteorological covariates for each premises.", [["semivariogram models", "TREATMENT", 108, 128]]], ["Our interpolation approach could have been refined by incorporating elevation (regression kriging), a spatial trend or even anisotropy into the method.", [["Our interpolation approach", "TREATMENT", 0, 26], ["regression kriging", "TEST", 79, 97], ["elevation", "OBSERVATION_MODIFIER", 68, 77]]], ["The study extent covered the Northern half of the Sydney basin, which is relatively flat, and bounded by a plateau of national parks where horses are prohibited.", [["horses", "ORGANISM", 139, 145], ["The study", "TEST", 0, 9], ["relatively", "OBSERVATION_MODIFIER", 73, 83], ["flat", "OBSERVATION_MODIFIER", 84, 88], ["plateau", "OBSERVATION_MODIFIER", 107, 114]]], ["These refinements would be recommended when conducting further similar research of clusters located in more varied terrain.Wind velocity and influenza spreadIn the cluster of infection investigated, disease did not appear to spread predominantly in any single direction.", [["infection", "DISEASE", 175, 184], ["Wind velocity", "TEST", 123, 136], ["influenza spread", "PROBLEM", 141, 157], ["infection", "PROBLEM", 175, 184], ["disease", "PROBLEM", 199, 206], ["more varied", "OBSERVATION_MODIFIER", 103, 114], ["velocity", "OBSERVATION_MODIFIER", 128, 136], ["influenza spread", "OBSERVATION", 141, 157], ["infection", "OBSERVATION", 175, 184], ["not appear to", "UNCERTAINTY", 211, 224], ["spread", "OBSERVATION", 225, 231]]], ["We purposefully focussed on this cluster rather than other large clusters in which a single global direction of spread has been noted [13] , with the intention of estimating the typical contribution of wind to disease spread rather than circumstantially associating prevailing wind with the global direction of disease spread.", [["disease spread", "PROBLEM", 210, 224], ["disease spread", "PROBLEM", 311, 325], ["large", "OBSERVATION_MODIFIER", 59, 64], ["clusters", "OBSERVATION", 65, 73], ["disease", "OBSERVATION", 311, 318]]], ["In any cluster in which an overall direction of spread is detected, an important further research question remains: What proportion of this anisotropic spread is directly attributable to windborne disease spread?", [["this anisotropic spread", "PROBLEM", 135, 158], ["windborne disease spread", "PROBLEM", 187, 211], ["cluster", "OBSERVATION_MODIFIER", 7, 14], ["spread", "OBSERVATION", 48, 54], ["anisotropic spread", "OBSERVATION", 140, 158]]], ["Our methods provide a means to answer this research question, and to retrospectively investigate the contribution of windborne aerosol spread to local disease spread during outbreaks such as the footand-mouth disease outbreak in the United Kingdom in 2001.Wind velocity and influenza spreadBy restricting this analysis to a study period after the horse movement ban was put in place, we focussed this study on factors influencing the local spread of equine influenza.", [["footand-mouth disease", "DISEASE", 195, 216], ["influenza", "DISEASE", 457, 466], ["mouth", "ORGANISM_SUBDIVISION", 203, 208], ["horse", "ORGANISM", 347, 352], ["equine", "ORGANISM", 450, 456], ["horse", "SPECIES", 347, 352], ["horse", "SPECIES", 347, 352], ["windborne aerosol", "TREATMENT", 117, 134], ["local disease spread", "PROBLEM", 145, 165], ["the footand-mouth disease outbreak", "PROBLEM", 191, 225], ["Wind velocity", "TEST", 256, 269], ["influenza", "PROBLEM", 274, 283], ["a study", "TEST", 322, 329], ["the horse movement ban", "TREATMENT", 343, 365], ["this study", "TEST", 396, 406], ["equine influenza", "PROBLEM", 450, 466], ["mouth", "ANATOMY", 203, 208], ["disease", "OBSERVATION", 209, 216], ["velocity", "OBSERVATION_MODIFIER", 261, 269], ["influenza", "OBSERVATION", 274, 283], ["equine influenza", "OBSERVATION", 450, 466]]], ["We also adjusted for a number of relevant confounders of the meteorological associations we aimed to estimate: vaccination status of horses on the premises, premises size (in terms of area and number of horses), whether premises were adjacent to another premises holding horses, and local human population density.", [["human", "ORGANISM", 289, 294], ["human", "SPECIES", 289, 294], ["human", "SPECIES", 289, 294], ["size", "OBSERVATION_MODIFIER", 166, 170], ["population", "OBSERVATION_MODIFIER", 295, 305], ["density", "OBSERVATION", 306, 313]]], ["A small misclassification bias is known to be present in the equine influenza dataset, due to under-reporting of infected premises by owners either attempting to avoid movement restrictions or who failed to detect infection [72] .", [["influenza", "DISEASE", 68, 77], ["infection", "DISEASE", 214, 223], ["A small misclassification bias", "PROBLEM", 0, 30], ["the equine influenza dataset", "PROBLEM", 57, 85], ["infection", "PROBLEM", 214, 223], ["small", "OBSERVATION_MODIFIER", 2, 7], ["misclassification bias", "OBSERVATION", 8, 30], ["known to be", "UNCERTAINTY", 34, 45], ["infected", "OBSERVATION", 113, 121]]], ["A previous analysis found ,1% under-reporting occurred in this region, suggesting that ,13 infected premises were misclassified as uninfected [72] ; we considered this bias negligible.Wind velocity and influenza spreadIn conclusion, by combining influenza outbreak and concurrent meteorological data, we have shown how relative humidity, air temperature and wind velocity combined to influence the spread of an actual influenza outbreak.", [["influenza", "DISEASE", 418, 427], ["A previous analysis", "TEST", 0, 19], ["this bias negligible", "PROBLEM", 163, 183], ["Wind velocity", "TEST", 184, 197], ["influenza spread", "PROBLEM", 202, 218], ["combining influenza outbreak", "PROBLEM", 236, 264], ["air temperature", "TEST", 338, 353], ["wind velocity", "TEST", 358, 371], ["an actual influenza outbreak", "PROBLEM", 408, 436], ["velocity", "OBSERVATION_MODIFIER", 189, 197], ["influenza spread", "OBSERVATION", 202, 218], ["influenza", "OBSERVATION", 418, 427]]], ["Hazard of equine influenza infection was higher when relative humidity was ,60% and lowest on days when daily maximum air temperature was 20-25uC.", [["influenza infection", "DISEASE", 17, 36], ["equine", "ORGANISM", 10, 16], ["equine", "SPECIES", 10, 16], ["equine influenza infection", "PROBLEM", 10, 36], ["daily maximum air temperature", "TEST", 104, 133], ["equine influenza infection", "OBSERVATION", 10, 36]]], ["Wind speeds .30 km hour 21 from the direction of nearby infected premises were associated with increased hazard of infection.", [["infection", "DISEASE", 115, 124], ["increased hazard of infection", "PROBLEM", 95, 124], ["infected", "OBSERVATION", 56, 64], ["increased", "OBSERVATION_MODIFIER", 95, 104], ["infection", "OBSERVATION", 115, 124]]], ["Our analysis supports, and extends, the findings of studies into influenza A transmission conducted under controlled conditions.", [["influenza A transmission", "DISEASE", 65, 89], ["influenza A", "SPECIES", 65, 76], ["Our analysis", "TEST", 0, 12], ["studies", "TEST", 52, 59], ["influenza", "PROBLEM", 65, 74]]], ["The relationships described are of direct importance for managing disease risk during influenza outbreaks in horses, and more generally, advance our understanding of the transmission of influenza A viruses under natural conditions.Supporting InformationSupporting Information S1 Survival analysis dataset formulation examples and correlations between explanatory variables in Cox regression modelling of factors associated with time to infection in the largest cluster of the 2007 outbreak of equine influenza in Australia.Supporting Information(DOCX)", [["influenza", "DISEASE", 86, 95], ["influenza A viruses", "DISEASE", 186, 205], ["infection", "DISEASE", 436, 445], ["influenza", "DISEASE", 500, 509], ["influenza A viruses", "ORGANISM", 186, 205], ["equine", "SPECIES", 493, 499], ["horses", "SPECIES", 109, 115], ["influenza A viruses", "SPECIES", 186, 205], ["equine", "SPECIES", 493, 499], ["managing disease risk", "PROBLEM", 57, 78], ["influenza outbreaks", "PROBLEM", 86, 105], ["influenza", "PROBLEM", 186, 195], ["dataset formulation examples", "TEST", 297, 325], ["infection", "PROBLEM", 436, 445], ["equine influenza", "PROBLEM", 493, 509], ["infection", "OBSERVATION", 436, 445], ["largest", "OBSERVATION_MODIFIER", 453, 460], ["equine influenza", "OBSERVATION", 493, 509]]]], "PMC7250614": [["IntroductionThe Web of Things (WoT) is an architectural principle that aims at bringing sensor and actuator data on the Web in order to increase interoperability between connected devices and develop arbitrarily complex mash-ups on that basis [4, 19].", [["interoperability between connected devices", "TREATMENT", 145, 187], ["arbitrarily complex mash", "PROBLEM", 200, 224]]], ["In particular, RDF shall improve the interoperability across sensors and actuators at the semantic level, such that autonomous Web agents can build their own representation of the physical world from data exposed by various WoT devices.IntroductionIn practice, semantic interoperability in the TD model translates into an annotation mechanism such that TD documents\u2014instances of the TD model serialized in JSON\u2014link to RDF terms defined in domain-specific vocabularies.", [["autonomous Web agents", "TREATMENT", 116, 137], ["various WoT devices", "TREATMENT", 216, 235], ["IntroductionIn practice", "TREATMENT", 236, 259], ["the TD model", "TREATMENT", 379, 391]]], ["It is indeed expected that most relevant vocabularies will be defined as specializations of SSN, as suggested by recent trends in ontology engineering for WoT [1, 2].IntroductionBoth the TD ontology and its alignment with SSN were designed as per the requirement that the TD annotation mechanism should remain as easy to use as possible, especially for developers with no particular knowledge of Semantic Web technologies.", [["TD ontology", "DNA", 187, 198], ["SSN", "DNA", 222, 225], ["the TD annotation mechanism", "TEST", 268, 295]]], ["In practice, developers are only asked to provide semantic \u201ctags\u201d at several places of a TD document.", [["TD", "DISEASE", 89, 91]]], ["We provide an evaluation on its effectiveness at the end of the paper, by looking at a collection of TD documents that serves as a test set in the W3C standardization process.IntroductionThe paper is structured as follows: Sect.", [["an evaluation", "TEST", 11, 24], ["a test", "TEST", 129, 135]]], ["5, the W3C TD test set is being analyzed in more detail.Ontologies for the Web of Things: State-of-the-ArtOver the last decade, research on WoT systems has moved from pre-defined sensor mash-ups to autonomous agents capable of selecting what sensor measurements to read and what actuator commands to activate to fulfill a global goal [3, 11, 13, 18].", [["the W3C TD test set", "TEST", 3, 22], ["autonomous agents", "TREATMENT", 198, 215]]], ["Among others, it aligns with the ontology for units of measure (OM) [17] and the ontology for Quantity Kinds, Units and Datatypes1 (QUDT), which both provide an extensive list of physical properties in OWL.", [["Datatypes1", "TREATMENT", 120, 130]]], ["All these ontologies are designed with compatibility with SSN in mind [14].Ontologies for the Web of Things: State-of-the-ArtWhile SSN and the ontologies that align to it model the physical world, the TD ontology shall provide metadata to guide autonomous Web agents in the network of interconnected devices that quantify it.", [["autonomous Web agents", "TREATMENT", 245, 266], ["interconnected devices", "TREATMENT", 285, 307]]], ["In particular, it formalizes the concept of \u2018affordance\u2019, introduced in the next section.Requirements ::: The Thing Description ModelRequirements for the TD model have been collected in the WoT architecture recommendation document [12].", [["the TD model", "TEST", 150, 162]]], ["The main requirements can be found in Sect.", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Assertions that include the keyword \u2018may\u2019 have been axiomatized using the lightweight schema.org semantics3.", [["org semantics", "TEST", 93, 106]]], ["One can indeed argue that it contributes little to semantic interoperability.Requirements ::: The Thing Description ModelIt is however important to introduce the RDF classes and properties of the TD model (loosely referred to as the TD ontology), in order to then provide an alignment with SSN, the key element of semantic interoperability.", [["semantic interoperability", "OBSERVATION", 51, 76], ["semantic interoperability", "OBSERVATION", 314, 339]]], ["Contrary to other RESTful systems, the internal state of WoT systems is not purely informational but is instead derived from observing physical world objects.", [["WoT systems", "CELL_LINE", 57, 68]]], ["The Figure shows sub-class relations and property relations whenever instances of two classes may be related in a TD document.", [["TD", "DISEASE", 114, 116], ["sub", "OBSERVATION_MODIFIER", 17, 20]]]], "e3145e338cee068928be96512f030df7425e5bbb": [["IntroductionInfectious disease parameters such as the serial interval, defined as the time between symptom onset from primary to secondary case, and the reproductive number, defined as the average number of secondary cases produced by a primary case over the course of their infection, are instrumental in managing outbreaks [1] .", [["infection", "DISEASE", 275, 284], ["their infection", "PROBLEM", 269, 284], ["infection", "OBSERVATION", 275, 284]]], ["These parameters are used to determine how fast an infection is spreading, how well it is controlled, and if public health interventions are working.IntroductionFor some diseases such as influenza A (H1N1) [1, 2] , Severe Acute Respiratory Syndrome (SARS) [3, 4] , and Ebola [5, 6] , in which disease progression happens shortly after infection, these parameters have been studied extensively.", [["infection", "DISEASE", 51, 60], ["influenza A", "DISEASE", 187, 198], ["Acute Respiratory Syndrome", "DISEASE", 222, 248], ["SARS", "DISEASE", 250, 254], ["Ebola", "DISEASE", 269, 274], ["infection", "DISEASE", 335, 344], ["influenza A", "ORGANISM", 187, 198], ["Ebola", "ORGANISM", 269, 274], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 215, 255], ["an infection", "PROBLEM", 48, 60], ["public health interventions", "TREATMENT", 109, 136], ["some diseases", "PROBLEM", 165, 178], ["influenza A (H1N1)", "PROBLEM", 187, 205], ["Severe Acute Respiratory Syndrome (SARS)", "PROBLEM", 215, 255], ["infection", "PROBLEM", 335, 344], ["infection", "OBSERVATION", 51, 60], ["Severe", "OBSERVATION_MODIFIER", 215, 221], ["Acute", "OBSERVATION_MODIFIER", 222, 227], ["Respiratory Syndrome", "OBSERVATION", 228, 248]]], ["For other diseases such as tuberculosis (TB), the estimates for the serial interval and reproductive number are few and inconsistent [7] [8] [9] .", [["tuberculosis", "DISEASE", 27, 39], ["TB", "DISEASE", 41, 43], ["other diseases", "PROBLEM", 4, 18], ["tuberculosis (TB)", "PROBLEM", 27, 44], ["diseases", "OBSERVATION", 10, 18], ["tuberculosis", "OBSERVATION", 27, 39]]], ["Methods to estimate both the serial interval and reproductive number rely on determining which cases are linked by direct transmission.", [["Methods", "TREATMENT", 0, 7]]], ["In recent years, pathogen whole genome sequence (WGS) data has been established as a powerful tool to link cases for many diseases [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] .IntroductionDidelot et al. [23] developed a method that infers transmission networks, estimates transmission probabilities, and estimates the serial interval and reproductive number.", [["[10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22]", "SIMPLE_CHEMICAL", 131, 195], ["pathogen whole genome sequence", "DNA", 17, 47], ["pathogen whole genome sequence", "TEST", 17, 47], ["many diseases", "PROBLEM", 117, 130]]], ["However, it has been shown that for some diseases, pathogen WGS data is less informative of transmission links for various reasons such as low mutation rates, short time intervals between infections, and within host diversity [24, 25] .IntroductionAnother way to effectively link cases by direct transmission is contact investigations.", [["infections", "DISEASE", 188, 198], ["some diseases", "PROBLEM", 36, 49], ["pathogen WGS data", "TEST", 51, 68], ["low mutation rates", "PROBLEM", 139, 157], ["infections", "PROBLEM", 188, 198]]], ["Contact investigations are often a component of the public health response to an infectious disease outbreak [24, 24, [26] [27] [28] [29] [30] [31] .", [["[26] [27] [28] [29] [30] [31]", "SIMPLE_CHEMICAL", 118, 147], ["Contact investigations", "TEST", 0, 22], ["an infectious disease outbreak", "PROBLEM", 78, 108]]], ["Campbell et al. [24] developed a method to that successfully infers transmission chains using contact investigation data alone and combined with WGS data.", [["WGS data", "TEST", 145, 153]]], ["However, even contact investigations cannot perfectly determine linked cases as some diseases can be transmitted through casual contact in public locations that would not be captured in typical contact investigations [32, 33] .", [["some diseases", "PROBLEM", 80, 93]]], ["Additionally, the effectiveness of contact investigations can depend upon characteristics of the disease such as the length of the latency period, the clustering of infections [29] , and the willingness of cases to share information about their contacts [31, 34] .IntroductionThe methods outlined by Didelot et al. [23] and Campbell et al. [24] are powerful tools for understanding transmission dynamics using the most discriminating pieces of information currently available: pathogen WGS and contact investigation.", [["infections", "DISEASE", 165, 175], ["contact investigations", "TEST", 35, 57], ["the disease", "PROBLEM", 93, 104], ["infections", "PROBLEM", 165, 175]]], ["However, even these data sources cannot perfectly capture outbreak dynamics, due to the complexity of pathogen genetics and human interactions.", [["human", "ORGANISM", 124, 129], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 124, 129]]], ["Furthermore, WGS data is expensive to obtain and requires bioinformatics expertise and contact investigations are time consuming and require significant human resources.", [["human", "ORGANISM", 153, 158], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 153, 158], ["WGS data", "TEST", 13, 21], ["significant human resources", "TREATMENT", 141, 168]]], ["Therefore, these data sources are not universally available for many established infectious disease study samples.", [["samples", "CANCER", 106, 113], ["many established infectious disease study samples", "PROBLEM", 64, 113], ["infectious", "OBSERVATION", 81, 91]]], ["We developed a method to predict the relative probability of direct transmission between infectious disease patients using pathogen WGS data and/or contact investigations when these data are only available on a small proportion of cases, paired with demographic, spatial, clinical, and social risk factor data.", [["infectious disease", "DISEASE", 89, 107], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["pathogen WGS data", "TEST", 123, 140], ["contact investigations", "TEST", 148, 170], ["infectious", "OBSERVATION_MODIFIER", 89, 99]]], ["We then applied our method to a TB outbreak in Hamburg, Germany that had extensive clinical and epidemiological data.Data StructureOur method starts with a dataset of individuals with the infectious disease of interest for whom various covariate values such as geographic location, clinical information, age, and time of sampling have been observed.", [["TB", "DISEASE", 32, 34], ["infectious", "OBSERVATION", 188, 198]]], ["Furthermore, additional information such as detailed contact investigation data and/or whole genome sequencing of the pathogen genome is available for at least some of the cases.", [["pathogen genome", "DNA", 118, 133], ["detailed contact investigation data", "TEST", 44, 79], ["the pathogen genome", "PROBLEM", 114, 133]]], ["We convert the individual-level covariates (X 1 , X 2 , . . .", [["the individual-level covariates", "TREATMENT", 11, 42]]], ["X p ) into pair-level covariates (Z 1 , Z 2 , . . .", [["pair-level covariates", "TEST", 11, 32], ["Z", "TEST", 34, 35]]], ["These \"distances\" identify how well the individuals match on the various covariates.Data StructureThese distances can be dichotomous where a value of 1 indicates that the covariate values match and 0 indicates that they do not match as in Equation 1 for covariate Z k (where k \u2208 1, 2, . . . , p):Data StructureOr the distances could be categorical where different combinations of individual-level values result in r different pair-level values such as:Data Structurewhere v 1 , v 2 , . . . , v w are the different values of X k .", [["covariate Z k", "TEST", 254, 267], ["individual-level values", "TEST", 380, 403]]], ["For example if the individual-level covariate X 1 is town of residence, then the pair-level covariate Z 1 could indicate if the individuals live in the same town, if they live in neighboring towns, or if they live in towns that are not neighboring.Naive BayesIn order to estimate the probability that cases i and j are linked by direct transmission, p(i \u2212 \u2192 j), we used a classification technique called naive Bayes.", [["X 1", "DNA", 46, 49], ["Z 1", "DNA", 102, 105]]], ["Naive Bayes has been used in many applications in machine learning and public health including text classification [35] , software defect testing [36] , and creation of genetic risk scores [37] .", [["software defect testing", "TEST", 122, 145]]], ["We call the outcome variable L ij , which takes the value 1 if case i infected case j and 0 otherwise.", [["L ij", "TREATMENT", 29, 33], ["ij", "ANATOMY", 31, 33]]], ["We know the probable value of this variable for case pairs in the training set based on pathogen WGS or contact investigation data and our method predicts the probability that L ij = 1 for the rest of the case pairs.Naive BayesWe first use the training set to calculate, P (Z k = z k |L = l), the probability that covariate Z k is equal to z k given link status, l, (l = 1 for linked pairs and l = 0 for non-linked pairs) for each covariate k \u2208 {1, 2, . . . , p} using:Naive BayesHere the function, 1, is the indicator function which takes the value 1, if the input is true and 0 if it is false and n k is the number of levels of Z k for k \u2208 {1, 2, . . . , p}.", [["pathogen WGS", "TEST", 88, 100], ["contact investigation data", "TEST", 104, 130], ["L ij", "TREATMENT", 176, 180], ["the training", "TREATMENT", 240, 252], ["calculate", "TEST", 260, 269], ["P", "TEST", 271, 272], ["Z k", "TEST", 274, 277], ["covariate Z k", "TEST", 314, 327], ["z k", "TEST", 340, 343], ["link status", "PROBLEM", 350, 361], ["pairs", "TEST", 384, 389], ["each covariate k \u2208", "TEST", 426, 444], ["levels", "TEST", 620, 626], ["Z k", "TEST", 630, 633], ["k \u2208", "TEST", 638, 641], ["ij", "ANATOMY", 178, 180]]], ["Therefore, the numerator, i,j 1{L ij = l, Z kij = z k }, counts the number of instances that a pair, i, j has linked status, l, and covariate value z k for covariate Z k , k \u2208 {1, 2, . . . , p}.", [["the numerator", "TEST", 11, 24], ["Z kij", "TEST", 42, 47], ["covariate value", "TEST", 132, 147], ["covariate Z k", "TEST", 156, 169], ["k \u2208", "TEST", 172, 175]]], ["Because sparse data can result in zero probabilities, we also apply a common technique of adding 1 to each cell called Laplace smoothing [35] .", [["cell", "ANATOMY", 107, 111], ["cell", "CELL", 107, 111], ["zero probabilities", "PROBLEM", 34, 52], ["a common technique", "TREATMENT", 68, 86]]], ["Then we use the training set to calculate P (L = l), the prior probability of link status for l \u2208 {1, 0}.Naive BayesWe now use Bayes rule to calculate the predicted probability that case i infected case j, p(i \u2212 \u2192 j) for all pairs in the prediction set as:Naive Bayes.Naive BayesWe can calculate the conditional probability of all covariate values given link status, P (Z 1 = z 1 , . . . , Z p = z p |L = l), as the product of the conditional probabilities of each covariate, P (Z k = z k |L = l) for k \u2208 {1, 2, . . . , p} in equation 5, under the assumption that covariates are conditionally independent.", [["the training", "TREATMENT", 12, 24], ["all covariate values", "TEST", 327, 347], ["status", "TEST", 359, 365], ["Z", "TEST", 370, 371], ["Z", "TEST", 390, 391], ["the product", "TEST", 412, 423], ["covariate", "TEST", 465, 474], ["k \u2208", "TEST", 501, 504], ["equation", "TEST", 526, 534]]], ["Note that the ordered nature of the pair dataset implies that if case j was observed before case i, then p(i \u2212 \u2192 j) = 0.Scaling ProbabilitiesIn order to compare probabilities obtained with different datasets, covariates, and ways of defining transmission events in the training set, the estimated probabilities are scaled so that they represent the relative likelihood that case j has been infected by case i as opposed to any other sampled case as:Scaling ProbabilitiesThis scaled probability, p(i \u2212 \u2192 j) S , will henceforward be referred to as the relative transmission probability.Training Dataset ConstructionThe implementation of naive Bayes involves using a training set in which the outcome is known to train the model and a prediction set in which the probabilities are estimated.", [["a training set", "TREATMENT", 662, 676]]], ["In the infectious disease applications we are considering though, we never know the true infector.", [["infectious", "OBSERVATION", 7, 17]]], ["However, many studies have more detailed information on a subset of cases, such as pathogen WGS and/or detailed contact investigation data which allow for the identification of probable linked and un-linked case pairs.", [["many studies", "TEST", 9, 21], ["pathogen WGS", "TEST", 83, 95], ["investigation data", "TEST", 120, 138]]], ["We can use one or both of these sources of information to create a training set of probable transmission events.", [["transmission events", "PROBLEM", 92, 111]]], ["Because the outcomes in our training set represent probable and not certain transmission events, we want to estimate the transmission probability of these case pairs as well as the other pairs which do not have pathogen WGS or contact investigation data.", [["contact investigation data", "TEST", 227, 253]]], ["Therefore, we use an iterative estimation procedure to ensure that each pair has a turn in the prediction set.", [["an iterative estimation procedure", "TREATMENT", 18, 51]]], ["We split our training set into n subsets called folds where n -1 folds are used to train the model and the remaining fold is included in the prediction set.", [["our training", "TREATMENT", 9, 21], ["n -1 folds", "TREATMENT", 60, 70]]], ["In our situation, this procedure is complicated by the fact that we assume that each case has only one true infector which presents two problems: 1) since the method of defining transmission events in the training set is not perfect, there could be multiple possible links for each infectee, and 2) once we denote a case pair as linked in the training set, all pairs that share that infectee have a zero-probability of being linked.Training Dataset ConstructionTo solve the first problem, we create the links in the training set by randomly choosing one of the possible infectors to be designated the linked case pair and then repeated this selection multiple times to capture the uncertainty around the true infector.", [["this procedure", "TREATMENT", 18, 32]]], ["Then when that linked pair is in the prediction dataset so are all of the other pairs involving the infectee, so the probability of all pairs involving that infectee can be estimated.Training Dataset ConstructionIn order to capture the valuable information provided by the pathogen WGS or contact investigation data used to define probable transmission events in the training set, when a pair is included in the training set, the predicted probability for that run is set to 1 if the pair is linked and 0 if the pair is not linked.", [["pathogen WGS", "DNA", 273, 285], ["contact investigation data", "TEST", 289, 315]]], ["The following algorithm describes the creation of the training dataset and the iterative estimation procedure which can be visualized in Figure 1 .Training Dataset Construction1.", [["the training dataset", "TREATMENT", 50, 70], ["the iterative estimation procedure", "TREATMENT", 75, 109]]], ["Split this dataset of possible training pairs into n folds (we used 10): n-1 for training and 1 for prediction.Training Dataset Construction(a) Reserve 1 fold for prediction and combine with all of the pairs not in the training set.Training Dataset Construction(b) For all linked pairs in the n-1 training folds, move all other pairs involving the infectee from the prediction set to the training set as non-links (L ij = 0).", [["all linked pairs", "PROBLEM", 269, 285]]], ["This is the final training set for this iteration.Training Dataset Construction(c) Set the predicted probabilities for training set pairs to 1 for links and 0 for non-links.Training Dataset Construction(d) Use the training set to train the model and calculate predicted probabilities in the prediction set.Training Dataset Construction(e) Repeat (a)-(d) n times so that each fold has a turn in the prediction set.Training Dataset Construction6.", [["this iteration", "TREATMENT", 35, 49], ["non-links", "PROBLEM", 163, 172], ["the training", "TREATMENT", 210, 222], ["Repeat (a)-(d)", "TREATMENT", 339, 353]]], ["Repeat steps 2-5 multiple times (we used 10) to allow for different possible infectors to be designated the true infector.Training Dataset Construction7.", [["Repeat steps", "TEST", 0, 12], ["infectors", "PROBLEM", 77, 86]]], ["Scale the resulting probabilities using equation 6 to obtain the relative transmission probabilities for all case pairs.Reproductive Number EstimationTo estimate the reproductive number we use the approach described by Wallinga and Teunis [4] .", [["the approach", "TREATMENT", 193, 205]]], ["These authors calculated the relative likelihood that each case had been infected by all other cases based on the serial interval distribution.", [["infected", "OBSERVATION", 73, 81], ["distribution", "OBSERVATION_MODIFIER", 130, 142]]], ["Finally, we average the monthly reproductive numbers for the stable portion of the outbreak to estimate the average effective reproductive number over the study period (R t ).Reproductive Number EstimationWe can estimate confidence intervals for R t andR t using parametric bootstrapping.", [["the study", "TEST", 151, 160], ["R t andR t using parametric bootstrapping", "TREATMENT", 246, 287], ["stable", "OBSERVATION_MODIFIER", 61, 67]]], ["The R i values are re-sampled 100 times using the estimated probabilities, p(i \u2212 \u2192 k) S , for all k according to their distribution:Reproductive Number Estimationas detailed in Wallinga and Teunis [4] .", [["R i", "GENE_OR_GENE_PRODUCT", 4, 7]]], ["We simulate 1000 outbreaks using the simula-teOutbreak function and generate the phylogenetic trees for those outbreaks using the phlyoFromPTree, function both from TransPhylo v1.0 [23] .", [["the simula-teOutbreak function", "TREATMENT", 33, 63], ["the phlyo", "TREATMENT", 126, 135], ["TransPhylo v", "TEST", 165, 177]]], ["Then we use the simSeq function in phagnorn v2.5.3 [38] to generate genetic sequences corresponding to the phylogenetic tree.", [["simSeq", "DNA", 16, 22], ["genetic sequences", "TEST", 68, 85], ["phylogenetic tree", "OBSERVATION", 107, 124]]], ["This method was used in Stimson et al. [39] for a similar purpose, though we extend it to include multiple transmission chains.", [["This method", "TREATMENT", 0, 11]]], ["Each outbreak is composed of numerous transmission chains of at least two cases which are simulated iteratively until the total sample size exceeded 500.", [["numerous transmission chains", "TREATMENT", 29, 57], ["the total sample size", "TEST", 118, 139]]], ["We simulate each transmission chain with the same outbreak parameters: a mean reproductive number (R t ) of 1.2, a serial interval distribution of gamma(shape = 1.05, scale = 2.0), and an effective population size times generation time (N eg ) of 0.25.", [["gamma", "PROTEIN", 147, 152], ["gamma(shape", "TEST", 147, 158], ["scale", "TEST", 167, 172], ["distribution", "OBSERVATION_MODIFIER", 131, 143], ["gamma", "ANATOMY", 147, 152], ["effective", "OBSERVATION_MODIFIER", 188, 197], ["population", "OBSERVATION_MODIFIER", 198, 208], ["size", "OBSERVATION_MODIFIER", 209, 213]]], ["We also include a delay between infection and sampling using the same distribution as the serial interval.", [["infection", "DISEASE", 32, 41], ["a delay between infection", "PROBLEM", 16, 41], ["infection", "OBSERVATION", 32, 41]]], ["We then simulate representative pathogen genomes for each case.", [["pathogen genomes", "DNA", 32, 48], ["pathogen genomes", "OBSERVATION", 32, 48]]], ["We also included the time between infection dates for each case pair into the model categorized as follows: less than 1 year, 1 to 2 years, 2 to 3 years, 3 to 4 years, 4 to 5 years, and more than 5 years.Simulation StudyAlthough pathogen genomes are thousands to millions of base-pairs long, we simulate a 300 base pair genome where each transmission chain starts with a unique set of base pairs to allow for genetic diversity across different strains.", [["infection", "DISEASE", 34, 43], ["StudyAlthough pathogen genomes", "DNA", 215, 245], ["300 base pair genome", "DNA", 306, 326], ["a 300 base pair genome", "TREATMENT", 304, 326], ["genetic diversity across different strains", "PROBLEM", 409, 451], ["base", "ANATOMY_MODIFIER", 275, 279]]], ["We aim to replicate a slow mutating pathogen such as TB which mutates at a rate of around 0.5 single-nucleotide polymorphisms (SNPs) per genome per year [11] .", [["TB", "DISEASE", 53, 55], ["a slow mutating pathogen", "PROBLEM", 20, 44], ["TB", "PROBLEM", 53, 55], ["a rate", "TEST", 73, 79], ["single-nucleotide polymorphisms (SNPs)", "TREATMENT", 94, 132]]], ["With this mutation rate, over the course of one 20 year transmission chain, very few mutations will accrue thus allowing a smaller genome to provide a good proxy for the full genome.", [["this mutation rate", "PROBLEM", 5, 23], ["very few mutations", "PROBLEM", 76, 94]]], ["The shortened genome length we simulate is meant to represent the locations that differ amongst cases sampled as part of one outbreak instead of the full genome.", [["length", "OBSERVATION_MODIFIER", 21, 27], ["full genome", "OBSERVATION", 149, 160]]], ["We also performed a sensitivity analysis which showed that the SNP distance for a fixed mutation rate did not notably change as genome length increased ( Figure 2 ).", [["SNP", "CHEMICAL", 63, 66], ["a sensitivity analysis", "TEST", 18, 40], ["the SNP distance", "PROBLEM", 59, 75], ["a fixed mutation rate", "TEST", 80, 101], ["length", "OBSERVATION_MODIFIER", 135, 141], ["increased", "OBSERVATION_MODIFIER", 142, 151]]], ["It is possible that this approach underestimates the true SNP distance distribution which makes it a conservative representation of the true SNP distance distribution using the full pathogen genome.Simulation StudyWe compare the performance of our method when we train the model using probable transmission events defined by SNP distances between case pairs verses training the model with truly linked and un-linked pairs case pairs (Table 1) .", [["SNP", "CHEMICAL", 58, 61], ["SNP", "CHEMICAL", 141, 144], ["SNP", "CHEMICAL", 325, 328], ["pathogen genome", "DNA", 182, 197], ["the true SNP distance distribution", "PROBLEM", 49, 83], ["the true SNP distance distribution", "PROBLEM", 132, 166], ["SNP distance", "OBSERVATION", 58, 70], ["conservative", "OBSERVATION_MODIFIER", 101, 113], ["true", "OBSERVATION_MODIFIER", 136, 140], ["SNP distance", "OBSERVATION", 141, 153], ["pathogen genome", "OBSERVATION", 182, 197]]], ["When we train the model using SNP distance, case pairs with less than 2 SNPs are considered links and those with more than 12 SNPs are considered non-links in the training set.", [["SNP", "CHEMICAL", 30, 33]]], ["Pairs with between 2 and 12 SNPs are considered indeterminate and thus are not included in the training set.", [["indeterminate", "OBSERVATION_MODIFIER", 48, 61]]], ["To simulate real scenarios when only a fraction of the cases have the discriminating information necessary to define probable transmission events, we randomly select a subset of 50% of all cases to make up the training set.", [["transmission events", "PROBLEM", 126, 145]]], ["For comparison we also compute the relative transmission probabilities based on the serial interval used to simulate the data and the time between infection dates of each pair.", [["infection", "DISEASE", 147, 156], ["the data", "TEST", 117, 125]]], ["We also compute probabilities using two mis-specified serial intervals, one that is too wide and one that is too narrow ( Table 1 ).", [["too wide", "OBSERVATION_MODIFIER", 84, 92], ["too narrow", "OBSERVATION_MODIFIER", 109, 119]]], ["This comparison is motivated by the Wallinga and Teunis [4] method for calculating the reproductive number in which the transmission probabilities are estimated from the serial interval distribution.", [["distribution", "OBSERVATION_MODIFIER", 186, 198]]], ["The wide and narrow serial intervals represent the prior and posterior distributions used by Didelot et al. [23] in the analysis of the same TB outbreak in Hamburg that we analyze below.", [["TB", "DISEASE", 141, 143], ["The wide and narrow serial intervals", "PROBLEM", 0, 36], ["the analysis", "TEST", 116, 128], ["wide", "OBSERVATION_MODIFIER", 4, 8], ["narrow", "OBSERVATION_MODIFIER", 13, 19], ["posterior", "ANATOMY_MODIFIER", 61, 70]]], ["All of these serial intervals are shifted by 90 days because a serial interval of less than 3 months is not possible for TB, our motivating example.", [["TB", "DISEASE", 121, 123], ["TB", "PROBLEM", 121, 123], ["not possible", "UNCERTAINTY", 104, 116]]], ["We also assign the probabilities randomly from a Uniform(0, 1) distribution as a negative control.Simulation StudyWe estimate the monthly effective reproductive number, R t for all of the scenarios.", [["negative", "OBSERVATION", 81, 89]]], ["To estimate the average effective reproductive number,R t , we average the monthly values for all months excluding the first 10% and last 30% of months for each outbreak due to the unobserved infectors or infectees at the beginning and the end of the sampling period.Simulation StudyIn order to determine what proportion of cases need to be included in the training set to achieve good performance, we also perform a sensitivity analysis where we simulate 300 outbreaks with sample sizes 6 ranging from 50-1000 cases.", [["the unobserved infectors", "PROBLEM", 177, 201], ["infectees", "PROBLEM", 205, 214], ["a sensitivity analysis", "TEST", 415, 437], ["sample sizes", "TEST", 475, 487]]], ["We assess how changing the proportion of cases sampled affects the performance of the model performance and the estimation of the reproductive number depending on the sample size.Application to a TB Outbreak in HamburgFinally, we apply our method to a small TB outbreak in Hamburg and Schleswig-Holstein, Germany that Roetzer et al. [10] also analyzed.", [["TB", "DISEASE", 196, 198], ["TB", "DISEASE", 258, 260], ["size", "OBSERVATION_MODIFIER", 174, 178], ["small", "OBSERVATION_MODIFIER", 252, 257], ["TB", "OBSERVATION", 258, 260]]], ["The outbreak included 86 individuals from the largest strain cluster in a long-term surveillance study conducted by the health departments in these cities.", [["surveillance study", "TEST", 84, 102], ["largest", "OBSERVATION_MODIFIER", 46, 53]]], ["The dataset includes pathogen WGS data for all individuals as well as clinical, demographic, and social risk factor data.", [["pathogen WGS data", "TEST", 21, 38]]], ["Furthermore a subset of these individuals were involved in contact investigations performed by the local health authorities.Application to a TB Outbreak in HamburgWe used two different methods of defining probable links in the training set: 1) SNP distances and 2) contact investigation.", [["TB", "DISEASE", 141, 143], ["SNP", "CHEMICAL", 244, 247], ["individuals", "ORGANISM", 30, 41], ["contact investigations", "TEST", 59, 81], ["contact investigation", "TEST", 265, 286]]], ["When the model was trained with SNP distances, pairs with < 2 SNPs between them were considered linked, pairs with > 12 SNPs between them were considered non-links, and pairs with between 2 and 12 SNPs were considered indeterminate and were not included in training set.", [["SNP", "CHEMICAL", 32, 35], ["indeterminate", "OBSERVATION_MODIFIER", 218, 231]]], ["When the model was trained using contact investigation, pairs that had confirmed contact with each other were considered linked, pairs without confirmed contact with each other were considered non-linked, and cases who did not undergo contact investigation were not included in the training set.", [["contact investigation", "TEST", 33, 54]]], ["We also calculated the relative transmission probabilities randomly and using the same serial intervals as the simulation study for comparison.Simulation StudyWe created 1000 simulated outbreaks composed of multiple transmission chains with a total of at least 500 cases.", [["the simulation study", "TEST", 107, 127], ["multiple transmission chains", "TREATMENT", 207, 235]]], ["The sample sizes ranged from 500 to 1178 (median: 545) and each outbreak consisted of between 2 and 39 (median: 14) individual transmission chains with 2 to 846 (median: 9) cases each.", [["sample", "ANATOMY", 4, 10], ["The sample sizes", "TEST", 0, 16], ["individual transmission chains", "TREATMENT", 116, 146], ["sizes", "OBSERVATION_MODIFIER", 11, 16]]], ["Figure 3 shows the distribution of relative transmission probabilities in one of the 1000 outbreaks for the different scenarios comparing truly linked and non-linked case pairs.", [["relative transmission probabilities", "PROBLEM", 35, 70], ["the different scenarios", "PROBLEM", 104, 127], ["distribution", "OBSERVATION_MODIFIER", 19, 31]]], ["For both ways of defining links in the training set, our method estimated relative transmission probabilities of less than 0.005 for most of the non-linked pairs (92% training using true links and 87% training using SNP distance).", [["SNP", "CHEMICAL", 216, 219]]], ["We also found that with either way of defining the training set, our method assigns more than 80% of truly linked case pairs higher probabilities than the serial interval method (Figure 4) .Simulation StudyIn order to assess how well the relative transmission probabilities could classify case pairs as linked and non-linked across all 1000 simulated outbreaks, we calculated the area under the receiver operating curve (AUC) for each simulation.", [["our method", "TEST", 65, 75], ["the serial interval method", "TREATMENT", 151, 177], ["AUC", "TEST", 421, 424]]], ["To determine how well our method performed in identifying the true infector, we evaluated how the relative transmission probability of the true infector ranked compared to all possible infectors. compared to 95% (SD 1.0) when the model was trained using SNP distances.", [["SNP", "CHEMICAL", 254, 257], ["SNP", "CHEMICAL", 254, 257], ["the true infector", "PROBLEM", 135, 152]]], ["The probability of the true infector was ranked in the top 25% of all possible source cases on average 94% (SD 2.0) of the time both when the model was trained with true links and links determined by SNP distances.", [["SNP", "CHEMICAL", 200, 203], ["the true infector", "PROBLEM", 19, 36], ["true", "OBSERVATION_MODIFIER", 23, 27], ["infector", "OBSERVATION", 28, 36]]], ["Figure 6 and Table 3 show the estimatesR t for each of the different scenarios compared to the value of 1.2 used to simulate the outbreaks.", [["Figure", "TEST", 0, 6]]], ["However, when incorrect serial intervals were used, the estimates ofR t were either too high or too low depending on whether the serial interval was too wide or too narrow respectively.", [["R t", "DNA", 68, 71]]], ["In our sensitivity analysis of the proportion of cases needed to train the model, as expected, we found that the performance improves and the variability in the metrics decreases as the proportion of cases in the training set increases (Figure 7) .", [["variability", "OBSERVATION_MODIFIER", 142, 153]]], ["However, if the sample size is at least 500 then only 10% of all cases are needed to train the model to obtain good performance.", [["the sample size", "TEST", 12, 27]]], ["If the sample size is between 200 and 500, training the model with 20% of cases results in good performance.", [["the sample size", "TEST", 3, 18], ["size", "OBSERVATION_MODIFIER", 14, 18]]], ["For smaller outbreaks, at least 40% of the cases need to be in the training set to obtain the same performance level (Figure 8) .", [["smaller outbreaks", "PROBLEM", 4, 21], ["smaller", "OBSERVATION_MODIFIER", 4, 11], ["outbreaks", "OBSERVATION", 12, 21]]], ["When there is a small proportion of cases in the dataset, our method over-estimates the average effective reproductive number slightly.", [["small", "OBSERVATION_MODIFIER", 16, 21], ["average", "OBSERVATION_MODIFIER", 88, 95], ["effective", "OBSERVATION_MODIFIER", 96, 105], ["reproductive", "OBSERVATION_MODIFIER", 106, 118], ["number", "OBSERVATION_MODIFIER", 119, 125], ["slightly", "OBSERVATION_MODIFIER", 126, 134]]], ["The estimates get increasingly accurate as the training dataset increases and as long as around 40% of cases are included in the training dataset the estimates are close to the true value ( Figure 9 ).Application to a TB Outbreak in HamburgWe applied our method to a small TB outbreak in Hamburg and Schleswig-Holstein, Germany that Roetzer et al. [10] also analyzed.", [["TB", "DISEASE", 218, 220], ["TB", "DISEASE", 273, 275], ["small", "OBSERVATION_MODIFIER", 267, 272], ["TB", "OBSERVATION", 273, 275]]], ["The outbreak included 86 individuals from the largest strain cluster in a long-term surveillance study conducted by the health departments in these cities.", [["surveillance study", "TEST", 84, 102], ["largest", "OBSERVATION_MODIFIER", 46, 53]]], ["The median age was 45 (range: 2-85) and 70 (81%) of the cases were men.", [["men", "ORGANISM", 67, 70], ["men", "SPECIES", 67, 70]]], ["Details on the other clinical and demographic characteristics can be seen in Table 4 .Application to a TB Outbreak in HamburgThese 86 cases resulted in 3633 possible ordered case pairs where the possible infector was observed before the possible infectee.", [["TB", "DISEASE", 103, 105], ["infector", "PROBLEM", 204, 212], ["infectee", "PROBLEM", 246, 254]]], ["These pairs were separated by between 0 and 20 SNPs, with a median of 4 SNPs between them.", [["a median of 4 SNPs", "TREATMENT", 58, 76]]], ["Of the 86 individuals, 31 (36%) were part of contact investigations performed by the local health authorities resulting in 51 case pairs with confirmed contact with each other.", [["contact investigations", "TEST", 45, 67]]], ["We used these covariates to estimate the relative transmission probability for all case pairs from this outbreak.", [["these covariates", "TREATMENT", 8, 24], ["this outbreak", "PROBLEM", 99, 112]]], ["We trained the model in two ways: using SNP distances or contact investigations.", [["SNP", "CHEMICAL", 40, 43], ["contact investigations", "TEST", 57, 79]]], ["Figure 11 shows heatmaps of all potential infectors for each infectee using our method compared to random probabilities ( Figure 11A ) and the correct serial interval ( Figure 11B ).", [["Figure", "TEST", 0, 6], ["all potential infectors", "PROBLEM", 28, 51], ["our method", "TEST", 76, 86]]], ["When our method is applied, either with SNP distance defining links in the training set ( Figure 11C ) or with confirmed contact defining links ( Figure 11D ), the plots display more variation in the relative transmission probability across possible infectors than the serial interval or random scenarios.", [["SNP", "CHEMICAL", 40, 43], ["the plots", "TEST", 160, 169], ["infectors", "PROBLEM", 250, 259]]], ["For some infectees there are infectors with a higher probability than all others in the row indicating the likely true infector.", [["some infectees", "PROBLEM", 4, 18], ["infectors", "PROBLEM", 29, 38], ["true infector", "PROBLEM", 114, 127], ["infectees", "OBSERVATION", 9, 18], ["higher", "OBSERVATION_MODIFIER", 46, 52], ["indicating the likely", "UNCERTAINTY", 92, 113], ["true", "OBSERVATION_MODIFIER", 114, 118], ["infector", "OBSERVATION", 119, 127]]], ["However, even for rows without a For all of the methods, we calculated R t per month andR t with bootstrap confidence intervals.", [["bootstrap confidence intervals", "TREATMENT", 97, 127]]], ["Since this was a smaller time frame than our simulations, when estimatingR t we only removed the last 10% of the months.", [["R t", "DNA", 73, 76], ["smaller", "OBSERVATION_MODIFIER", 17, 24]]], ["The monthly R t values for each scenario can be seen in Figure 12 .", [["The monthly R t values", "TEST", 0, 22]]], ["All of the methods except random probabilities show spikes in monthly reproductive numbers right around the second peak in case counts ( Figure 12 ), but to different degrees.Application to a TB Outbreak in HamburgThe estimates ofR t for all of the methods were approximately 1 with some variation (Table 5, Figure 13 ).", [["TB", "DISEASE", 192, 194], ["the methods", "TEST", 7, 18], ["spikes", "PROBLEM", 52, 58], ["a TB Outbreak", "PROBLEM", 190, 203], ["spikes", "OBSERVATION_MODIFIER", 52, 58], ["right", "ANATOMY_MODIFIER", 91, 96], ["second", "OBSERVATION_MODIFIER", 108, 114], ["peak", "OBSERVATION_MODIFIER", 115, 119], ["TB", "OBSERVATION_MODIFIER", 192, 194]]], ["When the probabilities were estimated using contact investigations to train the model and using the medium serial interval, we estimatedR t to be 1.0 (95% confidence interval [CI] 0.73-1.18 and 0.67-1.23, respectively).", [["contact investigations", "TEST", 44, 66], ["CI", "TEST", 176, 178]]], ["When the probabilities were estimated using the SNP distances to train the model and using the wide serial interval we estimatedR t to be 0.9 (95% CI 0.67-1.09 and 0.64-1.11, respectively).", [["SNP", "CHEMICAL", 48, 51], ["the SNP distances", "TREATMENT", 44, 61], ["CI", "TEST", 147, 149]]], ["Using random probabilities resulted in a lower estimate of 0.8 (95% CI 0.54-1.00) and using the narrow serial interval resulted in a higher estimate of 1.1 (95% CI 0.81-1.31).DiscussionWe have developed a method to estimate the relative transmission probability between pairs of infectious disease cases using clinical, demographic, geographic, and genetic characteristics that accurately distinguishes between linked and non-linked case pairs.", [["infectious disease", "DISEASE", 279, 297], ["CI", "TEST", 68, 70], ["CI", "TEST", 161, 163], ["infectious", "OBSERVATION_MODIFIER", 279, 289]]], ["These probabilities can be used to explore possible transmission chains, rule out transmission events, and estimate the reproductive number.", [["transmission chains", "PROBLEM", 52, 71], ["transmission events", "PROBLEM", 82, 101]]], ["Our method was assessed in a series of simulation studies as well as applied to a TB outbreak in Germany.DiscussionIn simulation studies, we found that the probabilities were able to distinguish between linked pairs and non-linked case pairs with high accuracy.", [["TB", "DISEASE", 82, 84], ["simulation studies", "TEST", 39, 57], ["simulation studies", "TEST", 118, 136]]], ["Using a SNP distance proxy for transmission to train the model, we achieved a classification accuracy of 95% and 94% of the time the true infector was assigned a probability in the top 25% of all possible infectors.", [["SNP", "CHEMICAL", 8, 11], ["a SNP distance proxy", "TREATMENT", 6, 26], ["a classification accuracy", "TEST", 76, 101], ["infectors", "PROBLEM", 205, 214]]], ["Therefore, in absence of a reliable serial interval estimate, the probabilities from our model better estimate the effective reproductive number than using the serial interval distribution.", [["effective", "OBSERVATION_MODIFIER", 115, 124], ["reproductive", "OBSERVATION_MODIFIER", 125, 137], ["distribution", "OBSERVATION_MODIFIER", 176, 188]]], ["This result is important because the serial interval is difficult to estimate and may vary across different settings [7, 8, 40] .DiscussionThe Hamburg outbreak provided a way to evaluate our method using two different ways of defining probable transmission events in the training set: SNP distance and contact investigation.", [["SNP", "CHEMICAL", 285, 288], ["contact investigation", "TEST", 302, 323]]], ["The two ways of training the model did not produce identical results which is expected because the two models are trained on different ways of defining probable transmission events, neither of which perfectly capture the truth.", [["transmission events", "PROBLEM", 161, 180]]], ["Using contact investigation to train the model is more discriminating than using SNP distance because the cases are known to have interacted, but it also could also miss links from unknown contacts.", [["SNP", "CHEMICAL", 81, 84], ["contact investigation", "TEST", 6, 27]]], ["Using SNP distances to train the model will result in fewer missed links, but it could connect cases who never interacted.", [["SNP", "CHEMICAL", 6, 9], ["SNP distances", "TREATMENT", 6, 19]]], ["The two methods result in similar estimates for theR t and we hypothesize that the true reproductive number for M. tuberculosis in this context lies in between these two estimates (0.9 -1.0).DiscussionMost established methods for exploring transmission within an outbreak focus on either identifying clusters of recent transmission [11, 14, 39, [41] [42] [43] [44] , recreating the transmission chain [12, 13, [15] [16] [17] [18] [19] [20] [21] [22] 45] , or attempting to identify the true source case [46] [47] [48] [49] [50] .", [["tuberculosis", "DISEASE", 115, 127], ["M. tuberculosis", "ORGANISM", 112, 127], ["M. tuberculosis", "SPECIES", 112, 127], ["M. tuberculosis", "SPECIES", 112, 127], ["M. tuberculosis", "PROBLEM", 112, 127], ["the transmission chain", "TEST", 378, 400], ["tuberculosis", "OBSERVATION", 115, 127]]], ["When it comes to estimating transmission parameters, simply knowing clusters does not provide enough information and identifying the true infector is often impossible in practical applications.", [["the true infector", "PROBLEM", 129, 146]]], ["The strength of our method is that it does not aim to find the one true infector but estimates the relative probability of transmission for all sampled infectors.", [["all sampled infectors", "PROBLEM", 140, 161]]], ["It can be used to find potential true infectors -pairs with very high probabilities or identify clusters of transmission -groups of pairs with high probabilities.", [["potential true infectors", "PROBLEM", 23, 47], ["very high probabilities", "PROBLEM", 60, 83], ["high probabilities", "PROBLEM", 143, 161], ["high probabilities", "OBSERVATION", 143, 161]]], ["The probabilistic nature of the estimates can then be used to further estimate transmission parameters incorporating the uncertainty around the true infector.DiscussionOther methods to estimate the transmission probability between cases either only use genetic data [23] or require prior knowledge of the relationship between the covariates and transmission [51] .", [["the true infector", "PROBLEM", 140, 157], ["true infector", "OBSERVATION", 144, 157]]], ["Although traditionally a naive Bayes model is trained with a training set of true events, this will never be available for real-life infectious disease applications; however, WGS data for a subset of cases may be readily available in some outbreak settings.", [["a training", "TREATMENT", 59, 69], ["true events", "PROBLEM", 77, 88], ["WGS data", "TEST", 175, 183]]], ["We have shown that our method performs almost as well when SNP distance is used as a proxy for transmission to train the model as when true transmission is used as to define links in the training set.DiscussionThe structure of a training and prediction set also means that not all cases need to have the highly discriminatory information such as contact investigation or pathogen WGS data to estimate the relative transmission probabilities.", [["SNP", "CHEMICAL", 59, 62], ["a training", "TREATMENT", 227, 237], ["contact investigation", "TEST", 346, 367], ["pathogen WGS data", "TEST", 371, 388]]], ["This is a useful feature because existing datasets often have rich demographic, clinical, and spatial data but lack detailed contact investigation or pathogen WGS data because both of these data sources require significant time and resources to obtain.", [["pathogen WGS data", "TEST", 150, 167]]], ["As long as a subset of cases, between 10% and 40% depending on the sample size, has this information, our method can be used to infer transmission patterns among the remaining cases as well.DiscussionOur method, as with any statistical model, makes certain assumptions which may or may not be universally appropriate.", [["size", "OBSERVATION_MODIFIER", 74, 78]]], ["Furthermore, many extensions of naive Bayes have been developed which relax this assumption [35, 57, 58] , which could be easily integrated into our method.DiscussionThe Wallinga and Teunis [4] approach for estimating the effective reproductive number, which we applied, assumes that every case has been infected by someone that has been sampled .", [["naive Bayes", "PROBLEM", 32, 43], ["approach", "TREATMENT", 194, 202], ["naive Bayes", "OBSERVATION", 32, 43]]], ["These authors and others found that simulations incorporating random incomplete reporting did not substantially decrease the accuracy of their reproductive number estimates, so we do not expect this to be an issue with our analysis [4, 59] .", [["our analysis", "TEST", 219, 231]]], ["However, our method could be affected by biased sampling -either because only certain types of cases are observed or only certain types of cases have the information needed to define probable links in the training set.", [["biased sampling", "TEST", 41, 56]]], ["Future work could more fully examine the effect of biased reporting and biased training sets.DiscussionFinally, our method has the same limitations as many other infectious disease analytical approaches in that it assumes that cases were infected in the same order that they were observed [44, 60] .", [["biased training sets", "TREATMENT", 72, 92]]], ["This is not a strong assumption for a disease that has clear symptoms and a short latent period where most patients seek care shortly after developing symptoms.", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["a disease", "PROBLEM", 36, 45], ["clear symptoms", "PROBLEM", 55, 69], ["developing symptoms", "PROBLEM", 140, 159], ["disease", "OBSERVATION", 38, 45]]], ["However, in diseases such as TB, where there can be months to years between infection and development of disease (if this ever occurs), and where delay in seeking care and getting properly diagnosed can be substantial [61, 62] it is possible that cases present to care in a different order than they were infected.", [["TB", "DISEASE", 29, 31], ["infection", "DISEASE", 76, 85], ["diseases", "PROBLEM", 12, 20], ["TB", "PROBLEM", 29, 31], ["infection", "PROBLEM", 76, 85], ["disease", "PROBLEM", 105, 112], ["diseases", "OBSERVATION", 12, 20], ["TB", "OBSERVATION", 29, 31], ["infection", "OBSERVATION", 76, 85], ["disease", "OBSERVATION", 105, 112], ["infected", "OBSERVATION", 305, 313]]], ["Although this assumption is a known problem in infectious disease research, it is frequently made [46, 47] because relaxing it complicates models substantially.DiscussionWe have developed a method to estimate the relative transmission probabilities between pairs of cases.", [["infectious disease", "DISEASE", 47, 65], ["infectious", "OBSERVATION_MODIFIER", 47, 57]]], ["The power of our method is that only a subset of cases (10-40% depending on the sample size) need to have pathogen WGS data or contact investigation data, allowing this method to be applied to a wide range of outbreak and surveillance datasets.", [["pathogen WGS data", "TEST", 106, 123], ["contact investigation data", "TEST", 127, 153], ["this method", "TREATMENT", 164, 175], ["surveillance datasets", "TEST", 222, 243], ["power", "OBSERVATION_MODIFIER", 4, 9]]], ["These probabilities can be used to better understand the transmission dynamics of an outbreak by identifying possible transmission events and estimating transmission parameters.", [["transmission events", "PROBLEM", 118, 137], ["estimating transmission parameters", "TEST", 142, 176]]], ["In a disease where determining transmission events can be extremely difficult, using probabilities of transmission between all possible cases provides a unique and powerful analysis tool.", [["disease", "OBSERVATION", 5, 12]]], ["Figure 1 : Flow-chart depicting the algorithm we used to create the training dataset and the iterative procedure to estimate the relative transmission probabilities.", [["the training dataset", "TREATMENT", 64, 84], ["the iterative procedure", "TREATMENT", 89, 112]]], ["13 Figure 2 : Violin plots representing the effect of changing genome length on the SNP distance distribution between case pairs.", [["SNP", "CHEMICAL", 84, 87], ["Violin plots", "PROBLEM", 14, 26]]], ["Pathogen genomes of various lengths from 50 to 4.4 million base pairs were simulated 100 times each for an outbreak of 200 cases.", [["various", "OBSERVATION_MODIFIER", 20, 27], ["lengths", "OBSERVATION_MODIFIER", 28, 35]]], ["The resulting SNP distance matix for all case pairs was computed.", [["SNP", "CHEMICAL", 14, 17], ["The resulting SNP distance matix", "TREATMENT", 0, 32]]], ["The figure shows the relationship between genome length on the quartiles of the SNP distance distribution as well as the maximum SNP distance and the percent of pairs with less than 2 SNPs and more than 12 SNPs.", [["SNP", "CHEMICAL", 80, 83], ["SNP", "CHEMICAL", 129, 132], ["length", "OBSERVATION_MODIFIER", 49, 55], ["SNP distance", "OBSERVATION", 80, 92], ["maximum", "OBSERVATION_MODIFIER", 121, 128], ["percent", "OBSERVATION_MODIFIER", 150, 157], ["less", "OBSERVATION_MODIFIER", 172, 176]]]], "382a0c21ca55d60885d80bf18345302fc026a245": [["A. TYPING AND CROSS MATCHINGThe ability of veterinarians to obtain blood types of potential donors and recipients is limited by the scarcity of reagents and laboratories that perform typing of animal blood.", [["blood", "ANATOMY", 67, 72], ["blood", "ANATOMY", 200, 205], ["blood", "ORGANISM_SUBSTANCE", 67, 72], ["donors", "ORGANISM", 92, 98], ["blood", "ORGANISM_SUBSTANCE", 200, 205], ["potential donors", "PROBLEM", 82, 98], ["recipients", "TREATMENT", 103, 113], ["animal blood", "PROBLEM", 193, 205]]], ["At this time, canine typing reagents are avaiable only through the laboratory of Dr. Robert Bull at Michigan State University.", [["canine", "ORGANISM", 14, 20], ["canine", "SPECIES", 14, 20], ["canine typing reagents", "TEST", 14, 36]]], ["In addition, several veterinary schools and at least one commercial laboratory (Stormont Laboratories, Vacaville, California) perform typing of canine blood using these reagents.", [["blood", "ANATOMY", 151, 156], ["canine", "ORGANISM", 144, 150], ["blood", "ORGANISM_SUBSTANCE", 151, 156], ["canine", "SPECIES", 144, 150], ["canine", "SPECIES", 144, 150], ["canine blood", "TREATMENT", 144, 156], ["these reagents", "TREATMENT", 163, 177]]], ["In most cases canine donors are typed only for the two alleles at the DEA-1 locus with antibodies combined and termed DEA-1.1,2.", [["DEA", "CHEMICAL", 118, 121], ["canine", "ORGANISM", 14, 20], ["donors", "ORGANISM", 21, 27], ["DEA-1", "GENE_OR_GENE_PRODUCT", 70, 75], ["DEA-1 locus", "DNA", 70, 81], ["antibodies", "PROTEIN", 87, 97], ["canine", "SPECIES", 14, 20], ["antibodies", "TEST", 87, 97]]], ["(For procedures for typing and cross matching, see Smith, this volume [\"Erythrocytes\"].)", [["Erythrocytes", "ANATOMY", 72, 84], ["typing", "TEST", 20, 26]]], ["Dogs that react with this reagent are commonly called A positive.", [["Dogs", "ORGANISM", 0, 4], ["A", "GENE_OR_GENE_PRODUCT", 54, 55], ["this reagent", "TREATMENT", 21, 33]]], ["Red cells that are A positive are most likely to sensitize recipients that lack these antigens.", [["Red cells", "ANATOMY", 0, 9], ["Red cells", "CELL", 0, 9], ["A", "GENE_OR_GENE_PRODUCT", 19, 20], ["recipients", "ORGANISM", 59, 69], ["Red cells", "CELL_TYPE", 0, 9], ["antigens", "PROTEIN", 86, 94], ["Red cells", "TEST", 0, 9], ["most likely", "UNCERTAINTY", 34, 45]]], ["Because A-positive dogs represent 60% of the population, they can be utilized as donors for recipients that are also positive.", [["dogs", "ORGANISM", 19, 23], ["donors", "ORGANISM", 81, 87], ["recipients", "ORGANISM", 92, 102], ["dogs", "SPECIES", 19, 23], ["A-positive dogs", "PROBLEM", 8, 23], ["recipients", "TREATMENT", 92, 102]]], ["This requires that typing be available for recipients.", [["recipients", "ORGANISM", 43, 53], ["typing", "TEST", 19, 25]]], ["Blood group A 2 dogs may develop antibodies when given Ai red cells, but this is rare (Swisher and Young, 1961) .", [["Blood", "ANATOMY", 0, 5], ["Ai red cells", "ANATOMY", 55, 67], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["dogs", "ORGANISM", 16, 20], ["Ai red cells", "CELL", 55, 67], ["antibodies", "PROTEIN", 33, 43], ["Ai red cells", "CELL_TYPE", 55, 67], ["dogs", "SPECIES", 16, 20], ["antibodies", "PROBLEM", 33, 43], ["Ai red cells", "TREATMENT", 55, 67]]], ["These antibodies would be detectable if a major cross match were done before subsequent transfusions.", [["antibodies", "PROTEIN", 6, 16], ["These antibodies", "TEST", 0, 16], ["subsequent transfusions", "TREATMENT", 77, 100]]], ["Although a single transfusion of A-positive blood could be given to an A-negative dog never previously transfused, antibodies may be formed that increase the risk for reaction on subsequent transfusion, for premature destruction of transfused cells 7-14 days after the first transfusion, and for neonatal hemolytic disease in pups of transfused bitches (see Paradis, this volume).", [["blood", "ANATOMY", 44, 49], ["cells", "ANATOMY", 243, 248], ["bitches", "ANATOMY", 345, 352], ["neonatal hemolytic disease", "DISEASE", 296, 322], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["dog", "ORGANISM", 82, 85], ["cells", "CELL", 243, 248], ["bitches", "ORGANISM_SUBDIVISION", 345, 352], ["antibodies", "PROTEIN", 115, 125], ["transfused cells", "CELL_TYPE", 232, 248], ["dog", "SPECIES", 82, 85], ["dog", "SPECIES", 82, 85], ["a single transfusion of A-positive blood", "TREATMENT", 9, 49], ["antibodies", "TREATMENT", 115, 125], ["reaction", "PROBLEM", 167, 175], ["subsequent transfusion", "TREATMENT", 179, 201], ["premature destruction", "PROBLEM", 207, 228], ["transfused cells", "TREATMENT", 232, 248], ["the first transfusion", "TREATMENT", 265, 286], ["neonatal hemolytic disease", "PROBLEM", 296, 322], ["transfused bitches", "TREATMENT", 334, 352], ["hemolytic", "OBSERVATION_MODIFIER", 305, 314]]], ["If typing is not immediately available, Anegative donors can be used for all transfusions.", [["donors", "ORGANISM", 50, 56], ["typing", "TEST", 3, 9], ["Anegative donors", "TREATMENT", 40, 56], ["all transfusions", "TREATMENT", 73, 89]]], ["Testing for blood group antigen DEA-7, present in 45% of dogs, is not routinely done, but this antigen may also elicit an antibody response in DEA-7 negative dogs (Swisher and Young, 1961) .", [["blood", "ANATOMY", 12, 17], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["DEA-7", "GENE_OR_GENE_PRODUCT", 32, 37], ["dogs", "ORGANISM", 57, 61], ["DEA-7", "ORGANISM", 143, 148], ["dogs", "ORGANISM", 158, 162], ["dogs", "SPECIES", 57, 61], ["dogs", "SPECIES", 158, 162], ["Testing", "TEST", 0, 7], ["blood group antigen DEA", "TEST", 12, 35]]], ["Some DEA-7-negative dogs have naturally occurring anti-7 antibody.", [["DEA", "CHEMICAL", 5, 8], ["DEA-7", "CHEMICAL", 5, 10], ["DEA-7", "GENE_OR_GENE_PRODUCT", 5, 10], ["dogs", "ORGANISM", 20, 24], ["anti-7 antibody", "GENE_OR_GENE_PRODUCT", 50, 65], ["anti-7 antibody", "PROTEIN", 50, 65], ["dogs", "SPECIES", 20, 24], ["Some DEA", "TEST", 0, 8]]], ["Although this has generally been thought not to be of clinical significance, R. W. Bull (personal communication, 1990) has observed shortened survival of transfused DEA-7-positive cells into these dogs.", [["DEA-7-positive cells", "ANATOMY", 165, 185], ["DEA-7", "GENE_OR_GENE_PRODUCT", 165, 170], ["cells", "CELL", 180, 185], ["dogs", "ORGANISM", 197, 201], ["transfused DEA-7-positive cells", "CELL_LINE", 154, 185], ["dogs", "SPECIES", 197, 201], ["transfused DEA", "TEST", 154, 168], ["thought not to be", "UNCERTAINTY", 33, 50]]], ["The remaining antigens are either weakly reactive, or else very prevalent or rare so that donor and recipient are likely to match.A. TYPING AND CROSS MATCHINGBecause typing is not done for all known (or unknown) antigens, dogs that have received transfusions more than 4 days previously should be cross matched.", [["dogs", "ORGANISM", 222, 226], ["dogs", "SPECIES", 222, 226], ["A.", "SPECIES", 130, 132], ["weakly reactive", "PROBLEM", 34, 49], ["CROSS MATCHINGBecause typing", "TEST", 144, 172], ["transfusions", "TREATMENT", 246, 258], ["weakly", "OBSERVATION_MODIFIER", 34, 40], ["reactive", "OBSERVATION", 41, 49]]], ["A major cross match, testing donor red cells against recipient plasma, will detect clinically significant antibodies that have formed after a previous transfusion.", [["red cells", "ANATOMY", 35, 44], ["plasma", "ANATOMY", 63, 69], ["donor red cells", "CELL", 29, 44], ["plasma", "ORGANISM_SUBSTANCE", 63, 69], ["donor red cells", "CELL_TYPE", 29, 44], ["antibodies", "PROTEIN", 106, 116], ["testing donor red cells", "TEST", 21, 44], ["recipient plasma", "TEST", 53, 69], ["clinically significant antibodies", "PROBLEM", 83, 116], ["a previous transfusion", "TREATMENT", 140, 162]]], ["The cross match does not prevent sensitization; it only detects sensitization already present.", [["sensitization", "PROBLEM", 33, 46]]], ["An autocontrol with recipient red cells and plasma is included because some recipients have immune-mediated hemolysis with autoagglutination or direct antiglobulin test (DAT) positivity interfering with both typing and cross matching.", [["red cells", "ANATOMY", 30, 39], ["plasma", "ANATOMY", 44, 50], ["hemolysis", "DISEASE", 108, 117], ["red cells", "CELL", 30, 39], ["plasma", "ORGANISM_SUBSTANCE", 44, 50], ["recipients", "ORGANISM", 76, 86], ["recipient red cells", "CELL_TYPE", 20, 39], ["recipient red cells", "TREATMENT", 20, 39], ["immune-mediated hemolysis", "PROBLEM", 92, 117], ["autoagglutination", "TREATMENT", 123, 140], ["direct antiglobulin test", "TEST", 144, 168], ["DAT", "TEST", 170, 173], ["hemolysis", "OBSERVATION", 108, 117]]], ["If the control is only weakly positive and the test sample is strong, results may be valid.", [["weakly positive", "PROBLEM", 23, 38], ["the test sample", "TEST", 43, 58]]], ["If both are equal, no conclusions as to compatibility can be drawn.", [["equal", "OBSERVATION", 12, 17]]], ["A minor cross match testing donor plasma with recipient red cells is not helpful in dogs.A. TYPING AND CROSS MATCHINGFeline typing reagents are not readily available, although potentially incompatible transfusions are detectable by a major cross match.", [["plasma", "ANATOMY", 34, 40], ["red cells", "ANATOMY", 56, 65], ["plasma", "ORGANISM_SUBSTANCE", 34, 40], ["recipient red cells", "CELL", 46, 65], ["dogs", "ORGANISM", 84, 88], ["recipient red cells", "CELL_TYPE", 46, 65], ["dogs", "SPECIES", 84, 88], ["A minor cross match testing donor plasma", "TREATMENT", 0, 40], ["recipient red cells", "TREATMENT", 46, 65], ["CROSS MATCHINGFeline typing reagents", "TEST", 103, 139], ["incompatible transfusions", "TREATMENT", 188, 213]]], ["The frequency of blood groups in cats varies geographically and by breed (Auer and Bell, 1981; Bird et al., 1988; Giger, 1989 Giger, , 1990 .", [["blood", "ANATOMY", 17, 22], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["cats", "ORGANISM", 33, 37], ["cats", "SPECIES", 33, 37]]], ["Greater than 99% of cats in the United States, over 90% in Europe and Japan, and approximately 70% in Australia are blood group A. Certain breeds, especially the Persian, Devon rex, British shorthair, Himalayan, Abyssinian, Birman, Scottish fold, and Somali, have a high prevalence of group B, up to 50% in some breeds (Giger, 1990) .", [["blood", "ANATOMY", 116, 121], ["cats", "ORGANISM", 20, 24], ["blood", "ORGANISM_SUBSTANCE", 116, 121], ["cats", "SPECIES", 20, 24]]], ["The oriental breeds such as Siamese and Burmese tend to be group A. Any feline transfusion across blood groups results in rapid destruction of the transfused cells, even if the recipient has never been previously transfused.", [["blood", "ANATOMY", 98, 103], ["cells", "ANATOMY", 158, 163], ["feline", "ORGANISM", 72, 78], ["blood", "ORGANISM_SUBSTANCE", 98, 103], ["cells", "CELL", 158, 163], ["transfused cells", "CELL_TYPE", 147, 163], ["blood groups", "TEST", 98, 110], ["rapid destruction", "PROBLEM", 122, 139], ["the transfused cells", "TREATMENT", 143, 163], ["rapid", "OBSERVATION_MODIFIER", 122, 127], ["destruction", "OBSERVATION", 128, 139], ["transfused cells", "OBSERVATION", 147, 163]]], ["The most severe clinical reactions have been seen in the group B cats given group A cells.", [["A cells", "ANATOMY", 82, 89], ["B cats", "ORGANISM", 63, 69], ["A cells", "CELL", 82, 89], ["group A cells", "CELL_LINE", 76, 89], ["The most severe clinical reactions", "PROBLEM", 0, 34], ["most", "OBSERVATION_MODIFIER", 4, 8], ["severe", "OBSERVATION_MODIFIER", 9, 15]]], ["These cats have high naturally occurring titers of anti-A antibody.", [["cats", "ORGANISM", 6, 10], ["anti-A antibody", "GENE_OR_GENE_PRODUCT", 51, 66], ["anti-A antibody", "PROTEIN", 51, 66], ["cats", "SPECIES", 6, 10], ["anti-A antibody", "TREATMENT", 51, 66], ["high naturally", "OBSERVATION_MODIFIER", 16, 30], ["anti-A antibody", "OBSERVATION", 51, 66]]], ["Less severe reactions are seen if group B blood is given to a group A cat, but survival of transfused cells is short.", [["blood", "ANATOMY", 42, 47], ["cells", "ANATOMY", 102, 107], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["cat", "ORGANISM", 70, 73], ["cells", "CELL", 102, 107], ["transfused cells", "CELL_TYPE", 91, 107], ["Less severe reactions", "PROBLEM", 0, 21], ["group B blood", "TEST", 34, 47], ["a group A cat", "TREATMENT", 60, 73], ["survival of transfused cells", "TREATMENT", 79, 107], ["severe", "OBSERVATION_MODIFIER", 5, 11], ["reactions", "OBSERVATION", 12, 21]]], ["A practical approach to feline transfusions is to have group A donors available.", [["feline", "ORGANISM", 24, 30], ["donors", "ORGANISM", 63, 69], ["A practical approach to feline transfusions", "TREATMENT", 0, 43], ["group A donors", "TREATMENT", 55, 69]]], ["Typing is available at the same locations that type canine blood.", [["blood", "ANATOMY", 59, 64], ["canine", "ORGANISM", 52, 58], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["canine", "SPECIES", 52, 58], ["canine", "SPECIES", 52, 58], ["Typing", "TEST", 0, 6]]], ["When a transfusion is needed, a major cross match is done.", [["a transfusion", "TREATMENT", 5, 18], ["a major cross match", "TREATMENT", 30, 49]]], ["If the recipient is a group B cat, strong agglutination occurs even without use of Coombs reagent.", [["B cat", "ORGANISM", 28, 33], ["strong agglutination", "PROBLEM", 35, 55], ["Coombs reagent", "TREATMENT", 83, 97]]], ["If group B blood is needed, a group B donor may be identified form one of the high-prevalence breeds.", [["B blood", "ANATOMY", 9, 16], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["group B blood", "TEST", 3, 16], ["a group B donor", "TREATMENT", 28, 43]]], ["If the need is not urgent, blood may be obtained from Dr. Urs Giger at the University of Pennsylvania.A. TYPING AND CROSS MATCHINGIn horses, compatibility tests including direct agglutination, antiglobulin, and hemolytic testing were not effective in predicting survival of transfused Fe 59 -labeled cells (Kallfelz et al., 1978) .", [["blood", "ANATOMY", 27, 32], ["cells", "ANATOMY", 300, 305], ["hemolytic", "DISEASE", 211, 220], ["Fe", "CHEMICAL", 285, 287], ["Fe 59", "CHEMICAL", 285, 290], ["blood", "ORGANISM_SUBSTANCE", 27, 32], ["Fe 59", "SIMPLE_CHEMICAL", 285, 290], ["cells", "CELL", 300, 305], ["transfused Fe 59 -labeled cells", "CELL_LINE", 274, 305], ["A.", "SPECIES", 102, 104], ["compatibility tests", "TEST", 141, 160], ["direct agglutination", "TEST", 171, 191], ["antiglobulin", "TEST", 193, 205], ["hemolytic testing", "TEST", 211, 228], ["Fe", "TEST", 285, 287]]], ["Despite lack of evidence of incompatibility on testing, transfusions were only of value for periods of 2-4 days.", [["incompatibility", "PROBLEM", 28, 43], ["testing", "TEST", 47, 54], ["transfusions", "TREATMENT", 56, 68], ["incompatibility", "OBSERVATION", 28, 43]]], ["Second transfusions in the same group of six horses resulted in two severe anaphylactic reactions.", [["anaphylactic reactions", "DISEASE", 75, 97], ["horses", "ORGANISM", 45, 51], ["Second transfusions", "TREATMENT", 0, 19], ["two severe anaphylactic reactions", "PROBLEM", 64, 97], ["transfusions", "OBSERVATION", 7, 19], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["anaphylactic reactions", "OBSERVATION", 75, 97]]], ["Similar short red cell survival was noted when labeled, cross match-compatible red cells were given to normal cattle (Kallfelz and Whitlock, 1973) .", [["red cell", "ANATOMY", 14, 22], ["red cells", "ANATOMY", 79, 88], ["cell", "CELL", 18, 22], ["red cells", "CELL", 79, 88], ["cattle", "ORGANISM", 110, 116], ["red cells", "CELL_TYPE", 79, 88], ["cattle", "SPECIES", 110, 116], ["cattle", "SPECIES", 110, 116], ["Similar short red cell survival", "PROBLEM", 0, 31], ["red cells", "PROBLEM", 79, 88], ["short", "OBSERVATION_MODIFIER", 8, 13], ["cell survival", "OBSERVATION", 18, 31], ["red cells", "OBSERVATION", 79, 88]]], ["From days 3 to 4 posttransfusion, the surviving fraction dropped from 60 to 24%.", [["the surviving fraction", "TEST", 34, 56]]], ["In goats and sheep the half-life of transfused autologous red cells was 8 days (Gulliani et al., 1975; Giles et al., 1975) .", [["red cells", "ANATOMY", 58, 67], ["goats", "ORGANISM", 3, 8], ["sheep", "ORGANISM", 13, 18], ["cells", "CELL", 62, 67], ["transfused autologous red cells", "CELL_TYPE", 36, 67], ["goats", "SPECIES", 3, 8], ["sheep", "SPECIES", 13, 18], ["goats", "SPECIES", 3, 8], ["sheep", "SPECIES", 13, 18], ["transfused autologous red cells", "TREATMENT", 36, 67]]], ["When unmatched homol-ogous goat red cells were transfused, the survival times were 3-4 days with no cells remaining in the circulation by the seventh day.", [["red cells", "ANATOMY", 32, 41], ["cells", "ANATOMY", 100, 105], ["goat", "ORGANISM", 27, 31], ["red cells", "CELL", 32, 41], ["cells", "CELL", 100, 105], ["homol-ogous goat red cells", "CELL_LINE", 15, 41], ["goat", "SPECIES", 27, 31], ["goat", "SPECIES", 27, 31], ["ogous goat red cells", "TREATMENT", 21, 41], ["the survival", "TREATMENT", 59, 71], ["cells", "PROBLEM", 100, 105], ["circulation", "ANATOMY", 123, 134]]], ["The most likely explanation for poor survival of transfused red cells in horses and ruminants is the presence of naturally occurring isoantibodies and numerous blood group antigens.", [["red cells", "ANATOMY", 60, 69], ["blood", "ANATOMY", 160, 165], ["red cells", "CELL", 60, 69], ["horses", "ORGANISM_SUBDIVISION", 73, 79], ["blood", "ORGANISM_SUBSTANCE", 160, 165], ["transfused red cells", "CELL_TYPE", 49, 69], ["blood group antigens", "PROTEIN", 160, 180], ["transfused red cells", "TREATMENT", 49, 69], ["naturally occurring isoantibodies", "PROBLEM", 113, 146], ["numerous blood group antigens", "PROBLEM", 151, 180], ["most likely explanation for", "UNCERTAINTY", 4, 31], ["red cells", "OBSERVATION", 60, 69]]], ["Any transfusions in these species must be given with caution because cross matching may not predict incompatibility.", [["Any transfusions", "TREATMENT", 0, 16], ["these species", "TREATMENT", 20, 33], ["transfusions", "OBSERVATION", 4, 16]]], ["Also, because survival of cells is so poor, maximum use of alternatives to transfusions should be made.B. PRETRANSFUSION TESTINGIn most animals needing a transfusion, the cause of the blood loss or anemia is known.", [["cells", "ANATOMY", 26, 31], ["blood", "ANATOMY", 184, 189], ["blood loss", "DISEASE", 184, 194], ["anemia", "DISEASE", 198, 204], ["cells", "CELL", 26, 31], ["blood", "ORGANISM_SUBSTANCE", 184, 189], ["survival of cells", "PROBLEM", 14, 31], ["alternatives", "TREATMENT", 59, 71], ["transfusions", "TREATMENT", 75, 87], ["a transfusion", "TREATMENT", 152, 165], ["the blood loss", "PROBLEM", 180, 194], ["anemia", "PROBLEM", 198, 204], ["blood loss", "OBSERVATION", 184, 194], ["anemia", "OBSERVATION", 198, 204]]], ["In cases of anemia of unknown cause, blood should be drawn for any tests anticipated before the transfusion is given.", [["blood", "ANATOMY", 37, 42], ["anemia", "DISEASE", 12, 18], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["anemia", "PROBLEM", 12, 18], ["any tests", "TEST", 63, 72], ["the transfusion", "TREATMENT", 92, 107], ["anemia", "OBSERVATION", 12, 18]]], ["The testing should include a complete blood count (CBC) with reticulocyte count (except in horses) and a platelet count.", [["blood", "ANATOMY", 38, 43], ["reticulocyte", "ANATOMY", 61, 73], ["platelet", "ANATOMY", 105, 113], ["blood", "ORGANISM_SUBSTANCE", 38, 43], ["reticulocyte", "CELL", 61, 73], ["platelet", "CELL", 105, 113], ["The testing", "TEST", 0, 11], ["a complete blood count", "TEST", 27, 49], ["CBC", "TEST", 51, 54], ["reticulocyte count", "TEST", 61, 79], ["a platelet count", "TEST", 103, 119], ["platelet count", "OBSERVATION", 105, 119]]], ["Red cell indices and morphology can be helpful in finding the cause.", [["Red cell", "ANATOMY", 0, 8], ["Red cell", "CELL", 0, 8], ["Red cell indices", "TEST", 0, 16], ["cell indices", "OBSERVATION", 4, 16]]], ["A DAT is run if there is any suspicion of immune-mediated disease, because a positive DAT posttransfusion could be caused by development of alloantibodies.", [["posttransfusion", "DISEASE", 90, 105], ["alloantibodies", "DISEASE", 140, 154], ["DAT", "GENE_OR_GENE_PRODUCT", 86, 89], ["alloantibodies", "PROTEIN", 140, 154], ["A DAT", "TEST", 0, 5], ["immune-mediated disease", "PROBLEM", 42, 65], ["a positive DAT posttransfusion", "PROBLEM", 75, 105], ["alloantibodies", "PROBLEM", 140, 154], ["disease", "OBSERVATION", 58, 65], ["alloantibodies", "OBSERVATION", 140, 154]]], ["If iron deficiency is present in an adult animal, one should search especially diligently for a bleeding gastrointestinal lesion such as ulcer or neoplasia.", [["bleeding gastrointestinal lesion", "ANATOMY", 96, 128], ["ulcer", "ANATOMY", 137, 142], ["neoplasia", "ANATOMY", 146, 155], ["iron", "CHEMICAL", 3, 7], ["bleeding gastrointestinal lesion", "DISEASE", 96, 128], ["ulcer", "DISEASE", 137, 142], ["neoplasia", "DISEASE", 146, 155], ["iron", "CHEMICAL", 3, 7], ["iron", "SIMPLE_CHEMICAL", 3, 7], ["gastrointestinal lesion", "PATHOLOGICAL_FORMATION", 105, 128], ["ulcer", "PATHOLOGICAL_FORMATION", 137, 142], ["neoplasia", "CANCER", 146, 155], ["iron deficiency", "PROBLEM", 3, 18], ["a bleeding gastrointestinal lesion", "PROBLEM", 94, 128], ["ulcer", "PROBLEM", 137, 142], ["neoplasia", "PROBLEM", 146, 155], ["iron deficiency", "OBSERVATION", 3, 18], ["gastrointestinal", "ANATOMY", 105, 121], ["lesion", "OBSERVATION", 122, 128], ["ulcer", "OBSERVATION", 137, 142], ["neoplasia", "OBSERVATION", 146, 155]]], ["If the anemia is nonregenerative, renal function should be evaluated.", [["renal", "ANATOMY", 34, 39], ["anemia", "DISEASE", 7, 13], ["renal", "ORGAN", 34, 39], ["the anemia", "PROBLEM", 3, 13], ["nonregenerative", "PROBLEM", 17, 32], ["renal function", "TEST", 34, 48], ["anemia", "OBSERVATION", 7, 13], ["renal", "ANATOMY", 34, 39]]], ["Human recombinant erythropoietin has been shown to be an effective treatment for dogs and cats with anemia associated with renal disease (Cowgill et al., 1990) .", [["renal", "ANATOMY", 123, 128], ["anemia", "DISEASE", 100, 106], ["renal disease", "DISEASE", 123, 136], ["Human", "ORGANISM", 0, 5], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 18, 32], ["dogs", "ORGANISM", 81, 85], ["cats", "ORGANISM", 90, 94], ["renal", "ORGAN", 123, 128], ["Human recombinant erythropoietin", "PROTEIN", 0, 32], ["Human", "SPECIES", 0, 5], ["dogs", "SPECIES", 81, 85], ["cats", "SPECIES", 90, 94], ["Human", "SPECIES", 0, 5], ["Human recombinant erythropoietin", "TREATMENT", 0, 32], ["an effective treatment", "TREATMENT", 54, 76], ["dogs and cats", "TREATMENT", 81, 94], ["anemia", "PROBLEM", 100, 106], ["renal disease", "PROBLEM", 123, 136], ["renal", "ANATOMY", 123, 128], ["disease", "OBSERVATION", 129, 136]]], ["Examination of the marrow is indicated in cases of nonregenerative anemia of unknown cause.", [["marrow", "ANATOMY", 19, 25], ["anemia", "DISEASE", 67, 73], ["marrow", "ORGAN", 19, 25], ["Examination of the marrow", "TEST", 0, 25], ["nonregenerative anemia", "PROBLEM", 51, 73], ["marrow", "ANATOMY", 19, 25], ["anemia", "OBSERVATION", 67, 73]]], ["Anemia of chronic disease is associated with a mild decrease in the hematocrit (Hct), and occurs secondary to many chronic or debilitating diseases.", [["Anemia", "DISEASE", 0, 6], ["chronic disease", "DISEASE", 10, 25], ["Anemia of chronic disease", "PROBLEM", 0, 25], ["a mild decrease in the hematocrit", "PROBLEM", 45, 78], ["Hct", "TEST", 80, 83], ["many chronic or debilitating diseases", "PROBLEM", 110, 147], ["chronic", "OBSERVATION_MODIFIER", 10, 17], ["disease", "OBSERVATION", 18, 25], ["mild", "OBSERVATION_MODIFIER", 47, 51], ["decrease", "OBSERVATION_MODIFIER", 52, 60], ["hematocrit", "OBSERVATION_MODIFIER", 68, 78], ["many", "OBSERVATION_MODIFIER", 110, 114], ["chronic", "OBSERVATION_MODIFIER", 115, 122], ["debilitating", "OBSERVATION_MODIFIER", 126, 138], ["diseases", "OBSERVATION", 139, 147]]], ["If the Hct drops below 20-25%, an additional problem must be sought.", [["the Hct drops", "TEST", 3, 16]]], ["Additional information on the clinical workup of the anemic patient is provided elsewhere (Cotter, 1989) .C. ASSESSMENT OF THE NEED FOR TRANSFUSIONRed blood cells are needed whenever the red cell number becomes so depleted that oxygen-carrying capacity is insufficient to maintain adequate performance.", [["blood cells", "ANATOMY", 151, 162], ["red cell", "ANATOMY", 187, 195], ["anemic", "DISEASE", 53, 59], ["oxygen", "CHEMICAL", 228, 234], ["oxygen", "CHEMICAL", 228, 234], ["patient", "ORGANISM", 60, 67], ["TRANSFUSIONRed blood cells", "CELL", 136, 162], ["red cell", "CELL", 187, 195], ["oxygen", "SIMPLE_CHEMICAL", 228, 234], ["patient", "SPECIES", 60, 67], ["the clinical workup", "TEST", 26, 45], ["TRANSFUSIONRed blood cells", "TREATMENT", 136, 162], ["the red cell number", "PROBLEM", 183, 202], ["oxygen", "TREATMENT", 228, 234], ["carrying capacity", "PROBLEM", 235, 252]]], ["The definition of adequate may vary.", [["adequate", "OBSERVATION", 18, 26]]], ["For example, an otherwise healthy animal with mild to moderate weakness after acute blood loss may be allowed to recover spontaneously.", [["blood", "ANATOMY", 84, 89], ["weakness", "DISEASE", 63, 71], ["acute blood loss", "DISEASE", 78, 94], ["blood", "ORGANISM_SUBSTANCE", 84, 89], ["mild to moderate weakness", "PROBLEM", 46, 71], ["acute blood loss", "PROBLEM", 78, 94], ["otherwise", "OBSERVATION_MODIFIER", 16, 25], ["healthy", "OBSERVATION", 26, 33], ["mild", "OBSERVATION_MODIFIER", 46, 50], ["moderate", "OBSERVATION_MODIFIER", 54, 62], ["weakness", "OBSERVATION", 63, 71], ["acute", "OBSERVATION_MODIFIER", 78, 83], ["blood loss", "OBSERVATION", 84, 94]]], ["A severely ill patient with the same degree of anemia caused by surgical blood loss may recover more quickly with fewer complications if transfused.", [["blood", "ANATOMY", 73, 78], ["anemia", "DISEASE", 47, 53], ["blood loss", "DISEASE", 73, 83], ["patient", "ORGANISM", 15, 22], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["patient", "SPECIES", 15, 22], ["A severely ill", "PROBLEM", 0, 14], ["anemia", "PROBLEM", 47, 53], ["surgical blood loss", "PROBLEM", 64, 83], ["fewer complications", "PROBLEM", 114, 133], ["severely", "OBSERVATION_MODIFIER", 2, 10], ["ill", "OBSERVATION", 11, 14], ["anemia", "OBSERVATION", 47, 53], ["surgical blood loss", "OBSERVATION", 64, 83]]], ["One must avoid the temptation of arbitrary transfusion at a given Hct.", [["Hct", "PROTEIN", 66, 69], ["arbitrary transfusion", "TREATMENT", 33, 54], ["Hct", "TEST", 66, 69]]], ["Several factors are considered, including the cause and severity of anemia, expectation of further blood loss, alternative treatment options, and the time of onset of anemia.", [["blood", "ANATOMY", 99, 104], ["anemia", "DISEASE", 68, 74], ["blood loss", "DISEASE", 99, 109], ["anemia", "DISEASE", 167, 173], ["blood", "ORGANISM_SUBSTANCE", 99, 104], ["severity of anemia", "PROBLEM", 56, 74], ["further blood loss", "PROBLEM", 91, 109], ["alternative treatment options", "TREATMENT", 111, 140], ["anemia", "PROBLEM", 167, 173], ["anemia", "OBSERVATION", 68, 74], ["anemia", "OBSERVATION", 167, 173]]], ["Typically, anemia caused by lack of red cell production is slow in onset and compensatory mechanisms are functioning by the time the anemia is severe.", [["red cell", "ANATOMY", 36, 44], ["anemia", "DISEASE", 11, 17], ["anemia", "DISEASE", 133, 139], ["red cell", "CELL", 36, 44], ["anemia", "PROBLEM", 11, 17], ["red cell production", "PROBLEM", 36, 55], ["slow in onset", "PROBLEM", 59, 72], ["compensatory mechanisms", "PROBLEM", 77, 100], ["the anemia", "PROBLEM", 129, 139], ["anemia", "OBSERVATION", 11, 17], ["red cell production", "OBSERVATION", 36, 55], ["slow", "OBSERVATION_MODIFIER", 59, 63], ["anemia", "OBSERVATION", 133, 139], ["severe", "OBSERVATION_MODIFIER", 143, 149]]], ["These mechanisms include increased cardiac output and pulmonary ventilation, and in some species, increased red cell 2,3-diphosphoglycerate (2,3-DPG).", [["cardiac", "ANATOMY", 35, 42], ["pulmonary", "ANATOMY", 54, 63], ["red cell", "ANATOMY", 108, 116], ["increased cardiac output", "DISEASE", 25, 49], ["red cell 2,3-diphosphoglycerate", "CHEMICAL", 108, 139], ["2,3-DPG", "CHEMICAL", 141, 148], ["2,3-diphosphoglycerate", "CHEMICAL", 117, 139], ["2,3-DPG", "CHEMICAL", 141, 148], ["cardiac", "ORGAN", 35, 42], ["pulmonary", "ORGAN", 54, 63], ["red cell 2,3-diphosphoglycerate", "SIMPLE_CHEMICAL", 108, 139], ["2,3-DPG", "SIMPLE_CHEMICAL", 141, 148], ["increased cardiac output", "PROBLEM", 25, 49], ["pulmonary ventilation", "TREATMENT", 54, 75], ["some species", "PROBLEM", 84, 96], ["increased red cell", "PROBLEM", 98, 116], ["diphosphoglycerate", "TEST", 121, 139], ["increased", "OBSERVATION_MODIFIER", 25, 34], ["cardiac output", "OBSERVATION", 35, 49], ["pulmonary", "ANATOMY", 54, 63], ["ventilation", "OBSERVATION", 64, 75], ["species", "OBSERVATION_MODIFIER", 89, 96], ["increased", "OBSERVATION_MODIFIER", 98, 107], ["red cell", "OBSERVATION", 108, 116]]], ["Thus, oxygen delivery is maximized and sedentary patients may show only mild clinical signs despite a Hct of less than 10%.", [["oxygen", "CHEMICAL", 6, 12], ["oxygen", "CHEMICAL", 6, 12], ["oxygen", "SIMPLE_CHEMICAL", 6, 12], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["oxygen delivery", "TREATMENT", 6, 21], ["mild clinical signs", "PROBLEM", 72, 91], ["a Hct", "TEST", 100, 105]]], ["Conversely, the acutely anemic patient may require red cell support at a higher Hct.", [["red cell", "ANATOMY", 51, 59], ["anemic", "DISEASE", 24, 30], ["patient", "ORGANISM", 31, 38], ["red cell", "CELL", 51, 59], ["patient", "SPECIES", 31, 38], ["the acutely anemic", "PROBLEM", 12, 30], ["red cell support", "TREATMENT", 51, 67], ["a higher Hct", "TEST", 71, 83], ["anemic", "OBSERVATION", 24, 30]]], ["In fact a patient with acute hemorrhage may die with a normal Hct.", [["hemorrhage", "DISEASE", 29, 39], ["patient", "ORGANISM", 10, 17], ["patient", "SPECIES", 10, 17], ["acute hemorrhage", "PROBLEM", 23, 39], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["hemorrhage", "OBSERVATION", 29, 39]]], ["The decision to transfuse also depends upon the overall evaluation of the patient, especially cardiac, pulmonary, and renal function.", [["cardiac", "ANATOMY", 94, 101], ["pulmonary", "ANATOMY", 103, 112], ["renal", "ANATOMY", 118, 123], ["cardiac, pulmonary, and renal function", "DISEASE", 94, 132], ["patient", "ORGANISM", 74, 81], ["cardiac", "ORGAN", 94, 101], ["pulmonary", "ORGAN", 103, 112], ["renal", "ORGAN", 118, 123], ["patient", "SPECIES", 74, 81], ["the overall evaluation", "TEST", 44, 66], ["pulmonary", "ANATOMY", 103, 112], ["renal", "ANATOMY", 118, 123]]], ["The availability of alternative treatment such as iron replacement after chronic blood loss may avert the need for blood.", [["blood", "ANATOMY", 81, 86], ["blood", "ANATOMY", 115, 120], ["iron", "CHEMICAL", 50, 54], ["blood loss", "DISEASE", 81, 91], ["iron", "CHEMICAL", 50, 54], ["iron", "SIMPLE_CHEMICAL", 50, 54], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["blood", "ORGANISM_SUBSTANCE", 115, 120], ["alternative treatment", "TREATMENT", 20, 41], ["iron replacement", "TREATMENT", 50, 66], ["chronic blood loss", "PROBLEM", 73, 91], ["blood", "PROBLEM", 115, 120]]], ["Ventricular function is depressed in animals when the Hct is less than 30%, however, oxygen extraction and central venous Po 2 remain normal until the Hct reaches 20% (Messmer, 1975) .C. ASSESSMENT OF THE NEED FOR TRANSFUSIONIn a chronically anemic patient, one must consider the benefit of transfusion in raising arterial oxygen content against the risk of overloading the already hyperkinetic circulation.D. RED CELL OPTIONSRed cells may be available as fresh or stored whole blood, packed red cells (PRBCs), or less commonly, as washed red cells.", [["Ventricular", "ANATOMY", 0, 11], ["venous", "ANATOMY", 115, 121], ["arterial", "ANATOMY", 314, 322], ["cells", "ANATOMY", 430, 435], ["whole blood", "ANATOMY", 472, 483], ["red cells", "ANATOMY", 492, 501], ["PRBCs", "ANATOMY", 503, 508], ["red cells", "ANATOMY", 539, 548], ["depressed", "DISEASE", 24, 33], ["oxygen", "CHEMICAL", 85, 91], ["chronically anemic", "DISEASE", 230, 248], ["oxygen", "CHEMICAL", 323, 329], ["hyperkinetic", "DISEASE", 382, 394], ["oxygen", "CHEMICAL", 85, 91], ["oxygen", "CHEMICAL", 323, 329], ["Ventricular", "MULTI-TISSUE_STRUCTURE", 0, 11], ["Hct", "GENE_OR_GENE_PRODUCT", 54, 57], ["oxygen", "SIMPLE_CHEMICAL", 85, 91], ["patient", "ORGANISM", 249, 256], ["arterial", "MULTI-TISSUE_STRUCTURE", 314, 322], ["oxygen", "SIMPLE_CHEMICAL", 323, 329], ["CELL OPTIONSRed cells", "CELL", 414, 435], ["blood", "ORGANISM_SUBSTANCE", 478, 483], ["red cells", "CELL", 492, 501], ["PRBCs", "CELL", 503, 508], ["red cells", "CELL", 539, 548], ["RED CELL OPTIONSRed cells", "CELL_LINE", 410, 435], ["packed red cells", "CELL_TYPE", 485, 501], ["PRBCs", "CELL_TYPE", 503, 508], ["washed red cells", "CELL_TYPE", 532, 548], ["patient", "SPECIES", 249, 256], ["Ventricular function", "TEST", 0, 20], ["depressed", "PROBLEM", 24, 33], ["the Hct", "TEST", 50, 57], ["oxygen extraction", "TREATMENT", 85, 102], ["central venous Po", "TREATMENT", 107, 124], ["the Hct", "TEST", 147, 154], ["a chronically anemic", "PROBLEM", 228, 248], ["transfusion", "TREATMENT", 291, 302], ["arterial oxygen content", "TREATMENT", 314, 337], ["overloading the already hyperkinetic circulation", "PROBLEM", 358, 406], ["whole blood", "TEST", 472, 483], ["packed red cells", "TREATMENT", 485, 501], ["PRBCs", "TREATMENT", 503, 508], ["function", "OBSERVATION", 12, 20], ["depressed", "OBSERVATION_MODIFIER", 24, 33], ["central", "ANATOMY_MODIFIER", 107, 114], ["venous", "ANATOMY", 115, 121], ["normal", "OBSERVATION", 134, 140], ["overloading", "OBSERVATION", 358, 369], ["hyperkinetic circulation", "OBSERVATION", 382, 406], ["RED CELL OPTIONSRed cells", "OBSERVATION", 410, 435]]], ["Because in most anemias the need is for red cells only, PRBCs are the treatment of choice.", [["red cells", "ANATOMY", 40, 49], ["PRBCs", "ANATOMY", 56, 61], ["anemias", "DISEASE", 16, 23], ["red cells", "CELL", 40, 49], ["PRBCs", "CELL", 56, 61], ["red cells", "CELL_TYPE", 40, 49], ["PRBCs", "CELL_TYPE", 56, 61], ["most anemias", "PROBLEM", 11, 23], ["red cells", "PROBLEM", 40, 49], ["PRBCs", "TREATMENT", 56, 61]]], ["This minimizes exposure to donor histocompatibility antigens and to citrate.", [["citrate", "CHEMICAL", 68, 75], ["citrate", "CHEMICAL", 68, 75], ["citrate", "SIMPLE_CHEMICAL", 68, 75], ["donor histocompatibility antigens", "PROTEIN", 27, 60], ["donor histocompatibility antigens", "TREATMENT", 27, 60], ["citrate", "TREATMENT", 68, 75]]], ["The volume of the transfusion can be adjusted to the individual patient's needs.", [["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71], ["the transfusion", "TREATMENT", 14, 29], ["volume", "OBSERVATION_MODIFIER", 4, 10]]], ["The Hct of PRBCs is approximately 80%, so saline is usually added to facilitate administration, using small volumes in congestive heart disease and larger volumes in dehydration or hypovolemia.D. RED CELL OPTIONSFresh whole blood may be indicated in actively bleeding, anemic animals with thrombocytopenia.", [["PRBCs", "ANATOMY", 11, 16], ["heart", "ANATOMY", 130, 135], ["whole blood", "ANATOMY", 218, 229], ["congestive heart disease", "DISEASE", 119, 143], ["dehydration", "DISEASE", 166, 177], ["hypovolemia", "DISEASE", 181, 192], ["bleeding", "DISEASE", 259, 267], ["anemic", "DISEASE", 269, 275], ["thrombocytopenia", "DISEASE", 289, 305], ["saline", "SIMPLE_CHEMICAL", 42, 48], ["heart", "ORGAN", 130, 135], ["blood", "ORGANISM_SUBSTANCE", 224, 229], ["Hct", "PROTEIN", 4, 7], ["The Hct of PRBCs", "TREATMENT", 0, 16], ["saline", "TREATMENT", 42, 48], ["congestive heart disease", "PROBLEM", 119, 143], ["dehydration", "PROBLEM", 166, 177], ["hypovolemia", "PROBLEM", 181, 192], ["whole blood", "TEST", 218, 229], ["actively bleeding", "PROBLEM", 250, 267], ["anemic animals", "PROBLEM", 269, 283], ["thrombocytopenia", "PROBLEM", 289, 305], ["small", "OBSERVATION_MODIFIER", 102, 107], ["volumes", "OBSERVATION_MODIFIER", 108, 115], ["congestive heart disease", "OBSERVATION", 119, 143], ["larger", "OBSERVATION_MODIFIER", 148, 154], ["volumes", "OBSERVATION_MODIFIER", 155, 162], ["dehydration", "OBSERVATION", 166, 177], ["hypovolemia", "OBSERVATION", 181, 192], ["RED CELL OPTIONSFresh", "OBSERVATION", 196, 217], ["bleeding", "OBSERVATION", 259, 267], ["thrombocytopenia", "OBSERVATION", 289, 305]]], ["For convenience, fresh whole blood is also used in cats and small dogs less than 5-6 kg.", [["whole blood", "ANATOMY", 23, 34], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["cats", "ORGANISM", 51, 55], ["dogs", "ORGANISM", 66, 70], ["cats", "SPECIES", 51, 55], ["dogs", "SPECIES", 66, 70], ["fresh whole blood", "TREATMENT", 17, 34]]], ["In ambulatory large animal practice, blood may be drawn from one animal in a herd and given immediately to another.", [["blood", "ANATOMY", 37, 42], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["large", "OBSERVATION_MODIFIER", 14, 19]]], ["Although fresh whole blood may supply some platelets, stored whole blood does not contain viable platelets after 12-24 hours.", [["whole blood", "ANATOMY", 15, 26], ["platelets", "ANATOMY", 43, 52], ["whole blood", "ANATOMY", 61, 72], ["platelets", "ANATOMY", 97, 106], ["blood", "ORGANISM_SUBSTANCE", 21, 26], ["platelets", "CELL", 43, 52], ["blood", "ORGANISM_SUBSTANCE", 67, 72], ["platelets", "CELL", 97, 106], ["platelets", "CELL_TYPE", 43, 52], ["platelets", "CELL_TYPE", 97, 106], ["fresh whole blood", "TEST", 9, 26], ["some platelets", "PROBLEM", 38, 52], ["whole blood", "TEST", 61, 72], ["viable platelets", "PROBLEM", 90, 106]]], ["If equipment and personnel are available to make components, there is no value in storing whole blood.", [["whole blood", "ANATOMY", 90, 101], ["blood", "ORGANISM_SUBSTANCE", 96, 101], ["value in storing whole blood", "PROBLEM", 73, 101]]], ["An exception would be in the cat, for which there is a limit to the amount of blood (approximately 50 ml) that can be drawn from a donor.", [["blood", "ANATOMY", 78, 83], ["cat", "ORGANISM", 29, 32], ["blood", "ORGANISM_SUBSTANCE", 78, 83]]], ["This volume can be collected in a standard human blood bag after citrate is removed by expelling it into a satellite bag.", [["blood", "ANATOMY", 49, 54], ["citrate", "CHEMICAL", 65, 72], ["citrate", "CHEMICAL", 65, 72], ["human", "ORGANISM", 43, 48], ["blood", "ORGANISM_SUBSTANCE", 49, 54], ["citrate", "SIMPLE_CHEMICAL", 65, 72], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["This volume", "TEST", 0, 11], ["a standard human blood bag", "TREATMENT", 32, 58], ["citrate", "TREATMENT", 65, 72], ["a satellite bag", "TREATMENT", 105, 120], ["satellite bag", "OBSERVATION", 107, 120]]], ["Enough citrate is left in the collection line for 50 ml, but the volume is too small for plasma removal by standard plasma extractors.", [["plasma", "ANATOMY", 89, 95], ["plasma", "ANATOMY", 116, 122], ["citrate", "CHEMICAL", 7, 14], ["citrate", "CHEMICAL", 7, 14], ["citrate", "SIMPLE_CHEMICAL", 7, 14], ["plasma", "ORGANISM_SUBSTANCE", 89, 95], ["plasma", "ORGANISM_SUBSTANCE", 116, 122], ["Enough citrate", "TREATMENT", 0, 14], ["the volume", "TEST", 61, 71], ["plasma removal", "TREATMENT", 89, 103], ["standard plasma extractors", "TREATMENT", 107, 133], ["left", "ANATOMY_MODIFIER", 18, 22], ["collection line", "OBSERVATION", 30, 45], ["too small", "OBSERVATION_MODIFIER", 75, 84]]], ["Presently, the only way that feline PRBCs can be collected is in an open system.", [["PRBCs", "ANATOMY", 36, 41], ["feline", "ORGANISM", 29, 35], ["PRBCs", "CANCER", 36, 41], ["feline PRBCs", "TREATMENT", 29, 41]]], ["Occasionally for treatment of neonatal hemolytic disease, washed maternal red cells may be given.", [["red cells", "ANATOMY", 74, 83], ["neonatal hemolytic disease", "DISEASE", 30, 56], ["cells", "CELL", 78, 83], ["washed maternal red cells", "CELL_TYPE", 58, 83], ["treatment", "TREATMENT", 17, 26], ["neonatal hemolytic disease", "PROBLEM", 30, 56], ["washed maternal red cells", "TREATMENT", 58, 83], ["hemolytic disease", "OBSERVATION", 39, 56]]], ["Most of the antibody can be removed with the plasma, allowing for survival of the remaining neonatal red cells along with the transfused maternal cells.D. RED CELL OPTIONSProducts rarely used in animals but used in humans are leukocytepoor red cells and frozen red cells.", [["plasma", "ANATOMY", 45, 51], ["neonatal red cells", "ANATOMY", 92, 110], ["cells", "ANATOMY", 146, 151], ["leukocytepoor red cells", "ANATOMY", 226, 249], ["red cells", "ANATOMY", 261, 270], ["plasma", "ORGANISM_SUBSTANCE", 45, 51], ["cells", "CELL", 105, 110], ["cells", "CELL", 146, 151], ["humans", "ORGANISM", 215, 221], ["leukocytepoor red cells", "CELL", 226, 249], ["frozen red cells", "CELL", 254, 270], ["neonatal red cells", "CELL_TYPE", 92, 110], ["transfused maternal cells", "CELL_TYPE", 126, 151], ["leukocytepoor red cells", "CELL_TYPE", 226, 249], ["frozen red cells", "CELL_TYPE", 254, 270], ["humans", "SPECIES", 215, 221], ["humans", "SPECIES", 215, 221], ["the antibody", "TREATMENT", 8, 20], ["survival", "TREATMENT", 66, 74], ["the remaining neonatal red cells", "TREATMENT", 78, 110], ["the transfused maternal cells", "TREATMENT", 122, 151], ["RED CELL OPTIONSProducts", "TREATMENT", 155, 179], ["red cells", "PROBLEM", 240, 249], ["frozen red cells", "PROBLEM", 254, 270], ["RED CELL OPTIONSProducts", "OBSERVATION", 155, 179], ["frozen red cells", "OBSERVATION", 254, 270]]], ["Leukocytes can be removed by centrifugation, washing, and filtration techniques to minimize febrile reactions that may occur in multiply transfused patients that have developed antibodies to histocompatibility antigens on donor white cells.", [["Leukocytes", "ANATOMY", 0, 10], ["white cells", "ANATOMY", 228, 239], ["febrile", "DISEASE", 92, 99], ["Leukocytes", "CELL", 0, 10], ["patients", "ORGANISM", 148, 156], ["antibodies to histocompatibility antigens", "GENE_OR_GENE_PRODUCT", 177, 218], ["donor white cells", "CELL", 222, 239], ["Leukocytes", "CELL_TYPE", 0, 10], ["antibodies to histocompatibility antigens", "PROTEIN", 177, 218], ["donor white cells", "CELL_TYPE", 222, 239], ["patients", "SPECIES", 148, 156], ["Leukocytes", "TEST", 0, 10], ["filtration techniques", "TREATMENT", 58, 79], ["febrile reactions", "PROBLEM", 92, 109], ["antibodies to histocompatibility antigens on donor white cells", "PROBLEM", 177, 239]]], ["Freezing of red cells is practiced for long-term storage of rare types, of autologous units, and for further removal of unwanted histocompatibility antigens.", [["red cells", "ANATOMY", 12, 21], ["red cells", "CELL", 12, 21], ["unwanted histocompatibility antigens", "GENE_OR_GENE_PRODUCT", 120, 156], ["red cells", "CELL_TYPE", 12, 21], ["unwanted histocompatibility antigens", "PROTEIN", 120, 156], ["Freezing of red cells", "PROBLEM", 0, 21], ["autologous units", "TREATMENT", 75, 91], ["further removal", "TREATMENT", 101, 116], ["unwanted histocompatibility antigens", "PROBLEM", 120, 156], ["red cells", "OBSERVATION", 12, 21]]], ["The process for freezing and preserving dog red cells has been described, but is somewhat expensive and time consuming, so is not practical for routine veterinary use (Contreras et al., 1979) .", [["red cells", "ANATOMY", 44, 53], ["dog", "ORGANISM", 40, 43], ["red cells", "CELL", 44, 53], ["dog red cells", "CELL_TYPE", 40, 53], ["freezing", "PROBLEM", 16, 24], ["preserving dog red cells", "PROBLEM", 29, 53]]], ["In addition, dog red cells are more prone to hemolysis during processing than are human cells.", [["red cells", "ANATOMY", 17, 26], ["cells", "ANATOMY", 88, 93], ["hemolysis", "DISEASE", 45, 54], ["dog", "ORGANISM", 13, 16], ["red cells", "CELL", 17, 26], ["human", "ORGANISM", 82, 87], ["cells", "CELL", 88, 93], ["dog red cells", "CELL_TYPE", 13, 26], ["human cells", "CELL_TYPE", 82, 93], ["human", "SPECIES", 82, 87], ["dog", "SPECIES", 13, 16], ["human", "SPECIES", 82, 87], ["dog red cells", "PROBLEM", 13, 26], ["hemolysis", "PROBLEM", 45, 54], ["dog red cells", "OBSERVATION", 13, 26]]], ["Freezing of red cells may be used for long-term storage from rare species of valuable animals where a donor may not be available when a transfusion is needed.E. ADMINISTRATION OF PACKED RED CELLS AND WHOLE BLOODVarious formulas have been derived to estimate the Hct increment expected in the recipient after red cell transfusion.", [["red cells", "ANATOMY", 12, 21], ["red cell", "ANATOMY", 308, 316], ["red cells", "CELL", 12, 21], ["red cell", "CELL", 308, 316], ["red cells", "CELL_TYPE", 12, 21], ["Freezing of red cells", "TREATMENT", 0, 21], ["long-term storage", "TREATMENT", 38, 55], ["a donor", "TREATMENT", 100, 107], ["a transfusion", "TREATMENT", 134, 147], ["PACKED RED CELLS", "TREATMENT", 179, 195], ["WHOLE BLOODVarious formulas", "TREATMENT", 200, 227], ["the Hct increment", "PROBLEM", 258, 275], ["red cell transfusion", "TREATMENT", 308, 328], ["red cells", "OBSERVATION", 12, 21], ["red cell transfusion", "OBSERVATION", 308, 328]]], ["This is assuming that transfused cells will survive normally and that the recipient has a normal blood volume.", [["cells", "ANATOMY", 33, 38], ["blood", "ANATOMY", 97, 102], ["cells", "CELL", 33, 38], ["blood", "ORGANISM_SUBSTANCE", 97, 102], ["transfused cells", "CELL_TYPE", 22, 38], ["transfused cells", "TREATMENT", 22, 38], ["transfused cells", "OBSERVATION", 22, 38], ["normal", "OBSERVATION", 90, 96], ["blood volume", "OBSERVATION", 97, 109]]], ["For example, if whole blood is given to a dehydrated animal over a 2-to 4-hour period and the Hct measured immediately afterward and 24 hours later, one will observe an initial rise in Hct followed by a further rise after 24 hours as fluid shifts from vasculature to interstitium.", [["whole blood", "ANATOMY", 16, 27], ["fluid", "ANATOMY", 234, 239], ["vasculature", "ANATOMY", 252, 263], ["interstitium", "ANATOMY", 267, 279], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["vasculature", "MULTI-TISSUE_STRUCTURE", 252, 263], ["interstitium", "MULTI-TISSUE_STRUCTURE", 267, 279], ["Hct", "PROTEIN", 185, 188], ["whole blood", "TEST", 16, 27], ["the Hct", "TEST", 90, 97], ["Hct", "TEST", 185, 188], ["fluid shifts from vasculature to interstitium", "PROBLEM", 234, 279], ["rise", "OBSERVATION_MODIFIER", 177, 181], ["fluid shifts", "OBSERVATION", 234, 246], ["vasculature", "ANATOMY", 252, 263], ["interstitium", "ANATOMY_MODIFIER", 267, 279]]], ["A secondary drop in Hct might occur in an animal given PRBCs as fluid is drawn into the vasculature by the effects of the red cells.E. ADMINISTRATION OF PACKED RED CELLS AND WHOLE BLOODA simple rule of thumb is that a transfusion of 20 ml/kg of whole blood or 10 ml/kg of PRBCs will raise the Hct of the recipient by 10 points.", [["PRBCs", "ANATOMY", 55, 60], ["fluid", "ANATOMY", 64, 69], ["vasculature", "ANATOMY", 88, 99], ["red cells", "ANATOMY", 122, 131], ["whole blood", "ANATOMY", 245, 256], ["PRBCs", "ANATOMY", 272, 277], ["Hct", "SIMPLE_CHEMICAL", 20, 23], ["PRBCs", "CANCER", 55, 60], ["fluid", "ORGANISM_SUBSTANCE", 64, 69], ["vasculature", "ANATOMICAL_SYSTEM", 88, 99], ["red cells", "CELL", 122, 131], ["thumb", "ORGANISM_SUBDIVISION", 202, 207], ["blood", "ORGANISM_SUBSTANCE", 251, 256], ["PRBCs", "SIMPLE_CHEMICAL", 272, 277], ["Hct", "PROTEIN", 20, 23], ["PRBCs", "CELL_TYPE", 55, 60], ["red cells", "CELL_TYPE", 122, 131], ["A secondary drop in Hct", "PROBLEM", 0, 23], ["PRBCs", "TREATMENT", 55, 60], ["fluid", "PROBLEM", 64, 69], ["the red cells", "TREATMENT", 118, 131], ["PACKED RED CELLS", "TREATMENT", 153, 169], ["a transfusion", "TREATMENT", 216, 229], ["PRBCs", "TREATMENT", 272, 277], ["the Hct", "TEST", 289, 296], ["secondary", "OBSERVATION_MODIFIER", 2, 11], ["drop", "OBSERVATION_MODIFIER", 12, 16], ["vasculature", "ANATOMY", 88, 99], ["red cells", "OBSERVATION", 122, 131], ["thumb", "ANATOMY", 202, 207]]], ["For practical reasons, canine blood is drawn into human \"unit\" bags holding 450 ml of blood and stored as approximately 200-ml \"units\" of PRBCs and 250-ml \"units\" of plasma.", [["blood", "ANATOMY", 30, 35], ["blood", "ANATOMY", 86, 91], ["plasma", "ANATOMY", 166, 172], ["canine", "ORGANISM", 23, 29], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["human", "ORGANISM", 50, 55], ["blood", "ORGANISM_SUBSTANCE", 86, 91], ["PRBCs", "SIMPLE_CHEMICAL", 138, 143], ["plasma", "ORGANISM_SUBSTANCE", 166, 172], ["canine", "SPECIES", 23, 29], ["human", "SPECIES", 50, 55], ["canine", "SPECIES", 23, 29], ["human", "SPECIES", 50, 55], ["canine blood", "TEST", 23, 35], ["bags", "TREATMENT", 63, 67], ["PRBCs", "TREATMENT", 138, 143], ["plasma", "TREATMENT", 166, 172]]], ["Because of this, most transfusions, except for dogs weighing less than 20 pounds are given in unit volumes, and the Hct is raised to a clinically safe range.", [["dogs", "ORGANISM", 47, 51], ["dogs", "SPECIES", 47, 51], ["most transfusions", "TREATMENT", 17, 34], ["dogs weighing", "TREATMENT", 47, 60], ["the Hct", "TEST", 112, 119]]], ["For cats, the unit is often defined as 50 ml, because this is the maximum amount safely drawn from a 5-to 6-kg cat.E. ADMINISTRATION OF PACKED RED CELLS AND WHOLE BLOODThe intravenous route should be used for all transfusions except for those in tiny pups or kittens.", [["intravenous", "ANATOMY", 172, 183], ["cats", "ORGANISM", 4, 8], ["cat", "ORGANISM", 111, 114], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 172, 183], ["pups", "ORGANISM_SUBDIVISION", 251, 255], ["cats", "SPECIES", 4, 8], ["PACKED RED CELLS", "TREATMENT", 136, 152], ["WHOLE BLOOD", "TEST", 157, 168], ["The intravenous route", "TREATMENT", 168, 189], ["all transfusions", "TREATMENT", 209, 225]]], ["This is true even if a cutdown is required for access.", [["a cutdown", "TREATMENT", 21, 30]]], ["An indwelling catheter should be placed into the vein so the transfusion can be given slowly without the need to restrain the recipi ent.", [["vein", "ANATOMY", 49, 53], ["vein", "MULTI-TISSUE_STRUCTURE", 49, 53], ["An indwelling catheter", "TREATMENT", 0, 22], ["the transfusion", "TREATMENT", 57, 72], ["the recipi ent", "TREATMENT", 122, 136], ["indwelling", "OBSERVATION_MODIFIER", 3, 13], ["catheter", "OBSERVATION", 14, 22], ["vein", "ANATOMY", 49, 53]]], ["The needle size should be at least 20-22 gauge even in cats.", [["cats", "ORGANISM", 55, 59], ["cats", "SPECIES", 55, 59], ["The needle size", "TREATMENT", 0, 15], ["size", "OBSERVATION_MODIFIER", 11, 15]]], ["Absorption from the intraperitoneal route is slow and inconsistent, whereas intramedullary transfusion allows 95% of the cells to enter the circulation within 5 minutes (Clark and Woodley, 1959) .E. ADMINISTRATION OF PACKED RED CELLS AND WHOLE BLOODThe rate that blood is given depends upon several factors.", [["intraperitoneal", "ANATOMY", 20, 35], ["cells", "ANATOMY", 121, 126], ["blood", "ANATOMY", 263, 268], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 20, 35], ["cells", "CELL", 121, 126], ["blood", "ORGANISM_SUBSTANCE", 263, 268], ["intramedullary transfusion", "TREATMENT", 76, 102], ["PACKED RED CELLS", "TREATMENT", 217, 233], ["WHOLE BLOOD", "TEST", 238, 249], ["intraperitoneal", "ANATOMY", 20, 35]]], ["In general, the transfusion should be completed within 4 hours according to stan dards set by the American Association of Blood Banks (Widmann, 1985) to prevent growth of bacteria in the event of contamination.", [["Blood", "ANATOMY", 122, 127], ["Blood", "ORGANISM_SUBSTANCE", 122, 127], ["the transfusion", "TREATMENT", 12, 27], ["bacteria", "PROBLEM", 171, 179], ["contamination", "PROBLEM", 196, 209], ["bacteria", "OBSERVATION", 171, 179], ["contamination", "OBSERVATION", 196, 209]]], ["In cases of acute massive hemorrhage, blood may be pumped in within minutes.", [["blood", "ANATOMY", 38, 43], ["hemorrhage", "DISEASE", 26, 36], ["blood", "ORGANISM_SUBSTANCE", 38, 43], ["acute massive hemorrhage", "PROBLEM", 12, 36], ["acute", "OBSERVATION_MODIFIER", 12, 17], ["massive", "OBSERVATION_MODIFIER", 18, 25], ["hemorrhage", "OBSERVATION", 26, 36]]], ["The full 4 hours is used in cases of cardiac insufficiency, either primary or secondary to chronic anemia.E. ADMINISTRATION OF PACKED RED CELLS AND WHOLE BLOODFor routine transfusion in treatment of anemia, it is not necessary to warm the blood after taking it from the refrigerator.", [["cardiac", "ANATOMY", 37, 44], ["blood", "ANATOMY", 239, 244], ["cardiac insufficiency", "DISEASE", 37, 58], ["anemia", "DISEASE", 99, 105], ["anemia", "DISEASE", 199, 205], ["cardiac", "ORGAN", 37, 44], ["blood", "ORGANISM_SUBSTANCE", 239, 244], ["cardiac insufficiency", "PROBLEM", 37, 58], ["chronic anemia", "PROBLEM", 91, 105], ["PACKED RED CELLS", "TREATMENT", 127, 143], ["WHOLE BLOOD", "TEST", 148, 159], ["routine transfusion", "TREATMENT", 163, 182], ["treatment", "TREATMENT", 186, 195], ["anemia", "PROBLEM", 199, 205], ["cardiac", "ANATOMY", 37, 44], ["insufficiency", "OBSERVATION", 45, 58], ["chronic", "OBSERVATION_MODIFIER", 91, 98], ["anemia", "OBSERVATION", 99, 105], ["anemia", "OBSERVATION", 199, 205]]], ["An unopened bag of saline may be stored in a 37\u00b0C waterbath and used to dilute PRBCs when a transfusion is needed.", [["PRBCs", "ANATOMY", 79, 84], ["saline", "SIMPLE_CHEMICAL", 19, 25], ["PRBCs", "SIMPLE_CHEMICAL", 79, 84], ["An unopened bag of saline", "TREATMENT", 0, 25], ["a 37\u00b0C waterbath", "TREATMENT", 43, 59], ["dilute PRBCs", "TREATMENT", 72, 84], ["a transfusion", "TREATMENT", 90, 103], ["bag", "OBSERVATION", 12, 15]]], ["Warming of blood is indicated for neona tal transfusion and for administration to hypothermic patients.", [["blood", "ANATOMY", 11, 16], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["Warming of blood", "TREATMENT", 0, 16], ["neona tal transfusion", "TREATMENT", 34, 55], ["hypothermic patients", "TREATMENT", 82, 102]]], ["Hypo thermia causes vasoconstriction and also interferes with platelet func tion (Valeri et al., 1987) .", [["platelet", "ANATOMY", 62, 70], ["platelet", "CELL", 62, 70], ["Hypo thermia", "PROBLEM", 0, 12], ["vasoconstriction", "PROBLEM", 20, 36], ["platelet func tion", "TREATMENT", 62, 80], ["vasoconstriction", "OBSERVATION", 20, 36]]], ["Warming should be done only with a waterbath with a thermostat or a standard blood warmer.", [["blood", "ANATOMY", 77, 82], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["Warming", "TREATMENT", 0, 7], ["a thermostat", "TREATMENT", 50, 62], ["a standard blood warmer", "TREATMENT", 66, 89]]], ["If blood is heated to a temperature greater than 50\u00b0C, hemolysis will occur.E. ADMINISTRATION OF PACKED RED CELLS AND WHOLE BLOODA blood administration set with a 170-\u03bc\u03b9\u03b7 filter is used to prevent clots from entering the recipient.", [["blood", "ANATOMY", 3, 8], ["blood", "ANATOMY", 131, 136], ["clots", "ANATOMY", 197, 202], ["hemolysis", "DISEASE", 55, 64], ["blood", "ORGANISM_SUBSTANCE", 3, 8], ["blood", "ORGANISM_SUBSTANCE", 131, 136], ["clots", "ORGANISM_SUBSTANCE", 197, 202], ["a temperature", "TEST", 22, 35], ["hemolysis", "PROBLEM", 55, 64], ["PACKED RED CELLS", "TREATMENT", 97, 113], ["WHOLE BLOODA blood administration", "TREATMENT", 118, 151], ["a 170-\u03bc\u03b9\u03b7 filter", "TREATMENT", 161, 177], ["clots", "PROBLEM", 197, 202], ["clots", "OBSERVATION", 197, 202]]], ["The 40-\u03bc\u03b7\u03b9 microaggregate filters are not indicated for routine transfusion, and are only used in massive transfusions of stored blood where microaggregates of white cells or platelets can accumulate and contribute to pulmonary insufficiency.F. SURVIVAL OF TRANSFUSED CELLSTransfused compatible cells stored in standard citrate anticoagu lants have a normal survival when transfused.", [["blood", "ANATOMY", 129, 134], ["microaggregates", "ANATOMY", 141, 156], ["white cells", "ANATOMY", 160, 171], ["platelets", "ANATOMY", 175, 184], ["pulmonary", "ANATOMY", 218, 227], ["cells", "ANATOMY", 295, 300], ["pulmonary insufficiency", "DISEASE", 218, 241], ["citrate", "CHEMICAL", 320, 327], ["citrate", "CHEMICAL", 320, 327], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["white cells", "CELL", 160, 171], ["platelets", "CELL", 175, 184], ["pulmonary", "ORGAN", 218, 227], ["cells", "CELL", 295, 300], ["citrate anticoagu lants", "SIMPLE_CHEMICAL", 320, 343], ["white cells", "CELL_TYPE", 160, 171], ["platelets", "CELL_TYPE", 175, 184], ["The 40-\u03bc\u03b7\u03b9 microaggregate filters", "TREATMENT", 0, 33], ["routine transfusion", "TREATMENT", 56, 75], ["massive transfusions of stored blood", "TREATMENT", 98, 134], ["white cells", "PROBLEM", 160, 171], ["platelets", "PROBLEM", 175, 184], ["pulmonary insufficiency", "PROBLEM", 218, 241], ["cells", "PROBLEM", 295, 300], ["standard citrate anticoagu lants", "TREATMENT", 311, 343], ["not indicated for", "UNCERTAINTY", 38, 55], ["massive", "OBSERVATION_MODIFIER", 98, 105], ["transfusions", "OBSERVATION", 106, 118], ["pulmonary", "ANATOMY", 218, 227], ["insufficiency", "OBSERVATION", 228, 241]]], ["Autologous or homol ogous transfused cells can be labeled, with 51 Cr or other isotopes, and persistence in the circulation studied (see Smith, this volume [\"Erythrocytes\"]).", [["cells", "ANATOMY", 37, 42], ["Erythrocytes", "ANATOMY", 158, 170], ["Cr", "CHEMICAL", 67, 69], ["Cr", "CHEMICAL", 67, 69], ["cells", "CELL", 37, 42], ["Cr", "SIMPLE_CHEMICAL", 67, 69], ["homol ogous transfused cells", "CELL_LINE", 14, 42], ["Autologous or homol ogous transfused cells", "TREATMENT", 0, 42], ["Cr", "TEST", 67, 69], ["other isotopes", "PROBLEM", 73, 87], ["isotopes", "OBSERVATION", 79, 87], ["circulation", "ANATOMY", 112, 123]]], ["Compatible red cells are removed steadily over a period of time up to the normal red cell life span for each species.", [["red cells", "ANATOMY", 11, 20], ["red cell", "ANATOMY", 81, 89], ["red cells", "CELL", 11, 20], ["cell", "CELL", 85, 89], ["red cells", "CELL_TYPE", 11, 20], ["Compatible red cells", "PROBLEM", 0, 20], ["red cells", "OBSERVATION", 11, 20], ["steadily", "OBSERVATION_MODIFIER", 33, 41], ["red cell", "OBSERVATION_MODIFIER", 81, 89]]], ["This is because transfused blood contains cells of all ages.", [["blood", "ANATOMY", 27, 32], ["cells", "ANATOMY", 42, 47], ["blood", "ORGANISM_SUBSTANCE", 27, 32], ["cells", "CELL", 42, 47], ["transfused blood", "PROBLEM", 16, 32]]], ["Transfused cells survive and undergo aging changes in the same manner as nontransfused cells.", [["cells", "ANATOMY", 11, 16], ["cells", "ANATOMY", 87, 92], ["cells", "CELL", 11, 16], ["cells", "CELL", 87, 92], ["Transfused cells", "CELL_LINE", 0, 16], ["nontransfused cells", "CELL_TYPE", 73, 92], ["Transfused cells", "TREATMENT", 0, 16], ["aging", "OBSERVATION", 37, 42]]], ["As they become senescent, IgG can be detected on the cell membrane (Garratty, 1987) .", [["cell membrane", "ANATOMY", 53, 66], ["IgG", "GENE_OR_GENE_PRODUCT", 26, 29], ["cell membrane", "CELLULAR_COMPONENT", 53, 66], ["IgG", "PROTEIN", 26, 29], ["senescent", "PROBLEM", 15, 24], ["IgG", "PROBLEM", 26, 29], ["senescent", "OBSERVATION", 15, 24]]], ["The autologous antibody is directed against membrane antigens normally hidden by sialic acid on the surface of the red cell.", [["membrane", "ANATOMY", 44, 52], ["surface", "ANATOMY", 100, 107], ["red cell", "ANATOMY", 115, 123], ["sialic acid", "CHEMICAL", 81, 92], ["sialic acid", "CHEMICAL", 81, 92], ["antibody is directed against membrane antigens", "GENE_OR_GENE_PRODUCT", 15, 61], ["sialic acid", "SIMPLE_CHEMICAL", 81, 92], ["surface", "CELLULAR_COMPONENT", 100, 107], ["red cell", "CELL", 115, 123], ["autologous antibody", "PROTEIN", 4, 23], ["membrane antigens", "PROTEIN", 44, 61], ["red cell", "CELL_TYPE", 115, 123], ["The autologous antibody", "TREATMENT", 0, 23], ["membrane antigens", "PROBLEM", 44, 61], ["sialic acid", "TEST", 81, 92], ["autologous antibody", "OBSERVATION", 4, 23], ["sialic acid", "OBSERVATION", 81, 92], ["red cell", "OBSERVATION", 115, 123]]], ["Antibody-covered red cells are removed by macrophages predominantly in the spleen.", [["red cells", "ANATOMY", 17, 26], ["macrophages", "ANATOMY", 42, 53], ["spleen", "ANATOMY", 75, 81], ["red cells", "CELL", 17, 26], ["macrophages", "CELL", 42, 53], ["spleen", "ORGAN", 75, 81], ["Antibody-covered red cells", "CELL_LINE", 0, 26], ["macrophages", "CELL_TYPE", 42, 53], ["Antibody", "TEST", 0, 8], ["covered red cells", "TREATMENT", 9, 26], ["red cells", "OBSERVATION", 17, 26], ["macrophages", "OBSERVATION", 42, 53], ["spleen", "ANATOMY", 75, 81]]], ["It is uncertain whether splenectomy prolongs red cell life span in normal individuals.", [["red cell", "ANATOMY", 45, 53], ["red cell", "CELL", 45, 53], ["splenectomy prolongs", "TREATMENT", 24, 44], ["uncertain whether", "UNCERTAINTY", 6, 23], ["splenectomy", "OBSERVATION", 24, 35]]], ["Two studies, one in rabbits and one in rats, provided conflicting results (Miescher, 1956; Belcher and Harriss, 1959) .II. Transfusion in Hemorrhagic ShockTrauma with subsequent internal or external hemorrhage and anticipated or unanticipated hemorrhage in surgery are common emergencies.", [["Hemorrhagic ShockTrauma", "DISEASE", 138, 161], ["internal or external hemorrhage", "DISEASE", 178, 209], ["hemorrhage", "DISEASE", 243, 253], ["rabbits", "ORGANISM", 20, 27], ["rats", "ORGANISM", 39, 43], ["rabbits", "SPECIES", 20, 27], ["rats", "SPECIES", 39, 43], ["Two studies", "TEST", 0, 11], ["Transfusion", "TREATMENT", 123, 134], ["Hemorrhagic ShockTrauma", "PROBLEM", 138, 161], ["subsequent internal or external hemorrhage", "PROBLEM", 167, 209], ["unanticipated hemorrhage", "PROBLEM", 229, 253], ["surgery", "TREATMENT", 257, 264], ["Hemorrhagic", "OBSERVATION_MODIFIER", 138, 149], ["ShockTrauma", "OBSERVATION", 150, 161], ["internal", "OBSERVATION_MODIFIER", 178, 186], ["external", "OBSERVATION_MODIFIER", 190, 198], ["hemorrhage", "OBSERVATION", 199, 209], ["hemorrhage", "OBSERVATION", 243, 253]]], ["In many cases the amount of blood lost is unknown.", [["blood", "ANATOMY", 28, 33], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["amount", "OBSERVATION_MODIFIER", 18, 24]]], ["Animals can withstand the loss of 25-30% of their total blood volume without replacement.", [["blood", "ANATOMY", 56, 61], ["Animals", "ORGANISM", 0, 7], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["replacement", "TREATMENT", 77, 88], ["replacement", "OBSERVATION", 77, 88]]], ["Following a sudden loss of 20% of the blood volume, it takes 20-60 hours to restore lost volume through endogenous plasma replacement (Sohmer, 1979) .", [["blood", "ANATOMY", 38, 43], ["plasma", "ANATOMY", 115, 121], ["sudden loss", "DISEASE", 12, 23], ["blood", "ORGANISM_SUBSTANCE", 38, 43], ["plasma", "ORGANISM_SUBSTANCE", 115, 121], ["a sudden loss", "PROBLEM", 10, 23], ["the blood volume", "TEST", 34, 50], ["endogenous plasma replacement", "TREATMENT", 104, 133], ["plasma replacement", "OBSERVATION", 115, 133]]], ["No alterations in plasma albumin levels occur.", [["plasma", "ANATOMY", 18, 24], ["plasma", "ORGANISM_SUBSTANCE", 18, 24], ["albumin", "GENE_OR_GENE_PRODUCT", 25, 32], ["alterations", "PROBLEM", 3, 14], ["plasma albumin levels", "TEST", 18, 39], ["alterations", "OBSERVATION", 3, 14], ["albumin levels", "OBSERVATION", 25, 39]]], ["After severe hemorrhage, levels of albumin and other serum proteins are decreased.", [["serum", "ANATOMY", 53, 58], ["hemorrhage", "DISEASE", 13, 23], ["albumin", "GENE_OR_GENE_PRODUCT", 35, 42], ["serum", "ORGANISM_SUBSTANCE", 53, 58], ["albumin", "PROTEIN", 35, 42], ["serum proteins", "PROTEIN", 53, 67], ["severe hemorrhage", "PROBLEM", 6, 23], ["levels of albumin", "TEST", 25, 42], ["other serum proteins", "TEST", 47, 67], ["severe", "OBSERVATION_MODIFIER", 6, 12], ["hemorrhage", "OBSERVATION", 13, 23], ["decreased", "OBSERVATION_MODIFIER", 72, 81]]], ["Increased synthesis of albumin begins in approximately 48 hours, so initially preformed albumin moves to circulation from the interstitial space (Malt et al., 1969) .", [["interstitial space", "ANATOMY", 126, 144], ["albumin", "GENE_OR_GENE_PRODUCT", 23, 30], ["albumin", "GENE_OR_GENE_PRODUCT", 88, 95], ["albumin", "PROTEIN", 23, 30], ["albumin", "PROTEIN", 88, 95], ["Increased synthesis of albumin", "TREATMENT", 0, 30], ["albumin", "TREATMENT", 88, 95], ["albumin", "OBSERVATION_MODIFIER", 23, 30], ["interstitial space", "ANATOMY", 126, 144]]], ["Erythropoietin levels begin to rise within about 6 hours.", [["Erythropoietin", "GENE_OR_GENE_PRODUCT", 0, 14], ["Erythropoietin", "PROTEIN", 0, 14], ["Erythropoietin levels", "TEST", 0, 21], ["rise", "OBSERVATION_MODIFIER", 31, 35]]], ["The Hct falls gradually over 2-3 days after acute blood loss.", [["blood", "ANATOMY", 50, 55], ["acute blood loss", "DISEASE", 44, 60], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["The Hct falls", "PROBLEM", 0, 13], ["acute blood loss", "PROBLEM", 44, 60], ["Hct", "OBSERVATION_MODIFIER", 4, 7], ["falls", "OBSERVATION_MODIFIER", 8, 13], ["gradually", "OBSERVATION_MODIFIER", 14, 23], ["blood loss", "OBSERVATION", 50, 60]]], ["A linear fall in the Hct causes a logarithmic rise in erythropoietin levels (Adamson and Hillman, 1968) .II. Transfusion in Hemorrhagic ShockAfter internal hemorrhage, the plasma and about 50% of the red cells will reenter the circulation after several hours.", [["plasma", "ANATOMY", 172, 178], ["red cells", "ANATOMY", 200, 209], ["Hemorrhagic ShockAfter internal hemorrhage", "DISEASE", 124, 166], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 54, 68], ["plasma", "ORGANISM_SUBSTANCE", 172, 178], ["red cells", "CELL", 200, 209], ["Hct", "PROTEIN", 21, 24], ["erythropoietin", "PROTEIN", 54, 68], ["red cells", "CELL_TYPE", 200, 209], ["A linear fall", "PROBLEM", 0, 13], ["the Hct", "TEST", 17, 24], ["a logarithmic rise in erythropoietin levels", "PROBLEM", 32, 75], ["Transfusion", "TREATMENT", 109, 120], ["Hemorrhagic ShockAfter internal hemorrhage", "PROBLEM", 124, 166], ["the plasma", "TEST", 168, 178], ["the red cells", "PROBLEM", 196, 209], ["linear", "OBSERVATION_MODIFIER", 2, 8], ["fall", "OBSERVATION", 9, 13], ["logarithmic", "OBSERVATION_MODIFIER", 34, 45], ["rise", "OBSERVATION_MODIFIER", 46, 50], ["erythropoietin levels", "OBSERVATION", 54, 75], ["Hemorrhagic", "OBSERVATION_MODIFIER", 124, 135], ["internal", "OBSERVATION_MODIFIER", 147, 155], ["hemorrhage", "OBSERVATION", 156, 166], ["red cells", "OBSERVATION", 200, 209]]], ["Blood in a body cavity initially clots, and then is defibrinated, leaving most of the red cells intact.", [["Blood", "ANATOMY", 0, 5], ["body cavity", "ANATOMY", 11, 22], ["clots", "ANATOMY", 33, 38], ["red cells", "ANATOMY", 86, 95], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["body cavity", "ORGANISM_SUBDIVISION", 11, 22], ["clots", "ORGANISM_SUBSTANCE", 33, 38], ["red cells", "CELL", 86, 95], ["red cells", "CELL_TYPE", 86, 95], ["Blood in a body cavity", "PROBLEM", 0, 22], ["clots", "PROBLEM", 33, 38], ["the red cells", "TREATMENT", 82, 95], ["body cavity", "ANATOMY", 11, 22], ["clots", "OBSERVATION", 33, 38], ["red cells", "OBSERVATION", 86, 95]]], ["Defibrinated blood has been transfused, both as autotransfusion from a body cavity and historically as cadaver blood (see Cotter, this volume [\"History of Transfusion Medicine\"], and Dodds, this volume [\"Autologous Transfusion\"]).A. CLINICAL AND PHYSIOLOGICAL CHANGESClinical manifestations of hemorrhagic shock become evident in dogs when about 30% of the blood volume is lost, especially if the dog is exercised.", [["blood", "ANATOMY", 13, 18], ["body cavity", "ANATOMY", 71, 82], ["cadaver blood", "ANATOMY", 103, 116], ["blood", "ANATOMY", 357, 362], ["hemorrhagic shock", "DISEASE", 294, 311], ["blood", "ORGANISM_SUBSTANCE", 13, 18], ["body cavity", "ORGANISM_SUBDIVISION", 71, 82], ["blood", "ORGANISM_SUBSTANCE", 111, 116], ["dogs", "ORGANISM", 330, 334], ["blood", "ORGANISM_SUBSTANCE", 357, 362], ["dog", "ORGANISM", 397, 400], ["dogs", "SPECIES", 330, 334], ["autotransfusion", "TREATMENT", 48, 63], ["a body cavity", "TREATMENT", 69, 82], ["Transfusion Medicine", "TREATMENT", 155, 175], ["Autologous Transfusion\"", "TREATMENT", 204, 227], ["hemorrhagic shock", "PROBLEM", 294, 311], ["the blood volume", "TEST", 353, 369], ["hemorrhagic", "OBSERVATION_MODIFIER", 294, 305], ["shock", "OBSERVATION", 306, 311]]], ["Initial signs are tachycardia, tachypnea, weak pulses, pale mucous membranes, and hypotension.", [["mucous membranes", "ANATOMY", 60, 76], ["tachycardia", "DISEASE", 18, 29], ["tachypnea", "DISEASE", 31, 40], ["hypotension", "DISEASE", 82, 93], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 60, 76], ["tachycardia", "PROBLEM", 18, 29], ["tachypnea", "PROBLEM", 31, 40], ["weak pulses", "PROBLEM", 42, 53], ["pale mucous membranes", "PROBLEM", 55, 76], ["hypotension", "PROBLEM", 82, 93], ["tachycardia", "OBSERVATION", 18, 29], ["tachypnea", "OBSERVATION", 31, 40], ["weak", "OBSERVATION_MODIFIER", 42, 46], ["pulses", "OBSERVATION_MODIFIER", 47, 53], ["pale", "OBSERVATION_MODIFIER", 55, 59], ["mucous membranes", "OBSERVATION", 60, 76], ["hypotension", "OBSERVATION", 82, 93]]], ["Compensatory changes that oc cur are increased rate and force of cardiac contraction, and increased oxygen extraction in the tissues.", [["cardiac", "ANATOMY", 65, 72], ["tissues", "ANATOMY", 125, 132], ["oxygen", "CHEMICAL", 100, 106], ["oxygen", "CHEMICAL", 100, 106], ["cardiac", "ORGAN", 65, 72], ["oxygen", "SIMPLE_CHEMICAL", 100, 106], ["tissues", "TISSUE", 125, 132], ["Compensatory changes", "PROBLEM", 0, 20], ["cardiac contraction", "PROBLEM", 65, 84], ["increased oxygen extraction", "TREATMENT", 90, 117], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["cardiac", "ANATOMY", 65, 72], ["contraction", "OBSERVATION", 73, 84], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["oxygen extraction", "OBSERVATION", 100, 117], ["tissues", "ANATOMY", 125, 132]]], ["In dogs, sudden loss of 40% of the blood volume was fatal 50% of the time if untreated, whereas, all survived 50% blood loss if blood volume was maintained with bovine albumin (Rawson et aL, 1959; Moores et aL, 1983) .", [["blood", "ANATOMY", 35, 40], ["blood", "ANATOMY", 114, 119], ["blood", "ANATOMY", 128, 133], ["sudden loss", "DISEASE", 9, 20], ["blood loss", "DISEASE", 114, 124], ["dogs", "ORGANISM", 3, 7], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["blood", "ORGANISM_SUBSTANCE", 114, 119], ["blood", "ORGANISM_SUBSTANCE", 128, 133], ["bovine", "ORGANISM", 161, 167], ["albumin", "GENE_OR_GENE_PRODUCT", 168, 175], ["dogs", "SPECIES", 3, 7], ["bovine", "SPECIES", 161, 167], ["bovine", "SPECIES", 161, 167], ["sudden loss", "PROBLEM", 9, 20], ["the blood volume", "TEST", 31, 47], ["blood volume", "TEST", 128, 140], ["bovine albumin", "TREATMENT", 161, 175], ["sudden", "OBSERVATION_MODIFIER", 9, 15], ["loss", "OBSERVATION_MODIFIER", 16, 20]]], ["Similarly, baboons survived an exchange transfusion with hetastarch replacement to a Hct of 15% (Levine et aL, 1990) .", [["hetastarch", "CHEMICAL", 57, 67], ["baboons", "ORGANISM", 11, 18], ["hetastarch", "SIMPLE_CHEMICAL", 57, 67], ["an exchange transfusion", "TREATMENT", 28, 51], ["hetastarch replacement", "TREATMENT", 57, 79], ["a Hct", "TEST", 83, 88], ["hetastarch replacement", "OBSERVATION", 57, 79]]], ["These studies indicate that a significant percent age of blood volume can be lost so long as circulating volume is main tained.A. CLINICAL AND PHYSIOLOGICAL CHANGESWhen bleeding occurs into tissues one may underestimate actual losses.", [["blood", "ANATOMY", 57, 62], ["tissues", "ANATOMY", 190, 197], ["bleeding", "DISEASE", 169, 177], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["tissues", "TISSUE", 190, 197], ["A.", "SPECIES", 127, 129], ["These studies", "TEST", 0, 13], ["a significant percent age of blood volume", "PROBLEM", 28, 69], ["circulating volume", "TEST", 93, 111], ["CLINICAL AND PHYSIOLOGICAL CHANGESWhen bleeding", "PROBLEM", 130, 177], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["main", "OBSERVATION_MODIFIER", 115, 119]]], ["In human patients, 1.5 liters of blood are commonly lost with a closed femur fracture and 1.5-2 liters are lost with a fractured pelvis.", [["blood", "ANATOMY", 33, 38], ["femur", "ANATOMY", 71, 76], ["pelvis", "ANATOMY", 129, 135], ["fracture", "DISEASE", 77, 85], ["human", "ORGANISM", 3, 8], ["patients", "ORGANISM", 9, 17], ["blood", "ORGANISM_SUBSTANCE", 33, 38], ["femur", "ORGAN", 71, 76], ["pelvis", "ORGAN", 129, 135], ["human", "SPECIES", 3, 8], ["patients", "SPECIES", 9, 17], ["human", "SPECIES", 3, 8], ["a closed femur fracture", "PROBLEM", 62, 85], ["a fractured pelvis", "PROBLEM", 117, 135], ["closed", "OBSERVATION_MODIFIER", 64, 70], ["femur", "ANATOMY", 71, 76], ["fracture", "OBSERVATION", 77, 85], ["fractured", "OBSERVATION", 119, 128], ["pelvis", "ANATOMY", 129, 135]]], ["Large amounts of blood may also be lost in gastrointestinal hemor rhage.", [["blood", "ANATOMY", 17, 22], ["gastrointestinal hemor rhage", "ANATOMY", 43, 71], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["gastrointestinal hemor rhage", "CANCER", 43, 71], ["Large amounts of blood", "PROBLEM", 0, 22], ["amounts", "OBSERVATION_MODIFIER", 6, 13], ["blood", "OBSERVATION", 17, 22], ["may also be", "UNCERTAINTY", 23, 34], ["lost", "OBSERVATION_MODIFIER", 35, 39], ["gastrointestinal", "ANATOMY", 43, 59], ["hemor rhage", "OBSERVATION", 60, 71]]], ["Surgical blood loss may be greater than commonly expected.", [["blood", "ANATOMY", 9, 14], ["blood loss", "DISEASE", 9, 19], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["Surgical blood loss", "PROBLEM", 0, 19], ["blood loss", "OBSERVATION", 9, 19], ["may be", "UNCERTAINTY", 20, 26], ["greater", "OBSERVATION_MODIFIER", 27, 34]]], ["For example, in a series of human patients undergoing meniscectomy, the red cell volume decreased by an average of 9% in the first week after surgery (Davies and Fisher, 1958) .A. CLINICAL AND PHYSIOLOGICAL CHANGESAfter acute hemorrhage, arterial pressure is maintained longer than is cardiac output.", [["red cell", "ANATOMY", 72, 80], ["arterial", "ANATOMY", 238, 246], ["cardiac", "ANATOMY", 285, 292], ["acute hemorrhage", "DISEASE", 220, 236], ["human", "ORGANISM", 28, 33], ["patients", "ORGANISM", 34, 42], ["red cell", "CELL", 72, 80], ["arterial", "MULTI-TISSUE_STRUCTURE", 238, 246], ["cardiac", "ORGAN", 285, 292], ["human", "SPECIES", 28, 33], ["patients", "SPECIES", 34, 42], ["human", "SPECIES", 28, 33], ["meniscectomy", "TREATMENT", 54, 66], ["the red cell volume", "TEST", 68, 87], ["acute hemorrhage", "PROBLEM", 220, 236], ["arterial pressure", "TEST", 238, 255], ["cardiac output", "TEST", 285, 299], ["meniscectomy", "OBSERVATION", 54, 66], ["red cell", "OBSERVATION", 72, 80], ["volume", "OBSERVATION_MODIFIER", 81, 87], ["decreased", "OBSERVATION_MODIFIER", 88, 97], ["acute", "OBSERVATION_MODIFIER", 220, 225], ["hemorrhage", "OBSERVATION", 226, 236], ["arterial", "ANATOMY", 238, 246], ["pressure", "OBSERVATION_MODIFIER", 247, 255], ["output", "OBSERVATION_MODIFIER", 293, 299]]], ["Release of catacholamines occurs quickly, after stim ulation by baroreceptors in the aortic arch and the carotid sinus. \u03b1-Adrenergic receptors in arterioles of the skin, and receptors in splanchnic tissues respond to norepinephrine by causing vasoconstriction.", [["aortic arch", "ANATOMY", 85, 96], ["carotid sinus", "ANATOMY", 105, 118], ["arterioles", "ANATOMY", 146, 156], ["skin", "ANATOMY", 164, 168], ["splanchnic tissues", "ANATOMY", 187, 205], ["catacholamines", "CHEMICAL", 11, 25], ["norepinephrine", "CHEMICAL", 217, 231], ["catacholamines", "CHEMICAL", 11, 25], ["norepinephrine", "CHEMICAL", 217, 231], ["catacholamines", "SIMPLE_CHEMICAL", 11, 25], ["aortic arch", "MULTI-TISSUE_STRUCTURE", 85, 96], ["carotid sinus", "MULTI-TISSUE_STRUCTURE", 105, 118], ["\u03b1-Adrenergic receptors", "GENE_OR_GENE_PRODUCT", 120, 142], ["arterioles", "MULTI-TISSUE_STRUCTURE", 146, 156], ["skin", "ORGAN", 164, 168], ["splanchnic tissues", "TISSUE", 187, 205], ["norepinephrine", "SIMPLE_CHEMICAL", 217, 231], ["\u03b1-Adrenergic receptors", "PROTEIN", 120, 142], ["catacholamines", "TREATMENT", 11, 25], ["stim ulation", "TREATMENT", 48, 60], ["Adrenergic receptors", "PROBLEM", 122, 142], ["receptors in splanchnic tissues", "PROBLEM", 174, 205], ["norepinephrine", "TREATMENT", 217, 231], ["vasoconstriction", "PROBLEM", 243, 259], ["aortic arch", "ANATOMY", 85, 96], ["carotid sinus", "ANATOMY", 105, 118], ["Adrenergic receptors", "OBSERVATION", 122, 142], ["arterioles", "ANATOMY_MODIFIER", 146, 156], ["skin", "ANATOMY", 164, 168], ["splanchnic tissues", "ANATOMY", 187, 205], ["vasoconstriction", "OBSERVATION", 243, 259]]], ["Renal blood flow is maintained by reflex relaxation of afferent arterioles.", [["Renal", "ANATOMY", 0, 5], ["blood", "ANATOMY", 6, 11], ["afferent arterioles", "ANATOMY", 55, 74], ["Renal blood", "MULTI-TISSUE_STRUCTURE", 0, 11], ["afferent arterioles", "MULTI-TISSUE_STRUCTURE", 55, 74], ["Renal blood flow", "TEST", 0, 16], ["blood", "ANATOMY", 6, 11], ["flow", "OBSERVATION", 12, 16], ["reflex relaxation", "OBSERVATION", 34, 51], ["afferent arterioles", "OBSERVATION", 55, 74]]], ["Eventually, urine production decreases to maintain circu lating volume.", [["urine", "ANATOMY", 12, 17], ["urine", "ORGANISM_SUBSTANCE", 12, 17], ["urine production", "TEST", 12, 28], ["decreases", "OBSERVATION_MODIFIER", 29, 38]]], ["Prolonged hypovolemia and hypotension lead to de creased glomerular filtration and eventually to tubular necrosis.", [["glomerular", "ANATOMY", 57, 67], ["tubular", "ANATOMY", 97, 104], ["hypovolemia", "DISEASE", 10, 21], ["hypotension", "DISEASE", 26, 37], ["necrosis", "DISEASE", 105, 113], ["glomerular", "TISSUE", 57, 67], ["tubular", "TISSUE", 97, 104], ["Prolonged hypovolemia", "PROBLEM", 0, 21], ["hypotension", "PROBLEM", 26, 37], ["de creased glomerular filtration", "PROBLEM", 46, 78], ["tubular necrosis", "PROBLEM", 97, 113], ["hypovolemia", "OBSERVATION", 10, 21], ["hypotension", "OBSERVATION", 26, 37], ["glomerular filtration", "OBSERVATION", 57, 78], ["tubular", "ANATOMY_MODIFIER", 97, 104], ["necrosis", "OBSERVATION", 105, 113]]], ["At the same time most of the circulation is diverted to vital organs such as the heart, adrenal glands, and the brain, which are low in adrenergic receptors.", [["organs", "ANATOMY", 62, 68], ["heart", "ANATOMY", 81, 86], ["adrenal glands", "ANATOMY", 88, 102], ["brain", "ANATOMY", 112, 117], ["organs", "ORGAN", 62, 68], ["heart", "ORGAN", 81, 86], ["adrenal glands", "ORGAN", 88, 102], ["brain", "ORGAN", 112, 117], ["adrenergic receptors", "GENE_OR_GENE_PRODUCT", 136, 156], ["adrenergic receptors", "PROTEIN", 136, 156], ["circulation", "OBSERVATION", 29, 40], ["diverted", "OBSERVATION", 44, 52], ["heart", "ANATOMY", 81, 86], ["adrenal glands", "ANATOMY", 88, 102], ["brain", "ANATOMY", 112, 117], ["low", "OBSERVATION_MODIFIER", 129, 132], ["adrenergic receptors", "OBSERVATION", 136, 156]]], ["With acute hemorrhage, epinephrine causes a rapid increase in the number of neutrophils and platelets.", [["neutrophils", "ANATOMY", 76, 87], ["platelets", "ANATOMY", 92, 101], ["hemorrhage", "DISEASE", 11, 21], ["epinephrine", "CHEMICAL", 23, 34], ["epinephrine", "CHEMICAL", 23, 34], ["epinephrine", "SIMPLE_CHEMICAL", 23, 34], ["neutrophils", "CELL", 76, 87], ["platelets", "CELL", 92, 101], ["neutrophils", "CELL_TYPE", 76, 87], ["platelets", "CELL_TYPE", 92, 101], ["acute hemorrhage", "PROBLEM", 5, 21], ["epinephrine", "TREATMENT", 23, 34], ["a rapid increase", "PROBLEM", 42, 58], ["neutrophils", "TEST", 76, 87], ["platelets", "TEST", 92, 101], ["acute", "OBSERVATION_MODIFIER", 5, 10], ["hemorrhage", "OBSERVATION", 11, 21], ["rapid", "OBSERVATION_MODIFIER", 44, 49], ["increase", "OBSERVATION_MODIFIER", 50, 58], ["number", "OBSERVATION_MODIFIER", 66, 72]]], ["The neutrophilia occurs because of mobilization of the marginated pool.A. CLINICAL AND PHYSIOLOGICAL CHANGESIf shock is untreated, vasomotor failure ensues followed by acidosis and formation of microthrombosis from slowed blood flow.", [["blood", "ANATOMY", 222, 227], ["neutrophilia", "DISEASE", 4, 16], ["shock", "DISEASE", 111, 116], ["vasomotor failure", "DISEASE", 131, 148], ["acidosis", "DISEASE", 168, 176], ["microthrombosis", "DISEASE", 194, 209], ["blood", "ORGANISM_SUBSTANCE", 222, 227], ["The neutrophilia", "PROBLEM", 0, 16], ["the marginated pool", "PROBLEM", 51, 70], ["PHYSIOLOGICAL CHANGESIf shock", "PROBLEM", 87, 116], ["vasomotor failure", "PROBLEM", 131, 148], ["acidosis", "PROBLEM", 168, 176], ["microthrombosis", "PROBLEM", 194, 209], ["slowed blood flow", "PROBLEM", 215, 232], ["neutrophilia", "OBSERVATION", 4, 16], ["mobilization", "OBSERVATION_MODIFIER", 35, 47], ["marginated", "OBSERVATION_MODIFIER", 55, 65], ["pool", "OBSERVATION_MODIFIER", 66, 70], ["vasomotor failure", "OBSERVATION", 131, 148], ["acidosis", "OBSERVATION", 168, 176], ["microthrombosis", "OBSERVATION", 194, 209], ["slowed", "OBSERVATION_MODIFIER", 215, 221], ["blood flow", "OBSERVATION", 222, 232]]], ["Factors con tributing to decompensation are prostaglandins, endogenous opioids, and capillary obstruction by neutrophils and fibrin.", [["capillary", "ANATOMY", 84, 93], ["neutrophils", "ANATOMY", 109, 120], ["decompensation", "DISEASE", 25, 39], ["prostaglandins", "CHEMICAL", 44, 58], ["prostaglandins", "CHEMICAL", 44, 58], ["prostaglandins", "SIMPLE_CHEMICAL", 44, 58], ["capillary", "TISSUE", 84, 93], ["neutrophils", "CELL", 109, 120], ["fibrin", "GENE_OR_GENE_PRODUCT", 125, 131], ["neutrophils", "CELL_TYPE", 109, 120], ["fibrin", "PROTEIN", 125, 131], ["decompensation", "PROBLEM", 25, 39], ["prostaglandins", "TREATMENT", 44, 58], ["endogenous opioids", "TREATMENT", 60, 78], ["capillary obstruction", "PROBLEM", 84, 105], ["neutrophils", "TEST", 109, 120], ["fibrin", "PROBLEM", 125, 131], ["decompensation", "OBSERVATION", 25, 39], ["capillary", "ANATOMY", 84, 93], ["obstruction", "OBSERVATION", 94, 105], ["fibrin", "OBSERVATION", 125, 131]]], ["Capillary perme ability increases and endotoxins are released form damaged tissues.", [["Capillary perme", "ANATOMY", 0, 15], ["tissues", "ANATOMY", 75, 82], ["tissues", "TISSUE", 75, 82], ["endotoxins", "PROBLEM", 38, 48], ["increases", "OBSERVATION_MODIFIER", 24, 33], ["damaged tissues", "OBSERVATION", 67, 82]]], ["When this happens the osmotic gradient is reversed and blood volume cannot be effectively restored.", [["blood", "ANATOMY", 55, 60], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["the osmotic gradient", "TEST", 18, 38], ["blood volume", "TEST", 55, 67], ["osmotic gradient", "OBSERVATION", 22, 38]]], ["In the lung, interstitial edema interferes with alveolar elasticity and impaired oxygenation may be unresponsive to oxygen therapy.", [["lung", "ANATOMY", 7, 11], ["interstitial edema", "ANATOMY", 13, 31], ["alveolar", "ANATOMY", 48, 56], ["interstitial edema", "DISEASE", 13, 31], ["impaired oxygenation", "DISEASE", 72, 92], ["oxygen", "CHEMICAL", 116, 122], ["oxygen", "CHEMICAL", 116, 122], ["lung", "ORGAN", 7, 11], ["interstitial edema", "PATHOLOGICAL_FORMATION", 13, 31], ["alveolar", "TISSUE", 48, 56], ["oxygen", "SIMPLE_CHEMICAL", 116, 122], ["interstitial edema", "PROBLEM", 13, 31], ["alveolar elasticity", "PROBLEM", 48, 67], ["impaired oxygenation", "PROBLEM", 72, 92], ["oxygen therapy", "TREATMENT", 116, 130], ["lung", "ANATOMY", 7, 11], ["interstitial", "ANATOMY_MODIFIER", 13, 25], ["edema", "OBSERVATION", 26, 31], ["alveolar elasticity", "OBSERVATION", 48, 67], ["impaired", "OBSERVATION_MODIFIER", 72, 80], ["oxygenation", "OBSERVATION_MODIFIER", 81, 92], ["oxygen therapy", "OBSERVATION", 116, 130]]], ["Other changes that occur are centrilobular hepatic necrosis and erosions of the small intestinal mucosa from hypoxia.A. CLINICAL AND PHYSIOLOGICAL CHANGESIntestinal lesions allow further loss of fluid and protein into the lumen as well of entry of Gram-negative bacteria and endotoxins into the circulation.A. CLINICAL AND PHYSIOLOGICAL CHANGESB.", [["centrilobular hepatic", "ANATOMY", 29, 50], ["small intestinal mucosa", "ANATOMY", 80, 103], ["CHANGESIntestinal lesions", "ANATOMY", 147, 172], ["fluid", "ANATOMY", 195, 200], ["lumen", "ANATOMY", 222, 227], ["centrilobular hepatic necrosis", "DISEASE", 29, 59], ["hypoxia", "DISEASE", 109, 116], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 86, 103], ["CHANGESIntestinal lesions", "CANCER", 147, 172], ["fluid", "ORGANISM_SUBSTANCE", 195, 200], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 222, 227], ["Gram-negative bacteria", "GENE_OR_GENE_PRODUCT", 248, 270], ["A.", "SPECIES", 117, 119], ["A.", "SPECIES", 307, 309], ["Other changes", "PROBLEM", 0, 13], ["centrilobular hepatic necrosis", "PROBLEM", 29, 59], ["erosions of the small intestinal mucosa", "PROBLEM", 64, 103], ["hypoxia", "PROBLEM", 109, 116], ["CLINICAL AND PHYSIOLOGICAL CHANGESIntestinal lesions", "PROBLEM", 120, 172], ["further loss of fluid and protein into the lumen", "PROBLEM", 179, 227], ["Gram", "TEST", 248, 252], ["endotoxins into the circulation", "PROBLEM", 275, 306], ["centrilobular", "OBSERVATION_MODIFIER", 29, 42], ["hepatic", "ANATOMY", 43, 50], ["necrosis", "OBSERVATION", 51, 59], ["erosions", "OBSERVATION", 64, 72], ["small", "ANATOMY_MODIFIER", 80, 85], ["intestinal mucosa", "ANATOMY", 86, 103], ["hypoxia", "OBSERVATION", 109, 116], ["CHANGESIntestinal", "OBSERVATION_MODIFIER", 147, 164], ["lesions", "OBSERVATION", 165, 172], ["fluid", "OBSERVATION", 195, 200], ["lumen", "ANATOMY", 222, 227], ["negative bacteria", "OBSERVATION", 253, 270], ["circulation", "ANATOMY", 295, 306]]], ["FLUID SUPPORT Survival from hypovolemic shock is dependent on the restoration of oxygen transport, blood volume, and blood flow.", [["blood", "ANATOMY", 99, 104], ["blood", "ANATOMY", 117, 122], ["hypovolemic shock", "DISEASE", 28, 45], ["oxygen", "CHEMICAL", 81, 87], ["oxygen", "CHEMICAL", 81, 87], ["oxygen", "SIMPLE_CHEMICAL", 81, 87], ["blood", "ORGANISM_SUBSTANCE", 99, 104], ["blood", "ORGANISM_SUBSTANCE", 117, 122], ["FLUID SUPPORT", "TREATMENT", 0, 13], ["hypovolemic shock", "PROBLEM", 28, 45], ["oxygen transport", "TEST", 81, 97], ["blood volume", "TEST", 99, 111], ["blood flow", "TEST", 117, 127], ["hypovolemic shock", "OBSERVATION", 28, 45], ["dependent", "OBSERVATION_MODIFIER", 49, 58], ["blood", "ANATOMY", 117, 122]]], ["It has been said that the controversy over the use of crystalloids or colloids in critically ill patients has an emotional tenor that is inversely proportional to the supporting physiologic data (Shoemaker, 1982) .", [["critically ill", "DISEASE", 82, 96], ["crystalloids", "ORGANISM_SUBSTANCE", 54, 66], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["crystalloids", "TREATMENT", 54, 66], ["colloids", "TREATMENT", 70, 78]]], ["All agree that the first approach to the acutely bleeding patient is to stop bleeding and restore circulating volume.", [["bleeding", "DISEASE", 49, 57], ["bleeding", "DISEASE", 77, 85], ["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["the acutely bleeding", "PROBLEM", 37, 57], ["bleeding", "PROBLEM", 77, 85], ["circulating volume", "TEST", 98, 116], ["bleeding", "OBSERVATION", 49, 57]]], ["Most clinicians prefer crystalloid replacement at least initially.", [["crystalloid", "IMMATERIAL_ANATOMICAL_ENTITY", 23, 34], ["crystalloid replacement", "TREATMENT", 23, 46], ["crystalloid replacement", "OBSERVATION", 23, 46]]], ["Several studies of experimentally induced hemorrhagic shock have reported improved survival when crystalloids were compared to colloids (Collins et al., 1973; Gaisford et al., 1972) .", [["crystalloids", "ANATOMY", 97, 109], ["hemorrhagic shock", "DISEASE", 42, 59], ["crystalloids", "ORGANISM_SUBSTANCE", 97, 109], ["Several studies", "TEST", 0, 15], ["hemorrhagic shock", "PROBLEM", 42, 59], ["crystalloids", "TREATMENT", 97, 109], ["hemorrhagic", "OBSERVATION_MODIFIER", 42, 53], ["shock", "OBSERVATION", 54, 59], ["improved", "OBSERVATION_MODIFIER", 74, 82], ["survival", "OBSERVATION_MODIFIER", 83, 91]]], ["Although smaller volumes of colloids are required they were more likely to cause pulmonary edema because of leakage into the pulmonary tissues (Vergilio et al., 1979) .", [["pulmonary", "ANATOMY", 81, 90], ["pulmonary tissues", "ANATOMY", 125, 142], ["pulmonary edema", "DISEASE", 81, 96], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 81, 96], ["pulmonary tissues", "TISSUE", 125, 142], ["smaller volumes of colloids", "PROBLEM", 9, 36], ["pulmonary edema", "PROBLEM", 81, 96], ["leakage into the pulmonary tissues", "PROBLEM", 108, 142], ["smaller", "OBSERVATION_MODIFIER", 9, 16], ["volumes", "OBSERVATION_MODIFIER", 17, 24], ["colloids", "OBSERVATION", 28, 36], ["more likely to cause", "UNCERTAINTY", 60, 80], ["pulmonary", "ANATOMY", 81, 90], ["edema", "OBSERVATION", 91, 96], ["leakage", "OBSERVATION", 108, 115], ["pulmonary tissues", "ANATOMY", 125, 142]]], ["In a randomized human study and an experimental primate study, colloids were associated with a lower incidence of pulmonary edema (Rackow et al., 1983; Gaisford et al., 1972) .", [["pulmonary", "ANATOMY", 114, 123], ["pulmonary edema", "DISEASE", 114, 129], ["human", "ORGANISM", 16, 21], ["pulmonary", "ORGAN", 114, 123], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21], ["a randomized human study", "TEST", 3, 27], ["an experimental primate study", "TEST", 32, 61], ["colloids", "TREATMENT", 63, 71], ["pulmonary edema", "PROBLEM", 114, 129], ["lower", "OBSERVATION_MODIFIER", 95, 100], ["pulmonary", "ANATOMY", 114, 123], ["edema", "OBSERVATION", 124, 129]]], ["In two additional studies, hemodynamic and oxygen transport responses were greater and more prolonged after infusion of colloids (Nees et al., 1978; Dawidson et al., 1979) .", [["oxygen", "CHEMICAL", 43, 49], ["oxygen", "CHEMICAL", 43, 49], ["oxygen", "SIMPLE_CHEMICAL", 43, 49], ["oxygen transport responses", "TEST", 43, 69], ["infusion of colloids", "TREATMENT", 108, 128]]], ["Colloids improved hemodynamic and oxygen transport whereas crystalloids improved arterial pressure and peripheral resistance, but not flow and oxygen transport.A. CLINICAL AND PHYSIOLOGICAL CHANGESIn most clinical situations outcomes have been comparable.", [["crystalloids", "ANATOMY", 59, 71], ["arterial", "ANATOMY", 81, 89], ["oxygen", "CHEMICAL", 34, 40], ["oxygen", "CHEMICAL", 143, 149], ["oxygen", "CHEMICAL", 34, 40], ["oxygen", "CHEMICAL", 143, 149], ["Colloids", "SIMPLE_CHEMICAL", 0, 8], ["oxygen", "SIMPLE_CHEMICAL", 34, 40], ["crystalloids", "ORGANISM_SUBSTANCE", 59, 71], ["arterial", "MULTI-TISSUE_STRUCTURE", 81, 89], ["oxygen", "SIMPLE_CHEMICAL", 143, 149], ["A.", "SPECIES", 160, 162], ["Colloids", "TREATMENT", 0, 8], ["oxygen transport", "TREATMENT", 34, 50], ["crystalloids", "TREATMENT", 59, 71], ["arterial pressure", "TEST", 81, 98], ["peripheral resistance", "TEST", 103, 124], ["oxygen transport", "TREATMENT", 143, 159], ["arterial pressure", "OBSERVATION", 81, 98], ["peripheral resistance", "OBSERVATION", 103, 124], ["not", "UNCERTAINTY", 130, 133], ["flow", "OBSERVATION", 134, 138]]], ["In one randomized human study, resuscitation times were shorter and complications were fewer when approximately 25% of the fluid given was colloid, and the rest was crystalloid (Shoemaker et al., 1981) .", [["fluid", "ANATOMY", 123, 128], ["human", "ORGANISM", 18, 23], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 18, 23], ["resuscitation", "TREATMENT", 31, 44], ["colloid", "TREATMENT", 139, 146], ["crystalloid", "TREATMENT", 165, 176]]], ["It may be that in previously healthy patients, either solution is effective, but in elderly patients, or those with underlying heart failure or hepatic or renal insufficiency, it may be prudent to avoid large doses of crystalloids (Rackow et al., 1983) .A. CLINICAL AND PHYSIOLOGICAL CHANGESAlbumin is used in human patients as a source of colloid, but speciesspecific albumin is not available for animals.", [["heart", "ANATOMY", 127, 132], ["hepatic", "ANATOMY", 144, 151], ["renal", "ANATOMY", 155, 160], ["heart failure", "DISEASE", 127, 140], ["hepatic or renal insufficiency", "DISEASE", 144, 174], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 92, 100], ["heart", "ORGAN", 127, 132], ["hepatic", "ORGAN", 144, 151], ["renal", "ORGAN", 155, 160], ["human", "ORGANISM", 310, 315], ["patients", "ORGANISM", 316, 324], ["albumin", "GENE_OR_GENE_PRODUCT", 369, 376], ["speciesspecific albumin", "PROTEIN", 353, 376], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 92, 100], ["human", "SPECIES", 310, 315], ["patients", "SPECIES", 316, 324], ["human", "SPECIES", 310, 315], ["underlying heart failure", "PROBLEM", 116, 140], ["renal insufficiency", "PROBLEM", 155, 174], ["large doses of crystalloids", "TREATMENT", 203, 230], ["colloid", "TREATMENT", 340, 347], ["speciesspecific albumin", "TEST", 353, 376], ["may be", "UNCERTAINTY", 3, 9], ["heart", "ANATOMY", 127, 132], ["failure", "OBSERVATION", 133, 140], ["hepatic", "ANATOMY", 144, 151], ["renal", "ANATOMY", 155, 160], ["insufficiency", "OBSERVATION", 161, 174]]], ["Hetastarch performs as well as albumin, is less antigenic, and although expensive could be used in dogs and cats.", [["Hetastarch", "SIMPLE_CHEMICAL", 0, 10], ["albumin", "GENE_OR_GENE_PRODUCT", 31, 38], ["dogs", "ORGANISM", 99, 103], ["cats", "ORGANISM", 108, 112], ["albumin", "PROTEIN", 31, 38], ["dogs", "SPECIES", 99, 103], ["cats", "SPECIES", 108, 112], ["Hetastarch", "TREATMENT", 0, 10], ["albumin", "TREATMENT", 31, 38], ["less antigenic", "OBSERVATION_MODIFIER", 43, 57]]], ["Because crystalloids are readily available, inexpensive, and free of allergic reactions, they have remained the mainstay for initial resuscitation.A. CLINICAL AND PHYSIOLOGICAL CHANGESRecently the use of hypertonic saline (7%) has been evaluated (Rocha et al., 1987) .", [["crystalloids", "ANATOMY", 8, 20], ["allergic reactions", "DISEASE", 69, 87], ["crystalloids", "ORGANISM_SUBSTANCE", 8, 20], ["hypertonic saline", "SIMPLE_CHEMICAL", 204, 221], ["A.", "SPECIES", 147, 149], ["crystalloids", "TREATMENT", 8, 20], ["allergic reactions", "PROBLEM", 69, 87], ["initial resuscitation", "TREATMENT", 125, 146], ["hypertonic saline", "TREATMENT", 204, 221], ["allergic", "OBSERVATION", 69, 77]]], ["The advantage over isotonic crystalloids is that a small volume of hypertonic saline more quickly draws fluid from the interstitial space to restore circulating volume.", [["fluid", "ANATOMY", 104, 109], ["interstitial space", "ANATOMY", 119, 137], ["saline", "SIMPLE_CHEMICAL", 78, 84], ["The advantage over isotonic crystalloids", "TREATMENT", 0, 40], ["a small volume of hypertonic saline", "TREATMENT", 49, 84], ["circulating volume", "TEST", 149, 167], ["small", "OBSERVATION_MODIFIER", 51, 56], ["volume", "OBSERVATION_MODIFIER", 57, 63], ["hypertonic saline", "OBSERVATION", 67, 84], ["interstitial", "ANATOMY_MODIFIER", 119, 131], ["circulating volume", "OBSERVATION", 149, 167]]], ["This can then be followed with additional support if needed.A. CLINICAL AND PHYSIOLOGICAL CHANGESReplacement of a volume of crystalloids equal to the volme of blood removed does not restore blood volume.", [["blood", "ANATOMY", 159, 164], ["blood", "ANATOMY", 190, 195], ["blood", "ORGANISM_SUBSTANCE", 159, 164], ["blood", "ORGANISM_SUBSTANCE", 190, 195], ["additional support", "TREATMENT", 31, 49], ["a volume of crystalloids", "TREATMENT", 112, 136], ["blood volume", "TEST", 190, 202]]], ["For canine and feline patients, a commonly used initial dose of Ringer's lactate for the dog is 90 ml/kg over the first 1-2 hours, and 50 ml/kg for the cat.", [["lactate", "CHEMICAL", 73, 80], ["lactate", "CHEMICAL", 73, 80], ["canine", "ORGANISM", 4, 10], ["feline", "ORGANISM", 15, 21], ["patients", "ORGANISM", 22, 30], ["lactate", "SIMPLE_CHEMICAL", 73, 80], ["dog", "ORGANISM", 89, 92], ["cat", "ORGANISM", 152, 155], ["canine", "SPECIES", 4, 10], ["feline", "SPECIES", 15, 21], ["patients", "SPECIES", 22, 30], ["canine", "SPECIES", 4, 10], ["Ringer's lactate", "TREATMENT", 64, 80]]], ["This represents replacement of one blood volume (Breznock and Strack, 1982) .", [["blood", "ANATOMY", 35, 40], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["replacement", "TREATMENT", 16, 27], ["one blood volume", "TEST", 31, 47], ["replacement", "OBSERVATION", 16, 27], ["volume", "OBSERVATION_MODIFIER", 41, 47]]], ["Adequacy of treatment is determined by overall clinical appearance of the patient, heart and respiratory rates, mucous membrane color, capillary refill time, pulse quality, Hct, and urine output.", [["heart", "ANATOMY", 83, 88], ["respiratory", "ANATOMY", 93, 104], ["mucous membrane", "ANATOMY", 112, 127], ["capillary", "ANATOMY", 135, 144], ["urine", "ANATOMY", 182, 187], ["patient", "ORGANISM", 74, 81], ["heart", "ORGAN", 83, 88], ["mucous membrane", "MULTI-TISSUE_STRUCTURE", 112, 127], ["capillary", "TISSUE", 135, 144], ["urine", "ORGANISM_SUBSTANCE", 182, 187], ["patient", "SPECIES", 74, 81], ["treatment", "TREATMENT", 12, 21], ["heart and respiratory rates", "TEST", 83, 110], ["mucous membrane color", "TEST", 112, 133], ["capillary refill", "TEST", 135, 151], ["pulse quality", "TEST", 158, 171], ["Hct", "TEST", 173, 176], ["urine output", "TEST", 182, 194], ["heart", "ANATOMY", 83, 88], ["respiratory rates", "ANATOMY", 93, 110]]], ["These are sometimes supplemented by serial measurements of arterial and central venous pressure, and in specialized centers, pulmonary wedge pressure.", [["arterial", "ANATOMY", 59, 67], ["central venous", "ANATOMY", 72, 86], ["pulmonary", "ANATOMY", 125, 134], ["arterial", "MULTI-TISSUE_STRUCTURE", 59, 67], ["central venous", "MULTI-TISSUE_STRUCTURE", 72, 86], ["pulmonary wedge", "MULTI-TISSUE_STRUCTURE", 125, 140], ["serial measurements", "TEST", 36, 55], ["central venous pressure", "TEST", 72, 95], ["pulmonary wedge pressure", "TEST", 125, 149], ["arterial", "ANATOMY", 59, 67], ["central venous", "ANATOMY", 72, 86], ["pressure", "OBSERVATION_MODIFIER", 87, 95], ["pulmonary", "ANATOMY", 125, 134], ["wedge pressure", "OBSERVATION", 135, 149]]], ["An additional evaluation may be made of the ability of the circulatory system to accept a large rapid infusion of fluid without producing pulmonary edema.", [["fluid", "ANATOMY", 114, 119], ["pulmonary", "ANATOMY", 138, 147], ["pulmonary edema", "DISEASE", 138, 153], ["fluid", "ORGANISM_SUBSTANCE", 114, 119], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 138, 153], ["An additional evaluation", "TEST", 0, 24], ["a large rapid infusion of fluid", "TREATMENT", 88, 119], ["pulmonary edema", "PROBLEM", 138, 153], ["large", "OBSERVATION_MODIFIER", 90, 95], ["rapid", "OBSERVATION_MODIFIER", 96, 101], ["fluid", "OBSERVATION", 114, 119], ["pulmonary", "ANATOMY", 138, 147], ["edema", "OBSERVATION", 148, 153]]], ["This assumes that hypovolemia is associated with normal venous compliance.", [["venous", "ANATOMY", 56, 62], ["hypovolemia", "DISEASE", 18, 29], ["venous", "MULTI-TISSUE_STRUCTURE", 56, 62], ["hypovolemia", "PROBLEM", 18, 29], ["hypovolemia", "OBSERVATION", 18, 29], ["normal", "OBSERVATION", 49, 55], ["venous compliance", "OBSERVATION", 56, 73]]], ["Complete descriptions of treatment and monitoring techniques for humans, dogs, and cats are provided by Shoemaker (1982) and Hartsfield (1985) .A. CLINICAL AND PHYSIOLOGICAL CHANGESThe most valuable indicators of response are restoration of oxygen transport and tissue perfusion.", [["tissue", "ANATOMY", 262, 268], ["oxygen", "CHEMICAL", 241, 247], ["oxygen", "CHEMICAL", 241, 247], ["humans", "ORGANISM", 65, 71], ["dogs", "ORGANISM", 73, 77], ["cats", "ORGANISM", 83, 87], ["oxygen", "SIMPLE_CHEMICAL", 241, 247], ["tissue", "TISSUE", 262, 268], ["humans", "SPECIES", 65, 71], ["dogs", "SPECIES", 73, 77], ["cats", "SPECIES", 83, 87], ["humans", "SPECIES", 65, 71], ["treatment", "TREATMENT", 25, 34], ["monitoring techniques", "TEST", 39, 60], ["oxygen transport", "TREATMENT", 241, 257], ["tissue perfusion", "TEST", 262, 278], ["oxygen transport", "OBSERVATION", 241, 257], ["tissue perfusion", "OBSERVATION", 262, 278]]], ["Therapeutic goals are to raise mean arterial pressure, maintain central venous pressure below 12 cm H 2 0 to avoid pulmonary edema, and to maintain normal urine output, blood gases, and heart rate.", [["arterial", "ANATOMY", 36, 44], ["central venous", "ANATOMY", 64, 78], ["pulmonary", "ANATOMY", 115, 124], ["urine", "ANATOMY", 155, 160], ["blood", "ANATOMY", 169, 174], ["heart", "ANATOMY", 186, 191], ["pulmonary edema", "DISEASE", 115, 130], ["arterial", "MULTI-TISSUE_STRUCTURE", 36, 44], ["venous", "MULTI-TISSUE_STRUCTURE", 72, 78], ["pulmonary", "ORGAN", 115, 124], ["urine", "ORGANISM_SUBSTANCE", 155, 160], ["blood", "ORGANISM_SUBSTANCE", 169, 174], ["heart", "ORGAN", 186, 191], ["mean arterial pressure", "TEST", 31, 53], ["central venous pressure", "TEST", 64, 87], ["pulmonary edema", "PROBLEM", 115, 130], ["blood gases", "TEST", 169, 180], ["heart rate", "TEST", 186, 196], ["central", "ANATOMY_MODIFIER", 64, 71], ["venous", "ANATOMY", 72, 78], ["pulmonary", "ANATOMY", 115, 124], ["edema", "OBSERVATION", 125, 130], ["urine output", "OBSERVATION", 155, 167], ["heart", "ANATOMY", 186, 191]]], ["The Hct is monitored as fluid is replaced, but is imprecise because massive hemorrhage can cause death with a minimal drop, and overhydration can lower the Hct leading to a false sense of urgency for red cell replacement.", [["red cell", "ANATOMY", 200, 208], ["hemorrhage", "DISEASE", 76, 86], ["death", "DISEASE", 97, 102], ["overhydration", "DISEASE", 128, 141], ["Hct", "SIMPLE_CHEMICAL", 4, 7], ["fluid", "ORGANISM_SUBSTANCE", 24, 29], ["red cell", "CELL", 200, 208], ["Hct", "PROTEIN", 4, 7], ["The Hct", "TEST", 0, 7], ["massive hemorrhage", "PROBLEM", 68, 86], ["death", "PROBLEM", 97, 102], ["a minimal drop", "PROBLEM", 108, 122], ["overhydration", "PROBLEM", 128, 141], ["the Hct", "TEST", 152, 159], ["a false sense of urgency", "PROBLEM", 171, 195], ["red cell replacement", "TREATMENT", 200, 220], ["massive", "OBSERVATION_MODIFIER", 68, 75], ["hemorrhage", "OBSERVATION", 76, 86], ["minimal", "OBSERVATION_MODIFIER", 110, 117], ["drop", "OBSERVATION_MODIFIER", 118, 122], ["overhydration", "OBSERVATION", 128, 141], ["red cell replacement", "OBSERVATION", 200, 220]]], ["The decision as to whether red cells are needed is based upon a combination of known and estimated blood loss, response to initial fluid resuscitation, Hct, and total serum protein level.A. CLINICAL AND PHYSIOLOGICAL CHANGESC.", [["red cells", "ANATOMY", 27, 36], ["blood", "ANATOMY", 99, 104], ["fluid", "ANATOMY", 131, 136], ["serum", "ANATOMY", 167, 172], ["blood loss", "DISEASE", 99, 109], ["red cells", "CELL", 27, 36], ["blood", "ORGANISM_SUBSTANCE", 99, 104], ["serum", "ORGANISM_SUBSTANCE", 167, 172], ["red cells", "CELL_TYPE", 27, 36], ["red cells", "PROBLEM", 27, 36], ["estimated blood loss", "PROBLEM", 89, 109], ["initial fluid resuscitation", "TREATMENT", 123, 150], ["Hct", "TEST", 152, 155], ["total serum protein level", "TEST", 161, 186], ["blood loss", "OBSERVATION", 99, 109]]], ["BLOOD TRANSFUSION Assuming that initial attempts at resuscitation with crystalloid or colloid replacement have been unsuccessful, red cells must then be replaced.", [["red cells", "ANATOMY", 130, 139], ["red cells", "CELL", 130, 139], ["red cells", "CELL_TYPE", 130, 139], ["BLOOD TRANSFUSION", "TREATMENT", 0, 17], ["resuscitation", "TREATMENT", 52, 65], ["crystalloid", "TREATMENT", 71, 82], ["colloid replacement", "TREATMENT", 86, 105], ["red cells", "TREATMENT", 130, 139]]], ["Historically, physicians and veterinarians have relied upon fresh or stored whole blood to replace losses.", [["blood", "ANATOMY", 82, 87], ["blood", "ORGANISM_SUBSTANCE", 82, 87]]], ["On first thought it seems logical that blood loss should be replaced with whole blood, but initial blood replacement should consist of PRBCs.", [["blood", "ANATOMY", 39, 44], ["whole blood", "ANATOMY", 74, 85], ["blood", "ANATOMY", 99, 104], ["PRBCs", "ANATOMY", 135, 140], ["blood loss", "DISEASE", 39, 49], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["blood", "ORGANISM_SUBSTANCE", 99, 104], ["PRBCs", "CANCER", 135, 140], ["PRBCs", "CELL_TYPE", 135, 140], ["blood loss", "PROBLEM", 39, 49], ["whole blood", "TREATMENT", 74, 85], ["initial blood replacement", "TREATMENT", 91, 116], ["PRBCs", "TREATMENT", 135, 140]]], ["The movement of albumin from the interstitial space to capillaries will replace up to 50% of lost blood volume without the need for supplementary plasma.", [["interstitial space", "ANATOMY", 33, 51], ["capillaries", "ANATOMY", 55, 66], ["blood", "ANATOMY", 98, 103], ["plasma", "ANATOMY", 146, 152], ["albumin", "GENE_OR_GENE_PRODUCT", 16, 23], ["interstitial space", "MULTI-TISSUE_STRUCTURE", 33, 51], ["capillaries", "TISSUE", 55, 66], ["blood", "ORGANISM_SUBSTANCE", 98, 103], ["plasma", "ORGANISM_SUBSTANCE", 146, 152], ["albumin", "PROTEIN", 16, 23], ["The movement of albumin", "TEST", 0, 23], ["blood volume", "TEST", 98, 110], ["supplementary plasma", "TREATMENT", 132, 152], ["movement", "OBSERVATION_MODIFIER", 4, 12], ["interstitial", "ANATOMY_MODIFIER", 33, 45]]], ["In addition, PRBCs have less adenine, citrate, sodium, ammonia, histocompatibility antigens, and antibodies than whole blood.", [["PRBCs", "ANATOMY", 13, 18], ["whole blood", "ANATOMY", 113, 124], ["adenine", "CHEMICAL", 29, 36], ["citrate", "CHEMICAL", 38, 45], ["sodium", "CHEMICAL", 47, 53], ["ammonia", "CHEMICAL", 55, 62], ["adenine", "CHEMICAL", 29, 36], ["citrate", "CHEMICAL", 38, 45], ["sodium", "CHEMICAL", 47, 53], ["ammonia", "CHEMICAL", 55, 62], ["PRBCs", "SIMPLE_CHEMICAL", 13, 18], ["adenine", "SIMPLE_CHEMICAL", 29, 36], ["citrate", "SIMPLE_CHEMICAL", 38, 45], ["sodium", "SIMPLE_CHEMICAL", 47, 53], ["ammonia", "SIMPLE_CHEMICAL", 55, 62], ["histocompatibility antigens", "GENE_OR_GENE_PRODUCT", 64, 91], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["PRBCs", "CELL_TYPE", 13, 18], ["citrate, sodium, ammonia, histocompatibility antigens", "PROTEIN", 38, 91], ["antibodies", "PROTEIN", 97, 107], ["PRBCs", "TREATMENT", 13, 18], ["adenine", "TREATMENT", 29, 36], ["citrate", "TREATMENT", 38, 45], ["sodium, ammonia, histocompatibility antigens", "TEST", 47, 91], ["antibodies", "TEST", 97, 107], ["whole blood", "TEST", 113, 124]]], ["Packed red cells are also active in increasing plasma volume.", [["red cells", "ANATOMY", 7, 16], ["plasma", "ANATOMY", 47, 53], ["Packed red cells", "CELL", 0, 16], ["plasma", "ORGANISM_SUBSTANCE", 47, 53], ["Packed red cells", "CELL_TYPE", 0, 16], ["Packed red cells", "TREATMENT", 0, 16], ["increasing plasma volume", "PROBLEM", 36, 60], ["red cells", "OBSERVATION", 7, 16], ["active", "OBSERVATION_MODIFIER", 26, 32], ["increasing", "OBSERVATION_MODIFIER", 36, 46], ["plasma volume", "OBSERVATION", 47, 60]]], ["Blood was removed from dogs and equal-volume replacement using PRBCs was given to one group, and plasma was given to the other group.", [["Blood", "ANATOMY", 0, 5], ["plasma", "ANATOMY", 97, 103], ["PRBCs", "CHEMICAL", 63, 68], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["dogs", "ORGANISM", 23, 27], ["PRBCs", "SIMPLE_CHEMICAL", 63, 68], ["plasma", "ORGANISM_SUBSTANCE", 97, 103], ["dogs", "SPECIES", 23, 27], ["Blood", "TEST", 0, 5], ["dogs", "TREATMENT", 23, 27], ["equal-volume replacement", "TREATMENT", 32, 56], ["PRBCs", "TREATMENT", 63, 68], ["plasma", "TREATMENT", 97, 103], ["volume replacement", "OBSERVATION", 38, 56]]], ["The red cells caused movement of interstitial plasma into the circulation, resulting in an equal increase in plasma volume in both groups (Valeri et al., 1986a) .", [["red cells", "ANATOMY", 4, 13], ["interstitial plasma", "ANATOMY", 33, 52], ["plasma", "ANATOMY", 109, 115], ["red cells", "CELL", 4, 13], ["interstitial", "IMMATERIAL_ANATOMICAL_ENTITY", 33, 45], ["plasma", "ORGANISM_SUBSTANCE", 46, 52], ["plasma", "ORGANISM_SUBSTANCE", 109, 115], ["red cells", "CELL_TYPE", 4, 13], ["The red cells", "TEST", 0, 13], ["interstitial plasma into the circulation", "PROBLEM", 33, 73], ["an equal increase in plasma volume", "PROBLEM", 88, 122], ["red cells", "OBSERVATION", 4, 13], ["movement", "OBSERVATION_MODIFIER", 21, 29], ["interstitial plasma", "ANATOMY", 33, 52], ["circulation", "ANATOMY", 62, 73], ["equal", "OBSERVATION_MODIFIER", 91, 96], ["increase", "OBSERVATION_MODIFIER", 97, 105], ["plasma volume", "OBSERVATION", 109, 122]]], ["Valeri and Altschule (1976) described a \"missing blood syndrome\" in soldiers re suscitated with crystalloid, colloid, and blood products.", [["blood", "ANATOMY", 49, 54], ["blood", "ANATOMY", 122, 127], ["blood syndrome", "DISEASE", 49, 63], ["blood", "ORGANISM_SUBSTANCE", 49, 54], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["a \"missing blood syndrome", "PROBLEM", 38, 63], ["crystalloid", "TREATMENT", 96, 107], ["colloid", "TREATMENT", 109, 116], ["blood products", "TREATMENT", 122, 136]]], ["These patients had chronic hypovolemia not detectable by measurement of Hct or blood pressure.", [["blood", "ANATOMY", 79, 84], ["hypovolemia", "DISEASE", 27, 38], ["patients", "ORGANISM", 6, 14], ["Hct", "SIMPLE_CHEMICAL", 72, 75], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["patients", "SPECIES", 6, 14], ["chronic hypovolemia", "PROBLEM", 19, 38], ["Hct", "TEST", 72, 75], ["blood pressure", "TEST", 79, 93], ["chronic", "OBSERVATION_MODIFIER", 19, 26], ["hypovolemia", "OBSERVATION", 27, 38]]], ["Large volumes of transfused red cells were required to raise the plasma volume and reexpand the peripheral circulation.A. CLINICAL AND PHYSIOLOGICAL CHANGESRapid transfusion is necessary in life-threatening hemorrhagic shock.", [["red cells", "ANATOMY", 28, 37], ["plasma", "ANATOMY", 65, 71], ["hemorrhagic shock", "DISEASE", 207, 224], ["red cells", "CELL", 28, 37], ["plasma", "ORGANISM_SUBSTANCE", 65, 71], ["peripheral circulation", "MULTI-TISSUE_STRUCTURE", 96, 118], ["transfused red cells", "CELL_TYPE", 17, 37], ["A.", "SPECIES", 119, 121], ["transfused red cells", "TREATMENT", 17, 37], ["the plasma volume", "TEST", 61, 78], ["PHYSIOLOGICAL CHANGESRapid transfusion", "TREATMENT", 135, 173], ["hemorrhagic shock", "PROBLEM", 207, 224], ["volumes", "OBSERVATION_MODIFIER", 6, 13], ["transfused red cells", "OBSERVATION", 17, 37], ["peripheral", "ANATOMY_MODIFIER", 96, 106], ["circulation", "ANATOMY", 107, 118], ["hemorrhagic", "OBSERVATION_MODIFIER", 207, 218], ["shock", "OBSERVATION", 219, 224]]], ["A large-bore needle is used with positive pressure achieved by wrapping a blood pressure cuff around the bag and blowing up the cuff.", [["blood", "ANATOMY", 74, 79], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["A large-bore needle", "TREATMENT", 0, 19], ["positive pressure", "TREATMENT", 33, 50], ["a blood pressure cuff", "TREATMENT", 72, 93], ["the bag", "TREATMENT", 101, 108], ["large", "OBSERVATION_MODIFIER", 2, 7], ["-bore", "OBSERVATION_MODIFIER", 7, 12], ["needle", "OBSERVATION", 13, 19], ["positive pressure", "OBSERVATION", 33, 50], ["pressure cuff", "OBSERVATION", 80, 93], ["bag", "OBSERVATION_MODIFIER", 105, 108], ["cuff", "ANATOMY", 128, 132]]], ["Because the Hct of PRBCs is approximately 80%, saline is added to achieve a more rapid flow.", [["saline", "SIMPLE_CHEMICAL", 47, 53], ["Hct", "PROTEIN", 12, 15], ["the Hct of PRBCs", "TREATMENT", 8, 24], ["saline", "TREATMENT", 47, 53], ["rapid", "OBSERVATION_MODIFIER", 81, 86], ["flow", "OBSERVATION", 87, 91]]], ["No fluid other than saline should be mixed with blood.", [["fluid", "ANATOMY", 3, 8], ["blood", "ANATOMY", 48, 53], ["saline", "SIMPLE_CHEMICAL", 20, 26], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["fluid", "PROBLEM", 3, 8], ["saline", "TREATMENT", 20, 26], ["fluid", "OBSERVATION", 3, 8]]], ["The amount of blood to be given depends upon the amount of blood lost and patient's response.", [["blood", "ANATOMY", 14, 19], ["blood", "ANATOMY", 59, 64], ["blood", "ORGANISM_SUBSTANCE", 14, 19], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["amount", "OBSERVATION_MODIFIER", 4, 10]]], ["An initial dose of 10 ml/kg PRBCs can be given and the patient is then reassessed.", [["PRBCs", "SIMPLE_CHEMICAL", 28, 33], ["patient", "ORGANISM", 55, 62], ["patient", "SPECIES", 55, 62], ["PRBCs", "TREATMENT", 28, 33]]], ["If large volumes of fluids and PRBCs are given, one must watch for signs of volume overload such as distended or pulsating jugular veins, increased central venous pres sure, or pulmonary edema.A. CLINICAL AND PHYSIOLOGICAL CHANGESIn cases requiring massive transfusion-defined as administration of a total estimated blood volume of red cells within 24 hours-loss of clotting factors and platelets and effects of red cell storage lesions on oxygen delivery must be considered.", [["pulsating jugular veins", "ANATOMY", 113, 136], ["venous", "ANATOMY", 156, 162], ["pulmonary", "ANATOMY", 177, 186], ["blood", "ANATOMY", 316, 321], ["red cells", "ANATOMY", 332, 341], ["platelets", "ANATOMY", 387, 396], ["red cell", "ANATOMY", 412, 420], ["lesions", "ANATOMY", 429, 436], ["volume overload", "DISEASE", 76, 91], ["pulmonary edema", "DISEASE", 177, 192], ["oxygen", "CHEMICAL", 440, 446], ["oxygen", "CHEMICAL", 440, 446], ["PRBCs", "SIMPLE_CHEMICAL", 31, 36], ["jugular veins", "MULTI-TISSUE_STRUCTURE", 123, 136], ["venous", "IMMATERIAL_ANATOMICAL_ENTITY", 156, 162], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 177, 192], ["blood", "ORGANISM_SUBSTANCE", 316, 321], ["red cells", "CELL", 332, 341], ["clotting factors", "GENE_OR_GENE_PRODUCT", 366, 382], ["platelets", "CELL", 387, 396], ["cell", "CELL", 416, 420], ["lesions", "PATHOLOGICAL_FORMATION", 429, 436], ["oxygen", "SIMPLE_CHEMICAL", 440, 446], ["PRBCs", "CELL_TYPE", 31, 36], ["red cells", "CELL_TYPE", 332, 341], ["clotting factors", "PROTEIN", 366, 382], ["platelets", "CELL_TYPE", 387, 396], ["A.", "SPECIES", 193, 195], ["large volumes of fluids", "TREATMENT", 3, 26], ["PRBCs", "TREATMENT", 31, 36], ["volume overload", "PROBLEM", 76, 91], ["distended or pulsating jugular veins", "PROBLEM", 100, 136], ["increased central venous pres", "PROBLEM", 138, 167], ["pulmonary edema", "PROBLEM", 177, 192], ["massive transfusion", "TREATMENT", 249, 268], ["a total estimated blood volume of red cells", "TREATMENT", 298, 341], ["loss of clotting factors", "PROBLEM", 358, 382], ["platelets", "TREATMENT", 387, 396], ["red cell storage lesions", "PROBLEM", 412, 436], ["oxygen delivery", "TREATMENT", 440, 455], ["large", "OBSERVATION_MODIFIER", 3, 8], ["volumes", "OBSERVATION_MODIFIER", 9, 16], ["volume overload", "OBSERVATION", 76, 91], ["distended", "OBSERVATION", 100, 109], ["pulsating", "OBSERVATION", 113, 122], ["jugular veins", "ANATOMY", 123, 136], ["increased", "OBSERVATION_MODIFIER", 138, 147], ["central", "ANATOMY_MODIFIER", 148, 155], ["venous", "ANATOMY", 156, 162], ["pulmonary", "ANATOMY", 177, 186], ["edema", "OBSERVATION", 187, 192], ["red cell storage", "OBSERVATION", 412, 428]]], ["Large reserves of platelets are present in the spleen of normal individuals.", [["platelets", "ANATOMY", 18, 27], ["spleen", "ANATOMY", 47, 53], ["platelets", "CELL", 18, 27], ["spleen", "ORGAN", 47, 53], ["platelets", "CELL_TYPE", 18, 27], ["Large reserves of platelets", "PROBLEM", 0, 27], ["reserves", "OBSERVATION_MODIFIER", 6, 14], ["platelets", "OBSERVATION", 18, 27], ["spleen", "ANATOMY", 47, 53], ["normal individuals", "OBSERVATION", 57, 75]]], ["These can be released in times of increased need.", [["increased", "OBSERVATION_MODIFIER", 34, 43]]], ["It is common for platelet counts to be increased after moderate hemorrhage.", [["platelet", "ANATOMY", 17, 25], ["hemorrhage", "DISEASE", 64, 74], ["platelet", "CELL", 17, 25], ["platelet counts", "TEST", 17, 32], ["moderate hemorrhage", "PROBLEM", 55, 74], ["increased", "OBSERVATION_MODIFIER", 39, 48], ["moderate", "OBSERVATION_MODIFIER", 55, 63], ["hemorrhage", "OBSERVATION", 64, 74]]], ["In humans the platelet count generally remains over 100,000/\u03bc1 until after transfusion of 18 units of stored blood, because platelets are not present in either stored whole blood or PRBCs (Counts et al., 1979) .", [["platelet", "ANATOMY", 14, 22], ["blood", "ANATOMY", 109, 114], ["platelets", "ANATOMY", 124, 133], ["whole blood", "ANATOMY", 167, 178], ["PRBCs", "ANATOMY", 182, 187], ["humans", "ORGANISM", 3, 9], ["platelet", "CELL", 14, 22], ["blood", "ORGANISM_SUBSTANCE", 109, 114], ["platelets", "CELL", 124, 133], ["blood", "ORGANISM_SUBSTANCE", 173, 178], ["PRBCs", "CELL", 182, 187], ["platelets", "CELL_TYPE", 124, 133], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["the platelet count", "TEST", 10, 28], ["blood", "TEST", 109, 114], ["platelets", "TEST", 124, 133], ["PRBCs", "TREATMENT", 182, 187], ["platelet count", "OBSERVATION", 14, 28]]], ["Some of the drop in platelet count that occurs after large volumes of fluids or PRBCs is dilutional.", [["platelet", "ANATOMY", 20, 28], ["platelet", "CELL", 20, 28], ["the drop", "PROBLEM", 8, 16], ["platelet count", "TEST", 20, 34], ["large volumes of fluids", "TREATMENT", 53, 76], ["PRBCs", "TREATMENT", 80, 85], ["drop", "OBSERVATION_MODIFIER", 12, 16], ["platelet count", "OBSERVATION", 20, 34], ["large", "OBSERVATION_MODIFIER", 53, 58], ["volumes", "OBSERVATION_MODIFIER", 59, 66]]], ["Platelet replacement is indicated only if abnormal bleeding is occurring, not just because the count is low.", [["Platelet", "ANATOMY", 0, 8], ["abnormal bleeding", "DISEASE", 42, 59], ["Platelet", "CELL", 0, 8], ["Platelet replacement", "TREATMENT", 0, 20], ["abnormal bleeding", "PROBLEM", 42, 59], ["the count", "TEST", 91, 100], ["abnormal", "OBSERVATION_MODIFIER", 42, 50], ["bleeding", "OBSERVATION", 51, 59], ["low", "OBSERVATION_MODIFIER", 104, 107]]], ["As fluid shifts reestablish equilibrium, an increase in platelet count and serum proteins occurs.", [["fluid", "ANATOMY", 3, 8], ["platelet", "ANATOMY", 56, 64], ["serum", "ANATOMY", 75, 80], ["platelet", "CELL", 56, 64], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["serum proteins", "PROTEIN", 75, 89], ["fluid shifts reestablish equilibrium", "PROBLEM", 3, 39], ["an increase", "PROBLEM", 41, 52], ["platelet count", "TEST", 56, 70], ["serum proteins", "TEST", 75, 89], ["fluid shifts", "OBSERVATION", 3, 15], ["equilibrium", "OBSERVATION_MODIFIER", 28, 39], ["increase", "OBSERVATION_MODIFIER", 44, 52], ["platelet count", "OBSERVATION", 56, 70]]], ["Decreased platelet counts after only moderate hemorrhage and transfusion might indicate the presence of diffuse intravascular coagulation (DIC) or some other underlying disease.A. CLINICAL AND PHYSIOLOGICAL CHANGESClotting factor depletion may occur after massive transfusion with PRBCs and may require replacement either by fresh-frozen plasma (FFP) or fresh whole blood.", [["platelet", "ANATOMY", 10, 18], ["intravascular", "ANATOMY", 112, 125], ["plasma", "ANATOMY", 338, 344], ["whole blood", "ANATOMY", 360, 371], ["hemorrhage", "DISEASE", 46, 56], ["intravascular coagulation", "DISEASE", 112, 137], ["DIC", "DISEASE", 139, 142], ["platelet", "CELL", 10, 18], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 112, 125], ["plasma", "ORGANISM_SUBSTANCE", 338, 344], ["FFP", "SIMPLE_CHEMICAL", 346, 349], ["blood", "ORGANISM_SUBSTANCE", 366, 371], ["A.", "SPECIES", 177, 179], ["Decreased platelet counts", "PROBLEM", 0, 25], ["moderate hemorrhage", "PROBLEM", 37, 56], ["transfusion", "TREATMENT", 61, 72], ["diffuse intravascular coagulation", "PROBLEM", 104, 137], ["DIC)", "PROBLEM", 139, 143], ["some other underlying disease", "PROBLEM", 147, 176], ["PHYSIOLOGICAL CHANGESClotting factor depletion", "PROBLEM", 193, 239], ["massive transfusion", "TREATMENT", 256, 275], ["PRBCs", "TREATMENT", 281, 286], ["replacement", "TREATMENT", 303, 314], ["fresh-frozen plasma (FFP", "TREATMENT", 325, 349], ["fresh whole blood", "PROBLEM", 354, 371], ["platelet counts", "OBSERVATION", 10, 25], ["moderate", "OBSERVATION_MODIFIER", 37, 45], ["hemorrhage", "OBSERVATION", 46, 56], ["diffuse", "OBSERVATION_MODIFIER", 104, 111], ["intravascular coagulation", "OBSERVATION", 112, 137], ["disease", "OBSERVATION", 169, 176]]], ["There is no advantage of stored whole blood over PRBCs as treatment for acute hemorrhage.", [["whole blood", "ANATOMY", 32, 43], ["PRBCs", "ANATOMY", 49, 54], ["acute hemorrhage", "DISEASE", 72, 88], ["blood", "ORGANISM_SUBSTANCE", 38, 43], ["PRBCs", "SIMPLE_CHEMICAL", 49, 54], ["PRBCs", "TREATMENT", 49, 54], ["treatment", "TREATMENT", 58, 67], ["acute hemorrhage", "PROBLEM", 72, 88], ["no", "UNCERTAINTY", 9, 11], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["hemorrhage", "OBSERVATION", 78, 88]]], ["A patient who has received a transfusion equivalent of one blood volume will retain approximately 25-30% of his original blood elements.", [["blood", "ANATOMY", 59, 64], ["blood", "ANATOMY", 121, 126], ["patient", "ORGANISM", 2, 9], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["patient", "SPECIES", 2, 9], ["a transfusion equivalent", "TREATMENT", 27, 51], ["one blood volume", "TREATMENT", 55, 71]]], ["Even without the additional consumption of clotting factors that occurs in hemorrhage, this begins to approach a level at which coagulation becomes impaired (Sohmer and Scott, 1982) .", [["hemorrhage", "DISEASE", 75, 85], ["clotting factors", "GENE_OR_GENE_PRODUCT", 43, 59], ["clotting factors", "PROTEIN", 43, 59], ["clotting factors", "PROBLEM", 43, 59], ["hemorrhage", "PROBLEM", 75, 85], ["clotting", "OBSERVATION", 43, 51], ["hemorrhage", "OBSERVATION", 75, 85], ["impaired", "OBSERVATION", 148, 156]]], ["Patients who receive a large volume of PRBCs may develop decreased levels of clotting factors, but the likelihood of severe depletion is low if coagulation was normal before the hemorrhage.", [["PRBCs", "ANATOMY", 39, 44], ["hemorrhage", "DISEASE", 178, 188], ["Patients", "ORGANISM", 0, 8], ["PRBCs", "CANCER", 39, 44], ["clotting factors", "GENE_OR_GENE_PRODUCT", 77, 93], ["clotting factors", "PROTEIN", 77, 93], ["Patients", "SPECIES", 0, 8], ["a large volume of PRBCs", "TREATMENT", 21, 44], ["decreased levels of clotting factors", "PROBLEM", 57, 93], ["severe depletion", "PROBLEM", 117, 133], ["the hemorrhage", "PROBLEM", 174, 188], ["decreased", "OBSERVATION_MODIFIER", 57, 66], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["depletion", "OBSERVATION", 124, 133], ["hemorrhage", "OBSERVATION", 178, 188]]], ["In normal individuals, circulating levels of clotting factors are in excess of those needed, and additional extra vascular distribution of most factors is present.", [["vascular", "ANATOMY", 114, 122], ["clotting factors", "GENE_OR_GENE_PRODUCT", 45, 61], ["vascular", "MULTI-TISSUE_STRUCTURE", 114, 122], ["clotting factors", "PROTEIN", 45, 61], ["clotting factors", "PROBLEM", 45, 61], ["normal individuals", "OBSERVATION", 3, 21], ["clotting factors", "OBSERVATION", 45, 61], ["extra", "OBSERVATION_MODIFIER", 108, 113], ["vascular", "ANATOMY", 114, 122], ["distribution", "OBSERVATION_MODIFIER", 123, 135], ["most factors", "OBSERVATION", 139, 151]]], ["Except for factors V, VIII, and fibrinogen, most of the factors are roughly the size of albumin and share its 40% intravascular and 60% extravascular distribution (Counts, 1984) .", [["intravascular", "ANATOMY", 114, 127], ["extravascular", "ANATOMY", 136, 149], ["factors V", "GENE_OR_GENE_PRODUCT", 11, 20], ["VIII", "GENE_OR_GENE_PRODUCT", 22, 26], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 32, 42], ["albumin", "GENE_OR_GENE_PRODUCT", 88, 95], ["extravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 136, 149], ["V", "PROTEIN", 19, 20], ["VIII", "PROTEIN", 22, 26], ["fibrinogen", "PROTEIN", 32, 42], ["albumin", "PROTEIN", 88, 95], ["factors V", "TEST", 11, 20], ["VIII", "TEST", 22, 26], ["fibrinogen", "TEST", 32, 42], ["albumin", "TEST", 88, 95], ["fibrinogen", "OBSERVATION", 32, 42], ["size", "OBSERVATION_MODIFIER", 80, 84], ["extravascular distribution", "OBSERVATION", 136, 162]]], ["A pool of factor VIII is bound to vascular endothelium and is released with stress or \u00df-adrenergic stimulation (Wall et aL, 1980) .", [["vascular endothelium", "ANATOMY", 34, 54], ["factor VIII", "GENE_OR_GENE_PRODUCT", 10, 21], ["vascular endothelium", "TISSUE", 34, 54], ["factor VIII", "PROTEIN", 10, 21], ["factor VIII", "PROBLEM", 10, 21], ["\u00df-adrenergic stimulation", "TREATMENT", 86, 110], ["factor VIII", "OBSERVATION_MODIFIER", 10, 21], ["vascular endothelium", "ANATOMY", 34, 54]]], ["It is difficult to predict whether replacement of clotting factors will be needed after massive transfusion.", [["clotting factors", "GENE_OR_GENE_PRODUCT", 50, 66], ["clotting factors", "PROTEIN", 50, 66], ["replacement of clotting factors", "TREATMENT", 35, 66], ["massive transfusion", "TREATMENT", 88, 107]]], ["Monitoring of prothrombin time (PT) and activated partial thromboplastin time (APTT) or at least activated clotting time (ACT) is useful to determine need for, and efficacy of, replacement.A. CLINICAL AND PHYSIOLOGICAL CHANGESThe transfusion of large volumes of cold blood extracts energy from the patient for heat production.", [["blood", "ANATOMY", 267, 272], ["prothrombin", "GENE_OR_GENE_PRODUCT", 14, 25], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 58, 72], ["blood", "ORGANISM_SUBSTANCE", 267, 272], ["extracts", "ORGANISM_SUBSTANCE", 273, 281], ["patient", "ORGANISM", 298, 305], ["patient", "SPECIES", 298, 305], ["A.", "SPECIES", 189, 191], ["prothrombin time", "TEST", 14, 30], ["PT", "TEST", 32, 34], ["activated partial thromboplastin time", "TREATMENT", 40, 77], ["APTT", "TEST", 79, 83], ["replacement", "TREATMENT", 177, 188], ["cold blood extracts energy", "PROBLEM", 262, 288], ["heat production", "PROBLEM", 310, 325], ["replacement", "OBSERVATION", 177, 188], ["large", "OBSERVATION_MODIFIER", 245, 250], ["volumes", "OBSERVATION_MODIFIER", 251, 258]]], ["Hypothermia also interferes with platelet function by inhibiting thromboxane B 2 production, decreases oxygen release in tissues, and interferes with metabolism of citrate (Valeri et aL, 1987) .", [["platelet", "ANATOMY", 33, 41], ["tissues", "ANATOMY", 121, 128], ["Hypothermia", "DISEASE", 0, 11], ["thromboxane B", "CHEMICAL", 65, 78], ["oxygen", "CHEMICAL", 103, 109], ["citrate", "CHEMICAL", 164, 171], ["thromboxane B 2", "CHEMICAL", 65, 80], ["oxygen", "CHEMICAL", 103, 109], ["citrate", "CHEMICAL", 164, 171], ["platelet", "CELL", 33, 41], ["thromboxane B 2", "GENE_OR_GENE_PRODUCT", 65, 80], ["oxygen", "SIMPLE_CHEMICAL", 103, 109], ["tissues", "TISSUE", 121, 128], ["citrate", "SIMPLE_CHEMICAL", 164, 171], ["Hypothermia", "PROBLEM", 0, 11], ["platelet function", "TEST", 33, 50], ["thromboxane B 2 production", "TREATMENT", 65, 91], ["oxygen release in tissues", "PROBLEM", 103, 128], ["metabolism of citrate", "TREATMENT", 150, 171], ["platelet function", "OBSERVATION", 33, 50]]], ["A reduction in bleeding time correlated well with warming of the patient, indicating that the platelet function defect is reversible.", [["platelet", "ANATOMY", 94, 102], ["bleeding", "DISEASE", 15, 23], ["patient", "ORGANISM", 65, 72], ["platelet", "CELL", 94, 102], ["patient", "SPECIES", 65, 72], ["A reduction in bleeding", "PROBLEM", 0, 23], ["warming", "TREATMENT", 50, 57], ["the platelet function defect", "PROBLEM", 90, 118], ["reduction", "OBSERVATION_MODIFIER", 2, 11], ["bleeding", "OBSERVATION", 15, 23], ["platelet", "OBSERVATION", 94, 102], ["function defect", "OBSERVATION", 103, 118], ["reversible", "OBSERVATION_MODIFIER", 122, 132]]], ["In situations of massive transfusions with stored PRBCs or whole blood, storage lesions such as decreased pH, 2,3-DPG, and ATP may interfere with oxygen delivery and red cell survival.", [["PRBCs", "ANATOMY", 50, 55], ["whole blood", "ANATOMY", 59, 70], ["lesions", "ANATOMY", 80, 87], ["red cell", "ANATOMY", 166, 174], ["2,3-DPG", "CHEMICAL", 110, 117], ["ATP", "CHEMICAL", 123, 126], ["oxygen", "CHEMICAL", 146, 152], ["2,3-DPG", "CHEMICAL", 110, 117], ["ATP", "CHEMICAL", 123, 126], ["oxygen", "CHEMICAL", 146, 152], ["PRBCs", "SIMPLE_CHEMICAL", 50, 55], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["lesions", "PATHOLOGICAL_FORMATION", 80, 87], ["2,3-DPG", "SIMPLE_CHEMICAL", 110, 117], ["ATP", "SIMPLE_CHEMICAL", 123, 126], ["oxygen", "SIMPLE_CHEMICAL", 146, 152], ["cell", "CELL", 170, 174], ["PRBCs", "CELL_TYPE", 50, 55], ["massive transfusions", "TREATMENT", 17, 37], ["stored PRBCs", "TREATMENT", 43, 55], ["whole blood", "PROBLEM", 59, 70], ["storage lesions", "PROBLEM", 72, 87], ["decreased pH", "PROBLEM", 96, 108], ["DPG", "TREATMENT", 114, 117], ["ATP", "TREATMENT", 123, 126], ["oxygen delivery", "TREATMENT", 146, 161], ["red cell survival", "TREATMENT", 166, 183], ["massive", "OBSERVATION_MODIFIER", 17, 24], ["transfusions", "OBSERVATION", 25, 37], ["lesions", "OBSERVATION", 80, 87], ["red cell survival", "OBSERVATION", 166, 183]]], ["The metabolism of citrate to bicarbonate tends to neutralize the drop in pH.", [["citrate", "CHEMICAL", 18, 25], ["bicarbonate", "CHEMICAL", 29, 40], ["citrate", "CHEMICAL", 18, 25], ["bicarbonate", "CHEMICAL", 29, 40], ["citrate", "SIMPLE_CHEMICAL", 18, 25], ["bicarbonate", "SIMPLE_CHEMICAL", 29, 40], ["citrate to bicarbonate", "TREATMENT", 18, 40], ["the drop in pH", "PROBLEM", 61, 75], ["drop", "OBSERVATION_MODIFIER", 65, 69]]], ["Although 2,3-DPG can be regenerated and other by-products of transfusion cleared, this places an increased burden on the patient, who is not in an ideal position for such demands.", [["2,3-DPG", "CHEMICAL", 9, 16], ["2,3-DPG", "CHEMICAL", 9, 16], ["2,3-DPG", "SIMPLE_CHEMICAL", 9, 16], ["patient", "ORGANISM", 121, 128], ["patient", "SPECIES", 121, 128], ["transfusion", "TREATMENT", 61, 72], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["burden", "OBSERVATION_MODIFIER", 107, 113]]], ["The patient undergoing massive transfusion is at greatest risk of suffering adverse effects of a transfusion.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["massive transfusion", "TREATMENT", 23, 42], ["a transfusion", "TREATMENT", 95, 108], ["massive", "OBSERVATION_MODIFIER", 23, 30], ["transfusion", "OBSERVATION", 31, 42]]], ["A practical outline for management of human patients in hemorrhagic shock has been outlined with crystalloid and colloid infusions followed by PRBCs (Sohmer and Scott, 1982) .", [["hemorrhagic shock", "DISEASE", 56, 73], ["human", "ORGANISM", 38, 43], ["patients", "ORGANISM", 44, 52], ["human", "SPECIES", 38, 43], ["patients", "SPECIES", 44, 52], ["human", "SPECIES", 38, 43], ["management", "TREATMENT", 24, 34], ["hemorrhagic shock", "PROBLEM", 56, 73], ["crystalloid", "TREATMENT", 97, 108], ["colloid infusions", "TREATMENT", 113, 130], ["PRBCs", "TREATMENT", 143, 148], ["hemorrhagic", "OBSERVATION_MODIFIER", 56, 67], ["shock", "OBSERVATION", 68, 73]]], ["Depending upon the PT, APTT, and platelet count, FFP or platelets are added.", [["platelet", "ANATOMY", 33, 41], ["platelets", "ANATOMY", 56, 65], ["APTT", "GENE_OR_GENE_PRODUCT", 23, 27], ["platelet", "CELL", 33, 41], ["FFP", "SIMPLE_CHEMICAL", 49, 52], ["platelets", "CELL", 56, 65], ["APTT", "PROTEIN", 23, 27], ["FFP", "CELL_TYPE", 49, 52], ["platelets", "CELL_TYPE", 56, 65], ["the PT", "TEST", 15, 21], ["APTT", "TEST", 23, 27], ["platelet count", "TEST", 33, 47], ["FFP", "TREATMENT", 49, 52], ["platelets", "TREATMENT", 56, 65]]], ["Occasionally cryoprecipitate may be needed if bleeding continues and fibrinogen levels remain low despite FFP administration.", [["cryoprecipitate", "ANATOMY", 13, 28], ["bleeding", "DISEASE", 46, 54], ["cryoprecipitate", "ORGANISM_SUBSTANCE", 13, 28], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 69, 79], ["FFP", "SIMPLE_CHEMICAL", 106, 109], ["fibrinogen", "PROTEIN", 69, 79], ["Occasionally cryoprecipitate", "TREATMENT", 0, 28], ["bleeding", "PROBLEM", 46, 54], ["fibrinogen levels", "TEST", 69, 86], ["FFP administration", "TREATMENT", 106, 124], ["cryoprecipitate", "OBSERVATION", 13, 28]]], ["Significant bleeding is not likely unless the PT and APTT are at least 1.5 times that of the control.A. CLINICAL AND PHYSIOLOGICAL CHANGESVeterinarians have the advantage of being able to give fresh whole blood when it is needed.", [["whole blood", "ANATOMY", 199, 210], ["bleeding", "DISEASE", 12, 20], ["APTT", "GENE_OR_GENE_PRODUCT", 53, 57], ["blood", "ORGANISM_SUBSTANCE", 205, 210], ["APTT", "PROTEIN", 53, 57], ["Significant bleeding", "PROBLEM", 0, 20], ["the PT", "TEST", 42, 48], ["APTT", "TEST", 53, 57], ["bleeding", "OBSERVATION", 12, 20], ["not likely", "UNCERTAINTY", 24, 34]]], ["Because of the requirement to test human blood for disease-causing organisms, fresh whole blood is not readily available.", [["blood", "ANATOMY", 41, 46], ["whole blood", "ANATOMY", 84, 95], ["human", "ORGANISM", 35, 40], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["blood", "ORGANISM_SUBSTANCE", 90, 95], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["disease", "PROBLEM", 51, 58], ["organisms", "PROBLEM", 67, 76], ["fresh whole blood", "TEST", 78, 95]]], ["The major indication for fresh whole blood is in patients who need red cells, clotting factors, and platelets, such as patients with massive hemorrhage or with bleeding from severe liver disease, DIC, or thrombocytopenia.III. Transfusion in SurgeryAs discussed in Section II, PRBCs are indicated first when additional oxygen-carrying capacity is needed.III. Transfusion in SurgeryHistorically, anesthesiologists and surgeons have felt that a Hct of 30% (hemoglobin of 10 gm/dl) was required for humans to undergo surgical procedures requiring general anesthesia (Levine et al., 1990) .", [["whole blood", "ANATOMY", 31, 42], ["red cells", "ANATOMY", 67, 76], ["platelets", "ANATOMY", 100, 109], ["liver", "ANATOMY", 181, 186], ["hemorrhage", "DISEASE", 141, 151], ["bleeding", "DISEASE", 160, 168], ["liver disease", "DISEASE", 181, 194], ["DIC", "DISEASE", 196, 199], ["thrombocytopenia", "DISEASE", 204, 220], ["oxygen", "CHEMICAL", 318, 324], ["oxygen", "CHEMICAL", 318, 324], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["patients", "ORGANISM", 49, 57], ["red cells", "CELL", 67, 76], ["clotting factors", "GENE_OR_GENE_PRODUCT", 78, 94], ["platelets", "CELL", 100, 109], ["patients", "ORGANISM", 119, 127], ["liver", "ORGAN", 181, 186], ["oxygen", "SIMPLE_CHEMICAL", 318, 324], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 454, 464], ["humans", "ORGANISM", 495, 501], ["red cells", "CELL_TYPE", 67, 76], ["clotting factors", "PROTEIN", 78, 94], ["platelets", "CELL_TYPE", 100, 109], ["hemoglobin", "PROTEIN", 454, 464], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 119, 127], ["humans", "SPECIES", 495, 501], ["humans", "SPECIES", 495, 501], ["fresh whole blood", "PROBLEM", 25, 42], ["red cells", "PROBLEM", 67, 76], ["clotting factors", "PROBLEM", 78, 94], ["platelets", "TEST", 100, 109], ["massive hemorrhage", "PROBLEM", 133, 151], ["bleeding", "PROBLEM", 160, 168], ["severe liver disease", "PROBLEM", 174, 194], ["DIC", "PROBLEM", 196, 199], ["thrombocytopenia", "PROBLEM", 204, 220], ["Transfusion in Surgery", "TREATMENT", 226, 248], ["PRBCs", "TREATMENT", 276, 281], ["additional oxygen", "TREATMENT", 307, 324], ["carrying capacity", "PROBLEM", 325, 342], ["a Hct", "TEST", 440, 445], ["hemoglobin", "TEST", 454, 464], ["surgical procedures", "TREATMENT", 513, 532], ["general anesthesia", "TREATMENT", 543, 561], ["massive", "OBSERVATION_MODIFIER", 133, 140], ["hemorrhage", "OBSERVATION", 141, 151], ["bleeding", "OBSERVATION", 160, 168], ["severe", "OBSERVATION_MODIFIER", 174, 180], ["liver", "ANATOMY", 181, 186], ["disease", "OBSERVATION", 187, 194], ["thrombocytopenia", "OBSERVATION", 204, 220]]], ["At this level compensatory mechanisms are in place if the anemia has been present for more than a few days.", [["anemia", "DISEASE", 58, 64], ["the anemia", "PROBLEM", 54, 64], ["compensatory", "OBSERVATION_MODIFIER", 14, 26], ["mechanisms", "OBSERVATION", 27, 37], ["anemia", "OBSERVATION", 58, 64]]], ["Coronary vessels are maximally dilated and cardiac output is increased.", [["Coronary vessels", "ANATOMY", 0, 16], ["cardiac", "ANATOMY", 43, 50], ["Coronary vessels", "MULTI-TISSUE_STRUCTURE", 0, 16], ["cardiac", "ORGAN", 43, 50], ["maximally dilated", "PROBLEM", 21, 38], ["cardiac output", "TEST", 43, 57], ["vessels", "ANATOMY", 9, 16], ["maximally", "OBSERVATION_MODIFIER", 21, 30], ["dilated", "OBSERVATION", 31, 38], ["output", "OBSERVATION_MODIFIER", 51, 57], ["increased", "OBSERVATION_MODIFIER", 61, 70]]], ["If pulmonary and cardiac function are normal, a Hct of 20% or even less might be acceptable in patients under anesthesia when activity requirements are not of concern (Moore, 1974 , Mollison et al., 1987 .", [["pulmonary", "ANATOMY", 3, 12], ["cardiac", "ANATOMY", 17, 24], ["pulmonary", "ORGAN", 3, 12], ["cardiac", "ORGAN", 17, 24], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["a Hct", "TEST", 46, 51], ["anesthesia", "TREATMENT", 110, 120], ["activity requirements", "PROBLEM", 126, 147], ["pulmonary", "ANATOMY", 3, 12], ["cardiac", "ANATOMY", 17, 24], ["normal", "OBSERVATION", 38, 44]]], ["If transfusion is needed for a surgical patient, and if it is not an emergency, it is better given near the end of the procedure.", [["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47], ["transfusion", "TREATMENT", 3, 14], ["the procedure", "TREATMENT", 115, 128]]], ["This allows for maximum conservation of transfused cells, (see Dodds, this volume [\"Autologous Transfusion\"], for discussion of intraoperative salvage).", [["cells", "ANATOMY", 51, 56], ["cells", "CELL", 51, 56], ["transfused cells", "CELL_TYPE", 40, 56], ["maximum conservation of transfused cells", "TREATMENT", 16, 56], ["Autologous Transfusion\"", "TREATMENT", 84, 107], ["intraoperative salvage", "TREATMENT", 128, 150], ["transfused cells", "OBSERVATION", 40, 56]]], ["All of these methods minimize the need for homologous blood and make use of an immediately available and safe supply of autologous blood.IV. Treatment of Hemolytic AnemiaHemolysis, or abnormal shortening of the red cell life span beyond the ability of the marrow to compensate, may be caused by intrinsic red cell defects or by exogenous effects from substances in the plasma.", [["blood", "ANATOMY", 54, 59], ["blood", "ANATOMY", 131, 136], ["red cell", "ANATOMY", 211, 219], ["marrow", "ANATOMY", 256, 262], ["red cell", "ANATOMY", 305, 313], ["plasma", "ANATOMY", 369, 375], ["Hemolytic AnemiaHemolysis", "DISEASE", 154, 179], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["blood", "ORGANISM_SUBSTANCE", 131, 136], ["red cell", "CELL", 211, 219], ["marrow", "ORGAN", 256, 262], ["red cell", "CELL", 305, 313], ["plasma", "ORGANISM_SUBSTANCE", 369, 375], ["these methods", "TREATMENT", 7, 20], ["homologous blood", "TREATMENT", 43, 59], ["autologous blood", "TREATMENT", 120, 136], ["IV", "TREATMENT", 137, 139], ["Hemolytic AnemiaHemolysis", "PROBLEM", 154, 179], ["abnormal shortening of the red cell life span", "PROBLEM", 184, 229], ["intrinsic red cell defects", "PROBLEM", 295, 321], ["the plasma", "TEST", 365, 375], ["Hemolytic", "OBSERVATION_MODIFIER", 154, 163], ["AnemiaHemolysis", "OBSERVATION", 164, 179], ["abnormal", "OBSERVATION_MODIFIER", 184, 192], ["shortening", "OBSERVATION_MODIFIER", 193, 203], ["red cell", "OBSERVATION", 211, 219], ["marrow", "ANATOMY", 256, 262], ["may be caused", "UNCERTAINTY", 278, 291], ["red cell defects", "OBSERVATION", 305, 321], ["exogenous effects", "OBSERVATION", 328, 345]]], ["Examples of intrinsic defects include inherited red cell enzyme abnormalities, such as pyruvate kinase deficiency in Basenji and beagle dogs and phosphofructokinase deficiency in English springer spaniels.", [["red cell", "ANATOMY", 48, 56], ["pyruvate", "CHEMICAL", 87, 95], ["pyruvate", "CHEMICAL", 87, 95], ["red cell", "CELL", 48, 56], ["pyruvate kinase", "GENE_OR_GENE_PRODUCT", 87, 102], ["Basenji", "SIMPLE_CHEMICAL", 117, 124], ["beagle dogs", "ORGANISM", 129, 140], ["phosphofructokinase", "GENE_OR_GENE_PRODUCT", 145, 164], ["red cell enzyme", "PROTEIN", 48, 63], ["pyruvate kinase", "PROTEIN", 87, 102], ["phosphofructokinase", "PROTEIN", 145, 164], ["dogs", "SPECIES", 136, 140], ["intrinsic defects", "PROBLEM", 12, 29], ["inherited red cell enzyme abnormalities", "PROBLEM", 38, 77], ["pyruvate kinase deficiency in Basenji", "PROBLEM", 87, 124], ["beagle dogs", "PROBLEM", 129, 140], ["phosphofructokinase deficiency", "PROBLEM", 145, 175], ["intrinsic defects", "OBSERVATION", 12, 29], ["inherited", "OBSERVATION_MODIFIER", 38, 47], ["red cell enzyme abnormalities", "OBSERVATION", 48, 77], ["pyruvate kinase deficiency", "OBSERVATION", 87, 113], ["beagle dogs", "OBSERVATION", 129, 140], ["phosphofructokinase deficiency", "OBSERVATION", 145, 175]]], ["Hemoglobinopathies such as sickle cell anemia and thalassemia are common causes of chronic hemolytic anemia in man.", [["sickle cell", "ANATOMY", 27, 38], ["Hemoglobinopathies", "DISEASE", 0, 18], ["sickle cell anemia", "DISEASE", 27, 45], ["thalassemia", "DISEASE", 50, 61], ["chronic hemolytic anemia", "DISEASE", 83, 107], ["sickle cell", "CELL", 27, 38], ["man", "ORGANISM", 111, 114], ["man", "SPECIES", 111, 114], ["Hemoglobinopathies", "PROBLEM", 0, 18], ["sickle cell anemia", "PROBLEM", 27, 45], ["thalassemia", "PROBLEM", 50, 61], ["chronic hemolytic anemia", "PROBLEM", 83, 107], ["sickle cell anemia", "OBSERVATION", 27, 45], ["chronic", "OBSERVATION_MODIFIER", 83, 90], ["hemolytic", "OBSERVATION_MODIFIER", 91, 100], ["anemia", "OBSERVATION", 101, 107]]], ["The only hemoglobinopathy reported in animals is congenital erythropoietic porphyria occurring rarely in cattle, cats, and pigs, usually not associated with significant anemia.", [["hemoglobinopathy", "DISEASE", 9, 25], ["congenital erythropoietic porphyria", "DISEASE", 49, 84], ["anemia", "DISEASE", 169, 175], ["cattle", "ORGANISM", 105, 111], ["cats", "ORGANISM", 113, 117], ["pigs", "ORGANISM", 123, 127], ["cattle", "SPECIES", 105, 111], ["cats", "SPECIES", 113, 117], ["pigs", "SPECIES", 123, 127], ["cattle", "SPECIES", 105, 111], ["pigs", "SPECIES", 123, 127], ["hemoglobinopathy", "PROBLEM", 9, 25], ["congenital erythropoietic porphyria", "PROBLEM", 49, 84], ["significant anemia", "PROBLEM", 157, 175], ["hemoglobinopathy", "OBSERVATION", 9, 25], ["congenital", "OBSERVATION_MODIFIER", 49, 59], ["erythropoietic porphyria", "OBSERVATION", 60, 84], ["significant", "OBSERVATION_MODIFIER", 157, 168], ["anemia", "OBSERVATION", 169, 175]]], ["If a compatible red cell transfusion is given to a dog with an intrinsic red cell disorder, the survival of the transfused cells is normal.", [["red cell", "ANATOMY", 16, 24], ["red cell", "ANATOMY", 73, 81], ["cells", "ANATOMY", 123, 128], ["intrinsic red cell disorder", "DISEASE", 63, 90], ["red cell", "CELL", 16, 24], ["dog", "ORGANISM", 51, 54], ["red cell", "CELL", 73, 81], ["cells", "CELL", 123, 128], ["transfused cells", "CELL_TYPE", 112, 128], ["dog", "SPECIES", 51, 54], ["a compatible red cell transfusion", "TREATMENT", 3, 36], ["an intrinsic red cell disorder", "PROBLEM", 60, 90], ["the transfused cells", "TREATMENT", 108, 128], ["red cell transfusion", "OBSERVATION", 16, 36], ["red cell disorder", "OBSERVATION", 73, 90], ["transfused cells", "OBSERVATION", 112, 128], ["normal", "OBSERVATION", 132, 138]]], ["Hemolysis of exogenous cause is much more common in both man and animals than that caused by intrinsic red cell defects.", [["red cell", "ANATOMY", 103, 111], ["Hemolysis", "DISEASE", 0, 9], ["man", "ORGANISM", 57, 60], ["red cell", "CELL", 103, 111], ["man", "SPECIES", 57, 60], ["Hemolysis of exogenous cause", "PROBLEM", 0, 28], ["intrinsic red cell defects", "PROBLEM", 93, 119], ["exogenous cause", "OBSERVATION", 13, 28], ["much more common", "OBSERVATION_MODIFIER", 32, 48], ["intrinsic red cell defects", "OBSERVATION", 93, 119]]], ["Exogenous causes include infectious agents, antibodies, and toxins.", [["antibodies", "PROTEIN", 44, 54], ["Exogenous causes", "PROBLEM", 0, 16], ["infectious agents", "TREATMENT", 25, 42], ["antibodies", "PROBLEM", 44, 54], ["toxins", "PROBLEM", 60, 66], ["infectious", "OBSERVATION", 25, 35]]], ["Transfused cells are destroyed as readily as the recipient's own cells in cases of hemolytic anemia of exogenous cause, provided the cause is still present.", [["cells", "ANATOMY", 11, 16], ["cells", "ANATOMY", 65, 70], ["hemolytic anemia", "DISEASE", 83, 99], ["cells", "CELL", 11, 16], ["cells", "CELL", 65, 70], ["Transfused cells", "CELL_LINE", 0, 16], ["Transfused cells", "TREATMENT", 0, 16], ["hemolytic anemia", "PROBLEM", 83, 99], ["exogenous cause", "PROBLEM", 103, 118], ["hemolytic", "OBSERVATION_MODIFIER", 83, 92], ["exogenous cause", "OBSERVATION", 103, 118]]], ["The oldest cells in donor blood will be most susceptible to hemolysis, whereas reticulocytes are most resistant.", [["cells", "ANATOMY", 11, 16], ["blood", "ANATOMY", 26, 31], ["reticulocytes", "ANATOMY", 79, 92], ["hemolysis", "DISEASE", 60, 69], ["cells", "CELL", 11, 16], ["blood", "ORGANISM_SUBSTANCE", 26, 31], ["reticulocytes", "CELL", 79, 92], ["reticulocytes", "CELL_TYPE", 79, 92], ["donor blood", "TEST", 20, 31], ["hemolysis", "PROBLEM", 60, 69], ["reticulocytes", "TEST", 79, 92], ["oldest cells", "OBSERVATION", 4, 16], ["hemolysis", "OBSERVATION", 60, 69]]], ["The rate of destruction of transfused cells is also increased in the presence of alloantibodies.IV. Treatment of Hemolytic AnemiaA.", [["cells", "ANATOMY", 38, 43], ["Hemolytic AnemiaA", "DISEASE", 113, 130], ["cells", "CELL", 38, 43], ["transfused cells", "CELL_TYPE", 27, 43], ["alloantibodies", "PROTEIN", 81, 95], ["destruction of transfused cells", "TREATMENT", 12, 43], ["alloantibodies", "PROBLEM", 81, 95], ["IV", "TREATMENT", 96, 98], ["Hemolytic AnemiaA", "PROBLEM", 113, 130], ["destruction", "OBSERVATION", 12, 23], ["transfused cells", "OBSERVATION", 27, 43], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["alloantibodies", "OBSERVATION", 81, 95], ["Hemolytic", "OBSERVATION_MODIFIER", 113, 122], ["AnemiaA", "OBSERVATION", 123, 130]]], ["IMMUNE-MEDIATED HEMOLYTIC ANEMIA A common problem encountered by veterinary clinicians is acute fulminating immune-mediated hemolytic anemia (IMHA).", [["hemolytic anemia", "DISEASE", 124, 140], ["IMHA", "DISEASE", 142, 146], ["HEMOLYTIC ANEMIA", "PROBLEM", 16, 32], ["A common problem", "PROBLEM", 33, 49], ["acute fulminating immune-mediated hemolytic anemia", "PROBLEM", 90, 140], ["HEMOLYTIC", "OBSERVATION_MODIFIER", 16, 25], ["ANEMIA", "OBSERVATION", 26, 32], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["hemolytic", "OBSERVATION_MODIFIER", 124, 133]]], ["This is one of the most common causes of anemia in dogs.", [["anemia", "DISEASE", 41, 47], ["dogs", "ORGANISM", 51, 55], ["dogs", "SPECIES", 51, 55], ["anemia in dogs", "PROBLEM", 41, 55], ["one of the most common", "OBSERVATION_MODIFIER", 8, 30], ["anemia", "OBSERVATION", 41, 47]]], ["Poodles, cocker spaniels, and old English sheep dogs may have a higher prevalence.", [["cocker spaniels", "ANATOMY", 9, 24], ["sheep", "ORGANISM", 42, 47], ["dogs", "ORGANISM", 48, 52], ["sheep", "SPECIES", 42, 47], ["dogs", "SPECIES", 48, 52], ["sheep", "SPECIES", 42, 47]]], ["The overall death rate is approximately 40%.IV. Treatment of Hemolytic AnemiaComplications of IMHA include cardiac, hepatic, and renal failure; hemoglobinemia; hemoglobinuria; icterus; pulmonary thromboembolism; and DIC (Klein et al., 1989) .", [["cardiac", "ANATOMY", 107, 114], ["hepatic", "ANATOMY", 116, 123], ["renal", "ANATOMY", 129, 134], ["pulmonary", "ANATOMY", 185, 194], ["death", "DISEASE", 12, 17], ["Hemolytic AnemiaComplications", "DISEASE", 61, 90], ["IMHA", "DISEASE", 94, 98], ["cardiac, hepatic, and renal failure", "DISEASE", 107, 142], ["hemoglobinemia", "DISEASE", 144, 158], ["hemoglobinuria", "DISEASE", 160, 174], ["icterus", "DISEASE", 176, 183], ["pulmonary thromboembolism", "DISEASE", 185, 210], ["DIC", "DISEASE", 216, 219], ["cardiac", "ORGAN", 107, 114], ["hepatic", "MULTI-TISSUE_STRUCTURE", 116, 123], ["renal", "ORGAN", 129, 134], ["pulmonary", "ORGAN", 185, 194], ["The overall death rate", "TEST", 0, 22], ["IV", "TREATMENT", 44, 46], ["Hemolytic AnemiaComplications of IMHA", "PROBLEM", 61, 98], ["cardiac, hepatic, and renal failure", "PROBLEM", 107, 142], ["hemoglobinemia", "PROBLEM", 144, 158], ["hemoglobinuria", "PROBLEM", 160, 174], ["icterus", "PROBLEM", 176, 183], ["pulmonary thromboembolism", "PROBLEM", 185, 210], ["DIC", "PROBLEM", 216, 219], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["death", "OBSERVATION_MODIFIER", 12, 17], ["rate", "OBSERVATION_MODIFIER", 18, 22], ["Hemolytic", "OBSERVATION", 61, 70], ["cardiac", "ANATOMY", 107, 114], ["hepatic", "ANATOMY", 116, 123], ["renal", "ANATOMY", 129, 134], ["failure", "OBSERVATION", 135, 142], ["hemoglobinuria", "OBSERVATION", 160, 174], ["icterus", "OBSERVATION_MODIFIER", 176, 183], ["pulmonary", "ANATOMY", 185, 194], ["thromboembolism", "OBSERVATION", 195, 210]]], ["Most are DAT positive, and some have spontaneous autoagglutination that is noted immediately when blood is drawn.", [["blood", "ANATOMY", 98, 103], ["DAT", "GENE_OR_GENE_PRODUCT", 9, 12], ["blood", "ORGANISM_SUBSTANCE", 98, 103], ["DAT positive", "PROBLEM", 9, 21], ["spontaneous autoagglutination", "PROBLEM", 37, 66], ["blood", "TEST", 98, 103], ["spontaneous", "OBSERVATION_MODIFIER", 37, 48], ["autoagglutination", "OBSERVATION", 49, 66]]], ["Most dogs with autoagglutination and intravascular hemolysis have IgG plus complement on their red cells (Slappendel, 1979) .", [["intravascular", "ANATOMY", 37, 50], ["red cells", "ANATOMY", 95, 104], ["intravascular hemolysis", "DISEASE", 37, 60], ["dogs", "ORGANISM", 5, 9], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 50], ["IgG", "GENE_OR_GENE_PRODUCT", 66, 69], ["red cells", "CELL", 95, 104], ["IgG", "PROTEIN", 66, 69], ["red cells", "CELL_TYPE", 95, 104], ["dogs", "SPECIES", 5, 9], ["autoagglutination", "TREATMENT", 15, 32], ["intravascular hemolysis", "PROBLEM", 37, 60], ["IgG", "TEST", 66, 69], ["hemolysis", "OBSERVATION", 51, 60]]], ["The mortality in this form is quite high, 75-80%.", [["mortality", "OBSERVATION", 4, 13], ["high", "OBSERVATION_MODIFIER", 36, 40]]], ["Most dogs with IMHA, and almost all with the severe form, require one or more transfusions in addition to immunosuppressant therapy.", [["IMHA", "DISEASE", 15, 19], ["dogs", "ORGANISM", 5, 9], ["dogs", "SPECIES", 5, 9], ["transfusions", "TREATMENT", 78, 90], ["immunosuppressant therapy", "TREATMENT", 106, 131]]], ["Those that are strongly DAT positive or that have autoagglutination are difficult or impossible to type or cross match.", [["DAT", "GENE_OR_GENE_PRODUCT", 24, 27], ["strongly DAT positive", "PROBLEM", 15, 36], ["autoagglutination", "PROBLEM", 50, 67]]], ["These patients may be serologically incompatible with their own red cells and with those of most if not all donors.", [["red cells", "ANATOMY", 64, 73], ["patients", "ORGANISM", 6, 14], ["red cells", "CELL", 64, 73], ["donors", "ORGANISM", 108, 114], ["red cells", "CELL_TYPE", 64, 73], ["patients", "SPECIES", 6, 14]]], ["If they have been previously transfused, they may also have alloantibodies that may be impossible to detect.", [["alloantibodies", "PROBLEM", 60, 74]]], ["Sometimes difficulties in typing human patients with positive controls are overcome by incubating the patient's red cells at 45\u00b0C for 5-10 minutes and washing at the same temperature.", [["red cells", "ANATOMY", 112, 121], ["human", "ORGANISM", 33, 38], ["patients", "ORGANISM", 39, 47], ["patient", "ORGANISM", 102, 109], ["red cells", "CELL", 112, 121], ["red cells", "CELL_TYPE", 112, 121], ["human", "SPECIES", 33, 38], ["patients", "SPECIES", 39, 47], ["patient", "SPECIES", 102, 109], ["human", "SPECIES", 33, 38]]], ["This may elute the antibody and allow typing to proceed, but must be done cautiously to prevent hemolysis (Petz, 1982) .", [["hemolysis", "DISEASE", 96, 105], ["hemolysis", "PROBLEM", 96, 105]]], ["This procedure has not been evaluated in dogs.", [["dogs", "ORGANISM", 41, 45], ["dogs", "SPECIES", 41, 45], ["This procedure", "TREATMENT", 0, 14]]], ["Destruction of transfused cells may also be increased in the presence of fever or splenomegaly, possibly from increased activity of mononuclear phagocytes.IV. Treatment of Hemolytic AnemiaAlthough it is true that rapid hemolysis of transfused red cells adds to morbidity, hypoxia from severe anemia may contribute even more to damage to heart, liver, and kidneys.", [["cells", "ANATOMY", 26, 31], ["mononuclear phagocytes", "ANATOMY", 132, 154], ["red cells", "ANATOMY", 243, 252], ["heart", "ANATOMY", 337, 342], ["liver", "ANATOMY", 344, 349], ["kidneys", "ANATOMY", 355, 362], ["fever", "DISEASE", 73, 78], ["splenomegaly", "DISEASE", 82, 94], ["Hemolytic AnemiaAlthough", "DISEASE", 172, 196], ["hemolysis", "DISEASE", 219, 228], ["hypoxia", "DISEASE", 272, 279], ["anemia", "DISEASE", 292, 298], ["damage to heart, liver, and kidneys", "DISEASE", 327, 362], ["cells", "CELL", 26, 31], ["splenomegaly", "PATHOLOGICAL_FORMATION", 82, 94], ["mononuclear phagocytes", "CELL", 132, 154], ["red cells", "CELL", 243, 252], ["heart", "ORGAN", 337, 342], ["liver", "ORGAN", 344, 349], ["kidneys", "ORGAN", 355, 362], ["transfused cells", "CELL_TYPE", 15, 31], ["mononuclear phagocytes", "CELL_TYPE", 132, 154], ["transfused red cells", "CELL_TYPE", 232, 252], ["Destruction of transfused cells", "PROBLEM", 0, 31], ["fever", "PROBLEM", 73, 78], ["splenomegaly", "PROBLEM", 82, 94], ["increased activity of mononuclear phagocytes", "PROBLEM", 110, 154], ["IV", "TREATMENT", 155, 157], ["Treatment", "TREATMENT", 159, 168], ["Hemolytic AnemiaAlthough", "PROBLEM", 172, 196], ["rapid hemolysis", "PROBLEM", 213, 228], ["transfused red cells", "TREATMENT", 232, 252], ["morbidity", "PROBLEM", 261, 270], ["hypoxia", "PROBLEM", 272, 279], ["severe anemia", "PROBLEM", 285, 298], ["damage to heart, liver, and kidneys", "PROBLEM", 327, 362], ["transfused cells", "OBSERVATION", 15, 31], ["may also be", "UNCERTAINTY", 32, 43], ["increased", "OBSERVATION_MODIFIER", 44, 53], ["fever", "OBSERVATION", 73, 78], ["splenomegaly", "OBSERVATION", 82, 94], ["possibly from", "UNCERTAINTY", 96, 109], ["increased", "OBSERVATION_MODIFIER", 110, 119], ["activity", "OBSERVATION_MODIFIER", 120, 128], ["mononuclear phagocytes", "OBSERVATION", 132, 154], ["Hemolytic", "OBSERVATION", 172, 181], ["rapid", "OBSERVATION_MODIFIER", 213, 218], ["hemolysis", "OBSERVATION", 219, 228], ["severe", "OBSERVATION_MODIFIER", 285, 291], ["anemia", "OBSERVATION", 292, 298], ["heart", "ANATOMY", 337, 342], ["liver", "ANATOMY", 344, 349], ["kidneys", "ANATOMY", 355, 362]]], ["Thus, transfusion should not be withheld in life-threatening IMHA.", [["IMHA", "DISEASE", 61, 65], ["transfusion", "TREATMENT", 6, 17]]], ["The decision as to when to transfuse must be made on an individual basis using more clinical parameters than simply the Hct to decide.", [["the Hct", "TEST", 116, 123]]], ["Serial determinations of the Hct are helpful in determining the rate of progression or stabilization of the disease.", [["Hct", "GENE_OR_GENE_PRODUCT", 29, 32], ["Hct", "PROTEIN", 29, 32], ["Serial determinations", "TEST", 0, 21], ["the Hct", "TEST", 25, 32], ["the disease", "PROBLEM", 104, 115], ["disease", "OBSERVATION", 108, 115]]], ["If a transfusion is needed, most human and canine patients will tolerate seemingly incompatible red cells with only infrequent reactions.", [["red cells", "ANATOMY", 96, 105], ["human", "ORGANISM", 33, 38], ["canine", "ORGANISM", 43, 49], ["patients", "ORGANISM", 50, 58], ["red cells", "CELL", 96, 105], ["red cells", "CELL_TYPE", 96, 105], ["human", "SPECIES", 33, 38], ["patients", "SPECIES", 50, 58], ["human", "SPECIES", 33, 38], ["canine", "SPECIES", 43, 49], ["a transfusion", "TREATMENT", 3, 16], ["seemingly incompatible red cells", "PROBLEM", 73, 105], ["infrequent reactions", "PROBLEM", 116, 136]]], ["Survival of the transfused cells is about equal to that of the patient's own cells and the net result is that the transfusion provides at least temporary benefit.", [["cells", "ANATOMY", 27, 32], ["cells", "ANATOMY", 77, 82], ["cells", "CELL", 27, 32], ["patient", "ORGANISM", 63, 70], ["cells", "CELL", 77, 82], ["transfused cells", "CELL_TYPE", 16, 32], ["patient", "SPECIES", 63, 70], ["the transfused cells", "TREATMENT", 12, 32], ["the transfusion", "TREATMENT", 110, 125], ["transfused cells", "OBSERVATION", 16, 32]]], ["Rarely in very severe IMHA, the transfused cells are destroyed rapidly (Petz, 1982) .", [["cells", "ANATOMY", 43, 48], ["IMHA", "DISEASE", 22, 26], ["IMHA", "CANCER", 22, 26], ["cells", "CELL", 43, 48], ["transfused cells", "CELL_TYPE", 32, 48], ["very severe IMHA", "PROBLEM", 10, 26], ["the transfused cells", "TREATMENT", 28, 48], ["very", "OBSERVATION_MODIFIER", 10, 14], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["transfused cells", "OBSERVATION", 32, 48]]], ["In humans patients with IMHA, the specificity of the autoantibody can sometimes be determined by elution techniques and testing the antibody against red cells of known phenotypes.", [["red cells", "ANATOMY", 149, 158], ["IMHA", "DISEASE", 24, 28], ["humans", "ORGANISM", 3, 9], ["patients", "ORGANISM", 10, 18], ["red cells", "CELL", 149, 158], ["autoantibody", "PROTEIN", 53, 65], ["red cells", "CELL_TYPE", 149, 158], ["humans", "SPECIES", 3, 9], ["patients", "SPECIES", 10, 18], ["humans", "SPECIES", 3, 9], ["elution techniques", "TEST", 97, 115], ["testing the antibody", "TEST", 120, 140], ["red cells", "TEST", 149, 158], ["known phenotypes", "PROBLEM", 162, 178]]], ["In dogs this is not practical, so the identity of canine autoantibodies remains unknown.IV. Treatment of Hemolytic AnemiaAbout 50% of human patients, and a slightly smaller percentage of dogs with warm-antibody IMHA, will respond to immunosuppressive doses of corticosteroids during the first few days, although the Hct may not reach a normal level until weeks later.", [["Hemolytic AnemiaAbout", "DISEASE", 105, 126], ["corticosteroids", "CHEMICAL", 260, 275], ["corticosteroids", "CHEMICAL", 260, 275], ["dogs", "ORGANISM", 3, 7], ["canine", "ORGANISM", 50, 56], ["human", "ORGANISM", 134, 139], ["patients", "ORGANISM", 140, 148], ["dogs", "ORGANISM", 187, 191], ["Hct", "GENE_OR_GENE_PRODUCT", 316, 319], ["canine autoantibodies", "PROTEIN", 50, 71], ["Hct", "PROTEIN", 316, 319], ["dogs", "SPECIES", 3, 7], ["human", "SPECIES", 134, 139], ["patients", "SPECIES", 140, 148], ["dogs", "SPECIES", 187, 191], ["canine", "SPECIES", 50, 56], ["human", "SPECIES", 134, 139], ["canine autoantibodies", "PROBLEM", 50, 71], ["IV", "TREATMENT", 88, 90], ["Treatment", "TREATMENT", 92, 101], ["Hemolytic AnemiaAbout", "PROBLEM", 105, 126], ["a slightly smaller percentage of dogs", "PROBLEM", 154, 191], ["warm-antibody IMHA", "PROBLEM", 197, 215], ["immunosuppressive doses", "TREATMENT", 233, 256], ["corticosteroids", "TREATMENT", 260, 275], ["the Hct", "TEST", 312, 319], ["Hemolytic", "OBSERVATION_MODIFIER", 105, 114], ["slightly", "OBSERVATION_MODIFIER", 156, 164], ["smaller", "OBSERVATION_MODIFIER", 165, 172]]], ["Dogs that fail to respond to corticosteroids may respond when stronger immunosuppressive drugs such as cyclophosphamide or azathiaprine are added.IV. Treatment of Hemolytic AnemiaB.", [["cyclophosphamide", "CHEMICAL", 103, 119], ["azathiaprine", "CHEMICAL", 123, 135], ["Hemolytic AnemiaB", "DISEASE", 163, 180], ["corticosteroids", "CHEMICAL", 29, 44], ["cyclophosphamide", "CHEMICAL", 103, 119], ["azathiaprine", "CHEMICAL", 123, 135], ["Dogs", "ORGANISM", 0, 4], ["cyclophosphamide", "SIMPLE_CHEMICAL", 103, 119], ["azathiaprine", "SIMPLE_CHEMICAL", 123, 135], ["corticosteroids", "TREATMENT", 29, 44], ["immunosuppressive drugs", "TREATMENT", 71, 94], ["cyclophosphamide", "TREATMENT", 103, 119], ["azathiaprine", "TREATMENT", 123, 135], ["IV", "TREATMENT", 146, 148], ["Hemolytic AnemiaB", "PROBLEM", 163, 180], ["Hemolytic", "OBSERVATION", 163, 172]]], ["OTHER CAUSES OF HEMOLYTIC ANEMIA Table I lists causes of hemolytic anemia in animals.", [["hemolytic anemia", "DISEASE", 57, 73], ["HEMOLYTIC ANEMIA", "PROBLEM", 16, 32], ["hemolytic anemia", "PROBLEM", 57, 73], ["HEMOLYTIC", "OBSERVATION_MODIFIER", 16, 25], ["ANEMIA", "OBSERVATION", 26, 32], ["hemolytic", "OBSERVATION_MODIFIER", 57, 66], ["anemia", "OBSERVATION", 67, 73]]], ["The general approach to treatment is to remove the cause when possible.", [["treatment", "TREATMENT", 24, 33]]], ["Those known to cause hemolysis must be discontinued along with any others that are not essential.", [["hemolysis", "DISEASE", 21, 30], ["hemolysis", "PROBLEM", 21, 30], ["hemolysis", "OBSERVATION", 21, 30]]], ["Semimoist cat foods containing propylene glycol shorten red cell life span and should not be fed to any anemic cat.", [["red cell", "ANATOMY", 56, 64], ["propylene glycol", "CHEMICAL", 31, 47], ["propylene glycol", "CHEMICAL", 31, 47], ["cat", "ORGANISM", 10, 13], ["propylene glycol", "SIMPLE_CHEMICAL", 31, 47], ["red cell", "CELL", 56, 64], ["cat", "ORGANISM", 111, 114], ["Semimoist cat foods", "TREATMENT", 0, 19], ["propylene glycol shorten red cell life span", "TREATMENT", 31, 74]]], ["If transfusion is required in treatment of hemolytic anemia of any cause, the approach is the same as for IMHA.", [["hemolytic anemia", "DISEASE", 43, 59], ["transfusion", "TREATMENT", 3, 14], ["hemolytic anemia", "PROBLEM", 43, 59], ["IMHA", "PROBLEM", 106, 110], ["hemolytic", "OBSERVATION_MODIFIER", 43, 52]]], ["Discussion of specific therapy for the underlying cause is beyond the scope of this article.V. Transfusion in Chronic Blood LossThe limiting factor for continued erythropoiesis is iron.", [["Blood", "ANATOMY", 118, 123], ["erythropoiesis", "DISEASE", 162, 176], ["iron", "CHEMICAL", 180, 184], ["iron", "CHEMICAL", 180, 184], ["Blood", "ORGANISM_SUBSTANCE", 118, 123], ["iron", "SIMPLE_CHEMICAL", 180, 184], ["specific therapy", "TREATMENT", 14, 30], ["the underlying cause", "PROBLEM", 35, 55], ["Transfusion", "TREATMENT", 95, 106], ["Chronic Blood Loss", "PROBLEM", 110, 128], ["continued erythropoiesis", "PROBLEM", 152, 176], ["iron", "TREATMENT", 180, 184], ["Transfusion", "OBSERVATION", 95, 106], ["Chronic", "OBSERVATION_MODIFIER", 110, 117], ["Blood Loss", "OBSERVATION", 118, 128], ["erythropoiesis", "OBSERVATION", 162, 176]]], ["As small amounts of blood are lost over a period of time, the marrow responds initially with reticulocytosis and the Hct remains normal.", [["blood", "ANATOMY", 20, 25], ["marrow", "ANATOMY", 62, 68], ["reticulocytosis", "DISEASE", 93, 108], ["blood", "ORGANISM_SUBSTANCE", 20, 25], ["marrow", "ORGAN", 62, 68], ["Hct", "GENE_OR_GENE_PRODUCT", 117, 120], ["Hct", "PROTEIN", 117, 120], ["small amounts of blood", "PROBLEM", 3, 25], ["reticulocytosis", "PROBLEM", 93, 108], ["the Hct", "TEST", 113, 120], ["small", "OBSERVATION_MODIFIER", 3, 8], ["amounts", "OBSERVATION_MODIFIER", 9, 16], ["marrow", "ANATOMY", 62, 68], ["normal", "OBSERVATION", 129, 135]]], ["Depending on the quantity of iron stores, microcytic and hypochromic anemia will eventually develop.", [["iron", "CHEMICAL", 29, 33], ["microcytic", "DISEASE", 42, 52], ["hypochromic anemia", "DISEASE", 57, 75], ["iron", "CHEMICAL", 29, 33], ["iron", "SIMPLE_CHEMICAL", 29, 33], ["iron stores", "PROBLEM", 29, 40], ["microcytic", "PROBLEM", 42, 52], ["hypochromic anemia", "PROBLEM", 57, 75], ["iron stores", "OBSERVATION", 29, 40], ["hypochromic anemia", "OBSERVATION", 57, 75]]], ["Neonatal animals with low iron stores become deficient if the diet is inadequate even in the absence of hemorrhage.", [["iron", "CHEMICAL", 26, 30], ["hemorrhage", "DISEASE", 104, 114], ["iron", "CHEMICAL", 26, 30], ["animals", "ORGANISM", 9, 16], ["iron", "SIMPLE_CHEMICAL", 26, 30], ["Neonatal animals", "PROBLEM", 0, 16], ["low iron stores", "PROBLEM", 22, 37], ["hemorrhage", "PROBLEM", 104, 114], ["hemorrhage", "OBSERVATION", 104, 114]]], ["Older animals with adequate stores are more resistant, and iron deficiency usually indicates that chronic blood loss has occurred.", [["blood", "ANATOMY", 106, 111], ["iron", "CHEMICAL", 59, 63], ["chronic blood loss", "DISEASE", 98, 116], ["iron", "CHEMICAL", 59, 63], ["iron", "SIMPLE_CHEMICAL", 59, 63], ["blood", "ORGANISM_SUBSTANCE", 106, 111], ["iron deficiency", "PROBLEM", 59, 74], ["chronic blood loss", "PROBLEM", 98, 116], ["chronic", "OBSERVATION_MODIFIER", 98, 105], ["blood loss", "OBSERVATION", 106, 116]]], ["Occult blood loss occurs most frequently via the gastrointestinal tract from blood-sucking parasites, ulcers, or tumors.", [["blood", "ANATOMY", 7, 12], ["gastrointestinal tract", "ANATOMY", 49, 71], ["blood", "ANATOMY", 77, 82], ["ulcers", "ANATOMY", 102, 108], ["tumors", "ANATOMY", 113, 119], ["blood loss", "DISEASE", 7, 17], ["ulcers", "DISEASE", 102, 108], ["tumors", "DISEASE", 113, 119], ["blood", "ORGANISM_SUBSTANCE", 7, 12], ["gastrointestinal tract", "ORGAN", 49, 71], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["ulcers", "PATHOLOGICAL_FORMATION", 102, 108], ["tumors", "CANCER", 113, 119], ["Occult blood loss", "PROBLEM", 0, 17], ["sucking parasites", "PROBLEM", 83, 100], ["ulcers", "PROBLEM", 102, 108], ["tumors", "PROBLEM", 113, 119], ["blood loss", "OBSERVATION", 7, 17], ["gastrointestinal tract", "ANATOMY", 49, 71], ["blood", "ANATOMY", 77, 82], ["ulcers", "OBSERVATION", 102, 108], ["tumors", "OBSERVATION", 113, 119]]], ["If the cause of the blood loss can be identified and removed, and if the patient is stable, iron replacement may prevent the need for transfusion.", [["blood", "ANATOMY", 20, 25], ["blood loss", "DISEASE", 20, 30], ["iron", "CHEMICAL", 92, 96], ["iron", "CHEMICAL", 92, 96], ["blood", "ORGANISM_SUBSTANCE", 20, 25], ["patient", "ORGANISM", 73, 80], ["iron", "SIMPLE_CHEMICAL", 92, 96], ["patient", "SPECIES", 73, 80], ["the blood loss", "PROBLEM", 16, 30], ["iron replacement", "TREATMENT", 92, 108], ["transfusion", "TREATMENT", 134, 145], ["blood loss", "OBSERVATION", 20, 30], ["stable", "OBSERVATION_MODIFIER", 84, 90]]], ["If the anemia is severe, especially if further losses are anticipated, transfusion with PRBC is indicated.V. Transfusion in Chronic Blood LossOne source of chronic blood loss in both human and animal patients is iatrogenic from repeated blood sampling.", [["Blood", "ANATOMY", 132, 137], ["blood", "ANATOMY", 164, 169], ["blood", "ANATOMY", 237, 242], ["anemia", "DISEASE", 7, 13], ["chronic blood loss", "DISEASE", 156, 174], ["PRBC", "CELL", 88, 92], ["Blood", "ORGANISM_SUBSTANCE", 132, 137], ["blood", "ORGANISM_SUBSTANCE", 164, 169], ["human", "ORGANISM", 183, 188], ["patients", "ORGANISM", 200, 208], ["blood", "ORGANISM_SUBSTANCE", 237, 242], ["PRBC", "CELL_TYPE", 88, 92], ["human", "SPECIES", 183, 188], ["patients", "SPECIES", 200, 208], ["human", "SPECIES", 183, 188], ["the anemia", "PROBLEM", 3, 13], ["severe", "PROBLEM", 17, 23], ["further losses", "PROBLEM", 39, 53], ["PRBC", "TREATMENT", 88, 92], ["Transfusion", "TREATMENT", 109, 120], ["chronic blood loss", "PROBLEM", 156, 174], ["iatrogenic", "PROBLEM", 212, 222], ["repeated blood sampling", "TEST", 228, 251], ["anemia", "OBSERVATION", 7, 13], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["Transfusion", "OBSERVATION", 109, 120], ["Chronic", "OBSERVATION_MODIFIER", 124, 131], ["chronic", "OBSERVATION_MODIFIER", 156, 163], ["blood loss", "OBSERVATION", 164, 174], ["both human", "OBSERVATION_MODIFIER", 178, 188], ["iatrogenic", "OBSERVATION_MODIFIER", 212, 222]]], ["In hospitalized human patients, it was reported that 50% of patients transfused had more than one unit of blood drawn for diagnostic testing (Smoller and Kruskall, 1986) .", [["blood", "ANATOMY", 106, 111], ["human", "ORGANISM", 16, 21], ["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 60, 68], ["blood", "ORGANISM_SUBSTANCE", 106, 111], ["human", "SPECIES", 16, 21], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 60, 68], ["human", "SPECIES", 16, 21], ["diagnostic testing", "TEST", 122, 140]]], ["This can also be a problem in small dogs and cats.", [["dogs", "ORGANISM", 36, 40], ["cats", "ORGANISM", 45, 49], ["dogs", "SPECIES", 36, 40], ["cats", "SPECIES", 45, 49], ["small", "OBSERVATION_MODIFIER", 30, 35], ["dogs", "OBSERVATION", 36, 40]]], ["Those drawing blood on a repeated basis should keep the Hct in mind and remember that less blood needs to be drawn from an anemic patient to obtain a needed volume of plasma or serum.VI. Transfusion in Anemia from Lack of Red Cell ProductionAnemia secondary to decreased production is most commonly associated with a primary bone marrow disease such as pure red cell aplasia, aplastic anemia, myelodysplasia, hematopoietic malignancy, or retroviral infection.", [["blood", "ANATOMY", 14, 19], ["blood", "ANATOMY", 91, 96], ["plasma", "ANATOMY", 167, 173], ["serum", "ANATOMY", 177, 182], ["Cell", "ANATOMY", 226, 230], ["bone marrow", "ANATOMY", 325, 336], ["red cell", "ANATOMY", 358, 366], ["hematopoietic malignancy", "ANATOMY", 409, 433], ["Anemia", "DISEASE", 202, 208], ["bone marrow disease", "DISEASE", 325, 344], ["red cell aplasia", "DISEASE", 358, 374], ["aplastic anemia", "DISEASE", 376, 391], ["myelodysplasia", "DISEASE", 393, 407], ["hematopoietic malignancy", "DISEASE", 409, 433], ["retroviral infection", "DISEASE", 438, 458], ["blood", "ORGANISM_SUBSTANCE", 14, 19], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["patient", "ORGANISM", 130, 137], ["plasma", "ORGANISM_SUBSTANCE", 167, 173], ["serum", "ORGANISM_SUBSTANCE", 177, 182], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 325, 336], ["retroviral", "ORGANISM", 438, 448], ["patient", "SPECIES", 130, 137], ["the Hct", "TEST", 52, 59], ["plasma or serum", "TEST", 167, 182], ["Transfusion", "TREATMENT", 187, 198], ["Anemia", "PROBLEM", 202, 208], ["Red Cell ProductionAnemia", "PROBLEM", 222, 247], ["decreased production", "PROBLEM", 261, 281], ["a primary bone marrow disease", "PROBLEM", 315, 344], ["pure red cell aplasia", "PROBLEM", 353, 374], ["aplastic anemia", "PROBLEM", 376, 391], ["myelodysplasia", "PROBLEM", 393, 407], ["hematopoietic malignancy", "PROBLEM", 409, 433], ["retroviral infection", "PROBLEM", 438, 458], ["Transfusion", "OBSERVATION", 187, 198], ["Anemia", "OBSERVATION", 202, 208], ["Red Cell ProductionAnemia", "OBSERVATION", 222, 247], ["decreased production", "OBSERVATION", 261, 281], ["most commonly", "OBSERVATION_MODIFIER", 285, 298], ["primary", "OBSERVATION_MODIFIER", 317, 324], ["bone", "ANATOMY", 325, 329], ["marrow disease", "OBSERVATION", 330, 344], ["pure", "OBSERVATION_MODIFIER", 353, 357], ["red cell aplasia", "OBSERVATION", 358, 374], ["aplastic", "OBSERVATION_MODIFIER", 376, 384], ["anemia", "OBSERVATION", 385, 391], ["myelodysplasia", "OBSERVATION", 393, 407], ["hematopoietic", "ANATOMY", 409, 422], ["malignancy", "OBSERVATION", 423, 433], ["retroviral infection", "OBSERVATION", 438, 458]]], ["Other causes include decreased erythropoietin from chronic renal disease, iron deficiency, immune-mediated destruction of red cell precursors, and anemia of chronic disease.VI. Transfusion in Anemia from Lack of Red Cell ProductionAnemia of chronic disease may be the most common form of anemia seen in hospitalized human or animal patients.", [["renal", "ANATOMY", 59, 64], ["red cell", "ANATOMY", 122, 130], ["Cell", "ANATOMY", 216, 220], ["chronic renal disease", "DISEASE", 51, 72], ["iron deficiency", "DISEASE", 74, 89], ["anemia", "DISEASE", 147, 153], ["chronic disease", "DISEASE", 157, 172], ["Anemia", "DISEASE", 192, 198], ["chronic disease", "DISEASE", 241, 256], ["anemia", "DISEASE", 288, 294], ["iron", "CHEMICAL", 74, 78], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 31, 45], ["renal", "ORGAN", 59, 64], ["iron", "SIMPLE_CHEMICAL", 74, 78], ["red cell", "CELL", 122, 130], ["human", "ORGANISM", 316, 321], ["patients", "ORGANISM", 332, 340], ["erythropoietin", "PROTEIN", 31, 45], ["red cell precursors", "CELL_TYPE", 122, 141], ["human", "SPECIES", 316, 321], ["patients", "SPECIES", 332, 340], ["human", "SPECIES", 316, 321], ["decreased erythropoietin", "PROBLEM", 21, 45], ["chronic renal disease", "PROBLEM", 51, 72], ["iron deficiency", "PROBLEM", 74, 89], ["immune-mediated destruction", "PROBLEM", 91, 118], ["red cell precursors", "PROBLEM", 122, 141], ["anemia of chronic disease", "PROBLEM", 147, 172], ["Transfusion", "TREATMENT", 177, 188], ["Anemia", "PROBLEM", 192, 198], ["Red Cell ProductionAnemia", "PROBLEM", 212, 237], ["chronic disease", "PROBLEM", 241, 256], ["anemia", "PROBLEM", 288, 294], ["decreased erythropoietin", "OBSERVATION", 21, 45], ["chronic", "OBSERVATION_MODIFIER", 51, 58], ["renal", "ANATOMY", 59, 64], ["disease", "OBSERVATION", 65, 72], ["iron deficiency", "OBSERVATION", 74, 89], ["destruction", "OBSERVATION_MODIFIER", 107, 118], ["red cell precursors", "OBSERVATION", 122, 141], ["anemia", "OBSERVATION_MODIFIER", 147, 153], ["chronic", "OBSERVATION_MODIFIER", 157, 164], ["disease", "OBSERVATION", 165, 172], ["Transfusion", "OBSERVATION", 177, 188], ["Anemia", "OBSERVATION", 192, 198], ["Red Cell ProductionAnemia", "OBSERVATION", 212, 237], ["chronic", "OBSERVATION_MODIFIER", 241, 248], ["disease", "OBSERVATION", 249, 256], ["most common", "OBSERVATION_MODIFIER", 268, 279], ["anemia", "OBSERVATION", 288, 294]]], ["Because the anemia is generally mild, it is often not commented upon.", [["anemia", "DISEASE", 12, 18], ["the anemia", "PROBLEM", 8, 18], ["anemia", "OBSERVATION", 12, 18], ["generally", "OBSERVATION_MODIFIER", 22, 31], ["mild", "OBSERVATION_MODIFIER", 32, 36]]], ["Pathogenesis includes shortened red cell life span by a hyperactive reticuloendothelial system.", [["red cell", "ANATOMY", 32, 40], ["reticuloendothelial system", "ANATOMY", 68, 94], ["cell", "CELL", 36, 40], ["reticuloendothelial system", "ANATOMICAL_SYSTEM", 68, 94], ["shortened red cell life span", "PROBLEM", 22, 50], ["a hyperactive reticuloendothelial system", "PROBLEM", 54, 94], ["shortened", "OBSERVATION_MODIFIER", 22, 31], ["red cell life", "OBSERVATION", 32, 45], ["hyperactive", "OBSERVATION_MODIFIER", 56, 67], ["reticuloendothelial system", "OBSERVATION", 68, 94]]], ["In addition, mobilization of iron from stores is decreased and the marrow fails to increase production to compensate for the loss.", [["marrow", "ANATOMY", 67, 73], ["iron", "CHEMICAL", 29, 33], ["iron", "CHEMICAL", 29, 33], ["iron", "SIMPLE_CHEMICAL", 29, 33], ["marrow", "ORGAN", 67, 73], ["mobilization of iron", "TREATMENT", 13, 33], ["the loss", "PROBLEM", 121, 129], ["decreased", "OBSERVATION_MODIFIER", 49, 58], ["marrow", "ANATOMY", 67, 73]]], ["Cats are especially prone to anemia of chronic disease because of their normally short red cell life span and small blood volume to body weight ratio compared to other species (Breznock and Strack, 1982) .", [["red cell", "ANATOMY", 87, 95], ["blood", "ANATOMY", 116, 121], ["body", "ANATOMY", 132, 136], ["anemia", "DISEASE", 29, 35], ["chronic disease", "DISEASE", 39, 54], ["cell", "CELL", 91, 95], ["blood", "ORGANISM_SUBSTANCE", 116, 121], ["body", "ORGANISM_SUBDIVISION", 132, 136], ["anemia of chronic disease", "PROBLEM", 29, 54], ["their normally short red cell life span", "PROBLEM", 66, 105], ["small blood volume", "PROBLEM", 110, 128], ["body weight ratio", "TEST", 132, 149], ["chronic", "OBSERVATION_MODIFIER", 39, 46], ["disease", "OBSERVATION", 47, 54], ["short red cell", "OBSERVATION", 81, 95], ["small", "OBSERVATION_MODIFIER", 110, 115], ["blood volume", "OBSERVATION_MODIFIER", 116, 128]]], ["In addition, many cats with various illnesses carry retroviruses such as feline leukemia or immunodeficiency viruses, which further suppress the marrow.", [["leukemia", "ANATOMY", 80, 88], ["marrow", "ANATOMY", 145, 151], ["feline leukemia or immunodeficiency viruses", "DISEASE", 73, 116], ["cats", "ORGANISM", 18, 22], ["retroviruses", "ORGANISM", 52, 64], ["feline", "ORGANISM", 73, 79], ["leukemia", "CANCER", 80, 88], ["immunodeficiency viruses", "ORGANISM", 92, 116], ["marrow", "ORGAN", 145, 151], ["cats", "SPECIES", 18, 22], ["feline", "SPECIES", 73, 79], ["feline leukemia or immunodeficiency viruses", "SPECIES", 73, 116], ["various illnesses carry retroviruses", "PROBLEM", 28, 64], ["feline leukemia", "PROBLEM", 73, 88], ["immunodeficiency viruses", "PROBLEM", 92, 116], ["feline leukemia", "OBSERVATION", 73, 88], ["immunodeficiency viruses", "OBSERVATION", 92, 116], ["marrow", "ANATOMY", 145, 151]]], ["Anemia of chronic disease usually requires no specific therapy and resolves if the underlying disease is corrected.", [["Anemia", "DISEASE", 0, 6], ["chronic disease", "DISEASE", 10, 25], ["Anemia of chronic disease", "PROBLEM", 0, 25], ["specific therapy", "TREATMENT", 46, 62], ["the underlying disease", "PROBLEM", 79, 101], ["chronic", "OBSERVATION_MODIFIER", 10, 17], ["disease", "OBSERVATION", 18, 25], ["disease", "OBSERVATION", 94, 101]]], ["Severe nonregenerative anemia should not be attributed to anemia of chronic disease, but probably has another cause.VI. Transfusion in Anemia from Lack of Red Cell ProductionWith decreased red cell production, anemia is slowly progressive and may be quite severe before clinical signs become evident.", [["Cell", "ANATOMY", 159, 163], ["red cell", "ANATOMY", 189, 197], ["anemia", "DISEASE", 23, 29], ["anemia", "DISEASE", 58, 64], ["chronic disease", "DISEASE", 68, 83], ["Anemia", "DISEASE", 135, 141], ["anemia", "DISEASE", 210, 216], ["Red Cell", "CELL", 155, 163], ["red cell", "CELL", 189, 197], ["Severe nonregenerative anemia", "PROBLEM", 0, 29], ["anemia of chronic disease", "PROBLEM", 58, 83], ["Transfusion", "TREATMENT", 120, 131], ["Anemia", "PROBLEM", 135, 141], ["Red Cell", "PROBLEM", 155, 163], ["decreased red cell production", "PROBLEM", 179, 208], ["anemia", "PROBLEM", 210, 216], ["clinical signs", "PROBLEM", 270, 284], ["nonregenerative", "OBSERVATION_MODIFIER", 7, 22], ["anemia", "OBSERVATION", 23, 29], ["should not be attributed to", "UNCERTAINTY", 30, 57], ["anemia", "OBSERVATION", 58, 64], ["chronic", "OBSERVATION_MODIFIER", 68, 75], ["disease", "OBSERVATION", 76, 83], ["Transfusion", "OBSERVATION", 120, 131], ["Anemia", "OBSERVATION", 135, 141], ["Red Cell", "OBSERVATION", 155, 163], ["decreased", "OBSERVATION_MODIFIER", 179, 188], ["red cell production", "OBSERVATION", 189, 208], ["anemia", "OBSERVATION", 210, 216], ["slowly", "OBSERVATION_MODIFIER", 220, 226], ["progressive", "OBSERVATION_MODIFIER", 227, 238], ["may be quite", "UNCERTAINTY", 243, 255], ["severe", "OBSERVATION_MODIFIER", 256, 262]]], ["Although compensatory mechanisms allow these patients to function at a low Hct, periodic transfusion of PRBCs may be required for survival.", [["PRBCs", "ANATOMY", 104, 109], ["patients", "ORGANISM", 45, 53], ["PRBCs", "CANCER", 104, 109], ["PRBCs", "CELL_TYPE", 104, 109], ["patients", "SPECIES", 45, 53], ["compensatory mechanisms", "PROBLEM", 9, 32], ["a low Hct", "PROBLEM", 69, 78], ["periodic transfusion of PRBCs", "TREATMENT", 80, 109]]], ["In contrast to anemia caused by hemolysis or blood loss, anemia from lack of production generally has a poorer prognosis for recovery.", [["blood", "ANATOMY", 45, 50], ["anemia", "DISEASE", 15, 21], ["hemolysis", "DISEASE", 32, 41], ["blood loss", "DISEASE", 45, 55], ["anemia", "DISEASE", 57, 63], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["anemia", "PROBLEM", 15, 21], ["hemolysis", "PROBLEM", 32, 41], ["blood loss", "PROBLEM", 45, 55], ["anemia", "PROBLEM", 57, 63], ["lack of production", "PROBLEM", 69, 87], ["anemia", "OBSERVATION", 15, 21], ["hemolysis", "OBSERVATION", 32, 41], ["blood loss", "OBSERVATION", 45, 55]]], ["Evaluation of bone marrow may provide clues to diagnosis as well as prognosis.", [["bone marrow", "ANATOMY", 14, 25], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 14, 25], ["Evaluation of bone marrow", "TEST", 0, 25], ["bone", "ANATOMY", 14, 18]]], ["If clinical signs of anemia such as tachycardia, tachypnea, and weakness are present at rest, transfusion is indicated.", [["anemia", "DISEASE", 21, 27], ["tachycardia", "DISEASE", 36, 47], ["tachypnea", "DISEASE", 49, 58], ["weakness", "DISEASE", 64, 72], ["anemia", "PROBLEM", 21, 27], ["tachycardia", "PROBLEM", 36, 47], ["tachypnea", "PROBLEM", 49, 58], ["weakness", "PROBLEM", 64, 72], ["transfusion", "TREATMENT", 94, 105], ["anemia", "OBSERVATION", 21, 27], ["weakness", "OBSERVATION", 64, 72]]], ["If the patient is asymptomatic, transfusion may be withheld.", [["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["asymptomatic", "PROBLEM", 18, 30], ["transfusion", "TREATMENT", 32, 43]]], ["However, if the Hct drops below 10%, the animal is at significant risk for acute collapse should it become stressed.", [["Hct", "PROTEIN", 16, 19], ["the Hct drops", "TEST", 12, 25], ["acute collapse", "PROBLEM", 75, 89], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["collapse", "OBSERVATION", 81, 89]]], ["Because the Hct in animals is rarely raised into the normal range by transfusion, one need not be concerned that the transfusion will further suppress hematopoiesis.", [["Hct", "GENE_OR_GENE_PRODUCT", 12, 15], ["Hct", "PROTEIN", 12, 15], ["the Hct", "TEST", 8, 15], ["the transfusion", "TREATMENT", 113, 128], ["hematopoiesis", "PROBLEM", 151, 164], ["normal range", "OBSERVATION_MODIFIER", 53, 65]]], ["Also, because hemosiderosis from iron overload becomes a possibility after multiple transfusions, additional iron supplementation should be avoided.", [["hemosiderosis", "DISEASE", 14, 27], ["iron", "CHEMICAL", 33, 37], ["iron", "CHEMICAL", 109, 113], ["iron", "CHEMICAL", 33, 37], ["iron", "CHEMICAL", 109, 113], ["iron", "SIMPLE_CHEMICAL", 33, 37], ["iron", "SIMPLE_CHEMICAL", 109, 113], ["hemosiderosis", "PROBLEM", 14, 27], ["iron overload", "PROBLEM", 33, 46], ["multiple transfusions", "TREATMENT", 75, 96], ["additional iron supplementation", "TREATMENT", 98, 129], ["iron overload", "OBSERVATION", 33, 46]]], ["Cross matching becomes progressively more important in animals receiving multiple transfusions because the risk of sensitization is greater.", [["multiple transfusions", "TREATMENT", 73, 94], ["sensitization", "PROBLEM", 115, 128], ["progressively", "OBSERVATION_MODIFIER", 23, 36], ["more important", "OBSERVATION_MODIFIER", 37, 51], ["greater", "OBSERVATION_MODIFIER", 132, 139]]], ["Advances in production and use of genetically engineered hematopoietic growth factors is discussed by Donahue (this volume).", [["genetically engineered hematopoietic growth factors", "PROTEIN", 34, 85], ["genetically engineered hematopoietic growth factors", "TREATMENT", 34, 85]]], ["Dogs and cats with anemia secondary to chronic renal failure often respond to treatment with recombinant human erythropoietin (Cowgill et al., 1990) .A. USES FOR FRESH-FROZEN PLASMAMilitary personnel were treated with plasma during World War II for treatment of hemorrhagic shock.", [["renal", "ANATOMY", 47, 52], ["plasma", "ANATOMY", 218, 224], ["anemia", "DISEASE", 19, 25], ["chronic renal failure", "DISEASE", 39, 60], ["hemorrhagic shock", "DISEASE", 262, 279], ["Dogs", "ORGANISM", 0, 4], ["cats", "ORGANISM", 9, 13], ["renal", "ORGAN", 47, 52], ["human", "ORGANISM", 105, 110], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 111, 125], ["plasma", "ORGANISM_SUBSTANCE", 218, 224], ["recombinant human erythropoietin", "PROTEIN", 93, 125], ["Dogs", "SPECIES", 0, 4], ["cats", "SPECIES", 9, 13], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["Dogs and cats", "PROBLEM", 0, 13], ["anemia", "PROBLEM", 19, 25], ["chronic renal failure", "PROBLEM", 39, 60], ["treatment", "TREATMENT", 78, 87], ["recombinant human erythropoietin", "TREATMENT", 93, 125], ["FRESH-FROZEN PLASMAMilitary personnel", "TREATMENT", 162, 199], ["plasma", "TREATMENT", 218, 224], ["hemorrhagic shock", "PROBLEM", 262, 279], ["anemia", "OBSERVATION", 19, 25], ["chronic", "OBSERVATION_MODIFIER", 39, 46], ["renal", "ANATOMY", 47, 52], ["failure", "OBSERVATION", 53, 60], ["hemorrhagic", "OBSERVATION_MODIFIER", 262, 273], ["shock", "OBSERVATION", 274, 279]]], ["The packed red cells obtained as a by-product were not recognized as a valuable resource until some time later.", [["red cells", "ANATOMY", 11, 20], ["red cells", "CELL", 11, 20], ["packed red cells", "CELL_TYPE", 4, 20], ["The packed red cells", "TREATMENT", 0, 20], ["packed red cells", "OBSERVATION", 4, 20]]], ["As more was learned about the value of crystalloids and colloids, and the risks associated with plasma, its use as a volume expander declined.", [["plasma", "ANATOMY", 96, 102], ["crystalloids", "ORGANISM_SUBSTANCE", 39, 51], ["plasma", "ORGANISM_SUBSTANCE", 96, 102], ["crystalloids", "TREATMENT", 39, 51], ["colloids", "TREATMENT", 56, 64], ["plasma", "TREATMENT", 96, 102], ["a volume expander", "TREATMENT", 115, 132], ["volume expander", "OBSERVATION", 117, 132]]], ["A conference at the National Institutes of Health in 1985 concluded that there was no justification for the use of plasma as a volume expander or nutritional supplement, although approximately 50% of fresh-frozen plasma transfusions in human hospitals were given for such reasons.", [["plasma", "ANATOMY", 115, 121], ["plasma", "ANATOMY", 213, 219], ["plasma", "ORGANISM_SUBSTANCE", 115, 121], ["plasma", "ORGANISM_SUBSTANCE", 213, 219], ["human", "ORGANISM", 236, 241], ["human", "SPECIES", 236, 241], ["human", "SPECIES", 236, 241], ["plasma", "TREATMENT", 115, 121], ["a volume expander", "TREATMENT", 125, 142], ["nutritional supplement", "TREATMENT", 146, 168], ["fresh-frozen plasma transfusions in human hospitals", "TREATMENT", 200, 251]]], ["As defined in American Association of Blood Banks (AABB) Standards (Widmann, 1985) , FFP is separated from fresh whole blood by centrifugation and frozen to -30\u00b0C within 6 hours of collection (see Authement, this volume).", [["Blood", "ANATOMY", 38, 43], ["whole blood", "ANATOMY", 113, 124], ["Blood", "ORGANISM_SUBSTANCE", 38, 43], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["FFP", "TREATMENT", 85, 88], ["collection", "PROBLEM", 181, 191]]], ["The major use for FFP both in animals and man is as a source of all clotting factors.A. USES FOR FRESH-FROZEN PLASMAWhen reasons for canine FFP transfusions were categorized at Tufts University School of Veterinary Medicine in 1987 and 1988, the most common use was for treatment of DIC (Stone et al., 1991) .", [["DIC", "DISEASE", 283, 286], ["FFP", "SIMPLE_CHEMICAL", 18, 21], ["man", "ORGANISM", 42, 45], ["clotting factors", "GENE_OR_GENE_PRODUCT", 68, 84], ["canine", "ORGANISM", 133, 139], ["FFP", "PROTEIN", 18, 21], ["clotting factors", "PROTEIN", 68, 84], ["man", "SPECIES", 42, 45], ["canine", "SPECIES", 133, 139], ["FFP", "TREATMENT", 18, 21], ["all clotting factors", "PROBLEM", 64, 84], ["FRESH-FROZEN PLASMAWhen reasons", "TREATMENT", 97, 128], ["canine FFP transfusions", "TREATMENT", 133, 156], ["DIC", "PROBLEM", 283, 286], ["clotting", "OBSERVATION", 68, 76]]], ["Dogs normally have short clotting times compared to man, and seem especially prone to develop DIC secondary to many serious illnesses.", [["DIC", "DISEASE", 94, 97], ["Dogs", "ORGANISM", 0, 4], ["man", "SPECIES", 52, 55], ["short clotting times", "PROBLEM", 19, 39], ["DIC", "PROBLEM", 94, 97], ["many serious illnesses", "PROBLEM", 111, 133], ["short clotting times", "OBSERVATION_MODIFIER", 19, 39]]], ["The most common causes of DIC include hemangiosarcoma, other malignancies, immune-mediated hemolytic anemia, gastric torsion, pancreatitis, heat stroke, liver disease, and infection, and were similar to those reported previously (Feldman et al., 1981) .A. USES FOR FRESH-FROZEN PLASMAThe laboratory diagnosis of DIC has been overemphasized and may be confusing (Westphal, 1984) .", [["hemangiosarcoma", "ANATOMY", 38, 53], ["malignancies", "ANATOMY", 61, 73], ["gastric", "ANATOMY", 109, 116], ["liver", "ANATOMY", 153, 158], ["DIC", "DISEASE", 26, 29], ["hemangiosarcoma", "DISEASE", 38, 53], ["malignancies", "DISEASE", 61, 73], ["hemolytic anemia", "DISEASE", 91, 107], ["gastric torsion", "DISEASE", 109, 124], ["pancreatitis", "DISEASE", 126, 138], ["heat stroke", "DISEASE", 140, 151], ["liver disease", "DISEASE", 153, 166], ["infection", "DISEASE", 172, 181], ["DIC", "DISEASE", 312, 315], ["hemangiosarcoma", "CANCER", 38, 53], ["malignancies", "CANCER", 61, 73], ["gastric", "ORGAN", 109, 116], ["liver", "ORGAN", 153, 158], ["DIC", "PROBLEM", 26, 29], ["hemangiosarcoma", "PROBLEM", 38, 53], ["other malignancies", "PROBLEM", 55, 73], ["immune-mediated hemolytic anemia", "PROBLEM", 75, 107], ["gastric torsion", "PROBLEM", 109, 124], ["pancreatitis", "PROBLEM", 126, 138], ["heat stroke", "PROBLEM", 140, 151], ["liver disease", "PROBLEM", 153, 166], ["infection", "PROBLEM", 172, 181], ["DIC", "PROBLEM", 312, 315], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["DIC", "OBSERVATION", 26, 29], ["hemangiosarcoma", "OBSERVATION", 38, 53], ["malignancies", "OBSERVATION", 61, 73], ["hemolytic", "OBSERVATION_MODIFIER", 91, 100], ["anemia", "OBSERVATION", 101, 107], ["gastric", "ANATOMY", 109, 116], ["torsion", "OBSERVATION", 117, 124], ["pancreatitis", "OBSERVATION", 126, 138], ["heat", "OBSERVATION_MODIFIER", 140, 144], ["stroke", "OBSERVATION", 145, 151], ["liver", "ANATOMY", 153, 158], ["disease", "OBSERVATION", 159, 166], ["infection", "OBSERVATION", 172, 181], ["may be", "UNCERTAINTY", 344, 350]]], ["Tests may change rapidly, and the classic picture of low platelets and fibrinogen, prolonged PT and PTT, and elevated fibrinogen degradation product (FDP) levels may not be present.", [["platelets", "ANATOMY", 57, 66], ["platelets", "CELL", 57, 66], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 71, 81], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 118, 128], ["FDP", "SIMPLE_CHEMICAL", 150, 153], ["low platelets", "CELL_TYPE", 53, 66], ["fibrinogen", "PROTEIN", 71, 81], ["fibrinogen", "PROTEIN", 118, 128], ["FDP", "PROTEIN", 150, 153], ["Tests", "TEST", 0, 5], ["low platelets", "PROBLEM", 53, 66], ["fibrinogen", "TEST", 71, 81], ["prolonged PT", "TEST", 83, 95], ["PTT", "TEST", 100, 103], ["elevated fibrinogen degradation product", "PROBLEM", 109, 148], ["FDP) levels", "TEST", 150, 161], ["low platelets", "OBSERVATION_MODIFIER", 53, 66], ["may not be", "UNCERTAINTY", 162, 172]]], ["Whenever the fibrinogen level is decreased below 80-100 mg/dl, the PT and PTT will be prolonged because fibrinogen is needed for fibrin formation in both tests.", [["fibrin", "ANATOMY", 129, 135], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 13, 23], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 104, 114], ["fibrin", "GENE_OR_GENE_PRODUCT", 129, 135], ["fibrinogen", "PROTEIN", 13, 23], ["fibrinogen", "PROTEIN", 104, 114], ["fibrin", "PROTEIN", 129, 135], ["the fibrinogen level", "TEST", 9, 29], ["the PT", "TEST", 63, 69], ["PTT", "TEST", 74, 77], ["fibrinogen", "TEST", 104, 114], ["fibrin formation", "PROBLEM", 129, 145]]], ["In one study in dogs, factor V was depleted but factor VIII was not (Feldman et al., 1981) .", [["dogs", "ORGANISM", 16, 20], ["factor V", "GENE_OR_GENE_PRODUCT", 22, 30], ["factor VIII", "GENE_OR_GENE_PRODUCT", 48, 59], ["factor V", "PROTEIN", 22, 30], ["factor VIII", "PROTEIN", 48, 59], ["dogs", "SPECIES", 16, 20], ["one study", "TEST", 3, 12]]], ["Although this differs from reports in humans and from experimental studies in dogs, it does not change the approach to treatment (Rabiner and Friedman, 1968) .", [["humans", "ORGANISM", 38, 44], ["dogs", "ORGANISM", 78, 82], ["humans", "SPECIES", 38, 44], ["dogs", "SPECIES", 78, 82], ["humans", "SPECIES", 38, 44], ["experimental studies", "TEST", 54, 74]]], ["Thrombocytopenia is so consistent that a diagnosis of DIC cannot be certain without it.", [["Thrombocytopenia", "DISEASE", 0, 16], ["DIC", "DISEASE", 54, 57], ["Thrombocytopenia", "PROBLEM", 0, 16], ["DIC", "PROBLEM", 54, 57]]], ["The platelet count returns to normal slowly over several days as DIC resolves.", [["platelet", "ANATOMY", 4, 12], ["DIC", "DISEASE", 65, 68], ["platelet", "CELL", 4, 12], ["The platelet count", "TEST", 0, 18], ["DIC", "PROBLEM", 65, 68], ["platelet count", "OBSERVATION", 4, 18], ["normal", "OBSERVATION", 30, 36], ["slowly", "OBSERVATION_MODIFIER", 37, 43]]], ["The fibrinogen level, however, rapidly returns to normal.", [["fibrinogen", "GENE_OR_GENE_PRODUCT", 4, 14], ["fibrinogen", "PROTEIN", 4, 14], ["The fibrinogen level", "TEST", 0, 20], ["normal", "OBSERVATION", 50, 56]]], ["FDPs are cleared primarily in the Kupffer cells of the liver and some are excreted in the urine.", [["Kupffer cells", "ANATOMY", 34, 47], ["liver", "ANATOMY", 55, 60], ["urine", "ANATOMY", 90, 95], ["FDPs", "SIMPLE_CHEMICAL", 0, 4], ["Kupffer cells", "CELL", 34, 47], ["liver", "ORGAN", 55, 60], ["urine", "ORGANISM_SUBSTANCE", 90, 95], ["FDPs", "PROTEIN", 0, 4], ["Kupffer cells", "CELL_TYPE", 34, 47], ["FDPs", "TEST", 0, 4], ["cleared", "OBSERVATION", 9, 16], ["Kupffer cells", "OBSERVATION", 34, 47], ["liver", "ANATOMY", 55, 60], ["some", "OBSERVATION_MODIFIER", 65, 69], ["excreted", "OBSERVATION", 74, 82], ["urine", "OBSERVATION", 90, 95]]], ["Elevated FDPs may sometimes be seen in hepatic or renal failure (Westphal, 1984) .", [["hepatic", "ANATOMY", 39, 46], ["renal", "ANATOMY", 50, 55], ["hepatic or renal failure", "DISEASE", 39, 63], ["FDPs", "SIMPLE_CHEMICAL", 9, 13], ["hepatic", "ORGAN", 39, 46], ["renal", "ORGAN", 50, 55], ["Elevated FDPs", "PROBLEM", 0, 13], ["renal failure", "PROBLEM", 50, 63], ["FDPs", "OBSERVATION", 9, 13], ["may sometimes be seen", "UNCERTAINTY", 14, 35], ["hepatic", "ANATOMY", 39, 46], ["renal", "ANATOMY", 50, 55], ["failure", "OBSERVATION", 56, 63]]], ["A discussion of treatment of DIC generates much of the same emotion as does the discussion of crystalloids versus colloids for treatment of shock.A. USES FOR FRESH-FROZEN PLASMABy the time DIC is clinically evident, clotting factors are severely depleted.", [["DIC", "DISEASE", 29, 32], ["shock", "DISEASE", 140, 145], ["DIC", "DISEASE", 189, 192], ["crystalloids", "ORGANISM_SUBSTANCE", 94, 106], ["colloids", "SIMPLE_CHEMICAL", 114, 122], ["clotting factors", "GENE_OR_GENE_PRODUCT", 216, 232], ["clotting factors", "PROTEIN", 216, 232], ["A.", "SPECIES", 146, 148], ["treatment", "TREATMENT", 16, 25], ["DIC", "PROBLEM", 29, 32], ["crystalloids", "TREATMENT", 94, 106], ["colloids", "TREATMENT", 114, 122], ["shock", "PROBLEM", 140, 145], ["DIC", "PROBLEM", 189, 192], ["clotting factors", "PROBLEM", 216, 232], ["severely depleted", "PROBLEM", 237, 254], ["shock", "OBSERVATION", 140, 145], ["severely", "OBSERVATION_MODIFIER", 237, 245], ["depleted", "OBSERVATION", 246, 254]]], ["Once a patient is bleeding and fibrinogen is low, and the PT and PTT are prolonged, replacement of clotting factors with FFP is needed in addition to supportive care (Burns, 1987) .", [["bleeding", "DISEASE", 18, 26], ["patient", "ORGANISM", 7, 14], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 31, 41], ["clotting factors", "GENE_OR_GENE_PRODUCT", 99, 115], ["FFP", "SIMPLE_CHEMICAL", 121, 124], ["fibrinogen", "PROTEIN", 31, 41], ["clotting factors", "PROTEIN", 99, 115], ["FFP", "PROTEIN", 121, 124], ["patient", "SPECIES", 7, 14], ["bleeding", "PROBLEM", 18, 26], ["fibrinogen", "TEST", 31, 41], ["the PT", "TEST", 54, 60], ["PTT", "TEST", 65, 68], ["replacement of clotting factors", "TREATMENT", 84, 115], ["FFP", "TREATMENT", 121, 124], ["bleeding", "OBSERVATION", 18, 26]]], ["Withholding FFP in the presence of significant ongoing hemorrhage is much like the old argument that nutritional support should be withheld from cancer patients because it \"feeds\" the tumor cells.", [["cancer", "ANATOMY", 145, 151], ["tumor cells", "ANATOMY", 184, 195], ["hemorrhage", "DISEASE", 55, 65], ["cancer", "DISEASE", 145, 151], ["tumor", "DISEASE", 184, 189], ["cancer", "CANCER", 145, 151], ["patients", "ORGANISM", 152, 160], ["tumor cells", "CELL", 184, 195], ["tumor cells", "CELL_TYPE", 184, 195], ["patients", "SPECIES", 152, 160], ["FFP", "TREATMENT", 12, 15], ["significant ongoing hemorrhage", "PROBLEM", 35, 65], ["nutritional support", "TREATMENT", 101, 120], ["the tumor cells", "PROBLEM", 180, 195], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["ongoing", "OBSERVATION_MODIFIER", 47, 54], ["hemorrhage", "OBSERVATION", 55, 65], ["tumor cells", "OBSERVATION", 184, 195]]], ["In addition to coagulation factors, FFP contains antithrombin III (AT III), a potent inhibitor of thrombin formation.", [["FFP", "SIMPLE_CHEMICAL", 36, 39], ["antithrombin III", "GENE_OR_GENE_PRODUCT", 49, 65], ["AT III", "GENE_OR_GENE_PRODUCT", 67, 73], ["thrombin", "GENE_OR_GENE_PRODUCT", 98, 106], ["coagulation factors", "PROTEIN", 15, 34], ["FFP", "PROTEIN", 36, 39], ["antithrombin III", "PROTEIN", 49, 65], ["AT III", "PROTEIN", 67, 73], ["thrombin", "PROTEIN", 98, 106], ["coagulation factors", "PROBLEM", 15, 34], ["FFP", "TREATMENT", 36, 39], ["antithrombin III", "TREATMENT", 49, 65], ["a potent inhibitor of thrombin formation", "TREATMENT", 76, 116], ["thrombin formation", "OBSERVATION", 98, 116]]], ["Replacement of AT III will help prevent further thrombosis.", [["thrombosis", "DISEASE", 48, 58], ["AT III", "GENE_OR_GENE_PRODUCT", 15, 21], ["Replacement of AT III", "TREATMENT", 0, 21], ["further thrombosis", "PROBLEM", 40, 58], ["thrombosis", "OBSERVATION", 48, 58]]], ["The endogenous production of AT III in dogs was shown to increase rapidly beginning within 6 hours of induction of DIC by endotoxin injection (Tanaka et al., 1986) .", [["DIC", "DISEASE", 115, 118], ["endotoxin", "CHEMICAL", 122, 131], ["AT III", "GENE_OR_GENE_PRODUCT", 29, 35], ["dogs", "ORGANISM", 39, 43], ["DIC", "SIMPLE_CHEMICAL", 115, 118], ["endotoxin", "SIMPLE_CHEMICAL", 122, 131], ["AT III", "PROTEIN", 29, 35], ["dogs", "SPECIES", 39, 43], ["DIC", "PROBLEM", 115, 118], ["endotoxin injection", "TREATMENT", 122, 141], ["endogenous", "OBSERVATION_MODIFIER", 4, 14], ["production", "OBSERVATION_MODIFIER", 15, 25], ["increase", "OBSERVATION_MODIFIER", 57, 65], ["rapidly", "OBSERVATION_MODIFIER", 66, 73]]], ["Production was able to surpass consumption after 1-2 days despite ongoing DIC.", [["DIC", "DISEASE", 74, 77], ["ongoing DIC", "PROBLEM", 66, 77]]], ["If one can eliminate the underlying cause of DIC and if bleeding is not evident, it is not necessary to \"treat\" the laboratory abnormalities; they can simply be monitored along with the patient.", [["DIC", "DISEASE", 45, 48], ["bleeding", "DISEASE", 56, 64], ["patient", "ORGANISM", 186, 193], ["patient", "SPECIES", 186, 193], ["DIC", "PROBLEM", 45, 48], ["bleeding", "PROBLEM", 56, 64], ["the laboratory abnormalities", "PROBLEM", 112, 140]]], ["In the most severe cases of DIC with excessive blood loss, replacement of red cells, clotting factors, and plate lets may be needed.", [["blood", "ANATOMY", 47, 52], ["red cells", "ANATOMY", 74, 83], ["DIC", "DISEASE", 28, 31], ["excessive blood loss", "DISEASE", 37, 57], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["cells", "CELL", 78, 83], ["clotting factors", "GENE_OR_GENE_PRODUCT", 85, 101], ["red cells", "CELL_TYPE", 74, 83], ["clotting factors", "PROTEIN", 85, 101], ["DIC", "PROBLEM", 28, 31], ["excessive blood loss", "PROBLEM", 37, 57], ["replacement of red cells", "TREATMENT", 59, 83], ["clotting factors", "TREATMENT", 85, 101], ["plate lets", "TREATMENT", 107, 117], ["most severe", "OBSERVATION_MODIFIER", 7, 18], ["DIC", "OBSERVATION", 28, 31], ["excessive", "OBSERVATION_MODIFIER", 37, 46], ["blood loss", "OBSERVATION", 47, 57], ["red cells", "OBSERVATION", 74, 83]]], ["Here fresh whole blood is indicated initially with individual components added later as needed.", [["whole blood", "ANATOMY", 11, 22], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["fresh whole blood", "TEST", 5, 22], ["individual components", "TREATMENT", 51, 72]]], ["For example, severe depletion of fibrinogen might best be treated with supplementary cryoprecipitate.", [["fibrinogen", "GENE_OR_GENE_PRODUCT", 33, 43], ["cryoprecipitate", "ORGANISM_SUBSTANCE", 85, 100], ["fibrinogen", "PROTEIN", 33, 43], ["severe depletion of fibrinogen", "PROBLEM", 13, 43], ["supplementary cryoprecipitate", "TREATMENT", 71, 100], ["severe", "OBSERVATION_MODIFIER", 13, 19], ["depletion", "OBSERVATION", 20, 29], ["fibrinogen", "OBSERVATION", 33, 43]]], ["Heparin is sometimes used in conjunction with FFP and controversy exists as to when and how it should be used.", [["Heparin", "CHEMICAL", 0, 7], ["Heparin", "SIMPLE_CHEMICAL", 0, 7], ["Heparin", "TREATMENT", 0, 7], ["FFP", "TREATMENT", 46, 49]]], ["There is general agreement that heparin used alone in the bleeding patient is risky and unlikely to be successful.", [["heparin", "CHEMICAL", 32, 39], ["bleeding", "DISEASE", 58, 66], ["heparin", "SIMPLE_CHEMICAL", 32, 39], ["patient", "ORGANISM", 67, 74], ["patient", "SPECIES", 67, 74], ["heparin", "TREATMENT", 32, 39], ["the bleeding", "PROBLEM", 54, 66], ["bleeding", "OBSERVATION", 58, 66], ["unlikely to be", "UNCERTAINTY", 88, 102], ["successful", "OBSERVATION", 103, 113]]], ["Heparin is a specific activator of AT III and requires its presence for its anticoagulant effect.", [["Heparin", "CHEMICAL", 0, 7], ["Heparin", "SIMPLE_CHEMICAL", 0, 7], ["AT III", "GENE_OR_GENE_PRODUCT", 35, 41], ["AT III", "PROTEIN", 35, 41], ["Heparin", "TREATMENT", 0, 7], ["its anticoagulant effect", "TREATMENT", 72, 96], ["anticoagulant", "OBSERVATION", 76, 89]]], ["If a patient continues to bleed or shows evidence of thrombosis 4 hours after ther apy is begun for the underlying disease and the clotting factors are replaced, then heparin should be added.", [["thrombosis", "DISEASE", 53, 63], ["heparin", "CHEMICAL", 167, 174], ["patient", "ORGANISM", 5, 12], ["clotting factors", "GENE_OR_GENE_PRODUCT", 131, 147], ["heparin", "SIMPLE_CHEMICAL", 167, 174], ["clotting factors", "PROTEIN", 131, 147], ["patient", "SPECIES", 5, 12], ["bleed", "PROBLEM", 26, 31], ["thrombosis", "PROBLEM", 53, 63], ["ther apy", "TREATMENT", 78, 86], ["the underlying disease", "PROBLEM", 100, 122], ["the clotting factors", "PROBLEM", 127, 147], ["heparin", "TREATMENT", 167, 174], ["thrombosis", "OBSERVATION", 53, 63], ["disease", "OBSERVATION", 115, 122]]], ["An exception to this rule would apply in cases in which the risk of development of DIC is very high.", [["DIC", "DISEASE", 83, 86], ["DIC", "PROBLEM", 83, 86], ["DIC", "OBSERVATION", 83, 86]]], ["For example, dogs with severe heat stroke frequently develop DIC and might benefit from prophylactic heparin when thrombosis is beginning and coagulation defects are not yet measurable.A. USES FOR FRESH-FROZEN PLASMAThe recommended doses of heparin vary from 80 units/kg every 4-6 hours (Bick, 1985) to 5-10 units/kg intravenously or subcutaneously every 8 hours (Ruehl et al., 1982) .", [["intravenously", "ANATOMY", 317, 330], ["subcutaneously", "ANATOMY", 334, 348], ["heat stroke", "DISEASE", 30, 41], ["DIC", "DISEASE", 61, 64], ["heparin", "CHEMICAL", 101, 108], ["thrombosis", "DISEASE", 114, 124], ["coagulation defects", "DISEASE", 142, 161], ["heparin", "CHEMICAL", 241, 248], ["dogs", "ORGANISM", 13, 17], ["heparin", "SIMPLE_CHEMICAL", 101, 108], ["heparin", "SIMPLE_CHEMICAL", 241, 248], ["dogs", "SPECIES", 13, 17], ["A.", "SPECIES", 185, 187], ["severe heat stroke", "PROBLEM", 23, 41], ["DIC", "PROBLEM", 61, 64], ["prophylactic heparin", "TREATMENT", 88, 108], ["thrombosis", "PROBLEM", 114, 124], ["coagulation defects", "PROBLEM", 142, 161], ["FRESH-FROZEN PLASMAThe", "TREATMENT", 197, 219], ["heparin", "TREATMENT", 241, 248], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["heat", "OBSERVATION_MODIFIER", 30, 34], ["stroke", "OBSERVATION", 35, 41], ["thrombosis", "OBSERVATION", 114, 124]]], ["Despite the controversy, heparin has never been shown to increase survival in Gram-negative sepsis or other states in which DIC is encountered (Corrigan and Jordan, 1970) .", [["heparin", "CHEMICAL", 25, 32], ["sepsis", "DISEASE", 92, 98], ["DIC", "DISEASE", 124, 127], ["heparin", "SIMPLE_CHEMICAL", 25, 32], ["heparin", "TREATMENT", 25, 32], ["Gram-negative sepsis", "PROBLEM", 78, 98], ["negative", "OBSERVATION_MODIFIER", 83, 91], ["sepsis", "OBSERVATION", 92, 98]]], ["Harker (1974) argued that heparin aggravates bleeding and the resulting rise in fibrinogen level reflects defective fibrin stabilization, not improved hemostasis.", [["fibrin", "ANATOMY", 116, 122], ["heparin", "CHEMICAL", 26, 33], ["bleeding", "DISEASE", 45, 53], ["heparin", "SIMPLE_CHEMICAL", 26, 33], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 80, 90], ["fibrin", "GENE_OR_GENE_PRODUCT", 116, 122], ["fibrinogen", "PROTEIN", 80, 90], ["fibrin", "PROTEIN", 116, 122], ["heparin aggravates bleeding", "PROBLEM", 26, 53], ["the resulting rise in fibrinogen level", "PROBLEM", 58, 96], ["defective fibrin stabilization", "TREATMENT", 106, 136], ["rise", "OBSERVATION_MODIFIER", 72, 76], ["defective", "OBSERVATION_MODIFIER", 106, 115], ["fibrin stabilization", "OBSERVATION", 116, 136], ["not", "UNCERTAINTY", 138, 141], ["improved", "OBSERVATION_MODIFIER", 142, 150], ["hemostasis", "OBSERVATION", 151, 161]]], ["Some have advocated incubating heparin with FFP before administering to activate antithrombin III to help prevent further thrombosis (Ruehl etal., 1982) .", [["heparin", "CHEMICAL", 31, 38], ["thrombosis", "DISEASE", 122, 132], ["heparin", "SIMPLE_CHEMICAL", 31, 38], ["FFP", "SIMPLE_CHEMICAL", 44, 47], ["antithrombin III", "GENE_OR_GENE_PRODUCT", 81, 97], ["antithrombin III", "PROTEIN", 81, 97], ["heparin", "TREATMENT", 31, 38], ["FFP", "TREATMENT", 44, 47], ["antithrombin III", "TREATMENT", 81, 97], ["further thrombosis", "PROBLEM", 114, 132], ["thrombosis", "OBSERVATION", 122, 132]]], ["Other therapeutic agents such as inhib itors of fibrinolysis (\u03b5-aminocaproic acid) and steroids are not likely to help and may be dangerous.", [["\u03b5-aminocaproic acid", "CHEMICAL", 62, 81], ["steroids", "CHEMICAL", 87, 95], ["\u03b5-aminocaproic acid", "CHEMICAL", 62, 81], ["steroids", "CHEMICAL", 87, 95], ["\u03b5-aminocaproic acid", "SIMPLE_CHEMICAL", 62, 81], ["steroids", "SIMPLE_CHEMICAL", 87, 95], ["Other therapeutic agents", "TREATMENT", 0, 24], ["fibrinolysis (\u03b5-aminocaproic acid)", "TREATMENT", 48, 82], ["steroids", "TREATMENT", 87, 95]]], ["Steroids slow the clearance of FDPs, bac teria, and immune complexes, but may be indicated in spetic shock from Gram-negative bacteria.", [["shock", "DISEASE", 101, 106], ["Steroids", "CHEMICAL", 0, 8], ["FDPs", "SIMPLE_CHEMICAL", 31, 35], ["bac teria", "SIMPLE_CHEMICAL", 37, 46], ["Gram", "GENE_OR_GENE_PRODUCT", 112, 116], ["immune complexes", "PROTEIN", 52, 68], ["Steroids", "TREATMENT", 0, 8], ["FDPs", "TEST", 31, 35], ["bac teria", "TREATMENT", 37, 46], ["spetic shock", "PROBLEM", 94, 106], ["Gram-negative bacteria", "PROBLEM", 112, 134], ["negative bacteria", "OBSERVATION", 117, 134]]], ["Antithrombin III concentrates have recently been used with some success in human patients, but are not available for animals.", [["Antithrombin III", "GENE_OR_GENE_PRODUCT", 0, 16], ["human", "ORGANISM", 75, 80], ["patients", "ORGANISM", 81, 89], ["Antithrombin III", "PROTEIN", 0, 16], ["human", "SPECIES", 75, 80], ["patients", "SPECIES", 81, 89], ["human", "SPECIES", 75, 80], ["Antithrombin III concentrates", "TREATMENT", 0, 29]]], ["In a thoughtful review of the topic, Feinstein (1982) stressed that beyond identification and removal of the underlying cause, treatment of DIC must be individualized and generalizations are difficult.", [["DIC", "DISEASE", 140, 143], ["removal", "TREATMENT", 94, 101], ["the underlying cause", "PROBLEM", 105, 125], ["DIC", "PROBLEM", 140, 143]]], ["Patients that are actively bleeding or require surgery should have factors replaced, and not receive heparin.A. USES FOR FRESH-FROZEN PLASMAIn hepatic failure, production of clotting factors, especially the vita min K-dependent factors, is decreased.", [["hepatic", "ANATOMY", 143, 150], ["bleeding", "DISEASE", 27, 35], ["heparin", "CHEMICAL", 101, 108], ["hepatic failure", "DISEASE", 143, 158], ["K", "CHEMICAL", 216, 217], ["Patients", "ORGANISM", 0, 8], ["heparin", "SIMPLE_CHEMICAL", 101, 108], ["hepatic", "ORGAN", 143, 150], ["clotting factors", "GENE_OR_GENE_PRODUCT", 174, 190], ["clotting factors", "PROTEIN", 174, 190], ["vita min K-dependent factors", "PROTEIN", 207, 235], ["Patients", "SPECIES", 0, 8], ["actively bleeding", "PROBLEM", 18, 35], ["surgery", "TREATMENT", 47, 54], ["heparin", "TREATMENT", 101, 108], ["FRESH-FROZEN PLASMAIn hepatic failure", "PROBLEM", 121, 158], ["clotting factors", "PROBLEM", 174, 190], ["dependent factors", "PROBLEM", 218, 235], ["bleeding", "OBSERVATION", 27, 35], ["hepatic", "ANATOMY", 143, 150], ["failure", "OBSERVATION", 151, 158], ["clotting factors", "OBSERVATION", 174, 190], ["decreased", "OBSERVATION_MODIFIER", 240, 249]]], ["If ascites or edema is present, the effectiveness of FFP is less because factors diffuse into the fluid.", [["ascites", "ANATOMY", 3, 10], ["edema", "ANATOMY", 14, 19], ["fluid", "ANATOMY", 98, 103], ["ascites", "DISEASE", 3, 10], ["edema", "DISEASE", 14, 19], ["edema", "PATHOLOGICAL_FORMATION", 14, 19], ["FFP", "SIMPLE_CHEMICAL", 53, 56], ["ascites", "PROBLEM", 3, 10], ["edema", "PROBLEM", 14, 19], ["FFP", "TREATMENT", 53, 56], ["factors diffuse into the fluid", "PROBLEM", 73, 103], ["ascites", "OBSERVATION", 3, 10], ["edema", "OBSERVATION", 14, 19], ["diffuse", "OBSERVATION_MODIFIER", 81, 88], ["fluid", "OBSERVATION", 98, 103]]], ["Vitamin K may be of benefit to these patients.", [["Vitamin K", "CHEMICAL", 0, 9], ["Vitamin K", "CHEMICAL", 0, 9], ["Vitamin K", "SIMPLE_CHEMICAL", 0, 9], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["Vitamin K", "TREATMENT", 0, 9]]], ["FFP has been used in treatment of hemophilia A and von Willebrand's disease, although cryoprecipitate, if available, is more appropriate.", [["FFP", "CHEMICAL", 0, 3], ["hemophilia", "DISEASE", 34, 44], ["von Willebrand's disease", "DISEASE", 51, 75], ["FFP", "SIMPLE_CHEMICAL", 0, 3], ["hemophilia A", "CANCER", 34, 46], ["cryoprecipitate", "ORGANISM_SUBSTANCE", 86, 101], ["FFP", "PROTEIN", 0, 3], ["FFP", "TREATMENT", 0, 3], ["hemophilia A", "PROBLEM", 34, 46], ["von Willebrand's disease", "PROBLEM", 51, 75], ["cryoprecipitate", "TREATMENT", 86, 101], ["hemophilia", "OBSERVATION", 34, 44]]], ["In these patients, unless bleeding has been extensive, it is advantageous to avoid transfusing red cells.", [["red cells", "ANATOMY", 95, 104], ["bleeding", "DISEASE", 26, 34], ["patients", "ORGANISM", 9, 17], ["red cells", "CELL", 95, 104], ["transfusing red cells", "CELL_TYPE", 83, 104], ["patients", "SPECIES", 9, 17], ["bleeding", "PROBLEM", 26, 34], ["transfusing red cells", "TREATMENT", 83, 104], ["red cells", "OBSERVATION", 95, 104]]], ["This will prevent or delay development of alloantibodies that could interfere with future transfusions.B. USES FOR FROZEN PLASMAFrozen plasma (FP) is defined as that salvaged from whole blood stored in the refrigerator for longer than 6 hours before freezing, or FFP that has been stored from 1 to 5 years.", [["plasma", "ANATOMY", 135, 141], ["whole blood", "ANATOMY", 180, 191], ["alloantibodies", "DISEASE", 42, 56], ["plasma", "ORGANISM_SUBSTANCE", 135, 141], ["blood", "ORGANISM_SUBSTANCE", 186, 191], ["alloantibodies", "PROBLEM", 42, 56], ["future transfusions", "TREATMENT", 83, 102], ["FROZEN PLASMAFrozen plasma (FP", "TREATMENT", 115, 145], ["whole blood", "TEST", 180, 191], ["FFP", "TREATMENT", 263, 266], ["alloantibodies", "OBSERVATION", 42, 56]]], ["Frozen plasma may be used as a source of stable clotting factors such as the vitamin K-dependent factors II, VII, IX, and X. Frozen plasma does not contain therapeutic levels of unstable factors such as VIII and V. Uses for FP include acute severe warfarin toxicity and hemophilia B. Plasma is sometimes used in animals as a source of albumin because species-specific albumin solutions are not available.", [["Frozen plasma", "ANATOMY", 0, 13], ["Frozen plasma", "ANATOMY", 125, 138], ["vitamin K-", "CHEMICAL", 77, 87], ["warfarin", "CHEMICAL", 248, 256], ["toxicity", "DISEASE", 257, 265], ["hemophilia", "DISEASE", 270, 280], ["vitamin K-", "CHEMICAL", 77, 87], ["warfarin", "CHEMICAL", 248, 256], ["plasma", "ORGANISM_SUBSTANCE", 7, 13], ["clotting factors", "GENE_OR_GENE_PRODUCT", 48, 64], ["vitamin K-dependent factors II", "GENE_OR_GENE_PRODUCT", 77, 107], ["VII", "GENE_OR_GENE_PRODUCT", 109, 112], ["IX", "GENE_OR_GENE_PRODUCT", 114, 116], ["plasma", "ORGANISM_SUBSTANCE", 132, 138], ["VIII", "GENE_OR_GENE_PRODUCT", 203, 207], ["Plasma", "ORGANISM_SUBSTANCE", 284, 290], ["albumin", "GENE_OR_GENE_PRODUCT", 335, 342], ["albumin", "GENE_OR_GENE_PRODUCT", 368, 375], ["clotting factors", "PROTEIN", 48, 64], ["vitamin K-dependent factors II", "PROTEIN", 77, 107], ["VII", "PROTEIN", 109, 112], ["IX", "PROTEIN", 114, 116], ["VIII", "PROTEIN", 203, 207], ["Frozen plasma", "TEST", 0, 13], ["stable clotting factors", "PROBLEM", 41, 64], ["the vitamin K-", "TEST", 73, 87], ["VII, IX, and X. Frozen plasma", "TEST", 109, 138], ["unstable factors", "PROBLEM", 178, 194], ["FP", "PROBLEM", 224, 226], ["acute severe warfarin toxicity", "PROBLEM", 235, 265], ["hemophilia B. Plasma", "PROBLEM", 270, 290], ["albumin", "TREATMENT", 335, 342], ["specific albumin solutions", "TREATMENT", 359, 385], ["stable", "OBSERVATION_MODIFIER", 41, 47], ["clotting", "OBSERVATION", 48, 56], ["acute", "OBSERVATION_MODIFIER", 235, 240], ["severe", "OBSERVATION_MODIFIER", 241, 247], ["warfarin", "OBSERVATION", 248, 256]]], ["When plasma was removed from normal dogs and replaced with crystalloid, hypoalbuminemic edema developed after 70% plasma dilution over a 3-hour period (Cervera and Moss, 1978) .", [["plasma", "ANATOMY", 5, 11], ["edema", "ANATOMY", 88, 93], ["plasma", "ANATOMY", 114, 120], ["edema", "DISEASE", 88, 93], ["plasma", "ORGANISM_SUBSTANCE", 5, 11], ["dogs", "ORGANISM", 36, 40], ["edema", "PATHOLOGICAL_FORMATION", 88, 93], ["plasma", "ORGANISM_SUBSTANCE", 114, 120], ["dogs", "SPECIES", 36, 40], ["crystalloid", "TREATMENT", 59, 70], ["hypoalbuminemic edema", "PROBLEM", 72, 93], ["70% plasma dilution", "TREATMENT", 110, 129], ["normal dogs", "OBSERVATION", 29, 40], ["edema", "OBSERVATION", 88, 93]]], ["Albumin is difficult to supply in adequate amounts to reverse hypoalbuminemia.", [["Albumin", "CHEMICAL", 0, 7], ["hypoalbuminemia", "DISEASE", 62, 77], ["Albumin", "GENE_OR_GENE_PRODUCT", 0, 7], ["Albumin", "TREATMENT", 0, 7], ["reverse hypoalbuminemia", "PROBLEM", 54, 77], ["hypoalbuminemia", "OBSERVATION", 62, 77]]], ["Approximately 60% of the total body albumin is located in the interstitial space and the concentration is in equilibrium with that in the plasma.", [["body", "ANATOMY", 31, 35], ["interstitial space", "ANATOMY", 62, 80], ["plasma", "ANATOMY", 138, 144], ["body", "ORGANISM_SUBDIVISION", 31, 35], ["albumin", "GENE_OR_GENE_PRODUCT", 36, 43], ["interstitial space", "MULTI-TISSUE_STRUCTURE", 62, 80], ["plasma", "ORGANISM_SUBSTANCE", 138, 144], ["the total body albumin", "TEST", 21, 43], ["total body", "ANATOMY_MODIFIER", 25, 35], ["albumin", "OBSERVATION", 36, 43], ["interstitial", "ANATOMY_MODIFIER", 62, 74], ["space", "ANATOMY_MODIFIER", 75, 80], ["concentration", "OBSERVATION_MODIFIER", 89, 102]]], ["If hypoalbuminemia develops, the calculated plasma albumin deficit represents only 40% of the whole-body deficit.", [["plasma", "ANATOMY", 44, 50], ["body", "ANATOMY", 100, 104], ["hypoalbuminemia", "DISEASE", 3, 18], ["albumin deficit", "DISEASE", 51, 66], ["plasma", "ORGANISM_SUBSTANCE", 44, 50], ["albumin", "GENE_OR_GENE_PRODUCT", 51, 58], ["body", "ORGANISM_SUBDIVISION", 100, 104], ["hypoalbuminemia", "PROBLEM", 3, 18], ["the calculated plasma albumin deficit", "TEST", 29, 66], ["the whole-body deficit", "PROBLEM", 90, 112], ["hypoalbuminemia", "OBSERVATION", 3, 18]]], ["If albumin is being lost via kidney or gastrointestinal tract, the albumin supplied by transfusion is quickly lost.", [["kidney", "ANATOMY", 29, 35], ["gastrointestinal tract", "ANATOMY", 39, 61], ["albumin", "GENE_OR_GENE_PRODUCT", 3, 10], ["kidney", "ORGAN", 29, 35], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 39, 61], ["albumin", "GENE_OR_GENE_PRODUCT", 67, 74], ["albumin", "PROTEIN", 3, 10], ["albumin", "PROTEIN", 67, 74], ["albumin", "TEST", 3, 10], ["the albumin", "TEST", 63, 74], ["transfusion", "TREATMENT", 87, 98], ["kidney", "ANATOMY", 29, 35], ["gastrointestinal tract", "ANATOMY", 39, 61]]], ["Acute reversible hypoalbuminemia, such as might occur with burns, might respond well to plasma transfusion.", [["plasma", "ANATOMY", 88, 94], ["hypoalbuminemia", "DISEASE", 17, 32], ["burns", "DISEASE", 59, 64], ["plasma", "ORGANISM_SUBSTANCE", 88, 94], ["Acute reversible hypoalbuminemia", "PROBLEM", 0, 32], ["burns", "PROBLEM", 59, 64], ["plasma transfusion", "TREATMENT", 88, 106], ["reversible", "OBSERVATION_MODIFIER", 6, 16], ["hypoalbuminemia", "OBSERVATION", 17, 32]]], ["Otherwise, hypoproteinemia is better treated by parenteral or enteral alimentation or other nutritional support.", [["hypoproteinemia", "DISEASE", 11, 26], ["hypoproteinemia", "PROBLEM", 11, 26], ["parenteral or enteral alimentation", "TREATMENT", 48, 82], ["other nutritional support", "TREATMENT", 86, 111], ["hypoproteinemia", "OBSERVATION", 11, 26]]], ["In catabolic states, infused albumin is metabolized as a calorie source.", [["albumin", "GENE_OR_GENE_PRODUCT", 29, 36], ["infused albumin", "TREATMENT", 21, 36], ["catabolic states", "OBSERVATION", 3, 19]]], ["The additional sodium contained in plasma might also aggravate edema or ascites.C. CRYOPRECIPITATECryoprecipitate is a concentrated solution of factor VIII, vWF, fibrinogen, and fibronectin, prepared from FFP by a slow thaw and separation of cryopoor plasma from the cryoprecipitate.", [["plasma", "ANATOMY", 35, 41], ["edema", "ANATOMY", 63, 68], ["ascites", "ANATOMY", 72, 79], ["cryopoor plasma", "ANATOMY", 242, 257], ["cryoprecipitate", "ANATOMY", 267, 282], ["sodium", "CHEMICAL", 15, 21], ["edema", "DISEASE", 63, 68], ["ascites", "DISEASE", 72, 79], ["sodium", "CHEMICAL", 15, 21], ["sodium", "SIMPLE_CHEMICAL", 15, 21], ["plasma", "ORGANISM_SUBSTANCE", 35, 41], ["edema", "PATHOLOGICAL_FORMATION", 63, 68], ["factor VIII", "GENE_OR_GENE_PRODUCT", 144, 155], ["vWF", "GENE_OR_GENE_PRODUCT", 157, 160], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 162, 172], ["fibronectin", "GENE_OR_GENE_PRODUCT", 178, 189], ["FFP", "SIMPLE_CHEMICAL", 205, 208], ["cryopoor", "ORGANISM_SUBSTANCE", 242, 250], ["plasma", "ORGANISM_SUBSTANCE", 251, 257], ["cryoprecipitate", "ORGANISM_SUBSTANCE", 267, 282], ["factor VIII", "PROTEIN", 144, 155], ["vWF", "PROTEIN", 157, 160], ["fibrinogen", "PROTEIN", 162, 172], ["fibronectin", "PROTEIN", 178, 189], ["The additional sodium", "TEST", 0, 21], ["aggravate edema", "PROBLEM", 53, 68], ["ascites", "PROBLEM", 72, 79], ["factor VIII", "TREATMENT", 144, 155], ["vWF", "TEST", 157, 160], ["fibrinogen", "TEST", 162, 172], ["fibronectin", "TREATMENT", 178, 189], ["FFP", "TREATMENT", 205, 208], ["a slow thaw", "TREATMENT", 212, 223], ["cryopoor plasma", "TREATMENT", 242, 257], ["the cryoprecipitate", "TREATMENT", 263, 282], ["aggravate", "OBSERVATION_MODIFIER", 53, 62], ["edema", "OBSERVATION", 63, 68], ["ascites", "OBSERVATION", 72, 79]]], ["It is used primarily to treat hemophilia A and von Willebrand's disease (vWD).", [["hemophilia", "DISEASE", 30, 40], ["von Willebrand's disease", "DISEASE", 47, 71], ["vWD", "DISEASE", 73, 76], ["hemophilia A", "PROBLEM", 30, 42], ["von Willebrand's disease", "PROBLEM", 47, 71], ["vWD", "PROBLEM", 73, 76], ["hemophilia", "OBSERVATION", 30, 40]]], ["Bleeding must be stopped as soon as possible in these animals, not only to conserve red cells but also to minimize damage to joints.", [["red cells", "ANATOMY", 84, 93], ["joints", "ANATOMY", 125, 131], ["Bleeding", "DISEASE", 0, 8], ["damage to joints", "DISEASE", 115, 131], ["red cells", "CELL", 84, 93], ["joints", "MULTI-TISSUE_STRUCTURE", 125, 131], ["red cells", "CELL_TYPE", 84, 93], ["Bleeding", "PROBLEM", 0, 8], ["red cells", "PROBLEM", 84, 93], ["damage to joints", "PROBLEM", 115, 131], ["joints", "ANATOMY", 125, 131]]], ["Other approaches to treatment of hemophilia A and vWD include deamino-8-D-arginine vasopressin (DDAVP) and danazol (a testosterone derivative), which have some efficacy of increasing levels of factor VIII and vWF.", [["hemophilia", "DISEASE", 33, 43], ["vWD", "DISEASE", 50, 53], ["deamino-8-D-arginine vasopressin", "CHEMICAL", 62, 94], ["DDAVP", "CHEMICAL", 96, 101], ["danazol", "CHEMICAL", 107, 114], ["testosterone", "CHEMICAL", 118, 130], ["deamino-8-D-arginine vasopressin", "CHEMICAL", 62, 94], ["DDAVP", "CHEMICAL", 96, 101], ["danazol", "CHEMICAL", 107, 114], ["testosterone", "CHEMICAL", 118, 130], ["deamino-8-D-arginine vasopressin", "SIMPLE_CHEMICAL", 62, 94], ["DDAVP", "SIMPLE_CHEMICAL", 96, 101], ["danazol", "SIMPLE_CHEMICAL", 107, 114], ["testosterone", "SIMPLE_CHEMICAL", 118, 130], ["factor VIII", "GENE_OR_GENE_PRODUCT", 193, 204], ["vWF", "GENE_OR_GENE_PRODUCT", 209, 212], ["factor VIII", "PROTEIN", 193, 204], ["WF", "PROTEIN", 210, 212], ["hemophilia A", "PROBLEM", 33, 45], ["vWD", "PROBLEM", 50, 53], ["deamino", "TEST", 62, 69], ["D-arginine vasopressin", "TREATMENT", 72, 94], ["DDAVP", "TREATMENT", 96, 101], ["danazol", "TREATMENT", 107, 114], ["a testosterone derivative", "TREATMENT", 116, 141], ["factor VIII", "PROBLEM", 193, 204], ["hemophilia", "OBSERVATION", 33, 43]]], ["Thyroid hormone has also been helpful in decreasing bleeding episodes in some dogs with vWD.", [["bleeding", "DISEASE", 52, 60], ["vWD", "DISEASE", 88, 91], ["Thyroid", "ORGAN", 0, 7], ["dogs", "ORGANISM", 78, 82], ["dogs", "SPECIES", 78, 82], ["decreasing bleeding episodes", "PROBLEM", 41, 69], ["vWD", "PROBLEM", 88, 91], ["decreasing", "OBSERVATION_MODIFIER", 41, 51], ["bleeding", "OBSERVATION", 52, 60]]], ["These approaches are described in more detail by Dodds (this volume [\"Blood Substitutes\"]).", [["Blood", "ANATOMY", 70, 75]]], ["Obviously, drugs, inhibiting platelet function, especially aspirin, should be avoided in patients with coagulopathies.", [["platelet", "ANATOMY", 29, 37], ["aspirin", "CHEMICAL", 59, 66], ["coagulopathies", "DISEASE", 103, 117], ["aspirin", "CHEMICAL", 59, 66], ["platelet", "CELL", 29, 37], ["aspirin", "SIMPLE_CHEMICAL", 59, 66], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["drugs", "TREATMENT", 11, 16], ["platelet function", "TEST", 29, 46], ["aspirin", "TREATMENT", 59, 66], ["coagulopathies", "PROBLEM", 103, 117]]], ["Although hypofibrinogenemia occurs in DIC, specific replacement of fibrinogen is usually not needed because adequate amounts are supplied in FFP.", [["hypofibrinogenemia", "DISEASE", 9, 27], ["DIC", "DISEASE", 38, 41], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 67, 77], ["fibrinogen", "PROTEIN", 67, 77], ["hypofibrinogenemia", "PROBLEM", 9, 27], ["DIC", "PROBLEM", 38, 41], ["specific replacement of fibrinogen", "TREATMENT", 43, 77], ["FFP", "TREATMENT", 141, 144], ["hypofibrinogenemia", "OBSERVATION", 9, 27]]], ["Cryoprecipitate has been used in human surgery as a source of tissue glue.D. ADMINISTRATION OF PLASMAIn dogs, plasma can be given without concern for blood type because few red cells are present, and plasma donors are unlikely to have preformed antibodies if they have not been previously transfused.", [["tissue", "ANATOMY", 62, 68], ["plasma", "ANATOMY", 110, 116], ["blood", "ANATOMY", 150, 155], ["red cells", "ANATOMY", 173, 182], ["plasma", "ANATOMY", 200, 206], ["Cryoprecipitate", "CHEMICAL", 0, 15], ["human", "ORGANISM", 33, 38], ["tissue", "TISSUE", 62, 68], ["dogs", "ORGANISM", 104, 108], ["plasma", "ORGANISM_SUBSTANCE", 110, 116], ["blood", "ORGANISM_SUBSTANCE", 150, 155], ["red cells", "CELL", 173, 182], ["plasma", "ORGANISM_SUBSTANCE", 200, 206], ["donors", "ORGANISM", 207, 213], ["red cells", "CELL_TYPE", 173, 182], ["antibodies", "PROTEIN", 245, 255], ["human", "SPECIES", 33, 38], ["dogs", "SPECIES", 104, 108], ["human", "SPECIES", 33, 38], ["Cryoprecipitate", "TREATMENT", 0, 15], ["human surgery", "TREATMENT", 33, 46], ["tissue glue", "PROBLEM", 62, 73], ["PLASMAIn dogs", "TREATMENT", 95, 108], ["plasma", "TREATMENT", 110, 116], ["blood type", "PROBLEM", 150, 160], ["few red cells", "PROBLEM", 169, 182], ["plasma donors", "TEST", 200, 213], ["preformed antibodies", "PROBLEM", 235, 255], ["tissue", "ANATOMY", 62, 68], ["glue", "OBSERVATION", 69, 73]]], ["When plasma is separated from PRBCs, the majority of the citrate remains in the plasma so it is generally given over a 2 to 4 hour period.", [["plasma", "ANATOMY", 5, 11], ["PRBCs", "ANATOMY", 30, 35], ["plasma", "ANATOMY", 80, 86], ["citrate", "CHEMICAL", 57, 64], ["citrate", "CHEMICAL", 57, 64], ["plasma", "ORGANISM_SUBSTANCE", 5, 11], ["PRBCs", "SIMPLE_CHEMICAL", 30, 35], ["citrate", "SIMPLE_CHEMICAL", 57, 64], ["plasma", "ORGANISM_SUBSTANCE", 80, 86], ["PRBCs", "CELL_TYPE", 30, 35], ["PRBCs", "TREATMENT", 30, 35], ["the citrate", "TREATMENT", 53, 64]]], ["The dose is dependent on the degree of clotting factor deficit, so pre-and post-transfusion evaluations of the PT and APTT are indicated.", [["clotting factor", "GENE_OR_GENE_PRODUCT", 39, 54], ["APTT", "GENE_OR_GENE_PRODUCT", 118, 122], ["clotting factor", "PROTEIN", 39, 54], ["APTT", "PROTEIN", 118, 122], ["clotting factor deficit", "PROBLEM", 39, 62], ["pre-and post-transfusion evaluations", "TEST", 67, 103], ["the PT", "TEST", 107, 113], ["APTT", "TEST", 118, 122], ["clotting", "OBSERVATION", 39, 47]]], ["If cryoprecipitate or FFP is to be given prior to surgery, the infusion should begin about 1 hour before anesthesia for maximum benefit.", [["cryoprecipitate", "ORGANISM_SUBSTANCE", 3, 18], ["FFP", "SIMPLE_CHEMICAL", 22, 25], ["cryoprecipitate", "TREATMENT", 3, 18], ["FFP", "TREATMENT", 22, 25], ["surgery", "TREATMENT", 50, 57], ["the infusion", "TREATMENT", 59, 71], ["anesthesia", "TREATMENT", 105, 115]]], ["For example, factor VIII has a half-life of 6-8 hours so minimal benefit is obtained by giving it several hours before surgery.VIII. Transfusion of PlateletsThe major indication for platelet transfusion is to stop bleeding in patients with decreased platelet production or function.", [["Platelets", "ANATOMY", 148, 157], ["platelet", "ANATOMY", 182, 190], ["platelet", "ANATOMY", 250, 258], ["bleeding", "DISEASE", 214, 222], ["factor VIII", "GENE_OR_GENE_PRODUCT", 13, 24], ["VIII", "GENE_OR_GENE_PRODUCT", 127, 131], ["Platelets", "CELL", 148, 157], ["platelet", "CELL", 182, 190], ["patients", "ORGANISM", 226, 234], ["platelet", "CELL", 250, 258], ["factor VIII", "PROTEIN", 13, 24], ["VIII", "PROTEIN", 127, 131], ["Platelets", "CELL_TYPE", 148, 157], ["patients", "SPECIES", 226, 234], ["factor VIII", "TEST", 13, 24], ["surgery", "TREATMENT", 119, 126], ["Transfusion of Platelets", "TREATMENT", 133, 157], ["platelet transfusion", "TREATMENT", 182, 202], ["bleeding", "PROBLEM", 214, 222], ["decreased platelet production", "PROBLEM", 240, 269], ["decreased platelet production", "OBSERVATION", 240, 269]]], ["Platelet transfusions are given less frequently in animals than in man because of difficulties in preparing the needed volumes and because storage time is so short.", [["Platelet", "ANATOMY", 0, 8], ["Platelet", "CELL", 0, 8], ["man", "SPECIES", 67, 70], ["Platelet transfusions", "TREATMENT", 0, 21], ["transfusions", "OBSERVATION", 9, 21]]], ["Essentially no functional platelets are present in stored refrigerated whole blood or packed red cells.", [["platelets", "ANATOMY", 26, 35], ["whole blood", "ANATOMY", 71, 82], ["red cells", "ANATOMY", 93, 102], ["platelets", "CELL", 26, 35], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["red cells", "CELL", 93, 102], ["functional platelets", "CELL_TYPE", 15, 35], ["packed red cells", "CELL_TYPE", 86, 102], ["functional platelets", "PROBLEM", 15, 35], ["packed red cells", "TREATMENT", 86, 102], ["no", "UNCERTAINTY", 12, 14], ["functional platelets", "OBSERVATION", 15, 35], ["red cells", "OBSERVATION", 93, 102]]], ["Even fresh whole blood will not contain adequate platelets in volumes commonly transfused to raise the platelet count of a thrombocytopenic animal.", [["whole blood", "ANATOMY", 11, 22], ["platelets", "ANATOMY", 49, 58], ["platelet", "ANATOMY", 103, 111], ["thrombocytopenic", "DISEASE", 123, 139], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["platelets", "CELL", 49, 58], ["platelet", "CELL", 103, 111], ["platelets", "CELL_TYPE", 49, 58], ["the platelet count", "TEST", 99, 117], ["a thrombocytopenic animal", "PROBLEM", 121, 146], ["adequate", "OBSERVATION_MODIFIER", 40, 48], ["platelets", "OBSERVATION", 49, 58], ["thrombocytopenic", "OBSERVATION", 123, 139]]], ["In humans patients, a standard platelet transfusion contains platelets concentrated from 6-8 units of blood.", [["platelet", "ANATOMY", 31, 39], ["platelets", "ANATOMY", 61, 70], ["blood", "ANATOMY", 102, 107], ["humans", "ORGANISM", 3, 9], ["patients", "ORGANISM", 10, 18], ["platelet", "CELL", 31, 39], ["platelets", "CELL", 61, 70], ["blood", "ORGANISM_SUBSTANCE", 102, 107], ["platelets", "CELL_TYPE", 61, 70], ["humans", "SPECIES", 3, 9], ["patients", "SPECIES", 10, 18], ["humans", "SPECIES", 3, 9], ["a standard platelet transfusion", "TREATMENT", 20, 51], ["platelets", "TEST", 61, 70], ["blood", "TEST", 102, 107]]], ["These are stored as platelet-rich plasma for up to 4-5 days at room temperature with constant rocking to prevent aggregation.", [["platelet", "ANATOMY", 20, 28], ["plasma", "ANATOMY", 34, 40], ["aggregation", "DISEASE", 113, 124], ["platelet", "CELL", 20, 28], ["plasma", "ORGANISM_SUBSTANCE", 34, 40], ["platelet", "CELL_TYPE", 20, 28], ["platelet", "TEST", 20, 28], ["aggregation", "PROBLEM", 113, 124], ["aggregation", "OBSERVATION", 113, 124]]], ["A platelet pack of 6 units is expected to raise the platelet count of the adult human recipient by approximately 60,000/\u03bc1 imme diately after the transfusion.", [["platelet", "ANATOMY", 2, 10], ["platelet", "ANATOMY", 52, 60], ["platelet", "CELL", 2, 10], ["platelet", "CELL", 52, 60], ["human", "ORGANISM", 80, 85], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85], ["A platelet pack of 6 units", "TREATMENT", 0, 26], ["the platelet count", "TEST", 48, 66], ["the transfusion", "TREATMENT", 142, 157], ["platelet count", "OBSERVATION", 52, 66]]], ["Thus a 50-pound dog receiving 1 unit of fresh whole blood or platelet-rich plasma would be expected to have an increase of approximately 20,000/\u03bc1; 1 unit per 10 kg has been estab lished as a reasonable starting dose.", [["whole blood", "ANATOMY", 46, 57], ["platelet-rich plasma", "ANATOMY", 61, 81], ["dog", "ORGANISM", 16, 19], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["platelet", "CELL", 61, 69], ["plasma", "ORGANISM_SUBSTANCE", 75, 81], ["platelet", "CELL_TYPE", 61, 69], ["fresh whole blood", "TREATMENT", 40, 57], ["platelet-rich plasma", "TREATMENT", 61, 81], ["increase", "OBSERVATION_MODIFIER", 111, 119]]], ["Further units can be given depend ing on the posttransfusion count and clinical status of the patient.", [["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101], ["Further units", "TREATMENT", 0, 13], ["the posttransfusion count", "TEST", 41, 66]]], ["A practical approach in bleeding thrombocytopenic animals is to supply at least some platelets as fresh whole blood.", [["platelets", "ANATOMY", 85, 94], ["whole blood", "ANATOMY", 104, 115], ["bleeding", "DISEASE", 24, 32], ["thrombocytopenic", "DISEASE", 33, 49], ["platelets", "CELL", 85, 94], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["platelets", "CELL_TYPE", 85, 94], ["A practical approach", "TREATMENT", 0, 20], ["bleeding thrombocytopenic animals", "PROBLEM", 24, 57], ["fresh whole blood", "PROBLEM", 98, 115], ["bleeding", "OBSERVATION_MODIFIER", 24, 32], ["thrombocytopenic", "OBSERVATION", 33, 49]]], ["Red cell replacement has the added benefit of increasing platelet-to-platelet and platelet-toendothelium interaction.", [["cell", "ANATOMY", 4, 8], ["platelet", "ANATOMY", 57, 65], ["platelet", "ANATOMY", 69, 77], ["platelet", "ANATOMY", 82, 90], ["Red cell", "CELL", 0, 8], ["platelet", "CELL", 57, 65], ["platelet", "CELL", 69, 77], ["platelet", "CELL", 82, 90], ["toendothelium", "GENE_OR_GENE_PRODUCT", 91, 104], ["Red cell replacement", "TREATMENT", 0, 20], ["increasing platelet", "TREATMENT", 46, 65], ["platelet", "TEST", 69, 77], ["platelet", "TEST", 82, 90], ["cell replacement", "OBSERVATION", 4, 20], ["increasing", "OBSERVATION_MODIFIER", 46, 56], ["platelet", "OBSERVATION", 57, 65]]], ["Thus bleeding time may be improved in thrombocytopenic patients through red cell transfusion (Escolar et al., 1988) .VIII. Transfusion of PlateletsMost patients with a platelet count over 50,000/\u03bc1 will tolerate sur gery without the need for platelets (Tomasulo and Lenes, 1984) .", [["red cell", "ANATOMY", 72, 80], ["Platelets", "ANATOMY", 138, 147], ["platelet", "ANATOMY", 168, 176], ["platelets", "ANATOMY", 242, 251], ["bleeding", "DISEASE", 5, 13], ["thrombocytopenic", "DISEASE", 38, 54], ["patients", "ORGANISM", 55, 63], ["red cell", "CELL", 72, 80], ["VIII", "GENE_OR_GENE_PRODUCT", 117, 121], ["Platelets", "CELL", 138, 147], ["patients", "ORGANISM", 152, 160], ["platelet", "CELL", 168, 176], ["platelets", "CELL", 242, 251], ["VIII", "PROTEIN", 117, 121], ["Platelets", "CELL_TYPE", 138, 147], ["platelets", "CELL_TYPE", 242, 251], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 152, 160], ["bleeding", "PROBLEM", 5, 13], ["red cell transfusion", "TREATMENT", 72, 92], ["Transfusion of Platelets", "TREATMENT", 123, 147], ["a platelet count", "TEST", 166, 182], ["platelets (Tomasulo and Lenes", "TREATMENT", 242, 271], ["bleeding", "OBSERVATION", 5, 13], ["may be", "UNCERTAINTY", 19, 25], ["improved", "OBSERVATION_MODIFIER", 26, 34], ["thrombocytopenic", "OBSERVATION", 38, 54], ["PlateletsMost", "OBSERVATION_MODIFIER", 138, 151]]], ["If unexpected bleeding occurs, platelets can be given, but the need is seldom urgent because bleeding from thrombocytopenia is not rapid.", [["platelets", "ANATOMY", 31, 40], ["bleeding", "DISEASE", 14, 22], ["bleeding", "DISEASE", 93, 101], ["thrombocytopenia", "DISEASE", 107, 123], ["platelets", "CELL", 31, 40], ["platelets", "CELL_TYPE", 31, 40], ["unexpected bleeding", "PROBLEM", 3, 22], ["platelets", "TREATMENT", 31, 40], ["bleeding", "PROBLEM", 93, 101], ["thrombocytopenia", "PROBLEM", 107, 123], ["bleeding", "OBSERVATION", 14, 22], ["thrombocytopenia", "OBSERVATION", 107, 123], ["not", "UNCERTAINTY", 127, 130], ["rapid", "OBSERVATION_MODIFIER", 131, 136]]], ["If bleeding is more severe it may indicate inadequate surgical hemostasis rather than effects of thrombocytopenia.", [["bleeding", "DISEASE", 3, 11], ["thrombocytopenia", "DISEASE", 97, 113], ["bleeding", "PROBLEM", 3, 11], ["inadequate surgical hemostasis", "TREATMENT", 43, 73], ["thrombocytopenia", "PROBLEM", 97, 113], ["bleeding", "OBSERVATION", 3, 11], ["more severe", "OBSERVATION_MODIFIER", 15, 26], ["inadequate", "OBSERVATION_MODIFIER", 43, 53], ["surgical hemostasis", "OBSERVATION", 54, 73], ["thrombocytopenia", "OBSERVATION", 97, 113]]], ["Platelet transfusions are con sidered urgent only if bleeding is into the central nervous system or eye.", [["Platelet", "ANATOMY", 0, 8], ["central nervous system", "ANATOMY", 74, 96], ["eye", "ANATOMY", 100, 103], ["bleeding", "DISEASE", 53, 61], ["Platelet", "CELL", 0, 8], ["central nervous system", "ANATOMICAL_SYSTEM", 74, 96], ["eye", "ORGAN", 100, 103], ["Platelet transfusions", "TREATMENT", 0, 21], ["bleeding", "PROBLEM", 53, 61], ["central", "ANATOMY_MODIFIER", 74, 81], ["nervous system", "ANATOMY", 82, 96], ["eye", "ANATOMY", 100, 103]]], ["Platelet transfusions may be ineffective in the presence of splenomeg aly, sepsis, DIC, or hypothermia.VIII. Transfusion of PlateletsThe adverse effects of local or systemic hypothermia on platelet func tion are often overlooked.", [["Platelet", "ANATOMY", 0, 8], ["Platelets", "ANATOMY", 124, 133], ["platelet", "ANATOMY", 189, 197], ["sepsis", "DISEASE", 75, 81], ["DIC", "DISEASE", 83, 86], ["hypothermia", "DISEASE", 91, 102], ["hypothermia", "DISEASE", 174, 185], ["Platelet", "CELL", 0, 8], ["VIII", "GENE_OR_GENE_PRODUCT", 103, 107], ["Platelets", "CELL", 124, 133], ["platelet", "CELL", 189, 197], ["VIII", "PROTEIN", 103, 107], ["Platelets", "CELL_TYPE", 124, 133], ["Platelet transfusions", "TREATMENT", 0, 21], ["splenomeg aly", "PROBLEM", 60, 73], ["sepsis", "PROBLEM", 75, 81], ["DIC", "PROBLEM", 83, 86], ["hypothermia", "PROBLEM", 91, 102], ["Transfusion of Platelets", "TREATMENT", 109, 133], ["systemic hypothermia", "PROBLEM", 165, 185], ["platelet func tion", "TREATMENT", 189, 207], ["transfusions", "OBSERVATION", 9, 21], ["may be", "UNCERTAINTY", 22, 28], ["ineffective", "OBSERVATION_MODIFIER", 29, 40], ["sepsis", "OBSERVATION", 75, 81], ["hypothermia", "OBSERVATION", 91, 102], ["systemic", "OBSERVATION_MODIFIER", 165, 173], ["hypothermia", "OBSERVATION", 174, 185]]], ["Blood coagulation reactions are enzymatic and are dependent on temperature.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood coagulation reactions", "TEST", 0, 27], ["temperature", "TEST", 63, 74], ["dependent", "OBSERVATION_MODIFIER", 50, 59]]], ["Cooling of the skin causes revers ible platelet dysfunction and prolongation of the bleeding time (Valeri et al., 1987) .VIII. Transfusion of PlateletsIn the presence of idiopathic thrombocytopenic purpura (ITP) or alloimmunization from previous transfusions, platelet transfusions may be totally ineffective.", [["skin", "ANATOMY", 15, 19], ["platelet", "ANATOMY", 39, 47], ["Platelets", "ANATOMY", 142, 151], ["platelet", "ANATOMY", 260, 268], ["platelet dysfunction", "DISEASE", 39, 59], ["prolongation of the bleeding", "DISEASE", 64, 92], ["idiopathic thrombocytopenic purpura", "DISEASE", 170, 205], ["ITP", "DISEASE", 207, 210], ["alloimmunization", "DISEASE", 215, 231], ["skin", "ORGAN", 15, 19], ["platelet", "CELL", 39, 47], ["VIII", "GENE_OR_GENE_PRODUCT", 121, 125], ["Platelets", "CELL", 142, 151], ["platelet", "CELL", 260, 268], ["VIII", "PROTEIN", 121, 125], ["Platelets", "CELL_TYPE", 142, 151], ["revers ible platelet dysfunction", "PROBLEM", 27, 59], ["the bleeding time", "PROBLEM", 80, 97], ["Transfusion of Platelets", "TREATMENT", 127, 151], ["idiopathic thrombocytopenic purpura", "PROBLEM", 170, 205], ["ITP)", "PROBLEM", 207, 211], ["alloimmunization", "TREATMENT", 215, 231], ["previous transfusions", "TREATMENT", 237, 258], ["platelet transfusions", "TREATMENT", 260, 281], ["skin", "ANATOMY", 15, 19], ["ible platelet dysfunction", "OBSERVATION", 34, 59], ["prolongation", "OBSERVATION_MODIFIER", 64, 76], ["bleeding", "OBSERVATION", 84, 92], ["idiopathic", "OBSERVATION_MODIFIER", 170, 180], ["thrombocytopenic purpura", "OBSERVATION", 181, 205]]], ["In humans, HLA-matched platelets, obtained by apheresis, are used for patients that have developed alloantibodies.", [["platelets", "ANATOMY", 23, 32], ["alloantibodies", "DISEASE", 99, 113], ["humans", "ORGANISM", 3, 9], ["platelets", "CELL", 23, 32], ["patients", "ORGANISM", 70, 78], ["platelets", "CELL_TYPE", 23, 32], ["alloantibodies", "PROTEIN", 99, 113], ["humans", "SPECIES", 3, 9], ["patients", "SPECIES", 70, 78], ["humans", "SPECIES", 3, 9], ["platelets", "TREATMENT", 23, 32], ["alloantibodies", "PROBLEM", 99, 113], ["alloantibodies", "OBSERVATION", 99, 113]]], ["Platelet transfusions, are frequently ineffective even in nonimmunized hosts (Tomasulo and Lenes, 1984) .", [["Platelet", "ANATOMY", 0, 8], ["Platelet", "CELL", 0, 8], ["Platelet transfusions", "TREATMENT", 0, 21], ["transfusions", "OBSERVATION", 9, 21], ["ineffective", "OBSERVATION_MODIFIER", 38, 49]]], ["The dog has been used as a model to study platelet function and survival.", [["platelet", "ANATOMY", 42, 50], ["dog", "ORGANISM", 4, 7], ["platelet", "CELL", 42, 50], ["dog", "SPECIES", 4, 7], ["study platelet function", "TEST", 36, 59]]], ["In one study, 18 of 21 (86%) dogs given up to eight platelet transfusions from a single, unrelated donor become immunized after an average of 2.3 transfusions (Slichter et al., 1988) .", [["platelet", "ANATOMY", 52, 60], ["dogs", "ORGANISM", 29, 33], ["platelet", "CELL", 52, 60], ["dogs", "SPECIES", 29, 33], ["one study", "TEST", 3, 12], ["eight platelet transfusions", "TREATMENT", 46, 73], ["a single, unrelated donor", "TREATMENT", 79, 104], ["transfusions", "TREATMENT", 146, 158]]], ["This alloimmunization resulted in a rapid destruction of trans fused platelets that could not be prevented by pretreatment with prednisone, splenectomy, cyclophosphamide, or vincristine.", [["platelets", "ANATOMY", 69, 78], ["alloimmunization", "DISEASE", 5, 21], ["prednisone", "CHEMICAL", 128, 138], ["cyclophosphamide", "CHEMICAL", 153, 169], ["vincristine", "CHEMICAL", 174, 185], ["prednisone", "CHEMICAL", 128, 138], ["cyclophosphamide", "CHEMICAL", 153, 169], ["vincristine", "CHEMICAL", 174, 185], ["platelets", "CELL", 69, 78], ["prednisone", "SIMPLE_CHEMICAL", 128, 138], ["cyclophosphamide", "SIMPLE_CHEMICAL", 153, 169], ["vincristine", "SIMPLE_CHEMICAL", 174, 185], ["trans fused platelets", "CELL_TYPE", 57, 78], ["This alloimmunization", "TREATMENT", 0, 21], ["a rapid destruction of trans fused platelets", "PROBLEM", 34, 78], ["prednisone", "TREATMENT", 128, 138], ["splenectomy", "TREATMENT", 140, 151], ["cyclophosphamide", "TREATMENT", 153, 169], ["vincristine", "TREATMENT", 174, 185], ["rapid", "OBSERVATION_MODIFIER", 36, 41], ["destruction", "OBSERVATION", 42, 53], ["could not be prevented", "UNCERTAINTY", 84, 106], ["splenectomy", "OBSERVATION", 140, 151]]], ["Those studies emphasized the highly immunogenic nature of platelet transfusions and the importance of posttransfusion monitoring.VIII. Transfusion of PlateletsIn situations of platelet destruction such as ITP, the survival of transfused platelets is a matter of minutes rather than 3-4 days as it may be in conditions of marrow failure.", [["platelet", "ANATOMY", 58, 66], ["Platelets", "ANATOMY", 150, 159], ["platelet", "ANATOMY", 176, 184], ["platelets", "ANATOMY", 237, 246], ["marrow", "ANATOMY", 321, 327], ["platelet destruction", "DISEASE", 176, 196], ["ITP", "DISEASE", 205, 208], ["marrow failure", "DISEASE", 321, 335], ["platelet", "CELL", 58, 66], ["VIII", "GENE_OR_GENE_PRODUCT", 129, 133], ["Platelets", "CELL", 150, 159], ["platelet", "CELL", 176, 184], ["platelets", "CELL", 237, 246], ["marrow", "ORGAN", 321, 327], ["VIII", "PROTEIN", 129, 133], ["Platelets", "CELL_TYPE", 150, 159], ["transfused platelets", "CELL_TYPE", 226, 246], ["Those studies", "TEST", 0, 13], ["platelet transfusions", "TREATMENT", 58, 79], ["posttransfusion monitoring", "TEST", 102, 128], ["Transfusion of Platelets", "TREATMENT", 135, 159], ["platelet destruction", "PROBLEM", 176, 196], ["ITP", "PROBLEM", 205, 208], ["transfused platelets", "TREATMENT", 226, 246], ["marrow failure", "PROBLEM", 321, 335], ["platelet transfusions", "OBSERVATION", 58, 79], ["platelet destruction", "OBSERVATION", 176, 196], ["marrow failure", "OBSERVATION", 321, 335]]], ["The spleen is where the major loss of platelets occurs.", [["spleen", "ANATOMY", 4, 10], ["platelets", "ANATOMY", 38, 47], ["spleen", "ORGAN", 4, 10], ["platelets", "CELL", 38, 47], ["platelets", "CELL_TYPE", 38, 47], ["the major loss of platelets", "PROBLEM", 20, 47], ["spleen", "ANATOMY", 4, 10], ["major", "OBSERVATION_MODIFIER", 24, 29], ["loss", "OBSERVATION", 30, 34], ["platelets", "OBSERVATION", 38, 47]]], ["It is imprudent to assume that platelet transfusions, once administered, have benefited the patient.", [["platelet", "ANATOMY", 31, 39], ["platelet", "CELL", 31, 39], ["patient", "ORGANISM", 92, 99], ["patient", "SPECIES", 92, 99], ["platelet transfusions", "TREATMENT", 31, 52], ["platelet transfusions", "OBSERVATION", 31, 52]]], ["The platelet count should be run before and within 1 hour after the transfusion.", [["platelet", "ANATOMY", 4, 12], ["platelet", "CELL", 4, 12], ["The platelet count", "TEST", 0, 18], ["the transfusion", "TREATMENT", 64, 79], ["platelet count", "OBSERVATION", 4, 18]]], ["If the count does not rise as expected, destruction of platelets may be occurring.", [["platelets", "ANATOMY", 55, 64], ["platelets", "CELL", 55, 64], ["platelets", "CELL_TYPE", 55, 64], ["the count", "TEST", 3, 12], ["destruction of platelets", "PROBLEM", 40, 64], ["may be", "UNCERTAINTY", 65, 71]]], ["Any platelet transfusion that does not result in an increase in platelet count immediately after the transfusion should be considered a failure (Tomasulo and Lenes, 1984) .", [["platelet", "ANATOMY", 4, 12], ["platelet", "ANATOMY", 64, 72], ["platelet", "CELL", 4, 12], ["platelet", "CELL", 64, 72], ["Any platelet transfusion", "TREATMENT", 0, 24], ["platelet count", "TEST", 64, 78], ["the transfusion", "TREATMENT", 97, 112], ["a failure", "PROBLEM", 134, 143], ["platelet transfusion", "OBSERVATION", 4, 24], ["increase", "OBSERVATION_MODIFIER", 52, 60], ["platelet count", "OBSERVATION", 64, 78], ["failure", "OBSERVATION", 136, 143]]], ["Animal studies have shown that an increment is necessary before the bleeding time is shortened (Roy and Djerassi, 1972) .", [["bleeding", "DISEASE", 68, 76], ["Animal studies", "TEST", 0, 14], ["the bleeding", "PROBLEM", 64, 76]]], ["Techniques have been developed for freezing human and canine platelets in dimethyl sulfoxide (Melaragno et al., 1985; Valeri et al., 1986b) .", [["platelets", "ANATOMY", 61, 70], ["dimethyl sulfoxide", "CHEMICAL", 74, 92], ["dimethyl sulfoxide", "CHEMICAL", 74, 92], ["human", "ORGANISM", 44, 49], ["canine", "ORGANISM", 54, 60], ["platelets", "CELL", 61, 70], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 74, 92], ["human and canine platelets", "CELL_TYPE", 44, 70], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["canine", "SPECIES", 54, 60], ["freezing human and canine platelets in dimethyl sulfoxide", "TREATMENT", 35, 92]]], ["The technology can be applied to other species, but is currently only done for research purposes.IX. Transfusion of GranulocytesGranulocyte transfusions were popular in the mid-1980s to treat human patients with sepsis and neutropenia.", [["Granulocytes", "ANATOMY", 116, 128], ["sepsis", "DISEASE", 212, 218], ["neutropenia", "DISEASE", 223, 234], ["IX", "GENE_OR_GENE_PRODUCT", 97, 99], ["GranulocytesGranulocyte", "CELL", 116, 139], ["human", "ORGANISM", 192, 197], ["patients", "ORGANISM", 198, 206], ["IX", "PROTEIN", 97, 99], ["human", "SPECIES", 192, 197], ["patients", "SPECIES", 198, 206], ["human", "SPECIES", 192, 197], ["research purposes", "TEST", 79, 96], ["Transfusion of GranulocytesGranulocyte transfusions", "TREATMENT", 101, 152], ["sepsis", "PROBLEM", 212, 218], ["neutropenia", "PROBLEM", 223, 234], ["GranulocytesGranulocyte transfusions", "OBSERVATION", 116, 152], ["sepsis", "OBSERVATION", 212, 218], ["neutropenia", "OBSERVATION", 223, 234]]], ["As new, improvedspectrum antibiotics have been developed, the use of granulocyte transfusions has declined.", [["granulocyte", "ANATOMY", 69, 80], ["granulocyte", "CELL", 69, 80], ["improvedspectrum antibiotics", "TREATMENT", 8, 36], ["granulocyte transfusions", "TREATMENT", 69, 93]]], ["An additional reason for the decline was the difficulty in collecting adequate numbers of cells daily for each patient.", [["cells", "ANATOMY", 90, 95], ["cells", "CELL", 90, 95], ["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 111, 118], ["the decline", "PROBLEM", 25, 36]]], ["Neutrophils are normally totally replaced at least twice daily, so large numbers (at least 10 x 10 10 /day) must be given (Mollison et al., 1987) .", [["Neutrophils", "ANATOMY", 0, 11], ["Neutrophils", "CELL", 0, 11], ["Neutrophils", "CELL_TYPE", 0, 11], ["Neutrophils", "TEST", 0, 11]]], ["Moreover, alloimmunization occurs rapidly even from previous whole blood transfusions, and pulmonary toxicity from sequestration of cells in the lungs is a problem (Westrick et al., 1977) .", [["blood", "ANATOMY", 67, 72], ["pulmonary", "ANATOMY", 91, 100], ["cells", "ANATOMY", 132, 137], ["lungs", "ANATOMY", 145, 150], ["alloimmunization", "DISEASE", 10, 26], ["pulmonary toxicity", "DISEASE", 91, 109], ["blood", "ORGANISM_SUBSTANCE", 67, 72], ["pulmonary", "ORGAN", 91, 100], ["cells", "CELL", 132, 137], ["lungs", "ORGAN", 145, 150], ["alloimmunization", "PROBLEM", 10, 26], ["previous whole blood transfusions", "TREATMENT", 52, 85], ["pulmonary toxicity", "PROBLEM", 91, 109], ["sequestration of cells in the lungs", "PROBLEM", 115, 150], ["pulmonary", "ANATOMY", 91, 100], ["toxicity", "OBSERVATION", 101, 109], ["lungs", "ANATOMY", 145, 150]]], ["Some benefit from granulocyte transfusions occurs in septic newborn infants and transfusions are still used in this situation.", [["granulocyte", "ANATOMY", 18, 29], ["granulocyte", "CELL", 18, 29], ["infants", "ORGANISM", 68, 75], ["infants", "SPECIES", 68, 75], ["granulocyte transfusions", "TREATMENT", 18, 42], ["septic newborn infants", "PROBLEM", 53, 75], ["transfusions", "TREATMENT", 80, 92], ["granulocyte transfusions", "OBSERVATION", 18, 42], ["septic newborn", "OBSERVATION", 53, 67]]], ["In veterinary medicine, some use has been made in septic newborn foals, but otherwise use in animals has been restricted to research protocols.", [["foals", "ORGANISM", 65, 70], ["septic newborn foals", "PROBLEM", 50, 70], ["research protocols", "TREATMENT", 124, 142], ["septic", "OBSERVATION", 50, 56]]], ["(For further discussion on white cell transfusions, see Weiss, this volume.)X. Adverse Effects of TransfusionsTransfusion of blood or its components is generally a safe procedure in animals, particularly in the dog and cat.", [["white cell", "ANATOMY", 27, 37], ["blood", "ANATOMY", 125, 130], ["white cell", "CELL", 27, 37], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["dog", "ORGANISM", 211, 214], ["cat", "ORGANISM", 219, 222], ["dog", "SPECIES", 211, 214], ["cat", "SPECIES", 219, 222], ["dog", "SPECIES", 211, 214], ["white cell transfusions", "TREATMENT", 27, 50], ["Transfusions", "TREATMENT", 98, 110], ["Transfusion of blood", "TREATMENT", 110, 130], ["a safe procedure", "TREATMENT", 162, 178]]], ["This discussion will primarily concern these species.", [["these species", "PROBLEM", 39, 52]]], ["The time of onset of side effects of transfusion varies from immediate, in a cat receiving as little of 2 ml of incompatible blood, to delayed for years, as with transfusiontransmitted retroviral diseases.", [["blood", "ANATOMY", 125, 130], ["retroviral diseases", "DISEASE", 185, 204], ["cat", "ORGANISM", 77, 80], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["retroviral", "ORGANISM", 185, 195], ["transfusion", "TREATMENT", 37, 48], ["incompatible blood", "PROBLEM", 112, 130], ["transfusiontransmitted retroviral diseases", "PROBLEM", 162, 204], ["retroviral diseases", "OBSERVATION", 185, 204]]], ["The severity of reactions varies from mild, transient pyrexia to death.", [["pyrexia", "DISEASE", 54, 61], ["death", "DISEASE", 65, 70], ["The severity of reactions", "PROBLEM", 0, 25], ["mild, transient pyrexia to death", "PROBLEM", 38, 70], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["reactions", "OBSERVATION", 16, 25], ["mild", "OBSERVATION_MODIFIER", 38, 42], ["transient", "OBSERVATION_MODIFIER", 44, 53], ["pyrexia", "OBSERVATION", 54, 61]]], ["Some of the reactions are preventable and some are not.", [["the reactions", "PROBLEM", 8, 21]]], ["The risks and benefits must be weighed in each situation in which transfusion is being considered.", [["transfusion", "TREATMENT", 66, 77]]], ["Because of an increasing concern about the dangers of human transfusions, especially concerning virus transmission, increasing emphasis is being placed on development of safe and effective alternatives to blood.X. Adverse Effects of TransfusionsA.", [["blood", "ANATOMY", 205, 210], ["TransfusionsA", "CHEMICAL", 233, 246], ["TransfusionsA", "CHEMICAL", 233, 246], ["human", "ORGANISM", 54, 59], ["blood", "ORGANISM_SUBSTANCE", 205, 210], ["TransfusionsA", "SIMPLE_CHEMICAL", 233, 246], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 54, 59], ["human transfusions", "TREATMENT", 54, 72], ["virus transmission", "PROBLEM", 96, 114], ["safe and effective alternatives", "TREATMENT", 170, 201], ["TransfusionsA", "TREATMENT", 233, 246], ["increasing", "OBSERVATION_MODIFIER", 14, 24]]], ["HEMOLYTIC REACTIONS When one thinks of a transfusion reaction, what usually comes to mind is an acute intravascular hemolytic catastrophe as might occur in an ABO-incompatible human transfusion.", [["intravascular", "ANATOMY", 102, 115], ["intravascular hemolytic catastrophe", "DISEASE", 102, 137], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 102, 115], ["human", "ORGANISM", 176, 181], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 176, 181], ["HEMOLYTIC REACTIONS", "PROBLEM", 0, 19], ["a transfusion reaction", "PROBLEM", 39, 61], ["an acute intravascular hemolytic catastrophe", "PROBLEM", 93, 137], ["an ABO", "TEST", 156, 162], ["incompatible human transfusion", "TREATMENT", 163, 193], ["acute", "OBSERVATION_MODIFIER", 96, 101], ["intravascular hemolytic catastrophe", "OBSERVATION", 102, 137]]], ["Fortunately in veterinary medicine, reactions are rare because of the low prevalence of naturally occurring isoantibodies.", [["naturally occurring isoantibodies", "PROBLEM", 88, 121], ["low prevalence", "OBSERVATION_MODIFIER", 70, 84]]], ["The group B cat is an exception because it is likely to have strong anti-A antibodies.", [["cat", "ORGANISM", 12, 15], ["anti-A antibodies", "GENE_OR_GENE_PRODUCT", 68, 85], ["anti-A antibodies", "PROTEIN", 68, 85], ["cat", "SPECIES", 12, 15], ["strong anti-A antibodies", "PROBLEM", 61, 85], ["anti-A antibodies", "OBSERVATION", 68, 85]]], ["If group A red cells are given to a group B cat, the cells are destroyed within minutes and the cat may also experience an acute complement-mediated shocklike reaction.", [["red cells", "ANATOMY", 11, 20], ["cells", "ANATOMY", 53, 58], ["red cells", "CELL", 11, 20], ["B cat", "ORGANISM", 42, 47], ["cells", "CELL", 53, 58], ["cat", "ORGANISM", 96, 99], ["group A red cells", "CELL_LINE", 3, 20], ["group A red cells", "PROBLEM", 3, 20], ["a group B cat", "TREATMENT", 34, 47], ["an acute complement-mediated shocklike reaction", "PROBLEM", 120, 167], ["acute", "OBSERVATION_MODIFIER", 123, 128]]], ["In dogs, clinically significant naturally occurring isoantibodies are not a problem.", [["dogs", "ORGANISM", 3, 7], ["dogs", "SPECIES", 3, 7]]], ["Antibodies can develop and persist after an initial transfusion and become a problem if a second transfusion is given containing the same antigen.X. Adverse Effects of TransfusionsSigns of an acute hemolytic reaction from incompatible red cells include acute fever, tachycardia, weakness, tremors, vomiting, and collapse.", [["red cells", "ANATOMY", 235, 244], ["acute hemolytic reaction", "DISEASE", 192, 216], ["fever", "DISEASE", 259, 264], ["tachycardia", "DISEASE", 266, 277], ["weakness", "DISEASE", 279, 287], ["tremors", "DISEASE", 289, 296], ["vomiting", "DISEASE", 298, 306], ["red cells", "CELL", 235, 244], ["red cells", "CELL_TYPE", 235, 244], ["an initial transfusion", "TREATMENT", 41, 63], ["a second transfusion", "TREATMENT", 88, 108], ["Transfusions", "TREATMENT", 168, 180], ["an acute hemolytic reaction", "PROBLEM", 189, 216], ["incompatible red cells", "PROBLEM", 222, 244], ["acute fever", "PROBLEM", 253, 264], ["tachycardia", "PROBLEM", 266, 277], ["weakness", "PROBLEM", 279, 287], ["tremors", "PROBLEM", 289, 296], ["vomiting", "PROBLEM", 298, 306], ["collapse", "PROBLEM", 312, 320], ["acute", "OBSERVATION_MODIFIER", 192, 197], ["hemolytic", "OBSERVATION", 198, 207], ["incompatible red cells", "OBSERVATION", 222, 244], ["acute", "OBSERVATION_MODIFIER", 253, 258], ["fever", "OBSERVATION", 259, 264], ["tachycardia", "OBSERVATION", 266, 277], ["weakness", "OBSERVATION", 279, 287], ["tremors", "OBSERVATION", 289, 296], ["collapse", "OBSERVATION", 312, 320]]], ["If signs occur the transfusion should be stopped and the line kept open with saline.", [["saline", "SIMPLE_CHEMICAL", 77, 83], ["signs", "PROBLEM", 3, 8], ["the transfusion", "TREATMENT", 15, 30], ["the line", "TREATMENT", 53, 61], ["saline", "TREATMENT", 77, 83]]], ["A blood sample is drawn into EDTA and a portion is spun in a capillary tube to check for hemoglobinemia.", [["blood sample", "ANATOMY", 2, 14], ["capillary tube", "ANATOMY", 61, 75], ["hemoglobinemia", "DISEASE", 89, 103], ["EDTA", "CHEMICAL", 29, 33], ["blood", "ORGANISM_SUBSTANCE", 2, 7], ["EDTA", "SIMPLE_CHEMICAL", 29, 33], ["capillary tube", "TISSUE", 61, 75], ["A blood sample", "TEST", 0, 14], ["a capillary tube", "TREATMENT", 59, 75], ["hemoglobinemia", "PROBLEM", 89, 103], ["capillary tube", "OBSERVATION", 61, 75]]], ["A positive DAT can also be seen, but if all transfused cells have been destroyed, it could be negative.", [["cells", "ANATOMY", 55, 60], ["DAT", "GENE_OR_GENE_PRODUCT", 11, 14], ["cells", "CELL", 55, 60], ["DAT", "PROTEIN", 11, 14], ["transfused cells", "CELL_TYPE", 44, 60], ["A positive DAT", "PROBLEM", 0, 14], ["all transfused cells", "PROBLEM", 40, 60]]], ["Both the recipient blood sample and any remaining donor blood in the bag should be saved for further testing for immunologic incompatibility, or for bacteriologic evaluation by gram stain and culture.X. Adverse Effects of TransfusionsIf intravascular hemolysis occurs, the potential for acute renal failure exists.", [["blood sample", "ANATOMY", 19, 31], ["blood", "ANATOMY", 56, 61], ["intravascular", "ANATOMY", 237, 250], ["renal", "ANATOMY", 293, 298], ["intravascular hemolysis", "DISEASE", 237, 260], ["acute renal failure", "DISEASE", 287, 306], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 237, 250], ["renal", "ORGAN", 293, 298], ["the recipient blood sample", "TEST", 5, 31], ["any remaining donor blood in the bag", "TREATMENT", 36, 72], ["further testing", "TEST", 93, 108], ["immunologic incompatibility", "PROBLEM", 113, 140], ["bacteriologic evaluation", "TEST", 149, 173], ["gram stain", "TEST", 177, 187], ["culture", "TEST", 192, 199], ["Transfusions", "TREATMENT", 222, 234], ["intravascular hemolysis", "PROBLEM", 237, 260], ["acute renal failure", "PROBLEM", 287, 306], ["hemolysis", "OBSERVATION", 251, 260], ["potential for", "UNCERTAINTY", 273, 286], ["acute", "OBSERVATION_MODIFIER", 287, 292], ["renal", "ANATOMY", 293, 298], ["failure", "OBSERVATION", 299, 306]]], ["Free hemoglobin was thought to cause renal damage, but antibody-coated red cell stroma is now known to cause renal vasoconstriction and ischemia.", [["renal", "ANATOMY", 37, 42], ["red cell stroma", "ANATOMY", 71, 86], ["renal", "ANATOMY", 109, 114], ["renal damage", "DISEASE", 37, 49], ["ischemia", "DISEASE", 136, 144], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 5, 15], ["renal", "ORGAN", 37, 42], ["renal", "ORGAN", 109, 114], ["hemoglobin", "PROTEIN", 5, 15], ["Free hemoglobin", "TEST", 0, 15], ["renal damage", "PROBLEM", 37, 49], ["antibody", "TEST", 55, 63], ["coated red cell stroma", "PROBLEM", 64, 86], ["renal vasoconstriction", "PROBLEM", 109, 131], ["ischemia", "PROBLEM", 136, 144], ["hemoglobin", "OBSERVATION", 5, 15], ["thought to cause", "UNCERTAINTY", 20, 36], ["renal", "ANATOMY", 37, 42], ["damage", "OBSERVATION", 43, 49], ["cell stroma", "OBSERVATION", 75, 86], ["renal", "ANATOMY", 109, 114], ["vasoconstriction", "OBSERVATION", 115, 131], ["ischemia", "OBSERVATION", 136, 144]]], ["As little as 3 g of stroma from incompatible red cells can induce renal failure (Schmidt and Holland, 1967) .", [["stroma", "ANATOMY", 20, 26], ["red cells", "ANATOMY", 45, 54], ["renal", "ANATOMY", 66, 71], ["renal failure", "DISEASE", 66, 79], ["stroma", "TISSUE", 20, 26], ["red cells", "CELL", 45, 54], ["renal", "ORGAN", 66, 71], ["red cells", "CELL_TYPE", 45, 54], ["stroma", "PROBLEM", 20, 26], ["incompatible red cells", "PROBLEM", 32, 54], ["renal failure", "PROBLEM", 66, 79], ["red cells", "OBSERVATION", 45, 54], ["renal", "ANATOMY", 66, 71], ["failure", "OBSERVATION", 72, 79]]], ["In dogs, the transfusion of even autologous hemolyzed red cells leads to decreases in factors X, VIII, and fibrinogen and pulmonary artery thrombosis (Rabiner and Friedman, 1968) .", [["hemolyzed red cells", "ANATOMY", 44, 63], ["pulmonary artery", "ANATOMY", 122, 138], ["pulmonary artery thrombosis", "DISEASE", 122, 149], ["dogs", "ORGANISM", 3, 7], ["hemolyzed red cells", "CELL", 44, 63], ["factors X", "GENE_OR_GENE_PRODUCT", 86, 95], ["VIII", "GENE_OR_GENE_PRODUCT", 97, 101], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 107, 117], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 122, 138], ["autologous hemolyzed red cells", "CELL_TYPE", 33, 63], ["X", "PROTEIN", 94, 95], ["VIII", "PROTEIN", 97, 101], ["fibrinogen", "PROTEIN", 107, 117], ["dogs", "SPECIES", 3, 7], ["the transfusion of even autologous hemolyzed red cells", "TREATMENT", 9, 63], ["VIII", "TEST", 97, 101], ["fibrinogen", "TEST", 107, 117], ["pulmonary artery thrombosis", "PROBLEM", 122, 149], ["red cells", "OBSERVATION", 54, 63], ["decreases", "OBSERVATION_MODIFIER", 73, 82], ["fibrinogen", "OBSERVATION", 107, 117], ["pulmonary artery", "ANATOMY", 122, 138], ["thrombosis", "OBSERVATION", 139, 149]]], ["Presumably thromboplastic substances in red cell membrane stroma are responsible (Shinowara, 1951) .", [["red cell membrane stroma", "ANATOMY", 40, 64], ["red cell membrane stroma", "TISSUE", 40, 64], ["thromboplastic substances in red cell membrane stroma", "PROBLEM", 11, 64], ["thromboplastic substances", "OBSERVATION", 11, 36], ["red cell membrane stroma", "OBSERVATION", 40, 64]]], ["Antigen-antibody complexes and the decrease in blood pressure from complement, serotonin, and histamine predispose to development of DIC.", [["blood", "ANATOMY", 47, 52], ["serotonin", "CHEMICAL", 79, 88], ["histamine", "CHEMICAL", 94, 103], ["DIC", "DISEASE", 133, 136], ["serotonin", "CHEMICAL", 79, 88], ["histamine", "CHEMICAL", 94, 103], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["complement", "GENE_OR_GENE_PRODUCT", 67, 77], ["serotonin", "SIMPLE_CHEMICAL", 79, 88], ["histamine", "SIMPLE_CHEMICAL", 94, 103], ["Antigen-antibody complexes", "PROTEIN", 0, 26], ["Antigen-antibody complexes", "TEST", 0, 26], ["blood pressure", "TEST", 47, 61], ["serotonin", "TREATMENT", 79, 88], ["histamine", "TREATMENT", 94, 103], ["DIC", "PROBLEM", 133, 136], ["antibody complexes", "OBSERVATION", 8, 26], ["decrease", "OBSERVATION_MODIFIER", 35, 43], ["DIC", "OBSERVATION", 133, 136]]], ["Clearly, recognition of an acute hemolytic transfusion reaction calls for immediate action, not just repetition of lab tests or monitoring.X. Adverse Effects of TransfusionsThe major aims of treatment are to maintain blood pressure and renal blood flow and prevent DIC.", [["blood", "ANATOMY", 217, 222], ["renal", "ANATOMY", 236, 241], ["blood", "ANATOMY", 242, 247], ["DIC", "DISEASE", 265, 268], ["blood", "ORGANISM_SUBSTANCE", 217, 222], ["renal", "MULTI-TISSUE_STRUCTURE", 236, 241], ["blood", "ORGANISM_SUBSTANCE", 242, 247], ["an acute hemolytic transfusion reaction", "PROBLEM", 24, 63], ["lab tests", "TEST", 115, 124], ["monitoring", "TEST", 128, 138], ["Transfusions", "TREATMENT", 161, 173], ["treatment", "TREATMENT", 191, 200], ["blood pressure", "TEST", 217, 231], ["renal blood flow", "TEST", 236, 252], ["DIC", "PROBLEM", 265, 268], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["hemolytic", "OBSERVATION", 33, 42], ["renal", "ANATOMY", 236, 241], ["DIC", "OBSERVATION", 265, 268]]], ["Fluid therapy is supplemented with furosemide.", [["furosemide", "CHEMICAL", 35, 45], ["furosemide", "CHEMICAL", 35, 45], ["furosemide", "SIMPLE_CHEMICAL", 35, 45], ["Fluid therapy", "TREATMENT", 0, 13], ["furosemide", "TREATMENT", 35, 45]]], ["Osmotic diuretics such as mannitol can also be used to increase urine output, but do not significantly increase renal blood flow (Peschel, 1986) .", [["urine", "ANATOMY", 64, 69], ["renal", "ANATOMY", 112, 117], ["blood", "ANATOMY", 118, 123], ["mannitol", "CHEMICAL", 26, 34], ["mannitol", "CHEMICAL", 26, 34], ["mannitol", "SIMPLE_CHEMICAL", 26, 34], ["urine", "ORGANISM_SUBSTANCE", 64, 69], ["renal", "ORGANISM_SUBSTANCE", 112, 117], ["blood", "ORGANISM_SUBSTANCE", 118, 123], ["Osmotic diuretics", "TREATMENT", 0, 17], ["mannitol", "TREATMENT", 26, 34], ["urine output", "TEST", 64, 76], ["renal", "ANATOMY", 112, 117], ["blood flow", "OBSERVATION", 118, 128]]], ["If pressor agents, are needed, dopamine hydrochloride is most effective because it dilates renal vasculature while increasing cardiac output.", [["renal vasculature", "ANATOMY", 91, 108], ["cardiac", "ANATOMY", 126, 133], ["dopamine hydrochloride", "CHEMICAL", 31, 53], ["dopamine hydrochloride", "CHEMICAL", 31, 53], ["dopamine hydrochloride", "SIMPLE_CHEMICAL", 31, 53], ["renal vasculature", "MULTI-TISSUE_STRUCTURE", 91, 108], ["cardiac", "ORGAN", 126, 133], ["pressor agents", "TREATMENT", 3, 17], ["dopamine hydrochloride", "TREATMENT", 31, 53], ["it dilates renal vasculature", "PROBLEM", 80, 108], ["increasing cardiac output", "PROBLEM", 115, 140], ["renal", "ANATOMY", 91, 96], ["vasculature", "ANATOMY_MODIFIER", 97, 108], ["output", "OBSERVATION_MODIFIER", 134, 140]]], ["Because the risk of DIC is high, prophylactic heparin should be given immediately as an initial loading dose and continued for approximately 6 hours.", [["DIC", "DISEASE", 20, 23], ["heparin", "CHEMICAL", 46, 53], ["heparin", "SIMPLE_CHEMICAL", 46, 53], ["DIC", "PROBLEM", 20, 23], ["prophylactic heparin", "TREATMENT", 33, 53], ["an initial loading dose", "TREATMENT", 85, 108], ["DIC", "OBSERVATION", 20, 23]]], ["Heparin is contraindicated if the underlying reason for the transfusion pertained to trauma, surgery, or hemorrhage.", [["Heparin", "CHEMICAL", 0, 7], ["trauma", "DISEASE", 85, 91], ["hemorrhage", "DISEASE", 105, 115], ["Heparin", "SIMPLE_CHEMICAL", 0, 7], ["Heparin", "TREATMENT", 0, 7], ["the transfusion", "TREATMENT", 56, 71], ["trauma", "PROBLEM", 85, 91], ["surgery", "TREATMENT", 93, 100], ["hemorrhage", "PROBLEM", 105, 115], ["hemorrhage", "OBSERVATION", 105, 115]]], ["A particularly difficult problem is an acute hemolytic reaction in a patient under anesthesia, wherein the only signs might be unexpected hypotension or increased capillary oozing of blood.", [["capillary", "ANATOMY", 163, 172], ["blood", "ANATOMY", 183, 188], ["acute hemolytic reaction", "DISEASE", 39, 63], ["hypotension", "DISEASE", 138, 149], ["patient", "ORGANISM", 69, 76], ["capillary", "TISSUE", 163, 172], ["blood", "ORGANISM_SUBSTANCE", 183, 188], ["patient", "SPECIES", 69, 76], ["A particularly difficult problem", "PROBLEM", 0, 32], ["an acute hemolytic reaction", "PROBLEM", 36, 63], ["anesthesia", "TREATMENT", 83, 93], ["unexpected hypotension", "PROBLEM", 127, 149], ["increased capillary oozing of blood", "PROBLEM", 153, 188], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["hemolytic", "OBSERVATION", 45, 54], ["hypotension", "OBSERVATION", 138, 149], ["increased", "OBSERVATION_MODIFIER", 153, 162], ["capillary oozing", "OBSERVATION", 163, 179]]], ["If a reaction is suspected, the workup is the same as for the awake patient.X. Adverse Effects of TransfusionsAlthough hemolytic reactions are most serious, they also are the most rare reactions.", [["hemolytic reactions", "DISEASE", 119, 138], ["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75], ["a reaction", "PROBLEM", 3, 13], ["the workup", "TEST", 28, 38], ["Transfusions", "TREATMENT", 98, 110], ["hemolytic reactions", "PROBLEM", 119, 138], ["hemolytic", "OBSERVATION_MODIFIER", 119, 128]]], ["These should be preventable by pretransfusion testing, but the most common reasons for human acute hemolytic reactions are administrative errors, such as mixups in patient identification, rather than laboratory errors.", [["acute hemolytic reactions", "DISEASE", 93, 118], ["human", "ORGANISM", 87, 92], ["patient", "ORGANISM", 164, 171], ["human", "SPECIES", 87, 92], ["patient", "SPECIES", 164, 171], ["human", "SPECIES", 87, 92], ["pretransfusion testing", "TEST", 31, 53], ["human acute hemolytic reactions", "PROBLEM", 87, 118], ["administrative errors", "PROBLEM", 123, 144], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["hemolytic", "OBSERVATION", 99, 108]]], ["There is no evidence that pretreating the recipient with antihistamines or steroids can prevent or suppress a hemolytic transfusion reaction (Schmidt, 1982) .X. Adverse Effects of TransfusionsWhen red cells are transfused to sensitized individuals or when sensitization occurs after the first transfusion, the most common reaction is delayed hemolysis.", [["red cells", "ANATOMY", 197, 206], ["antihistamines", "CHEMICAL", 57, 71], ["steroids", "CHEMICAL", 75, 83], ["hemolytic transfusion reaction", "DISEASE", 110, 140], ["hemolysis", "DISEASE", 342, 351], ["steroids", "CHEMICAL", 75, 83], ["antihistamines", "SIMPLE_CHEMICAL", 57, 71], ["steroids", "SIMPLE_CHEMICAL", 75, 83], ["red cells", "CELL", 197, 206], ["red cells", "CELL_TYPE", 197, 206], ["antihistamines", "TREATMENT", 57, 71], ["steroids", "TREATMENT", 75, 83], ["a hemolytic transfusion reaction", "PROBLEM", 108, 140], ["Transfusions", "TREATMENT", 180, 192], ["red cells", "PROBLEM", 197, 206], ["sensitization", "PROBLEM", 256, 269], ["the first transfusion", "TREATMENT", 283, 304], ["delayed hemolysis", "PROBLEM", 334, 351], ["no evidence", "UNCERTAINTY", 9, 20], ["hemolytic", "OBSERVATION_MODIFIER", 110, 119], ["delayed", "OBSERVATION_MODIFIER", 334, 341], ["hemolysis", "OBSERVATION", 342, 351]]], ["In a delayed reaction, hemolysis may occur from a few days to 2 weeks later as antibodies are produced.", [["hemolysis", "DISEASE", 23, 32], ["antibodies", "PROTEIN", 79, 89], ["a delayed reaction", "PROBLEM", 3, 21], ["hemolysis", "PROBLEM", 23, 32], ["antibodies", "PROBLEM", 79, 89], ["delayed", "OBSERVATION_MODIFIER", 5, 12], ["reaction", "OBSERVATION", 13, 21], ["hemolysis", "OBSERVATION", 23, 32]]], ["This occurs most frequently in previously transfused patients that have developed an antibody titer too low to be detected on cross match.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["an antibody titer", "PROBLEM", 82, 99], ["most frequently", "OBSERVATION_MODIFIER", 12, 27]]], ["The transfusion initiates a secondary immune response with a rapid rise in antibody.", [["The transfusion", "TREATMENT", 0, 15], ["a rapid rise in antibody", "PROBLEM", 59, 83]]], ["This may be subclinical and not noticeable unless transfused cells were labeled and survival measured.", [["cells", "ANATOMY", 61, 66], ["cells", "CELL", 61, 66], ["transfused cells", "CELL_TYPE", 50, 66], ["transfused cells", "PROBLEM", 50, 66], ["may be", "UNCERTAINTY", 5, 11], ["subclinical", "OBSERVATION", 12, 23], ["not noticeable", "UNCERTAINTY", 28, 42]]], ["If destruction is more rapid, icterus may develop and the beneficial effect of the transfusion is shortened.", [["icterus", "DISEASE", 30, 37], ["destruction", "PROBLEM", 3, 14], ["icterus", "PROBLEM", 30, 37], ["the transfusion", "TREATMENT", 79, 94], ["destruction", "OBSERVATION", 3, 14], ["more", "OBSERVATION_MODIFIER", 18, 22], ["rapid", "OBSERVATION_MODIFIER", 23, 28], ["icterus", "OBSERVATION", 30, 37], ["transfusion", "OBSERVATION", 83, 94], ["shortened", "OBSERVATION_MODIFIER", 98, 107]]], ["The DAT should be checked whenever the drop in Hct is more rapid than expected because antibody-coated transfused cells will be positive.", [["cells", "ANATOMY", 114, 119], ["DAT", "SIMPLE_CHEMICAL", 4, 7], ["Hct", "SIMPLE_CHEMICAL", 47, 50], ["cells", "CELL", 114, 119], ["DAT", "PROTEIN", 4, 7], ["Hct", "PROTEIN", 47, 50], ["antibody-coated transfused cells", "CELL_LINE", 87, 119], ["The DAT", "TEST", 0, 7], ["the drop", "PROBLEM", 35, 43], ["Hct", "TEST", 47, 50], ["antibody", "TEST", 87, 95], ["coated transfused cells", "TREATMENT", 96, 119]]], ["This effect is difficult to appreciate in patients transfused for treatment of immune-mediated hemolytic anemia.", [["hemolytic anemia", "DISEASE", 95, 111], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["treatment", "TREATMENT", 66, 75], ["immune-mediated hemolytic anemia", "PROBLEM", 79, 111], ["hemolytic", "OBSERVATION_MODIFIER", 95, 104], ["anemia", "OBSERVATION", 105, 111]]], ["These patients are DATpositive pretransfusion and often destroy transfused cells rapidly.", [["cells", "ANATOMY", 75, 80], ["patients", "ORGANISM", 6, 14], ["cells", "CELL", 75, 80], ["transfused cells", "CELL_TYPE", 64, 80], ["patients", "SPECIES", 6, 14], ["DATpositive pretransfusion", "TREATMENT", 19, 45], ["transfused cells", "TREATMENT", 64, 80]]], ["The antibody may not be detectable in the patient's serum because it is all absorbed onto the red cells.", [["serum", "ANATOMY", 52, 57], ["red cells", "ANATOMY", 94, 103], ["patient", "ORGANISM", 42, 49], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["cells", "CELL", 98, 103], ["red cells", "CELL_TYPE", 94, 103], ["patient", "SPECIES", 42, 49], ["The antibody", "TEST", 0, 12], ["the patient's serum", "TEST", 38, 57], ["may not be", "UNCERTAINTY", 13, 23], ["red cells", "OBSERVATION", 94, 103]]], ["Typically, antibody becomes detectable at peak levels 10-15 days after the transfusions (Mollison et al., 1987) .X. Adverse Effects of TransfusionsHemolytic reactions can occur from nonimmunologic causes if blood is hemolyzed prior to transfusion.", [["blood", "ANATOMY", 207, 212], ["Hemolytic reactions", "DISEASE", 147, 166], ["blood", "ORGANISM_SUBSTANCE", 207, 212], ["antibody", "TEST", 11, 19], ["peak levels", "TEST", 42, 53], ["the transfusions", "TREATMENT", 71, 87], ["Transfusions", "TREATMENT", 135, 147], ["Hemolytic reactions", "PROBLEM", 147, 166], ["blood", "TEST", 207, 212], ["transfusion", "TREATMENT", 235, 246]]], ["Causes include (1) overheating above 50\u00b0C, (2) freezing if refrigerator temperature drops too low, (3) mixing with hypotonic solutions such as 5% dextrose in water, (4) mechanical trauma to red cells during drawing or administration of blood, and (5) contamination with hemolytic bacteria (Peschel, 1986 ).B. FEVER AND ALLERGIC REACTIONSThe development of fever during transfusion could indicate bacterial contamination of the blood, however, this is rare.", [["red cells", "ANATOMY", 190, 199], ["blood", "ANATOMY", 236, 241], ["blood", "ANATOMY", 427, 432], ["dextrose", "CHEMICAL", 146, 154], ["trauma", "DISEASE", 180, 186], ["hemolytic", "DISEASE", 270, 279], ["fever", "DISEASE", 356, 361], ["bacterial contamination of the blood", "DISEASE", 396, 432], ["dextrose", "CHEMICAL", 146, 154], ["dextrose", "SIMPLE_CHEMICAL", 146, 154], ["red cells", "CELL", 190, 199], ["blood", "ORGANISM_SUBSTANCE", 236, 241], ["blood", "ORGANISM_SUBSTANCE", 427, 432], ["red cells", "CELL_TYPE", 190, 199], ["overheating above 50\u00b0C", "PROBLEM", 19, 41], ["refrigerator temperature drops too low", "PROBLEM", 59, 97], ["hypotonic solutions", "TREATMENT", 115, 134], ["5% dextrose in water", "TREATMENT", 143, 163], ["mechanical trauma to red cells", "PROBLEM", 169, 199], ["administration of blood", "TREATMENT", 218, 241], ["hemolytic bacteria", "PROBLEM", 270, 288], ["FEVER", "PROBLEM", 309, 314], ["ALLERGIC REACTIONS", "PROBLEM", 319, 337], ["fever", "PROBLEM", 356, 361], ["transfusion", "TREATMENT", 369, 380], ["bacterial contamination of the blood", "PROBLEM", 396, 432], ["ALLERGIC", "OBSERVATION", 319, 327], ["fever", "OBSERVATION", 356, 361], ["bacterial contamination", "OBSERVATION", 396, 419], ["blood", "ANATOMY", 427, 432]]], ["If blood is contaminated, the reaction of the recipient is usually immediate and severe.", [["blood", "ANATOMY", 3, 8], ["blood", "ORGANISM_SUBSTANCE", 3, 8], ["blood", "PROBLEM", 3, 8], ["contaminated", "OBSERVATION", 12, 24], ["severe", "OBSERVATION_MODIFIER", 81, 87]]], ["In addition to fever, trembling and acute collapse usually occur.", [["fever", "DISEASE", 15, 20], ["trembling", "DISEASE", 22, 31], ["fever", "PROBLEM", 15, 20], ["trembling", "PROBLEM", 22, 31], ["acute collapse", "PROBLEM", 36, 50], ["fever", "OBSERVATION", 15, 20], ["acute", "OBSERVATION_MODIFIER", 36, 41], ["collapse", "OBSERVATION", 42, 50]]], ["If such a reaction occurs, the transfusion is stopped immediately and the remaining contents of the bag are Gram stained and cultured.", [["a reaction", "PROBLEM", 8, 18], ["the transfusion", "TREATMENT", 27, 42], ["the bag", "TREATMENT", 96, 103], ["Gram stained", "TEST", 108, 120], ["bag", "ANATOMY", 100, 103]]], ["Intravenous antibiotics and treatment for shock are instituted immediately.B. FEVER AND ALLERGIC REACTIONSMost febrile reactions are mild and not related to infection.", [["shock", "DISEASE", 42, 47], ["febrile reactions", "DISEASE", 111, 128], ["infection", "DISEASE", 157, 166], ["Intravenous antibiotics", "TREATMENT", 0, 23], ["treatment", "TREATMENT", 28, 37], ["shock", "PROBLEM", 42, 47], ["B. FEVER", "PROBLEM", 75, 83], ["ALLERGIC REACTIONSMost febrile reactions", "PROBLEM", 88, 128], ["infection", "PROBLEM", 157, 166], ["FEVER", "OBSERVATION", 78, 83], ["ALLERGIC", "OBSERVATION_MODIFIER", 88, 96], ["mild", "OBSERVATION_MODIFIER", 133, 137], ["not related to", "UNCERTAINTY", 142, 156], ["infection", "OBSERVATION", 157, 166]]], ["Previously transfused animals become sensitized to histocompatibility antigens of donors and react with fever during or after the transfusion.", [["fever", "DISEASE", 104, 109], ["donors", "ORGANISM", 82, 88], ["histocompatibility antigens", "PROTEIN", 51, 78], ["fever", "PROBLEM", 104, 109], ["the transfusion", "TREATMENT", 126, 141]]], ["Despite the fever, the patient usually is clinically better after the transfusion than before.", [["fever", "DISEASE", 12, 17], ["patient", "ORGANISM", 23, 30], ["patient", "SPECIES", 23, 30], ["the fever", "PROBLEM", 8, 17], ["the transfusion", "TREATMENT", 66, 81], ["fever", "OBSERVATION", 12, 17]]], ["Sometimes severely anemic cats are presented to the hospital with normal or subnormal temperatures and develop a fever 8-24 hours after transfusion.", [["fever", "DISEASE", 113, 118], ["cats", "ORGANISM", 26, 30], ["cats", "SPECIES", 26, 30], ["severely anemic cats", "PROBLEM", 10, 30], ["subnormal temperatures", "PROBLEM", 76, 98], ["a fever", "PROBLEM", 111, 118], ["transfusion", "TREATMENT", 136, 147], ["severely", "OBSERVATION_MODIFIER", 10, 18], ["anemic", "OBSERVATION", 19, 25], ["fever", "OBSERVATION", 113, 118]]], ["In some of these cats, the fever is caused by the underlying disease, and this becomes evident after the cat's condition is improved by transfusion.", [["fever", "DISEASE", 27, 32], ["cats", "ORGANISM", 17, 21], ["cat", "ORGANISM", 105, 108], ["cats", "SPECIES", 17, 21], ["the fever", "PROBLEM", 23, 32], ["the underlying disease", "PROBLEM", 46, 68], ["the cat's condition", "PROBLEM", 101, 120], ["transfusion", "TREATMENT", 136, 147], ["cats", "OBSERVATION", 17, 21], ["fever", "OBSERVATION", 27, 32], ["disease", "OBSERVATION", 61, 68], ["improved", "OBSERVATION_MODIFIER", 124, 132]]], ["When a fever develops after transfusion but the patient appears stable or improved, it is often advantageous to monitor without treatment for 24 hours because nonspecific transfusion-induced fevers often spontaneously resolve within that time.B. FEVER AND ALLERGIC REACTIONSAllergic reactions are rare and have been seen more in canine and human patients than in other species.", [["fever", "DISEASE", 7, 12], ["fevers", "DISEASE", 191, 197], ["patient", "ORGANISM", 48, 55], ["canine", "ORGANISM", 329, 335], ["human", "ORGANISM", 340, 345], ["patients", "ORGANISM", 346, 354], ["patient", "SPECIES", 48, 55], ["human", "SPECIES", 340, 345], ["patients", "SPECIES", 346, 354], ["canine", "SPECIES", 329, 335], ["human", "SPECIES", 340, 345], ["a fever", "PROBLEM", 5, 12], ["transfusion", "TREATMENT", 28, 39], ["treatment", "TREATMENT", 128, 137], ["nonspecific transfusion", "PROBLEM", 159, 182], ["induced fevers", "PROBLEM", 183, 197], ["B. FEVER", "PROBLEM", 243, 251], ["ALLERGIC REACTIONSAllergic reactions", "PROBLEM", 256, 292], ["stable", "OBSERVATION_MODIFIER", 64, 70], ["FEVER", "OBSERVATION", 246, 251], ["ALLERGIC REACTIONSAllergic", "OBSERVATION", 256, 282]]], ["The most common manifestations are urticaria and angioneurotic edema.", [["urticaria", "DISEASE", 35, 44], ["angioneurotic edema", "DISEASE", 49, 68], ["angioneurotic edema", "PATHOLOGICAL_FORMATION", 49, 68], ["urticaria", "PROBLEM", 35, 44], ["angioneurotic edema", "PROBLEM", 49, 68], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["urticaria", "OBSERVATION", 35, 44], ["angioneurotic", "OBSERVATION_MODIFIER", 49, 62], ["edema", "OBSERVATION", 63, 68]]], ["The cause is probably donor plasma antigens to which the recipient is sensitive.", [["plasma", "ANATOMY", 28, 34], ["plasma", "ORGANISM_SUBSTANCE", 28, 34], ["donor plasma antigens", "PROBLEM", 22, 43]]], ["This is one reason why donors should not be receiving medications at the time of donation.", [["donors", "ORGANISM", 23, 29], ["medications", "TREATMENT", 54, 65]]], ["In a series of atopic human patients known to be sensitive to such common allergens as pollen, dust, milk, and eggs, the transfusion of pooled serum was almost always followed by moderate to severe urticaria, whereas normal subjects rarely had any reaction (Maunsell, 1944) .", [["pollen", "ANATOMY", 87, 93], ["milk", "ANATOMY", 101, 105], ["eggs", "ANATOMY", 111, 115], ["serum", "ANATOMY", 143, 148], ["urticaria", "DISEASE", 198, 207], ["human", "ORGANISM", 22, 27], ["patients", "ORGANISM", 28, 36], ["pollen", "DEVELOPING_ANATOMICAL_STRUCTURE", 87, 93], ["dust", "ORGANISM_SUBSTANCE", 95, 99], ["milk", "ORGANISM_SUBSTANCE", 101, 105], ["serum", "ORGANISM_SUBSTANCE", 143, 148], ["human", "SPECIES", 22, 27], ["patients", "SPECIES", 28, 36], ["human", "SPECIES", 22, 27], ["such common allergens", "PROBLEM", 62, 83], ["eggs", "TREATMENT", 111, 115], ["pooled serum", "PROBLEM", 136, 148], ["moderate to severe urticaria", "PROBLEM", 179, 207], ["moderate", "OBSERVATION_MODIFIER", 179, 187], ["severe", "OBSERVATION_MODIFIER", 191, 197], ["urticaria", "OBSERVATION", 198, 207]]], ["If an allergic reaction occurs, the transfusion is stopped and intravenous antihistamines such as diphenhydramine given.", [["intravenous", "ANATOMY", 63, 74], ["allergic reaction", "DISEASE", 6, 23], ["diphenhydramine", "CHEMICAL", 98, 113], ["diphenhydramine", "CHEMICAL", 98, 113], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 63, 74], ["antihistamines", "SIMPLE_CHEMICAL", 75, 89], ["diphenhydramine", "SIMPLE_CHEMICAL", 98, 113], ["an allergic reaction", "PROBLEM", 3, 23], ["the transfusion", "TREATMENT", 32, 47], ["intravenous antihistamines", "TREATMENT", 63, 89], ["diphenhydramine", "TREATMENT", 98, 113], ["allergic", "OBSERVATION", 6, 14]]], ["If the reaction is severe with any sign of laryngeal or bronchopulmonary involvement, corticosteroids or even epinephrine (0.1 ml of 1:1000 solution intravenously to dog or cat) can be given as well.", [["laryngeal", "ANATOMY", 43, 52], ["bronchopulmonary", "ANATOMY", 56, 72], ["epinephrine", "CHEMICAL", 110, 121], ["corticosteroids", "CHEMICAL", 86, 101], ["epinephrine", "CHEMICAL", 110, 121], ["laryngeal", "ORGAN", 43, 52], ["bronchopulmonary", "ORGAN", 56, 72], ["corticosteroids", "SIMPLE_CHEMICAL", 86, 101], ["epinephrine", "SIMPLE_CHEMICAL", 110, 121], ["dog", "ORGANISM", 166, 169], ["cat", "ORGANISM", 173, 176], ["the reaction", "PROBLEM", 3, 15], ["laryngeal or bronchopulmonary involvement", "PROBLEM", 43, 84], ["corticosteroids", "TREATMENT", 86, 101], ["epinephrine", "TREATMENT", 110, 121], ["severe", "OBSERVATION_MODIFIER", 19, 25], ["laryngeal", "ANATOMY", 43, 52], ["bronchopulmonary", "ANATOMY", 56, 72]]], ["Most typically, the reaction is mild and subsides quickly, in which case the transfusion may be continued.", [["the reaction", "PROBLEM", 16, 28], ["the transfusion", "TREATMENT", 73, 88], ["mild", "OBSERVATION_MODIFIER", 32, 36], ["subsides", "OBSERVATION_MODIFIER", 41, 49]]], ["It can be argued that it is dangerous to continue to deliver a proved allergen, but there are no clinical reports to support that contention.C. CIRCULATORY OVERLOADCirculatory overload is most likely to occur in cats or small dogs if large volumes of blood are given to a normovolemic patient, or if a standard volume is given to an animal with underlying cardiac insufficiency.", [["blood", "ANATOMY", 251, 256], ["cardiac", "ANATOMY", 356, 363], ["OVERLOADCirculatory overload", "DISEASE", 156, 184], ["cardiac insufficiency", "DISEASE", 356, 377], ["cats", "ORGANISM", 212, 216], ["blood", "ORGANISM_SUBSTANCE", 251, 256], ["patient", "ORGANISM", 285, 292], ["cardiac", "ORGAN", 356, 363], ["cats", "SPECIES", 212, 216], ["patient", "SPECIES", 285, 292], ["C. CIRCULATORY OVERLOADCirculatory overload", "PROBLEM", 141, 184], ["small dogs", "PROBLEM", 220, 230], ["large volumes of blood", "PROBLEM", 234, 256], ["a standard volume", "TREATMENT", 300, 317], ["underlying cardiac insufficiency", "PROBLEM", 345, 377], ["CIRCULATORY", "OBSERVATION", 144, 155], ["OVERLOADCirculatory overload", "OBSERVATION", 156, 184], ["most likely", "UNCERTAINTY", 188, 199], ["small", "OBSERVATION_MODIFIER", 220, 225], ["large", "OBSERVATION_MODIFIER", 234, 239], ["cardiac", "ANATOMY", 356, 363], ["insufficiency", "OBSERVATION", 364, 377]]], ["Anemic animals susceptible to circulatory overload should always receive slowly infused PRBCs, not whole blood.", [["circulatory", "ANATOMY", 30, 41], ["PRBCs", "ANATOMY", 88, 93], ["whole blood", "ANATOMY", 99, 110], ["circulatory overload", "DISEASE", 30, 50], ["PRBCs", "CELL", 88, 93], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["PRBCs", "CELL_TYPE", 88, 93], ["Anemic animals", "PROBLEM", 0, 14], ["circulatory overload", "PROBLEM", 30, 50], ["slowly infused PRBCs", "TREATMENT", 73, 93], ["whole blood", "PROBLEM", 99, 110], ["circulatory overload", "OBSERVATION", 30, 50]]], ["Chronically anemic animals are more at risk because cardiac hypertrophy or dilatation is often present from long-term increased cardiac output.", [["cardiac", "ANATOMY", 52, 59], ["cardiac", "ANATOMY", 128, 135], ["cardiac hypertrophy", "DISEASE", 52, 71], ["cardiac", "ORGAN", 52, 59], ["cardiac", "ORGAN", 128, 135], ["Chronically anemic animals", "PROBLEM", 0, 26], ["cardiac hypertrophy", "PROBLEM", 52, 71], ["dilatation", "PROBLEM", 75, 85], ["long-term increased cardiac output", "PROBLEM", 108, 142], ["anemic", "OBSERVATION", 12, 18], ["cardiac", "ANATOMY", 52, 59], ["hypertrophy", "OBSERVATION", 60, 71], ["dilatation", "OBSERVATION", 75, 85], ["long-term", "OBSERVATION_MODIFIER", 108, 117], ["increased", "OBSERVATION_MODIFIER", 118, 127], ["cardiac", "ANATOMY", 128, 135], ["output", "OBSERVATION", 136, 142]]], ["By the time the animal requires a transfusion, the cardiac compensatory mechanisms are already stressed maximally.", [["cardiac", "ANATOMY", 51, 58], ["cardiac", "ORGAN", 51, 58], ["a transfusion", "TREATMENT", 32, 45], ["cardiac", "ANATOMY", 51, 58], ["compensatory", "OBSERVATION", 59, 71]]], ["The additional blood volume may produce pulmonary edema.", [["blood", "ANATOMY", 15, 20], ["pulmonary", "ANATOMY", 40, 49], ["pulmonary edema", "DISEASE", 40, 55], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 40, 55], ["The additional blood volume", "TEST", 0, 27], ["pulmonary edema", "PROBLEM", 40, 55], ["blood volume", "OBSERVATION", 15, 27], ["may produce", "UNCERTAINTY", 28, 39], ["pulmonary", "ANATOMY", 40, 49], ["edema", "OBSERVATION", 50, 55]]], ["Signs include, cough, cyanosis, dyspnea, and moist lung sounds.", [["lung", "ANATOMY", 51, 55], ["cough", "DISEASE", 15, 20], ["cyanosis", "DISEASE", 22, 30], ["dyspnea", "DISEASE", 32, 39], ["lung", "ORGAN", 51, 55], ["cough", "PROBLEM", 15, 20], ["cyanosis", "PROBLEM", 22, 30], ["dyspnea", "PROBLEM", 32, 39], ["moist lung sounds", "PROBLEM", 45, 62], ["cough", "OBSERVATION", 15, 20], ["cyanosis", "OBSERVATION", 22, 30], ["dyspnea", "OBSERVATION", 32, 39], ["moist", "OBSERVATION_MODIFIER", 45, 50], ["lung", "ANATOMY", 51, 55], ["sounds", "OBSERVATION", 56, 62]]], ["If overload is suspected, the transfusion is stopped and furosemide and oxygen are administered.D. ELECTROLYTE AND ACID-BASE ABNORMALITIESCitrate is an ideal anticoagulant from the standpoint of safety, because it is metabolized in the liver within minutes of administration.", [["liver", "ANATOMY", 236, 241], ["furosemide", "CHEMICAL", 57, 67], ["oxygen", "CHEMICAL", 72, 78], ["furosemide", "CHEMICAL", 57, 67], ["oxygen", "CHEMICAL", 72, 78], ["furosemide", "SIMPLE_CHEMICAL", 57, 67], ["oxygen", "SIMPLE_CHEMICAL", 72, 78], ["liver", "ORGAN", 236, 241], ["overload", "PROBLEM", 3, 11], ["the transfusion", "TREATMENT", 26, 41], ["furosemide", "TREATMENT", 57, 67], ["oxygen", "TREATMENT", 72, 78], ["ACID-BASE ABNORMALITIESCitrate", "TEST", 115, 145], ["overload", "OBSERVATION", 3, 11], ["BASE", "ANATOMY_MODIFIER", 120, 124], ["liver", "ANATOMY", 236, 241]]], ["Experimentally, citrate toxicity is hard to produce.", [["citrate", "CHEMICAL", 16, 23], ["toxicity", "DISEASE", 24, 32], ["citrate", "CHEMICAL", 16, 23], ["citrate", "SIMPLE_CHEMICAL", 16, 23], ["citrate toxicity", "PROBLEM", 16, 32]]], ["The equivalent dose of citrate to that in 7 liters of citrated blood was given without reaction to an adult man in 90 minutes (Nakasone et aL, 1954) .", [["blood", "ANATOMY", 63, 68], ["citrate", "CHEMICAL", 23, 30], ["citrate", "CHEMICAL", 23, 30], ["citrate", "SIMPLE_CHEMICAL", 23, 30], ["citrated", "ORGANISM_SUBSTANCE", 54, 62], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["man", "ORGANISM", 108, 111], ["man", "SPECIES", 108, 111], ["citrate", "TREATMENT", 23, 30], ["citrated blood", "TREATMENT", 54, 68], ["reaction", "PROBLEM", 87, 95]]], ["When toxic changes were produced in dogs, signs included EKG changes: prolongation of QT, pulsus alternans, and depression of P and T waves.", [["depression", "DISEASE", 112, 122], ["dogs", "ORGANISM", 36, 40], ["dogs", "SPECIES", 36, 40], ["toxic changes", "PROBLEM", 5, 18], ["EKG changes", "PROBLEM", 57, 68], ["prolongation of QT", "PROBLEM", 70, 88], ["pulsus alternans", "PROBLEM", 90, 106], ["depression of P and T waves", "PROBLEM", 112, 139]]], ["Muscle tremors occurred as well.", [["Muscle", "ANATOMY", 0, 6], ["Muscle tremors", "DISEASE", 0, 14], ["Muscle", "ORGAN", 0, 6], ["Muscle tremors", "PROBLEM", 0, 14], ["tremors", "OBSERVATION", 7, 14]]], ["If additional doses were given, ventricular fibrillation occurred.", [["ventricular", "ANATOMY", 32, 43], ["ventricular fibrillation", "DISEASE", 32, 56], ["ventricular", "MULTI-TISSUE_STRUCTURE", 32, 43], ["additional doses", "TREATMENT", 3, 19], ["ventricular fibrillation", "PROBLEM", 32, 56], ["fibrillation", "OBSERVATION", 44, 56]]], ["Diagnosis cannot be made by measuring serum calcium because only the ionized fraction is decreased.", [["serum", "ANATOMY", 38, 43], ["calcium", "CHEMICAL", 44, 51], ["calcium", "CHEMICAL", 44, 51], ["serum", "ORGANISM_SUBSTANCE", 38, 43], ["calcium", "SIMPLE_CHEMICAL", 44, 51], ["serum calcium", "TEST", 38, 51], ["the ionized fraction", "TEST", 65, 85], ["ionized fraction", "OBSERVATION", 69, 85], ["decreased", "OBSERVATION_MODIFIER", 89, 98]]], ["Animals with portosystemic shunts, severe liver disease, or hypothermia will metabolize citrate more slowly than normal and are more prone to toxicity.", [["liver", "ANATOMY", 42, 47], ["portosystemic shunts", "DISEASE", 13, 33], ["liver disease", "DISEASE", 42, 55], ["hypothermia", "DISEASE", 60, 71], ["citrate", "CHEMICAL", 88, 95], ["toxicity", "DISEASE", 142, 150], ["citrate", "CHEMICAL", 88, 95], ["Animals", "ORGANISM", 0, 7], ["liver", "ORGAN", 42, 47], ["citrate", "SIMPLE_CHEMICAL", 88, 95], ["portosystemic shunts", "TREATMENT", 13, 33], ["severe liver disease", "PROBLEM", 35, 55], ["hypothermia", "PROBLEM", 60, 71], ["citrate", "TREATMENT", 88, 95], ["portosystemic shunts", "OBSERVATION", 13, 33], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["liver", "ANATOMY", 42, 47], ["disease", "OBSERVATION", 48, 55], ["hypothermia", "OBSERVATION", 60, 71]]], ["Components with the most citrate are FFP, PRP, and whole blood.", [["whole blood", "ANATOMY", 51, 62], ["citrate", "CHEMICAL", 25, 32], ["citrate", "CHEMICAL", 25, 32], ["citrate", "SIMPLE_CHEMICAL", 25, 32], ["FFP", "SIMPLE_CHEMICAL", 37, 40], ["PRP", "SIMPLE_CHEMICAL", 42, 45], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["FFP", "PROTEIN", 37, 40], ["PRP", "PROTEIN", 42, 45], ["the most citrate", "TREATMENT", 16, 32], ["FFP", "TREATMENT", 37, 40], ["PRP", "TREATMENT", 42, 45], ["whole blood", "TEST", 51, 62]]], ["Packed red cells are low in citrate and unlikely to cause toxicity.", [["red cells", "ANATOMY", 7, 16], ["citrate", "CHEMICAL", 28, 35], ["toxicity", "DISEASE", 58, 66], ["citrate", "CHEMICAL", 28, 35], ["Packed red cells", "CELL", 0, 16], ["citrate", "SIMPLE_CHEMICAL", 28, 35], ["Packed red cells", "CELL_TYPE", 0, 16], ["Packed red cells", "TREATMENT", 0, 16], ["citrate", "TREATMENT", 28, 35], ["toxicity", "PROBLEM", 58, 66], ["red cells", "OBSERVATION", 7, 16], ["low", "OBSERVATION_MODIFIER", 21, 24], ["unlikely to cause", "UNCERTAINTY", 40, 57], ["toxicity", "OBSERVATION", 58, 66]]], ["In most cases, citrate toxicity is reversible if the transfusion is stopped for 5-10 minutes and restarted at a lower rate.", [["citrate", "CHEMICAL", 15, 22], ["toxicity", "DISEASE", 23, 31], ["citrate", "CHEMICAL", 15, 22], ["citrate", "SIMPLE_CHEMICAL", 15, 22], ["citrate toxicity", "PROBLEM", 15, 31], ["the transfusion", "TREATMENT", 49, 64]]], ["Injection of calcium gluco-nate reverses the effect but is rarely needed.", [["calcium gluco-nate", "CHEMICAL", 13, 31], ["calcium gluco-nate", "CHEMICAL", 13, 31], ["calcium gluco-nate", "SIMPLE_CHEMICAL", 13, 31], ["calcium gluco", "TREATMENT", 13, 26]]], ["The alkaline by-product of citrate metabolism offsets the acidosis induced by stored blood (Collins et al. y 1971) .", [["blood", "ANATOMY", 85, 90], ["citrate", "CHEMICAL", 27, 34], ["acidosis", "DISEASE", 58, 66], ["citrate", "CHEMICAL", 27, 34], ["alkaline", "SIMPLE_CHEMICAL", 4, 12], ["citrate", "SIMPLE_CHEMICAL", 27, 34], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["citrate metabolism offsets", "PROBLEM", 27, 53], ["the acidosis", "PROBLEM", 54, 66], ["citrate metabolism offsets", "OBSERVATION", 27, 53], ["acidosis", "OBSERVATION", 58, 66]]], ["Because of this, acidosis is rare after transfusion of stored blood.D. ELECTROLYTE AND ACID-BASE ABNORMALITIESPotassium toxicity is primarily a concern in humans and horses receiving stored blood.", [["blood", "ANATOMY", 62, 67], ["blood", "ANATOMY", 190, 195], ["acidosis", "DISEASE", 17, 25], ["toxicity", "DISEASE", 120, 128], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["humans", "ORGANISM", 155, 161], ["horses", "ORGANISM", 166, 172], ["blood", "ORGANISM_SUBSTANCE", 190, 195], ["humans", "SPECIES", 155, 161], ["humans", "SPECIES", 155, 161], ["acidosis", "PROBLEM", 17, 25], ["transfusion of stored blood", "PROBLEM", 40, 67], ["ACID-BASE ABNORMALITIESPotassium toxicity", "PROBLEM", 87, 128], ["acidosis", "OBSERVATION", 17, 25], ["ACID-BASE", "OBSERVATION_MODIFIER", 87, 96], ["ABNORMALITIESPotassium toxicity", "OBSERVATION", 97, 128]]], ["Animals other than horses have potassium con centrations in red cells equal to that in plasma, so hyperkalemia is not a concern.", [["red cells", "ANATOMY", 60, 69], ["plasma", "ANATOMY", 87, 93], ["potassium", "CHEMICAL", 31, 40], ["hyperkalemia", "DISEASE", 98, 110], ["potassium", "CHEMICAL", 31, 40], ["Animals", "ORGANISM", 0, 7], ["horses", "ORGANISM", 19, 25], ["potassium", "SIMPLE_CHEMICAL", 31, 40], ["red cells", "CELL", 60, 69], ["plasma", "ORGANISM_SUBSTANCE", 87, 93], ["red cells", "CELL_TYPE", 60, 69], ["potassium con centrations", "TREATMENT", 31, 56], ["red cells", "TEST", 60, 69], ["hyperkalemia", "PROBLEM", 98, 110], ["hyperkalemia", "OBSERVATION", 98, 110]]], ["Even in man, clinically significant hyperkalemia is rare and occurs less frequently than hypokalemia.", [["hyperkalemia", "DISEASE", 36, 48], ["hypokalemia", "DISEASE", 89, 100], ["man", "ORGANISM", 8, 11], ["man", "SPECIES", 8, 11], ["clinically significant hyperkalemia", "PROBLEM", 13, 48], ["hypokalemia", "PROBLEM", 89, 100], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["hyperkalemia", "OBSERVATION", 36, 48]]], ["Increased potassium predis poses to citrate toxicity because potassium and citrate both adversely affect cardiac rhythm and function.", [["cardiac", "ANATOMY", 105, 112], ["potassium", "CHEMICAL", 10, 19], ["citrate", "CHEMICAL", 36, 43], ["toxicity", "DISEASE", 44, 52], ["potassium", "CHEMICAL", 61, 70], ["citrate", "CHEMICAL", 75, 82], ["potassium", "CHEMICAL", 10, 19], ["citrate", "CHEMICAL", 36, 43], ["potassium", "CHEMICAL", 61, 70], ["citrate", "CHEMICAL", 75, 82], ["potassium predis", "SIMPLE_CHEMICAL", 10, 26], ["citrate", "SIMPLE_CHEMICAL", 36, 43], ["potassium", "SIMPLE_CHEMICAL", 61, 70], ["citrate", "SIMPLE_CHEMICAL", 75, 82], ["cardiac", "ORGAN", 105, 112], ["Increased potassium predis", "TREATMENT", 0, 26], ["citrate toxicity", "PROBLEM", 36, 52], ["potassium", "TREATMENT", 61, 70], ["citrate", "TREATMENT", 75, 82]]], ["Ammonia levels rise in stored blood and may cause a problem in patients with liver failure.E. MISCELLANEOUS REACTIONSMuch has been written about the dangers to pulmonary function caused by microaggregates after massive transfusions.", [["blood", "ANATOMY", 30, 35], ["liver", "ANATOMY", 77, 82], ["pulmonary", "ANATOMY", 160, 169], ["Ammonia", "CHEMICAL", 0, 7], ["liver failure", "DISEASE", 77, 90], ["Ammonia", "CHEMICAL", 0, 7], ["Ammonia", "SIMPLE_CHEMICAL", 0, 7], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["patients", "ORGANISM", 63, 71], ["liver", "ORGAN", 77, 82], ["pulmonary", "ORGAN", 160, 169], ["patients", "SPECIES", 63, 71], ["Ammonia levels", "TEST", 0, 14], ["liver failure", "PROBLEM", 77, 90], ["massive transfusions", "TREATMENT", 211, 231], ["rise", "OBSERVATION_MODIFIER", 15, 19], ["liver", "ANATOMY", 77, 82], ["failure", "OBSERVATION", 83, 90], ["MISCELLANEOUS REACTIONSMuch", "OBSERVATION", 94, 121], ["pulmonary", "ANATOMY", 160, 169]]], ["These consist of platelet, white cell, and red cell stromal debris, which increase after the first week of storage.", [["platelet", "ANATOMY", 17, 25], ["white cell", "ANATOMY", 27, 37], ["red cell stromal debris", "ANATOMY", 43, 66], ["platelet", "CELL", 17, 25], ["white cell", "CELL", 27, 37], ["red cell", "CELL", 43, 51], ["stromal debris", "TISSUE", 52, 66], ["platelet", "CELL_TYPE", 17, 25], ["white cell", "CELL_TYPE", 27, 37], ["red cell stromal debris", "CELL_TYPE", 43, 66], ["platelet", "TEST", 17, 25], ["white cell", "PROBLEM", 27, 37], ["red cell stromal debris", "PROBLEM", 43, 66], ["platelet", "OBSERVATION", 17, 25], ["white cell", "OBSERVATION", 27, 37], ["red cell stromal debris", "OBSERVATION", 43, 66], ["increase", "OBSERVATION_MODIFIER", 74, 82]]], ["These can be removed by the use of a 40-\u03bc\u03b9\u03b7 filter.", [["a 40-\u03bc\u03b9\u03b7 filter", "TREATMENT", 35, 50]]], ["Recent clinical studies indicate that the problem of microaggregates has been overemphasized (Seldon, 1979) .", [["microaggregates", "DISEASE", 53, 68], ["Recent clinical studies", "TEST", 0, 23]]], ["Routine use of millipore filters is not only unnecessary, but may be detrimental because rapid transfu sion cannot be delivered through such a small filter.E. MISCELLANEOUS REACTIONSHemosiderosis is a rare complication that can occur in a patient that has received numerous transfusions and is not bleeding.", [["bleeding", "DISEASE", 298, 306], ["patient", "ORGANISM", 239, 246], ["patient", "SPECIES", 239, 246], ["millipore filters", "TREATMENT", 15, 32], ["rapid transfu sion", "TREATMENT", 89, 107], ["a small filter", "TREATMENT", 141, 155], ["a rare complication", "PROBLEM", 199, 218], ["numerous transfusions", "TREATMENT", 265, 286], ["bleeding", "PROBLEM", 298, 306], ["small filter", "OBSERVATION", 143, 155], ["MISCELLANEOUS REACTIONSHemosiderosis", "OBSERVATION", 159, 195], ["rare", "OBSERVATION_MODIFIER", 201, 205], ["complication", "OBSERVATION", 206, 218], ["not", "UNCERTAINTY", 294, 297], ["bleeding", "OBSERVATION", 298, 306]]], ["Packed red cells contain 1 mg Fe/ml, and the normal daily excretion of iron from the body is only about 1 mg.", [["red cells", "ANATOMY", 7, 16], ["body", "ANATOMY", 85, 89], ["Fe", "CHEMICAL", 30, 32], ["iron", "CHEMICAL", 71, 75], ["Fe", "CHEMICAL", 30, 32], ["iron", "CHEMICAL", 71, 75], ["Packed red cells", "CELL", 0, 16], ["iron", "SIMPLE_CHEMICAL", 71, 75], ["body", "ORGANISM_SUBDIVISION", 85, 89], ["Packed red cells", "CELL_TYPE", 0, 16], ["Packed red cells", "TREATMENT", 0, 16], ["iron", "TREATMENT", 71, 75]]], ["Initially, excess iron is stored in reticuloendothelial cells and does not cause clinical signs.", [["reticuloendothelial cells", "ANATOMY", 36, 61], ["iron", "CHEMICAL", 18, 22], ["iron", "CHEMICAL", 18, 22], ["iron", "SIMPLE_CHEMICAL", 18, 22], ["reticuloendothelial cells", "CELL", 36, 61], ["reticuloendothelial cells", "CELL_TYPE", 36, 61], ["excess iron", "PROBLEM", 11, 22], ["clinical signs", "PROBLEM", 81, 95], ["reticuloendothelial cells", "OBSERVATION", 36, 61]]], ["Once transferrin is saturated, additional iron stored in hepatic parenchymal cells may damage the liver (Marcus and Huehns, 1985) .", [["hepatic parenchymal cells", "ANATOMY", 57, 82], ["liver", "ANATOMY", 98, 103], ["iron", "CHEMICAL", 42, 46], ["iron", "CHEMICAL", 42, 46], ["transferrin", "GENE_OR_GENE_PRODUCT", 5, 16], ["iron", "SIMPLE_CHEMICAL", 42, 46], ["hepatic parenchymal cells", "CELL", 57, 82], ["liver", "ORGAN", 98, 103], ["transferrin", "PROTEIN", 5, 16], ["hepatic parenchymal cells", "CELL_TYPE", 57, 82], ["additional iron", "TREATMENT", 31, 46], ["hepatic", "ANATOMY", 57, 64], ["parenchymal cells", "OBSERVATION", 65, 82], ["liver", "ANATOMY", 98, 103]]], ["Few animals receive multiple transfusions, but hematinic therapy should be avoided in animals that are being transfused, unless iron deficiency is present.E. MISCELLANEOUS REACTIONSImmunological effects of transfusions are not limited to alloimmunization of recipients.", [["iron", "CHEMICAL", 128, 132], ["alloimmunization", "DISEASE", 238, 254], ["iron", "CHEMICAL", 128, 132], ["iron", "SIMPLE_CHEMICAL", 128, 132], ["recipients", "ORGANISM", 258, 268], ["multiple transfusions", "TREATMENT", 20, 41], ["hematinic therapy", "TREATMENT", 47, 64], ["iron deficiency", "PROBLEM", 128, 143], ["transfusions", "TREATMENT", 206, 218], ["alloimmunization of recipients", "TREATMENT", 238, 268], ["multiple", "OBSERVATION_MODIFIER", 20, 28], ["transfusions", "OBSERVATION", 29, 41]]], ["The first suspicion that transfusion might be immunosuppressive was related to the observation of improved renal allograft survival in transfused patients (Opelz and Terasaki, 1978) .", [["renal allograft", "ANATOMY", 107, 122], ["renal allograft", "MULTI-TISSUE_STRUCTURE", 107, 122], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["transfusion", "TREATMENT", 25, 36], ["immunosuppressive", "TREATMENT", 46, 63], ["improved renal allograft survival", "TREATMENT", 98, 131], ["renal", "ANATOMY", 107, 112], ["allograft", "OBSERVATION", 113, 122]]], ["More recently, human cancer patients that were transfused at the time of tumor resection had shorter survival times than patients of the same stage of disease that were not transfused (Blumberg and Heal, 1987) .", [["cancer", "ANATOMY", 21, 27], ["tumor", "ANATOMY", 73, 78], ["cancer", "DISEASE", 21, 27], ["tumor", "DISEASE", 73, 78], ["human", "ORGANISM", 15, 20], ["cancer", "CANCER", 21, 27], ["patients", "ORGANISM", 28, 36], ["tumor", "CANCER", 73, 78], ["patients", "ORGANISM", 121, 129], ["human", "SPECIES", 15, 20], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 121, 129], ["human", "SPECIES", 15, 20], ["human cancer", "PROBLEM", 15, 27], ["tumor resection", "TREATMENT", 73, 88], ["disease", "PROBLEM", 151, 158], ["cancer", "OBSERVATION", 21, 27], ["tumor", "OBSERVATION_MODIFIER", 73, 78], ["resection", "OBSERVATION", 79, 88], ["disease", "OBSERVATION", 151, 158]]], ["In addition, those patients that received whole blood did worse than those receiving packed red cells.", [["whole blood", "ANATOMY", 42, 53], ["red cells", "ANATOMY", 92, 101], ["patients", "ORGANISM", 19, 27], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["cells", "CELL", 96, 101], ["packed red cells", "CELL_TYPE", 85, 101], ["patients", "SPECIES", 19, 27], ["whole blood", "TEST", 42, 53], ["packed red cells", "TREATMENT", 85, 101]]], ["It has been suggested that plasma contains histocompatibility antigens, antiidiotypic antibodies, or other immunoregulatory substances that could cause immunosuppression.", [["plasma", "ANATOMY", 27, 33], ["plasma", "ORGANISM_SUBSTANCE", 27, 33], ["histocompatibility antigens", "GENE_OR_GENE_PRODUCT", 43, 70], ["histocompatibility antigens", "PROTEIN", 43, 70], ["antiidiotypic antibodies", "PROTEIN", 72, 96], ["plasma contains histocompatibility antigens", "TREATMENT", 27, 70], ["antiidiotypic antibodies", "TREATMENT", 72, 96], ["other immunoregulatory substances", "TREATMENT", 101, 134], ["immunosuppression", "TREATMENT", 152, 169]]], ["In an animal model of blood transfusion and tumor recurrence, plasma was the component associated with the highest rate of tumor growth (Horimi et al., 1983) .", [["blood", "ANATOMY", 22, 27], ["tumor", "ANATOMY", 44, 49], ["plasma", "ANATOMY", 62, 68], ["tumor", "ANATOMY", 123, 128], ["tumor", "DISEASE", 44, 49], ["tumor", "DISEASE", 123, 128], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["tumor", "CANCER", 44, 49], ["plasma", "ORGANISM_SUBSTANCE", 62, 68], ["tumor", "CANCER", 123, 128], ["blood transfusion", "TREATMENT", 22, 39], ["tumor recurrence", "PROBLEM", 44, 60], ["tumor growth", "PROBLEM", 123, 135], ["blood transfusion", "OBSERVATION", 22, 39], ["tumor", "OBSERVATION_MODIFIER", 44, 49], ["recurrence", "OBSERVATION", 50, 60], ["tumor", "OBSERVATION", 123, 128]]], ["In addition to immune suppression, transfusion, especially with stored red cells, has been thought to cause reticuloendothelial blockade.", [["red cells", "ANATOMY", 71, 80], ["reticuloendothelial", "ANATOMY", 108, 127], ["red cells", "CELL", 71, 80], ["reticuloendothelial", "ANATOMICAL_SYSTEM", 108, 127], ["red cells", "CELL_TYPE", 71, 80], ["immune suppression", "TREATMENT", 15, 33], ["transfusion", "TREATMENT", 35, 46], ["stored red cells", "PROBLEM", 64, 80], ["reticuloendothelial blockade", "TREATMENT", 108, 136], ["immune suppression", "OBSERVATION", 15, 33], ["thought to cause", "UNCERTAINTY", 91, 107], ["reticuloendothelial blockade", "OBSERVATION", 108, 136]]], ["The fixed macrophages in the spleen and liver engulf red cells and then are unable to phagocytize organisms.", [["macrophages", "ANATOMY", 10, 21], ["spleen", "ANATOMY", 29, 35], ["liver", "ANATOMY", 40, 45], ["red cells", "ANATOMY", 53, 62], ["macrophages", "CELL", 10, 21], ["spleen", "ORGAN", 29, 35], ["liver", "ORGAN", 40, 45], ["red cells", "CELL", 53, 62], ["fixed macrophages", "CELL_TYPE", 4, 21], ["red cells", "CELL_TYPE", 53, 62], ["The fixed macrophages in the spleen and liver engulf red cells", "PROBLEM", 0, 62], ["fixed", "OBSERVATION_MODIFIER", 4, 9], ["macrophages", "OBSERVATION", 10, 21], ["spleen", "ANATOMY", 29, 35], ["liver", "ANATOMY", 40, 45], ["engulf red cells", "OBSERVATION", 46, 62]]], ["This phenomenon is not likely to be clinically significant.E. MISCELLANEOUS REACTIONSMost human deaths caused by transfusions result from transmission of infectious diseases.", [["deaths", "DISEASE", 96, 102], ["infectious diseases", "DISEASE", 154, 173], ["human", "ORGANISM", 90, 95], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 90, 95], ["transfusions", "TREATMENT", 113, 125], ["infectious diseases", "PROBLEM", 154, 173], ["not likely to be", "UNCERTAINTY", 19, 35], ["MISCELLANEOUS REACTIONSMost", "OBSERVATION_MODIFIER", 62, 89], ["infectious", "OBSERVATION", 154, 164]]], ["Examples of transfusion-transmitted infections include AIDS and HTLV-I infection, hepatitis, malaria, babesiosis, Chagas' disease, cytomegalovirus and Epstein-Barr virus infections, syphilis and, rarely, other infections such as brucellosis, salmonellosis, toxoplasmosis, trypanosomiasis, and filariasis.", [["transfusion-transmitted infections", "DISEASE", 12, 46], ["AIDS", "DISEASE", 55, 59], ["HTLV-I infection", "DISEASE", 64, 80], ["hepatitis", "DISEASE", 82, 91], ["malaria", "DISEASE", 93, 100], ["babesiosis", "DISEASE", 102, 112], ["Chagas' disease", "DISEASE", 114, 129], ["Epstein-Barr virus infections", "DISEASE", 151, 180], ["syphilis", "DISEASE", 182, 190], ["infections", "DISEASE", 210, 220], ["brucellosis", "DISEASE", 229, 240], ["salmonellosis", "DISEASE", 242, 255], ["toxoplasmosis", "DISEASE", 257, 270], ["trypanosomiasis", "DISEASE", 272, 287], ["filariasis", "DISEASE", 293, 303], ["HTLV-I", "ORGANISM", 64, 70], ["cytomegalovirus", "ORGANISM", 131, 146], ["Epstein-Barr virus", "ORGANISM", 151, 169], ["HTLV-I", "SPECIES", 64, 70], ["Epstein-Barr virus", "SPECIES", 151, 169], ["transfusion", "TREATMENT", 12, 23], ["transmitted infections", "PROBLEM", 24, 46], ["AIDS", "PROBLEM", 55, 59], ["HTLV-I infection", "PROBLEM", 64, 80], ["hepatitis", "PROBLEM", 82, 91], ["malaria", "PROBLEM", 93, 100], ["babesiosis", "PROBLEM", 102, 112], ["Chagas' disease", "PROBLEM", 114, 129], ["cytomegalovirus", "PROBLEM", 131, 146], ["Epstein-Barr virus infections", "PROBLEM", 151, 180], ["syphilis", "PROBLEM", 182, 190], ["other infections", "PROBLEM", 204, 220], ["brucellosis", "PROBLEM", 229, 240], ["salmonellosis", "PROBLEM", 242, 255], ["toxoplasmosis", "PROBLEM", 257, 270], ["trypanosomiasis", "PROBLEM", 272, 287], ["filariasis", "PROBLEM", 293, 303], ["transfusion", "OBSERVATION", 12, 23], ["infections", "OBSERVATION", 36, 46], ["HTLV-I", "OBSERVATION_MODIFIER", 64, 70], ["infection", "OBSERVATION", 71, 80], ["hepatitis", "OBSERVATION", 82, 91], ["malaria", "OBSERVATION", 93, 100], ["babesiosis", "OBSERVATION", 102, 112], ["Chagas' disease", "OBSERVATION", 114, 129], ["cytomegalovirus", "OBSERVATION", 131, 146], ["Barr virus infections", "OBSERVATION", 159, 180], ["infections", "OBSERVATION", 210, 220], ["brucellosis", "OBSERVATION", 229, 240], ["salmonellosis", "OBSERVATION", 242, 255], ["toxoplasmosis", "OBSERVATION", 257, 270], ["filariasis", "OBSERVATION", 293, 303]]], ["These agents share common properties of prolonged persistence in the blood of healthy carriers, long incubation periods, and stability in stored blood.", [["blood", "ANATOMY", 69, 74], ["blood", "ANATOMY", 145, 150], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["blood", "ORGANISM_SUBSTANCE", 145, 150], ["long incubation periods", "TREATMENT", 96, 119], ["stability in stored blood", "PROBLEM", 125, 150], ["prolonged", "OBSERVATION_MODIFIER", 40, 49], ["persistence", "OBSERVATION_MODIFIER", 50, 61], ["stability", "OBSERVATION_MODIFIER", 125, 134]]], ["Ideally, testing should be done for all agents, but accurate tests are only available for a few, and some carriers are not detectable.E. MISCELLANEOUS REACTIONSThe same or related organisms can be expected to be transmitted from animal to animal by transfusion.", [["testing", "TEST", 9, 16], ["all agents", "TREATMENT", 36, 46], ["accurate tests", "TEST", 52, 66], ["transfusion", "TREATMENT", 249, 260]]], ["Retro viruses are of major importance in cats, cattle, and horses.", [["cats", "ORGANISM", 41, 45], ["cats", "SPECIES", 41, 45], ["cattle", "SPECIES", 47, 53], ["cattle", "SPECIES", 47, 53], ["viruses", "OBSERVATION", 6, 13]]], ["The cat is most at risk, with up to 5 % of random cats carrying either feline leukemia virus or feline immunodeficiency virus.", [["feline leukemia virus", "DISEASE", 71, 92], ["feline immunodeficiency virus", "DISEASE", 96, 125], ["cat", "ORGANISM", 4, 7], ["cats", "ORGANISM", 50, 54], ["feline leukemia virus", "ORGANISM", 71, 92], ["feline immunodeficiency virus", "ORGANISM", 96, 125], ["feline", "SPECIES", 71, 77], ["feline immunodeficiency virus", "SPECIES", 96, 125], ["feline leukemia virus", "SPECIES", 71, 92], ["feline immunodeficiency virus", "SPECIES", 96, 125], ["random cats carrying either feline leukemia virus", "PROBLEM", 43, 92], ["feline immunodeficiency virus", "PROBLEM", 96, 125], ["feline leukemia virus", "OBSERVATION", 71, 92], ["feline immunodeficiency", "OBSERVATION", 96, 119]]], ["Although horses and cattle are less frequently transfused than are dogs and cats, bovine leukemia virus and equine anemia virus are relatively prevalent.", [["bovine leukemia virus", "DISEASE", 82, 103], ["equine anemia", "DISEASE", 108, 121], ["horses", "ORGANISM", 9, 15], ["cattle", "ORGANISM", 20, 26], ["dogs", "ORGANISM", 67, 71], ["cats", "ORGANISM", 76, 80], ["bovine leukemia virus", "ORGANISM", 82, 103], ["equine anemia virus", "ORGANISM", 108, 127], ["horses", "SPECIES", 9, 15], ["cattle", "SPECIES", 20, 26], ["dogs", "SPECIES", 67, 71], ["cats", "SPECIES", 76, 80], ["bovine", "SPECIES", 82, 88], ["equine anemia virus", "SPECIES", 108, 127], ["horses", "SPECIES", 9, 15], ["cattle", "SPECIES", 20, 26], ["bovine leukemia virus", "SPECIES", 82, 103], ["equine anemia virus", "SPECIES", 108, 127], ["dogs and cats", "TREATMENT", 67, 80], ["bovine leukemia virus", "PROBLEM", 82, 103], ["equine anemia virus", "PROBLEM", 108, 127], ["bovine leukemia virus", "OBSERVATION", 82, 103]]], ["Depending on geographic prevalence of disease, dogs are at risk for transfusion transmitted babesiosis, ehrlichiosis, and the microfilarial stage of dirofilariasis.", [["transfusion transmitted babesiosis", "DISEASE", 68, 102], ["ehrlichiosis", "DISEASE", 104, 116], ["dirofilariasis", "DISEASE", 149, 163], ["dogs", "ORGANISM", 47, 51], ["dogs", "SPECIES", 47, 51], ["disease", "PROBLEM", 38, 45], ["transfusion transmitted babesiosis", "PROBLEM", 68, 102], ["ehrlichiosis", "PROBLEM", 104, 116], ["the microfilarial stage of dirofilariasis", "PROBLEM", 122, 163], ["disease", "OBSERVATION", 38, 45], ["babesiosis", "OBSERVATION", 92, 102], ["ehrlichiosis", "OBSERVATION", 104, 116], ["microfilarial stage", "OBSERVATION_MODIFIER", 126, 145], ["dirofilariasis", "OBSERVATION", 149, 163]]], ["In addition to retro viruses, cats may carry the corona virus that causes feline infectious peritonitis, although transmission by blood has not been proved.", [["blood", "ANATOMY", 130, 135], ["feline infectious peritonitis", "DISEASE", 74, 103], ["retro viruses", "ORGANISM", 15, 28], ["cats", "ORGANISM", 30, 34], ["corona virus", "ORGANISM", 49, 61], ["feline", "ORGANISM", 74, 80], ["blood", "ORGANISM_SUBSTANCE", 130, 135], ["cats", "SPECIES", 30, 34], ["feline", "SPECIES", 74, 80], ["retro viruses", "PROBLEM", 15, 28], ["the corona virus", "PROBLEM", 45, 61], ["feline infectious peritonitis", "PROBLEM", 74, 103], ["retro viruses", "OBSERVATION", 15, 28], ["corona virus", "OBSERVATION", 49, 61], ["feline", "OBSERVATION_MODIFIER", 74, 80], ["infectious", "OBSERVATION_MODIFIER", 81, 91], ["peritonitis", "OBSERVATION", 92, 103]]], ["Hemobartonellosis is another disease that increases the risk of transfusion of cats.XI. Therapeutic ApheresisThe use of apheresis to obtain single-donor platelets or plasma for administration to a patient has been described by Authement (this volume).", [["platelets", "ANATOMY", 153, 162], ["plasma", "ANATOMY", 166, 172], ["Hemobartonellosis", "DISEASE", 0, 17], ["cats", "ORGANISM", 79, 83], ["platelets", "CELL", 153, 162], ["plasma", "ORGANISM_SUBSTANCE", 166, 172], ["patient", "ORGANISM", 197, 204], ["XI", "PROTEIN", 84, 86], ["single-donor platelets", "CELL_TYPE", 140, 162], ["patient", "SPECIES", 197, 204], ["Hemobartonellosis", "PROBLEM", 0, 17], ["another disease", "PROBLEM", 21, 36], ["transfusion of cats", "TREATMENT", 64, 83], ["Therapeutic Apheresis", "TREATMENT", 88, 109], ["apheresis", "TREATMENT", 120, 129], ["single-donor platelets", "TREATMENT", 140, 162], ["plasma", "TREATMENT", 166, 172], ["administration", "TREATMENT", 177, 191], ["disease", "OBSERVATION", 29, 36], ["Therapeutic Apheresis", "OBSERVATION", 88, 109]]], ["The procedure has also been used to remove abnormal components from the blood, either cells or plasma.", [["blood", "ANATOMY", 72, 77], ["cells", "ANATOMY", 86, 91], ["plasma", "ANATOMY", 95, 101], ["blood", "ORGANISM_SUBSTANCE", 72, 77], ["cells", "CELL", 86, 91], ["plasma", "ORGANISM_SUBSTANCE", 95, 101], ["The procedure", "TREATMENT", 0, 13], ["abnormal components", "PROBLEM", 43, 62], ["the blood", "TEST", 68, 77]]], ["Examples of clinical indications are removal of very large numbers of blasts in acute leukemia (leukopheresis); excess red cells in polycythemia vera; abnormal antibodies, lipids, or proteins (plasmapheresis); and excess platelets in thrombocythemia (plateletpheresis).XI. Therapeutic ApheresisSeveral machines are available that collect the desired component by continuous-flow separation and centrifugation or filtration.", [["blasts", "ANATOMY", 70, 76], ["acute leukemia", "ANATOMY", 80, 94], ["red cells", "ANATOMY", 119, 128], ["platelets", "ANATOMY", 221, 230], ["blasts", "DISEASE", 70, 76], ["acute leukemia", "DISEASE", 80, 94], ["leukopheresis", "DISEASE", 96, 109], ["polycythemia vera", "DISEASE", 132, 149], ["thrombocythemia", "DISEASE", 234, 249], ["plateletpheresis", "DISEASE", 251, 267], ["blasts", "CELL", 70, 76], ["acute leukemia", "CANCER", 80, 94], ["leukopheresis", "CANCER", 96, 109], ["red cells", "CELL", 119, 128], ["lipids", "SIMPLE_CHEMICAL", 172, 178], ["platelets", "CELL", 221, 230], ["blasts", "CELL_TYPE", 70, 76], ["red cells", "CELL_TYPE", 119, 128], ["abnormal antibodies", "PROTEIN", 151, 170], ["platelets", "CELL_TYPE", 221, 230], ["XI", "PROTEIN", 269, 271], ["removal", "TREATMENT", 37, 44], ["very large numbers of blasts", "PROBLEM", 48, 76], ["acute leukemia (leukopheresis", "PROBLEM", 80, 109], ["excess red cells", "PROBLEM", 112, 128], ["polycythemia vera", "PROBLEM", 132, 149], ["abnormal antibodies", "PROBLEM", 151, 170], ["lipids", "TEST", 172, 178], ["plasmapheresis", "TREATMENT", 193, 207], ["excess platelets", "PROBLEM", 214, 230], ["thrombocythemia", "PROBLEM", 234, 249], ["plateletpheresis", "TREATMENT", 251, 267], ["Therapeutic ApheresisSeveral machines", "TREATMENT", 273, 310], ["continuous-flow separation", "TREATMENT", 363, 389], ["centrifugation", "TREATMENT", 394, 408], ["filtration", "TREATMENT", 412, 422], ["very", "OBSERVATION_MODIFIER", 48, 52], ["large", "OBSERVATION_MODIFIER", 53, 58], ["numbers", "OBSERVATION_MODIFIER", 59, 66], ["blasts", "OBSERVATION", 70, 76], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["leukemia", "OBSERVATION", 86, 94], ["red cells", "OBSERVATION", 119, 128], ["polycythemia vera", "OBSERVATION", 132, 149], ["thrombocythemia", "OBSERVATION", 234, 249], ["flow separation", "OBSERVATION", 374, 389]]], ["These are most efficient for rapid processing of large volumes of blood.", [["blood", "ANATOMY", 66, 71], ["blood", "ORGANISM_SUBSTANCE", 66, 71], ["large volumes of blood", "PROBLEM", 49, 71], ["large", "OBSERVATION_MODIFIER", 49, 54], ["volumes", "OBSERVATION_MODIFIER", 55, 62], ["blood", "OBSERVATION", 66, 71]]], ["Because the extracorporial volume is relatively large, these machines are not readily adaptable for animals under 10-15 kg.", [["the extracorporial volume", "TEST", 8, 33], ["extracorporial", "OBSERVATION_MODIFIER", 12, 26], ["volume", "OBSERVATION", 27, 33], ["relatively", "OBSERVATION_MODIFIER", 37, 47], ["large", "OBSERVATION", 48, 53]]], ["If equipment is unavailable or if the patient is very small, apheresis may be done manually by removing a volume of blood, separating the component by centrifugation, and returning the rest to the animal.", [["blood", "ANATOMY", 116, 121], ["patient", "ORGANISM", 38, 45], ["blood", "ORGANISM_SUBSTANCE", 116, 121], ["patient", "SPECIES", 38, 45], ["apheresis", "TREATMENT", 61, 70], ["small", "OBSERVATION_MODIFIER", 54, 59], ["component", "OBSERVATION_MODIFIER", 138, 147], ["centrifugation", "OBSERVATION", 151, 165]]], ["Because the volume exchanged in a standard protocol is usually one plasma volume, manual apheresis requires removal of approximately four samples of 20 ml/kg each.", [["plasma", "ANATOMY", 67, 73], ["samples", "ANATOMY", 138, 145], ["plasma", "ORGANISM_SUBSTANCE", 67, 73], ["a standard protocol", "TREATMENT", 32, 51], ["manual apheresis", "TREATMENT", 82, 98], ["removal", "TREATMENT", 108, 115], ["volume exchanged", "OBSERVATION", 12, 28]]], ["Each exchange results in a progressive decrease in removal of the abnormal substance, because of dilution of plasma by replacement fluid.", [["plasma", "ANATOMY", 109, 115], ["plasma", "ORGANISM_SUBSTANCE", 109, 115], ["fluid", "ORGANISM_SUBSTANCE", 131, 136], ["a progressive decrease", "PROBLEM", 25, 47], ["removal", "TREATMENT", 51, 58], ["the abnormal substance", "PROBLEM", 62, 84], ["plasma", "TREATMENT", 109, 115], ["replacement fluid", "TREATMENT", 119, 136], ["progressive", "OBSERVATION_MODIFIER", 27, 38], ["decrease", "OBSERVATION_MODIFIER", 39, 47], ["removal", "OBSERVATION_MODIFIER", 51, 58], ["abnormal", "OBSERVATION_MODIFIER", 66, 74], ["substance", "OBSERVATION", 75, 84], ["replacement", "OBSERVATION_MODIFIER", 119, 130], ["fluid", "OBSERVATION", 131, 136]]], ["Plasmapheresis has been shown to be of definite value in treatment of hyperviscosity syndrome both in human and canine patients (Nose et al., 1983; Klausner et al., 1986) .", [["hyperviscosity syndrome", "DISEASE", 70, 93], ["human", "ORGANISM", 102, 107], ["canine", "ORGANISM", 112, 118], ["patients", "ORGANISM", 119, 127], ["human", "SPECIES", 102, 107], ["canine", "SPECIES", 112, 118], ["patients", "SPECIES", 119, 127], ["human", "SPECIES", 102, 107], ["canine", "SPECIES", 112, 118], ["Plasmapheresis", "TREATMENT", 0, 14], ["hyperviscosity syndrome", "PROBLEM", 70, 93], ["hyperviscosity syndrome", "OBSERVATION", 70, 93]]], ["Because the paraprotein is confined primarily to the vascular space and the rate of synthesis is slow, removal every few weeks may be the only treatment required early in the disease.", [["vascular space", "ANATOMY", 53, 67], ["paraprotein", "GENE_OR_GENE_PRODUCT", 12, 23], ["vascular space", "MULTI-TISSUE_STRUCTURE", 53, 67], ["paraprotein", "PROTEIN", 12, 23], ["the paraprotein", "PROBLEM", 8, 23], ["removal", "TREATMENT", 103, 110], ["treatment", "TREATMENT", 143, 152], ["the disease", "PROBLEM", 171, 182], ["paraprotein", "OBSERVATION", 12, 23], ["vascular space", "ANATOMY", 53, 67], ["slow", "OBSERVATION_MODIFIER", 97, 101]]], ["In certain immune-mediated diseases in which antibody production is more rapid, removal results in temporary improvement, but rapid rebound of antibody systhesis requires follow-up immunosuppressive therapy.", [["mediated diseases", "PROBLEM", 18, 35], ["removal", "TREATMENT", 80, 87], ["rapid rebound of antibody systhesis", "PROBLEM", 126, 161], ["immunosuppressive therapy", "TREATMENT", 181, 206], ["diseases", "OBSERVATION", 27, 35]]], ["Immune-mediated diseases most likely to respond to plasmapheresis are myasthenia gravis, Guillian-Barre syndrome, immune-mediated hemolytic anemia, and thrombocytopenia.", [["myasthenia gravis", "DISEASE", 70, 87], ["Guillian-Barre syndrome", "DISEASE", 89, 112], ["immune-mediated hemolytic anemia", "DISEASE", 114, 146], ["thrombocytopenia", "DISEASE", 152, 168], ["Guillian-Barre", "ORGANISM", 89, 103], ["Immune-mediated diseases", "PROBLEM", 0, 24], ["plasmapheresis", "TREATMENT", 51, 65], ["myasthenia gravis", "PROBLEM", 70, 87], ["Guillian", "PROBLEM", 89, 97], ["Barre syndrome", "PROBLEM", 98, 112], ["immune-mediated hemolytic anemia", "PROBLEM", 114, 146], ["thrombocytopenia", "PROBLEM", 152, 168], ["diseases", "OBSERVATION", 16, 24], ["most likely", "UNCERTAINTY", 25, 36], ["myasthenia gravis", "OBSERVATION", 70, 87], ["Barre syndrome", "OBSERVATION", 98, 112], ["hemolytic", "OBSERVATION_MODIFIER", 130, 139], ["anemia", "OBSERVATION", 140, 146], ["thrombocytopenia", "OBSERVATION", 152, 168]]], ["Plasmapheresis is the treatment of choice for thrombotic thrombocytopenic purpura in human patients; this condition has not been reported in animals.", [["thrombotic thrombocytopenic purpura", "DISEASE", 46, 81], ["human", "ORGANISM", 85, 90], ["patients", "ORGANISM", 91, 99], ["human", "SPECIES", 85, 90], ["patients", "SPECIES", 91, 99], ["human", "SPECIES", 85, 90], ["Plasmapheresis", "TREATMENT", 0, 14], ["thrombotic thrombocytopenic purpura", "PROBLEM", 46, 81], ["thrombotic", "OBSERVATION_MODIFIER", 46, 56], ["thrombocytopenic", "OBSERVATION_MODIFIER", 57, 73], ["purpura", "OBSERVATION", 74, 81]]], ["Therapeutic apheresis has been used clinically by this author and others in small numbers of dogs (Matus et al., 1985; Klausner et al., 1986) .XI. Therapeutic ApheresisThe amount of the specific pathologic substance to be removed depends upon the volume of plasma exchanged and the frequency of the procedure.", [["plasma", "ANATOMY", 257, 263], ["Apheresis", "CHEMICAL", 159, 168], ["dogs", "ORGANISM", 93, 97], ["plasma", "ORGANISM_SUBSTANCE", 257, 263], ["dogs", "SPECIES", 93, 97], ["Therapeutic apheresis", "TREATMENT", 0, 21], ["Therapeutic Apheresis", "TREATMENT", 147, 168], ["the procedure", "TREATMENT", 295, 308], ["apheresis", "OBSERVATION", 12, 21], ["small", "OBSERVATION_MODIFIER", 76, 81], ["Apheresis", "OBSERVATION", 159, 168], ["amount", "OBSERVATION_MODIFIER", 172, 178]]], ["If a large volume of plasma is removed, clotting factors and antithrombin III are removed as well.", [["plasma", "ANATOMY", 21, 27], ["plasma", "ORGANISM_SUBSTANCE", 21, 27], ["clotting factors", "GENE_OR_GENE_PRODUCT", 40, 56], ["antithrombin III", "GENE_OR_GENE_PRODUCT", 61, 77], ["clotting factors", "PROTEIN", 40, 56], ["antithrombin III", "PROTEIN", 61, 77], ["a large volume of plasma", "PROBLEM", 3, 27], ["clotting factors", "PROBLEM", 40, 56], ["antithrombin III", "TREATMENT", 61, 77], ["large", "OBSERVATION_MODIFIER", 5, 10], ["volume", "OBSERVATION_MODIFIER", 11, 17]]], ["Despite this, very few thrombotic or hemorrhagic complications have been reported (Mollison et al., 1987) .", [["thrombotic", "DISEASE", 23, 33], ["hemorrhagic", "DISEASE", 37, 48], ["very few thrombotic or hemorrhagic complications", "PROBLEM", 14, 62], ["very", "OBSERVATION_MODIFIER", 14, 18], ["few", "OBSERVATION_MODIFIER", 19, 22], ["thrombotic", "OBSERVATION", 23, 33], ["hemorrhagic", "OBSERVATION_MODIFIER", 37, 48], ["complications", "OBSERVATION", 49, 62]]], ["Plasma levels of immunoglobulins and albumin are decreased, and result in immunosuppression and decreased colloid osmotic pressure.", [["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 17, 32], ["albumin", "GENE_OR_GENE_PRODUCT", 37, 44], ["immunoglobulins", "PROTEIN", 17, 32], ["albumin", "PROTEIN", 37, 44], ["Plasma levels", "TEST", 0, 13], ["immunoglobulins", "TEST", 17, 32], ["albumin", "TEST", 37, 44], ["immunosuppression", "TREATMENT", 74, 91], ["decreased colloid osmotic pressure", "PROBLEM", 96, 130], ["immunoglobulins", "OBSERVATION", 17, 32], ["decreased", "OBSERVATION_MODIFIER", 49, 58], ["decreased", "OBSERVATION_MODIFIER", 96, 105], ["colloid osmotic pressure", "OBSERVATION", 106, 130]]], ["Because species-specific albumin is not available for animals, the replacement fluid should contain some colloid or homologous plasma.XI. Therapeutic ApheresisClinical applications for apheresis in humans and animals are continuing to expand into diseases that are difficult to treat by other means.", [["plasma", "ANATOMY", 127, 133], ["albumin", "GENE_OR_GENE_PRODUCT", 25, 32], ["fluid", "ORGANISM_SUBSTANCE", 79, 84], ["colloid", "SIMPLE_CHEMICAL", 105, 112], ["plasma", "ORGANISM_SUBSTANCE", 127, 133], ["humans", "ORGANISM", 198, 204], ["albumin", "PROTEIN", 25, 32], ["XI", "PROTEIN", 134, 136], ["humans", "SPECIES", 198, 204], ["humans", "SPECIES", 198, 204], ["specific albumin", "TEST", 16, 32], ["the replacement fluid", "TREATMENT", 63, 84], ["some colloid", "TREATMENT", 100, 112], ["homologous plasma", "TREATMENT", 116, 133], ["Therapeutic ApheresisClinical applications", "TREATMENT", 138, 180], ["apheresis", "TREATMENT", 185, 194]]], ["As equipment becomes more available in academic veterinary centers, the procedure should become more available for veterinary patients as well.", [["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 126, 134], ["the procedure", "TREATMENT", 68, 81]]]], "PMC7468343": [["IntroductionViruses belonging to the Parvoviridae family include 4\u20136-kb-long linear, single-stranded DNA genomes (P\u00e9nzes et al., 2019).", [["Parvoviridae", "GENE_OR_GENE_PRODUCT", 37, 49], ["DNA", "CELLULAR_COMPONENT", 101, 104], ["Parvoviridae family", "DNA", 37, 56], ["4\u20136-kb-long linear, single-stranded DNA genomes", "DNA", 65, 112]]], ["Recently, Parvoviridae family has been re-organized by International Committee on Taxonomy of Viruses (ICTV).", [["ICTV", "CANCER", 103, 107], ["ICTV", "SPECIES", 103, 107]]], ["The novel subfamily Hamaparvovirinae comprises the current genera Hepandensoviruses, Penstyldensovirus, and Brevidensovirus, together with the yet unclassified chapparvoviruses (ChPV) (Cotmore et al., 2019).", [["Hepandensoviruses", "GENE_OR_GENE_PRODUCT", 66, 83], ["Penstyldensovirus", "GENE_OR_GENE_PRODUCT", 85, 102], ["Brevidensovirus", "GENE_OR_GENE_PRODUCT", 108, 123], ["Penstyldensovirus", "TREATMENT", 85, 102], ["Brevidensovirus", "TREATMENT", 108, 123]]], ["Phylogeny evidence suggested the ChPV detected in many kinds of vertebrates, harbored close relation to members of other genera of subfamily Hamaparvovirinae, which evidently derive from ancient members of this lineage, have been identified in several arthropod genomes.", [["ChPV", "GENE_OR_GENE_PRODUCT", 33, 37], ["Hamaparvovirinae", "GENE_OR_GENE_PRODUCT", 141, 157], ["ChPV", "DNA", 33, 37], ["the ChPV", "PROBLEM", 29, 37], ["several", "OBSERVATION_MODIFIER", 244, 251], ["arthropod genomes", "OBSERVATION", 252, 269]]], ["These reports suggested that ChPV lineage infects both vertebrates and invertebrates, and transmission of ChPVs between distantly related host species may have occurred in the past.IntroductionRecently, cases of ChPV infection in various organisms have been reported.", [["ChPV lineage", "ANATOMY", 29, 41], ["infection", "DISEASE", 217, 226], ["ChPV lineage", "CELL", 29, 41], ["ChPVs", "GENE_OR_GENE_PRODUCT", 106, 111], ["ChPV", "GENE_OR_GENE_PRODUCT", 212, 216], ["ChPV lineage", "CELL_TYPE", 29, 41], ["ChPV", "SPECIES", 212, 216], ["ChPV lineage infects", "PROBLEM", 29, 49], ["ChPVs", "PROBLEM", 106, 111], ["host species", "PROBLEM", 138, 150], ["ChPV infection in various organisms", "PROBLEM", 212, 247], ["lineage infects", "OBSERVATION", 34, 49], ["host species", "OBSERVATION", 138, 150], ["infection", "OBSERVATION", 217, 226]]], ["In addition to rat parvovirus 2 (RPV2), ChPV include fruit bat (Eidolon helvum) parvovirus 1 (Yinda et al., 2018), E. helvum parvovirus 2 (Baker et al., 2013), common vampire bat (Desmodus rotundus) parvovirus (Souza et al., 2017), murine kidney parvovirus (Roediger et al., 2018), murine ChPV (Williams et al., 2018), simian parvo-like virus 3 (Kapusinszky et al., 2017), turkey parvovirus 1 (Reuter et al., 2014), porcine parvovirus 7 (Palinski et al., 2016), Tasmanian devil-associated ChPV strains (Chong et al., 2019), red-crowned crane-associated parvovirus (Wang et al., 2019), chicken ChPV 1 and 2 (Lima et al., 2019), and peafowl parvovirus (PePV) 1 and PePV2 (Liu et al., 2020).", [["kidney", "ANATOMY", 239, 245], ["Desmodus rotundus) parvovirus", "DISEASE", 180, 209], ["kidney parvovirus", "DISEASE", 239, 256], ["simian parvo-like virus", "DISEASE", 319, 342], ["turkey parvovirus", "DISEASE", 373, 390], ["porcine parvovirus", "DISEASE", 416, 434], ["parvovirus", "DISEASE", 553, 563], ["peafowl parvovirus", "DISEASE", 631, 649], ["rat parvovirus 2", "ORGANISM", 15, 31], ["RPV2", "ORGANISM", 33, 37], ["ChPV", "GENE_OR_GENE_PRODUCT", 40, 44], ["fruit bat", "ORGANISM", 53, 62], ["Eidolon helvum", "ORGANISM", 64, 78], ["parvovirus 1", "ORGANISM", 80, 92], ["E. helvum parvovirus 2", "ORGANISM", 115, 137], ["vampire bat", "ORGANISM", 167, 178], ["Desmodus rotundus", "ORGANISM", 180, 197], ["parvovirus", "ORGANISM", 199, 209], ["murine", "ORGANISM", 232, 238], ["kidney", "ORGAN", 239, 245], ["parvovirus", "ORGANISM", 246, 256], ["murine", "ORGANISM", 282, 288], ["simian parvo-like virus 3", "ORGANISM", 319, 344], ["turkey parvovirus 1", "ORGANISM", 373, 392], ["porcine parvovirus 7", "ORGANISM", 416, 436], ["ChPV", "ORGANISM", 489, 493], ["parvovirus", "ORGANISM", 553, 563], ["chicken", "ORGANISM", 585, 592], ["ChPV 1", "ORGANISM", 593, 599], ["peafowl parvovirus", "ORGANISM", 631, 649], ["PePV2", "ORGANISM", 663, 668], ["rat", "SPECIES", 15, 18], ["parvovirus", "SPECIES", 19, 29], ["Eidolon helvum", "SPECIES", 64, 78], ["parvovirus", "SPECIES", 80, 90], ["E. helvum parvovirus", "SPECIES", 115, 135], ["Desmodus rotundus", "SPECIES", 180, 197], ["parvovirus", "SPECIES", 199, 209], ["murine", "SPECIES", 232, 238], ["kidney parvovirus", "SPECIES", 239, 256], ["murine", "SPECIES", 282, 288], ["simian parvo", "SPECIES", 319, 331], ["turkey parvovirus", "SPECIES", 373, 390], ["porcine parvovirus", "SPECIES", 416, 434], ["chicken", "SPECIES", 585, 592], ["peafowl parvovirus", "SPECIES", 631, 649], ["rat parvovirus 2", "SPECIES", 15, 31], ["RPV2", "SPECIES", 33, 37], ["Eidolon helvum", "SPECIES", 64, 78], ["E. helvum parvovirus", "SPECIES", 115, 135], ["Desmodus rotundus", "SPECIES", 180, 197], ["murine kidney parvovirus", "SPECIES", 232, 256], ["simian parvo-like virus", "SPECIES", 319, 342], ["turkey parvovirus 1", "SPECIES", 373, 392], ["chicken", "SPECIES", 585, 592], ["peafowl parvovirus", "SPECIES", 631, 649], ["rat parvovirus", "PROBLEM", 15, 29], ["ChPV", "TEST", 40, 44], ["fruit bat", "TEST", 53, 62], ["parvovirus", "TEST", 80, 90], ["E. helvum parvovirus", "TEST", 115, 135], ["parvovirus", "PROBLEM", 199, 209], ["murine kidney parvovirus", "PROBLEM", 232, 256], ["simian parvo", "TEST", 319, 331], ["porcine parvovirus", "TREATMENT", 416, 434], ["ChPV strains", "PROBLEM", 489, 501], ["parvovirus", "PROBLEM", 553, 563], ["peafowl parvovirus (PePV)", "TREATMENT", 631, 656], ["parvovirus", "OBSERVATION", 19, 29], ["fruit bat", "OBSERVATION", 53, 62], ["common vampire", "ANATOMY", 160, 174], ["kidney", "ANATOMY", 239, 245], ["parvovirus", "OBSERVATION", 246, 256], ["parvovirus", "OBSERVATION", 553, 563]]], ["Meanwhile, Cachavirus, which is very similar to ChPV, was first detected in dog feces in the United States in 2019 (Fahsbender et al., 2019), raising concerns regarding the emergence and coinfection of Cachavirus in dogs.", [["Cachavirus", "CHEMICAL", 11, 21], ["Cachavirus", "CHEMICAL", 202, 212], ["Cachavirus", "GENE_OR_GENE_PRODUCT", 11, 21], ["ChPV", "GENE_OR_GENE_PRODUCT", 48, 52], ["dog", "ORGANISM", 76, 79], ["feces", "ORGANISM_SUBDIVISION", 80, 85], ["Cachavirus", "ORGANISM", 202, 212], ["dogs", "ORGANISM", 216, 220], ["ChPV", "PROTEIN", 48, 52], ["dog", "SPECIES", 76, 79], ["dogs", "SPECIES", 216, 220], ["dog", "SPECIES", 76, 79], ["Cachavirus", "PROBLEM", 11, 21], ["Cachavirus in dogs", "PROBLEM", 202, 220]]], ["The Cachavirus was shown to harbor two major open reading frames (ORFs) encoding NS1 and VP1.", [["NS1", "GENE_OR_GENE_PRODUCT", 81, 84], ["VP1", "GENE_OR_GENE_PRODUCT", 89, 92], ["open reading frames", "DNA", 45, 64], ["ORFs", "DNA", 66, 70], ["NS1", "PROTEIN", 81, 84], ["VP1", "PROTEIN", 89, 92], ["VP1", "TEST", 89, 92]]], ["Therefore, Cachavirus may show an extensive geographic distribution and may infect diverse hosts (Souza et al., 2017).", [["Cachavirus", "CHEMICAL", 11, 21], ["Cachavirus", "TEST", 11, 21], ["extensive", "OBSERVATION_MODIFIER", 34, 43], ["geographic", "OBSERVATION_MODIFIER", 44, 54], ["distribution", "OBSERVATION_MODIFIER", 55, 67]]], ["To obtain detailed understanding of the prevalence and evolution of Cachavirus in dogs, we performed a large-scale investigation using rectal swabs from healthy and diarrheic dogs.Sample collection and DNA extraction ::: Materials and methodsRectal swabs from 85 healthy and 323 diarrheic dogs were collected from veterinary hospitals in Henan, Hubei, and Zhejiang Provinces, China, during 2018\u20132019.", [["rectal swabs", "ANATOMY", 135, 147], ["Rectal swabs", "ANATOMY", 242, 254], ["dogs", "ORGANISM", 82, 86], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 135, 147], ["dogs", "ORGANISM", 175, 179], ["DNA", "CELLULAR_COMPONENT", 202, 205], ["Rectal swabs", "CANCER", 242, 254], ["dogs", "ORGANISM", 289, 293], ["dogs", "SPECIES", 82, 86], ["dogs", "SPECIES", 175, 179], ["dogs", "SPECIES", 289, 293], ["Cachavirus in dogs", "PROBLEM", 68, 86], ["a large-scale investigation", "TREATMENT", 101, 128], ["rectal swabs", "TREATMENT", 135, 147], ["Sample collection", "TEST", 180, 197], ["Rectal swabs", "TEST", 242, 254], ["diarrheic dogs", "PROBLEM", 279, 293], ["rectal", "ANATOMY", 135, 141], ["Rectal", "ANATOMY", 242, 248]]], ["Viral DNA and RNA were extracted using the EasyPure Viral DNA/RNA Kit (TransGen Biotechnology, Inc., Beijing, China) in accordance with the manufacturer's instructions.", [["Viral", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["Viral DNA and RNA", "PROBLEM", 0, 17], ["the EasyPure Viral DNA", "TREATMENT", 39, 61]]], ["The extracted DNA and RNA sample were stored at \u221280 \u00b0C until use.Virus screening and isolation ::: Materials and methodsThe extracted DNA and RNA samples were tested for Cachavirus (Fahsbender et al., 2019), canine coronavirus (CCV) (Nguyen et al., 2017), canine distemper virus (CDV) (Wang et al., 2017), and canine parvovirus (CPV) (Han et al., 2015) using RT-PCR as previously described.Virus screening and isolation ::: Materials and methodsSupernatants from the diluted Cachavirus -positive samples were filtered through a 0.22-\u03bcm membrane and inoculated onto a monolayer of Crandell\u2013Rees feline kidney (CRFK, originating from cats) cells and Madin\u2013Darby canine kidney (originating from dogs) cells.", [["sample", "ANATOMY", 26, 32], ["samples", "ANATOMY", 146, 153], ["Supernatants", "ANATOMY", 445, 457], ["samples", "ANATOMY", 496, 503], ["membrane", "ANATOMY", 536, 544], ["monolayer", "ANATOMY", 567, 576], ["kidney", "ANATOMY", 601, 607], ["CRFK", "ANATOMY", 609, 613], ["cells", "ANATOMY", 638, 643], ["kidney", "ANATOMY", 667, 673], ["cells", "ANATOMY", 698, 703], ["canine coronavirus", "DISEASE", 208, 226], ["canine distemper virus", "DISEASE", 256, 278], ["canine parvovirus", "DISEASE", 310, 327], ["DNA", "CELLULAR_COMPONENT", 14, 17], ["Virus", "ORGANISM", 65, 70], ["DNA", "CELLULAR_COMPONENT", 134, 137], ["canine coronavirus", "ORGANISM", 208, 226], ["CCV", "ORGANISM", 228, 231], ["canine distemper virus", "ORGANISM", 256, 278], ["CDV", "ORGANISM", 280, 283], ["canine parvovirus", "ORGANISM", 310, 327], ["CPV", "ORGANISM", 329, 332], ["Virus", "ORGANISM", 390, 395], ["Cachavirus", "GENE_OR_GENE_PRODUCT", 475, 485], ["monolayer", "CELL", 567, 576], ["feline", "ORGANISM", 594, 600], ["kidney", "ORGAN", 601, 607], ["CRFK", "CELL", 609, 613], ["cats", "ORGANISM", 632, 636], ["cells", "CELL", 638, 643], ["canine kidney", "TISSUE", 660, 673], ["dogs", "ORGANISM", 692, 696], ["cells", "CELL", 698, 703], ["canine coronavirus", "SPECIES", 208, 226], ["canine distemper virus", "SPECIES", 256, 278], ["canine parvovirus", "SPECIES", 310, 327], ["feline", "SPECIES", 594, 600], ["cats", "SPECIES", 632, 636], ["dogs", "SPECIES", 692, 696], ["canine coronavirus", "SPECIES", 208, 226], ["CCV", "SPECIES", 228, 231], ["canine distemper virus", "SPECIES", 256, 278], ["CDV", "SPECIES", 280, 283], ["canine parvovirus", "SPECIES", 310, 327], ["CPV", "SPECIES", 329, 332], ["canine", "SPECIES", 660, 666], ["The extracted DNA", "PROBLEM", 0, 17], ["RNA sample", "TEST", 22, 32], ["Virus screening", "TEST", 65, 80], ["The extracted DNA", "TEST", 120, 137], ["RNA samples", "TEST", 142, 153], ["Cachavirus", "TEST", 170, 180], ["canine coronavirus", "PROBLEM", 208, 226], ["canine distemper virus", "PROBLEM", 256, 278], ["canine parvovirus", "PROBLEM", 310, 327], ["RT-PCR", "TEST", 359, 365], ["Virus screening", "TEST", 390, 405], ["methodsSupernatants", "TEST", 438, 457], ["the diluted Cachavirus", "TEST", 463, 485], ["positive samples", "PROBLEM", 487, 503], ["a 0.22-\u03bcm membrane", "TREATMENT", 526, 544], ["CRFK", "TEST", 609, 613], ["Madin", "TREATMENT", 648, 653], ["Darby canine kidney", "TREATMENT", 654, 673], ["DNA", "OBSERVATION_MODIFIER", 14, 17], ["kidney", "ANATOMY", 601, 607], ["kidney", "ANATOMY", 667, 673]]], ["After 1-h incubation, the inocula were removed, placed in Dulbecco's modified Eagle's medium (Gibco, USA) supplemented with 2% fetal bovine serum, and incubated at 37 \u00b0C with 5% CO2.", [["fetal bovine serum", "ANATOMY", 127, 145], ["CO2", "CHEMICAL", 178, 181], ["CO2", "CHEMICAL", 178, 181], ["bovine", "ORGANISM", 133, 139], ["serum", "ORGANISM_SUBSTANCE", 140, 145], ["CO2", "SIMPLE_CHEMICAL", 178, 181], ["bovine", "SPECIES", 133, 139], ["bovine", "SPECIES", 133, 139], ["the inocula", "TREATMENT", 22, 33], ["2% fetal bovine serum", "TREATMENT", 124, 145], ["5% CO2", "TREATMENT", 175, 181]]], ["Cultures were directly inspected daily by microscopy for cytopathic effect (CPE) until 4 days after inoculation.", [["Cultures", "TEST", 0, 8], ["cytopathic effect (CPE", "PROBLEM", 57, 79], ["inoculation", "PROBLEM", 100, 111]]], ["The harvested supernatant was subjected to 3 freezing and thawing cycles, followed by inoculation on a new monolayer of each cell line until the fifth generation.", [["supernatant", "ANATOMY", 14, 25], ["monolayer", "ANATOMY", 107, 116], ["cell line", "ANATOMY", 125, 134], ["monolayer", "CELL", 107, 116], ["cell line", "CELL", 125, 134], ["cell line", "CELL_LINE", 125, 134], ["The harvested supernatant", "TREATMENT", 0, 25], ["a new monolayer of each cell line", "TREATMENT", 101, 134], ["harvested", "OBSERVATION", 4, 13], ["cell line", "OBSERVATION", 125, 134]]], ["Culture lysates and supernatant were also collected for pathogen screening as described above.Amplification, cloning, and sequencing of partial Cachavirus genomes ::: Materials and methodsFour specific primer pairs for genomic amplification covering fragments of ORFs encoding NS1 and VP1 were designed based on Cachavirus sequences [Cachavirus-1A (accession no.: MH893826) and Cachavirus-1B (accession no.: MK448316)] deposited in GenBank.", [["Culture lysates", "ANATOMY", 0, 15], ["supernatant", "ANATOMY", 20, 31], ["lysates", "ORGANISM_SUBSTANCE", 8, 15], ["NS1", "GENE_OR_GENE_PRODUCT", 277, 280], ["VP1", "GENE_OR_GENE_PRODUCT", 285, 288], ["Cachavirus-1A", "ORGANISM", 334, 347], ["Cachavirus-1B", "GENE_OR_GENE_PRODUCT", 378, 391], ["Cachavirus genomes", "DNA", 144, 162], ["primer pairs", "DNA", 202, 214], ["ORFs", "DNA", 263, 267], ["NS1", "PROTEIN", 277, 280], ["VP1", "PROTEIN", 285, 288], ["Cachavirus sequences", "DNA", 312, 332], ["Cachavirus-1A", "SPECIES", 334, 347], ["Cachavirus-1B (accession no.: MK448316)", "SPECIES", 378, 417], ["Culture lysates", "TEST", 0, 15], ["supernatant", "TEST", 20, 31], ["pathogen screening", "TEST", 56, 74], ["Materials", "TREATMENT", 167, 176], ["methods", "TREATMENT", 181, 188], ["genomic amplification covering fragments of ORFs", "PROBLEM", 219, 267], ["NS1 and VP1", "TEST", 277, 288], ["Cachavirus sequences", "TEST", 312, 332], ["Cachavirus", "TEST", 334, 344], ["Cachavirus", "TEST", 378, 388]]], ["Primer sequences are listed in Table S1.", [["Primer sequences", "DNA", 0, 16], ["Primer sequences", "TEST", 0, 16]]], ["Gene amplification was performed via PCR using a 20-\u03bcL reaction mixture containing DNA template (>100 ng/\u03bcL), 6-pmol upstream/downstream primers, PrimeSTAR HS DNA polymerase, and supporting reaction buffer (TaKaRa Biotechnology Co., Ltd., Dalian, China).", [["DNA", "CELLULAR_COMPONENT", 83, 86], ["DNA", "CELLULAR_COMPONENT", 159, 162], ["DNA template", "DNA", 83, 95], ["upstream/downstream primers", "DNA", 117, 144], ["PrimeSTAR HS DNA polymerase", "DNA", 146, 173], ["Gene amplification", "TEST", 0, 18], ["PCR", "TEST", 37, 40], ["a 20-\u03bcL reaction mixture", "TREATMENT", 47, 71], ["DNA template", "TREATMENT", 83, 95], ["downstream primers", "TREATMENT", 126, 144], ["PrimeSTAR HS DNA polymerase", "TREATMENT", 146, 173]]], ["The following cycling conditions were used: initial denaturation at 95 \u00b0C for 3 min; 30 cycles of denaturation at 95 \u00b0C for 30 s, annealing at 55 \u00b0C for 30 s, and extension at 72 \u00b0C for 1 min; and final extension at 72 \u00b0C for 10 min.", [["initial denaturation", "PROBLEM", 44, 64], ["denaturation", "TREATMENT", 98, 110], ["extension", "TEST", 163, 172]]], ["The obtained amplicons were cloned into pMD18-T Easy Vector (TaKaRa Biotechnology Co., Ltd.) for subsequent sequencing (Syn-Biotechnology, Suzhou, China).", [["pMD18", "PROTEIN", 40, 45], ["The obtained amplicons", "TREATMENT", 0, 22]]], ["PCR and partial-genome sequencing were performed at least three times.Identity and phylogenetic analyses ::: Materials and methodsThe ClustalW method was employed using MEGA 7.0 to analyze the identity between the obtained and reference strains.", [["PCR", "TEST", 0, 3], ["partial-genome sequencing", "TEST", 8, 33], ["The ClustalW method", "TREATMENT", 130, 149], ["MEGA", "TREATMENT", 169, 173], ["partial", "OBSERVATION_MODIFIER", 8, 15]]], ["Moreover, phylogenetic trees were constructed based on NS1 and VP1 sequences to analyze the relationships between the tested Chinese strains and reference strains.", [["NS1", "GENE_OR_GENE_PRODUCT", 55, 58], ["NS1 and VP1 sequences", "DNA", 55, 76], ["NS1 and VP1 sequences", "TEST", 55, 76]]], ["Specific information of each viral strain is presented in Fig. 1A and B. Specifically, the maximum likelihood method was used.", [["each viral strain", "PROBLEM", 24, 41]]], ["MEGA 7.0 was used with the settings of pairwise deletion option and 1000 bootstrap replicates.Mutation and protein structure prediction for NS1 and VP1 ::: Materials and methodsIllustrator for Biological Sequences was used to obtain a visual overview of NS1 and VP1 from the five Chinese strains and Cachavirus-1A.", [["NS1", "GENE_OR_GENE_PRODUCT", 140, 143], ["NS1", "GENE_OR_GENE_PRODUCT", 254, 257], ["VP1", "GENE_OR_GENE_PRODUCT", 262, 265], ["Cachavirus-1A", "ORGANISM", 300, 313], ["NS1", "PROTEIN", 140, 143], ["VP1", "PROTEIN", 148, 151], ["NS1", "PROTEIN", 254, 257], ["VP1", "PROTEIN", 262, 265], ["Cachavirus-1A", "SPECIES", 300, 313], ["pairwise deletion option", "TREATMENT", 39, 63], ["Mutation and protein structure prediction", "PROBLEM", 94, 135], ["NS1", "PROBLEM", 140, 143], ["VP1", "TEST", 148, 151], ["Biological Sequences", "TEST", 193, 213], ["NS1", "TREATMENT", 254, 257], ["VP1", "TREATMENT", 262, 265]]], ["Based on the sequence alignment results, mutated amino acid sequences were marked on SWISS-MODEL (https://swissmodel.expasy.org/interactive), and post-modeling Pdb files were constructed using PyMOL for collation and preservation.Statistical analysis ::: Materials and methodsChi square or fisher's exact test was used to compare the frequency of Cachavirus between healthy and diarrheic dogs.", [["amino acid", "CHEMICAL", 49, 59], ["amino acid", "CHEMICAL", 49, 59], ["amino acid", "AMINO_ACID", 49, 59], ["dogs", "ORGANISM", 388, 392], ["SWISS", "DNA", 85, 90], ["post-modeling Pdb files", "DNA", 146, 169], ["dogs", "SPECIES", 388, 392], ["the sequence alignment", "TEST", 9, 31], ["mutated amino acid sequences", "TEST", 41, 69], ["post-modeling Pdb files", "TEST", 146, 169], ["PyMOL", "TREATMENT", 193, 198], ["preservation", "TREATMENT", 217, 229], ["fisher's exact test", "TEST", 290, 309], ["diarrheic dogs", "PROBLEM", 378, 392], ["diarrheic dogs", "OBSERVATION", 378, 392]]], ["Statistical analyses were performed using GraphPad Prism 8.0 (San Diego, CA, USA).", [["Statistical analyses", "TEST", 0, 20], ["GraphPad Prism", "TEST", 42, 56]]], ["A p < 0.05 was considered statistically significant.Positivity and coinfection rates ::: ResultsUpon viral screening, five Cachavirus-positive samples were collected from diarrheic dogs in Henan and Hubei Provinces and no infected samples were identified from healthy dogs.", [["samples", "ANATOMY", 143, 150], ["samples", "ANATOMY", 231, 238], ["coinfection", "DISEASE", 67, 78], ["Cachavirus", "GENE_OR_GENE_PRODUCT", 123, 133], ["dogs", "ORGANISM", 181, 185], ["samples", "CANCER", 231, 238], ["dogs", "ORGANISM", 268, 272], ["dogs", "SPECIES", 181, 185], ["dogs", "SPECIES", 268, 272], ["viral screening", "TEST", 101, 116], ["Cachavirus", "TEST", 123, 133], ["positive samples", "PROBLEM", 134, 150], ["infected samples", "PROBLEM", 222, 238], ["coinfection", "OBSERVATION", 67, 78], ["no", "UNCERTAINTY", 219, 221], ["infected", "OBSERVATION_MODIFIER", 222, 230]]], ["Moreover, CDV and CPV coinfection with the five Chinese strains was identified (Table 1).", [["coinfection", "DISEASE", 22, 33], ["CDV", "ORGANISM", 10, 13], ["CPV", "ORGANISM", 18, 21], ["CDV", "SPECIES", 10, 13], ["CPV", "SPECIES", 18, 21], ["CDV", "PROBLEM", 10, 13], ["CPV coinfection", "PROBLEM", 18, 33], ["the five Chinese strains", "TREATMENT", 39, 63], ["CPV coinfection", "OBSERVATION", 18, 33]]], ["The positivity rate in healthy or diarrheic dogs was 0% and 1.55%, respectively.", [["dogs", "ORGANISM", 44, 48], ["dogs", "SPECIES", 44, 48], ["The positivity rate", "TEST", 0, 19], ["diarrheic dogs", "PROBLEM", 34, 48]]], ["Statistical analysis showed no association between the presence of the virus and clinical signs (p > 0.05).Positivity and coinfection rates ::: ResultsThe positive rates of CPV, CDV, and CCV were 60.1% (194/323), 32.2% (104/323), and 44.0% (142/323), respectively, and these were only detected in diarrheic dogs.", [["coinfection", "DISEASE", 122, 133], ["CPV", "ORGANISM", 173, 176], ["CDV", "ORGANISM", 178, 181], ["dogs", "ORGANISM", 307, 311], ["dogs", "SPECIES", 307, 311], ["CPV", "SPECIES", 173, 176], ["CDV", "SPECIES", 178, 181], ["CCV", "SPECIES", 187, 190], ["Statistical analysis", "TEST", 0, 20], ["the virus", "PROBLEM", 67, 76], ["clinical signs", "TEST", 81, 95], ["CPV", "TEST", 173, 176], ["CDV", "TEST", 178, 181], ["CCV", "TEST", 187, 190], ["no association", "UNCERTAINTY", 28, 42], ["virus", "OBSERVATION", 71, 76], ["coinfection", "OBSERVATION", 122, 133], ["diarrheic dogs", "OBSERVATION", 297, 311]]], ["In positive samples, coinfections with two (CPV + CDV, n = 35; CPV + CCV, n = 41; or CDV + CCV, n = 29) or three (Cachavirus + CPV + CDV, n = 1; Cachavirus + CPV + CCV, n = 1; CPV + CDV + CCV, n = 14) pathogens were identified, indicating universal coinfection.Virus isolation ::: ResultsUntil the fifth generation, CPE was only observed in the cultured cells inoculated with the 3 Cachavirus-positive samples coinfected with CPV, and Cachavirus DNA was not detected in culture lysates and supernatant by PCR.NS1 and VP1 identity ::: ResultsPartial genomes [covering ORFs encoding NS1 (length = 1992 nt; GC contents = ~37.7%) and VP1 (length = 1515 nt; GC contents = ~36.3%)] of the five Chinese strains were deposited in GenBank under the accession nos.", [["samples", "ANATOMY", 12, 19], ["CCV", "ANATOMY", 91, 94], ["CCV", "ANATOMY", 164, 167], ["cells", "ANATOMY", 354, 359], ["samples", "ANATOMY", 402, 409], ["lysates", "ANATOMY", 478, 485], ["supernatant", "ANATOMY", 490, 501], ["coinfections", "DISEASE", 21, 33], ["coinfection", "DISEASE", 249, 260], ["CPV + CDV", "ORGANISM", 44, 53], ["CPV + CCV", "ORGANISM", 63, 72], ["CDV + CCV", "ORGANISM", 85, 94], ["Cachavirus + CPV + CDV", "ORGANISM", 114, 136], ["Cachavirus + CPV + CCV", "ORGANISM", 145, 167], ["CPV + CDV + CCV", "ORGANISM", 176, 191], ["Virus", "ORGANISM", 261, 266], ["cells", "CELL", 354, 359], ["Cachavirus", "GENE_OR_GENE_PRODUCT", 382, 392], ["CPV", "ORGANISM", 426, 429], ["Cachavirus", "ORGANISM", 435, 445], ["DNA", "CELLULAR_COMPONENT", 446, 449], ["lysates", "ORGANISM_SUBSTANCE", 478, 485], ["NS1", "GENE_OR_GENE_PRODUCT", 509, 512], ["VP1", "GENE_OR_GENE_PRODUCT", 517, 520], ["NS1", "GENE_OR_GENE_PRODUCT", 581, 584], ["cultured cells", "CELL_LINE", 345, 359], ["Cachavirus DNA", "DNA", 435, 449], ["NS1", "PROTEIN", 509, 512], ["VP1", "PROTEIN", 517, 520], ["ResultsPartial genomes", "DNA", 534, 556], ["ORFs", "DNA", 567, 571], ["NS1", "PROTEIN", 581, 584], ["VP1", "PROTEIN", 630, 633], ["CPV", "SPECIES", 44, 47], ["CDV", "SPECIES", 50, 53], ["CPV", "SPECIES", 63, 66], ["CCV", "SPECIES", 69, 72], ["CDV", "SPECIES", 85, 88], ["CCV", "SPECIES", 91, 94], ["CPV", "SPECIES", 127, 130], ["CDV", "SPECIES", 133, 136], ["CPV", "SPECIES", 158, 161], ["CCV", "SPECIES", 164, 167], ["CPV", "SPECIES", 176, 179], ["CDV", "SPECIES", 182, 185], ["CCV", "SPECIES", 188, 191], ["CPV", "SPECIES", 426, 429], ["Cachavirus", "SPECIES", 435, 445], ["coinfections", "PROBLEM", 21, 33], ["CPV", "TEST", 44, 47], ["CDV", "TEST", 50, 53], ["CPV", "TEST", 63, 66], ["CCV", "TEST", 69, 72], ["CDV", "TEST", 85, 88], ["CCV", "TEST", 91, 94], ["Cachavirus", "TEST", 114, 124], ["CPV", "TEST", 127, 130], ["CDV", "TEST", 133, 136], ["Cachavirus", "TEST", 145, 155], ["CPV", "TEST", 158, 161], ["CCV", "TEST", 164, 167], ["CPV", "TEST", 176, 179], ["CDV", "PROBLEM", 182, 185], ["CCV", "PROBLEM", 188, 191], ["pathogens", "PROBLEM", 201, 210], ["universal coinfection", "PROBLEM", 239, 260], ["CPE", "PROBLEM", 316, 319], ["the cultured cells", "TEST", 341, 359], ["the 3 Cachavirus", "TEST", 376, 392], ["CPV", "TEST", 426, 429], ["Cachavirus DNA", "PROBLEM", 435, 449], ["culture lysates", "TEST", 470, 485], ["PCR", "TEST", 505, 508], ["ResultsPartial genomes", "PROBLEM", 534, 556], ["length", "TEST", 586, 592], ["nt", "TEST", 600, 602], ["GC contents", "TEST", 604, 615], ["VP1", "TEST", 630, 633], ["length", "TEST", 635, 641], ["nt", "TEST", 649, 651], ["GC contents", "TEST", 653, 664], ["the five Chinese strains", "PROBLEM", 679, 703], ["universal coinfection", "OBSERVATION", 239, 260], ["VP1 identity", "OBSERVATION", 517, 529]]], ["MT123283\u2013MT123287.", [["MT123283\u2013MT123287", "CHEMICAL", 0, 17], ["MT123283\u2013MT123287", "CHEMICAL", 0, 17]]], ["Nucleotide identity was 98.2%\u201398.9% for NS1 and 98.6%\u201399.1% for VP1, and amino acid identity was 97.9%\u201398.7% for NS1 and 98.8%\u201399.6% for VP1.", [["amino acid", "CHEMICAL", 73, 83], ["amino acid", "CHEMICAL", 73, 83], ["NS1", "GENE_OR_GENE_PRODUCT", 40, 43], ["VP1", "GENE_OR_GENE_PRODUCT", 64, 67], ["amino acid", "AMINO_ACID", 73, 83], ["NS1", "GENE_OR_GENE_PRODUCT", 113, 116], ["VP1", "GENE_OR_GENE_PRODUCT", 137, 140], ["NS1", "PROTEIN", 40, 43], ["VP1", "PROTEIN", 64, 67], ["NS1", "PROTEIN", 113, 116], ["VP1", "PROTEIN", 137, 140], ["Nucleotide identity", "TEST", 0, 19], ["NS1", "TEST", 40, 43], ["VP1", "TEST", 64, 67], ["amino acid identity", "TEST", 73, 92], ["NS1", "TEST", 113, 116], ["VP1", "TEST", 137, 140]]], ["Compared with ChPV strains from other hosts, the five Chinese strains showed the highest NS1 nucleotide (73.4%) and amino acid (66.9%) identity with bat parvovirus and the highest VP1 nucleotide identity (65.3%) with bat parvovirus and VP1 amino acid identity (70.0%) with simian parvo-like virus 3.Phylogenetic analysis of NS1 and VP1 ::: ResultsIn the phylogenetic tree based on NS1 and VP1 sequences (Fig. 1), the reference strains and the five Chinese strains were generally divided into two major branches.", [["nucleotide", "CHEMICAL", 93, 103], ["amino acid", "CHEMICAL", 116, 126], ["nucleotide", "CHEMICAL", 184, 194], ["amino acid", "CHEMICAL", 240, 250], ["nucleotide", "CHEMICAL", 93, 103], ["amino acid", "CHEMICAL", 116, 126], ["nucleotide", "CHEMICAL", 184, 194], ["amino acid", "CHEMICAL", 240, 250], ["ChPV strains", "ORGANISM", 14, 26], ["NS1", "GENE_OR_GENE_PRODUCT", 89, 92], ["amino acid", "AMINO_ACID", 116, 126], ["bat parvovirus", "ORGANISM", 149, 163], ["bat parvovirus", "ORGANISM", 217, 231], ["VP1", "ORGANISM", 236, 239], ["amino acid", "AMINO_ACID", 240, 250], ["simian parvo-like virus 3", "ORGANISM", 273, 298], ["NS1", "ORGANISM", 324, 327], ["VP1", "ORGANISM", 332, 335], ["NS1", "GENE_OR_GENE_PRODUCT", 381, 384], ["NS1", "PROTEIN", 89, 92], ["NS1", "PROTEIN", 324, 327], ["VP1", "PROTEIN", 332, 335], ["NS1 and VP1 sequences", "DNA", 381, 402], ["bat parvovirus", "SPECIES", 149, 163], ["bat parvovirus", "SPECIES", 217, 231], ["simian parvo", "SPECIES", 273, 285], ["ChPV", "SPECIES", 14, 18], ["bat parvovirus", "SPECIES", 149, 163], ["bat parvovirus", "SPECIES", 217, 231], ["simian parvo", "SPECIES", 273, 285], ["ChPV strains", "PROBLEM", 14, 26], ["the five Chinese strains", "TEST", 45, 69], ["the highest NS1 nucleotide", "TEST", 77, 103], ["amino acid", "TEST", 116, 126], ["bat parvovirus", "TEST", 149, 163], ["the highest VP1 nucleotide identity", "TEST", 168, 203], ["bat parvovirus", "TEST", 217, 231], ["VP1 amino acid identity", "TEST", 236, 259], ["simian parvo-like virus", "PROBLEM", 273, 296], ["Phylogenetic analysis", "TEST", 299, 320], ["NS1", "TEST", 324, 327], ["VP1", "TEST", 332, 335], ["NS1 and VP1 sequences", "TEST", 381, 402], ["the reference strains", "PROBLEM", 413, 434], ["the five Chinese strains", "PROBLEM", 439, 463], ["NS1", "OBSERVATION", 324, 327], ["phylogenetic", "ANATOMY_MODIFIER", 354, 366], ["tree", "ANATOMY_MODIFIER", 367, 371], ["branches", "ANATOMY_MODIFIER", 502, 510]]], ["Intuitively, the five Chinese strains were more closely related to Cachavirus-1A and Cachavirus-1B.Mutation and protein structural analyses ::: ResultsCachavirus-1A was used as a reference to display the putative structure of proteins in the five Chinese strains (Fig. 2).", [["Cachavirus-1A", "ORGANISM", 67, 80], ["Cachavirus-1B", "ORGANISM", 85, 98], ["ResultsCachavirus-1A", "GENE_OR_GENE_PRODUCT", 144, 164], ["Cachavirus-1A", "SPECIES", 67, 80], ["Cachavirus-1B", "SPECIES", 85, 98], ["the five Chinese strains", "PROBLEM", 13, 37], ["Cachavirus", "TEST", 67, 77], ["Cachavirus", "TEST", 85, 95], ["Mutation and protein structural analyses", "TEST", 99, 139], ["ResultsCachavirus", "TEST", 144, 161]]], ["The genomic structure of the five strains was consistent with that of Cachavirus-1A, with two major ORFs encoding NS1 and VP1 (Fig. 2); the putative nucleoprotein (NP) was 210-amino acid long.", [["210-amino acid", "CHEMICAL", 172, 186], ["210-amino acid", "CHEMICAL", 172, 186], ["Cachavirus-1A", "GENE_OR_GENE_PRODUCT", 70, 83], ["NS1", "GENE_OR_GENE_PRODUCT", 114, 117], ["VP1", "GENE_OR_GENE_PRODUCT", 122, 125], ["amino acid", "AMINO_ACID", 176, 186], ["ORFs", "DNA", 100, 104], ["NS1", "PROTEIN", 114, 117], ["VP1", "PROTEIN", 122, 125], ["Fig. 2", "PROTEIN", 127, 133], ["putative nucleoprotein", "PROTEIN", 140, 162], ["NP", "PROTEIN", 164, 166], ["Cachavirus-1A", "SPECIES", 70, 83], ["the five strains", "PROBLEM", 25, 41], ["Cachavirus", "TEST", 70, 80], ["VP1 (Fig.", "TEST", 122, 131], ["consistent with", "UNCERTAINTY", 46, 61]]], ["The five strains shared 99.4% NP nucleotide identity and 99.5% amino acid identity with Cachavirus-1A.", [["nucleotide", "CHEMICAL", 33, 43], ["amino acid", "CHEMICAL", 63, 73], ["nucleotide", "CHEMICAL", 33, 43], ["amino acid", "CHEMICAL", 63, 73], ["amino acid", "AMINO_ACID", 63, 73], ["Cachavirus-1A", "GENE_OR_GENE_PRODUCT", 88, 101], ["Cachavirus-1A", "SPECIES", 88, 101], ["The five strains", "TEST", 0, 16], ["NP nucleotide identity", "TEST", 30, 52], ["amino acid identity", "TEST", 63, 82], ["Cachavirus", "TEST", 88, 98]]], ["The ATP-binding Walker loop motif GPSNTGKS was also present in NS1 ORF of the five strains similar to that of Cachavirus-1A.Mutation and protein structural analyses ::: ResultsThe site analysis of VP1 of Cachavirus-1A revealed the following mutated sites in the five Chinese strains: Ala(A)2Pro(P) (40%) and Val(V)265Ile(I) (40%).", [["ATP", "CHEMICAL", 4, 7], ["ATP", "CHEMICAL", 4, 7], ["Ala", "CHEMICAL", 284, 287], ["Val", "CHEMICAL", 308, 311], ["ATP", "SIMPLE_CHEMICAL", 4, 7], ["GPSNTGKS", "GENE_OR_GENE_PRODUCT", 34, 42], ["NS1", "ORGANISM", 63, 66], ["Cachavirus-1A", "GENE_OR_GENE_PRODUCT", 110, 123], ["Cachavirus-1A", "GENE_OR_GENE_PRODUCT", 204, 217], ["Ala(A)2Pro", "GENE_OR_GENE_PRODUCT", 284, 294], ["ATP-binding Walker loop motif", "PROTEIN", 4, 33], ["GPSNTGKS", "PROTEIN", 34, 42], ["NS1 ORF", "DNA", 63, 70], ["VP1", "DNA", 197, 200], ["Cachavirus-1A", "SPECIES", 110, 123], ["Cachavirus-1A", "SPECIES", 204, 217], ["The ATP-binding Walker loop motif GPSNTGKS", "TREATMENT", 0, 42], ["the five strains", "PROBLEM", 74, 90], ["Mutation and protein structural analyses", "TEST", 124, 164], ["The site analysis", "TEST", 176, 193], ["VP1 of Cachavirus", "TEST", 197, 214], ["Val(V", "TEST", 308, 313]]], ["Most mutations were found in NS1 of Chinese Cachavirus strains compared with the two strains from the United States, and the mutated sites of the five Chinese strains were displayed in Table 2.", [["NS1", "GENE_OR_GENE_PRODUCT", 29, 32], ["Chinese Cachavirus strains", "ORGANISM", 36, 62], ["NS1", "PROTEIN", 29, 32], ["Chinese Cachavirus", "SPECIES", 36, 54], ["Most mutations", "PROBLEM", 0, 14], ["Chinese Cachavirus strains", "PROBLEM", 36, 62]]], ["Due to these mutations, predict changes based on tertiary structure modeling with NS1 structure in Cachavirus-1A as a reference were shown in Fig. 3.DiscussionViral enteritis is a major threat to pet dogs that can lead to life-threating illness.", [["DiscussionViral enteritis", "DISEASE", 149, 174], ["NS1", "GENE_OR_GENE_PRODUCT", 82, 85], ["Cachavirus-1A", "GENE_OR_GENE_PRODUCT", 99, 112], ["dogs", "ORGANISM", 200, 204], ["NS1", "PROTEIN", 82, 85], ["dogs", "SPECIES", 200, 204], ["Cachavirus-1", "SPECIES", 99, 111], ["these mutations", "PROBLEM", 7, 22], ["predict changes", "PROBLEM", 24, 39], ["DiscussionViral enteritis", "PROBLEM", 149, 174], ["NS1 structure", "OBSERVATION", 82, 95], ["enteritis", "OBSERVATION", 165, 174]]], ["Canine parvovirus (CPV-2), canine distemper virus (CDV), canine coronavirus (CCoV) and canine adenovirus (CAV) are the main pathogens that cause canine viral enteritis (Cardillo et al., 2020; Deng et al., 2018).", [["Canine parvovirus", "DISEASE", 0, 17], ["canine distemper virus", "DISEASE", 27, 49], ["canine coronavirus", "DISEASE", 57, 75], ["viral enteritis", "DISEASE", 152, 167], ["Canine parvovirus", "ORGANISM", 0, 17], ["CPV-2", "ORGANISM", 19, 24], ["canine distemper virus", "ORGANISM", 27, 49], ["CDV", "ORGANISM", 51, 54], ["canine coronavirus", "ORGANISM", 57, 75], ["CCoV", "ORGANISM", 77, 81], ["canine adenovirus", "ORGANISM", 87, 104], ["CAV", "ORGANISM", 106, 109], ["canine", "ORGANISM", 145, 151], ["Canine parvovirus", "SPECIES", 0, 17], ["CPV-2", "SPECIES", 19, 24], ["canine distemper virus", "SPECIES", 27, 49], ["canine coronavirus", "SPECIES", 57, 75], ["canine adenovirus", "SPECIES", 87, 104], ["canine", "SPECIES", 145, 151], ["Canine parvovirus (CPV-2", "SPECIES", 0, 24], ["canine distemper virus", "SPECIES", 27, 49], ["CDV", "SPECIES", 51, 54], ["canine coronavirus", "SPECIES", 57, 75], ["CCoV", "SPECIES", 77, 81], ["canine", "SPECIES", 87, 93], ["CAV", "SPECIES", 106, 109], ["Canine parvovirus (CPV", "TEST", 0, 22], ["canine distemper virus", "PROBLEM", 27, 49], ["CDV", "PROBLEM", 51, 54], ["canine coronavirus (CCoV)", "PROBLEM", 57, 82], ["canine adenovirus (CAV", "PROBLEM", 87, 109], ["the main pathogens", "PROBLEM", 115, 133], ["canine viral enteritis", "PROBLEM", 145, 167], ["parvovirus", "OBSERVATION", 7, 17], ["distemper virus", "OBSERVATION", 34, 49], ["main", "OBSERVATION_MODIFIER", 119, 123], ["viral enteritis", "OBSERVATION", 152, 167]]], ["In this study, Cachavirus, belonging to ChPV, was reported for the first time in diarrheic dogs in China; however, statistical analysis showed no association between the presence of the virus and clinical signs (p > 0.05).", [["Cachavirus", "ORGANISM", 15, 25], ["ChPV", "GENE_OR_GENE_PRODUCT", 40, 44], ["dogs", "ORGANISM", 91, 95], ["ChPV", "DNA", 40, 44], ["dogs", "SPECIES", 91, 95], ["this study", "TEST", 3, 13], ["Cachavirus", "PROBLEM", 15, 25], ["statistical analysis", "TEST", 115, 135], ["the virus", "PROBLEM", 182, 191], ["clinical signs", "TEST", 196, 210], ["virus", "OBSERVATION", 186, 191]]], ["As previously reported, only 3 of the 203 fecal samples from healthy dogs tested positive, and statistically significant differences (p < 0.05) were not detected among 803 diarrhea samples from 2017 (4.0%; p = 0.08), but detected among 965 diarrhea samples from 2018 (4.66%, p = 0.037) with the increment positive rate (Fahsbender et al., 2019).", [["fecal samples", "ANATOMY", 42, 55], ["samples", "ANATOMY", 181, 188], ["diarrhea", "DISEASE", 172, 180], ["diarrhea", "DISEASE", 240, 248], ["fecal samples", "CANCER", 42, 55], ["dogs", "ORGANISM", 69, 73], ["dogs", "SPECIES", 69, 73], ["the 203 fecal samples", "TEST", 34, 55], ["healthy dogs", "TEST", 61, 73], ["diarrhea samples", "TEST", 172, 188], ["p", "TEST", 206, 207], ["diarrhea samples", "TEST", 240, 256], ["p", "TEST", 275, 276], ["the increment positive rate", "PROBLEM", 291, 318], ["significant", "OBSERVATION_MODIFIER", 109, 120]]], ["Meanwhile, virus screening revealed Cachavirus coinfection with CPV, CDV and CCV in dogs, which should be studied further in the context of pathogenesis.DiscussionSome ChPVs and other viruses belonging to Parvoviridae family are mainly detected in diarrhea samples.(P\u00e9nzes et al., 2019; Souza et al., 2017).", [["samples", "ANATOMY", 257, 264], ["diarrhea", "DISEASE", 248, 256], ["Cachavirus coinfection", "ORGANISM", 36, 58], ["CPV", "ORGANISM", 64, 67], ["CDV", "ORGANISM", 69, 72], ["CCV", "ORGANISM", 77, 80], ["dogs", "ORGANISM", 84, 88], ["Parvoviridae", "GENE_OR_GENE_PRODUCT", 205, 217], ["diarrhea samples", "CANCER", 248, 264], ["dogs", "SPECIES", 84, 88], ["CPV", "SPECIES", 64, 67], ["CDV", "SPECIES", 69, 72], ["CCV", "SPECIES", 77, 80], ["virus screening", "TEST", 11, 26], ["Cachavirus coinfection", "PROBLEM", 36, 58], ["CPV", "PROBLEM", 64, 67], ["CDV", "PROBLEM", 69, 72], ["CCV in dogs", "PROBLEM", 77, 88], ["pathogenesis", "PROBLEM", 140, 152], ["Parvoviridae", "TREATMENT", 205, 217], ["diarrhea samples", "PROBLEM", 248, 264], ["coinfection", "OBSERVATION", 47, 58], ["pathogenesis", "OBSERVATION", 140, 152]]], ["Pathogenicity of chicken Parvovirus have recently determined in specific pathogen-free chicks infected experimentally (Nu\u00f1ez et al., 2020).", [["chicken Parvovirus", "ORGANISM", 17, 35], ["chicks", "ORGANISM", 87, 93], ["chicken", "SPECIES", 17, 24], ["chicks", "SPECIES", 87, 93], ["chicken", "SPECIES", 17, 24], ["chicken Parvovirus", "PROBLEM", 17, 35], ["chicken Parvovirus", "OBSERVATION", 17, 35], ["free", "OBSERVATION_MODIFIER", 82, 86], ["chicks", "OBSERVATION_MODIFIER", 87, 93], ["infected", "OBSERVATION_MODIFIER", 94, 102]]], ["However, report about pathogenicity of the ChPVs in vertebrate hosts is still very limited.", [["ChPVs", "GENE_OR_GENE_PRODUCT", 43, 48], ["the ChPVs in vertebrate hosts", "PROBLEM", 39, 68], ["vertebrate hosts", "OBSERVATION", 52, 68]]], ["However, a ChPV called mouse kidney parvovirus (MKPV) circulates among laboratory mice populations has been demonstrated to cause a kidney disease known as inclusion body nephropathy (Roediger et al., 2018).", [["kidney", "ANATOMY", 29, 35], ["kidney", "ANATOMY", 132, 138], ["body", "ANATOMY", 166, 170], ["kidney parvovirus", "DISEASE", 29, 46], ["kidney disease", "DISEASE", 132, 146], ["inclusion body nephropathy", "DISEASE", 156, 182], ["ChPV", "GENE_OR_GENE_PRODUCT", 11, 15], ["mouse kidney parvovirus", "ORGANISM", 23, 46], ["MKPV", "GENE_OR_GENE_PRODUCT", 48, 52], ["mice", "ORGANISM", 82, 86], ["kidney", "ORGAN", 132, 138], ["body", "ORGANISM_SUBDIVISION", 166, 170], ["ChPV", "PROTEIN", 11, 15], ["mouse", "SPECIES", 23, 28], ["kidney parvovirus", "SPECIES", 29, 46], ["mice", "SPECIES", 82, 86], ["mouse kidney parvovirus", "SPECIES", 23, 46], ["MKPV", "SPECIES", 48, 52], ["mice", "SPECIES", 82, 86], ["a ChPV called mouse kidney parvovirus", "PROBLEM", 9, 46], ["a kidney disease", "PROBLEM", 130, 146], ["inclusion body nephropathy", "PROBLEM", 156, 182], ["kidney", "ANATOMY", 29, 35], ["parvovirus", "OBSERVATION", 36, 46], ["kidney", "ANATOMY", 132, 138], ["disease", "OBSERVATION", 139, 146], ["nephropathy", "OBSERVATION", 171, 182]]], ["Meanwhile, murine ChPV, has been detected at a very high prevalence in murine liver tissue, suggesting it is a gastrointestinal agent (Williams et al., 2018).", [["liver tissue", "ANATOMY", 78, 90], ["gastrointestinal", "ANATOMY", 111, 127], ["murine", "ORGANISM", 11, 17], ["ChPV", "GENE_OR_GENE_PRODUCT", 18, 22], ["murine", "ORGANISM", 71, 77], ["liver tissue", "TISSUE", 78, 90], ["gastrointestinal", "ORGAN", 111, 127], ["murine ChPV", "PROTEIN", 11, 22], ["murine", "SPECIES", 11, 17], ["murine", "SPECIES", 71, 77], ["liver tissue", "ANATOMY", 78, 90], ["gastrointestinal", "ANATOMY", 111, 127]]], ["Herein, whether ChPV infection leads to gastroenteritis in dogs needs warrants further investigation.DiscussionPrimers targeting the whole genome have been designed based on the genome sequences of Cachavirus-1A and Cachavirus-1B; however, these primers failed to amplify the 5\u2032 untranslated region (1\u2013493); this may be because of the special DNA structure or the Chinese strains may markedly differs from that of strains reported from the United States.", [["infection", "DISEASE", 21, 30], ["gastroenteritis", "DISEASE", 40, 55], ["ChPV", "GENE_OR_GENE_PRODUCT", 16, 20], ["dogs", "ORGANISM", 59, 63], ["Cachavirus-1A", "ORGANISM", 198, 211], ["Cachavirus-1B", "ORGANISM", 216, 229], ["DNA", "CELLULAR_COMPONENT", 343, 346], ["genome sequences", "DNA", 178, 194], ["Cachavirus-1A and Cachavirus-1B", "DNA", 198, 229], ["5\u2032 untranslated region", "DNA", 276, 298], ["dogs", "SPECIES", 59, 63], ["Cachavirus-1A", "SPECIES", 198, 211], ["Cachavirus-1B", "SPECIES", 216, 229], ["ChPV infection", "PROBLEM", 16, 30], ["gastroenteritis in dogs", "PROBLEM", 40, 63], ["further investigation", "TEST", 79, 100], ["Cachavirus", "TEST", 198, 208], ["Cachavirus", "TEST", 216, 226], ["these primers", "PROBLEM", 240, 253], ["the special DNA structure", "PROBLEM", 331, 356], ["the Chinese strains", "PROBLEM", 360, 379], ["strains", "PROBLEM", 414, 421], ["infection", "OBSERVATION", 21, 30]]], ["Therefore, future research should explore the mechanism of virus propagation using second-generation sequencing to obtain accurate whole genome sequences.", [["whole genome sequences", "DNA", 131, 153], ["virus propagation", "TREATMENT", 59, 76], ["accurate whole genome sequences", "TEST", 122, 153]]], ["Unfortunately, Cachavirus replication was not detected in CRFK and MDCK cell line.", [["CRFK", "ANATOMY", 58, 62], ["MDCK cell line", "ANATOMY", 67, 81], ["CRFK", "CELL", 58, 62], ["MDCK cell line", "CELL", 67, 81], ["CRFK", "CELL_LINE", 58, 62], ["MDCK cell line", "CELL_LINE", 67, 81], ["Cachavirus replication", "PROBLEM", 15, 37], ["MDCK cell line", "TREATMENT", 67, 81], ["MDCK cell line", "OBSERVATION", 67, 81]]], ["The reason for the non-cultivatable nature of the viruses remains unclear.DiscussionAccording to identity and phylogenetic analyses based on NS1 and VP1 of the five Chinese strains, all strains are closely related to the two strains detected in the United States.", [["NS1", "GENE_OR_GENE_PRODUCT", 141, 144], ["VP1", "GENE_OR_GENE_PRODUCT", 149, 152], ["NS1", "PROTEIN", 141, 144], ["VP1", "PROTEIN", 149, 152], ["the viruses", "PROBLEM", 46, 57], ["phylogenetic analyses", "TEST", 110, 131], ["NS1", "TREATMENT", 141, 144], ["VP1", "TEST", 149, 152], ["the five Chinese strains", "PROBLEM", 156, 180], ["all strains", "PROBLEM", 182, 193], ["the two strains", "PROBLEM", 217, 232], ["viruses", "OBSERVATION", 50, 57]]], ["Besides these two Cachavirus strains, the detected Chinese strains shared the highest NS1 and VP1 identity with bat parvovirus from Cameroon and simian parvo-like virus 3 from diarrheic rhesus macaques in the United States (Kapusinszky et al., 2017; Yinda et al., 2018).", [["bat parvovirus", "DISEASE", 112, 126], ["NS1", "GENE_OR_GENE_PRODUCT", 86, 89], ["VP1", "GENE_OR_GENE_PRODUCT", 94, 97], ["bat parvovirus", "ORGANISM", 112, 126], ["simian parvo-like virus 3", "ORGANISM", 145, 170], ["rhesus", "ORGANISM", 186, 192], ["macaques", "ORGANISM", 193, 201], ["NS1", "PROTEIN", 86, 89], ["VP1", "PROTEIN", 94, 97], ["bat parvovirus", "SPECIES", 112, 126], ["simian parvo", "SPECIES", 145, 157], ["rhesus macaques", "SPECIES", 186, 201], ["bat parvovirus", "SPECIES", 112, 126], ["simian parvo-like virus", "SPECIES", 145, 168], ["diarrheic rhesus macaques", "SPECIES", 176, 201], ["these two Cachavirus strains", "PROBLEM", 8, 36], ["Chinese strains", "PROBLEM", 51, 66], ["the highest NS1 and VP1 identity", "PROBLEM", 74, 106], ["bat parvovirus", "PROBLEM", 112, 126], ["simian parvo-like virus", "PROBLEM", 145, 168], ["two", "OBSERVATION_MODIFIER", 14, 17], ["Cachavirus strains", "OBSERVATION", 18, 36]]], ["Frequent recombination between mouse parvoviruses (MPVs), Minute viruses of mice (MVMs) and hamster parvovirus (HaPV) has been predicted (Shackelton et al., 2007).", [["hamster parvovirus", "DISEASE", 92, 110], ["mouse parvoviruses", "ORGANISM", 31, 49], ["MPVs", "CANCER", 51, 55], ["Minute viruses", "ORGANISM", 58, 72], ["mice", "ORGANISM", 76, 80], ["MVMs", "CANCER", 82, 86], ["hamster parvovirus", "ORGANISM", 92, 110], ["HaPV", "CANCER", 112, 116], ["mouse", "SPECIES", 31, 36], ["mice", "SPECIES", 76, 80], ["hamster parvovirus", "SPECIES", 92, 110], ["mouse parvoviruses", "SPECIES", 31, 49], ["mice", "SPECIES", 76, 80], ["hamster parvovirus", "SPECIES", 92, 110], ["HaPV", "SPECIES", 112, 116], ["Frequent recombination between mouse parvoviruses", "PROBLEM", 0, 49], ["hamster parvovirus", "PROBLEM", 92, 110]]], ["Phylogenetic analysis also revealed the closer relationship between the five Chinese Cachavirus strains with bat parvovirus from Cameroon than with other ChPVs; however, no recombination events occurred based on recombination analysis (data not shown).", [["Cachavirus strains", "ORGANISM", 85, 103], ["bat parvovirus", "ORGANISM", 109, 123], ["ChPVs", "PATHOLOGICAL_FORMATION", 154, 159], ["bat parvovirus", "SPECIES", 109, 123], ["Chinese Cachavirus", "SPECIES", 77, 95], ["bat parvovirus", "SPECIES", 109, 123], ["Phylogenetic analysis", "TEST", 0, 21], ["bat parvovirus", "PROBLEM", 109, 123], ["recombination events", "PROBLEM", 173, 193], ["recombination analysis", "TEST", 212, 234]]], ["Hence, the role of bats and primates in the transmission and evolution of ChPVs remains unknown.", [["ChPVs", "DISEASE", 74, 79], ["bats", "ORGANISM", 19, 23], ["ChPVs", "GENE_OR_GENE_PRODUCT", 74, 79], ["ChPVs", "PROBLEM", 74, 79]]], ["The five Chinese strains harbored increased number of mutations compared with the two strains from the United States.", [["increased", "OBSERVATION_MODIFIER", 34, 43], ["number", "OBSERVATION_MODIFIER", 44, 50]]], ["Previous report have highlighted the importance of obtaining the NS1 coding sequence in molecular epidemiology investigations of CPV-2 (Cotmore et al., 2014; Mira et al., 2019).", [["NS1", "GENE_OR_GENE_PRODUCT", 65, 68], ["CPV-2", "ORGANISM", 129, 134], ["NS1 coding sequence", "DNA", 65, 84], ["CPV-2", "SPECIES", 129, 134], ["CPV", "TEST", 129, 132]]], ["NS1 of Cachavirus-1A, Cachavirus-CN20181128, and Cachavirus-CN20190714 shows the SGGY252-255CLTF mutation, whereas NS1 of the three Chinese strains showed the GGY253-255VTF mutation.", [["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["Cachavirus-1A", "ORGANISM", 7, 20], ["Cachavirus-CN20181128", "ORGANISM", 22, 43], ["Cachavirus-CN20190714", "GENE_OR_GENE_PRODUCT", 49, 70], ["SGGY252", "GENE_OR_GENE_PRODUCT", 81, 88], ["255CLTF", "GENE_OR_GENE_PRODUCT", 89, 96], ["GGY253-255VTF", "GENE_OR_GENE_PRODUCT", 159, 172], ["NS1", "PROTEIN", 0, 3], ["NS1", "PROTEIN", 115, 118], ["GGY253", "PROTEIN", 159, 165], ["255VTF", "PROTEIN", 166, 172], ["Cachavirus-1A", "SPECIES", 7, 20], ["Cachavirus-CN20181128", "SPECIES", 22, 43], ["Cachavirus-CN20190714", "SPECIES", 49, 70], ["NS1", "TEST", 0, 3], ["Cachavirus", "TEST", 7, 17], ["Cachavirus", "TEST", 22, 32], ["Cachavirus", "TEST", 49, 59], ["the SGGY252", "TEST", 77, 88], ["NS1", "TEST", 115, 118], ["Chinese strains", "TEST", 132, 147]]], ["However, these continuous mutations did not lead to remarkable changes in protein structure.", [["these continuous mutations", "PROBLEM", 9, 35], ["remarkable changes in protein structure", "PROBLEM", 52, 91], ["protein structure", "OBSERVATION", 74, 91]]], ["In contrast, mutation at the 442 site led to significant structural changes in Cachavirus-CN20190917 and Cachavirus-CN20191013 (Glu442Lys).", [["Cachavirus-CN20191013", "GENE_OR_GENE_PRODUCT", 105, 126], ["442 site", "DNA", 29, 37], ["Cachavirus-CN20190917", "SPECIES", 79, 100], ["Cachavirus-CN20191013", "SPECIES", 105, 126], ["mutation", "PROBLEM", 13, 21], ["significant structural changes in Cachavirus", "PROBLEM", 45, 89], ["Cachavirus", "TEST", 105, 115], ["significant", "OBSERVATION_MODIFIER", 45, 56]]], ["Meanwhile, Cachavirus-CN20181128, Cachavirus-CN20190714, and Cachavirus-CN20191013 showed different structural changes of the 406\u2013416 loci without mutations, whether these changes are caused by the neighboring effect of adjacent mutations should be studied in future.", [["Cachavirus-CN20190714", "CELL", 34, 55], ["Cachavirus-CN20191013", "CELL", 61, 82], ["406\u2013416 loci", "DNA", 126, 138], ["Cachavirus-CN20181128", "SPECIES", 11, 32], ["Cachavirus-CN20190714", "SPECIES", 34, 55], ["Cachavirus-CN20191013", "SPECIES", 61, 82], ["Cachavirus", "TEST", 11, 21], ["Cachavirus", "TEST", 34, 44], ["Cachavirus", "TEST", 61, 71], ["different structural changes", "PROBLEM", 90, 118], ["mutations", "PROBLEM", 147, 156], ["adjacent mutations", "PROBLEM", 220, 238]]], ["Furthermore, these mutation sites may show different origins due to regional variations.ConclusionTo sum up, this is the first report about the presence of Cachavirus in dogs in China.", [["Cachavirus", "CHEMICAL", 156, 166], ["dogs", "ORGANISM", 170, 174], ["dogs", "SPECIES", 170, 174], ["these mutation sites", "PROBLEM", 13, 33], ["regional variations", "OBSERVATION", 68, 87]]], ["Phylogenetic analysis of NS1 and VP1 of the five Chinese strains revealed a close relationship with the two Cachavirus strains from the United States.", [["NS1", "GENE_OR_GENE_PRODUCT", 25, 28], ["VP1", "GENE_OR_GENE_PRODUCT", 33, 36], ["NS1", "PROTEIN", 25, 28], ["VP1", "PROTEIN", 33, 36], ["Phylogenetic analysis", "TEST", 0, 21], ["NS1", "PROBLEM", 25, 28], ["VP1", "TEST", 33, 36]]], ["These findings provide a reference for studying the transmission and evolution of ChPV.", [["ChPV", "GENE_OR_GENE_PRODUCT", 82, 86], ["ChPV", "PROTEIN", 82, 86], ["ChPV", "TREATMENT", 82, 86]]], ["Nonetheless, large-scale studies are warranted to confirm the pathogenicity of this virus.Ethics statementSampling was not harmful to the dogs.", [["dogs", "ORGANISM", 138, 142], ["dogs", "SPECIES", 138, 142], ["large-scale studies", "TEST", 13, 32], ["this virus", "PROBLEM", 79, 89], ["Sampling", "TEST", 106, 114]]], ["The research protocol was approved by the Animal Welfare and Ethics Committee of Nanyang Normal University (approval number: 18032, year: 2018).", [["The research protocol", "TREATMENT", 0, 21]]], ["An ethical statement was not needed sample collection.Author contributionsConceived and designed the experiments: JJ.", [["JJ", "ANATOMY", 114, 116]]]], "PMC7129199": [["In the past 5 years, The Lancet Global Health has reported seminal Articles about typhoid, typhus, tuberculosis, and antimicrobial resistance.", [["typhoid", "DISEASE", 82, 89], ["typhus", "DISEASE", 91, 97], ["tuberculosis", "DISEASE", 99, 111], ["typhus", "ORGANISM", 91, 97], ["seminal Articles", "PROBLEM", 59, 75], ["typhoid", "PROBLEM", 82, 89], ["typhus", "PROBLEM", 91, 97], ["tuberculosis", "PROBLEM", 99, 111], ["antimicrobial resistance", "TREATMENT", 117, 141], ["seminal", "ANATOMY", 59, 66], ["typhus", "OBSERVATION", 91, 97], ["tuberculosis", "OBSERVATION", 99, 111], ["antimicrobial resistance", "OBSERVATION", 117, 141]]], ["Typhoid and typhus fevers are the first two chapters in William Osler's The Principles and Practice of Medicine, published in 1892.1 It is disheartening that well over a century later, south Asia continues to have a large burden of these diseases, despite antibiotics.", [["Typhoid and typhus fevers", "DISEASE", 0, 25], ["Typhoid", "PROBLEM", 0, 7], ["typhus fevers", "PROBLEM", 12, 25], ["these diseases", "PROBLEM", 232, 246], ["antibiotics", "TREATMENT", 256, 267], ["typhus", "OBSERVATION", 12, 18], ["large", "OBSERVATION_MODIFIER", 216, 221], ["burden", "OBSERVATION_MODIFIER", 222, 228], ["diseases", "OBSERVATION", 238, 246]]], ["Additionally, antimicrobial resistance\u2014including antibiotic-resistant typhoid fever\u2014is on the increase.", [["typhoid", "DISEASE", 70, 77], ["antimicrobial resistance\u2014including antibiotic", "TREATMENT", 14, 59], ["resistant typhoid fever\u2014is", "PROBLEM", 60, 86], ["resistant", "OBSERVATION_MODIFIER", 60, 69], ["typhoid", "OBSERVATION", 70, 77]]], ["For example, extensive drug-resistant typhoid fever in Pakistan's Sindh province has been documented since November, 2016.2 The H58 strain of Salmonella enterica serotype Typhi, which is ubiquitous in south Asia, became extensively drug resistant by acquiring a so-called highly promiscuous DNA molecule (ie, a plasmid) from another common bacterium such as Escherichia coli.", [["typhoid fever", "DISEASE", 38, 51], ["H58 strain", "ORGANISM", 128, 138], ["Salmonella enterica", "ORGANISM", 142, 161], ["serotype Typhi", "ORGANISM", 162, 176], ["DNA", "CELLULAR_COMPONENT", 291, 294], ["Escherichia coli", "ORGANISM", 358, 374], ["promiscuous DNA molecule", "PROTEIN", 279, 303], ["Salmonella enterica serotype Typhi", "SPECIES", 142, 176], ["Escherichia coli", "SPECIES", 358, 374], ["Salmonella enterica serotype Typhi", "SPECIES", 142, 176], ["Escherichia coli", "SPECIES", 358, 374], ["extensive drug-resistant typhoid fever", "PROBLEM", 13, 51], ["Salmonella enterica serotype Typhi", "PROBLEM", 142, 176], ["a so-called highly promiscuous DNA molecule", "PROBLEM", 260, 303], ["another common bacterium", "PROBLEM", 325, 349], ["Escherichia coli", "PROBLEM", 358, 374], ["extensive", "OBSERVATION_MODIFIER", 13, 22], ["resistant", "OBSERVATION_MODIFIER", 28, 37], ["typhoid", "OBSERVATION_MODIFIER", 38, 45], ["Salmonella enterica", "OBSERVATION", 142, 161], ["serotype Typhi", "OBSERVATION", 162, 176], ["Escherichia coli", "OBSERVATION", 358, 374]]], ["It will be no surprise if the extensively drug-resistant typhoid organism (which currently responds to only azithromycin and not ceftriaxone among the commonly used, effective typhoid drugs) spreads to other parts of Pakistan, or indeed the rest of the subcontinent, making treatment of this common disease daunting.", [["typhoid", "DISEASE", 57, 64], ["azithromycin", "CHEMICAL", 108, 120], ["ceftriaxone", "CHEMICAL", 129, 140], ["typhoid", "DISEASE", 176, 183], ["azithromycin", "CHEMICAL", 108, 120], ["ceftriaxone", "CHEMICAL", 129, 140], ["azithromycin", "SIMPLE_CHEMICAL", 108, 120], ["ceftriaxone", "SIMPLE_CHEMICAL", 129, 140], ["the extensively drug-resistant typhoid organism", "PROBLEM", 26, 73], ["azithromycin", "TREATMENT", 108, 120], ["ceftriaxone", "TREATMENT", 129, 140], ["effective typhoid drugs", "TREATMENT", 166, 189], ["this common disease daunting", "PROBLEM", 287, 315], ["resistant", "OBSERVATION_MODIFIER", 47, 56], ["typhoid", "OBSERVATION", 57, 64]]]], "5d1dda983b4e851da348765ac777b82cd66569ae": [["IntroductionVaccines are one of the most powerful and cost-effective health interventions to have been invented.", [["IntroductionVaccines", "TREATMENT", 0, 20], ["cost-effective health interventions", "TREATMENT", 54, 89]]], ["Vaccines not only provide benefits at the level of the individual, but also to society at large.", [["Vaccines", "TREATMENT", 0, 8], ["large", "OBSERVATION_MODIFIER", 90, 95]]], ["These are powerful as they not only prevent the primary disease, but also its complications or sequelae.", [["the primary disease", "PROBLEM", 44, 63], ["its complications", "PROBLEM", 74, 91], ["sequelae", "PROBLEM", 95, 103], ["primary", "OBSERVATION_MODIFIER", 48, 55], ["disease", "OBSERVATION", 56, 63]]], ["Of the many medically important viral diseases prevalent in India, vaccines for only two, namely polio and measles, find a place in the Universal Immunization Programme (UIP) implemented by the Government of India.", [["viral diseases", "DISEASE", 32, 46], ["measles", "DISEASE", 107, 114], ["viral diseases", "PROBLEM", 32, 46], ["vaccines", "TREATMENT", 67, 75], ["viral diseases", "OBSERVATION", 32, 46]]], ["The other diseases that find a place in the UIP are of bacterial origin, namely, diphtheria, pertussis, tetanus, and childhood tuberculosis.", [["UIP", "DISEASE", 44, 47], ["diphtheria, pertussis, tetanus", "DISEASE", 81, 111], ["tuberculosis", "DISEASE", 127, 139], ["UIP", "CANCER", 44, 47], ["The other diseases", "PROBLEM", 0, 18], ["bacterial origin", "PROBLEM", 55, 71], ["diphtheria", "PROBLEM", 81, 91], ["pertussis", "PROBLEM", 93, 102], ["tetanus", "PROBLEM", 104, 111], ["childhood tuberculosis", "PROBLEM", 117, 139], ["diseases", "OBSERVATION", 10, 18], ["UIP", "ANATOMY", 44, 47], ["bacterial origin", "OBSERVATION", 55, 71], ["childhood", "OBSERVATION_MODIFIER", 117, 126], ["tuberculosis", "OBSERVATION", 127, 139]]], ["All these UIP vaccines are available free of cost.", [["All these UIP vaccines", "TREATMENT", 0, 22], ["UIP", "OBSERVATION", 10, 13]]], ["The UIP is one of the largest programs of its kind in the world, in terms of the number of vaccine doses used and the number of people reached.IntroductionUndoubtedly, there are multiple issues that hinder the introduction of vaccines in the national programme, in spite of the availability of these vaccines.", [["UIP", "DISEASE", 4, 7], ["people", "ORGANISM", 128, 134], ["people", "SPECIES", 128, 134], ["vaccine doses", "TREATMENT", 91, 104], ["multiple issues", "PROBLEM", 178, 193], ["vaccines", "TREATMENT", 226, 234], ["these vaccines", "TREATMENT", 294, 308], ["UIP", "OBSERVATION", 4, 7], ["multiple", "OBSERVATION_MODIFIER", 178, 186]]], ["One of the major hindrances is cost, while others include programmatic and logistic issues, as well as the absence of disease-burden data in certain cases.", [["programmatic and logistic issues", "PROBLEM", 58, 90], ["disease", "PROBLEM", 118, 125], ["major", "OBSERVATION_MODIFIER", 11, 16], ["hindrances", "OBSERVATION", 17, 27], ["cost", "OBSERVATION", 31, 35]]], ["While for many viral diseases total eradication is impossible due to their zoonotic nature, but for diseases like polio and measles the story is different.", [["viral diseases", "DISEASE", 15, 29], ["polio", "DISEASE", 114, 119], ["measles", "DISEASE", 124, 131], ["many viral diseases", "PROBLEM", 10, 29], ["total eradication", "TREATMENT", 30, 47], ["diseases", "PROBLEM", 100, 108], ["polio", "PROBLEM", 114, 119]]], ["These two childhood viral diseases can be totally eradicated since human beings are the only host.", [["viral diseases", "DISEASE", 20, 34], ["human", "ORGANISM", 67, 72], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["These two childhood viral diseases", "PROBLEM", 0, 34], ["viral diseases", "OBSERVATION", 20, 34]]], ["What is required is a concerted and sustained global effort, with active public participation and co-operation, as was the case when smallpox was eradicated from the planet Earth.", [["smallpox", "DISEASE", 133, 141], ["smallpox", "TREATMENT", 133, 141]]], ["India is a major supplier of vaccines to the United Nations Children's Fund (UNICEF), which meets 40% of the global vaccine demand for routine childhood immunization programs in approximately 100 developing countries [3] .IntroductionDevelopment of biologicals such as vaccines goes handin-hand with other endeavors such as development of drugs and diagnostics.", [["Children", "SPECIES", 60, 68], ["the global vaccine demand", "TREATMENT", 105, 130], ["routine childhood immunization programs", "TREATMENT", 135, 174], ["biologicals", "TREATMENT", 249, 260], ["vaccines", "TREATMENT", 269, 277], ["drugs", "TREATMENT", 339, 344]]], ["India has been able to contribute to allround development in the health sector since it has an excellent R&D infrastructure, both in the public as well as the private sectors.", [["excellent", "OBSERVATION_MODIFIER", 95, 104], ["R&D", "OBSERVATION_MODIFIER", 105, 108], ["infrastructure", "OBSERVATION", 109, 123]]], ["It has excellent drug testing laboratories, bio-safety labs, clinical trial centers, clinical research organizations (CRO) and other world-class facilities.", [["excellent", "OBSERVATION_MODIFIER", 7, 16]]], ["The major R&D facilities in the public sector include Indian Immunologicals Ltd., Bharat Immunologicals & Biologicals Corp. Ltd., Haffkine Bio-Pharmaceutical Corp. Ltd., and the Central Research Institute (Kasauli).", [["Central", "ANATOMY_MODIFIER", 178, 185]]], ["Their counterparts in the private sector include Serum Institute of India Ltd., Bharat Biotech International Ltd., Shantha Biotech, and Panacea Biotec Ltd.", [["Serum", "ORGANISM_SUBSTANCE", 49, 54], ["Shantha Biotech", "TREATMENT", 115, 130]]], ["A new vaccine production plant has been completed at Dholka (Gujarat) by CPL Biologicals (a joint venture between Cadila Pharmaceuticals Ltd. and Novavax Inc., USA).", [["A new vaccine production plant", "TREATMENT", 0, 30], ["a joint venture", "TREATMENT", 90, 105], ["Cadila Pharmaceuticals", "TREATMENT", 114, 136], ["new", "OBSERVATION_MODIFIER", 2, 5], ["joint", "ANATOMY", 92, 97]]], ["The plant will have the capacity to manufacture 60 million doses of seasonal and pandemic (H1N1) flu vaccines annually [4] .", [["pandemic", "DISEASE", 81, 89], ["the capacity", "PROBLEM", 20, 32], ["seasonal and pandemic (H1N1) flu vaccines", "TREATMENT", 68, 109]]], ["Pune-based Serum Institute of India makes one out of every two vaccines produced in the world.", [["Serum", "ORGANISM_SUBSTANCE", 11, 16]]], ["Interestingly, Serum Institute of India was the first Indian company to be approached by the World Health Organization (WHO) to develop and manufacture the pandemic influenza vaccine.", [["influenza", "DISEASE", 165, 174], ["Serum", "ORGANISM_SUBSTANCE", 15, 20], ["the pandemic influenza vaccine", "TREATMENT", 152, 182]]], ["The institute launched its intranasal H1N1 vaccine (NASOVAC TM ) in July 2010 [5] .", [["The institute launched its intranasal H1N1 vaccine", "TREATMENT", 0, 50]]], ["Panacea Biotec (New Delhi) has been playing a major role in the polio eradication programme by supplying over 6 billion doses of oral polio vaccine (OPV) to the Government of India and UNICEF [6] .", [["oral", "ANATOMY", 129, 133], ["oral", "ORGANISM_SUBDIVISION", 129, 133], ["OPV", "SPECIES", 149, 152], ["the polio eradication programme", "TREATMENT", 60, 91], ["oral polio vaccine", "TREATMENT", 129, 147], ["New", "OBSERVATION_MODIFIER", 16, 19]]], ["From the South, Shantha Biotech's Shanvac-B was the first Indian Hepatitis B vaccine to be pre-qualified by WHO for global distribution through the UN agencies.", [["Hepatitis B", "DISEASE", 65, 76], ["Shanvac-B", "ORGANISM", 34, 43], ["Hepatitis B", "ORGANISM", 65, 76], ["the first Indian Hepatitis B vaccine", "TREATMENT", 48, 84]]], ["With Shantha's Hepatitis B vaccine priced at just one-tenth of the imported vaccine, along with five other Indian companies entering the market, India has the cheapest Hepatitis B vaccine in the world [7] .", [["Hepatitis B", "DISEASE", 15, 26], ["Hepatitis B", "DISEASE", 168, 179], ["Shantha's Hepatitis B", "ORGANISM", 5, 26], ["Hepatitis B", "ORGANISM", 168, 179], ["Shantha's Hepatitis B vaccine", "TREATMENT", 5, 34], ["the cheapest Hepatitis B vaccine", "TREATMENT", 155, 187]]], ["Hence, this is indeed an exciting time for vaccine production in India.IntroductionThe present overview aims to highlight the major viral diseases where vaccines are either available in India or are under clinical or pre-clinical development in the country.", [["viral diseases", "DISEASE", 132, 146], ["vaccine production", "TREATMENT", 43, 61], ["the major viral diseases", "PROBLEM", 122, 146], ["vaccines", "TREATMENT", 153, 161]]], ["It provides a bird's eye view of the epidemiology, clinical features, current diagnostic and treatment modalities, as well as preventive measures, with special stress on vaccination.", [["eye", "ANATOMY", 21, 24], ["eye", "ORGAN", 21, 24], ["treatment modalities", "TREATMENT", 93, 113], ["preventive measures", "TREATMENT", 126, 145], ["vaccination", "TREATMENT", 170, 181]]], ["Table 1 provides some of the key details of the viral vaccines produced in India.Arboviral Diseases Relevant to IndiaArboviral (arthropod-borne viral) diseases constitute a major category of viral diseases that are transmitted by arthropods (e.g. mosquitoes, sandflies, or ticks).", [["Arboviral Diseases", "DISEASE", 81, 99], ["arthropod-borne viral) diseases", "DISEASE", 128, 159], ["viral diseases", "DISEASE", 191, 205], ["the viral vaccines", "TREATMENT", 44, 62], ["Arboviral Diseases", "PROBLEM", 81, 99], ["IndiaArboviral (arthropod", "TREATMENT", 112, 137], ["borne viral) diseases", "PROBLEM", 138, 159], ["viral diseases", "PROBLEM", 191, 205], ["viral diseases", "OBSERVATION", 191, 205]]], ["The importance accorded to this group of viral diseases stems from the fact that India has a significantly high density of mosquito population and a wide distribution of various mosquito species.", [["viral diseases", "DISEASE", 41, 55], ["viral diseases stems", "PROBLEM", 41, 61], ["a significantly high density of mosquito population", "PROBLEM", 91, 142], ["various mosquito species", "PROBLEM", 170, 194], ["viral diseases", "OBSERVATION", 41, 55], ["significantly", "OBSERVATION_MODIFIER", 93, 106], ["high density", "OBSERVATION_MODIFIER", 107, 119], ["mosquito population", "OBSERVATION", 123, 142], ["wide", "OBSERVATION_MODIFIER", 149, 153], ["distribution", "OBSERVATION_MODIFIER", 154, 166], ["various", "OBSERVATION_MODIFIER", 170, 177], ["mosquito species", "OBSERVATION", 178, 194]]], ["Globally, more than 130 arboviruses are known to cause human diseases and some of these have a significant presence in India.", [["arboviruses", "DISEASE", 24, 35], ["arboviruses", "ORGANISM", 24, 35], ["human", "ORGANISM", 55, 60], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["human diseases", "PROBLEM", 55, 69], ["significant", "OBSERVATION_MODIFIER", 95, 106]]], ["Most arboviruses of public health importance belong to one of the three virus genuses: Flavivirus, Alphavirus, and Bunyavirus.", [["Alphavirus", "GENE_OR_GENE_PRODUCT", 99, 109], ["Flavivirus", "PROBLEM", 87, 97], ["Alphavirus", "TREATMENT", 99, 109], ["Bunyavirus", "PROBLEM", 115, 125], ["Flavivirus", "OBSERVATION", 87, 97]]], ["In the Indian context, Japanese encephalitis virus (JEV) and Dengue virus (DENV) are two important Flaviviruses, whereas Chikungunya virus (CHIKV) is an important Alphavirus.", [["Japanese encephalitis", "DISEASE", 23, 44], ["JEV", "DISEASE", 52, 55], ["Dengue virus (DENV)", "DISEASE", 61, 80], ["Chikungunya virus (CHIKV)", "DISEASE", 121, 146], ["Japanese encephalitis virus", "ORGANISM", 23, 50], ["JEV", "ORGANISM", 52, 55], ["Dengue virus", "ORGANISM", 61, 73], ["DENV", "ORGANISM", 75, 79], ["Flaviviruses", "GENE_OR_GENE_PRODUCT", 99, 111], ["Chikungunya virus", "ORGANISM", 121, 138], ["CHIKV", "ORGANISM", 140, 145], ["Japanese encephalitis virus", "SPECIES", 23, 50], ["Dengue virus", "SPECIES", 61, 73], ["Chikungunya virus", "SPECIES", 121, 138], ["Japanese encephalitis virus", "SPECIES", 23, 50], ["JEV", "SPECIES", 52, 55], ["Dengue virus", "SPECIES", 61, 73], ["DENV", "SPECIES", 75, 79], ["Chikungunya virus", "SPECIES", 121, 138], ["CHIKV", "SPECIES", 140, 145], ["Japanese encephalitis virus (JEV)", "PROBLEM", 23, 56], ["Dengue virus (DENV", "PROBLEM", 61, 79], ["Chikungunya virus (CHIKV", "PROBLEM", 121, 145]]], ["Although the epidemiology of each of these diseases is unique, there is a certain degree of similarity that underlies all these diseases, particularly with reference to socioeconomic, ecological and environmental factors that substantially contribute to the emergence, spread and sustenance of these diseases in nature [9] .Arboviral Diseases Relevant to IndiaJapanese Encephalitis Virus (JEV): Leading Cause of ''Brain Fever'' in Children JEV is a Flavivirus that is spread to humans and animals by Culicine mosquitoes.", [["Arboviral Diseases", "DISEASE", 324, 342], ["IndiaJapanese Encephalitis Virus", "DISEASE", 355, 387], ["JEV", "DISEASE", 389, 392], ["Brain Fever", "DISEASE", 414, 425], ["JEV", "DISEASE", 440, 443], ["Flavivirus", "DISEASE", 449, 459], ["IndiaJapanese Encephalitis Virus", "ORGANISM", 355, 387], ["JEV", "ORGANISM", 389, 392], ["JEV", "ORGANISM", 440, 443], ["humans", "ORGANISM", 478, 484], ["Culicine mosquitoes", "ORGANISM", 500, 519], ["IndiaJapanese Encephalitis Virus", "SPECIES", 355, 387], ["Children", "SPECIES", 431, 439], ["humans", "SPECIES", 478, 484], ["IndiaJapanese Encephalitis Virus", "SPECIES", 355, 387], ["JEV", "SPECIES", 389, 392], ["JEV", "SPECIES", 440, 443], ["humans", "SPECIES", 478, 484], ["Culicine mosquitoes", "SPECIES", 500, 519], ["all these diseases", "PROBLEM", 118, 136], ["the emergence", "PROBLEM", 254, 267], ["these diseases", "PROBLEM", 294, 308], ["Arboviral Diseases", "PROBLEM", 324, 342], ["IndiaJapanese Encephalitis Virus", "PROBLEM", 355, 387], ["Brain Fever", "PROBLEM", 414, 425], ["Children JEV", "PROBLEM", 431, 443], ["a Flavivirus", "PROBLEM", 447, 459], ["diseases", "OBSERVATION", 43, 51], ["diseases", "OBSERVATION", 128, 136], ["diseases", "OBSERVATION", 300, 308], ["Brain", "ANATOMY", 414, 419], ["Fever", "OBSERVATION", 420, 425], ["Flavivirus", "OBSERVATION", 449, 459]]], ["The virion particles are spherical (50,000 cases and 65 cases being reported between 1955 and 1966 from the area [12] .", [["virion particles", "OBSERVATION", 4, 20], ["spherical", "OBSERVATION_MODIFIER", 25, 34]]], ["The first major outbreak occurred in 1973 in Burdwan and Bankura districts of West Bengal, with 50-70 nm diameter), that possess a single-stranded, positive-sense RNA genome of approximately 12 kb length.", [["positive-sense RNA genome", "DNA", 148, 173]]], ["The genome is organized into two distinct regions; the 5 0 two-thirds encoding the non-structural proteins (NSP) (NSP1, NSP2, NSP3, NSP4) and the 3 0 one-third encoding the four major structural proteins, including the capsid protein and three envelope proteins (E1, E2, E3) [29] .Chikungunya Virus (CHIKV): An Important Re-Emerging Arbovirus in IndiaChikungunya fever (CHIKF) is clinically characterized by a triad of symptoms, including fever, rash and arthralgia.", [["Chikungunya Virus", "DISEASE", 281, 298], ["IndiaChikungunya fever", "DISEASE", 346, 368], ["CHIKF", "DISEASE", 370, 375], ["fever", "DISEASE", 439, 444], ["rash", "DISEASE", 446, 450], ["arthralgia", "DISEASE", 455, 465], ["NSP", "GENE_OR_GENE_PRODUCT", 108, 111], ["NSP1", "GENE_OR_GENE_PRODUCT", 114, 118], ["NSP2", "GENE_OR_GENE_PRODUCT", 120, 124], ["NSP3", "GENE_OR_GENE_PRODUCT", 126, 130], ["NSP4", "GENE_OR_GENE_PRODUCT", 132, 136], ["E1", "GENE_OR_GENE_PRODUCT", 263, 265], ["E2", "GENE_OR_GENE_PRODUCT", 267, 269], ["E3", "GENE_OR_GENE_PRODUCT", 271, 273], ["Chikungunya Virus", "ORGANISM", 281, 298], ["CHIKV", "ORGANISM", 300, 305], ["IndiaChikungunya fever", "ORGANISM", 346, 368], ["5 0 two-thirds", "DNA", 55, 69], ["non-structural proteins", "PROTEIN", 83, 106], ["NSP", "PROTEIN", 108, 111], ["NSP1", "PROTEIN", 114, 118], ["NSP2", "PROTEIN", 120, 124], ["NSP3", "PROTEIN", 126, 130], ["NSP4", "PROTEIN", 132, 136], ["major structural proteins", "PROTEIN", 178, 203], ["capsid protein", "PROTEIN", 219, 233], ["envelope proteins", "PROTEIN", 244, 261], ["E1", "PROTEIN", 263, 265], ["E2", "PROTEIN", 267, 269], ["E3", "PROTEIN", 271, 273], ["Chikungunya Virus", "SPECIES", 281, 298], ["Chikungunya Virus", "SPECIES", 281, 298], ["CHIKV", "SPECIES", 300, 305], ["NSP1", "TEST", 114, 118], ["NSP2", "TEST", 120, 124], ["NSP3", "TEST", 126, 130], ["NSP4", "TEST", 132, 136], ["the capsid protein", "TEST", 215, 233], ["three envelope proteins", "TEST", 238, 261], ["Chikungunya Virus", "PROBLEM", 281, 298], ["IndiaChikungunya fever", "PROBLEM", 346, 368], ["a triad of symptoms", "PROBLEM", 408, 427], ["fever", "PROBLEM", 439, 444], ["rash", "PROBLEM", 446, 450], ["arthralgia", "PROBLEM", 455, 465], ["genome", "OBSERVATION", 4, 10], ["two", "OBSERVATION_MODIFIER", 29, 32], ["distinct", "OBSERVATION_MODIFIER", 33, 41], ["non-structural proteins", "OBSERVATION", 83, 106], ["structural proteins", "OBSERVATION", 184, 203], ["capsid protein", "OBSERVATION", 219, 233], ["arthralgia", "OBSERVATION", 455, 465]]], ["Clinical diagnosis of CHIKF is complicated by the fact that many clinical features overlap with those of DENF.", [["CHIKF", "DISEASE", 22, 27], ["DENF", "DISEASE", 105, 109], ["DENF", "GENE_OR_GENE_PRODUCT", 105, 109], ["DENF", "PROTEIN", 105, 109], ["CHIKF", "PROBLEM", 22, 27]]], ["Hence, efforts need to be directed towards development of CHIKV-specific diagnostics that can be used in field situations, especially during epidemics.", [["CHIKV", "ORGANISM", 58, 63], ["CHIKV", "SPECIES", 58, 63], ["CHIKV", "PROBLEM", 58, 63], ["CHIKV", "OBSERVATION", 58, 63]]], ["CHIKF has no specific treatment.", [["CHIKF", "CHEMICAL", 0, 5], ["specific treatment", "TREATMENT", 13, 31], ["no", "UNCERTAINTY", 10, 12], ["specific", "OBSERVATION_MODIFIER", 13, 21], ["treatment", "OBSERVATION", 22, 31]]], ["Treatment is purely symptomatic and supportive.Chikungunya Virus (CHIKV): An Important Re-Emerging Arbovirus in IndiaNo commercial CHIK vaccine is currently available anywhere in the world, although efforts are on to develop tissue culture derived or virus-like particle (VLP) based vaccines, following the recent re-emergence of the virus in many parts of Asia, including the explosive outbreak in India in 2006 that amounted to a staggering 40%) of these deaths, estimated at 55 nm diameter) with double stranded DNA as the genetic material.", [["tissue culture", "ANATOMY", 225, 239], ["Chikungunya Virus", "DISEASE", 47, 64], ["CHIK", "CHEMICAL", 131, 135], ["deaths", "DISEASE", 457, 463], ["Chikungunya Virus", "ORGANISM", 47, 64], ["CHIKV", "ORGANISM", 66, 71], ["tissue", "TISSUE", 225, 231], ["virus-like particle", "ORGANISM", 251, 270], ["VLP", "ORGANISM", 272, 275], ["DNA", "CELLULAR_COMPONENT", 515, 518], ["double stranded DNA", "DNA", 499, 518], ["Chikungunya Virus", "SPECIES", 47, 64], ["Chikungunya Virus", "SPECIES", 47, 64], ["CHIKV", "SPECIES", 66, 71], ["purely symptomatic", "PROBLEM", 13, 31], ["Chikungunya Virus", "PROBLEM", 47, 64], ["Arbovirus in IndiaNo commercial CHIK vaccine", "TREATMENT", 99, 143], ["tissue culture", "TEST", 225, 239], ["virus-like particle (VLP) based vaccines", "TREATMENT", 251, 291], ["the virus", "PROBLEM", 330, 339], ["these deaths", "PROBLEM", 451, 463], ["double stranded DNA", "PROBLEM", 499, 518], ["symptomatic", "OBSERVATION_MODIFIER", 20, 31], ["explosive", "OBSERVATION_MODIFIER", 377, 386], ["stranded DNA", "OBSERVATION_MODIFIER", 506, 518]]], ["HPV is an epitheliotropic virus of humans that causes proliferative lesions in epidermal or mucosal epithelia.", [["lesions", "ANATOMY", 68, 75], ["epidermal", "ANATOMY", 79, 88], ["mucosal epithelia", "ANATOMY", 92, 109], ["HPV", "ORGANISM", 0, 3], ["humans", "ORGANISM", 35, 41], ["proliferative lesions", "PATHOLOGICAL_FORMATION", 54, 75], ["epidermal", "TISSUE", 79, 88], ["mucosal epithelia", "TISSUE", 92, 109], ["humans", "SPECIES", 35, 41], ["HPV", "SPECIES", 0, 3], ["humans", "SPECIES", 35, 41], ["an epitheliotropic virus of humans", "PROBLEM", 7, 41], ["proliferative lesions in epidermal or mucosal epithelia", "PROBLEM", 54, 109], ["epitheliotropic virus", "OBSERVATION", 10, 31], ["proliferative", "OBSERVATION_MODIFIER", 54, 67], ["lesions", "OBSERVATION", 68, 75], ["epidermal", "ANATOMY_MODIFIER", 79, 88], ["mucosal epithelia", "ANATOMY", 92, 109]]], ["Of the 150 or so types of HPV that have been identified, at least 30 types infect the genital mucosa in humans, and hence, are sexually transmitted.", [["genital mucosa", "ANATOMY", 86, 100], ["HPV", "ORGANISM", 26, 29], ["genital mucosa", "MULTI-TISSUE_STRUCTURE", 86, 100], ["humans", "ORGANISM", 104, 110], ["humans", "SPECIES", 104, 110], ["HPV", "SPECIES", 26, 29], ["humans", "SPECIES", 104, 110], ["HPV", "PROBLEM", 26, 29], ["genital mucosa", "ANATOMY", 86, 100]]], ["These HPV types are categorized as low-and high-risk types.", [["HPV", "ORGANISM", 6, 9]]], ["The former are responsible for genital warts, as well as recurrent respiratory papillomatosis (RRP), while the latter are responsible for cervical cancer.", [["genital warts", "ANATOMY", 31, 44], ["respiratory papillomatosis", "ANATOMY", 67, 93], ["cervical cancer", "ANATOMY", 138, 153], ["genital warts", "DISEASE", 31, 44], ["respiratory papillomatosis", "DISEASE", 67, 93], ["RRP", "DISEASE", 95, 98], ["cervical cancer", "DISEASE", 138, 153], ["genital warts", "PATHOLOGICAL_FORMATION", 31, 44], ["cervical cancer", "CANCER", 138, 153], ["genital warts", "PROBLEM", 31, 44], ["recurrent respiratory papillomatosis", "PROBLEM", 57, 93], ["cervical cancer", "PROBLEM", 138, 153], ["warts", "OBSERVATION", 39, 44], ["respiratory", "ANATOMY", 67, 78], ["papillomatosis", "OBSERVATION", 79, 93], ["responsible for", "UNCERTAINTY", 122, 137], ["cervical", "ANATOMY", 138, 146], ["cancer", "OBSERVATION", 147, 153]]], ["The most common low-risk HPV types that cause up to 90% of all genital warts are HPV-6 and HPV-11 [74] , while the most common high-risk HPV types that account for USD 50-80 per dose, one of the costliest vaccines at the time.", [["genital warts", "ANATOMY", 63, 76], ["genital warts", "DISEASE", 63, 76], ["HPV", "ORGANISM", 25, 28], ["genital warts", "CANCER", 63, 76], ["HPV-6", "ORGANISM", 81, 86], ["HPV-11", "ORGANISM", 91, 97], ["HPV", "ORGANISM", 137, 140], ["HPV-6", "SPECIES", 81, 86], ["HPV-11", "SPECIES", 91, 97], ["all genital warts", "TEST", 59, 76], ["HPV", "TEST", 81, 84], ["HPV", "TEST", 91, 94], ["USD", "TEST", 164, 167], ["the costliest vaccines", "TREATMENT", 191, 213]]], ["However, within a decade, companies from developing countries like India developed and introduced the vaccine at USD 3 per dose, which due to the ensuing competition, came down to less than 30 cents per dose by 2001 [81] .", [["the vaccine", "TREATMENT", 98, 109]]], ["This same approach should be feasible for the HPV vaccine.", [["HPV", "ORGANISM", 46, 49], ["HPV", "SPECIES", 46, 49], ["This same approach", "TREATMENT", 0, 18], ["the HPV vaccine", "TREATMENT", 42, 57]]], ["Four leading Indian companies, namely Shantha Biotech, Serum Institute of India, Bharat Biotech and Indian Immunologicals are currently developing HPV vaccines that could be much cheaper than the current vaccines [82] .", [["HPV", "ORGANISM", 147, 150], ["HPV", "SPECIES", 147, 150], ["HPV vaccines", "TREATMENT", 147, 159], ["the current vaccines", "TREATMENT", 192, 212]]], ["Shantha has even indicated that its vaccine could be initially priced at just USD 15 [83] .", [["Shantha", "CHEMICAL", 0, 7], ["its vaccine", "TREATMENT", 32, 43]]], ["Besides these companies, two others, namely, Virchow Biotech and Gennova Biopharmaceuticals are also developing HPV vaccines with support from the Department of Biotechnology (DBT), Government of India, under the Biotechnology Industry Partnership Programme (BIPP) [84] .", [["HPV", "ORGANISM", 112, 115], ["HPV", "SPECIES", 112, 115], ["Gennova Biopharmaceuticals", "TREATMENT", 65, 91], ["HPV vaccines", "TREATMENT", 112, 124]]], ["All these efforts are still in their infancy and it's going to be some time before an Indian HPV vaccine becomes available.Measles, Mumps, Rubella (MMR): Important but Often Neglected in IndiaMeasles is an acute viral illness in infants and children that is a major public health problem in developing countries like India, and is one of the single-most important causes of childhood mortality.", [["Measles, Mumps, Rubella (MMR)", "DISEASE", 123, 152], ["acute viral illness", "DISEASE", 206, 225], ["HPV", "ORGANISM", 93, 96], ["infants", "ORGANISM", 229, 236], ["children", "ORGANISM", 241, 249], ["infants", "SPECIES", 229, 236], ["children", "SPECIES", 241, 249], ["an Indian HPV vaccine", "TREATMENT", 83, 104], ["Measles", "PROBLEM", 123, 130], ["Mumps", "PROBLEM", 132, 137], ["Rubella", "PROBLEM", 139, 146], ["an acute viral illness", "PROBLEM", 203, 225], ["acute", "OBSERVATION_MODIFIER", 206, 211], ["viral", "OBSERVATION", 212, 217]]], ["The prodromal stage of the disease exhibits non-specific symptoms as for most viral infections, and is characterized by fever, malaise, conjunctivitis and respiratory symptoms such as coryza and coughing.", [["respiratory", "ANATOMY", 155, 166], ["viral infections", "DISEASE", 78, 94], ["fever", "DISEASE", 120, 125], ["conjunctivitis", "DISEASE", 136, 150], ["respiratory symptoms", "DISEASE", 155, 175], ["coryza", "DISEASE", 184, 190], ["coughing", "DISEASE", 195, 203], ["the disease", "PROBLEM", 23, 34], ["non-specific symptoms", "PROBLEM", 44, 65], ["most viral infections", "PROBLEM", 73, 94], ["fever", "PROBLEM", 120, 125], ["malaise", "PROBLEM", 127, 134], ["conjunctivitis", "PROBLEM", 136, 150], ["respiratory symptoms", "PROBLEM", 155, 175], ["coryza", "PROBLEM", 184, 190], ["coughing", "PROBLEM", 195, 203], ["prodromal stage", "OBSERVATION_MODIFIER", 4, 19], ["disease", "OBSERVATION", 27, 34], ["non-specific", "OBSERVATION_MODIFIER", 44, 56], ["infections", "OBSERVATION", 84, 94], ["fever", "OBSERVATION", 120, 125], ["malaise", "OBSERVATION", 127, 134], ["conjunctivitis", "OBSERVATION", 136, 150], ["respiratory", "ANATOMY", 155, 166]]], ["A characteristic clinical feature of measles is the appearance of rash, which is erythematous and maculopapular in nature, and begins in the head, then spreads to the trunk and finally to the limbs over a span of 3-4 days.", [["head", "ANATOMY", 141, 145], ["trunk", "ANATOMY", 167, 172], ["limbs", "ANATOMY", 192, 197], ["measles", "DISEASE", 37, 44], ["rash", "DISEASE", 66, 70], ["measles", "ORGANISM", 37, 44], ["head", "ORGAN", 141, 145], ["trunk", "ORGANISM_SUBDIVISION", 167, 172], ["limbs", "ORGANISM_SUBDIVISION", 192, 197], ["measles", "PROBLEM", 37, 44], ["rash", "PROBLEM", 66, 70], ["erythematous", "PROBLEM", 81, 93], ["maculopapular", "PROBLEM", 98, 111], ["measles", "OBSERVATION", 37, 44], ["rash", "OBSERVATION", 66, 70], ["erythematous", "OBSERVATION_MODIFIER", 81, 93], ["maculopapular", "OBSERVATION_MODIFIER", 98, 111], ["head", "ANATOMY", 141, 145], ["trunk", "ANATOMY", 167, 172], ["limbs", "ANATOMY", 192, 197]]], ["Two to 3 days before the onset of the rash, Koplik's spots, the pathognomonic enanthem of measles, appear in the mucosa of the buccal cavity.", [["mucosa", "ANATOMY", 113, 119], ["buccal cavity", "ANATOMY", 127, 140], ["rash", "DISEASE", 38, 42], ["measles", "DISEASE", 90, 97], ["mucosa", "MULTI-TISSUE_STRUCTURE", 113, 119], ["buccal cavity", "MULTI-TISSUE_STRUCTURE", 127, 140], ["the rash", "PROBLEM", 34, 42], ["Koplik's spots", "PROBLEM", 44, 58], ["measles", "PROBLEM", 90, 97], ["rash", "OBSERVATION", 38, 42], ["pathognomonic", "OBSERVATION_MODIFIER", 64, 77], ["enanthem", "OBSERVATION_MODIFIER", 78, 86], ["measles", "OBSERVATION", 90, 97], ["mucosa", "ANATOMY", 113, 119], ["buccal cavity", "ANATOMY", 127, 140]]], ["This disease is highly contagious and spreads by droplet transmission.", [["This disease", "PROBLEM", 0, 12], ["disease", "OBSERVATION", 5, 12], ["highly", "OBSERVATION_MODIFIER", 16, 22], ["contagious", "OBSERVATION_MODIFIER", 23, 33], ["droplet", "OBSERVATION_MODIFIER", 49, 56]]], ["The most common complications of measles are otitis media, pneumonia, diarrhea and convulsions.", [["measles", "DISEASE", 33, 40], ["otitis media", "DISEASE", 45, 57], ["pneumonia", "DISEASE", 59, 68], ["diarrhea", "DISEASE", 70, 78], ["convulsions", "DISEASE", 83, 94], ["measles", "PROBLEM", 33, 40], ["otitis media", "PROBLEM", 45, 57], ["pneumonia", "PROBLEM", 59, 68], ["diarrhea", "PROBLEM", 70, 78], ["convulsions", "PROBLEM", 83, 94], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["measles", "OBSERVATION", 33, 40], ["otitis", "OBSERVATION", 45, 51], ["pneumonia", "OBSERVATION", 59, 68], ["diarrhea", "OBSERVATION", 70, 78]]], ["More rare complications include encephalitis and sub-acute sclerosing pan-encephalitis (SSPE) [85] .Measles, Mumps, Rubella (MMR): Important but Often Neglected in IndiaThe measles virus (MV) is a member of the Family Paramyxoviridae, with 33.6% of the global figures [86] .", [["encephalitis", "DISEASE", 32, 44], ["acute sclerosing pan-encephalitis", "DISEASE", 53, 86], ["SSPE", "DISEASE", 88, 92], ["Measles, Mumps, Rubella (MMR)", "DISEASE", 100, 129], ["measles virus", "DISEASE", 173, 186], ["IndiaThe measles virus", "ORGANISM", 164, 186], ["IndiaThe measles virus", "SPECIES", 164, 186], ["IndiaThe measles virus", "SPECIES", 164, 186], ["MV", "SPECIES", 188, 190], ["More rare complications", "PROBLEM", 0, 23], ["encephalitis", "PROBLEM", 32, 44], ["sub-acute sclerosing pan-encephalitis", "PROBLEM", 49, 86], ["Measles", "PROBLEM", 100, 107], ["Mumps", "PROBLEM", 109, 114], ["Rubella", "PROBLEM", 116, 123], ["rare", "OBSERVATION_MODIFIER", 5, 9], ["complications", "OBSERVATION", 10, 23], ["encephalitis", "OBSERVATION", 32, 44], ["sub-", "OBSERVATION_MODIFIER", 49, 53], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["sclerosing pan-encephalitis", "OBSERVATION", 59, 86]]], ["India is the only country in the world not to have introduced a second dose of measles vaccine in spite of documented evidence of the efficacy of two doses of the vaccine in reducing measles related mortality [87] .", [["measles", "DISEASE", 183, 190], ["measles", "SPECIES", 183, 190], ["measles vaccine", "TREATMENT", 79, 94], ["the vaccine", "TREATMENT", 159, 170]]], ["Moreover, India has not followed the recommendations made by the WHO Strategic Advisory Group of Experts (SAGE) on immunization in November 2008 for administering two doses of the measles vaccine [88] .", [["immunization", "TREATMENT", 115, 127], ["the measles vaccine", "TREATMENT", 176, 195]]], ["In recent times, death of four infants shortly after administration of measles vaccine, possibly due to human error has led to public distrust in vaccination efforts [89] .", [["death", "DISEASE", 17, 22], ["infants", "ORGANISM", 31, 38], ["human", "ORGANISM", 104, 109], ["infants", "SPECIES", 31, 38], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["measles vaccine", "TREATMENT", 71, 86], ["human error", "PROBLEM", 104, 115]]], ["There is an urgent need to initiate the second-dose measles vaccination in India, as well as catch-up vaccination for those children who are yet to receive the first dose of the measles vaccine.Measles, Mumps, Rubella (MMR): Important but Often Neglected in IndiaThe mumps virus is also a member of the Family Paramyxoviridae.", [["Measles, Mumps, Rubella", "DISEASE", 194, 217], ["children", "ORGANISM", 124, 132], ["mumps virus", "ORGANISM", 267, 278], ["children", "SPECIES", 124, 132], ["mumps virus", "SPECIES", 267, 278], ["the second-dose measles vaccination", "TREATMENT", 36, 71], ["catch-up vaccination", "TREATMENT", 93, 113], ["the measles vaccine", "TREATMENT", 174, 193], ["Measles", "PROBLEM", 194, 201], ["Mumps", "PROBLEM", 203, 208], ["Rubella", "PROBLEM", 210, 217], ["The mumps virus", "PROBLEM", 263, 278]]], ["Mumps is spread by droplet infection and mainly affects school-going children.", [["Mumps", "DISEASE", 0, 5], ["infection", "DISEASE", 27, 36], ["children", "ORGANISM", 69, 77], ["children", "SPECIES", 69, 77], ["Mumps", "PROBLEM", 0, 5], ["droplet infection", "PROBLEM", 19, 36], ["droplet infection", "OBSERVATION", 19, 36]]], ["Mumps, also known as ''Parotitis'', is clinically characterized by swelling and pain in the parotid salivary glands.", [["parotid salivary glands", "ANATOMY", 92, 115], ["Mumps", "DISEASE", 0, 5], ["Parotitis''", "DISEASE", 23, 34], ["swelling", "DISEASE", 67, 75], ["pain", "DISEASE", 80, 84], ["parotid salivary", "ORGAN", 92, 108], ["glands", "ORGAN", 109, 115], ["Mumps", "PROBLEM", 0, 5], ["Parotitis", "PROBLEM", 23, 32], ["swelling", "PROBLEM", 67, 75], ["pain in the parotid salivary glands", "PROBLEM", 80, 115], ["Parotitis", "OBSERVATION", 23, 32], ["swelling", "OBSERVATION", 67, 75], ["pain", "OBSERVATION", 80, 84], ["parotid", "ANATOMY", 92, 99], ["salivary glands", "ANATOMY", 100, 115]]], ["Orchitis occurs in about one in four males who develop mumps after puberty.", [["Orchitis", "DISEASE", 0, 8], ["mumps", "DISEASE", 55, 60], ["Orchitis", "PROBLEM", 0, 8], ["mumps", "PROBLEM", 55, 60], ["mumps", "OBSERVATION", 55, 60]]], ["Oophoritis is the corresponding symptom in adolescent females.", [["Oophoritis", "DISEASE", 0, 10], ["Oophoritis", "PROBLEM", 0, 10]]], ["The incubation period is 1.9 million deaths annually, with 20% of these deaths occurring in India alone [98, 99] .", [["deaths", "DISEASE", 37, 43], ["deaths", "DISEASE", 72, 78], ["1.9 million", "OBSERVATION_MODIFIER", 25, 36]]], ["Influenza is the most frequent cause of ARI requiring medical attention because it affects all age groups and because of its recurrence [100] .", [["Influenza", "DISEASE", 0, 9], ["ARI", "DISEASE", 40, 43], ["Influenza", "PROBLEM", 0, 9], ["ARI", "PROBLEM", 40, 43], ["medical attention", "TREATMENT", 54, 71], ["its recurrence", "PROBLEM", 121, 135], ["most frequent", "OBSERVATION_MODIFIER", 17, 30]]], ["Influenza virus (INFV) belongs to the Family Orthomyxoviridae where enveloped virions have a segmented negativestranded RNA genome.", [["virions", "ANATOMY", 78, 85], ["Influenza virus", "DISEASE", 0, 15], ["Influenza virus", "ORGANISM", 0, 15], ["INFV", "GENE_OR_GENE_PRODUCT", 17, 21], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 45, 61], ["enveloped virions", "ORGANISM", 68, 85], ["negativestranded RNA genome", "DNA", 103, 130], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["INFV", "SPECIES", 17, 21], ["Influenza virus", "PROBLEM", 0, 15], ["a segmented negativestranded RNA genome", "PROBLEM", 91, 130], ["RNA genome", "OBSERVATION", 120, 130]]], ["Influenza viruses are classified into three genera, namely, A, B and C, of which the first two are known to cause human disease.", [["Influenza viruses", "DISEASE", 0, 17], ["Influenza viruses", "ORGANISM", 0, 17], ["B", "GENE_OR_GENE_PRODUCT", 63, 64], ["C", "GENE_OR_GENE_PRODUCT", 69, 70], ["human", "ORGANISM", 114, 119], ["human", "SPECIES", 114, 119], ["Influenza viruses", "SPECIES", 0, 17], ["human", "SPECIES", 114, 119], ["Influenza viruses", "PROBLEM", 0, 17], ["human disease", "PROBLEM", 114, 127]]], ["INFV are typed on the basis of two surface proteins-hemagglutinin (HA) and neuraminidase (NA).", [["surface", "ANATOMY", 35, 42], ["INFV", "CHEMICAL", 0, 4], ["INFV", "GENE_OR_GENE_PRODUCT", 0, 4], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 52, 65], ["HA", "GENE_OR_GENE_PRODUCT", 67, 69], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 75, 88], ["INFV", "PROTEIN", 0, 4], ["surface proteins", "PROTEIN", 35, 51], ["hemagglutinin", "PROTEIN", 52, 65], ["HA", "PROTEIN", 67, 69], ["neuraminidase", "PROTEIN", 75, 88], ["NA", "PROTEIN", 90, 92], ["two surface proteins", "TREATMENT", 31, 51], ["hemagglutinin (HA)", "TREATMENT", 52, 70], ["neuraminidase (NA)", "TREATMENT", 75, 93]]], ["Influenza A and B viruses possess eight different RNA segments that code for 10 and 11 different proteins respectively.", [["Influenza A and B viruses", "ORGANISM", 0, 25], ["Influenza A", "SPECIES", 0, 11], ["B viruses", "SPECIES", 16, 25], ["Influenza A and B viruses", "PROBLEM", 0, 25]]], ["Influenza C viruses lack an NA gene and thus have only seven RNAs, which code for at least nine different polypeptides [101] .Influenza: Need for Surveillance and Pandemic PreparednessIn India, seasonal influenza cases are influenced by climatic fluctuations.", [["Influenza", "DISEASE", 126, 135], ["influenza", "DISEASE", 203, 212], ["Influenza C viruses", "ORGANISM", 0, 19], ["NA gene", "DNA", 28, 35], ["Influenza C viruses", "SPECIES", 0, 19], ["Influenza C viruses", "PROBLEM", 0, 19], ["Influenza", "PROBLEM", 126, 135], ["Surveillance", "TEST", 146, 158], ["seasonal influenza cases", "PROBLEM", 194, 218]]], ["Although there is no defined seasonal pattern, it has been generally observed that in northern India cases occur during winter, while in the south cases occur during the monsoon season.", [["no defined", "UNCERTAINTY", 18, 28], ["seasonal pattern", "OBSERVATION", 29, 45]]], ["Viral ARI in India is caused primarily by influenza A and B viruses, parainfluenza virus and respiratory syncytial virus (RSV) [102, 103] .", [["Viral ARI", "DISEASE", 0, 9], ["influenza A and B viruses", "DISEASE", 42, 67], ["parainfluenza virus", "DISEASE", 69, 88], ["respiratory syncytial virus", "DISEASE", 93, 120], ["influenza A and B viruses", "ORGANISM", 42, 67], ["parainfluenza virus", "ORGANISM", 69, 88], ["respiratory syncytial virus", "ORGANISM", 93, 120], ["RSV", "ORGANISM", 122, 125], ["parainfluenza virus", "SPECIES", 69, 88], ["respiratory syncytial virus", "SPECIES", 93, 120], ["influenza A", "SPECIES", 42, 53], ["B viruses", "SPECIES", 58, 67], ["parainfluenza virus", "SPECIES", 69, 88], ["respiratory syncytial virus", "SPECIES", 93, 120], ["RSV", "SPECIES", 122, 125], ["Viral ARI in India", "PROBLEM", 0, 18], ["influenza A", "PROBLEM", 42, 53], ["B viruses", "PROBLEM", 58, 67], ["parainfluenza virus", "PROBLEM", 69, 88], ["respiratory syncytial virus", "PROBLEM", 93, 120], ["ARI", "OBSERVATION", 6, 9], ["influenza", "OBSERVATION", 42, 51], ["syncytial virus", "OBSERVATION", 105, 120]]], ["The burden of seasonal influenza in India appears to be low [104] , although further cross-sectional studies as well as active surveillance are required.", [["influenza", "DISEASE", 23, 32], ["seasonal influenza", "PROBLEM", 14, 32], ["further cross-sectional studies", "TEST", 77, 108], ["active surveillance", "TEST", 120, 139], ["burden", "OBSERVATION_MODIFIER", 4, 10], ["seasonal", "OBSERVATION_MODIFIER", 14, 22], ["influenza", "OBSERVATION", 23, 32]]], ["However, influenza does account for a large number of absentees at schools, colleges and offices annually.", [["influenza", "DISEASE", 9, 18], ["absentees", "DISEASE", 54, 63], ["influenza", "PROBLEM", 9, 18], ["large", "OBSERVATION_MODIFIER", 38, 43]]], ["We believe that currently there are no sufficient reasons to initiate vaccination against seasonal influenza in India and the seasonal influenza should be prevented by implementation of simple public health interventions such as hand washing with soap and inculcating habits for improving general respiratory hygiene.", [["hand", "ANATOMY", 229, 233], ["respiratory", "ANATOMY", 297, 308], ["influenza", "DISEASE", 99, 108], ["influenza", "DISEASE", 135, 144], ["hand", "ORGANISM_SUBDIVISION", 229, 233], ["vaccination", "TREATMENT", 70, 81], ["seasonal influenza", "PROBLEM", 90, 108], ["the seasonal influenza", "PROBLEM", 122, 144], ["simple public health interventions", "TREATMENT", 186, 220], ["hand washing", "TREATMENT", 229, 241], ["soap", "TREATMENT", 247, 251], ["respiratory hygiene", "OBSERVATION", 297, 316]]], ["However, surveillance systems should be in place so that vaccination options may be kept open for special cases, such as mass human congregations that occur during religious occasions like the Maha-Kumbh Mela, Ganga Sagar Mela and the Muslim pilgrimage of Hajj [105] .Influenza: Need for Surveillance and Pandemic PreparednessIt should be kept in mind that influenza viruses can mutate rapidly (antigenic shift) as opposed to the slower changes (antigenic drift) that occur over a longer period of time.", [["Influenza", "DISEASE", 268, 277], ["influenza viruses", "DISEASE", 357, 374], ["human", "ORGANISM", 126, 131], ["influenza viruses", "ORGANISM", 357, 374], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 126, 131], ["surveillance systems", "TEST", 9, 29], ["vaccination options", "TREATMENT", 57, 76], ["mass human congregations", "PROBLEM", 121, 145], ["Influenza", "PROBLEM", 268, 277], ["Surveillance", "TEST", 288, 300], ["influenza viruses", "PROBLEM", 357, 374], ["the slower changes (antigenic drift", "PROBLEM", 426, 461]]], ["Moreover, the genes of INFV from different species can recombine and undergo reassortment, giving rise to INFV with pandemic potential, such as the influenza A (H1N1) virus that caused the 2009 influenza (swine flu) pandemic [106] .", [["influenza A (H1N1) virus", "DISEASE", 148, 172], ["influenza", "DISEASE", 194, 203], ["swine flu) pandemic", "DISEASE", 205, 224], ["INFV", "GENE_OR_GENE_PRODUCT", 23, 27], ["INFV", "GENE_OR_GENE_PRODUCT", 106, 110], ["influenza A (H1N1) virus", "ORGANISM", 148, 172], ["INFV", "DNA", 23, 27], ["influenza A (H1N1) virus", "SPECIES", 148, 172], ["swine flu", "SPECIES", 205, 214], ["influenza A (H1N1) virus", "SPECIES", 148, 172], ["different species", "PROBLEM", 33, 50], ["the influenza A (H1N1) virus", "PROBLEM", 144, 172], ["influenza", "PROBLEM", 194, 203]]], ["The virus can also ''jump'' the species barrier, as occurred during the avian influenza outbreaks, when a bird-specific influenza A (H5N1) virus infected humans.", [["influenza", "DISEASE", 78, 87], ["influenza A (H5N1) virus infected", "DISEASE", 120, 153], ["bird-specific", "ORGANISM", 106, 119], ["influenza A (H5N1) virus", "ORGANISM", 120, 144], ["humans", "ORGANISM", 154, 160], ["influenza A (H5N1", "SPECIES", 120, 137], ["humans", "SPECIES", 154, 160], ["humans", "SPECIES", 154, 160], ["The virus", "PROBLEM", 0, 9], ["the avian influenza outbreaks", "PROBLEM", 68, 97], ["a bird-specific influenza A (H5N1) virus infected humans", "PROBLEM", 104, 160], ["virus", "OBSERVATION", 4, 9]]], ["This bird flu virus originated in China, but rapidly spread across three continents-Asia, Africa and Europe, causing outbreaks in over 30 countries, including India [107] .", [["bird flu virus", "ORGANISM", 5, 19], ["bird flu virus", "SPECIES", 5, 19], ["bird flu virus", "SPECIES", 5, 19], ["This bird flu virus", "PROBLEM", 0, 19], ["flu virus", "OBSERVATION", 10, 19], ["rapidly", "OBSERVATION_MODIFIER", 45, 52], ["spread", "OBSERVATION_MODIFIER", 53, 59]]], ["Threats like bird flu are very real and can only be checked by implementing a surveillance system that can closely monitor viruses circulating in birds, especially those that have a direct bearing on humans, such as poultry.", [["birds", "ORGANISM", 146, 151], ["humans", "ORGANISM", 200, 206], ["humans", "SPECIES", 200, 206], ["humans", "SPECIES", 200, 206], ["bird flu", "PROBLEM", 13, 21], ["a surveillance system", "TEST", 76, 97], ["bird", "OBSERVATION_MODIFIER", 13, 17], ["flu", "OBSERVATION", 18, 21]]], ["There is really no justification for developing a bird flu vaccine due to its limited human-to-human transmission potential.", [["human", "ORGANISM", 86, 91], ["human", "ORGANISM", 95, 100], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 95, 100], ["a bird flu vaccine", "TREATMENT", 48, 66], ["really no justification for", "UNCERTAINTY", 9, 36]]], ["Moreover, human cases can be treated with antivirals such as Oseltamivir and Amantadine, while outbreaks in poultry can be controlled by effective culling activities.", [["Oseltamivir", "CHEMICAL", 61, 72], ["Amantadine", "CHEMICAL", 77, 87], ["Oseltamivir", "CHEMICAL", 61, 72], ["Amantadine", "CHEMICAL", 77, 87], ["human", "ORGANISM", 10, 15], ["Oseltamivir", "SIMPLE_CHEMICAL", 61, 72], ["Amantadine", "SIMPLE_CHEMICAL", 77, 87], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 10, 15], ["poultry", "SPECIES", 108, 115], ["antivirals", "TREATMENT", 42, 52], ["Oseltamivir", "TREATMENT", 61, 72], ["Amantadine", "TREATMENT", 77, 87]]], ["However, for pandemic influenza A (H1N1) virus, a vaccine is essential.", [["influenza A (H1N1) virus", "DISEASE", 22, 46], ["pandemic influenza A (H1N1) virus", "ORGANISM", 13, 46], ["pandemic influenza A (H1N1) virus", "SPECIES", 13, 46], ["pandemic influenza A (H1N1) virus", "SPECIES", 13, 46], ["pandemic influenza A (H1N1) virus", "PROBLEM", 13, 46], ["a vaccine", "TREATMENT", 48, 57]]], ["Currently, India has its own swine flu vaccine manufactured by the Serum Institute of India (Pune).", [["swine", "ORGANISM", 29, 34], ["swine", "SPECIES", 29, 34], ["swine flu", "SPECIES", 29, 38], ["swine flu vaccine", "TREATMENT", 29, 46]]], ["This is a live-attenuated vaccine (NASO-VAC TM ) that uses the California isolate (A/17/California/ 2009/38) of human H1N1, which is propagated in specific pathogen free (SPF) embryonated hen eggs, followed by lyophilization, and is formulated for intranasal administration.", [["eggs", "ANATOMY", 192, 196], ["human", "ORGANISM", 112, 117], ["H1N1", "ORGANISM", 118, 122], ["hen", "ORGANISM", 188, 191], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 192, 196], ["human", "SPECIES", 112, 117], ["hen", "SPECIES", 188, 191], ["A/17/California/ 2009/38", "SPECIES", 83, 107], ["human H1N1", "SPECIES", 112, 122], ["hen", "SPECIES", 188, 191], ["a live-attenuated vaccine", "TREATMENT", 8, 33], ["NASO-VAC TM", "TREATMENT", 35, 46], ["human H1N1", "TREATMENT", 112, 122], ["lyophilization", "TREATMENT", 210, 224], ["intranasal administration", "TREATMENT", 248, 273]]], ["Serum Institute of India is also developing other immunogens and monoclonal antibodies against pandemic H1N1 with funding from DBT under BIPP [84] .", [["H1N1", "DISEASE", 104, 108], ["DBT", "CHEMICAL", 127, 130], ["BIPP", "CHEMICAL", 137, 141], ["DBT", "CHEMICAL", 127, 130], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["monoclonal antibodies", "PROTEIN", 65, 86], ["other immunogens", "PROBLEM", 44, 60], ["monoclonal antibodies", "PROBLEM", 65, 86], ["pandemic H1N1", "PROBLEM", 95, 108]]], ["Moreover, Panacea Biotec is also developing a H1N1 pandemic influenza vaccine with funding from the same source.", [["influenza", "DISEASE", 60, 69], ["Panacea Biotec", "PROTEIN", 10, 24], ["H1N1 pandemic influenza", "SPECIES", 46, 69], ["a H1N1 pandemic influenza vaccine", "TREATMENT", 44, 77], ["H1N1", "OBSERVATION", 46, 50]]], ["Bharat Biotech also has a pandemic influenza vaccine in its product pipeline [108] .", [["influenza", "DISEASE", 35, 44], ["a pandemic influenza vaccine", "TREATMENT", 24, 52]]], ["We are of the opinion that the pandemic H1N1 influenza (swine flu) vaccine should be reserved for individuals at high-risk of contracting infection, and for the management of outbreak situations.Polio: An Unfinished AgendaPoliomyelitis, commonly referred to as polio, is an age-old viral disease that has affected humanity since time immemorial.", [["influenza", "DISEASE", 45, 54], ["infection", "DISEASE", 138, 147], ["AgendaPoliomyelitis", "DISEASE", 216, 235], ["polio", "DISEASE", 261, 266], ["viral disease", "DISEASE", 282, 295], ["H1N1 influenza", "ORGANISM", 40, 54], ["swine flu", "ORGANISM", 56, 65], ["pandemic H1N1 influenza", "SPECIES", 31, 54], ["swine", "SPECIES", 56, 61], ["swine flu", "SPECIES", 56, 65], ["the pandemic H1N1 influenza (swine flu) vaccine", "TREATMENT", 27, 74], ["individuals", "PROBLEM", 98, 109], ["contracting infection", "PROBLEM", 126, 147], ["outbreak situations", "PROBLEM", 175, 194], ["An Unfinished AgendaPoliomyelitis", "PROBLEM", 202, 235], ["old viral disease", "PROBLEM", 278, 295], ["contracting", "OBSERVATION_MODIFIER", 126, 137], ["infection", "OBSERVATION", 138, 147], ["viral disease", "OBSERVATION", 282, 295]]], ["In fact, Egyptian stone carvings suggest that polio could have existed since pre-biblical times; as far back as 1580 B.C. Polio is an acute illness that follows invasion through the gastro-intestinal (GI) tract by one of the three serotypes of polio virus.", [["stone", "ANATOMY", 18, 23], ["gastro-intestinal (GI) tract", "ANATOMY", 182, 210], ["polio", "DISEASE", 46, 51], ["gastro-intestinal (GI) tract", "DISEASE", 182, 210], ["polio virus", "DISEASE", 244, 255], ["gastro-intestinal", "ORGAN", 182, 199], ["GI) tract", "PATHOLOGICAL_FORMATION", 201, 210], ["polio virus", "ORGANISM", 244, 255], ["polio virus", "SPECIES", 244, 255], ["Egyptian stone carvings", "TEST", 9, 32], ["polio", "PROBLEM", 46, 51], ["an acute illness", "PROBLEM", 131, 147], ["the gastro-intestinal (GI) tract", "TREATMENT", 178, 210], ["polio virus", "PROBLEM", 244, 255], ["stone", "OBSERVATION", 18, 23], ["polio", "OBSERVATION", 46, 51], ["acute", "OBSERVATION_MODIFIER", 134, 139], ["illness", "OBSERVATION", 140, 147], ["gastro", "ANATOMY", 182, 188], ["intestinal", "ANATOMY", 189, 199], ["GI", "ANATOMY", 201, 203], ["polio virus", "OBSERVATION", 244, 255]]], ["Polio viruses are enteroviruses that belong to the Family Picornaviridae, since they are very small (pico) and possess an RNA genome.", [["Polio viruses", "ORGANISM", 0, 13], ["RNA genome", "DNA", 122, 132], ["Polio viruses", "SPECIES", 0, 13], ["Polio viruses", "PROBLEM", 0, 13], ["enteroviruses", "PROBLEM", 18, 31], ["Picornaviridae", "TREATMENT", 58, 72], ["an RNA genome", "PROBLEM", 119, 132], ["viruses", "OBSERVATION", 6, 13], ["RNA genome", "OBSERVATION", 122, 132]]], ["As indicated above, wild polio viruses (WPV) are of three types-WPV1, WPV2 and WPV3 [109] .", [["polio viruses", "DISEASE", 25, 38], ["wild polio viruses", "ORGANISM", 20, 38], ["WPV", "CANCER", 40, 43], ["WPV1", "GENE_OR_GENE_PRODUCT", 64, 68], ["WPV2", "GENE_OR_GENE_PRODUCT", 70, 74], ["wild polio viruses", "SPECIES", 20, 38], ["WPV", "SPECIES", 40, 43], ["wild polio viruses", "PROBLEM", 20, 38], ["WPV3", "TEST", 79, 83], ["polio viruses", "OBSERVATION", 25, 38]]], ["The virus replicates in the gut, and then invades the bloodstream.", [["gut", "ANATOMY", 28, 31], ["bloodstream", "ANATOMY", 54, 65], ["gut", "ORGANISM_SUBDIVISION", 28, 31], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["gut", "ANATOMY", 28, 31], ["bloodstream", "OBSERVATION_MODIFIER", 54, 65]]], ["It has a high degree of tropism for nervous tissue, and once the peripheral nerves become infected, the virus reaches the central nervous system (CNS) by retrograde axonal transport.", [["nervous tissue", "ANATOMY", 36, 50], ["peripheral nerves", "ANATOMY", 65, 82], ["central nervous system", "ANATOMY", 122, 144], ["CNS", "ANATOMY", 146, 149], ["axonal", "ANATOMY", 165, 171], ["nervous tissue", "TISSUE", 36, 50], ["peripheral nerves", "MULTI-TISSUE_STRUCTURE", 65, 82], ["central nervous system", "ANATOMICAL_SYSTEM", 122, 144], ["CNS", "ANATOMICAL_SYSTEM", 146, 149], ["axonal", "MULTI-TISSUE_STRUCTURE", 165, 171], ["nervous tissue", "PROBLEM", 36, 50], ["infected", "PROBLEM", 90, 98], ["the virus", "PROBLEM", 100, 109], ["high degree", "OBSERVATION_MODIFIER", 9, 20], ["tropism", "OBSERVATION", 24, 31], ["nervous tissue", "OBSERVATION", 36, 50], ["peripheral", "ANATOMY_MODIFIER", 65, 75], ["nerves", "ANATOMY", 76, 82], ["infected", "OBSERVATION", 90, 98], ["virus", "OBSERVATION", 104, 109], ["central", "ANATOMY_MODIFIER", 122, 129], ["nervous system", "ANATOMY", 130, 144]]], ["Infection might be clinically asymptomatic, but when symptoms appear, they may range from fever to aseptic meningitis or paralysis.", [["Infection", "DISEASE", 0, 9], ["fever", "DISEASE", 90, 95], ["meningitis", "DISEASE", 107, 117], ["paralysis", "DISEASE", 121, 130], ["Infection", "PROBLEM", 0, 9], ["symptoms", "PROBLEM", 53, 61], ["fever", "PROBLEM", 90, 95], ["aseptic meningitis", "PROBLEM", 99, 117], ["paralysis", "PROBLEM", 121, 130], ["aseptic", "OBSERVATION_MODIFIER", 99, 106], ["meningitis", "OBSERVATION", 107, 117], ["paralysis", "OBSERVATION", 121, 130]]], ["Infection is spread by feco-oral route, as well as from pharyngeal secretions from infected individuals.", [["pharyngeal secretions", "ANATOMY", 56, 77], ["Infection", "DISEASE", 0, 9], ["pharyngeal secretions", "ORGAN", 56, 77], ["Infection", "PROBLEM", 0, 9], ["pharyngeal secretions", "PROBLEM", 56, 77], ["infected individuals", "PROBLEM", 83, 103], ["pharyngeal", "ANATOMY", 56, 66], ["secretions", "OBSERVATION", 67, 77], ["infected", "OBSERVATION", 83, 91]]], ["Over-crowding and poor sanitation facilitate the rapid spread of polio, a major reason for this disease being endemic in developing countries.Polio: An Unfinished AgendaPolio is a VPD, and vaccines against the disease have been developed over half a century ago.", [["polio", "DISEASE", 65, 70], ["polio", "PROBLEM", 65, 70], ["this disease", "PROBLEM", 91, 103], ["vaccines", "TREATMENT", 189, 197], ["the disease", "PROBLEM", 206, 217], ["rapid", "OBSERVATION_MODIFIER", 49, 54], ["spread", "OBSERVATION_MODIFIER", 55, 61], ["disease", "OBSERVATION", 210, 217]]], ["The IPV was developed by Jonas Salk in 1955, while the live-attenuated OPV was developed by Albert Sabin in 1961.", [["OPV", "ORGANISM", 71, 74]]], ["Vaccination efforts have essentially eradicated the disease from the western hemisphere.", [["Vaccination efforts", "TREATMENT", 0, 19], ["the disease", "PROBLEM", 48, 59], ["disease", "OBSERVATION", 52, 59]]], ["The Global Polio Eradication Initiative (GPEI) a public-private partnership (established in 1988) led by *200 national governments and spearheaded by the WHO, CDC, UNICEF and Rotary International is the driving force behind all efforts directed at global polio eradication.", [["Global", "OBSERVATION_MODIFIER", 4, 10], ["Polio Eradication", "OBSERVATION", 11, 28]]], ["Largely due to this huge global effort, polio is on the verge of eradication.", [["polio", "DISEASE", 40, 45], ["this huge global effort", "PROBLEM", 15, 38], ["polio", "PROBLEM", 40, 45], ["eradication", "TREATMENT", 65, 76], ["huge", "OBSERVATION_MODIFIER", 20, 24], ["global", "OBSERVATION_MODIFIER", 25, 31], ["effort", "OBSERVATION", 32, 38]]], ["Currently, four countries (Afghanistan, India, Nigeria, Pakistan) are polio endemic, while four others (all in Africa) are having re-established polio transmission.", [["polio endemic", "PROBLEM", 70, 83]]], ["Due to sustained vaccination efforts, WPV2 has been eradicated from the wild, the last case being detected in India in 1999.", [["WPV2", "CHEMICAL", 38, 42], ["WPV2", "GENE_OR_GENE_PRODUCT", 38, 42], ["WPV2", "DNA", 38, 42], ["WPV2", "SPECIES", 38, 42], ["sustained vaccination efforts", "PROBLEM", 7, 36], ["WPV2", "TREATMENT", 38, 42], ["sustained", "OBSERVATION_MODIFIER", 7, 16], ["vaccination", "OBSERVATION", 17, 28]]], ["In this final stage of the eradication process, the goal is to wipe out the remaining WPV1 and 3.", [["eradication", "OBSERVATION", 27, 38]]], ["Both these types circulate in endemic areas and are highly infectious, and both cause paralysis.", [["paralysis", "DISEASE", 86, 95], ["paralysis", "PROBLEM", 86, 95], ["types", "OBSERVATION_MODIFIER", 11, 16], ["circulate", "OBSERVATION_MODIFIER", 17, 26], ["endemic", "OBSERVATION_MODIFIER", 30, 37], ["highly", "OBSERVATION_MODIFIER", 52, 58], ["infectious", "OBSERVATION", 59, 69], ["paralysis", "OBSERVATION", 86, 95]]], ["While WPV1 is more widespread, WPV3 is more localized in northern India, northern Nigeria, Pakistan and Afghanistan.", [["WPV1", "GENE_OR_GENE_PRODUCT", 6, 10], ["WPV3", "GENE_OR_GENE_PRODUCT", 31, 35], ["WPV1", "PROTEIN", 6, 10], ["more", "OBSERVATION_MODIFIER", 14, 18], ["widespread", "OBSERVATION_MODIFIER", 19, 29]]], ["In order to tackle this problem, a bivalent OPV (bOPV) has been developed.", [["bOPV", "CHEMICAL", 49, 53], ["bOPV", "SIMPLE_CHEMICAL", 49, 53], ["this problem", "PROBLEM", 19, 31], ["a bivalent OPV (bOPV", "TREATMENT", 33, 53]]], ["A randomized, doubleblind, controlled trial indicated the superiority of bOPV compared to trivalent OPV (tOPV), and non-inferiority compared with monovalent OPV1 (mOPV1) and monovalent OPV3 (mOPV3) [111] .", [["bOPV", "CHEMICAL", 73, 77], ["trivalent OPV", "CHEMICAL", 90, 103], ["OPV1", "CHEMICAL", 157, 161], ["OPV3", "CHEMICAL", 185, 189], ["OPV3", "CHEMICAL", 185, 189], ["mOPV3", "CHEMICAL", 191, 196], ["bOPV", "SIMPLE_CHEMICAL", 73, 77], ["OPV1", "SIMPLE_CHEMICAL", 157, 161], ["mOPV1", "SIMPLE_CHEMICAL", 163, 168], ["OPV1", "PROTEIN", 157, 161], ["mOPV1", "PROTEIN", 163, 168], ["mOPV3", "PROTEIN", 191, 196], ["doubleblind", "TREATMENT", 14, 25], ["bOPV", "TREATMENT", 73, 77], ["trivalent OPV", "TREATMENT", 90, 103]]], ["The bOPV was first introduced in Afghanistan in December 2009, when 2.8 million children years old received the vaccine.", [["bOPV", "CHEMICAL", 4, 8], ["children", "ORGANISM", 80, 88], ["children", "SPECIES", 80, 88], ["the vaccine", "TREATMENT", 108, 119]]], ["This vaccine was introduced in India in January 2010, following which polio cases decreased dramatically.", [["This vaccine", "TREATMENT", 0, 12]]], ["As of April 20, 2011, the historically polio-prone State of Uttar Pradesh has not reported a single case of polio for over a year, the last case being reported on April 21, 2010, from Ferozabad.", [["polio", "DISEASE", 108, 113]]], ["Only a single paralytic-polio case has been reported so far this year (WPV1 infection, reported on January 13, 2011) from Howrah district in West Bengal.", [["paralytic-polio", "DISEASE", 14, 29], ["infection", "DISEASE", 76, 85], ["a single paralytic-polio case", "TREATMENT", 5, 34], ["WPV1 infection", "PROBLEM", 71, 85], ["infection", "OBSERVATION", 76, 85]]], ["In fact, India is currently faring better than some other countries, for example, the Democratic Republic of Congo (36 cases; all WPV1), Pakistan (28 cases; all WPV1), and Chad (20 cases; 18 WPV1; 2 WPV3), which have reported comparatively much higher number of polio cases so far this year [112] .Polio: An Unfinished AgendaIndia currently manufactures all types of OPV, and has contributed immensely to the polio eradication programme by supplying vaccines to international organizations like UNICEF.", [["AgendaIndia", "CHEMICAL", 319, 330], ["the polio eradication programme", "TREATMENT", 405, 436]]], ["Panacea Biotec, India's leading manufacturer of polio vaccines manufactures the entire range-mOPV1, mOPV2 (discontinued), mOPV3, tOPV (phased out), and bOPV.", [["mOPV2", "CHEMICAL", 100, 105], ["mOPV2", "SIMPLE_CHEMICAL", 100, 105], ["tOPV", "PROTEIN", 129, 133], ["bOPV", "PROTEIN", 152, 156], ["polio vaccines", "TREATMENT", 48, 62], ["mOPV2", "TREATMENT", 100, 105], ["mOPV3", "TREATMENT", 122, 127], ["tOPV", "TREATMENT", 129, 133]]], ["(HBPCL) manufactures mOPV1, tOPV (phased out), and bOPV.", [["mOPV1", "CHEMICAL", 21, 26], ["mOPV1", "SIMPLE_CHEMICAL", 21, 26], ["tOPV", "SIMPLE_CHEMICAL", 28, 32], ["tOPV", "PROTEIN", 28, 32], ["bOPV", "PROTEIN", 51, 55]]], ["Needless to say, these OPVs are of international quality, and except for Bharat Biotech's tOPV, all are WHO prequalified vaccines [113] .Polio: An Unfinished AgendaIt seems that the stage is all set for polio to be eradicated once and for all from the globe.", [["polio", "PROBLEM", 203, 208], ["globe", "ANATOMY", 252, 257]]], ["However, extensive surveillance is required, for gathering evidence for any WPV that might be circulating in the environment, as well as for vaccine-associated paralytic polio (VAPP) cases, which appears to be an emerging problem-a by-product of the intensive polio vaccination campaigns over the years.HIV/AIDS: An Ideal Vaccine Still a Long Way OffThe Acquired Immune Deficiency Syndrome (AIDS) pandemic, caused by the Human Immunodeficiency Virus (HIV) has ravaged the globe for nearly three decades, and is still showing no signs of abating.", [["paralytic polio", "DISEASE", 160, 175], ["VAPP", "DISEASE", 177, 181], ["HIV/AIDS", "DISEASE", 303, 311], ["Acquired Immune Deficiency Syndrome", "DISEASE", 354, 389], ["AIDS", "DISEASE", 391, 395], ["Human Immunodeficiency Virus (HIV)", "DISEASE", 421, 455], ["WPV", "GENE_OR_GENE_PRODUCT", 76, 79], ["Human Immunodeficiency Virus", "ORGANISM", 421, 449], ["HIV", "SPECIES", 303, 306], ["Human", "SPECIES", 421, 426], ["Immunodeficiency Virus", "SPECIES", 427, 449], ["HIV", "SPECIES", 451, 454], ["HIV", "SPECIES", 303, 306], ["Human Immunodeficiency Virus", "SPECIES", 421, 449], ["HIV", "SPECIES", 451, 454], ["extensive surveillance", "TEST", 9, 31], ["any WPV", "PROBLEM", 72, 79], ["vaccine", "TREATMENT", 141, 148], ["paralytic polio (VAPP) cases", "PROBLEM", 160, 188], ["the intensive polio vaccination campaigns", "TREATMENT", 246, 287], ["An Ideal Vaccine", "TREATMENT", 313, 329], ["The Acquired Immune Deficiency Syndrome", "PROBLEM", 350, 389], ["pandemic", "PROBLEM", 397, 405], ["the Human Immunodeficiency Virus", "PROBLEM", 417, 449], ["signs of abating", "PROBLEM", 528, 544], ["Immune Deficiency", "OBSERVATION", 363, 380], ["globe", "ANATOMY", 472, 477], ["no signs of", "UNCERTAINTY", 525, 536]]], ["Currently, with over 33 million people living with HIV/AIDS worldwide, with over 7,000 becoming infected every day, this is undoubtedly one of the greatest human calamities caused by a virus in modern times.", [["HIV/AIDS", "DISEASE", 51, 59], ["calamities", "DISEASE", 162, 172], ["people", "ORGANISM", 32, 38], ["human", "ORGANISM", 156, 161], ["people", "SPECIES", 32, 38], ["HIV", "SPECIES", 51, 54], ["human", "SPECIES", 156, 161], ["HIV", "SPECIES", 51, 54], ["human", "SPECIES", 156, 161], ["infected", "OBSERVATION", 96, 104], ["virus", "OBSERVATION", 185, 190]]], ["HIV belongs to the Family Retroviridae, where virions possess an enzyme called reverse transcriptase (RT).", [["virions", "ANATOMY", 46, 53], ["HIV", "ORGANISM", 0, 3], ["reverse transcriptase", "PROTEIN", 79, 100], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["an enzyme", "TEST", 62, 71]]], ["The enzyme causes reverse transcription of the viral genetic information contained in the RNA genome into DNA.", [["DNA", "CELLULAR_COMPONENT", 106, 109], ["RNA genome", "DNA", 90, 100], ["The enzyme", "TEST", 0, 10], ["reverse transcription", "OBSERVATION", 18, 39], ["RNA genome", "OBSERVATION", 90, 100]]], ["This is unique in the sense that it goes against the general flow of genetic information (DNA ?", [["DNA", "CELLULAR_COMPONENT", 90, 93]]], ["RNA ?", [["RNA", "RNA", 0, 3]]], ["Protein) as per the Central Dogma.", [["Central Dogma", "OBSERVATION", 20, 33]]], ["There are two types of HIV-HIV-1 and HIV-2, both of which cause human disease.", [["HIV-HIV-1", "ORGANISM", 23, 32], ["HIV-2", "ORGANISM", 37, 42], ["human", "ORGANISM", 64, 69], ["HIV-HIV-1", "SPECIES", 23, 32], ["HIV-2", "SPECIES", 37, 42], ["human", "SPECIES", 64, 69], ["HIV-HIV-1", "SPECIES", 23, 32], ["HIV-2", "SPECIES", 37, 42], ["human", "SPECIES", 64, 69], ["HIV", "PROBLEM", 23, 26], ["HIV", "PROBLEM", 27, 30], ["HIV", "PROBLEM", 37, 40], ["human disease", "PROBLEM", 64, 77], ["two", "OBSERVATION_MODIFIER", 10, 13], ["types", "OBSERVATION_MODIFIER", 14, 19], ["HIV", "OBSERVATION", 23, 26], ["human disease", "OBSERVATION", 64, 77]]], ["HIV-1 is responsible for the global AIDS pandemic.", [["AIDS", "DISEASE", 36, 40], ["HIV-1", "ORGANISM", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "PROBLEM", 0, 3], ["the global AIDS pandemic", "PROBLEM", 25, 49]]], ["HIV-2 also causes AIDS, but the progression is much slower, and is essentially limited to countries in West Africa and to Portugal [114] .HIV/AIDS: An Ideal Vaccine Still a Long Way OffWith the discovery of HIV in the early 1980s, early optimism indicated that a vaccine would soon be developed.", [["AIDS", "DISEASE", 18, 22], ["HIV/AIDS", "DISEASE", 138, 146], ["HIV-2", "ORGANISM", 0, 5], ["HIV", "ORGANISM", 207, 210], ["HIV-2", "SPECIES", 0, 5], ["HIV", "SPECIES", 138, 141], ["HIV", "SPECIES", 207, 210], ["HIV-2", "SPECIES", 0, 5], ["HIV", "SPECIES", 138, 141], ["HIV", "SPECIES", 207, 210], ["HIV", "PROBLEM", 0, 3], ["AIDS", "PROBLEM", 18, 22], ["An Ideal Vaccine", "TREATMENT", 148, 164], ["HIV", "PROBLEM", 207, 210], ["a vaccine", "TREATMENT", 261, 270], ["progression", "OBSERVATION_MODIFIER", 32, 43], ["much slower", "OBSERVATION_MODIFIER", 47, 58]]], ["Some of the major obstacles included the vast genetic variability of HIV, arising from the absence of a proof-reading mechanism in RT that allows mutations to happen rapidly during the replication cycle.", [["HIV", "ORGANISM", 69, 72], ["HIV", "SPECIES", 69, 72], ["HIV", "PROBLEM", 69, 72], ["mutations", "PROBLEM", 146, 155], ["major", "OBSERVATION_MODIFIER", 12, 17], ["obstacles", "OBSERVATION", 18, 27], ["HIV", "OBSERVATION", 69, 72]]], ["Absence of a suitable animal model has also been a major hindrance in vaccine development efforts, with the chimpanzee model being far from ideal.", [["chimpanzee", "ORGANISM", 108, 118], ["the chimpanzee model", "TREATMENT", 104, 124], ["major", "OBSERVATION_MODIFIER", 51, 56], ["hindrance", "OBSERVATION", 57, 66]]], ["Moreover, there are no clear correlates of protection, necessitating Phase III human clinical trials in order to establish the efficacy of a vaccine.HIV/AIDS: An Ideal Vaccine Still a Long Way OffThree separate large-scale Phase III clinical trials (VAX 004, VAX 003, RV 144) have been conducted in a total of over 24,000 human volunteers, yet the vaccine candidates were unable to prevent HIV-1 infection [115] [116] [117] .", [["HIV/AIDS", "DISEASE", 149, 157], ["VAX 004", "CHEMICAL", 250, 257], ["VAX 003", "CHEMICAL", 259, 266], ["HIV-1 infection", "DISEASE", 390, 405], ["human", "ORGANISM", 79, 84], ["human", "ORGANISM", 322, 327], ["volunteers", "ORGANISM", 328, 338], ["HIV-1", "ORGANISM", 390, 395], ["human", "SPECIES", 79, 84], ["HIV", "SPECIES", 149, 152], ["human", "SPECIES", 322, 327], ["HIV-1", "SPECIES", 390, 395], ["human", "SPECIES", 79, 84], ["HIV", "SPECIES", 149, 152], ["human", "SPECIES", 322, 327], ["HIV-1", "SPECIES", 390, 395], ["Phase III human clinical trials", "TREATMENT", 69, 100], ["a vaccine", "TREATMENT", 139, 148], ["An Ideal Vaccine", "TREATMENT", 159, 175], ["RV", "TEST", 268, 270], ["the vaccine", "TREATMENT", 344, 355], ["HIV-1 infection", "PROBLEM", 390, 405], ["no", "UNCERTAINTY", 20, 22], ["clear", "OBSERVATION_MODIFIER", 23, 28]]], ["The International AIDS Vaccine Initiative (IAVI), founded in 1996, is a global not-for-profit, public-private partnership that has been working to accelerate the development of a HIV/AIDS vaccine.", [["AIDS", "DISEASE", 18, 22], ["HIV/AIDS", "DISEASE", 179, 187], ["HIV", "ORGANISM", 179, 182], ["HIV", "SPECIES", 179, 182], ["a HIV/AIDS vaccine", "TREATMENT", 177, 195]]], ["IAVI currently supports five clinical trials of candidate AIDS vaccines and two trials of an intermittent pre-exposure prophylaxis (PrEP) regimen.", [["AIDS", "DISEASE", 58, 62], ["AIDS vaccines", "TREATMENT", 58, 71], ["an intermittent pre-exposure prophylaxis (PrEP) regimen", "TREATMENT", 90, 145]]], ["In collaboration with the Indian Council of Medical Research (ICMR), IAVI is supporting a Phase I clinical trial to evaluate the safety and immunogenicity of a prime-boost regimen of two AIDS vaccine candidates, ADVAX and TBC-M4.", [["AIDS", "DISEASE", 187, 191], ["ADVAX", "CHEMICAL", 212, 217], ["ADVAX", "SIMPLE_CHEMICAL", 212, 217], ["TBC-M4", "CELL", 222, 228], ["a prime-boost regimen", "TREATMENT", 158, 179], ["two AIDS vaccine", "TREATMENT", 183, 199], ["ADVAX", "TREATMENT", 212, 217], ["TBC", "TEST", 222, 225]]], ["Initial analyses of the data gathered in this trial suggest that the vaccine regimen is both safe and immunogenic [118] .HIV/AIDS: An Ideal Vaccine Still a Long Way OffIn spite of sub-optimal results, the clinical trials have generated new knowledge that will be helpful in designing and developing new vaccine candidates.", [["HIV/AIDS", "DISEASE", 121, 129], ["HIV", "SPECIES", 121, 124], ["HIV", "SPECIES", 121, 124], ["the data", "TEST", 20, 28], ["the vaccine regimen", "TREATMENT", 65, 84], ["An Ideal Vaccine", "TREATMENT", 131, 147], ["new vaccine candidates", "TREATMENT", 299, 321]]], ["In fact, recent modeling studies indicate that if a HIV/AIDS vaccine (possessing 70% efficacy) could be developed by 2015, and administered to 40% of the population, it would reduce the annual number of new infections by 81% by 2030 [119] .", [["HIV/AIDS", "DISEASE", 52, 60], ["infections", "DISEASE", 207, 217], ["HIV", "ORGANISM", 52, 55], ["HIV", "SPECIES", 52, 55], ["recent modeling studies", "TEST", 9, 32], ["a HIV/AIDS vaccine", "TREATMENT", 50, 68], ["new infections", "PROBLEM", 203, 217], ["new", "OBSERVATION_MODIFIER", 203, 206], ["infections", "OBSERVATION", 207, 217]]], ["However, with over three decades of sustained global efforts, it is now widely accepted that developing a HIV/AIDS vaccine is one of the most difficult challenges confronting bio-medical scientists today.", [["HIV/AIDS", "DISEASE", 106, 114], ["HIV", "ORGANISM", 106, 109], ["HIV", "SPECIES", 106, 109], ["a HIV/AIDS vaccine", "TREATMENT", 104, 122], ["sustained", "OBSERVATION_MODIFIER", 36, 45], ["global efforts", "OBSERVATION", 46, 60]]], ["But the quest goes on.Concluding RemarksViral diseases have a major impact on the health of all Indians.", [["RemarksViral diseases", "DISEASE", 33, 54], ["RemarksViral diseases", "PROBLEM", 33, 54]]], ["With the burgeoning population, zoonotic nich\u00e9 that were previously undisturbed are increasingly being encroached by humans.", [["humans", "ORGANISM", 117, 123], ["humans", "SPECIES", 117, 123], ["humans", "SPECIES", 117, 123], ["zoonotic", "OBSERVATION_MODIFIER", 32, 40]]], ["As a consequence, many viral diseases that were previously unheard-of are emerging, while those that were quiescent for decades are re-emerging.", [["viral diseases", "DISEASE", 23, 37], ["many viral diseases", "PROBLEM", 18, 37], ["many", "OBSERVATION_MODIFIER", 18, 22], ["viral diseases", "OBSERVATION", 23, 37]]], ["Vaccines could confer protection against many of these emerging viral diseases.", [["viral diseases", "DISEASE", 64, 78], ["Vaccines", "TREATMENT", 0, 8], ["protection", "TREATMENT", 22, 32], ["these emerging viral diseases", "PROBLEM", 49, 78], ["viral", "OBSERVATION", 64, 69]]], ["However, there are several key programmatic areas that need to be looked into and properly addressed, in order to ensure that vaccines become a reality.", [["several key programmatic areas", "PROBLEM", 19, 49], ["vaccines", "TREATMENT", 126, 134], ["several", "OBSERVATION_MODIFIER", 19, 26], ["key", "OBSERVATION_MODIFIER", 27, 30], ["programmatic", "OBSERVATION_MODIFIER", 31, 43], ["areas", "OBSERVATION", 44, 49]]], ["One of the areas that require attention is improving the understanding of disease burden through surveillance.", [["disease burden", "PROBLEM", 74, 88], ["surveillance", "TEST", 97, 109], ["disease", "OBSERVATION", 74, 81]]], ["This will help in detecting diseases like Severe Acute Respiratory Syndrome (SARS) before they cause large outbreaks.", [["Acute Respiratory Syndrome", "DISEASE", 49, 75], ["SARS", "DISEASE", 77, 81], ["diseases", "PROBLEM", 28, 36], ["Severe Acute Respiratory Syndrome", "PROBLEM", 42, 75], ["large outbreaks", "PROBLEM", 101, 116], ["Severe", "OBSERVATION_MODIFIER", 42, 48], ["Acute", "OBSERVATION_MODIFIER", 49, 54], ["Respiratory Syndrome", "OBSERVATION", 55, 75], ["large", "OBSERVATION_MODIFIER", 101, 106], ["outbreaks", "OBSERVATION", 107, 116]]], ["India was lucky last time, with only one imported case of SARS.", [["SARS", "DISEASE", 58, 62], ["SARS", "PROBLEM", 58, 62]]], ["Next time, luck might not be on India's side, since improvements in aviation can now send infected people to any part of the globe within 24 h.", [["people", "ORGANISM", 99, 105], ["people", "SPECIES", 99, 105], ["might not be", "UNCERTAINTY", 16, 28], ["globe", "ANATOMY", 125, 130]]], ["For surveillance to be sustainable, financial support needs to be garnered for the economically weaker countries.", [["surveillance", "TEST", 4, 16], ["financial support", "TREATMENT", 36, 53]]], ["Moreover, dedicated advocacy is a must, in order to keep the topic of vaccine preventable viral diseases on the national, regional and international agendas.Concluding RemarksHowever, we should simultaneously ask the question: A vaccine for every viral disease-is it practicable?", [["viral diseases", "DISEASE", 90, 104], ["viral disease", "DISEASE", 247, 260], ["vaccine", "TREATMENT", 70, 77], ["viral diseases", "PROBLEM", 90, 104], ["A vaccine", "TREATMENT", 227, 236], ["every viral disease", "PROBLEM", 241, 260]]], ["Vaccines for all viral diseases are not feasible in a vast and diverse country like India.", [["viral diseases", "DISEASE", 17, 31], ["Vaccines", "TREATMENT", 0, 8], ["all viral diseases", "PROBLEM", 13, 31], ["viral diseases", "OBSERVATION", 17, 31]]], ["Disease burden is not clear for many viral diseases.", [["viral diseases", "DISEASE", 37, 51], ["Disease burden", "PROBLEM", 0, 14], ["many viral diseases", "PROBLEM", 32, 51], ["not clear for", "UNCERTAINTY", 18, 31], ["many", "OBSERVATION_MODIFIER", 32, 36], ["viral", "OBSERVATION", 37, 42]]], ["Hence the need for disease burden studies.", [["disease burden studies", "TEST", 19, 41]]], ["Resources should be properly utilized so that indigenous vaccine development efforts focus on viral diseases with a proven and established burden of disease.", [["viral diseases", "DISEASE", 94, 108], ["indigenous vaccine", "TREATMENT", 46, 64], ["viral diseases", "PROBLEM", 94, 108], ["disease", "PROBLEM", 149, 156], ["disease", "OBSERVATION", 149, 156]]], ["Many viruses mutate so rapidly that strain replacement occurs every year e.g. seasonal influenza.", [["influenza", "DISEASE", 87, 96], ["Many viruses mutate", "PROBLEM", 0, 19], ["strain replacement", "TREATMENT", 36, 54], ["seasonal influenza", "PROBLEM", 78, 96], ["viruses", "OBSERVATION", 5, 12], ["influenza", "OBSERVATION", 87, 96]]], ["Here, India cannot afford to mimic the West by trying to introduce a seasonal influenza vaccine.", [["influenza", "DISEASE", 78, 87], ["a seasonal influenza vaccine", "TREATMENT", 67, 95]]], ["For viruses like HIV, for which vaccines are not available, and probably will not be for quite some time, efforts need to be focused in bringing about behavioral changes as an adjunct to therapeutic interventions.", [["HIV", "ORGANISM", 17, 20], ["HIV", "SPECIES", 17, 20], ["HIV", "SPECIES", 17, 20], ["viruses", "PROBLEM", 4, 11], ["HIV", "PROBLEM", 17, 20], ["vaccines", "TREATMENT", 32, 40], ["therapeutic interventions", "TREATMENT", 187, 212], ["HIV", "OBSERVATION", 17, 20]]], ["For diseases like Hepatitis B, for which cheap and effective vaccines are already available, the programmatic deadlock should be broken so that every newborn gets the vaccine.", [["Hepatitis B", "DISEASE", 18, 29], ["Hepatitis B", "ORGANISM", 18, 29], ["newborn", "ORGANISM", 150, 157], ["Hepatitis B", "SPECIES", 18, 29], ["diseases", "PROBLEM", 4, 12], ["Hepatitis B", "PROBLEM", 18, 29], ["cheap and effective vaccines", "TREATMENT", 41, 69], ["the vaccine", "TREATMENT", 163, 174], ["Hepatitis", "OBSERVATION", 18, 27]]], ["Other types of hepatitis, like Hepatitis A and E should be managed by implementation of simple public health measures such as handwashing and improvements in sanitation.", [["hepatitis", "DISEASE", 15, 24], ["Hepatitis A", "DISEASE", 31, 42], ["Hepatitis A", "ORGANISM", 31, 42], ["Hepatitis A", "SPECIES", 31, 42], ["hepatitis", "PROBLEM", 15, 24], ["Hepatitis A", "PROBLEM", 31, 42], ["simple public health measures", "TREATMENT", 88, 117], ["hepatitis", "OBSERVATION", 15, 24], ["Hepatitis", "OBSERVATION", 31, 40]]], ["There is now renewed hope of treating Hepatitis C with a new potent oral HCV-protease inhibitor (Boceprevir).", [["oral", "ANATOMY", 68, 72], ["Hepatitis C", "DISEASE", 38, 49], ["Boceprevir", "CHEMICAL", 97, 107], ["Boceprevir", "CHEMICAL", 97, 107], ["Hepatitis C", "ORGANISM", 38, 49], ["oral", "ORGANISM_SUBDIVISION", 68, 72], ["Boceprevir", "SIMPLE_CHEMICAL", 97, 107], ["Hepatitis C", "SPECIES", 38, 49], ["HCV", "SPECIES", 73, 76], ["Hepatitis C", "PROBLEM", 38, 49], ["a new potent oral HCV-protease inhibitor", "TREATMENT", 55, 95], ["Boceprevir", "TREATMENT", 97, 107]]], ["Moreover, there is a need for health education activities so that parents can make informed choices about vaccines for their children, some of which are not mandatory (Varicella vaccine), while others are highly expensive (HPV vaccine).", [["children", "ORGANISM", 125, 133], ["HPV", "ORGANISM", 223, 226], ["children", "SPECIES", 125, 133], ["health education activities", "TREATMENT", 30, 57], ["vaccines", "TREATMENT", 106, 114], ["Varicella vaccine", "TREATMENT", 168, 185], ["HPV vaccine", "TREATMENT", 223, 234]]], ["Lastly, unfinished programmes like Polio eradication should be completed as soon as possible, and at the same time, the second dose measles vaccination initiative should be kickstarted, so that it picks up momentum, in time to achieve the targets set in the Millennium Development Goals by 2015.", [["Polio", "ORGANISM", 35, 40], ["Polio eradication", "TREATMENT", 35, 52], ["the second dose measles vaccination", "TREATMENT", 116, 151]]]]}